<graphml xmlns="http://graphml.graphdrawing.org/xmlns" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://graphml.graphdrawing.org/xmlns http://graphml.graphdrawing.org/xmlns/1.0/graphml.xsd">
  <key id="d6" for="edge" attr.name="source_id" attr.type="string" />
  <key id="d5" for="edge" attr.name="description" attr.type="string" />
  <key id="d4" for="edge" attr.name="weight" attr.type="double" />
  <key id="d3" for="node" attr.name="entity_type" attr.type="string" />
  <key id="d2" for="node" attr.name="source_id" attr.type="string" />
  <key id="d1" for="node" attr.name="description" attr.type="string" />
  <key id="d0" for="node" attr.name="type" attr.type="string" />
  <graph edgedefault="undirected">
    <node id="HIDRADENITIS SUPPURATIVA">
      <data key="d0">DISEASE</data>
      <data key="d1">Hidradenitis Suppurativa (HS) is a chronic, inflammatory, recurrent, debilitating skin disease of the hair follicle that usually presents after puberty with painful, deep-seated, inflamed lesions in the apocrine gland-bearing areas of the body, most commonly at the axillae, inguinal and anogenital regions.
Hidradenitis Suppurativa (HS) is a debilitating chronic inflammatory skin disease characterized by chronic abscess formation and development of multiple draining sinus tracts in the groin, axillae, and perineum
Hidradenitis Suppurativa, also known as HS, is a chronic skin condition characterized by inflamed and swollen lumps
Hidradenitis suppurativa is a chronic inflammatory skin disorder causing painful nodules and abscesses</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b,523bbfee1ae3b4ecabf9b11d10eea9ff,661a4cc53cee3ca36afa676952adc7fb,b28eeca0ff01a7715947d55a04978a43</data>
    </node>
    <node id="ACNE INVERSA">
      <data key="d0">DISEASE</data>
      <data key="d1">Acne Inversa is another name for Hidradenitis Suppurativa (HS).</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="ADALIMUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Adalimumab is a drug that has been approved for the treatment of Hidradenitis Suppurativa (HS).
Adalimumab is a medication used to treat autoimmune diseases by inhibiting TNF-&#945;
A drug registered for the treatment of HS
Adalimumab is a TNF-&#945; inhibitor targeting TNF, used in the treatment of autoimmune diseases
Adalimumab is an anti-TNF biologic therapy approved for the treatment of HS
Adalimumab is a TNF antagonist used in the treatment of inflammatory diseases
Adalimumab is a monoclonal antibody used in anti-TNF therapy
Adalimumab is a monoclonal antibody used to treat autoimmune diseases by inhibiting TNF&#945;</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3,523bbfee1ae3b4ecabf9b11d10eea9ff,5ec1ebf4e260eb1f8fda8acdf06cd39e,661a4cc53cee3ca36afa676952adc7fb,c44ec79872ab10cbe7336182f183ff60,c95d22c2a90e77cd22bd0d280d55b26a,f3b0f42501dbe75c224f7af44e0885f9,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="HAIR FOLLICLE">
      <data key="d0">TISSUE</data>
      <data key="d1">The hair follicle is the tissue primarily affected in Hidradenitis Suppurativa (HS).
Hair follicles are structures in the skin that produce hair</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="KERATINOCYTES">
      <data key="d0">CELL</data>
      <data key="d1">Keratinocytes are the primary cell type in the epidermis, involved in epithelial differentiation and inflammation in HS.
Keratinocytes are the primary type of cell found in the epidermis, the outermost layer of the skin
Keratinocytes are skin cells that release cytokines in response to tissue damage in atopic dermatitis
Keratinocytes are the primary cell type in the epidermis, responsible for forming the barrier against environmental damage
Keratinocytes are the primary cell type in the epidermis and produce cytokines like IL-6 and IL-1&#946; in HS
Keratinocytes are a type of cell found in the skin
Keratinocytes are the predominant cell type in the epidermis, responsible for forming a barrier against environmental damage
Keratinocytes are skin cells affected by IL-4 and IL-13, leading to reduced filaggrin expression
Cells in the epidermis expressing AhR, involved in AD
Keratinocytes are the primary type of cell found in the epidermis, the outer layer of the skin
Keratinocytes are the primary cell type in the epidermis, involved in skin barrier function
Keratinocytes are the primary cell type in the epidermis, involved in skin barrier function
Keratinocytes are skin cells involved in the proliferation and downregulation of FLG by IL-22
Keratinocytes are the primary cell type in the epidermis, responsible for the formation of the barrier against environmental damage</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd,2e0cdefd62bed7c674d7fb93ef336c2b,3ea70e257330c812b52334ca1f90d807,41ccc4b41bd57cf2bda4dbb6c7ae4198,48288f3ec2832850282f95d4e38d10e1,4842292208575bd45b2b5998513dd087,48de7eebab3f3b418feb35a152df38fd,523bbfee1ae3b4ecabf9b11d10eea9ff,5f37466ca41c9b8b06ed8be0303d49f2,6309eeea565f06479830cec32938abc9,661a4cc53cee3ca36afa676952adc7fb,bae090d8a29c15868ba1c4f29ae79e99,e075bccd45593ae008b2ce7f9ed8ff6c,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="OBESITY">
      <data key="d0">DISEASE</data>
      <data key="d1">Obesity is considered an important risk factor for Hidradenitis Suppurativa (HS).
Obesity is a condition characterized by excessive body fat
Obesity is a comorbidity associated with HS
Obesity is a condition characterized by excessive body fat and is a contributing factor in HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff,661a4cc53cee3ca36afa676952adc7fb,e340a83f7cba0ea5be731b1f682ea7c7,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="METABOLIC SYNDROME">
      <data key="d0">DISEASE</data>
      <data key="d1">Metabolic Syndrome is considered an important risk factor for Hidradenitis Suppurativa (HS).
Metabolic syndrome is a cluster of conditions that increase the risk of heart disease, stroke, and diabetes, associated with HS</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="INFLAMMATORY BOWEL DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">Inflammatory Bowel Disease is a comorbid disorder associated with Hidradenitis Suppurativa (HS).
Inflammatory bowel disease is a group of inflammatory conditions of the colon and small intestine
Inflammatory bowel disease is a chronic inflammation of the digestive tract
Inflammatory bowel disease is a group of inflammatory conditions of the colon and small intestine
Inflammatory bowel disease is a group of inflammatory conditions of the colon and small intestine
Inflammatory bowel disease is a group of inflammatory conditions of the colon and small intestine
Inflammatory Bowel Disease is a group of inflammatory conditions of the colon and small intestine</data>
      <data key="d2">05c97152fe02249153103be341d65b67,4a1ab1e50481cdd86d237db424a95719,573fb6fa0673eb9462aa9862888079f3,661a4cc53cee3ca36afa676952adc7fb,7f559ad7372a4e35e90b43cc67047b0f,990bc0f89db6ad8683c7a06a3ab356d9,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="ARTHRITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Arthritis is a comorbid disorder associated with Hidradenitis Suppurativa (HS).
Arthritis is inflammation of the joints
Arthritis is inflammation of the joints
Arthritis is a condition causing inflammation and pain in the joints
Arthritis is inflammation of the joints</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,62b4bd8f530adae989e4349d1e58f11d,661a4cc53cee3ca36afa676952adc7fb,baf4dec7fda8d8b8571a343b034f7092,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="TYPE I DIABETES MELLITUS">
      <data key="d0">DISEASE</data>
      <data key="d1">Type I Diabetes Mellitus is a comorbid disorder associated with Hidradenitis Suppurativa (HS).
Type I diabetes mellitus is an autoimmune disease where the pancreas produces little or no insulin
Type I diabetes mellitus is a chronic condition characterized by high blood sugar levels due to the body's inability to produce insulin</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719,661a4cc53cee3ca36afa676952adc7fb,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="ATHEROSCLEROSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Atherosclerosis is a comorbid disorder associated with Hidradenitis Suppurativa (HS).
Atherosclerosis is a disease in which plaque builds up inside arteries
Atherosclerosis is a disease in which plaque builds up inside arteries
Atherosclerosis is a type of heart fibrosis
Atherosclerosis is a disease characterized by the buildup of fats, cholesterol, and other substances in and on the artery walls
Atherosclerosis is a disease characterized by the buildup of plaques in the arteries, associated with OX40-OX40L signaling</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,1b656cfce91ff9ccec4223703489dab3,661a4cc53cee3ca36afa676952adc7fb,990bc0f89db6ad8683c7a06a3ab356d9,a10787d7fbb1307be263e86dc7b33a51,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="ADIPOGENESIS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Adipogenesis is a pathway involved in the comorbid disorders associated with Hidradenitis Suppurativa (HS).
Adipogenesis is the process of cell differentiation by which preadipocytes become adipocytes, involved in the formation of fat cells
Adipogenesis is the process of cell differentiation by which preadipocytes become adipocytes, dysregulated in HS
The process of cell differentiation by which preadipocytes become adipocytes, linked to HS</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719,661a4cc53cee3ca36afa676952adc7fb,f3b0f42501dbe75c224f7af44e0885f9,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="FOLLICULAR HYPERKERATOSIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Follicular Hyperkeratosis is a consistent finding in Hidradenitis Suppurativa (HS), leading to follicular rupture and inflammation.</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="LYMPHOHISTIOCYTIC INFLAMMATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Lymphohistiocytic Inflammation is an initial inflammatory response in Hidradenitis Suppurativa (HS).</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="GRANULOMATOUS REACTION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Granulomatous Reaction is a type of inflammation associated with Hidradenitis Suppurativa (HS).</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="SINUS TRACT FORMATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Sinus Tract Formation is a symptom of Hidradenitis Suppurativa (HS).</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="SCARRING">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Scarring is a symptom of Hidradenitis Suppurativa (HS).
Scarring is the formation of fibrous tissue as a result of injury or disease</data>
      <data key="d2">516e41e96d2e72d45bf1e2c69da7f18a,661a4cc53cee3ca36afa676952adc7fb</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="EPITHELIAL SKIN CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Epithelial Skin Cells are involved in the innate immunity response in Hidradenitis Suppurativa (HS).</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="ADIPOSE TISSUE">
      <data key="d0">TISSUE</data>
      <data key="d1">Adipose Tissue is involved in Hidradenitis Suppurativa (HS) as shown in immune histochemical studies.Adipose tissue is involved in Hidradenitis Suppurativa (HS) as shown in immune histochemical studies.
Adipose tissue is a type of connective tissue that stores fat
Adipose tissue is a type of connective tissue that stores fat</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb,b2aae16813e647959b783a39ef9a19a7,fa1f4687a5326fccd5d518845839e5f2</data>
      <data key="d3">TISSUE</data>
    </node>
    <node id="INVERSE VIRTUAL SCREENING">
      <data key="d0">PATHWAY</data>
      <data key="d1">Inverse Virtual Screening is a technology used to identify existing compounds as potential drugs for various diseases, including Hidradenitis Suppurativa (HS).Inverse virtual screening is a technology used to identify existing compounds as potential drugs for Hidradenitis Suppurativa (HS).</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="COMPUTATIONAL DRUG REPURPOSING">
      <data key="d0">PATHWAY</data>
      <data key="d1">Computational Drug Repurposing is a technology used to identify existing compounds as potential drugs for various diseases, including Hidradenitis Suppurativa (HS).Computational drug repurposing is a technology used to identify existing compounds as potential drugs for Hidradenitis Suppurativa (HS).</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="GENE EXPRESSION OMNIBUS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Gene Expression Omnibus is a database used for obtaining records related to Hidradenitis Suppurativa (HS).
Gene Expression Omnibus is a database for storing gene expression data</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7,661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="NATIONAL INSTITUTES OF HEALTH">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">National Institutes of Health is an organization involved in the research of Hidradenitis Suppurativa (HS).</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="TRANSCRIPTOME">
      <data key="d0">PATHWAY</data>
      <data key="d1">Transcriptome studies are used to detect HS signature pathways and molecular characteristics.
Transcriptome analysis involves studying the expression of genes in atopic dermatitis lesions</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb,f66eb51473925a8084dad1745be63b78</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="PROTEOME">
      <data key="d0">PATHWAY</data>
      <data key="d1">Proteome studies are used to detect HS signature pathways and molecular characteristics.</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="HUGO GENE NOMENCLATURE COMMITTEE">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">HUGO Gene Nomenclature Committee is an organization that verifies gene nomenclature in studies related to Hidradenitis Suppurativa (HS).
The HUGO Gene Nomenclature Committee is responsible for approving unique symbols and names for human loci</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb,990bc0f89db6ad8683c7a06a3ab356d9</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="CHRONIC INFLAMMATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Chronic inflammation is a major pathogenetic pathway of Hidradenitis Suppurativa (HS).
Chronic inflammation is a prolonged inflammatory response that can lead to tissue damage
Chronic inflammation is a prolonged inflammatory response that can lead to tissue damage</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1,4cf23e218b6aab3c77115173b5c7c2fd,661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="DYSREGULATED EPITHELIAL DIFFERENTIATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Dysregulated epithelial differentiation is a major pathogenetic pathway of Hidradenitis Suppurativa (HS).</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="INFLAMMATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Inflammation is a key component of the pathogenesis of Hidradenitis Suppurativa (HS).
A key symptom in HS characterized by upregulated inflammatory responses
A biological response to harmful stimuli, characterized by redness, swelling, heat, and pain
Inflammation is a key feature of atopic dermatitis, involving various cytokines and immune cells
Inflammation is a symptom of AD, driven by cytokines like IL-4 and IL-13
Inflammation is the body's response to injury or infection, often seen in AD
Inflammation is a symptom characterized by redness, swelling, and pain, commonly seen in atopic dermatitis
Inflammation is a response of body tissues to injury or infection
Inflammation is a biological response to harmful stimuli, characterized by redness, swelling, and pain
Inflammation is a key symptom in Atopic Dermatitis and other comorbidities
Inflammation is a symptom characterized by redness, swelling, and pain, often seen in AD patients
Inflammation is a key symptom of AD that treatments aim to reduce
Inflammation is the body's response to injury or infection, characterized by redness, swelling, heat, and pain
Inflammation is a clinical manifestation observed in SSc
Inflammation is a localized physical condition in which part of the body becomes reddened, swollen, hot, and often painful
Inflammation is the body's response to injury or infection, characterized by redness, swelling, and pain</data>
      <data key="d2">05c97152fe02249153103be341d65b67,1412a7a7fef5f18cc09a030b97b18e13,143d2dc302af5606656797bff162e23e,1596d061dbe1a1c9e8f31a02a21e5524,27a7e95c7d3ad59a948aa46741fee456,2cec06c4d46f5ff9ee936a78d8b077cd,3ce96e927d65736b305f792977fed4b9,48de7eebab3f3b418feb35a152df38fd,6059a6e2710b7df94c6a09e5eb7b024a,661a4cc53cee3ca36afa676952adc7fb,855c455b4c9592746834ee3a4e0e6b81,8ce8c356713490cd2c680f505bcd050b,90f4809673ca34628b0e607908f0bf0b,a867a1e73cef039eb3f28e072463b838,f3b0f42501dbe75c224f7af44e0885f9,f66eb51473925a8084dad1745be63b78</data>
    </node>
    <node id="BACTERIAL COLONIZATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Bacterial colonization is a possible secondary effect in Hidradenitis Suppurativa (HS).</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="INNATE IMMUNITY RESPONSE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Innate immunity response is induced in epithelial skin cells in Hidradenitis Suppurativa (HS).</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="IMPAIRED BARRIER FUNCTION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Impaired barrier function is detected at the follicular and epidermal keratinocyte level in Hidradenitis Suppurativa (HS).</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="EPIDERMAL KERATINOCYTE">
      <data key="d0">CELL</data>
      <data key="d1">Epidermal keratinocytes are involved in the inflammatory process in Hidradenitis Suppurativa (HS).</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="SKIN-GLAND LEVEL">
      <data key="d0">TISSUE</data>
      <data key="d1">The skin-gland level is involved to a minor degree in Hidradenitis Suppurativa (HS).</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="APOCRINE GLAND">
      <data key="d0">TISSUE</data>
      <data key="d1">Apocrine glands are areas of the body commonly affected by Hidradenitis Suppurativa (HS).
Apocrine glands are sweat glands involved in HS pathology</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="AXILLAE">
      <data key="d0">TISSUE</data>
      <data key="d1">The axillae are commonly affected areas in Hidradenitis Suppurativa (HS).</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="INGUINAL REGION">
      <data key="d0">TISSUE</data>
      <data key="d1">The inguinal region is commonly affected in Hidradenitis Suppurativa (HS).</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="ANOGENITAL REGION">
      <data key="d0">TISSUE</data>
      <data key="d1">The anogenital region is commonly affected in Hidradenitis Suppurativa (HS).</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="FOLLICULAR RUPTURE">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Follicular rupture is a consistent finding in Hidradenitis Suppurativa (HS).</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="SINUS TRACT">
      <data key="d0">TISSUE</data>
      <data key="d1">Sinus tracts are formed as a result of Hidradenitis Suppurativa (HS).
A sinus tract is a channel that can form in the skin, often associated with chronic inflammation in HS</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606,661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="IMMUNE-RELATED DRIVERS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune-related drivers induce an innate immunity response in Hidradenitis Suppurativa (HS).</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="DRUG REPURPOSING">
      <data key="d0">PATHWAY</data>
      <data key="d1">Drug repurposing is a method used to find new treatments for Hidradenitis Suppurativa (HS).</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="DRUG-GENE INTERACTION PROFILING">
      <data key="d0">PATHWAY</data>
      <data key="d1">Drug-gene interaction profiling is used to identify potential drugs for Hidradenitis Suppurativa (HS).</data>
      <data key="d2">661a4cc53cee3ca36afa676952adc7fb</data>
    </node>
    <node id="HS">
      <data key="d0">DISEASE</data>
      <data key="d1">Hidradenitis Suppurativa, an autoimmune disease characterized by chronic inflammation and abscess formation
Hidradenitis Suppurativa is a chronic skin condition characterized by inflamed and swollen lumps
Hidradenitis Suppurativa, a chronic skin condition characterized by inflamed and painful lumps under the skin
Hidradenitis Suppurativa, a chronic skin condition characterized by inflamed and painful lumps under the skin
Hidradenitis Suppurativa is a chronic skin condition characterized by inflamed and painful lumps
Hidradenitis Suppurativa is a complex inflammatory disease distinct from psoriasis or atopic dermatitis
Hidradenitis Suppurativa, a chronic skin condition characterized by inflamed and swollen lumps
Hidradenitis Suppurativa, a chronic skin condition characterized by inflamed and painful lumps
Hidradenitis Suppurativa, a chronic inflammatory skin disease characterized by painful nodules, abscesses, and scarring
Hidradenitis Suppurativa (HS) is a chronic skin condition characterized by inflamed and painful lumps
Hidradenitis Suppurativa, also known as HS, is a chronic skin condition characterized by inflamed and swollen lumps
Hidradenitis Suppurativa, an autoimmune disease characterized by chronic inflammation and abscess formation in the skin
Hidradenitis Suppurativa, a chronic skin condition characterized by inflamed and painful lumps
Hidradenitis Suppurativa, a chronic skin condition characterized by lumps under the skin</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,2e0cdefd62bed7c674d7fb93ef336c2b,411a4d246f0a9321e52971446a5a0606,4a1ab1e50481cdd86d237db424a95719,6309eeea565f06479830cec32938abc9,990bc0f89db6ad8683c7a06a3ab356d9,b28eeca0ff01a7715947d55a04978a43,b62ecc47bf54393bc78dd65986b949d6,bae090d8a29c15868ba1c4f29ae79e99,c44ec79872ab10cbe7336182f183ff60,e340a83f7cba0ea5be731b1f682ea7c7,e4d25b1cd44df240a29591bc46a875ab,f3b0f42501dbe75c224f7af44e0885f9,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="CXCL10">
      <data key="d0">GENE</data>
      <data key="d1">CXCL10 is a gene encoding a chemokine involved in immune responses
CXCL10 encodes C-X-C Motif Chemokine Ligand 10, involved in immune responses
CXCL10 is a gene encoding a chemokine involved in immune cell recruitment
CXCL10 is a chemokine whose expression is increased in HS, suggesting a role in the IFN response
CXCL10 is a chemokine involved in immune cell recruitment</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9,b19f42c9497f71b231222cd953036d6b,b62ecc47bf54393bc78dd65986b949d6,cdfcc39154accbac074c924676dc701e,e340a83f7cba0ea5be731b1f682ea7c7</data>
    </node>
    <node id="IL6">
      <data key="d0">GENE</data>
      <data key="d1">IL6 is a gene encoding interleukin-6, a cytokine involved in inflammation and immune response
IL6 is a gene associated with the IL-1 signaling pathway
IL6 encodes Interleukin 6, involved in the regulation of immune responses
Interleukin 6 is a cytokine involved in inflammation and the immune response
IL6 is a gene encoding the Interleukin 6
IL6 is a gene encoding the cytokine interleukin-6, which plays a role in inflammation and immune response</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,62b4bd8f530adae989e4349d1e58f11d,990bc0f89db6ad8683c7a06a3ab356d9,c44ec79872ab10cbe7336182f183ff60,cdfcc39154accbac074c924676dc701e,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="IL17A">
      <data key="d0">GENE</data>
      <data key="d1">IL17A is a gene encoding interleukin-17A, a cytokine involved in inflammatory responses
Interleukin 17A is a pro-inflammatory cytokine involved in autoimmune diseases
IL17A is a gene encoding interleukin 17A, involved in immune response
IL17A is a gene encoding for IL-17A with increased mRNA expression in HS
IL17A is a pro-inflammatory cytokine produced by Th17 cells
IL17A is a gene encoding the cytokine IL-17A</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b,573fb6fa0673eb9462aa9862888079f3,990bc0f89db6ad8683c7a06a3ab356d9,bae090d8a29c15868ba1c4f29ae79e99,c44ec79872ab10cbe7336182f183ff60,e340a83f7cba0ea5be731b1f682ea7c7</data>
    </node>
    <node id="IL36A">
      <data key="d0">GENE</data>
      <data key="d1">IL36A is a gene encoding interleukin-36 alpha, a cytokine involved in skin inflammation
IL36A is a gene associated with the IL-1 signaling pathway
Interleukin 36&#945; is a cytokine involved in inflammatory responses
IL36A is a gene encoding for IL-36A with increased mRNA expression in HS
IL36A is a gene encoding the cytokine IL-36A</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b,573fb6fa0673eb9462aa9862888079f3,990bc0f89db6ad8683c7a06a3ab356d9,e340a83f7cba0ea5be731b1f682ea7c7,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="IL36G">
      <data key="d0">GENE</data>
      <data key="d1">IL36G is a gene encoding interleukin-36 gamma, a cytokine involved in skin inflammation
IL36G is a gene associated with the IL-1 signaling pathway
Interleukin 36&#947; is a cytokine involved in inflammatory responses
IL36G is a gene encoding for IL-36G with increased mRNA expression in HS
IL36G encodes a cytokine involved in inflammatory responses
IL36G is a gene encoding the cytokine IL-36G</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b,573fb6fa0673eb9462aa9862888079f3,990bc0f89db6ad8683c7a06a3ab356d9,bae090d8a29c15868ba1c4f29ae79e99,e340a83f7cba0ea5be731b1f682ea7c7,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="S100A8">
      <data key="d0">GENE</data>
      <data key="d1">S100A8 is a gene encoding a protein involved in the regulation of inflammatory processes and immune response
S100A8 is a gene associated with the IL-1 signaling pathway
S100A8 is a gene encoding S100 Calcium-Binding Protein A8
S100A8 is a gene encoding S100 calcium binding protein A8, involved in immune response
S100A8 is an epidermal differentiation protein upregulated in atopic dermatitis lesions</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9,baf4dec7fda8d8b8571a343b034f7092,c44ec79872ab10cbe7336182f183ff60,f66eb51473925a8084dad1745be63b78,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="S100A9">
      <data key="d0">GENE</data>
      <data key="d1">S100A9 is a gene encoding a protein involved in the regulation of inflammatory processes and immune response
S100A9 is a gene associated with the IL-1 signaling pathway
S100A9 is a gene encoding S100 Calcium-Binding Protein A9
S100A9 is a gene encoding S100 calcium binding protein A9, involved in immune response
S100A9 is an epidermal differentiation protein upregulated in atopic dermatitis lesions</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9,baf4dec7fda8d8b8571a343b034f7092,c44ec79872ab10cbe7336182f183ff60,f66eb51473925a8084dad1745be63b78,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="C&#8211;C RECEPTOR INTERACTION PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">A signaling pathway involving cytokine-cytokine receptor interactions</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="JAK-STAT SIGNALING PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">A signaling pathway involved in the transmission of information from chemical signals outside the cell to the cell nucleus
The JAK-STAT signaling pathway is involved in transmitting information from chemical signals outside the cell to the cell nucleus, resulting in DNA transcription and cellular function changes
A pathway involved in HS, with genes showing diversified regulation</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719,990bc0f89db6ad8683c7a06a3ab356d9,f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="CHEMOKINE SIGNALING PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">A signaling pathway involving chemokines, which are a type of cytokine</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="IL-17 SIGNALING PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">A signaling pathway involving interleukin-17, which plays a role in inflammatory responses
A pathway involved in HS, with genes showing diversified regulation</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9,f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="TH17 CELL DIFFERENTIATION PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">A signaling pathway involved in the differentiation of Th17 cells, a type of T helper cell
The Th17 cell differentiation pathway involves the differentiation of naive T cells into Th17 cells, which are involved in autoimmune and inflammatory responses</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719,990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="TOLL-LIKE RECEPTOR PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">A signaling pathway involving Toll-like receptors, which play a key role in the innate immune system</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="INFLAMMATORY BOWEL DISEASE PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">A signaling pathway involved in the pathogenesis of inflammatory bowel diseases
A pathway associated with inflammatory bowel disease, linked to HS</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9,f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="RHEUMATOID ARTHRITIS PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">A signaling pathway involved in the pathogenesis of rheumatoid arthritis
Rheumatoid arthritis pathway is involved in the autoimmune disease rheumatoid arthritis, associated with HS
A pathway associated with rheumatoid arthritis, linked to HS</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9,f3b0f42501dbe75c224f7af44e0885f9,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="LIPID AND ATHEROSCLEROSIS PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">A signaling pathway involved in lipid metabolism and the development of atherosclerosis
The lipid and atherosclerosis pathway involves the accumulation of lipids in the arterial walls, leading to atherosclerosis</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719,990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="SKIN">
      <data key="d0">TISSUE</data>
      <data key="d1">The skin is a tissue affected by Hidradenitis Suppurativa
The tissue affected by HS, showing differences between lesional and non-lesional areas
The skin is the primary tissue affected by atopic dermatitis
Skin biopsy specimens were collected to analyze transcriptomic and proteomic profiles in AD patients
The skin is the primary tissue affected by atopic dermatitis
The skin is the primary tissue affected by HS, characterized by chronic abscess formation and sinus tracts
Skin is the tissue where HS, psoriasis, and atopic dermatitis manifest
The skin is the body's largest organ, providing a barrier against environmental damage
The skin is the primary tissue affected in Hidradenitis Suppurativa
The skin is the body's largest organ and is affected in HS
The skin is the primary tissue affected in HS, psoriasis, and AD
The skin is a tissue affected by various diseases, including psoriasis and hidradenitis suppurativa
The skin is a tissue that can be affected by various diseases and conditions
The skin is the body's largest organ, serving as a protective barrier and involved in various immune responses
The skin is the body's largest organ and is affected in HS
The skin is the primary tissue affected by Atopic Dermatitis, characterized by inflammation and epidermal barrier dysfunction
The skin is the primary tissue affected by atopic dermatitis
The skin is a tissue affected by AD, showing pathological changes such as fibrosis and epidermal barrier dysfunction
The largest organ of the body, affected in atopic dermatitis
The outer layer of the body affected by atopic dermatitis
The skin is the primary tissue affected by AD, characterized by inflammation and eczematous lesions
The skin is the primary tissue affected in atopic dermatitis, showing signs of inflammation and barrier dysfunction
The outermost layer of the body, affected in atopic dermatitis
The outermost layer of the body, affected by AD
The skin is the tissue affected by atopic dermatitis
The skin is the body's largest organ, providing a protective barrier against environmental hazards
The skin is the tissue affected by AD and psoriasis
The skin is the body's largest organ and serves as a protective barrier
The skin is the body's largest organ, involved in protection and sensation
The skin is the body's largest organ and is affected in atopic dermatitis
The skin is a primary tissue affected by Atopic Dermatitis
The skin is the primary tissue affected by atopic dermatitis, characterized by inflammation and itchiness
The skin is the primary tissue affected by Atopic Dermatitis, showing symptoms like irritation, redness, and eczematous lesions.
The skin is the outermost layer of the body, serving as a barrier and involved in immune responses
The skin is the primary tissue affected by atopic dermatitis (AD)
The skin is affected by AD, requiring treatment to heal and reduce inflammation
Skin is the primary tissue affected in AD and other skin conditions
The skin is the body's largest organ and a primary target for topical treatments
The skin is a tissue affected by dermatological treatments and formulations
The skin is the body's largest organ and is affected by various treatments and conditions
The skin is the primary tissue affected by Atopic Dermatitis
The skin is the body's largest organ, providing a protective barrier against environmental factors
The skin, involved in biopsies for patients with AD and HC
Skin, the tissue where OX40 and OX40L are co-localized in AD patients
The skin is the outer tissue of the body, affected in AD
The skin is the body's largest organ and is affected in conditions like atopic dermatitis
The skin is one of the tissues affected by systemic sclerosis
The skin is one of the tissues affected by systemic sclerosis
The skin is one of the tissues affected by systemic sclerosis
The skin is one of the tissues affected by systemic sclerosis
The skin is a tissue affected by systemic sclerosis and other conditions
The skin is one of the tissues affected by systemic sclerosis
The skin is one of the organs affected by fibrosis
The skin is a tissue affected by systemic sclerosis
The skin is the body's largest organ and acts as a barrier to the environment
The skin is the body's largest organ and is affected in systemic sclerosis
The skin is one of the tissues affected by systemic sclerosis
The skin is the body's largest organ and can be affected by various diseases, including fibrosis</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,0829313703a7d2bae5436a9ee542334d,100dd7646c10899301b3c0631183da16,104cc78517b2eca2e9cb7e00de1fe4b0,1412a7a7fef5f18cc09a030b97b18e13,143d2dc302af5606656797bff162e23e,1596d061dbe1a1c9e8f31a02a21e5524,1d0c4a4cd555b7ecd0b9d7b0310e9fe9,27a7e95c7d3ad59a948aa46741fee456,2a0384addc6e7fd709e0508b83496cd7,2cec06c4d46f5ff9ee936a78d8b077cd,2e0cdefd62bed7c674d7fb93ef336c2b,2e9a8d71f6bd251a0b13458c39e69746,3ce96e927d65736b305f792977fed4b9,3dfbb4c51838e0951f53ce951395225f,3ea70e257330c812b52334ca1f90d807,411a4d246f0a9321e52971446a5a0606,41ccc4b41bd57cf2bda4dbb6c7ae4198,442e7fad2fab75fa2449309783294d89,44f2592262cac835560b4c149fee8d2b,475995d7d211bbfde6d8ba52f324d688,48de7eebab3f3b418feb35a152df38fd,4cf23e218b6aab3c77115173b5c7c2fd,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,523bbfee1ae3b4ecabf9b11d10eea9ff,5ec1ebf4e260eb1f8fda8acdf06cd39e,6059a6e2710b7df94c6a09e5eb7b024a,68015074236b0144899baa38d01ae467,693a2aac101eaaadf92614317a1e4da8,6ada075e562abd7bd445164e9fc309b4,6aef5adb1be227170f66c76a292c25e5,6b099960b0a39866e3aa6b908f1886e4,78e26c66107dba37ac4bab65406b43a0,8246ea974dfb00cb5e3d984004e21a9e,83eb9003d42977bb83fea1d123dd5ab9,855c455b4c9592746834ee3a4e0e6b81,89dbac0da39e4de2b602052cd792b90d,90f4809673ca34628b0e607908f0bf0b,9867d43adab0ba5db44961fae4863eee,990bc0f89db6ad8683c7a06a3ab356d9,a867a1e73cef039eb3f28e072463b838,b28eeca0ff01a7715947d55a04978a43,b2aae16813e647959b783a39ef9a19a7,b62ecc47bf54393bc78dd65986b949d6,bae090d8a29c15868ba1c4f29ae79e99,bddc3b1a7f098e71f0aa64adec047124,c46e8b6ee0c29e37b7f18c42558d7a3e,cccfd5ff480e281556e2210cd0e5c4b5,d4797ed1483e5057bcd8301eaa509d5e,d8a485eb1e9435b083d5ef6a17f06ea5,dc905ba8b6eb7d84cf2776303211010d,e075bccd45593ae008b2ce7f9ed8ff6c,e340a83f7cba0ea5be731b1f682ea7c7,e4d25b1cd44df240a29591bc46a875ab,f1897c89e321a3a80924fd72a56e90df,f3b0f42501dbe75c224f7af44e0885f9,f66eb51473925a8084dad1745be63b78</data>
    </node>
    <node id="BLOOD">
      <data key="d0">TISSUE</data>
      <data key="d1">Blood is a tissue where differentially expressed genes and proteins are detected in Hidradenitis Suppurativa patients
A tissue used for biomarker studies in HS patients
Blood is the tissue where cell type signatures were analyzed in HS
Blood is a tissue composed of cells and plasma, involved in transporting nutrients and waste
Blood is a bodily fluid that delivers necessary substances such as nutrients and oxygen to cells and transports metabolic waste products away from those same cells
Blood is a body fluid that delivers necessary substances to cells and transports waste products away</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,2a0384addc6e7fd709e0508b83496cd7,2e0cdefd62bed7c674d7fb93ef336c2b,990bc0f89db6ad8683c7a06a3ab356d9,c46e8b6ee0c29e37b7f18c42558d7a3e,f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="FIBROSIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Fibrosis is characterized by excessive tissue scarring, often seen in chronic inflammatory diseases
Fibrosis is a symptom characterized by excessive tissue scarring
Tissue fibrosis is triggered by type 2 pathway activation in AD
Fibrosis is characterized by excessive tissue scarring, promoted by IL-13 in skin remodeling
Fibrosis is characterized by excessive tissue scarring
Fibrosis is characterized by excessive tissue scarring, often seen in systemic sclerosis
Fibrosis is characterized by excessive tissue scarring
Fibrosis is characterized by excessive tissue scarring, a hallmark of SSc
Fibrosis is characterized by excessive tissue scarring
Fibrosis is the formation of excess fibrous connective tissue in an organ or tissue
Fibrosis is the thickening and scarring of connective tissue
Fibrosis is characterized by excessive tissue scarring, commonly seen in systemic sclerosis
Fibrosis is the result of extracellular matrix protein deposition and is a leading cause of death in the USA
Fibrosis is characterized by the thickening and scarring of connective tissue
Fibrosis is the formation of excess fibrous connective tissue in an organ or tissue
Fibrosis is the thickening and scarring of connective tissue
Fibrosis is the formation of excess fibrous connective tissue in an organ or tissue
Fibrosis is characterized by excessive tissue scarring and is a complication of chronic inflammation
Fibrosis is characterized by excessive tissue scarring
Fibrosis is characterized by excessive tissue scarring and can develop from a pro-inflammatory environment
Fibrosis is characterized by excessive tissue scarring and is associated with OX40-OX40L signaling

Fibrosis is characterized by excessive tissue scarring
Fibrosis is the thickening and scarring of connective tissue
Fibrosis is characterized by excessive tissue scarring
Fibrosis is characterized by excessive tissue scarring and is driven by TNFSF members</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14,05c97152fe02249153103be341d65b67,080b1dc5fcc0eee3645a06983a0de603,1b656cfce91ff9ccec4223703489dab3,28f548554737fcc026b968db6bbafa30,44f2592262cac835560b4c149fee8d2b,48de7eebab3f3b418feb35a152df38fd,4cf23e218b6aab3c77115173b5c7c2fd,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,516e41e96d2e72d45bf1e2c69da7f18a,5ec1ebf4e260eb1f8fda8acdf06cd39e,68015074236b0144899baa38d01ae467,7b454335c2f5651d86f712037a0dc0ff,7c13f41d7349d9d2e56c36e00c0ca2d9,855c455b4c9592746834ee3a4e0e6b81,8ce8c356713490cd2c680f505bcd050b,9867d43adab0ba5db44961fae4863eee,990bc0f89db6ad8683c7a06a3ab356d9,a10787d7fbb1307be263e86dc7b33a51,b28eeca0ff01a7715947d55a04978a43,b2aae16813e647959b783a39ef9a19a7,c525762bb827485bceeb9f09bb4bcfe0,c95d22c2a90e77cd22bd0d280d55b26a,d4797ed1483e5057bcd8301eaa509d5e,df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="EUROPEAN BIOINFORMATICS INSTITUTE">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">The European Bioinformatics Institute is a center for research and services in bioinformatics</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="NATIONAL CANCER INSTITUTE">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">The National Cancer Institute is part of the U.S. National Institutes of Health and conducts cancer research</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="G:PROFILER">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">g:Profiler is a toolset for functional profiling of gene lists from large-scale experiments</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="KYOTO ENCYCLOPEDIA OF GENES AND GENOMES (KEGG)">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">KEGG is a database resource for understanding high-level functions and utilities of the biological system</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="REACTOME">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Reactome is a free, open-source, curated and peer-reviewed pathway database</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="WIKIPATHWAYS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">WikiPathways is a database of biological pathways maintained by and for the scientific community</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="HUMAN PHENOTYPE ONTOLOGY (HP)">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">The Human Phenotype Ontology provides a standardized vocabulary of phenotypic abnormalities encountered in human disease</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="THE DRUG REPURPOSING HUB">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">The Drug Repurposing Hub is a curated and annotated collection of FDA-approved drugs, clinical trial drugs, and pre-clinical tool compounds</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="GENE CARDS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Gene Cards is a database of human genes that provides concise genomic related information</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="ELI AND EDY L. BROAD INSTITUTE">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">The Broad Institute is a biomedical and genomic research center</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="MIT">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">The Massachusetts Institute of Technology is a private research university</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="HARVARD UNIVERSITY">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Harvard University is a private Ivy League research university</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="WEIZMANN INSTITUTE OF SCIENCE">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">The Weizmann Institute of Science is a public research university in Rehovot, Israel</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="OREGON HEALTH AND SCIENCE UNIVERSITY">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Oregon Health and Science University is a public university in Oregon, USA</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="NEW YORK UNIVERSITY">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">New York University is a private research university in New York City</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="ONTARIO INSTITUTE FOR CANCER RESEARCH">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">The Ontario Institute for Cancer Research is a collaborative research institute in Ontario, Canada</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="JACKSON LABORATORY FOR GENOMIC MEDICINE">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">The Jackson Laboratory for Genomic Medicine is a research institution focused on genetics and genomics</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="IL-17">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-17 is a cytokine that plays a role in inflammatory responses
IL-17 is a pro-inflammatory cytokine produced by Th17 cells
IL-17 is a cytokine involved in the pathogenesis of autoimmune and inflammatory diseases
Interleukin-17, a cytokine involved in inflammatory responses, targeted by anti-IL-17 compounds for HS treatment
IL-17 is a pro-inflammatory cytokine involved in immune responses
IL-17 is a pro-inflammatory cytokine produced by T cells
Interleukin-17 (IL-17) is a proinflammatory cytokine involved in immune responses
IL-17 is a cytokine involved in the pathophysiology of atopic dermatitis, particularly in chronic lesions
Interleukin-17, a cytokine involved in inflammatory responses
IL-17 is a cytokine involved in immune response and inflammation
A family of cytokines involved in inflammatory responses, including IL-17A and IL-17C
IL-17 is a cytokine involved in the immune response and related to psoriasis
IL-17 is a cytokine involved in the IL-23&#8211;IL-17 axis, implicated in psoriasis and AD
IL-17 is a cytokine involved in the immune response and associated with Atopic Dermatitis.
Interleukin-17, involved in inflammation and immune response
IL-17 is a cytokine involved in inflammatory responses and is being explored in clinical studies for conditions like psoriasis
IL-17 is a proinflammatory cytokine involved in immune response
IL-17 is a proinflammatory cytokine induced by ICOS in activated T cells
Interleukin 17, a cytokine involved in T helper cell responses
Interleukin 17 is a pro-inflammatory cytokine produced by T cells</data>
      <data key="d2">1d0c4a4cd555b7ecd0b9d7b0310e9fe9,3df8535e965efb96f5094169610507ff,44f2592262cac835560b4c149fee8d2b,48288f3ec2832850282f95d4e38d10e1,4a1ab1e50481cdd86d237db424a95719,503107475d2e9dac49abd8ebcbadd9f5,6309eeea565f06479830cec32938abc9,6ada075e562abd7bd445164e9fc309b4,849e0980ffd6a7e1cf0b8d3d1fbacd98,855c455b4c9592746834ee3a4e0e6b81,8ce8c356713490cd2c680f505bcd050b,990bc0f89db6ad8683c7a06a3ab356d9,b19f42c9497f71b231222cd953036d6b,b62ecc47bf54393bc78dd65986b949d6,bae090d8a29c15868ba1c4f29ae79e99,e340a83f7cba0ea5be731b1f682ea7c7,e95d4d15e4f3110c91a3d3fcb5910d06,f3b0f42501dbe75c224f7af44e0885f9,f66eb51473925a8084dad1745be63b78,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="TH17 CELL">
      <data key="d0">CELL</data>
      <data key="d1">Th17 cells are a subset of T helper cells involved in autoimmune diseases
A type of T cell involved in the immune response and inflammation</data>
      <data key="d2">849e0980ffd6a7e1cf0b8d3d1fbacd98,990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="TOLL-LIKE RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Toll-like receptors are proteins that play a key role in the innate immune system</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="CYTOKINE">
      <data key="d0">PROTEIN</data>
      <data key="d1">Cytokines are small proteins important in cell signaling
Cytokines are small proteins important in cell signaling, especially in immune responses
Small proteins important in cell signaling, particularly in immune responses
Cytokines are small proteins important in cell signaling, involved in immune responses
Cytokines are signaling proteins that mediate and regulate immunity, inflammation, and hematopoiesis
Cytokines are small proteins that are important in cell signaling
Cytokines are signaling molecules that mediate and regulate immunity, inflammation, and hematopoiesis</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,1596d061dbe1a1c9e8f31a02a21e5524,44f2592262cac835560b4c149fee8d2b,7c13f41d7349d9d2e56c36e00c0ca2d9,8ce8c356713490cd2c680f505bcd050b,990bc0f89db6ad8683c7a06a3ab356d9,bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="CHEMOKINE">
      <data key="d0">PROTEIN</data>
      <data key="d1">Chemokines are a family of small cytokines that induce chemotaxis in nearby cells
Chemokines are a family of small cytokines involved in the immune response and cell migration</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="JAK-STAT">
      <data key="d0">PROTEIN</data>
      <data key="d1">JAK-STAT is a signaling pathway that transmits information from chemical signals outside the cell to the cell nucleus</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="C&#8211;C RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">C&#8211;C receptors are a type of cytokine receptor</data>
      <data key="d2">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </node>
    <node id="RHEUMATOID ARTHRITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Rheumatoid arthritis is an autoimmune disease that causes chronic inflammation of the joints
Rheumatoid arthritis is an autoimmune disorder that primarily affects joints
Rheumatoid arthritis is an autoimmune disease that causes joint inflammation
Rheumatoid arthritis is a chronic inflammatory disorder affecting the joints
Rheumatoid arthritis is an autoimmune disorder that primarily affects joints
Rheumatoid arthritis is an autoimmune disease that causes chronic inflammation of the joints
Rheumatoid Arthritis is an autoimmune disease causing chronic inflammation of joints
Rheumatoid arthritis is an autoimmune disease that causes chronic inflammation of the joints
Rheumatoid arthritis is a chronic inflammatory disorder affecting joints
Rheumatoid Arthritis is a condition that children with Atopic Dermatitis may develop.
Rheumatoid arthritis is an autoimmune disease characterized by chronic inflammation of the joints
Rheumatoid arthritis is an inflammatory disease treated with TNF antagonists
Rheumatoid arthritis is a chronic inflammatory disorder affecting the joints
Rheumatoid Arthritis is a chronic inflammatory disorder affecting joints
Rheumatoid arthritis is an autoimmune disease characterized by chronic inflammation of the joints
Rheumatoid arthritis is an autoimmune disease characterized by chronic inflammation of the joints
Rheumatoid arthritis, a disease treated with TNF inhibitorsRheumatoid arthritis is an autoimmune disease characterized by chronic inflammation of the joints</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,0c7502a2bfe653785647d754ed10f4e3,423195c6b63ad0a6773374364ebf3612,4a1ab1e50481cdd86d237db424a95719,516e41e96d2e72d45bf1e2c69da7f18a,573fb6fa0673eb9462aa9862888079f3,5ec1ebf4e260eb1f8fda8acdf06cd39e,62b4bd8f530adae989e4349d1e58f11d,68015074236b0144899baa38d01ae467,6ada075e562abd7bd445164e9fc309b4,8e5a1be9981340d419f7b3ad27076009,990bc0f89db6ad8683c7a06a3ab356d9,a867a1e73cef039eb3f28e072463b838,baf4dec7fda8d8b8571a343b034f7092,c46e8b6ee0c29e37b7f18c42558d7a3e,cdfcc39154accbac074c924676dc701e,e30574e513dd250992d637d808759c34</data>
    </node>
    <node id="TLR PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">The TLR pathway involves Toll-like receptors that play a key role in the innate immune system</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
    </node>
    <node id="C-TYPE LEPTIN RECEPTOR SIGNALING PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">The C-type leptin receptor signaling pathway is involved in regulating energy balance and body weight</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
    </node>
    <node id="TNF SIGNALING PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">The TNF signaling pathway involves tumor necrosis factor, which is involved in systemic inflammation</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
    </node>
    <node id="IL-4">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-4 is a cytokine that induces differentiation of naive helper T cells to Th2 cells
IL-4 is a cytokine involved in the immune response and targeted by dupilumab in the treatment of atopic dermatitis
IL-4 is a cytokine produced by Th2 cells that plays a role in inflammation and immune response
IL-4 is a cytokine with no significant response in HS lesional skin
Interleukin-4 (IL-4) is a cytokine implicated in tissue inflammation and epidermal barrier dysfunction in Atopic Dermatitis
IL-4 is a type 2 cytokine involved in the pathophysiology of atopic dermatitis
IL-4 is a key type 2 immune mediator involved in AD pathophysiology
IL-4 is a cytokine involved in immune signaling, targeted by dupilumab
Interleukin-4, a cytokine involved in type 2 immune responses
IL-4 is a type 2 cytokine involved in immune response
IL-4 is a cytokine involved in immune response, signaling through both type 1 and type 2 heterodimeric receptors
Interleukin-4, a cytokine involved in the immune response
IL-4 is a cytokine involved in the immune response and TH2 polarization
IL-4 is a cytokine involved in the TH2 immune response and cutaneous inflammation in atopic dermatitis
Interleukin-4, a cytokine involved in the immune response
Interleukin-4, a cytokine that induces differentiation of T helper 2 cells and is involved in the immune response
IL-4 (Interleukin-4) is a cytokine involved in the immune response and inflammation
IL-4 is a cytokine involved in the immune response and inflammation
Interleukin-4, involved in Th2 cell activation and immune response
IL-4 is a cytokine crucial in the pathophysiology of AD and enhances S. aureus infections

Interleukin-4 (IL-4) is a cytokine whose levels are reduced in an AD animal model treated with CsA-loaded nanoparticles
Interleukin-4 (IL-4) is a cytokine involved in the immune response
Interleukin-4 (IL-4) is a cytokine involved in the regulation of immune responses and inflammation
IL-4 is a cytokine inhibited by dupilumab
Interleukin-4 (IL-4) is a cytokine produced by mast cells, central to the pathogenesis of Atopic Dermatitis
IL-4 is a cytokine involved in promoting fibroblast activation and extracellular matrix synthesis
IL-4 is a pro-fibrotic cytokine induced by ICOS in activated T cells
Interleukin 4, a cytokine involved in T helper cell responses</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,0ba9fbea14e0c2c1d01a12ffaacfda9b,104cc78517b2eca2e9cb7e00de1fe4b0,27a7e95c7d3ad59a948aa46741fee456,286730b1c1f680ac465cc21d522fda0c,28f548554737fcc026b968db6bbafa30,2cec06c4d46f5ff9ee936a78d8b077cd,2e0cdefd62bed7c674d7fb93ef336c2b,3df8535e965efb96f5094169610507ff,3dfbb4c51838e0951f53ce951395225f,41ccc4b41bd57cf2bda4dbb6c7ae4198,44f2592262cac835560b4c149fee8d2b,4842292208575bd45b2b5998513dd087,48de7eebab3f3b418feb35a152df38fd,4a1ab1e50481cdd86d237db424a95719,503107475d2e9dac49abd8ebcbadd9f5,6309eeea565f06479830cec32938abc9,691cb2e23ac3c6e591129d16714f8ef8,693a2aac101eaaadf92614317a1e4da8,78e26c66107dba37ac4bab65406b43a0,849e0980ffd6a7e1cf0b8d3d1fbacd98,855c455b4c9592746834ee3a4e0e6b81,96e553a44a27e728c27c4892045ec5c2,b19f42c9497f71b231222cd953036d6b,bddc3b1a7f098e71f0aa64adec047124,e075bccd45593ae008b2ce7f9ed8ff6c,e95d4d15e4f3110c91a3d3fcb5910d06,e9841b88c9fab58c5175af409653da50,f66eb51473925a8084dad1745be63b78</data>
    </node>
    <node id="IL-13">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-13 is a cytokine involved in the regulation of inflammatory and immune responses
IL-13 is a cytokine involved in the immune response and targeted by dupilumab in the treatment of atopic dermatitis
IL-13 is a cytokine produced by Th2 cells that is involved in inflammation and immune response
Interleukin-13 (IL-13) is a cytokine implicated in tissue inflammation and epidermal barrier dysfunction in Atopic Dermatitis
IL-13 is a type 2 cytokine involved in the pathophysiology of atopic dermatitis
IL-13 is a key type 2 immune mediator involved in AD pathophysiology
IL-13 is a cytokine involved in immune signaling, targeted by various monoclonal antibodies
Interleukin-13, a cytokine involved in type 2 immune responses
IL-13 is a type 2 cytokine involved in immune response
IL-13 is a cytokine involved in immune response, signaling through type 2 heterodimeric receptors and associated with chronic inflammatory phenotype
IL-13 is a cytokine involved in type 2 immune responses, contributing to allergic inflammation
Interleukin-13, a cytokine involved in the immune response
IL-13 is a cytokine involved in the immune response and inflammation
Interleukin-13, a key mediator negatively impacting epidermal barrier function in AD
IL-13 is a cytokine involved in the immune response and TH2 polarization
IL-13 is a cytokine involved in the TH2 immune response and cutaneous inflammation in atopic dermatitis
Interleukin-13, a cytokine involved in the immune response
IL-13 is a cytokine involved in allergic diseases, targeted by antibodies in preclinical experiments
Interleukin-13, a cytokine involved in the regulation of inflammatory and immune responses
IL-13 (Interleukin-13) is a cytokine involved in the inflammatory response
IL-13 (Interleukin-13) is a cytokine that plays a role in the immune response and is involved in the pathogenesis of allergic diseases
IL-13 is a cytokine involved in the immune response and inflammation
Interleukin-13, involved in Th2 cell activation and immune response
IL-13 is a cytokine crucial in the pathophysiology of AD and impairs the skin barrier
IL-13 is a cytokine involved in the immune response and inflammation
IL-13 is a protein targeted by tralokinumab
Interleukin-13 (IL-13) is a cytokine involved in the immune response
IL-13 is a cytokine inhibited by dupilumab
IL-13 is a cytokine involved in the regulation of immune responses and tissue remodeling
Interleukin-13 is a cytokine involved in the regulation of immune response and inflammation
IL-13 is a cytokine upregulated by TL1A and is a major indicator of TL1A-driven inflammation
Interleukin-13 is a cytokine that plays a supporting role to IL-5 in EoE
IL-13 is a cytokine that plays a supporting role to IL-5 and is TRAIL dependent</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,05c97152fe02249153103be341d65b67,0ba9fbea14e0c2c1d01a12ffaacfda9b,104cc78517b2eca2e9cb7e00de1fe4b0,1596d061dbe1a1c9e8f31a02a21e5524,286730b1c1f680ac465cc21d522fda0c,28f548554737fcc026b968db6bbafa30,2cec06c4d46f5ff9ee936a78d8b077cd,3ce96e927d65736b305f792977fed4b9,3df8535e965efb96f5094169610507ff,3dfbb4c51838e0951f53ce951395225f,3ea70e257330c812b52334ca1f90d807,41ccc4b41bd57cf2bda4dbb6c7ae4198,4842292208575bd45b2b5998513dd087,48de7eebab3f3b418feb35a152df38fd,4a1ab1e50481cdd86d237db424a95719,5f37466ca41c9b8b06ed8be0303d49f2,6309eeea565f06479830cec32938abc9,693a2aac101eaaadf92614317a1e4da8,78e26c66107dba37ac4bab65406b43a0,8246ea974dfb00cb5e3d984004e21a9e,849e0980ffd6a7e1cf0b8d3d1fbacd98,96e553a44a27e728c27c4892045ec5c2,a867a1e73cef039eb3f28e072463b838,b19f42c9497f71b231222cd953036d6b,c525762bb827485bceeb9f09bb4bcfe0,c95d22c2a90e77cd22bd0d280d55b26a,d4797ed1483e5057bcd8301eaa509d5e,e075bccd45593ae008b2ce7f9ed8ff6c,e95d4d15e4f3110c91a3d3fcb5910d06,e9841b88c9fab58c5175af409653da50,f2aa3fd6ae3f1853347874c50afb60ea,f66eb51473925a8084dad1745be63b78</data>
    </node>
    <node id="IL-10">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-10 is an anti-inflammatory cytokine
IL-10 is an anti-inflammatory cytokine
IL-10 (Interleukin-10) is a cytokine with anti-inflammatory properties
IL-10 is a cytokine involved in the immune response and inflammation
IL-10 is an anti-inflammatory cytokine involved in immune regulation
Interleukin 10, secreted by Treg cells to promote M2 macrophage activation
IL-10 production is decreased in SSc patient T cells after TNF-co-stimulation
IL-10 is an anti-inflammatory cytokine</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198,4a1ab1e50481cdd86d237db424a95719,503107475d2e9dac49abd8ebcbadd9f5,5ec1ebf4e260eb1f8fda8acdf06cd39e,855c455b4c9592746834ee3a4e0e6b81,a867a1e73cef039eb3f28e072463b838,b19f42c9497f71b231222cd953036d6b,b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="IL-20 FAMILY">
      <data key="d0">PROTEIN</data>
      <data key="d1">The IL-20 family consists of cytokines involved in skin inflammation and immune responses</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
    </node>
    <node id="IL-1 FAMILY">
      <data key="d0">PROTEIN</data>
      <data key="d1">The IL-1 family consists of cytokines involved in the regulation of immune and inflammatory responses</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
    </node>
    <node id="IL-18">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-18 is a pro-inflammatory cytokine
Interleukin-18, involved in inflammation and immune response
IL-18 is a cytokine with a high receptor affinity for IL-18R&#945;, involved in the immune response
IL-18 is a biomarker used to monitor the severity of AD</data>
      <data key="d2">286730b1c1f680ac465cc21d522fda0c,2cec06c4d46f5ff9ee936a78d8b077cd,4a1ab1e50481cdd86d237db424a95719,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </node>
    <node id="IL-36">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-36 is a cytokine involved in inflammatory responses
IL-36 is a cytokine involved in immune responses and is implicated in the inflammatory responses in HS
IL-36 is a cytokine with significant response in HS lesional skin
IL-36 is a cytokine involved in inflammatory responses
Interleukin-36, a group of cytokines involved in inflammatory responses, particularly in skin diseases
IL-36 is a cytokine involved in the innate immune system and upregulated in psoriasis and atopic dermatitis
IL-36 is a cytokine involved in inflammatory responses and implicated in psoriasis and AD
Interleukin-36, part of the innate immune system and increased in the skin of psoriasis and AD patientsInterleukin-36, involved in inflammation and immune response
IL-36 is a cytokine associated with inflammatory responses and is being explored in clinical studies for conditions like psoriasis</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,2e0cdefd62bed7c674d7fb93ef336c2b,3df8535e965efb96f5094169610507ff,48288f3ec2832850282f95d4e38d10e1,4a1ab1e50481cdd86d237db424a95719,523bbfee1ae3b4ecabf9b11d10eea9ff,6309eeea565f06479830cec32938abc9,849e0980ffd6a7e1cf0b8d3d1fbacd98,bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="IL-2 FAMILY">
      <data key="d0">PROTEIN</data>
      <data key="d1">The IL-2 family consists of cytokines involved in the regulation of immune responses</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
    </node>
    <node id="IL-21">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-21 is a cytokine involved in the regulation of immune responses</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
    </node>
    <node id="IL-12 FAMILY">
      <data key="d0">PROTEIN</data>
      <data key="d1">The IL-12 family consists of cytokines involved in the regulation of immune responses</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
    </node>
    <node id="EPIDERMAL GROWTH FACTOR RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Epidermal growth factor receptor is a cell surface receptor that binds epidermal growth factor</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
    </node>
    <node id="IL-1 RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-1 receptor is a receptor that binds interleukin-1</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
    </node>
    <node id="CORNIFIED ENVELOPE">
      <data key="d0">PATHWAY</data>
      <data key="d1">The formation of the cornified envelope is a process in the skin that provides a barrier to protect against environmental damage</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
    </node>
    <node id="ANTIMICROBIAL PEPTIDES">
      <data key="d0">PROTEIN</data>
      <data key="d1">Antimicrobial peptides are part of the innate immune response and provide a first line of defense against pathogens</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
    </node>
    <node id="INNATE IMMUNE SYSTEM">
      <data key="d0">PATHWAY</data>
      <data key="d1">The innate immune system is the body's first line of defense against pathogens
The innate immune system is the body's first line of defense against pathogens, involved in atopic dermatitis
The body's first line of defense against pathogens, involving non-specific immune responses</data>
      <data key="d2">143d2dc302af5606656797bff162e23e,3ea70e257330c812b52334ca1f90d807,4a1ab1e50481cdd86d237db424a95719</data>
    </node>
    <node id="IFNG SIGNALING">
      <data key="d0">PATHWAY</data>
      <data key="d1">IFNG signaling involves interferon-gamma, which is critical for innate and adaptive immunity</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
    </node>
    <node id="SIGNAL TRANSDUCTION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Signal transduction is the process by which a chemical or physical signal is transmitted through a cell</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
    </node>
    <node id="NUCLEAR RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Nuclear receptors are a class of proteins involved in sensing steroid and thyroid hormones</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="GPCR">
      <data key="d0">PROTEIN</data>
      <data key="d1">G protein-coupled receptors are a large family of cell surface receptors that respond to various external signalsG protein-coupled receptors (GPCRs) are a large family of cell surface receptors that respond to various external signals</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="LEPTIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Leptin is a hormone involved in regulating energy balance
Leptin is a hormone involved in regulating energy balance and hunger</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719,a867a1e73cef039eb3f28e072463b838</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="DEVELOPMENTAL BIOLOGY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Developmental biology is the study of the process by which organisms grow and develop</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
    </node>
    <node id="ABAT">
      <data key="d0">GENE</data>
      <data key="d1">ABAT is a gene encoding the enzyme 4-aminobutyrate aminotransferase</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
      <data key="d3">GENE</data>
    </node>
    <node id="ADRA1A">
      <data key="d0">GENE</data>
      <data key="d1">ADRA1A is a gene encoding the alpha-1A adrenergic receptor</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
      <data key="d3">GENE</data>
    </node>
    <node id="CYP3A4">
      <data key="d0">GENE</data>
      <data key="d1">CYP3A4 is a gene encoding an enzyme involved in drug metabolism</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
      <data key="d3">GENE</data>
    </node>
    <node id="GRM4">
      <data key="d0">GENE</data>
      <data key="d1">GRM4 is a gene encoding the metabotropic glutamate receptor 4</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
      <data key="d3">GENE</data>
    </node>
    <node id="HRH1">
      <data key="d0">GENE</data>
      <data key="d1">HRH1 is a gene encoding the histamine H1 receptor</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
      <data key="d3">GENE</data>
    </node>
    <node id="OPRD1">
      <data key="d0">GENE</data>
      <data key="d1">OPRD1 is a gene encoding the delta opioid receptor</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
      <data key="d3">GENE</data>
    </node>
    <node id="OPRM">
      <data key="d0">GENE</data>
      <data key="d1">OPRM is a gene encoding the mu opioid receptor</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
      <data key="d3">GENE</data>
    </node>
    <node id="PRKAB1">
      <data key="d0">GENE</data>
      <data key="d1">PRKAB1 is a gene encoding the regulatory subunit of AMP-activated protein kinase
PRKAB1 is a gene encoding protein kinase AMP-activated non-catalytic subunit beta 1, involved in cellular energy homeostasisPRKAB1 is a protein involved in cellular energy homeostasis</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719,c44ec79872ab10cbe7336182f183ff60</data>
      <data key="d3">GENE</data>
    </node>
    <node id="PTGS1">
      <data key="d0">GENE</data>
      <data key="d1">PTGS1 is a gene encoding the enzyme cyclooxygenase-1
PTGS1 is a gene encoding the Prostaglandin-Endoperoxide Synthase 1</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719,62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="PTGS2">
      <data key="d0">GENE</data>
      <data key="d1">PTGS2 is a gene encoding the enzyme cyclooxygenase-2
PTGS2 is a gene encoding the Prostaglandin-Endoperoxide Synthase 2</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719,62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="SLC6A4">
      <data key="d0">GENE</data>
      <data key="d1">SLC6A4 is a gene encoding the serotonin transporter</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
      <data key="d3">GENE</data>
    </node>
    <node id="CD4+ LYMPHOCYTES">
      <data key="d0">CELL</data>
      <data key="d1">CD4+ lymphocytes are a type of white blood cell that plays a significant role in the immune system
CD4+ lymphocytes are a type of white blood cell that plays a significant role in the immune system</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719,fa1f4687a5326fccd5d518845839e5f2</data>
      <data key="d3">CELL</data>
    </node>
    <node id="CD45+CD4+ T CELLS">
      <data key="d0">CELL</data>
      <data key="d1">CD45+CD4+ T cells are a subset of T cells involved in immune responses
CD45+CD4+ T cells are a subset of T cells responsible for IL-17 production</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719,fa1f4687a5326fccd5d518845839e5f2</data>
      <data key="d3">CELL</data>
    </node>
    <node id="CD11C+CD1A-CD14+ DENDRITIC CELLS">
      <data key="d0">CELL</data>
      <data key="d1">CD11c+CD1a-CD14+ dendritic cells are a type of dendritic cell involved in immune responses
CD11c+CD1a-CD14+ dendritic cells are the main producers of IL-1&#946; in lesional HS skin</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719,fa1f4687a5326fccd5d518845839e5f2</data>
      <data key="d3">CELL</data>
    </node>
    <node id="IL-1&#914;">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-1 beta (IL-1&#946;) is a pro-inflammatory cytokine produced by activated macrophagesIL-1&#946; is a pro-inflammatory cytokine produced by activated macrophages
IL-1&#946; is a pro-inflammatory cytokine produced by dendritic cells in HS
IL-1&#946; is a cytokine derived from keratinocytes and is involved in the inflammatory response in HS
IL-1&#946; is a pro-inflammatory cytokine
IL-1&#946; is a pro-inflammatory cytokine
IL-1&#946; is a cytokine involved in the immune response and inflammation
Interleukin-1 beta (IL-1&#946;) is a cytokine involved in inflammatory responses
Interleukin-1 beta (IL-1&#946;) is a cytokine involved in the inflammatory response
IL-1&#946; is a pro-inflammatory cytokine involved in immune responses</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,41ccc4b41bd57cf2bda4dbb6c7ae4198,4a1ab1e50481cdd86d237db424a95719,523bbfee1ae3b4ecabf9b11d10eea9ff,6aef5adb1be227170f66c76a292c25e5,b19f42c9497f71b231222cd953036d6b,b2aae16813e647959b783a39ef9a19a7,e340a83f7cba0ea5be731b1f682ea7c7,fa1f4687a5326fccd5d518845839e5f2</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="IL-17 CYTOKINE FAMILY">
      <data key="d0">PROTEIN</data>
      <data key="d1">The IL-17 cytokine family consists of cytokines involved in inflammatory responses</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="DEGS">
      <data key="d0">GENE</data>
      <data key="d1">Differentially expressed genes (DEGs) are genes that show significant differences in expression levels between different conditions or treatments
Differentially Expressed Genes, genes with altered expression in HS
Differentially expressed genes are genes that show different levels of expression in different conditions
Differentially expressed genes, which show significant changes in expression levels in HS</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606,4a1ab1e50481cdd86d237db424a95719,e340a83f7cba0ea5be731b1f682ea7c7,f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="EGFR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Epidermal growth factor receptor (EGFR) is a cell surface receptor that binds epidermal growth factor and is involved in the regulation of cell growth and differentiation
EGFR is a gene encoding the Epidermal Growth Factor Receptor
EGFR is a receptor involved in cell growth and differentiationEGFR is a gene encoding the epidermal growth factor receptor, involved in cell growth and differentiation</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719,62b4bd8f530adae989e4349d1e58f11d,c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="TLRS">
      <data key="d0">PROTEIN</data>
      <data key="d1">Toll-like receptors (TLRs) are a class of proteins that play a key role in the innate immune system
TLRs are proteins involved in the pathophysiology of AD</data>
      <data key="d2">286730b1c1f680ac465cc21d522fda0c,4a1ab1e50481cdd86d237db424a95719</data>
    </node>
    <node id="RESISTIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Resistin is a hormone secreted by adipose tissue that is involved in inflammation and insulin resistance
Resistin is a hormone that is believed to link obesity to diabetes</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="IFNG">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interferon-gamma (IFNG) is a cytokine that is critical for innate and adaptive immunity
IFNG is a gene associated with the IL-1 signaling pathway
IFNG encodes Interferon &#947;, involved in immune responses
IFNG is a gene encoding the Interferon Gamma
IFNG is a gene encoding the cytokine interferon-gamma, involved in immune response regulation
IFNG is a gene encoding for IFN-&#947; with increased mRNA expression in HS
IFNG encodes the cytokine IFN-&#947;
IFNG is a gene encoding the cytokine IFN-&#947;
IFNG is a gene encoding interferon-gamma, which contributes to the IFN response in HS</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b,4a1ab1e50481cdd86d237db424a95719,62b4bd8f530adae989e4349d1e58f11d,b62ecc47bf54393bc78dd65986b949d6,bae090d8a29c15868ba1c4f29ae79e99,c44ec79872ab10cbe7336182f183ff60,cdfcc39154accbac074c924676dc701e,e340a83f7cba0ea5be731b1f682ea7c7,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="CD4+ T CELLS">
      <data key="d0">CELL</data>
      <data key="d1">CD4+ T cells are a type of white blood cell that plays a significant role in the immune system
CD4+ T cells are a type of T cell that expresses OX40 and is involved in the immune response in Atopic Dermatitis
CD4+ T cells, a subset of T cells expressing OX40 in AD patients
CD4+ T cells are a subset of T cells that play a key role in the immune system
Na&#239;ve CD4+ T cells undergo expansion and differentiation during T cell receptor binding</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b,4a1ab1e50481cdd86d237db424a95719,691cb2e23ac3c6e591129d16714f8ef8,6b099960b0a39866e3aa6b908f1886e4,855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="CD11C+ DENDRITIC CELLS">
      <data key="d0">CELL</data>
      <data key="d1">CD11c+ dendritic cells are a type of dendritic cell involved in immune responses</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
    </node>
    <node id="EXTRANUCLEAR SIGNALING">
      <data key="d0">PATHWAY</data>
      <data key="d1">Extranuclear signaling involves signaling pathways that occur outside the cell nucleus</data>
      <data key="d2">4a1ab1e50481cdd86d237db424a95719</data>
    </node>
    <node id="TH17">
      <data key="d0">CELL</data>
      <data key="d1">Th17 cells are a subset of CD4+ T cells involved in autoimmune and inflammatory responses
Th17 cells are variably involved in the immune response in atopic dermatitis
Th17 cells are a subset of T-helper cells involved in the immune response
Th17 cells are a subset of T-cells involved in pro-inflammatory responses
Th17 cells are a type of T cell involved in the immune response
A subset of T helper cells involved in autoimmune and inflammatory responses
Th17 cells are a subset of T-helper cells involved in the immune response and associated with inflammation
T helper 17 cells are involved in immune responses and are implicated in atopic dermatitis
TH17 cells are a subset of T helper cells involved in the immune response
T helper 17 (TH17) cells are involved in the adaptive immune response in atopic dermatitis
Th17 cells are a subtype of T helper cells involved in the immune response and inflammation
Th17 cells are a type of T helper cell involved in allergic airway inflammation
Th17 cells are a subset of T helper cells involved in the immune response against extracellular bacteria and fungi
Th17 cells are a subset of T helper cells involved in the immune response, particularly in producing interleukin-17</data>
      <data key="d2">05c97152fe02249153103be341d65b67,143d2dc302af5606656797bff162e23e,1596d061dbe1a1c9e8f31a02a21e5524,1d0c4a4cd555b7ecd0b9d7b0310e9fe9,2e0cdefd62bed7c674d7fb93ef336c2b,41ccc4b41bd57cf2bda4dbb6c7ae4198,475995d7d211bbfde6d8ba52f324d688,48288f3ec2832850282f95d4e38d10e1,5ec1ebf4e260eb1f8fda8acdf06cd39e,5f37466ca41c9b8b06ed8be0303d49f2,83eb9003d42977bb83fea1d123dd5ab9,b876251511f570468eb5b6ee6a239cc6,e075bccd45593ae008b2ce7f9ed8ff6c,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="HUMAN &#914;-DEFENSIN 2">
      <data key="d0">PROTEIN</data>
      <data key="d1">Human &#946;-defensin 2 is an antimicrobial peptide whose expression is increased by IL-17</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="PSORIASIN (S100A7)">
      <data key="d0">PROTEIN</data>
      <data key="d1">Psoriasin (S100A7) is an antimicrobial peptide whose expression is increased by IL-17</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="CALPROTECTIN (S100A8/9)">
      <data key="d0">PROTEIN</data>
      <data key="d1">Calprotectin (S100A8/9) is an antimicrobial peptide whose expression is increased by IL-17</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="IL-1">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-1 is a cytokine involved in the inflammatory response and immune cell infiltration
IL-1 is a cytokine involved in inflammatory responses
Interleukin-1, a crucial cytokine for innate immunity and inflammation</data>
      <data key="d2">849e0980ffd6a7e1cf0b8d3d1fbacd98,c44ec79872ab10cbe7336182f183ff60,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="IL1R1">
      <data key="d0">GENE</data>
      <data key="d1">IL1R1 is a gene associated with the IL-1 signaling pathway
IL1R1 is a gene encoding interleukin 1 receptor type 1, involved in immune response</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="IL1RN">
      <data key="d0">GENE</data>
      <data key="d1">IL1RN is a gene associated with the IL-1 signaling pathway</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="IL18">
      <data key="d0">GENE</data>
      <data key="d1">IL18 is a gene associated with the IL-1 signaling pathway
Interleukin 18 is a pro-inflammatory cytokine involved in immune responses
IL18 is a cytokine that promotes IFN-&#947; production</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,bae090d8a29c15868ba1c4f29ae79e99,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="IL18R1">
      <data key="d0">GENE</data>
      <data key="d1">IL18R1 is a gene associated with the IL-1 signaling pathway</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="IL32">
      <data key="d0">GENE</data>
      <data key="d1">IL32 is a gene associated with the IL-1 signaling pathway
Interleukin 32 is a cytokine involved in inflammatory responses</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="IL33">
      <data key="d0">GENE</data>
      <data key="d1">IL33 is a gene associated with the IL-1 signaling pathway</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="IL36B">
      <data key="d0">GENE</data>
      <data key="d1">IL36B is a gene associated with the IL-1 signaling pathway
Interleukin 36&#946; is a cytokine involved in inflammatory responses</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="IL36RN">
      <data key="d0">GENE</data>
      <data key="d1">IL36RN is a gene associated with the IL-1 signaling pathway
IL36RN is a gene encoding interleukin 36 receptor antagonist, involved in immune response</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="IL37">
      <data key="d0">GENE</data>
      <data key="d1">IL37 is a gene associated with the IL-1 signaling pathway
Interleukin 37 is a cytokine involved in the regulation of immune responses</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="TLR2">
      <data key="d0">GENE</data>
      <data key="d1">TLR2 is a gene associated with the IL-1 signaling pathway</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="TLR3">
      <data key="d0">GENE</data>
      <data key="d1">TLR3 is a gene associated with the IL-1 signaling pathway</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="TLR4">
      <data key="d0">GENE</data>
      <data key="d1">TLR4 is a gene associated with the IL-1 signaling pathway</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="S100A7">
      <data key="d0">GENE</data>
      <data key="d1">S100A7 is a gene associated with the IL-1 signaling pathway
S100A7 is a gene encoding S100 Calcium-Binding Protein A7
S100A7 is an epidermal differentiation protein upregulated in atopic dermatitis lesions
S100A7 is a protein involved in skin inflammation</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b,baf4dec7fda8d8b8571a343b034f7092,f66eb51473925a8084dad1745be63b78,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="S100A7A">
      <data key="d0">GENE</data>
      <data key="d1">S100A7A is a gene associated with the IL-1 signaling pathway
S100A7A is a gene encoding S100 Calcium-Binding Protein A7A
S100A7A is a gene encoding S100 calcium binding protein A7A, involved in immune response
S100A7A encodes a protein involved in the immune response</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99,baf4dec7fda8d8b8571a343b034f7092,c44ec79872ab10cbe7336182f183ff60,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="S100A12">
      <data key="d0">GENE</data>
      <data key="d1">S100A12 is a gene associated with the IL-1 signaling pathway
S100A12 is a gene encoding S100 Calcium-Binding Protein A12
S100A12 is a protein involved in skin inflammation</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b,baf4dec7fda8d8b8571a343b034f7092,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="ADIPONECTIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Adiponectin is a protein hormone involved in regulating glucose levels and fatty acid breakdown, reduced in HS patientsAdiponectin is a protein hormone involved in regulating glucose levels and fatty acid breakdown</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="ADIPOQ">
      <data key="d0">GENE</data>
      <data key="d1">ADIPOQ is a gene that encodes adiponectin
Adiponectin, a gene downregulated in HS</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="PLIN1">
      <data key="d0">GENE</data>
      <data key="d1">PLIN1 is a gene associated with lipid metabolism
PLIN1 is a gene encoding Perilipin 1</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="PPAR&#915;">
      <data key="d0">PROTEIN</data>
      <data key="d1">PPAR&#947; is a protein that regulates the expression of genes involved in adipogenesis
Peroxisome Proliferator-Activated Receptor Gamma, a nuclear receptor targeted by PPAR&#947; ligands for HS treatment</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="THIAZOLIDINE DERIVATIVES">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Thiazolidine derivatives are compounds that act as PPAR&#947; agonists</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="IGF">
      <data key="d0">PROTEIN</data>
      <data key="d1">IGF is a protein involved in growth and development</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="IGF-BINDING PROTEINS">
      <data key="d0">PROTEIN</data>
      <data key="d1">IGF-binding proteins regulate the availability of IGF</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="LIPID">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Lipids are a group of naturally occurring molecules that include fats, waxes, and certain vitamins</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="C-TYPE LEPTIN RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">C-type leptin receptor is involved in regulating energy balance and body weight</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="INFLAMMATORY BOWEL DISEASES">
      <data key="d0">DISEASE</data>
      <data key="d1">Inflammatory bowel diseases are chronic inflammatory conditions of the gastrointestinal tract
Inflammatory Bowel Diseases are chronic inflammatory conditions of the gastrointestinal tract
Inflammatory bowel diseases are chronic inflammatory conditions of the gastrointestinal tract</data>
      <data key="d2">68015074236b0144899baa38d01ae467,c46e8b6ee0c29e37b7f18c42558d7a3e,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="CROHN&#8217;S DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">Crohn&#8217;s disease is a type of inflammatory bowel disease
Crohn&#8217;s disease is a type of inflammatory bowel disease that affects the gastrointestinal tract
Crohn&#8217;s disease is a chronic inflammatory bowel disease that affects the lining of the digestive tract
Crohn&#8217;s disease is a type of gastrointestinal tract fibrosis
Crohn&#8217;s disease is an inflammatory disease treated with TNF antagonists
Crohn&#8217;s disease is a type of inflammatory bowel disease that affects the gastrointestinal tract
Crohn&#8217;s disease is an inflammatory bowel disease that affects the lining of the digestive tractCrohn&#8217;s disease, a disease treated with TNF inhibitors</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,516e41e96d2e72d45bf1e2c69da7f18a,573fb6fa0673eb9462aa9862888079f3,5ec1ebf4e260eb1f8fda8acdf06cd39e,a10787d7fbb1307be263e86dc7b33a51,baf4dec7fda8d8b8571a343b034f7092,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="AXIAL SPONDYLARTHRITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Axial spondylarthritis is a type of arthritis that affects the spine and the sacroiliac joints</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="PACHYONYCHIA CONGENITA">
      <data key="d0">DISEASE</data>
      <data key="d1">Pachyonychia congenita is a genetic disorder characterized by thickened nails and other skin abnormalities
Pachyonychia congenita is a rare genetic disorder characterized by thickened nails and other skin abnormalities
Pachyonychia congenita is a genetic disorder characterized by thickened nails and skin</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,baf4dec7fda8d8b8571a343b034f7092,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="STEATOCYSTOMA MULTIPLEX">
      <data key="d0">DISEASE</data>
      <data key="d1">Steatocystoma multiplex is a genetic disorder characterized by multiple cysts in the skin</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="DOWLING-DEGOS DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">Dowling-Degos disease is a genetic disorder characterized by dark spots on the skin</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="KERATITIS&#8211;ICHTHYOSIS&#8211;DEAFNESS SYNDROME">
      <data key="d0">DISEASE</data>
      <data key="d1">Keratitis&#8211;ichthyosis&#8211;deafness syndrome is a genetic disorder characterized by eye problems, skin abnormalities, and hearing loss</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="DOWN SYNDROME">
      <data key="d0">DISEASE</data>
      <data key="d1">Down syndrome is a genetic disorder caused by the presence of an extra chromosome 21</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="NEUTROPHILS">
      <data key="d0">CELL</data>
      <data key="d1">Neutrophils are a type of white blood cell involved in the immune response and inflammation
Neutrophils are a type of white blood cell involved in the immune response and are prominent in HS skin
Neutrophils are a type of white blood cell involved in the immune response and are present in HS skin
Neutrophils are a type of white blood cell that are elevated in the skin of Atopic Dermatitis patients.
Neutrophils are a type of white blood cell involved in the body's immune response
Neutrophils are hyperactive inflammatory cells calmed down by methotrexate
Neutrophils are a type of cell that can express TNF
Neutrophils are a type of white blood cell that helps fight infection
Neutrophils are a type of white blood cell that are part of the innate immune system</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,27a7e95c7d3ad59a948aa46741fee456,286730b1c1f680ac465cc21d522fda0c,411a4d246f0a9321e52971446a5a0606,523bbfee1ae3b4ecabf9b11d10eea9ff,6ada075e562abd7bd445164e9fc309b4,7c13f41d7349d9d2e56c36e00c0ca2d9,d2c44662af9752fc9f82c86121ede7c0,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="IL-1 RECEPTOR ANTAGONIST">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-1 receptor antagonist is a protein that can reverse the effects of IL-1 signaling in HS</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="EPIDERMAL CELL">
      <data key="d0">CELL</data>
      <data key="d1">Epidermal cells are the outermost cells of the skin involved in barrier function</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="FOLLICULAR KERATINOCYTES">
      <data key="d0">CELL</data>
      <data key="d1">Follicular keratinocytes are specialized cells in hair follicles involved in HS lesions</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="SKIN GLANDS">
      <data key="d0">TISSUE</data>
      <data key="d1">Skin glands, including sebaceous and apocrine glands, are involved in HS pathology</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="SERPINS">
      <data key="d0">PROTEIN</data>
      <data key="d1">Serpins are a family of proteins involved in regulating protease activity, dysregulated in HS</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="SMALL PROLINE-RICH PROTEINS">
      <data key="d0">PROTEIN</data>
      <data key="d1">Small proline-rich proteins are involved in skin barrier function and are dysregulated in HS</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="KERATINS">
      <data key="d0">PROTEIN</data>
      <data key="d1">Keratins are structural proteins in the skin and hair, dysregulated in HS</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="FOLLICULAR INFUNDIBULUM">
      <data key="d0">TISSUE</data>
      <data key="d1">Follicular infundibulum is the upper part of the hair follicle involved in HS lesions</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="DUCTUS SEBOGLANDULARIS">
      <data key="d0">TISSUE</data>
      <data key="d1">Ductus seboglandularis is a duct in the skin associated with sebaceous glands, involved in HS</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="INSULIN RESISTANCE">
      <data key="d0">DISEASE</data>
      <data key="d1">Insulin resistance is a condition where cells fail to respond to insulin properly, associated with HS
Insulin resistance is a condition where cells fail to respond to the hormone insulin properly</data>
      <data key="d2">05c97152fe02249153103be341d65b67,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="EICOSANOIDS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Eicosanoids are signaling molecules involved in inflammation and immunity, function similarly to thiazolidine derivatives in HS</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="NON-STEROIDAL ANTI-INFLAMMATORY DRUGS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Non-steroidal anti-inflammatory drugs (NSAIDs) are medications that reduce inflammation and pain, function similarly to thiazolidine derivatives in HS</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="IGF-BINDING PROTEINS PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">IGF-binding proteins pathway regulates the availability of IGF, dysregulated in HS</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="LIPID METABOLISM">
      <data key="d0">PATHWAY</data>
      <data key="d1">Lipid metabolism involves the synthesis and degradation of lipids, dysregulated in HS</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="C-TYPE LEPTIN RECEPTOR SIGNALING">
      <data key="d0">PATHWAY</data>
      <data key="d1">C-type leptin receptor signaling is involved in regulating energy balance and body weight, dysregulated in HS</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="RETN SIGNALING">
      <data key="d0">PATHWAY</data>
      <data key="d1">RETN signaling encodes resistin, a hormone linking obesity to diabetes, dysregulated in HS</data>
      <data key="d2">fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="ADIPOCYTES">
      <data key="d0">CELL</data>
      <data key="d1">Adipocytes are fat cells involved in storing energy as fat, affected in HS
Adipocytes are cells specialized in storing fat</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="TNF-&#913;">
      <data key="d0">PROTEIN</data>
      <data key="d1">TNF-&#945; is a pro-inflammatory cytokine inhibited by adiponectin, involved in HS
TNF-&#945; is a cytokine involved in systemic inflammation
Tumor necrosis factor-alpha, involved in inflammation
Tumor Necrosis Factor-alpha (TNF-&#945;) is a cytokine involved in systemic inflammation
Tumor necrosis factor-alpha (TNF-&#945;) is a cytokine involved in systemic inflammation
TNF-&#945; is a protein involved in the pathophysiology of AD
TNF-&#945; is a proinflammatory cytokine involved in systemic inflammation</data>
      <data key="d2">286730b1c1f680ac465cc21d522fda0c,3dfbb4c51838e0951f53ce951395225f,6aef5adb1be227170f66c76a292c25e5,849e0980ffd6a7e1cf0b8d3d1fbacd98,9867d43adab0ba5db44961fae4863eee,c44ec79872ab10cbe7336182f183ff60,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="IL-6">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-6 is a pro-inflammatory cytokine inhibited by adiponectin, involved in HS
IL-6 is a cytokine involved in inflammatory responses
IL-6 is a cytokine derived from keratinocytes and is involved in the inflammatory response in HS
IL-6 is a cytokine involved in inflammation and immune response
IL-6 is a cytokine involved in the immune response and inflammation
Interleukin-6 (IL-6) is a cytokine involved in inflammation
Interleukin-6 (IL-6) is a pro-inflammatory cytokine whose levels are reduced by PLGA-based nanoparticles loaded with CsA
Interleukin-6 (IL-6) is a cytokine involved in inflammation and immune response
IL-6 is a proinflammatory cytokine involved in the immune response
IL-6 is a proinflammatory cytokine involved in immune responses
IL-6 is a cytokine involved in inflammation and immune response
IL-6 is a cytokine involved in inflammation and the maturation of B cells
IL-6 is a cytokine involved in inflammation and immune responses</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,41ccc4b41bd57cf2bda4dbb6c7ae4198,503107475d2e9dac49abd8ebcbadd9f5,523bbfee1ae3b4ecabf9b11d10eea9ff,5f37466ca41c9b8b06ed8be0303d49f2,6aef5adb1be227170f66c76a292c25e5,9867d43adab0ba5db44961fae4863eee,a10787d7fbb1307be263e86dc7b33a51,b2aae16813e647959b783a39ef9a19a7,bddc3b1a7f098e71f0aa64adec047124,c44ec79872ab10cbe7336182f183ff60,e340a83f7cba0ea5be731b1f682ea7c7,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="CHEMOKINES">
      <data key="d0">PROTEIN</data>
      <data key="d1">Chemokines are signaling proteins that attract immune cells, inhibited by adiponectin, involved in HS
Chemokines are a family of small cytokines that induce chemotaxis in nearby cells
Chemokines are signaling proteins that attract cells to sites of infection or inflammation</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198,4cf23e218b6aab3c77115173b5c7c2fd,fa1f4687a5326fccd5d518845839e5f2</data>
    </node>
    <node id="TYPE I DIABETES MELLITUS SIGNALING">
      <data key="d0">PATHWAY</data>
      <data key="d1">A signaling pathway associated with type I diabetes mellitus, linked to HS</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="LIPID AND ATHEROSCLEROSIS">
      <data key="d0">PATHWAY</data>
      <data key="d1">A pathway associated with lipid metabolism and atherosclerosis, linked to HS</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="ADIPOGENESIS SIGNALING">
      <data key="d0">PATHWAY</data>
      <data key="d1">A signaling pathway associated with adipogenesis, linked to HS</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="JAK-STAT INHIBITORS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A class of drugs that inhibit the JAK-STAT signaling pathway, proposed for HS treatment</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="PI3K INHIBITORS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A class of drugs that inhibit the PI3K pathway, proposed for HS treatment</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="MMP INHIBITORS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A class of drugs that inhibit matrix metalloproteinases, proposed for HS treatment</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="GENTAMICIN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">An antibiotic reported as a repurposing drug for HS</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="IBUDILAST">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A drug reported as a repurposing drug for HS</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="SPIRONOLACTONE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A drug reported as a repurposing drug for HS</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="TRASTUZUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A drug reported as a repurposing drug for HS
Trastuzumab is a monoclonal antibody used to treat breast cancer</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="THALIDOMIDE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A drug reported as a repurposing drug for HS
Thalidomide is a medication used to treat certain cancers and inflammatory conditions</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e,f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="APREMILAST">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A drug reported as a repurposing drug for HS
Apremilast is an oral PDE4 inhibitor approved for the treatment of moderate to severe psoriasis</data>
      <data key="d2">442e7fad2fab75fa2449309783294d89,f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="GLUCOSAMINE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A compound reported as a repurposing drug for HS
Glucosamine is a chemical used as a dietary supplement for joint health</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e,f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="INTERFERON-A-2B">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A drug reported as a repurposing drug for HS</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="BINIMETINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A drug reported as a repurposing drug for HS</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="MIDOSTAURIN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A drug reported as a repurposing drug for HS</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="TYROSINE KINASE RECEPTOR INHIBITORS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A class of drugs that inhibit tyrosine kinase receptors, proposed for HS treatment</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="TNF INHIBITORS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A class of drugs that inhibit tumor necrosis factor, proposed for HS treatment
TNF inhibitors are medications that suppress the physiologic response to tumor necrosis factor, used in the treatment of inflammatory diseasesTNF inhibitors are medications that suppress the physiologic response to tumor necrosis factor
TNF inhibitors are chemical agents used to treat various autoimmune and inflammatory diseases</data>
      <data key="d2">516e41e96d2e72d45bf1e2c69da7f18a,df74aa1b86eeeb811ca5586767ae3a71,f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="CYCLOOXYGENASE INHIBITORS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A class of drugs that inhibit cyclooxygenase, proposed for HS treatment</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="EGF RECEPTOR INHIBITORS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A class of drugs that inhibit epidermal growth factor receptors, proposed for HS treatment</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="PPAR&#915; LIGANDS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A class of drugs that act on peroxisome proliferator-activated receptor gamma, proposed for HS treatment</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="EPITHELIAL CELL DIFFERENTIATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">A dysregulated process in HS involving the differentiation of epithelial cells</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="OBESITY SIGNALING">
      <data key="d0">PATHWAY</data>
      <data key="d1">A signaling pathway involving hormone regulation, linked to HS</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="ADAM12">
      <data key="d0">GENE</data>
      <data key="d1">ADAM Metallopeptidase Domain 12, a gene upregulated in HS</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
      <data key="d3">GENE</data>
    </node>
    <node id="AR">
      <data key="d0">GENE</data>
      <data key="d1">Androgen Receptor, a gene upregulated in HS
AR is a gene encoding the Androgen Receptor
AR is a gene encoding androgen receptor, involved in the regulation of gene expressionAR is a receptor involved in the regulation of gene expression</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d,c44ec79872ab10cbe7336182f183ff60,f3b0f42501dbe75c224f7af44e0885f9</data>
      <data key="d3">GENE</data>
    </node>
    <node id="BTK">
      <data key="d0">GENE</data>
      <data key="d1">Betacellulin, a gene with diversified regulation in HS
Bruton&#8217;s tyrosine kinase is involved in B cell receptor signaling and is a potential therapeutic target in HS
Bruton's tyrosine kinase, a gene involved in B cell development and signaling
BTK is a protein involved in B cell signaling and is a potential therapeutic target in HS
BTK is a protein involved in B cell receptor signaling
Bruton's tyrosine kinase, a protein involved in B cell signaling
BTK, or Bruton tyrosine kinase, is a protein involved in the regulation of B cell development</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7,411a4d246f0a9321e52971446a5a0606,b62ecc47bf54393bc78dd65986b949d6,e340a83f7cba0ea5be731b1f682ea7c7,e4d25b1cd44df240a29591bc46a875ab,f14a13d54127c3baadeb0b34d40928c9,f3b0f42501dbe75c224f7af44e0885f9</data>
      <data key="d3">GENE</data>
    </node>
    <node id="C3">
      <data key="d0">GENE</data>
      <data key="d1">Complement C3, a gene with mixed regulation in HS
Complement component 3, a central protein in the complement system</data>
      <data key="d2">e4d25b1cd44df240a29591bc46a875ab,f3b0f42501dbe75c224f7af44e0885f9</data>
      <data key="d3">GENE</data>
    </node>
    <node id="C5AR1">
      <data key="d0">GENE</data>
      <data key="d1">Complement C5a Receptor 1, a gene upregulated in HS
C5AR1 is a gene encoding complement component 5a receptor 1, involved in immune response</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60,f3b0f42501dbe75c224f7af44e0885f9</data>
      <data key="d3">GENE</data>
    </node>
    <node id="CASP1">
      <data key="d0">GENE</data>
      <data key="d1">Caspase 1, a gene upregulated in HS
CASP1 encodes Caspase 1, an enzyme involved in the inflammatory process</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e,f3b0f42501dbe75c224f7af44e0885f9</data>
      <data key="d3">GENE</data>
    </node>
    <node id="CCL18">
      <data key="d0">GENE</data>
      <data key="d1">C-C Motif Chemokine Ligand 18, a gene upregulated in HS
CCL18 encodes C-C Motif Chemokine Ligand 18, involved in immune responses
CCL18 is a chemokine involved in immune cell recruitment
Chemokine ligand 18 (CCL18) is a chemokine involved in the immune response and inflammation
CCL18 is a chemokine ligand that ascends in the skin during inflammation and promotes the attraction of inflammatory T cells and DC subtypes</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198,6059a6e2710b7df94c6a09e5eb7b024a,b19f42c9497f71b231222cd953036d6b,cdfcc39154accbac074c924676dc701e,f3b0f42501dbe75c224f7af44e0885f9</data>
      <data key="d3">GENE</data>
    </node>
    <node id="CCL26">
      <data key="d0">GENE</data>
      <data key="d1">C-C Motif Chemokine Ligand 26, a gene upregulated in HS
CCL26 encodes C-C Motif Chemokine Ligand 26, involved in immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e,f3b0f42501dbe75c224f7af44e0885f9</data>
      <data key="d3">GENE</data>
    </node>
    <node id="CCR4">
      <data key="d0">GENE</data>
      <data key="d1">C-C Motif Chemokine Receptor 4, a gene upregulated in HS
CCR4 encodes C-C Motif Chemokine Receptor 4, involved in immune responses
CCR4 is a gene encoding the C-C Motif Chemokine Receptor 4
CCR4 is a gene involved in immune responses and is upregulated in HS skin and blood
CCR4 (CD194) is a receptor on memory TH2 cells that binds to chemokines and is involved in AD
CCR4 (C-C chemokine receptor type 4) is a protein involved in the immune response and inflammation
CCR4, or C-C chemokine receptor 4, is a protein involved in immune cell trafficking</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9,523bbfee1ae3b4ecabf9b11d10eea9ff,62b4bd8f530adae989e4349d1e58f11d,cdfcc39154accbac074c924676dc701e,e9841b88c9fab58c5175af409653da50,f14a13d54127c3baadeb0b34d40928c9,f3b0f42501dbe75c224f7af44e0885f9</data>
      <data key="d3">GENE</data>
    </node>
    <node id="KEGG GO">
      <data key="d0">PATHWAY</data>
      <data key="d1">A database used for pathway analysis in HS studies</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="RECEPTOR INTERACTION PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">A pathway involved in HS, with genes showing diversified regulation</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="JAK INHIBITORS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A class of drugs that inhibit Janus kinases, proposed for HS treatment
JAK inhibitors are small molecules used to treat atopic dermatitis by inhibiting Janus kinase enzymes
JAK inhibitors are compounds that block the signal transduction pathways of multiple cytokine receptors
JAK inhibitors are used to treat ADJAK inhibitors are used in systemic therapy for AD
JAK inhibitors are small molecule drugs that inhibit Janus kinases, used in the treatment of autoimmune diseases like rheumatoid arthritis and AD</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd,c46e8b6ee0c29e37b7f18c42558d7a3e,dc905ba8b6eb7d84cf2776303211010d,e30574e513dd250992d637d808759c34,f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="CYTOKINE INHIBITORS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A class of drugs that inhibit cytokines, proposed for HS treatment</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="TYROSINE KINASE INHIBITORS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A class of drugs that inhibit tyrosine kinases, proposed for HS treatment</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="TNF">
      <data key="d0">PROTEIN</data>
      <data key="d1">Tumor Necrosis Factor, a cytokine involved in systemic inflammation, targeted by TNF inhibitors for HS treatment
TNF is a gene encoding the Tumor Necrosis Factor
TNF is a gene encoding tumor necrosis factor, involved in systemic inflammation
TNF is a cytokine involved in systemic inflammation and is implicated in the inflammatory responses in HS
TNF is a cytokine with no significant response in HS lesional skin
TNF is a cytokine involved in systemic inflammation
Tumor necrosis factor is an inflammatory mediator prominently colocalized with plasma cells in HS
Tumor necrosis factor is a cytokine involved in systemic inflammation
Tumor necrosis factor (TNF) is a cytokine involved in systemic inflammation and is a target for biologic treatment in HS
TNF is a cytokine involved in systemic inflammation and immune system regulation
Tumor Necrosis Factor, a cytokine involved in systemic inflammation and stimulation of the acute phase reaction
Tumor necrosis factor, a cytokine involved in systemic inflammation
TNF is a proinflammatory cytokine involved in the immune response
Tumor necrosis factor, a cytokine involved in T helper cell responses
Tumor necrosis factor (TNF), also known as TNF&#945; or TNFSF2, is a pleiotropic cytokine involved in inflammation and fibrosis
Tumor necrosis factor (TNF) is involved in fibrotic disease progression and resolution
TNF is a cytokine involved in systemic inflammation and is part of the body's immune response
Tumor necrosis factor, a cytokine involved in systemic inflammationTumor necrosis factor, a cytokine involved in systemic inflammation and stimulation of the acute phase reaction
TNF, also known as TNF&#945;, is a cytokine involved in systemic inflammation
</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,1412a7a7fef5f18cc09a030b97b18e13,2a0384addc6e7fd709e0508b83496cd7,2e0cdefd62bed7c674d7fb93ef336c2b,411a4d246f0a9321e52971446a5a0606,503107475d2e9dac49abd8ebcbadd9f5,523bbfee1ae3b4ecabf9b11d10eea9ff,5ec1ebf4e260eb1f8fda8acdf06cd39e,62b4bd8f530adae989e4349d1e58f11d,7f559ad7372a4e35e90b43cc67047b0f,855c455b4c9592746834ee3a4e0e6b81,a10787d7fbb1307be263e86dc7b33a51,b62ecc47bf54393bc78dd65986b949d6,bae090d8a29c15868ba1c4f29ae79e99,c44ec79872ab10cbe7336182f183ff60,c95d22c2a90e77cd22bd0d280d55b26a,df74aa1b86eeeb811ca5586767ae3a71,e340a83f7cba0ea5be731b1f682ea7c7,e4d25b1cd44df240a29591bc46a875ab,f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="CYCLOOXYGENASE">
      <data key="d0">PROTEIN</data>
      <data key="d1">An enzyme responsible for the formation of prostanoids, targeted by cyclooxygenase inhibitors for HS treatment</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="EGF RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Epidermal Growth Factor Receptor, a protein targeted by EGF receptor inhibitors for HS treatment</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="EPITHELIAL CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Cells that line the surfaces of the body, involved in dysregulated differentiation in HS
Epithelial cells are involved in the process of fibrosis
Epithelial cells line the surfaces of organs and structures throughout the body
Epithelial cells form the lining of surfaces and cavities in the body, playing roles in protection, secretion, and absorption
Epithelial cells line the surfaces of organs and structures in the body
Epithelial cells are structural cells that LIGHT can act upon</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,516e41e96d2e72d45bf1e2c69da7f18a,5f37466ca41c9b8b06ed8be0303d49f2,68015074236b0144899baa38d01ae467,df74aa1b86eeeb811ca5586767ae3a71,f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="HORMONES">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Signaling molecules involved in obesity signaling, linked to HS</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="KEGG">
      <data key="d0">PATHWAY</data>
      <data key="d1">Kyoto Encyclopedia of Genes and Genomes, a database used for pathway analysis in HS studies
Kyoto Encyclopedia of Genes and Genomes, a collection of databases dealing with genomes, biological pathways, diseases, drugs, and chemical substances</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="GO">
      <data key="d0">PATHWAY</data>
      <data key="d1">Gene Ontology, a database used for pathway analysis in HS studies</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="RECEPTOR INTERACTION">
      <data key="d0">PATHWAY</data>
      <data key="d1">A pathway involved in HS, with genes showing diversified regulation</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="IL-17 SIGNALING">
      <data key="d0">PATHWAY</data>
      <data key="d1">A pathway involved in HS, with genes showing diversified regulation</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="JAK-STAT SIGNALING">
      <data key="d0">PATHWAY</data>
      <data key="d1">A pathway involved in HS, with genes showing diversified regulation</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="TRANSCRIPTOMIC PROFILES">
      <data key="d0">PATHWAY</data>
      <data key="d1">Profiles of gene expression used to study HS</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="PROTEIN EXPRESSION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Profiles of protein levels used to study HS</data>
      <data key="d2">f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="LESIONAL SKIN">
      <data key="d0">TISSUE</data>
      <data key="d1">Skin areas affected by HS
Lesional skin is skin affected by lesions</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b,f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="NON-LESIONAL SKIN">
      <data key="d0">TISSUE</data>
      <data key="d1">Skin areas not affected by HS
Non-lesional skin refers to areas of skin not visibly affected by atopic dermatitis but still showing molecular abnormalities
Non-lesional skin is skin not affected by lesions</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b,f3b0f42501dbe75c224f7af44e0885f9,f66eb51473925a8084dad1745be63b78</data>
    </node>
    <node id="HEALTHY CONTROLS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Individuals without HS used as a comparison group in studies

Healthy controls are individuals without atopic dermatitis, used for comparison in studies</data>
      <data key="d2">348f2797841cbef27311b03f2cd788dd,691cb2e23ac3c6e591129d16714f8ef8,f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="BIOMARKERS">
      <data key="d0">GENE</data>
      <data key="d1">Genes or proteins used as indicators of HS
Biological markers that can help clarify AD diagnosis and assess disease severity
Biomarkers are measurable indicators of some biological state or condition, often used in clinical studies</data>
      <data key="d2">100dd7646c10899301b3c0631183da16,e95d4d15e4f3110c91a3d3fcb5910d06,f3b0f42501dbe75c224f7af44e0885f9</data>
    </node>
    <node id="CASPASE 1">
      <data key="d0">PROTEIN</data>
      <data key="d1">Caspase 1 is an enzyme that plays a role in the inflammatory process</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="SCHNITZLER SYNDROME">
      <data key="d0">DISEASE</data>
      <data key="d1">Schnitzler syndrome is a rare autoinflammatory disorder</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="FAMILIAL MEDITERRANEAN FEVER">
      <data key="d0">DISEASE</data>
      <data key="d1">Familial Mediterranean fever is an inherited inflammatory disorder</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="MINOCYCLINE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Minocycline is an antibiotic used to treat various infections
Minocycline is an antibiotic used to treat bacterial infections</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="C-C MOTIF CHEMOKINE LIGAND 18">
      <data key="d0">PROTEIN</data>
      <data key="d1">C-C Motif Chemokine Ligand 18 is involved in immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="ECZEMA">
      <data key="d0">DISEASE</data>
      <data key="d1">Eczema is a condition that makes the skin red and itchy
Eczema, also known as atopic dermatitis, is a chronic inflammatory skin disease characterized by itchy and inflamed skin
Eczema is a condition characterized by inflamed, itchy, and red skin
Eczema is a group of conditions that cause the skin to become inflamed or irritated
Eczema is another term for Atopic Dermatitis, an autoimmune skin disease.
Eczema is a skin condition that can be treated using nanotechnology
Eczema is a chronic inflammatory skin condition characterized by itchy and inflamed skin
Eczema is a skin condition caused by immune system cells in the skin
Eczema is a symptom of Atopic Dermatitis characterized by inflamed, itchy, cracked, and rough skin
Eczema is a condition that makes the skin red, inflamed, and itchy, often associated with AD</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,27a7e95c7d3ad59a948aa46741fee456,286730b1c1f680ac465cc21d522fda0c,442e7fad2fab75fa2449309783294d89,691cb2e23ac3c6e591129d16714f8ef8,6ada075e562abd7bd445164e9fc309b4,8246ea974dfb00cb5e3d984004e21a9e,89dbac0da39e4de2b602052cd792b90d,cdfcc39154accbac074c924676dc701e,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </node>
    <node id="C-C MOTIF CHEMOKINE LIGAND 26">
      <data key="d0">PROTEIN</data>
      <data key="d1">C-C Motif Chemokine Ligand 26 is involved in immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="C-C MOTIF CHEMOKINE RECEPTOR 4">
      <data key="d0">PROTEIN</data>
      <data key="d1">C-C Motif Chemokine Receptor 4 is involved in immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="MYCOSIS FUNGOIDES">
      <data key="d0">DISEASE</data>
      <data key="d1">Mycosis fungoides is a type of cutaneous T cell lymphoma</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="CUTANEOUS T CELL LYMPHOMA">
      <data key="d0">DISEASE</data>
      <data key="d1">Cutaneous T cell lymphoma is a type of cancer that begins in T cells</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="ALLERGIC CONTACT DERMATITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Allergic contact dermatitis is a form of eczema caused by an allergic reaction
Allergic contact dermatitis is a form of eczema triggered by contact with an allergen</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="CD80">
      <data key="d0">GENE</data>
      <data key="d1">CD80 encodes CD80 Molecule, involved in T cell activation
CD80 is a co-stimulatory molecule involved in T-cell activation
CD80 is a protein that binds to CD28 to provide a costimulatory signal for T-cell activation
CD80 is a protein that binds to CTLA-4 and CD28, involved in T cell activation
CD80 is a protein that interacts with CD28 to provide costimulatory signals for T-cell activation
CD80 is involved in positive costimulatory pathways
CD80 is a protein involved in T cell activation, also known as B7-1</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b,4842292208575bd45b2b5998513dd087,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,855c455b4c9592746834ee3a4e0e6b81,9867d43adab0ba5db44961fae4863eee,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="CD80 MOLECULE">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD80 Molecule is involved in T cell activation</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="ABATACEPT">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Abatacept is a medication used to treat autoimmune diseases
Abatacept (CTLA-4-Ig) is a drug used to block T-cell costimulation
Abatacept is a recombinant fusion protein used for the treatment of rheumatoid arthritis
Abatacept is a drug that induced clinical improvement in SSc patients, particularly effective on inflammatory joint involvement
Abatacept is a targeted immunotherapy used in the treatment of autoimmune diseases</data>
      <data key="d2">4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,855c455b4c9592746834ee3a4e0e6b81,9867d43adab0ba5db44961fae4863eee,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="BELATACEPT">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Belatacept is a medication used to prevent organ rejection</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="CHI3L1">
      <data key="d0">GENE</data>
      <data key="d1">CHI3L1 encodes Chitinase 3-Like 1, involved in inflammation and tissue remodeling</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="CHITINASE 3-LIKE 1">
      <data key="d0">PROTEIN</data>
      <data key="d1">Chitinase 3-Like 1 is involved in inflammation and tissue remodeling</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="ERYSIPELAS">
      <data key="d0">DISEASE</data>
      <data key="d1">Erysipelas is a bacterial infection of the skin
Erysipelas is a bacterial infection of the skin's outer layers</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="CSF1">
      <data key="d0">GENE</data>
      <data key="d1">CSF1 encodes Colony-Stimulating Factor 1, involved in the production of white blood cells</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="COLONY-STIMULATING FACTOR 1">
      <data key="d0">PROTEIN</data>
      <data key="d1">Colony-Stimulating Factor 1 is involved in the production of white blood cells</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="CXCL1">
      <data key="d0">GENE</data>
      <data key="d1">CXCL1 encodes C-X-C Motif Chemokine Ligand 1, involved in immune responses
CXCL1 is a neutrophil chemokine gene with a 2.8-fold increased expression in the study
CXCL1 is a chemokine involved in immune cell recruitment</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b,b19f42c9497f71b231222cd953036d6b,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="C-X-C MOTIF CHEMOKINE LIGAND 1">
      <data key="d0">PROTEIN</data>
      <data key="d1">C-X-C Motif Chemokine Ligand 1 is involved in immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="KAPOSI SARCOMA">
      <data key="d0">DISEASE</data>
      <data key="d1">Kaposi sarcoma is a type of cancer that forms in the lining of blood and lymph vessels
Kaposi sarcoma is a type of cancer that forms in the lining of blood and lymph vessels
Kaposi sarcoma is a type of cancer that forms in the lining of blood and lymph vessels</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d,baf4dec7fda8d8b8571a343b034f7092,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="FORMIC ACID">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Formic acid is a chemical used in various industrial processes</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="CXCL8">
      <data key="d0">GENE</data>
      <data key="d1">CXCL8 encodes C-X-C Motif Chemokine Ligand 8, involved in immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="C-X-C MOTIF CHEMOKINE LIGAND 8">
      <data key="d0">PROTEIN</data>
      <data key="d1">C-X-C Motif Chemokine Ligand 8 is involved in immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="MELANOMA">
      <data key="d0">DISEASE</data>
      <data key="d1">Melanoma is a type of skin cancer
Melanoma is a type of skin cancer that develops from melanocytes
A type of skin cancer treated with pembrolizumab</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,855c455b4c9592746834ee3a4e0e6b81,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="SIMVASTATIN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Simvastatin is a medication used to control high cholesterol
Simvastatin is a medication used to control high cholesterol</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="C-X-C MOTIF CHEMOKINE LIGAND 10">
      <data key="d0">PROTEIN</data>
      <data key="d1">C-X-C Motif Chemokine Ligand 10 is involved in immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="ELDELUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Eldelumab is a medication used to treat autoimmune diseases</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="CXCL13">
      <data key="d0">GENE</data>
      <data key="d1">CXCL13 encodes C-X-C Motif Chemokine Ligand 13, involved in immune responses
CXCL13 is a B cell chemoattractant gene that is upregulated in HS skin
CXCL13 is a B cell chemoattractant gene with a 16-fold increased expression in the study</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b,523bbfee1ae3b4ecabf9b11d10eea9ff,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="C-X-C MOTIF CHEMOKINE LIGAND 13">
      <data key="d0">PROTEIN</data>
      <data key="d1">C-X-C Motif Chemokine Ligand 13 is involved in immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="T CELL LYMPHOMA">
      <data key="d0">DISEASE</data>
      <data key="d1">T cell lymphoma is a type of cancer that begins in T cells</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="CXCR5">
      <data key="d0">GENE</data>
      <data key="d1">CXCR5 encodes C-X-C Motif Chemokine Receptor 5, involved in immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="C-X-C MOTIF CHEMOKINE RECEPTOR 5">
      <data key="d0">PROTEIN</data>
      <data key="d1">C-X-C Motif Chemokine Receptor 5 is involved in immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="DCD">
      <data key="d0">GENE</data>
      <data key="d1">DCD encodes Dermcidin, an antimicrobial peptide</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="DERMCIDIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Dermcidin is an antimicrobial peptide
Dermcidin is an antimicrobial peptide involved in the immune response</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="NETHERTON SYNDROME">
      <data key="d0">DISEASE</data>
      <data key="d1">Netherton syndrome is a genetic disorder affecting the skin, hair, and immune system</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="TINEA PEDIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Tinea pedis is a fungal infection of the foot</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="BASILIXIMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Basiliximab is a medication used to prevent organ rejection</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="ZINC SULFATE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Zinc sulfate is a chemical used as a dietary supplement</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="DEFB4A">
      <data key="d0">GENE</data>
      <data key="d1">DEFB4A encodes Defensin &#946; 4A, an antimicrobial peptide
DEFB4A is an antimicrobial gene that is upregulated in HS skin
DEFB4A is an antimicrobial gene with a 24-fold increased expression in the study
DEFB4A encodes a defensin, an antimicrobial peptide</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b,523bbfee1ae3b4ecabf9b11d10eea9ff,bae090d8a29c15868ba1c4f29ae79e99,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="DEFENSIN &#914; 4A">
      <data key="d0">PROTEIN</data>
      <data key="d1">Defensin &#946; 4A is an antimicrobial peptide</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="TINEA CORPORIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Tinea corporis is a fungal infection of the skin</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="ORAL CANDIDIASIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Oral candidiasis is a fungal infection in the mouth</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="DEFB103B">
      <data key="d0">GENE</data>
      <data key="d1">DEFB103B encodes Defensin &#946; 103B, an antimicrobial peptide</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="DEFENSIN &#914; 103B">
      <data key="d0">PROTEIN</data>
      <data key="d1">Defensin &#946; 103B is an antimicrobial peptide</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="EGF">
      <data key="d0">GENE</data>
      <data key="d1">EGF encodes Epidermal Growth Factor, involved in cell growth and differentiation</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="EPIDERMAL GROWTH FACTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Epidermal Growth Factor is involved in cell growth and differentiation</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="CETUXIMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Cetuximab is a medication used to treat certain types of cancer</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="AG 490">
      <data key="d0">CHEMICAL</data>
      <data key="d1">AG 490 is a chemical used in research to inhibit certain signaling pathways</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="CGP 52411">
      <data key="d0">CHEMICAL</data>
      <data key="d1">CGP 52411 is a chemical used in research to inhibit certain signaling pathways</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="GENISTEIN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Genistein is a chemical found in soy products with various biological activities</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="ZANUBRUTINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Zanubrutinib is a medication used to treat certain types of cancer
Zanubrutinib is a JAK3/ITR/EGFR inhibitor</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="EPGN">
      <data key="d0">GENE</data>
      <data key="d1">EPGN encodes Epithelial Mitogen, involved in cell growth and differentiation</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="EPITHELIAL MITOGEN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Epithelial Mitogen is involved in cell growth and differentiation</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="SEBORRHEIC DERMATITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Seborrheic dermatitis is a common skin condition that causes scaly patches and red skin</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="ERBB4">
      <data key="d0">GENE</data>
      <data key="d1">ERBB4 encodes Erb-B2 Receptor Tyrosine Kinase 4, involved in cell signaling</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="ERB-B2 RECEPTOR TYROSINE KINASE 4">
      <data key="d0">PROTEIN</data>
      <data key="d1">Erb-B2 Receptor Tyrosine Kinase 4 is involved in cell signaling</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="GEFITINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Gefitinib is a medication used to treat certain types of cancer</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="AFATINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Afatinib is a medication used to treat certain types of cancer</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="FOSTAMATINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Fostamatinib is a medication used to treat certain autoimmune diseases
Fostamatinib is a SYK inhibitor used as a potential therapeutic in HS
Fostamatinib is a SYK inhibitor used in the treatment of autoimmune diseases
Fostamatinib is a SYK inhibitor used in the treatment of HS
Fostamatinib is a SYK inhibitor used in the treatment of certain autoimmune diseases</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606,b62ecc47bf54393bc78dd65986b949d6,cdfcc39154accbac074c924676dc701e,e340a83f7cba0ea5be731b1f682ea7c7,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="GAS6">
      <data key="d0">GENE</data>
      <data key="d1">GAS6 encodes Growth Arrest Specific 6, involved in cell growth and survival</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="GROWTH ARREST SPECIFIC 6">
      <data key="d0">PROTEIN</data>
      <data key="d1">Growth Arrest Specific 6 is involved in cell growth and survival</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="LUPUS ERYTHEMATOSUS">
      <data key="d0">DISEASE</data>
      <data key="d1">Lupus erythematosus is an autoimmune disease that affects various parts of the body</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="GDNF">
      <data key="d0">GENE</data>
      <data key="d1">GDNF encodes Glial Cell Derived Neurotrophic Factor, involved in the survival of neurons</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="GLIAL CELL DERIVED NEUROTROPHIC FACTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Glial Cell Derived Neurotrophic Factor is involved in the survival of neurons</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="CHONDROITIN SULPHATE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Chondroitin sulphate is a chemical used as a dietary supplement for joint health</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="GJB2">
      <data key="d0">GENE</data>
      <data key="d1">GJB2 encodes Gap Junction Protein &#946;2, involved in cell communication</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="GAP JUNCTION PROTEIN &#914;2">
      <data key="d0">PROTEIN</data>
      <data key="d1">Gap Junction Protein &#946;2 is involved in cell communication</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="KERATITIS-ICHTHYOSIS-DEAFNESS SYNDROME">
      <data key="d0">DISEASE</data>
      <data key="d1">Keratitis-Ichthyosis-Deafness Syndrome is a genetic disorder affecting the skin, eyes, and hearing</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="CARBENOXOLONE DISODIUM">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Carbenoxolone disodium is a medication used to treat ulcers and inflammation</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="HBEGF">
      <data key="d0">GENE</data>
      <data key="d1">HBEGF encodes Heparin Binding EGF-Like Growth Factor, involved in cell growth and differentiation</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="HEPARIN BINDING EGF-LIKE GROWTH FACTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Heparin Binding EGF-Like Growth Factor is involved in cell growth and differentiation</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="HGF">
      <data key="d0">GENE</data>
      <data key="d1">HGF encodes Hepatocyte Growth Factor, involved in cell growth and differentiation</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="HEPATOCYTE GROWTH FACTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Hepatocyte Growth Factor is involved in cell growth and differentiation</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="DEXAMETHASONE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Dexamethasone is a medication used to treat inflammation and autoimmune diseases
Dexamethasone is a corticosteroid medication used to treat inflammation</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="NERATINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Neratinib is a medication used to treat certain types of cancer</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="ERLOTINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Erlotinib is a medication used to treat certain types of cancer</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="HRG">
      <data key="d0">GENE</data>
      <data key="d1">HRG encodes Histidine-Rich Glycoprotein, involved in immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="HISTIDINE-RICH GLYCOPROTEIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Histidine-Rich Glycoprotein is involved in immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="IFNA1">
      <data key="d0">GENE</data>
      <data key="d1">IFNA1 encodes Interferon &#945;1, involved in antiviral responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="INTERFERON &#913;1">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interferon &#945;1 is involved in antiviral responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="CRYOBLOBULINEMIA">
      <data key="d0">DISEASE</data>
      <data key="d1">Cryoblobulinemia is a condition where abnormal proteins in the blood thicken in cold temperatures</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="INTERFERON &#915;">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interferon &#947; is involved in immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="OKSALAZINE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Oksalazine is a medication used to treat inflammatory bowel disease</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="EMAPALUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Emapalumab is a medication used to treat certain autoimmune diseases</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="IGF2">
      <data key="d0">GENE</data>
      <data key="d1">IGF2 encodes Insulin-Like Growth Factor 2, involved in growth and development</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="INSULIN-LIKE GROWTH FACTOR 2">
      <data key="d0">PROTEIN</data>
      <data key="d1">Insulin-Like Growth Factor 2 is involved in growth and development</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="IGHD">
      <data key="d0">GENE</data>
      <data key="d1">IGHD encodes Immunoglobulin Heavy Constant &#948;, involved in immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="IMMUNOGLOBULIN HEAVY CONSTANT &#916;">
      <data key="d0">PROTEIN</data>
      <data key="d1">Immunoglobulin Heavy Constant &#948; is involved in immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="IGHG3">
      <data key="d0">GENE</data>
      <data key="d1">IGHG3 encodes Immunoglobulin Heavy Constant &#947;3, involved in immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="IMMUNOGLOBULIN HEAVY CONSTANT &#915;3">
      <data key="d0">PROTEIN</data>
      <data key="d1">Immunoglobulin Heavy Constant &#947;3 is involved in immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="IGKV1D-13">
      <data key="d0">GENE</data>
      <data key="d1">IGKV1D-13 encodes Immunoglobulin &#954; Variable 1D-13, involved in immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="IMMUNOGLOBULIN &#922; VARIABLE 1D-13">
      <data key="d0">PROTEIN</data>
      <data key="d1">Immunoglobulin &#954; Variable 1D-13 is involved in immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="IGLV">
      <data key="d0">GENE</data>
      <data key="d1">IGLV encodes Immunoglobulin &#955; Variable Cluster, involved in immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="IMMUNOGLOBULIN &#923; VARIABLE CLUSTER">
      <data key="d0">PROTEIN</data>
      <data key="d1">Immunoglobulin &#955; Variable Cluster is involved in immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="IL1A">
      <data key="d0">GENE</data>
      <data key="d1">IL1A encodes Interleukin 1&#945;, involved in inflammatory responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="INTERLEUKIN 1&#913;">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin 1&#945; is involved in inflammatory responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="ACNE">
      <data key="d0">DISEASE</data>
      <data key="d1">Acne is a skin condition that occurs when hair follicles are clogged with oil and dead skin cells
Acne is a skin condition characterized by inflamed or infected sebaceous glands
Acne is a skin condition characterized by red pimples, often on the face</data>
      <data key="d2">a867a1e73cef039eb3f28e072463b838,c46e8b6ee0c29e37b7f18c42558d7a3e,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="IRRITANT DERMATITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Irritant dermatitis is a form of eczema caused by direct contact with an irritating substance</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="ANAKINRA">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Anakinra is a medication used to treat rheumatoid arthritis
Anakinra is an IL-1 receptor antagonist targeting IL1R1, used in the treatment of rheumatoid arthritis</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="RINOLACEPT">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Rinolacept is a medication used to treat certain inflammatory conditions</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="OLANZAPINE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Olanzapine is a medication used to treat mental health conditions</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="PIRFENIDONE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Pirfenidone is a medication used to treat idiopathic pulmonary fibrosis</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="AMG-108">
      <data key="d0">CHEMICAL</data>
      <data key="d1">AMG-108 is a medication used in research to inhibit certain signaling pathways</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="IL1B">
      <data key="d0">GENE</data>
      <data key="d1">IL1B encodes Interleukin 1&#946;, involved in inflammatory responsesInterleukin 1&#946; is involved in inflammatory responses
IL1B is a gene encoding the Interleukin 1 Beta</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d,cdfcc39154accbac074c924676dc701e</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="GINGIVITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Gingivitis is a common form of gum disease</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="MUCKLE&#8211;WELLS SYNDROME">
      <data key="d0">DISEASE</data>
      <data key="d1">Muckle&#8211;Wells syndrome is a rare autoinflammatory disorder</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="TOXIC SHOCK SYNDROME">
      <data key="d0">DISEASE</data>
      <data key="d1">Toxic shock syndrome is a rare, life-threatening complication of certain bacterial infections</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="CANAKIZUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Canakizumab is a medication used to treat certain inflammatory conditions</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="IL2">
      <data key="d0">GENE</data>
      <data key="d1">IL2 encodes Interleukin 2, involved in the regulation of white blood cells</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="INTERLEUKIN 2">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin 2 is involved in the regulation of white blood cells</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="GRAFT-VERSUS-HOST DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">Graft-versus-host disease is a condition that occurs when donor bone marrow or stem cells attack the recipient
Graft-versus-host disease is a condition that occurs when donor bone marrow or stem cells attack the recipient</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="LEPROSY">
      <data key="d0">DISEASE</data>
      <data key="d1">Leprosy is a chronic infectious disease caused by Mycobacterium leprae</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="SUPLATAST TOSYLATE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Suplatast tosylate is a medication used to treat allergic conditions
Suplatast tosylate is an anti-allergic drug</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="DACLIZUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Daclizumab is a medication used to prevent organ rejection</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="RITUXIMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Rituximab is a medication used to treat certain autoimmune diseases and cancers
Rituximab is an anti-CD20 agent used to target B cells in HS and other immune disorders
Rituximab is a traditional biologic not recommended for treating AD
Rituximab is a monoclonal antibody used to treat autoimmune diseases and certain types of cancer
Rituximab is a monoclonal antibody used to treat autoimmune diseases by targeting CD20 on B cells</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3,423195c6b63ad0a6773374364ebf3612,8246ea974dfb00cb5e3d984004e21a9e,b62ecc47bf54393bc78dd65986b949d6,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="CAFAZOLIN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Cafazolin is an antibiotic used to treat bacterial infections</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="IL2RA">
      <data key="d0">GENE</data>
      <data key="d1">IL2RA encodes Interleukin 2 Receptor Subunit &#945;, involved in the regulation of white blood cells</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="INTERLEUKIN 2 RECEPTOR SUBUNIT &#913;">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin 2 Receptor Subunit &#945; is involved in the regulation of white blood cells</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="TYPE 1 DIABETES MELLITUS">
      <data key="d0">DISEASE</data>
      <data key="d1">Type 1 diabetes mellitus is a chronic condition in which the pancreas produces little or no insulin</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="JUVENILE ARTHRITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Juvenile arthritis is a type of arthritis that occurs in children</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="IL4">
      <data key="d0">GENE</data>
      <data key="d1">IL4 encodes Interleukin 4, involved in the regulation of immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="INTERLEUKIN 4">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin 4 is involved in the regulation of immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="ATOPY">
      <data key="d0">DISEASE</data>
      <data key="d1">Atopy is a genetic tendency to develop allergic diseases</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="ALLERGIC RHINITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Allergic rhinitis is an allergic reaction that causes sneezing, congestion, and a runny nose
Allergic rhinitis is an allergic reaction that causes sneezing, congestion, and a runny nose
Allergic rhinitis is an allergic reaction that causes sneezing, congestion, and runny nose
Allergic Rhinitis is a condition that children with Atopic Dermatitis may develop.
Allergic Rhinitis is an allergic reaction causing sneezing, congestion, and runny nose, associated with Atopic Dermatitis
Allergic rhinitis is an allergic reaction causing sneezing, congestion, and runny nose</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,573fb6fa0673eb9462aa9862888079f3,691cb2e23ac3c6e591129d16714f8ef8,6ada075e562abd7bd445164e9fc309b4,89dbac0da39e4de2b602052cd792b90d,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="FOOD ALLERGY">
      <data key="d0">DISEASE</data>
      <data key="d1">Food allergy is an immune system reaction that occurs soon after eating a certain food
Food allergy is an atopic disorder that can be a comorbidity of AD
Food allergy is an immune system reaction that occurs soon after eating a certain food</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b,1596d061dbe1a1c9e8f31a02a21e5524,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="DUPILUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Dupilumab is a medication used to treat certain inflammatory conditions
Dupilumab is a receptor antagonist used in the treatment of various autoimmune diseases
Dupilumab is a fully human IgG4 monoclonal antibody directed against the IL-4R&#945; subunit of IL-4 and IL-13 receptors, used in the treatment of atopic dermatitis
Dupilumab is a biologic therapy that inhibits the IL-4 and IL-13 pathways, used to treat atopic dermatitis
Dupilumab is a human anti&#8211;IL&#8208;4R&#945; antibody approved for the treatment of moderate&#8208;to&#8208;severe Atopic Dermatitis
Dupilumab is a monoclonal antibody approved for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents
Dupilumab is a monoclonal antibody targeting IL-4R&#945;, used to treat AD
Dupilumab is a monoclonal antibody that antagonizes IL-4R&#945;, blocking IL-4 and IL-13 signaling
Dupilumab is a biologic targeting IL-4 and IL-13, approved for treating moderate to severe atopic dermatitis
A biologic drug targeting IL-4R&#945;, used in the treatment of atopic dermatitis
Dupilumab is an IL-4Ra inhibitor approved for the treatment of AD
Dupilumab is a drug that binds to IL-4R&#945; and is approved for atopic dermatitis
A monoclonal antibody that blocks IL-4 and IL-13, used in the treatment of atopic dermatitis and other atopic conditions
Dupilumab is a monoclonal antibody used to treat moderate-to-severe atopic dermatitis by inhibiting IL-4 and IL-13 signaling
Dupilumab is a monoclonal antibody used in the treatment of atopic dermatitis
Dupilumab is a biologic injection targeting IL-4R&#945; used in the treatment of atopic dermatitis
Dupilumab is a biological molecule that regulates the JAK/STAT pathway and inhibits JAK
Dupilumab is an IgG4 monoclonal antibody that targets IL-4R, used for treating AD
Dupilumab is a biologic agent targeting interleukin-4Ra in atopic dermatitis treatment
Dupilumab is a human monoclonal antibody used to treat atopic dermatitis and other inflammatory conditions
Dupilumab is a human monoclonal antibody licensed for subcutaneous injection in severe AD patients</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,0ba9fbea14e0c2c1d01a12ffaacfda9b,104cc78517b2eca2e9cb7e00de1fe4b0,1596d061dbe1a1c9e8f31a02a21e5524,27a7e95c7d3ad59a948aa46741fee456,286730b1c1f680ac465cc21d522fda0c,28f548554737fcc026b968db6bbafa30,2cec06c4d46f5ff9ee936a78d8b077cd,3df8535e965efb96f5094169610507ff,3dfbb4c51838e0951f53ce951395225f,48de7eebab3f3b418feb35a152df38fd,573fb6fa0673eb9462aa9862888079f3,693a2aac101eaaadf92614317a1e4da8,78e26c66107dba37ac4bab65406b43a0,96e553a44a27e728c27c4892045ec5c2,a867a1e73cef039eb3f28e072463b838,cdfcc39154accbac074c924676dc701e,dc905ba8b6eb7d84cf2776303211010d,e075bccd45593ae008b2ce7f9ed8ff6c,e9841b88c9fab58c5175af409653da50,f66eb51473925a8084dad1745be63b78</data>
    </node>
    <node id="CALCITRIOL">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Calcitriol is a medication used to treat calcium deficiency
Calcitriol is the active form of vitamin D, used in the treatment of various conditions
Calcitriol is the active form of vitamin D, used to treat calcium deficiency</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,62b4bd8f530adae989e4349d1e58f11d,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="INTERLEUKIN 6">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin 6 is involved in the regulation of immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="SILTUXIMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Siltuximab is a medication used to treat certain inflammatory conditions
Siltuximab is a receptor antagonist targeting IL6</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="TOCILIZUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Tocilizumab is a medication used to treat certain inflammatory conditions
Tocilizumab is a receptor antagonist targeting IL6
Tocilizumab is an anti-IL-6 receptor monoclonal antibody used in the treatment of autoimmune diseases</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,cdfcc39154accbac074c924676dc701e,e340a83f7cba0ea5be731b1f682ea7c7</data>
    </node>
    <node id="SARILUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Sarilumab is a medication used to treat certain inflammatory conditions
Sarilumab is a receptor antagonist targeting IL6</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="SATRALIZUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Satralizumab is a medication used to treat certain inflammatory conditions
Satralizumab is a receptor antagonist targeting IL6</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="VITAMIN C">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Vitamin C is a vitamin used to prevent and treat scurvy
Vitamin C is an essential nutrient involved in the repair of tissue and enzymatic production of certain neurotransmitters</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="VITAMIN E">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Vitamin E is a vitamin used to treat and prevent vitamin E deficiency
Vitamin E is a fat-soluble antioxidant that protects cell membranes from oxidative damage
Vitamin E is a nutrient that has potential to increase skin hydration and is used in cosmetic applications
Vitamin E is an antioxidant that helps protect cells from damage</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456,573fb6fa0673eb9462aa9862888079f3,bddc3b1a7f098e71f0aa64adec047124,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="IL10">
      <data key="d0">GENE</data>
      <data key="d1">IL10 encodes Interleukin 10, involved in the regulation of immune responses
Interleukin 10 is an anti-inflammatory cytokine
IL10 is a gene encoding the Interleukin 10</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,62b4bd8f530adae989e4349d1e58f11d,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="INTERLEUKIN 10">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin 10 is involved in the regulation of immune responses</data>
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="NICOTINAMIDE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Nicotinamide is a form of vitamin B3 used to treat and prevent niacin deficiency
Nicotinamide is a form of vitamin B3 used in the treatment of various skin conditions
Nicotinamide is a form of vitamin B3 used as a dietary supplement and medication
Nicotinamide is a form of vitamin B3 used in nanotechnology-based therapeutic approaches
Nicotinamide, also known as niacinamide, is a form of vitamin B3 used to improve skin health</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456,573fb6fa0673eb9462aa9862888079f3,baf4dec7fda8d8b8571a343b034f7092,cccfd5ff480e281556e2210cd0e5c4b5,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="NIACIN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Niacin is a form of vitamin B3 used to treat and prevent niacin deficiency
Niacin is a form of vitamin B3 used to treat high cholesterol and pellagra
Niacin is a form of vitamin B3 used to treat and prevent niacin deficiency</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,baf4dec7fda8d8b8571a343b034f7092,cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="CYCLOSPORINE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Cyclosporine is a medication used to prevent organ rejection and treat certain autoimmune diseases
Cyclosporine is an immunosuppressant drug used to treat atopic dermatitis
An immunosuppressant drug used in the treatment of autoimmune diseases
Cyclosporine is a drug used in systemic therapy for AD
Cyclosporine is the only AD treatment recognized by most countries</data>
      <data key="d2">286730b1c1f680ac465cc21d522fda0c,2cec06c4d46f5ff9ee936a78d8b077cd,cdfcc39154accbac074c924676dc701e,dc905ba8b6eb7d84cf2776303211010d,e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="INTERLEUKIN 1&#914;">
      <data key="d0" />
      <data key="d1" />
      <data key="d2">cdfcc39154accbac074c924676dc701e</data>
    </node>
    <node id="CYCLOSPORINE A">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Cyclosporine A is an immunosuppressant drug used to prevent organ rejection and treat autoimmune diseases
Cyclosporine A is an immunosuppressant used in the systemic treatment of Atopic Dermatitis
Cyclosporine A is a systemic immunosuppressant used to treat AD
Cyclosporine A is an immunosuppressive drug used in nanotechnology-based therapeutic approaches
Cyclosporine A is an immunosuppressant drug used to treat autoimmune diseases and prevent organ transplant rejection</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456,48de7eebab3f3b418feb35a152df38fd,573fb6fa0673eb9462aa9862888079f3,693a2aac101eaaadf92614317a1e4da8,cccfd5ff480e281556e2210cd0e5c4b5</data>
    </node>
    <node id="METHOTREXATE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Methotrexate is a chemotherapy agent and immune system suppressant
Methotrexate is an immunosuppressant drug used to treat atopic dermatitis
Methotrexate is an immunosuppressant used in the systemic treatment of Atopic Dermatitis
Methotrexate is a systemic immunosuppressant used to treat AD
Methotrexate is an immunosuppressant used to treat severe forms of AD
Methotrexate is a drug used in systemic therapy for AD
Methotrexate is a chemotherapy agent and immune system suppressant used to treat various conditions
Methotrexate is an immunosuppressant drug used to treat autoimmune diseases by controlling the immune system
Methotrexate is an immunosuppressant drug that controls the skin&#8217;s immune system, modifies immunological signals, and calms down hyperactive inflammatory cells
Methotrexate is a medication used to treat autoimmune diseases such as rheumatoid arthritis</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3,1596d061dbe1a1c9e8f31a02a21e5524,27a7e95c7d3ad59a948aa46741fee456,286730b1c1f680ac465cc21d522fda0c,2cec06c4d46f5ff9ee936a78d8b077cd,48de7eebab3f3b418feb35a152df38fd,573fb6fa0673eb9462aa9862888079f3,693a2aac101eaaadf92614317a1e4da8,6aef5adb1be227170f66c76a292c25e5,dc905ba8b6eb7d84cf2776303211010d</data>
    </node>
    <node id="MYCOPHENOLATE MOFETIL">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Mycophenolate mofetil is an immunosuppressant drug used to prevent organ rejection and treat autoimmune diseases
Mycophenolate mofetil is an immunosuppressant drug used to treat atopic dermatitis
Mycophenolate mofetil is an immunosuppressant used to treat severe forms of AD
Mycophenolate mofetil is a standard therapy drug used in the treatment of SSc
Mycophenolate Mofetil is an immunosuppressant drug used to prevent organ rejection and treat autoimmune diseases</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,573fb6fa0673eb9462aa9862888079f3,855c455b4c9592746834ee3a4e0e6b81,8e5a1be9981340d419f7b3ad27076009,dc905ba8b6eb7d84cf2776303211010d</data>
    </node>
    <node id="IL12A">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin 12A is a subunit of the cytokine IL-12, involved in the differentiation of T cells</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="ADAMANTIADES&#8211;BEH&#199;ET&#8217;S DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">Adamantiades&#8211;Beh&#231;et&#8217;s disease is a rare, chronic, inflammatory disorder</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="PRIMARY BILIARY CHOLANGIITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Primary biliary cholangiitis is a chronic disease that causes the small bile ducts in the liver to become inflamed and damaged</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="USTEKINUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Ustekinumab is a monoclonal antibody targeting IL-12/23
Ustekinumab is an IL12/IL23 inhibitor targeting FSH, HCG, LH, and LTA4H, used in the treatment of autoimmune diseases
A human IgG1&#954;, anti&#8211;IL-12/IL-23p40 monoclonal antibody used in the treatment of moderate-to-severe atopic dermatitis
Ustekinumab is a traditional biologic not recommended for treating AD</data>
      <data key="d2">1d0c4a4cd555b7ecd0b9d7b0310e9fe9,573fb6fa0673eb9462aa9862888079f3,8246ea974dfb00cb5e3d984004e21a9e,c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="BRIAKINUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Briakinumab is a monoclonal antibody targeting IL-12/23</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
    </node>
    <node id="IL12B">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin 12B is a subunit of the cytokine IL-12, involved in the differentiation of T cells</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="PSORIASIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Psoriasis is a chronic autoimmune condition that causes the rapid buildup of skin cells
Psoriasis is a chronic autoimmune condition that causes rapid skin cell production resulting in scaling on the skin's surface
Psoriasis is a chronic inflammatory skin disease
Psoriasis is a chronic autoimmune condition characterized by red, scaly skin patches
Psoriasis is a chronic autoimmune disease that causes rapid skin cell production resulting in scaling on the skin's surface
Psoriasis is a chronic autoimmune condition that causes rapid skin cell production, leading to scaling on the skin's surface
A chronic autoimmune disease characterized by patches of abnormal skin
A chronic autoimmune skin disease characterized by red, scaly patches
A chronic inflammatory skin disorder, similar to AD
Psoriasis is a chronic autoimmune skin disease characterized by red, scaly patches
Psoriasis is a chronic autoimmune condition that causes the rapid buildup of skin cells
Psoriasis is a chronic autoimmune skin disease
Psoriasis is a chronic autoimmune condition that causes the rapid build-up of skin cells
Psoriasis is a chronic autoimmune condition that causes the rapid buildup of skin cells
A chronic inflammatory skin condition
Psoriasis is a chronic autoimmune condition that causes rapid skin cell production, leading to scaling on the skin's surface
Psoriasis is a skin condition that can be treated using nanotechnology
Psoriasis is a disease with biomarkers indicative of disease progression</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b,1412a7a7fef5f18cc09a030b97b18e13,1d0c4a4cd555b7ecd0b9d7b0310e9fe9,286730b1c1f680ac465cc21d522fda0c,2e0cdefd62bed7c674d7fb93ef336c2b,3ce96e927d65736b305f792977fed4b9,3df8535e965efb96f5094169610507ff,3ea70e257330c812b52334ca1f90d807,442e7fad2fab75fa2449309783294d89,48288f3ec2832850282f95d4e38d10e1,573fb6fa0673eb9462aa9862888079f3,8246ea974dfb00cb5e3d984004e21a9e,849e0980ffd6a7e1cf0b8d3d1fbacd98,b28eeca0ff01a7715947d55a04978a43,b62ecc47bf54393bc78dd65986b949d6,baf4dec7fda8d8b8571a343b034f7092,c46e8b6ee0c29e37b7f18c42558d7a3e,e95d4d15e4f3110c91a3d3fcb5910d06</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="IL13">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin 13 is a cytokine involved in the regulation of inflammatory and immune responses
IL13 is a gene with overall decreased expression in HS</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b,573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="PENICILLIN ALLERGY">
      <data key="d0">DISEASE</data>
      <data key="d1">Penicillin allergy is an allergic reaction to penicillin antibiotics</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="MONTELUKAST">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Montelukast is a leukotriene receptor antagonist used to manage allergies and asthma
Montelukast is a medication used to manage allergies and prevent asthma attacks</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,baf4dec7fda8d8b8571a343b034f7092</data>
    </node>
    <node id="OMALIZUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Omalizumab is a monoclonal antibody used to treat severe allergic asthma
Omalizumab is a humanized IgG1&#954; monoclonal antibody used in the treatment of severe recalcitrant atopic eczema
A monoclonal antibody used in the treatment of atopic dermatitis
A monoclonal antibody targeting IgE, used in the treatment of allergic asthma
Omalizumab is an anti-IgE biologic used in the treatment of allergic conditions
Omalizumab is a biologic injection targeting IgE used in the treatment of atopic dermatitis
Omalizumab is a biological molecule that regulates the JAK/STAT pathway and inhibits JAK
Omalizumab is a traditional biologic not recommended for treating AD
Omalizumab is a biologic drug targeting Immunoglobulin E</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,104cc78517b2eca2e9cb7e00de1fe4b0,3df8535e965efb96f5094169610507ff,48288f3ec2832850282f95d4e38d10e1,573fb6fa0673eb9462aa9862888079f3,8246ea974dfb00cb5e3d984004e21a9e,cccfd5ff480e281556e2210cd0e5c4b5,e9841b88c9fab58c5175af409653da50,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </node>
    <node id="IL16">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin 16 is a cytokine that acts as a chemoattractant for certain immune cells</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="ALLERGIC ASTHMA">
      <data key="d0">DISEASE</data>
      <data key="d1">Allergic asthma is a type of asthma triggered by allergens
Allergic asthma is an atopic disorder that can be a comorbidity of AD
Allergic asthma is a type of asthma triggered by allergens
Allergic asthma is a type of asthma triggered by allergens</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,08e39958b85d84950ab7173daab9111b,1596d061dbe1a1c9e8f31a02a21e5524,573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="SECUKIZUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Secukizumab is a monoclonal antibody targeting IL-17A</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
    </node>
    <node id="IXEKIZUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Ixekizumab is a monoclonal antibody targeting IL-17A</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
    </node>
    <node id="BIMEKIZUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Bimekizumab is a monoclonal antibody targeting IL-17A/F
Bimekizumab is an IL-17A/F inhibitor targeting IL17A and IL17F, used in the treatment of autoimmune diseases</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="BRODALUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Brodalumab is a receptor antagonist targeting IL-17 receptor
Brodalumab is an IL-17 receptor inhibitor targeting IL17R, KRT6A, S100A7A, S100A8, and S100A9, used in the treatment of psoriasis</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="VIDOFLUDIMUS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Vidofludimus is an immunomodulatory drug</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
    </node>
    <node id="IL17F">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin 17F is a pro-inflammatory cytokine involved in autoimmune diseases
IL17F is a gene encoding interleukin 17F, involved in immune response
IL17F is a gene encoding for IL-17F with increased mRNA expression in HS</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b,573fb6fa0673eb9462aa9862888079f3,c44ec79872ab10cbe7336182f183ff60</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="CANDIDIASIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Candidiasis is a fungal infection caused by Candida species</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Acute generalized exanthematous pustulosis is a severe skin reaction characterized by pustules</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="MAIL DISEASES">
      <data key="d0">DISEASE</data>
      <data key="d1">Mail diseases refer to a group of conditions affecting the skin and mucous membranes</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="IL17R">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin 17 Receptor is a receptor for IL-17 cytokines
IL17R is a gene encoding interleukin 17 receptor, involved in immune response</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,c44ec79872ab10cbe7336182f183ff60</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="IAP ANTAGONIST">
      <data key="d0">CHEMICAL</data>
      <data key="d1">IAP antagonist is a class of drugs that inhibit Inhibitor of Apoptosis Proteins</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
    </node>
    <node id="IBOCTADEKIN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Iboctadekin is a recombinant interleukin-18</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
    </node>
    <node id="DOXIL">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Doxil is a liposomal formulation of the chemotherapy drug doxorubicin</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
    </node>
    <node id="IL19">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin 19 is a cytokine involved in inflammatory responses</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="IL20">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin 20 is a cytokine involved in inflammatory responses</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="IL21">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin 21 is a cytokine involved in the regulation of immune responses</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="DACRYOADENITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Dacryoadenitis is inflammation of the lacrimal gland</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="IL22">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin 22 is a cytokine involved in inflammatory responses</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="IL22RA1">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin 22 Receptor Subunit &#945;1 is a receptor for IL-22</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="SPONDYLOARTHROPATHY">
      <data key="d0">DISEASE</data>
      <data key="d1">Spondyloarthropathy is a group of inflammatory diseases that affect the joints and spine</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="AUTOIMMUNE UVEITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Autoimmune uveitis is inflammation of the uvea caused by an autoimmune response</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="IL23A">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin 23 Subunit &#945; is a subunit of the cytokine IL-23, involved in inflammatory responses</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="AUTOIMMUNE DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">Autoimmune disease is a condition in which the immune system attacks the body's own tissues
An autoimmune disease is a condition in which the immune system attacks the body's own tissues
Autoimmune diseases occur when the immune system attacks the body's own tissues</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,573fb6fa0673eb9462aa9862888079f3,68015074236b0144899baa38d01ae467</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="GUSELKUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Guselkumab is a monoclonal antibody targeting IL-23</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
    </node>
    <node id="RISANKINUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Risankinumab is a monoclonal antibody targeting IL-23</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
    </node>
    <node id="TILDRAKIZUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Tildrakizumab is a monoclonal antibody targeting IL-23</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
    </node>
    <node id="IL24">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin 24 is a cytokine involved in inflammatory responses</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="CHRONIC SPONTANEOUS URTICARIA">
      <data key="d0">DISEASE</data>
      <data key="d1">Chronic spontaneous urticaria is a condition characterized by the spontaneous appearance of hives</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="SPONDYLARTHROPATHY">
      <data key="d0">DISEASE</data>
      <data key="d1">Spondylarthropathy is a group of inflammatory diseases that affect the joints and spine</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
    </node>
    <node id="IL26">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin 26 is a cytokine involved in inflammatory responses</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="CUTANEOUS DIPHTHERIA">
      <data key="d0">DISEASE</data>
      <data key="d1">Cutaneous diphtheria is a bacterial infection of the skin caused by Corynebacterium diphtheriae</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="PERIOSTITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Periostitis is inflammation of the periosteum, a layer of connective tissue that surrounds bone</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="STILL&#8217;S DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">Still&#8217;s disease is a rare type of inflammatory arthritis</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="JAK3">
      <data key="d0">PROTEIN</data>
      <data key="d1">Janus Kinase 3 is a protein involved in the signaling of various cytokines
JAK3 is a gene encoding the Janus Kinase 3
JAK3 is a gene encoding Janus kinase 3, involved in cytokine signaling
Janus kinase 3, a member of the JAK family of tyrosine kinases involved in cytokine signaling
JAK3 is a member of the JAK family of tyrosine kinases involved in cytokine receptor signaling
JAK3, or Janus kinase 3, is a protein involved in the regulation of immune responses
JAK3 is a member of the Janus kinase family involved in the JAK/STAT signaling pathway</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b,3df8535e965efb96f5094169610507ff,573fb6fa0673eb9462aa9862888079f3,62b4bd8f530adae989e4349d1e58f11d,c44ec79872ab10cbe7336182f183ff60,c46e8b6ee0c29e37b7f18c42558d7a3e,f14a13d54127c3baadeb0b34d40928c9</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="NK CELL ENTEROPATHY">
      <data key="d0">DISEASE</data>
      <data key="d1">NK cell enteropathy is a condition characterized by the abnormal proliferation of natural killer cells in the gastrointestinal tract</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="DECERNATINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Decernatinib is a JAK3 inhibitor</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
    </node>
    <node id="TOFACITINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Tofacitinib is a JAK1/3 inhibitor
Tofacitinib is a JAK inhibitor</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="RUXOLITINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Ruxolitinib is a JAK1/3 inhibitor
Ruxolitinib is a JAK inhibitor
Ruxolitinib is a topical therapy used in the treatment of atopic dermatitis
Ruxolitinib is a dual JAK1/JAK2 inhibitor used for treating AD, vitiligo, and cutaneous lupus
Ruxolitinib is a small molecule drug developed by Incyte, targeting JAK1/JAK2
Ruxolitinib is a selective JAK inhibitor used in AD therapy
Ruxolitinib is a small molecule drug targeting JAK1
Ruxolitinib is the active ingredient in Opzelura</data>
      <data key="d2">286730b1c1f680ac465cc21d522fda0c,3df8535e965efb96f5094169610507ff,573fb6fa0673eb9462aa9862888079f3,62b4bd8f530adae989e4349d1e58f11d,c46e8b6ee0c29e37b7f18c42558d7a3e,cccfd5ff480e281556e2210cd0e5c4b5,e075bccd45593ae008b2ce7f9ed8ff6c,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="PF-06651600">
      <data key="d0">CHEMICAL</data>
      <data key="d1">PF-06651600 is a JAK3 inhibitor
PF-06651600 is a JAK inhibitor</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="AT-501">
      <data key="d0">CHEMICAL</data>
      <data key="d1">AT-501 is a JAK3 inhibitor</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
    </node>
    <node id="ATI-502">
      <data key="d0">CHEMICAL</data>
      <data key="d1">ATI-502 is a JAK3 inhibitor</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
    </node>
    <node id="CERDULATINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Cerdulatinib is a JAK1/2/3 and SYK inhibitor
Cerdulatinib is a non-selective JAK and SYK inhibitor used for treating AD and haematological malignancies
Cerdulatinib (RVT/DMVT502) is a small molecule drug developed by Dermavant, targeting Pan-JAK/SYK
Cerdulatinib is a selective JAK inhibitor used in AD therapy
Cerdulatinib is a small molecule drug targeting JAK1</data>
      <data key="d2">3df8535e965efb96f5094169610507ff,573fb6fa0673eb9462aa9862888079f3,c46e8b6ee0c29e37b7f18c42558d7a3e,cccfd5ff480e281556e2210cd0e5c4b5,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="DELGOCITINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Delgocitinib is a JAK1/2/3 inhibitor
Delgocitinib is a JAK inhibitor
Delgocitinib is a first-generation, non-selective JAK inhibitor used for treating AD and chronic hand eczema
Delgocitinib is a JAK inhibitor that was under clinical development for Atopic Dermatitis
Delgocitinib is a small molecule drug developed by Japan Tobacco/LEO, targeting Pan-JAK
Delgocitinib is a TYK2 and JAK1/2/3 inhibitor used in AD treatment
Delgocitinib is a small molecule drug targeting JAK1</data>
      <data key="d2">3df8535e965efb96f5094169610507ff,573fb6fa0673eb9462aa9862888079f3,62b4bd8f530adae989e4349d1e58f11d,90f4809673ca34628b0e607908f0bf0b,c46e8b6ee0c29e37b7f18c42558d7a3e,cccfd5ff480e281556e2210cd0e5c4b5,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="PEFICITINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Peficitinib is a JAK1/2/3 inhibitor
Peficitinib is a JAK inhibitor</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="CERCOSPORAMIDE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Cercosporamide is a JAK3/Mnk2 inhibitor</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
    </node>
    <node id="KRT6A">
      <data key="d0">GENE</data>
      <data key="d1">Keratin 6A is a gene associated with Pachyonychia congenita, Lingua plicata, and Cheilitis
KRT6A is a gene encoding keratin 6A, involved in the structural integrity of epithelial cells</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,c44ec79872ab10cbe7336182f183ff60</data>
      <data key="d3">GENE</data>
    </node>
    <node id="LINGUA PLICATA">
      <data key="d0">DISEASE</data>
      <data key="d1">Lingua plicata is a condition characterized by grooves or fissures on the tongue</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="CHEILITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Cheilitis is inflammation of the lips</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="ZINC">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Zinc is an essential mineral involved in numerous aspects of cellular metabolism
Zinc is a mineral essential for immune function and enzyme activity</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,baf4dec7fda8d8b8571a343b034f7092</data>
    </node>
    <node id="ZINC ACETATE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Zinc acetate is a form of zinc used in the treatment of various conditions
Zinc acetate is a form of zinc used as a dietary supplement and in medications</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,baf4dec7fda8d8b8571a343b034f7092</data>
    </node>
    <node id="KRT16">
      <data key="d0">GENE</data>
      <data key="d1">Keratin 16 is a gene associated with Pachyonychia congenita and palmoplantar keratoderma
KRT16 is a gene encoding Keratin 16
KRT16 is a gene encoding keratin 16, involved in the structural integrity of epithelial cells</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,baf4dec7fda8d8b8571a343b034f7092,c44ec79872ab10cbe7336182f183ff60</data>
      <data key="d3">GENE</data>
    </node>
    <node id="PALMOPLANTAR KERATODERMA">
      <data key="d0">DISEASE</data>
      <data key="d1">Palmoplantar keratoderma is a condition characterized by thickening of the skin on the palms and soles
Palmoplantar keratoderma is a condition characterized by thickening of the skin on the palms and soles</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="KRT77">
      <data key="d0">GENE</data>
      <data key="d1">Keratin 77 is a gene associated with Epidermolytic palmoplantar keratoderma and Buschke-Ollendorff syndrome
KRT77 is a gene encoding Keratin 77</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">GENE</data>
    </node>
    <node id="EPIDERMOLYTIC PALMOPLANTAR KERATODERMA">
      <data key="d0">DISEASE</data>
      <data key="d1">Epidermolytic palmoplantar keratoderma is a genetic skin disorder characterized by thickened skin on the palms and soles
Epidermolytic palmoplantar keratoderma is a genetic skin disorder characterized by thickened skin on the palms and soles</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="BUSCHKE-OLLENDORFF SYNDROME">
      <data key="d0">DISEASE</data>
      <data key="d1">Buschke-Ollendorff syndrome is a rare genetic disorder characterized by skin and bone abnormalities
Buschke-Ollendorff syndrome is a genetic disorder characterized by skin lesions and bone abnormalities</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="LCE3D">
      <data key="d0">GENE</data>
      <data key="d1">Late Cornified Envelope 3D is a gene associated with Psoriasis
LCE3D is a gene encoding Late Cornified Envelope 3D</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">GENE</data>
    </node>
    <node id="LGR5">
      <data key="d0">GENE</data>
      <data key="d1">Leucine Rich Repeat Containing G Protein-Coupled Receptor 5 is a gene involved in stem cell regulation
LGR5 is a gene encoding Leucine Rich Repeat Containing G Protein-Coupled Receptor 5</data>
      <data key="d2">573fb6fa0673eb9462aa9862888079f3,baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">GENE</data>
    </node>
    <node id="KERATIN 77">
      <data key="d0">PROTEIN</data>
      <data key="d1">Keratin 77 is a protein encoded by the KRT77 gene</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
    </node>
    <node id="LATE CORNIFIED ENVELOPE 3D">
      <data key="d0">PROTEIN</data>
      <data key="d1">Late Cornified Envelope 3D is a protein encoded by the LCE3D gene</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="LEUCINE RICH REPEAT CONTAINING G PROTEIN-COUPLED RECEPTOR 5">
      <data key="d0">PROTEIN</data>
      <data key="d1">Leucine Rich Repeat Containing G Protein-Coupled Receptor 5 is a protein encoded by the LGR5 gene</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="TYPE II DIABETES MELLITUS">
      <data key="d0">DISEASE</data>
      <data key="d1">Type II diabetes mellitus is a chronic condition that affects the way the body processes blood sugar (glucose)</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="LTA4H">
      <data key="d0">GENE</data>
      <data key="d1">LTA4H is a gene encoding Leukotriene A4 Hydrolase
LTA4H is an enzyme involved in inflammationLTA4H is a gene encoding leukotriene A4 hydrolase, involved in inflammation</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092,c44ec79872ab10cbe7336182f183ff60</data>
      <data key="d3">GENE</data>
    </node>
    <node id="LEUKOTRIENE A4 HYDROLASE">
      <data key="d0">PROTEIN</data>
      <data key="d1">Leukotriene A4 Hydrolase is an enzyme involved in the inflammatory response</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="CAPTOPRIL">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Captopril is a medication used to treat high blood pressure and heart failure</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="MMP1">
      <data key="d0">GENE</data>
      <data key="d1">MMP1 is a gene encoding Matrix Metallopeptidase 1
MMP1 is a gene encoding the Matrix Metallopeptidase 1
MMP1 is a gene encoding matrix metallopeptidase 1, involved in the breakdown of extracellular matrixMMP1 is an enzyme involved in the breakdown of extracellular matrix</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d,baf4dec7fda8d8b8571a343b034f7092,c44ec79872ab10cbe7336182f183ff60</data>
      <data key="d3">GENE</data>
    </node>
    <node id="MATRIX METALLOPEPTIDASE 1">
      <data key="d0">PROTEIN</data>
      <data key="d1">Matrix Metallopeptidase 1 is an enzyme involved in the breakdown of extracellular matrix</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="EPIDERMOLYSIS BULLOSA ATROPHICA">
      <data key="d0">DISEASE</data>
      <data key="d1">Epidermolysis bullosa atrophica is a genetic skin disorder causing fragile skin that blisters easily</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="SCLERODERMA">
      <data key="d0">DISEASE</data>
      <data key="d1">Scleroderma is an autoimmune disease characterized by hardening and tightening of the skin and connective tissues
Scleroderma is a type of skin fibrosis</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="COLLAGENASE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Collagenase is an enzyme that breaks down collagen in damaged tissues</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="MMP3">
      <data key="d0">GENE</data>
      <data key="d1">MMP3 is a gene encoding Matrix Metallopeptidase 3</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">GENE</data>
    </node>
    <node id="MATRIX METALLOPEPTIDASE 3">
      <data key="d0">PROTEIN</data>
      <data key="d1">Matrix Metallopeptidase 3 is an enzyme involved in the breakdown of extracellular matrix</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="CORONARY HEART DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">Coronary heart disease is a condition characterized by reduced blood flow to the heart muscle</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="PRAVASTATIN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Pravastatin is a medication used to lower cholesterol and prevent cardiovascular disease</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="PROTHALIDONE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Prothalidone is a medication used to treat high blood pressure</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="LISINOPRIL">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Lisinopril is a medication used to treat high blood pressure and heart failure</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="MMP9">
      <data key="d0">GENE</data>
      <data key="d1">MMP9 is a gene encoding Matrix Metallopeptidase 9
MMP9 is a gene encoding the Matrix Metallopeptidase 9</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d,baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">GENE</data>
    </node>
    <node id="MATRIX METALLOPEPTIDASE 9">
      <data key="d0">PROTEIN</data>
      <data key="d1">Matrix Metallopeptidase 9 is an enzyme involved in the breakdown of extracellular matrix</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="MMP12">
      <data key="d0">GENE</data>
      <data key="d1">MMP12 is a gene encoding Matrix Metallopeptidase 12
Matrix metalloproteinase 12 is an enzyme involved in tissue remodeling</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b,baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">GENE</data>
    </node>
    <node id="MATRIX METALLOPEPTIDASE 12">
      <data key="d0">PROTEIN</data>
      <data key="d1">Matrix Metallopeptidase 12 is an enzyme involved in the breakdown of extracellular matrix</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="DERMATITIS HERPETIFORMIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Dermatitis herpetiformis is a chronic skin condition characterized by blistering, itchy skin</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="MIDDERMAL ELASTOLYSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Middermal elastolysis is a skin condition characterized by loss of elastic tissue in the mid-dermis</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="ACETOHYDROXAMIC ACID">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Acetohydroxamic acid is a medication used to treat urinary tract infections</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="BATIMASTAT">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Batimastat is a medication used to inhibit matrix metalloproteinases</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="NAMPT">
      <data key="d0">GENE</data>
      <data key="d1">NAMPT is a gene encoding Nicotinamide Phosphoribosyl transferase</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">GENE</data>
    </node>
    <node id="NICOTINAMIDE PHOSPHORIBOSYL TRANSFERASE">
      <data key="d0">PROTEIN</data>
      <data key="d1">Nicotinamide Phosphoribosyl transferase is an enzyme involved in NAD biosynthesis</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="SKIN AGING">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Skin aging is characterized by wrinkles, loss of elasticity, and other changes in the skin</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="PELLAGRA">
      <data key="d0">DISEASE</data>
      <data key="d1">Pellagra is a disease caused by niacin deficiency, characterized by dermatitis, diarrhea, and dementia</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="DIABETES MELLITUS TYPE 2">
      <data key="d0">DISEASE</data>
      <data key="d1">Diabetes mellitus type 2 is a chronic condition that affects the way the body processes blood sugar (glucose)</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="POLYCYSTIC OVARY SYNDROME">
      <data key="d0">DISEASE</data>
      <data key="d1">Polycystic ovary syndrome is a hormonal disorder causing enlarged ovaries with small cysts on the outer edges</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="NGF">
      <data key="d0">GENE</data>
      <data key="d1">NGF is a gene encoding Nerve Growth Factor</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">GENE</data>
    </node>
    <node id="NERVE GROWTH FACTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Nerve Growth Factor is a protein involved in the growth, maintenance, and survival of nerve cells
Nerve growth factor is involved in pathways related to inflammation in atopic dermatitis</data>
      <data key="d2">83eb9003d42977bb83fea1d123dd5ab9,baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="CLENBUTEROL">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Clenbuterol is a medication used to treat asthma and other respiratory conditions</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="OSM">
      <data key="d0">GENE</data>
      <data key="d1">OSM is a gene encoding Oncostatin M</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">GENE</data>
    </node>
    <node id="ONCOSTATIN M">
      <data key="d0">PROTEIN</data>
      <data key="d1">Oncostatin M is a cytokine involved in inflammation and the regulation of cell growth</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="PI3">
      <data key="d0">GENE</data>
      <data key="d1">PI3 is a gene encoding Peptidase Inhibitor 3
PI3 is a gene involved in various cellular processes
PI3 is a gene encoding peptidase inhibitor 3, involved in immune responsePI3 is an enzyme involved in immune response
Elafin is a protein involved in skin inflammation</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d,b19f42c9497f71b231222cd953036d6b,baf4dec7fda8d8b8571a343b034f7092,c44ec79872ab10cbe7336182f183ff60</data>
      <data key="d3">GENE</data>
    </node>
    <node id="PEPTIDASE INHIBITOR 3">
      <data key="d0">PROTEIN</data>
      <data key="d1">Peptidase Inhibitor 3 is a protein involved in the inhibition of serine proteases</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="PUSTULAR PSORIASIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Pustular psoriasis is a rare form of psoriasis characterized by white pustules surrounded by red skin</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="IMPETIGO HERPETIFORMIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Impetigo herpetiformis is a rare form of pustular psoriasis that occurs during pregnancy</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="PIP">
      <data key="d0">GENE</data>
      <data key="d1">PIP is a gene encoding Prolactin Induced Protein</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">GENE</data>
    </node>
    <node id="PROLACTIN INDUCED PROTEIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Prolactin Induced Protein is a protein involved in the immune response and found in various bodily fluids</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="PERILIPIN 1">
      <data key="d0">PROTEIN</data>
      <data key="d1">Perilipin 1 is a protein involved in the regulation of lipid storage in adipocytes</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="ROSIGLITAZONE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Rosiglitazone is a medication used to treat type 2 diabetes</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="S100 CALCIUM-BINDING PROTEIN A7">
      <data key="d0">PROTEIN</data>
      <data key="d1">S100 Calcium-Binding Protein A7 is a protein involved in the regulation of inflammatory processes and immune response</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="SQUAMOUS CELL CARCINOMA">
      <data key="d0">DISEASE</data>
      <data key="d1">Squamous cell carcinoma is a type of skin cancer that begins in the squamous cells</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="ANAL FISTULA">
      <data key="d0">DISEASE</data>
      <data key="d1">Anal fistula is an abnormal connection between the epithelialized surface of the anal canal and the perianal skin</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="IBUPROFEN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Ibuprofen is a nonsteroidal anti-inflammatory drug used to reduce fever and treat pain or inflammation</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="DEXIBUPROFEN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Dexibuprofen is a nonsteroidal anti-inflammatory drug used to treat pain and inflammation</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="ZINC CHLORIDE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Zinc chloride is a chemical compound used in various applications, including as a dietary supplement</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="S100 CALCIUM-BINDING PROTEIN A7A">
      <data key="d0">PROTEIN</data>
      <data key="d1">S100 Calcium-Binding Protein A7A is a protein involved in the regulation of inflammatory processes and immune response</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="S100 CALCIUM-BINDING PROTEIN A8">
      <data key="d0">PROTEIN</data>
      <data key="d1">S100 Calcium-Binding Protein A8 is a protein involved in the regulation of inflammatory processes and immune response</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="COPPER">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Copper is a mineral essential for various bodily functions, including the formation of red blood cells</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="S100 CALCIUM-BINDING PROTEIN A9">
      <data key="d0">PROTEIN</data>
      <data key="d1">S100 Calcium-Binding Protein A9 is a protein involved in the regulation of inflammatory processes and immune response</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="CALCIUM">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Calcium is a mineral essential for bone health and various bodily functions</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="S100 CALCIUM-BINDING PROTEIN A12">
      <data key="d0">PROTEIN</data>
      <data key="d1">S100 Calcium-Binding Protein A12 is a protein involved in the regulation of inflammatory processes and immune response</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="KAWASAKI DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">Kawasaki disease is a condition that causes inflammation in the walls of some blood vessels in the body</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="PSORIATIC ARTHRITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Psoriatic arthritis is a form of arthritis that affects some people who have psoriasis
Psoriatic arthritis is an inflammatory arthritis associated with psoriasis
A type of inflammatory arthritis associated with psoriasis
Psoriatic Arthritis is a form of arthritis that affects some people who have psoriasis
Psoriatic arthritis, a disease treated with TNF inhibitorsPsoriatic arthritis is an inflammatory arthritis associated with psoriasis</data>
      <data key="d2">1d0c4a4cd555b7ecd0b9d7b0310e9fe9,516e41e96d2e72d45bf1e2c69da7f18a,62b4bd8f530adae989e4349d1e58f11d,baf4dec7fda8d8b8571a343b034f7092,c46e8b6ee0c29e37b7f18c42558d7a3e</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="AMLEXANOX">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Amlexanox is a medication used to treat aphthous ulcers</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="OLOPATADINE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Olopatadine is an antihistamine used to treat allergic reactions</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="SCGB1D2">
      <data key="d0">GENE</data>
      <data key="d1">SCGB1D2 is a gene encoding Secretoglobin Family 1D Member 2</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">GENE</data>
    </node>
    <node id="SECRETOGLOBIN FAMILY 1D MEMBER 2">
      <data key="d0">PROTEIN</data>
      <data key="d1">Secretoglobin Family 1D Member 2 is a protein involved in the immune response</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="SCGB2A2">
      <data key="d0">GENE</data>
      <data key="d1">SCGB2A2 is a gene encoding Secretoglobin Family 2A Member 2</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">GENE</data>
    </node>
    <node id="SECRETOGLOBIN FAMILY 2A MEMBER 2">
      <data key="d0">PROTEIN</data>
      <data key="d1">Secretoglobin Family 2A Member 2 is a protein involved in the immune response</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="SERPINB3">
      <data key="d0">GENE</data>
      <data key="d1">SERPINB3 is a gene encoding Serpin Family B Member 3</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">GENE</data>
    </node>
    <node id="SERPIN FAMILY B MEMBER 3">
      <data key="d0">PROTEIN</data>
      <data key="d1">Serpin Family B Member 3 is a protein involved in the inhibition of serine proteases</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="PHOSPHOSERINE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Phosphoserine is a phosphorylated form of the amino acid serine</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="SERPINB4">
      <data key="d0">GENE</data>
      <data key="d1">SERPINB4 is a gene encoding Serpin Family B Member 4</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">GENE</data>
    </node>
    <node id="SERPIN FAMILY B MEMBER 4">
      <data key="d0">PROTEIN</data>
      <data key="d1">Serpin Family B Member 4 is a protein involved in the inhibition of serine proteases</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="SLAMF7">
      <data key="d0">GENE</data>
      <data key="d1">SLAMF7 is a gene encoding SLAM Family Member 7</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">GENE</data>
    </node>
    <node id="SLAM FAMILY MEMBER 7">
      <data key="d0">PROTEIN</data>
      <data key="d1">SLAM Family Member 7 is a protein involved in the regulation of immune responses</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="IGG4-RELATED DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">IgG4-related disease is a condition characterized by inflammation and fibrosis in various organs</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="ELOTUZUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Elotuzumab is a medication used to treat multiple myeloma</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="SPRR2B">
      <data key="d0">GENE</data>
      <data key="d1">SPRR2B is a gene encoding Small Proline Rich Protein 2B</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">GENE</data>
    </node>
    <node id="SMALL PROLINE RICH PROTEIN 2B">
      <data key="d0">PROTEIN</data>
      <data key="d1">Small Proline Rich Protein 2B is a protein involved in the formation of the cornified cell envelope in the skin</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="PHOTOSENSITIVE TRICHOTHIODYSTROPHY 1">
      <data key="d0">DISEASE</data>
      <data key="d1">Photosensitive trichothiodystrophy 1 is a genetic disorder characterized by sensitivity to sunlight and brittle hair</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="AUTOSOMAL RECESSIVE CONGENITAL ICHTHYOSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Autosomal recessive congenital ichthyosis is a group of genetic skin disorders characterized by dry, scaly skin</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="SPRR2C (PSEUDOGENE)">
      <data key="d0">GENE</data>
      <data key="d1">SPRR2C (pseudogene) is a pseudogene related to Small Proline Rich Protein 2C</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">GENE</data>
    </node>
    <node id="SMALL PROLINE RICH PROTEIN 2C (PSEUDOGENE)">
      <data key="d0">PROTEIN</data>
      <data key="d1">Small Proline Rich Protein 2C (Pseudogene) is a pseudogene related to the formation of the cornified cell envelope in the skin</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="KERATIN 16">
      <data key="d0">PROTEIN</data>
      <data key="d1">Keratin 16 is a protein encoded by the KRT16 gene</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
    </node>
    <node id="SPRR3">
      <data key="d0">GENE</data>
      <data key="d1">SPRR3 is a gene encoding Small Proline Rich Protein</data>
      <data key="d2">baf4dec7fda8d8b8571a343b034f7092</data>
    </node>
    <node id="LENALIDOMIDE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Lenalidomide is a drug used in the treatment of multiple myeloma and other conditions</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="POMALIDOMIDE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Pomalidomide is a drug used to treat multiple myeloma</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="BAY 11-7821">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Bay 11-7821 is an inhibitor of NF-&#954;B activation</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="(R)-DOI">
      <data key="d0">CHEMICAL</data>
      <data key="d1">(R)-DOI is a psychoactive drug and research chemical</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="CANNABIDIOL">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Cannabidiol is a chemical compound found in cannabis, used for various medical conditions</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="TNFRSF4">
      <data key="d0">GENE</data>
      <data key="d1">TNFRSF4 is a gene encoding the TNF Receptor Superfamily Member 4
TNFRSF4 is a gene involved in immune responses and is upregulated in HS skin and blood
TNFRSF4 is the TNF receptor superfamily nomenclature for OX40</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff,62b4bd8f530adae989e4349d1e58f11d,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="DRUG REACTION WITH EOSINOPHILIA">
      <data key="d0">DISEASE</data>
      <data key="d1">Drug reaction with eosinophilia is a severe drug reaction characterized by rash, fever, and organ involvement</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="OX-40 LIGAND">
      <data key="d0">PROTEIN</data>
      <data key="d1">OX-40 ligand is a protein that binds to OX40 and is involved in T-cell activation</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="TNFSF11">
      <data key="d0">GENE</data>
      <data key="d1">TNFSF11 is a gene encoding the TNF Superfamily Member 11
TNFSF11 is the gene encoding RANKL, involved in bone metabolism and fibrosis
TNFSF11 is the TNF superfamily nomenclature for RANKL</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d,b2aae16813e647959b783a39ef9a19a7,c95d22c2a90e77cd22bd0d280d55b26a</data>
      <data key="d3">GENE</data>
    </node>
    <node id="LETROZOLE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Letrozole is a drug used to treat breast cancer</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="THIOCOLCHICOSIDE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Thiocolchicoside is a muscle relaxant used to treat muscle spasms</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="TNFSF13">
      <data key="d0">GENE</data>
      <data key="d1">TNFSF13 is a gene encoding the TNF Superfamily Member 13TNFSF13 is a gene encoding the TNF Superfamily Member 13, also known as APRIL
TNFSF13 is the TNF superfamily nomenclature for APRIL</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d,c95d22c2a90e77cd22bd0d280d55b26a</data>
      <data key="d3">GENE</data>
    </node>
    <node id="AUTOIMMUNE DISEASES">
      <data key="d0">DISEASE</data>
      <data key="d1">Autoimmune diseases are conditions where the immune system attacks the body's own tissues
Autoimmune diseases are conditions where the immune system mistakenly attacks the body's own tissues
A group of diseases where the immune system attacks the body's own tissues</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b,62b4bd8f530adae989e4349d1e58f11d,7b454335c2f5651d86f712037a0dc0ff</data>
    </node>
    <node id="TACI-IG">
      <data key="d0">CHEMICAL</data>
      <data key="d1">TACI-IG is a therapeutic agent targeting BAFF and APRILTACI-IG is a therapeutic agent targeting B-cell activating factor</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="TNFSF13B">
      <data key="d0">GENE</data>
      <data key="d1">TNFSF13B is a gene encoding the TNF Superfamily Member 13bTNFSF13B is a gene encoding the TNF Superfamily Member 13b, also known as BAFF
TNFSF13B is the TNF superfamily nomenclature for BAFF
TNFSF13B is the gene encoding the protein BAFF</data>
      <data key="d2">516e41e96d2e72d45bf1e2c69da7f18a,62b4bd8f530adae989e4349d1e58f11d,c95d22c2a90e77cd22bd0d280d55b26a</data>
      <data key="d3">GENE</data>
    </node>
    <node id="SIALADENITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Sialadenitis is inflammation of the salivary glands</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="SJOGREN SYNDROME">
      <data key="d0">DISEASE</data>
      <data key="d1">Sjogren syndrome is an autoimmune disease characterized by dry eyes and dry mouth</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="BELIMUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Belimumab is a monoclonal antibody that inhibits BAFFBelimumab is a drug used to treat systemic lupus erythematosus
Belimumab is a monoclonal antibody used to treat autoimmune diseases by inhibiting BAFF
Belimumab is a monoclonal antibody targeting BAFF, used in the treatment of autoimmune diseases
Belimumab is a monoclonal antibody used to treat autoimmune diseases by inhibiting BAFF
Belimumab is a monoclonal antibody used in various dosages in clinical trials for rheumatoid arthritis</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3,423195c6b63ad0a6773374364ebf3612,62b4bd8f530adae989e4349d1e58f11d,68015074236b0144899baa38d01ae467,8e5a1be9981340d419f7b3ad27076009</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="BLISIBIMOD">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Blisibimod is a drug that inhibits BAFFBlisibimod is a drug targeting B-cell activating factor
Blisibimod is a therapeutic agent targeting BAFF, used in the treatment of autoimmune diseases</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d,8e5a1be9981340d419f7b3ad27076009</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="LY2127399">
      <data key="d0">CHEMICAL</data>
      <data key="d1">LY2127399 is a drug that inhibits BAFFLY2127399 is a drug targeting B-cell activating factor
LY2127399 (Tabalumab) is a monoclonal antibody targeting BAFF, used in the treatment of autoimmune diseases
LY2127399 is a drug used in clinical trials for treating autoimmune diseases</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3,62b4bd8f530adae989e4349d1e58f11d,8e5a1be9981340d419f7b3ad27076009</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="TNFSF14">
      <data key="d0">GENE</data>
      <data key="d1">TNFSF14 is a gene encoding the TNF Superfamily Member 14
TNFSF14 is the gene encoding LIGHT
TNFSF14 is the TNF superfamily nomenclature for LIGHT
TNFSF14 is another name for LIGHT, a cytokine involved in immune responses and fibrosis
TNFSF14 is the gene encoding the protein LIGHT</data>
      <data key="d2">516e41e96d2e72d45bf1e2c69da7f18a,62b4bd8f530adae989e4349d1e58f11d,68015074236b0144899baa38d01ae467,c95d22c2a90e77cd22bd0d280d55b26a,df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">GENE</data>
    </node>
    <node id="HERPES SIMPLEX">
      <data key="d0">DISEASE</data>
      <data key="d1">Herpes simplex is a viral infection caused by the herpes simplex virus
Herpes Simplex is a viral infection causing sores, primarily around the mouth or genitals
Herpes simplex is a viral infection that can cause sores on the mouth or genitals</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d,a867a1e73cef039eb3f28e072463b838,c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </node>
    <node id="TNIP1">
      <data key="d0">GENE</data>
      <data key="d1">TNIP1 is a gene encoding the TNFAIP3 Interacting Protein 1</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="SYSTEMIC LUPUS ERYTHEMATOSUS">
      <data key="d0">DISEASE</data>
      <data key="d1">Systemic lupus erythematosus is an autoimmune disease that affects multiple organs
Systemic Lupus Erythematosus (SLE) is an autoimmune disease
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by chronic inflammation</data>
      <data key="d2">442e7fad2fab75fa2449309783294d89,48288f3ec2832850282f95d4e38d10e1,62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="WIF1">
      <data key="d0">GENE</data>
      <data key="d1">WIF1 is a gene encoding the WNT Inhibitory Factor 1</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="3,3&#8217;-DIINDOLYLMETHANE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">3,3&#8217;-Diindolylmethane is a CHK inhibitor, cytochrome P450 activator, and indoleamine 2,3-dioxygenase inhibitor</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="HIF1A">
      <data key="d0">GENE</data>
      <data key="d1">HIF1A is a gene encoding the Hypoxia-Inducible Factor 1-alpha</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="AG-490">
      <data key="d0">CHEMICAL</data>
      <data key="d1">AG-490 is an EGFR inhibitor and JAK inhibitor</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="JAK2">
      <data key="d0">GENE</data>
      <data key="d1">JAK2 is a gene encoding the Janus Kinase 2
JAK2 is a gene encoding Janus kinase 2, involved in cytokine signaling
JAK2 is a protein involved in the JAK-STAT signaling pathway and targeted by baricitinib in the treatment of atopic dermatitis
Janus kinase 2, a protein involved in signaling pathways for immune responses
Janus kinase 2, a member of the JAK family of tyrosine kinases involved in cytokine signaling
JAK2 is a member of the JAK family of tyrosine kinases involved in cytokine receptor signaling
JAK2 is a gene encoding a protein that is part of the Janus kinase family, involved in cytokine receptor signaling
Janus kinase 2 is a protein involved in the signaling of various cytokines
JAK2, or Janus kinase 2, is a protein involved in the regulation of immune responses
JAK2 is a member of the Janus kinase family involved in the JAK/STAT signaling pathway</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,0ba9fbea14e0c2c1d01a12ffaacfda9b,3df8535e965efb96f5094169610507ff,62b4bd8f530adae989e4349d1e58f11d,a867a1e73cef039eb3f28e072463b838,c44ec79872ab10cbe7336182f183ff60,c46e8b6ee0c29e37b7f18c42558d7a3e,e075bccd45593ae008b2ce7f9ed8ff6c,e95d4d15e4f3110c91a3d3fcb5910d06,f14a13d54127c3baadeb0b34d40928c9</data>
      <data key="d3">GENE</data>
    </node>
    <node id="ANDROGRAPHOLIDE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Andrographolide is a tumor necrosis factor production inhibitor</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="NFKB1">
      <data key="d0">GENE</data>
      <data key="d1">NFKB1 is a gene encoding the Nuclear Factor Kappa B Subunit 1</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="NFKB2">
      <data key="d0">GENE</data>
      <data key="d1">NFKB2 is a gene encoding the Nuclear Factor Kappa B Subunit 2</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="APRATASTAT">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Apratastat is a matrix metalloprotease inhibitor and tumor necrosis factor production inhibitor</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="ADAM17">
      <data key="d0">GENE</data>
      <data key="d1">ADAM17 is a gene encoding the ADAM Metallopeptidase Domain 17
A disintegrin and metalloproteinase 17, involved in the cleavage of membrane-bound proteins</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d,a10787d7fbb1307be263e86dc7b33a51</data>
      <data key="d3">GENE</data>
    </node>
    <node id="MMP13">
      <data key="d0">GENE</data>
      <data key="d1">MMP13 is a gene encoding the Matrix Metallopeptidase 13</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="ATRACTYLENOLIDE-I">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Atractylenolide-I is a JAK inhibitor</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="JAK1">
      <data key="d0">GENE</data>
      <data key="d1">JAK1 is a gene encoding the Janus Kinase 1
JAK1 is a gene encoding Janus kinase 1, involved in cytokine signaling
JAK1 is a protein involved in the JAK-STAT signaling pathway and targeted by upadacitinib and abrocitinib in the treatment of atopic dermatitis
JAK1 is a kinase involved in the phosphorylation of STAT6 in IL-4 and IL-13 signaling
Janus kinase 1, a protein involved in signaling pathways for immune responses
Janus kinase 1, a member of the JAK family of tyrosine kinases involved in cytokine signaling
JAK1 is a member of the JAK family of tyrosine kinases involved in cytokine receptor signaling
JAK1 is a gene encoding a protein that is part of the Janus kinase family, involved in cytokine receptor signaling
Janus kinase 1 is a protein involved in the signaling of various cytokines
JAK1, or Janus kinase 1, is a protein involved in the regulation of immune responses
JAK1 is a member of the Janus kinase family involved in the JAK/STAT signaling pathway
Janus kinase 1, involved in cytokine signaling
JAK1 is a protein inhibited by cibinqo</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,0ba9fbea14e0c2c1d01a12ffaacfda9b,286730b1c1f680ac465cc21d522fda0c,3df8535e965efb96f5094169610507ff,48de7eebab3f3b418feb35a152df38fd,62b4bd8f530adae989e4349d1e58f11d,a867a1e73cef039eb3f28e072463b838,c44ec79872ab10cbe7336182f183ff60,c46e8b6ee0c29e37b7f18c42558d7a3e,cccfd5ff480e281556e2210cd0e5c4b5,e075bccd45593ae008b2ce7f9ed8ff6c,e95d4d15e4f3110c91a3d3fcb5910d06,f14a13d54127c3baadeb0b34d40928c9</data>
      <data key="d3">GENE</data>
    </node>
    <node id="AZD1480">
      <data key="d0">CHEMICAL</data>
      <data key="d1">AZD1480 is a JAK inhibitor</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="BALSALAZIDE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Balsalazide is a cyclooxygenase inhibitor</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="ALOX5">
      <data key="d0">GENE</data>
      <data key="d1">ALOX5 is a gene encoding the Arachidonate 5-Lipoxygenase</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="PPARG">
      <data key="d0">GENE</data>
      <data key="d1">PPARG is a gene encoding the Peroxisome Proliferator-Activated Receptor Gamma</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="BMS-911543">
      <data key="d0">CHEMICAL</data>
      <data key="d1">BMS-911543 is a JAK inhibitor</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="CIGLITAZONE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Ciglitazone is a PPAR&#947; agonist</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="GPD1">
      <data key="d0">GENE</data>
      <data key="d1">GPD1 is a gene encoding the Glycerol-3-Phosphate Dehydrogenase 1</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="TBXA2R">
      <data key="d0">GENE</data>
      <data key="d1">TBXA2R is a gene encoding the Thromboxane A2 Receptor</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="CURCUMOL">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Curcumol is a JAK inhibitor</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="CYT387">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Cyt387 is a JAK inhibitor</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="FEDRATINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Fedratinib is a FLT3 inhibitor and JAK inhibitor</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="BRD4">
      <data key="d0">GENE</data>
      <data key="d1">BRD4 is a gene encoding the Bromodomain Containing 4</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="TYK2">
      <data key="d0">GENE</data>
      <data key="d1">TYK2 is a gene encoding the Tyrosine Kinase 2
Tyrosine kinase 2, a member of the JAK family of tyrosine kinases involved in cytokine signaling
TYK2 is a member of the JAK family of tyrosine kinases involved in cytokine receptor signaling
TYK2, or tyrosine kinase 2, is a protein involved in the regulation of immune responses
Tyrosine Kinase 2 (TYK2) is a protein involved in the JAK/STAT signaling pathway</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b,3df8535e965efb96f5094169610507ff,62b4bd8f530adae989e4349d1e58f11d,c46e8b6ee0c29e37b7f18c42558d7a3e,f14a13d54127c3baadeb0b34d40928c9</data>
      <data key="d3">GENE</data>
    </node>
    <node id="FILGOTINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Filgotinib is a JAK inhibitor</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="GANODERIC-ACID-A">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Ganoderic-acid-a is a JAK inhibitor</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="JTE-607">
      <data key="d0">CHEMICAL</data>
      <data key="d1">JTE-607 is a cytokine production inhibitor</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="LATAMOXEF">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Latamoxef is a cephalosporine antibiotic</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="DACB">
      <data key="d0">GENE</data>
      <data key="d1">DACB is a gene involved in antibiotic resistance</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="MRCA">
      <data key="d0">GENE</data>
      <data key="d1">MRCA is a gene involved in antibiotic resistance</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="MRCB">
      <data key="d0">GENE</data>
      <data key="d1">MRCB is a gene involved in antibiotic resistance</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="PBPC">
      <data key="d0">GENE</data>
      <data key="d1">PBPC is a gene involved in antibiotic resistance</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="LXR-623">
      <data key="d0">CHEMICAL</data>
      <data key="d1">LXR-623 is a Liver X receptor agonist</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="NR1H2">
      <data key="d0">GENE</data>
      <data key="d1">NR1H2 is a gene encoding the Nuclear Receptor Subfamily 1 Group H Member 2</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="NR1H3">
      <data key="d0">GENE</data>
      <data key="d1">NR1H3 is a gene encoding the Nuclear Receptor Subfamily 1 Group H Member 3</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="NR1I2">
      <data key="d0">GENE</data>
      <data key="d1">NR1I2 is a gene encoding the Nuclear Receptor Subfamily 1 Group I Member 2
NR1I2 is a gene encoding nuclear receptor subfamily 1 group I member 2, involved in the regulation of drug metabolismNR1I2 is a receptor involved in the regulation of drug metabolism</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d,c44ec79872ab10cbe7336182f183ff60</data>
      <data key="d3">GENE</data>
    </node>
    <node id="NR3C1">
      <data key="d0">GENE</data>
      <data key="d1">NR3C1 is a gene encoding the Nuclear Receptor Subfamily 3 Group C Member 1</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="NS-018">
      <data key="d0">CHEMICAL</data>
      <data key="d1">NS-018 is a JAK inhibitor</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="PACRITINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Pacritinib is a FLT3 inhibitor and JAK inhibitor</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="PARACETAMOL">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Paracetamol is a cyclooxygenase inhibitor</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="FAAH">
      <data key="d0">GENE</data>
      <data key="d1">FAAH is a gene encoding the Fatty Acid Amide Hydrolase</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="PLERIXAFOR">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Plerixafor is a CC chemokine receptor antagonist</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="ACKR3">
      <data key="d0">GENE</data>
      <data key="d1">ACKR3 is a gene encoding the Atypical Chemokine Receptor 3</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="CXCR4">
      <data key="d0">GENE</data>
      <data key="d1">CXCR4 is a gene encoding the C-X-C Motif Chemokine Receptor 4</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="SIROLIMUS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Sirolimus is an mTOR inhibitor</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="CFD1">
      <data key="d0">GENE</data>
      <data key="d1">CFD1 is a gene involved in cellular processes</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="FKBP1A">
      <data key="d0">GENE</data>
      <data key="d1">FKBP1A is a gene encoding the FK506 Binding Protein 1A</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="MTOR">
      <data key="d0">GENE</data>
      <data key="d1">MTOR is a gene encoding the Mechanistic Target of Rapamycin</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="RPL38">
      <data key="d0">GENE</data>
      <data key="d1">RPL38 is a gene encoding the Ribosomal Protein L38</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="TROFINETIDE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Trofinetide is a cytokine production inhibitor</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="UPADACITINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Upadacitinib is a JAK inhibitor
Upadacitinib is a JAK inhibitor targeting JAK1, JAK2, and JAK3, used in the treatment of autoimmune diseases
Upadacitinib is a JAK1 inhibitor used in the treatment of atopic dermatitis
Upadacitinib is a JAK inhibitor used to treat atopic dermatitis
An oral JAK1 inhibitor used in the treatment of moderate-to-severe AD
Upadacitinib is a JAK1-selective inhibitor used in the treatment of autoimmune diseases
Upadacitinib is a small molecule drug developed by AbbVie, targeting JAK1
Upadacitinib is a Janus kinase (JAK) inhibitor used as a targeted therapy for Atopic Dermatitis.
Upadacitinib is a JAK inhibitor licensed for treating AD
Upadacitinib is a JAK inhibitor used for treating moderate to severe AD
Upadacitinib is a small molecule drug targeting JAK1</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd,3df8535e965efb96f5094169610507ff,62b4bd8f530adae989e4349d1e58f11d,6ada075e562abd7bd445164e9fc309b4,a867a1e73cef039eb3f28e072463b838,c44ec79872ab10cbe7336182f183ff60,cccfd5ff480e281556e2210cd0e5c4b5,dc905ba8b6eb7d84cf2776303211010d,e075bccd45593ae008b2ce7f9ed8ff6c,e95d4d15e4f3110c91a3d3fcb5910d06,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="WHI-P154">
      <data key="d0">CHEMICAL</data>
      <data key="d1">WHI-P154 is a JAK inhibitor
WHI-P154 is a JAK inhibitor targeting EGFR, JAK1, JAK2, and JAK3, currently in preclinical development</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d,c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="XL019">
      <data key="d0">CHEMICAL</data>
      <data key="d1">XL019 is a JAK inhibitor
XL019 is a JAK inhibitor targeting JAK1, JAK2, and JAK3, in early clinical development</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d,c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="TNFAIP3">
      <data key="d0">GENE</data>
      <data key="d1">TNFAIP3 is a gene encoding the Tumor Necrosis Factor Alpha-Induced Protein 3</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="APRIL">
      <data key="d0">PROTEIN</data>
      <data key="d1">APRIL is a protein encoded by the TNFSF13 gene, involved in immune regulation
APRIL is a proliferation-inducing ligand involved in B cell maturation and fibrosis
APRIL is a protein involved in immune responses and is associated with fibrosis and atopic skin diseases
APRIL is a ligand in the TNF superfamily, also known as CD256, TALL-2
APRIL is a protein involved in immune regulation and is a target for fusion protein therapies
APRIL (A Proliferation-Inducing Ligand) is a protein involved in the regulation of B-cell development and survival
APRIL (A Proliferation-Inducing Ligand) is a protein involved in the regulation of B cells</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3,423195c6b63ad0a6773374364ebf3612,62b4bd8f530adae989e4349d1e58f11d,8e5a1be9981340d419f7b3ad27076009,b2aae16813e647959b783a39ef9a19a7,c525762bb827485bceeb9f09bb4bcfe0,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="BAFF">
      <data key="d0">PROTEIN</data>
      <data key="d1">BAFF is a protein encoded by the TNFSF13B gene, involved in B-cell development and survival
BAFF is a B lymphocyte stimulator involved in B cell maturation and fibrosis
BAFF is a protein involved in immune responses and is associated with fibrosis in various tissues
BAFF is a ligand in the TNF superfamily, also known as CD257, BLyS, TALL-2
BAFF is a protein involved in B-cell development and is a target for monoclonal antibody therapies
BAFF (B-cell activating factor) is a protein involved in the regulation of B-cell development and survival
BAFF (B-cell activating factor) is a protein involved in the survival and maturation of B cells
BAFF (TNFSF13B) is a protein that can act on structural and immune cells to drive pro-fibrotic and anti-fibrotic effects</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3,423195c6b63ad0a6773374364ebf3612,516e41e96d2e72d45bf1e2c69da7f18a,62b4bd8f530adae989e4349d1e58f11d,8e5a1be9981340d419f7b3ad27076009,b2aae16813e647959b783a39ef9a19a7,c525762bb827485bceeb9f09bb4bcfe0,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="CHK">
      <data key="d0">PROTEIN</data>
      <data key="d1">CHK is a protein involved in cell cycle regulation</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="CYTOCHROME P450">
      <data key="d0">PROTEIN</data>
      <data key="d1">Cytochrome P450 is a family of enzymes involved in drug metabolism</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="INDOLEAMINE 2,3-DIOXYGENASE">
      <data key="d0">PROTEIN</data>
      <data key="d1">Indoleamine 2,3-dioxygenase is an enzyme involved in tryptophan metabolism</data>
      <data key="d2">62b4bd8f530adae989e4349d1e58f11d</data>
    </node>
    <node id="TNFSF4">
      <data key="d0">GENE</data>
      <data key="d1">TNFSF4 is a gene encoding the TNF Receptor Superfamily Member 4
TNFSF4, also known as OX40L, is a gene that encodes the T cell costimulatory molecule OX40 ligand
TNFSF4, a gene associated with susceptibility to SLE and SSc
TNFSF4 is a gene from the tumour necrosis factor ligand superfamily member 4 that is associated with SSc susceptibility
TNFSF4 is a gene from the tumour necrosis factor ligand superfamily member 4 that is associated with SSc susceptibility
TNFSF4 is a gene from the tumour necrosis factor ligand superfamily member 4 that is associated with systemic sclerosis susceptibility
TNFSF4 is a gene from the tumour necrosis factor ligand superfamily member 4 that is associated with SSc susceptibility
TNFSF4 is a gene associated with susceptibility to systemic sclerosis and other autoimmune diseases
TNFSF4 is another name for OX40L, the ligand for OX40
TNFSF4, also known as OX40L or CD252, is a gene encoding the OX40 ligand
TNFSF4 is the TNF superfamily nomenclature for OX40L</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14,1b656cfce91ff9ccec4223703489dab3,40ad2241836485e0bf264bdfb62fd789,62b4bd8f530adae989e4349d1e58f11d,7b454335c2f5651d86f712037a0dc0ff,7c13f41d7349d9d2e56c36e00c0ca2d9,8ce8c356713490cd2c680f505bcd050b,c69c7fb997f95c56cc077b3975f41923,c95d22c2a90e77cd22bd0d280d55b26a,d8a485eb1e9435b083d5ef6a17f06ea5,f9c444698bb08349abe4244fb771c1ee</data>
    </node>
    <node id="TNFA">
      <data key="d0">GENE</data>
      <data key="d1">TNFA is a gene encoding the cytokine tumor necrosis factor-alpha, involved in systemic inflammation</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="ACITRETIN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Acitretin is a retinoid receptor agonist targeting KRT16, PI3, RARA, RARB, RARG, RBP1, RXRA, RXRB, RXRG, and STAT3, used in the treatment of psoriasis</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="RARA">
      <data key="d0">GENE</data>
      <data key="d1">RARA is a gene encoding retinoic acid receptor alpha, involved in gene expression regulation</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="RARB">
      <data key="d0">GENE</data>
      <data key="d1">RARB is a gene encoding retinoic acid receptor beta, involved in gene expression regulation</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="RARG">
      <data key="d0">GENE</data>
      <data key="d1">RARG is a gene encoding retinoic acid receptor gamma, involved in gene expression regulation</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="RBP1">
      <data key="d0">GENE</data>
      <data key="d1">RBP1 is a gene encoding retinol binding protein 1, involved in vitamin A metabolism</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="RXRA">
      <data key="d0">GENE</data>
      <data key="d1">RXRA is a gene encoding retinoid X receptor alpha, involved in gene expression regulation</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="RXRB">
      <data key="d0">GENE</data>
      <data key="d1">RXRB is a gene encoding retinoid X receptor beta, involved in gene expression regulation</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="RXRG">
      <data key="d0">GENE</data>
      <data key="d1">RXRG is a gene encoding retinoid X receptor gamma, involved in gene expression regulation</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="STAT3">
      <data key="d0">GENE</data>
      <data key="d1">STAT3 is a transcription factor involved in cytokine signalingSTAT3 is a gene encoding signal transducer and activator of transcription 3, involved in cytokine signaling</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="AVACOPAN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Avacopan is a C5&#945; receptor antagonist targeting C5AR1, used in the treatment of autoimmune diseases</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="CLINDAMYCIN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Clindamycin is a protein synthesis inhibitor used in the treatment of bacterial infections</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="CYPROTERONE ACETATE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Cyproterone acetate is an AR antagonist targeting ADORA1 and AR, used in the treatment of androgen-dependent conditions</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="ADORA1">
      <data key="d0">GENE</data>
      <data key="d1">ADORA1 is a gene encoding adenosine A1 receptor, involved in various physiological processes</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="DOXYCYCLINE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Doxycycline is a bacterial 30S ribosomal subunit inhibitor and metalloproteinase inhibitor targeting MMP1, MMP8, and PI3, used in the treatment of bacterial infections</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="MMP8">
      <data key="d0">GENE</data>
      <data key="d1">MMP8 is a gene encoding matrix metallopeptidase 8, involved in the breakdown of extracellular matrixMMP8 is an enzyme involved in the breakdown of extracellular matrix</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="ETANERCEPT">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Etanercept is a TNF-&#945; receptor antagonist targeting TNFRSF1A, used in the treatment of autoimmune diseases
Etanercept is a TNF antagonist used in the treatment of inflammatory diseases
Etanercept is a TNF antagonist used in the treatment of autoimmune diseases
Etanercept is a biopharmaceutical that treats autoimmune diseases by inhibiting TNF</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e,7f559ad7372a4e35e90b43cc67047b0f,a10787d7fbb1307be263e86dc7b33a51,c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="TNFRSF1A">
      <data key="d0">GENE</data>
      <data key="d1">TNFRSF1A is a receptor involved in immune responseTNFRSF1A is a gene encoding tumor necrosis factor receptor superfamily member 1A, involved in immune response
TNFRSF1A is the TNF receptor superfamily nomenclature for TNFR1</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60,c95d22c2a90e77cd22bd0d280d55b26a</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="GOLIMUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Golimumab is a TNF inhibitor targeting TNF, used in the treatment of autoimmune diseases
Golimumab is a TNF antagonist used in the treatment of inflammatory diseases</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e,c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="INCB 54707">
      <data key="d0">CHEMICAL</data>
      <data key="d1">INCB 54707 is a JAK1 inhibitor targeting JAK1, in early clinical development</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="INFLIXIMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Infliximab is a TNF inhibitor targeting IL6 and TNF, used in the treatment of autoimmune diseases
Infliximab is a TNF antagonist used in the treatment of inflammatory diseases</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e,c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="METFORMIN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Metformin is an insulin sensitizer targeting ACACB and PRKAB1, used in the treatment of type 2 diabetes</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="ACACB">
      <data key="d0">GENE</data>
      <data key="d1">ACACB is a gene encoding acetyl-CoA carboxylase beta, involved in fatty acid metabolismACACB is an enzyme involved in fatty acid metabolism</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="RIFAMPICIN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Rifampicin is an RNA polymerase inhibitor targeting NR1I2, SLCO1A2, SLCO1B1, and SLCO1B3, used in the treatment of bacterial infections</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="SLCO1A2">
      <data key="d0">GENE</data>
      <data key="d1">SLCO1A2 is a transporter involved in drug transportSLCO1A2 is a gene encoding solute carrier organic anion transporter family member 1A2, involved in drug transport</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="SLCO1B1">
      <data key="d0">GENE</data>
      <data key="d1">SLCO1B1 is a gene encoding solute carrier organic anion transporter family member 1B1, involved in drug transportSLCO1B1 is a transporter involved in drug transport</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="SLCO1B3">
      <data key="d0">GENE</data>
      <data key="d1">SLCO1B3 is a transporter involved in drug transportSLCO1B3 is a gene encoding solute carrier organic anion transporter family member 1B3, involved in drug transport</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="SECUKINUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Secukinumab is an IL-17A inhibitor targeting IL17A, used in the treatment of autoimmune diseases
A human IgG1&#954;, anti&#8211;IL-17A monoclonal antibody used in the treatment of moderate-to-severe atopic dermatitis
Secukinumab is an anti-IL-17A antibody investigated for the treatment of moderate to severe AD
Secukinumab is a biologic injection targeting IL-17A used in the treatment of atopic dermatitis
Secukinumab is an anti-IL-17A antibody used to treat plaque psoriasis and explored for AD treatment
Secukinumab is a biologic drug targeting Interleukin-17a</data>
      <data key="d2">1d0c4a4cd555b7ecd0b9d7b0310e9fe9,2cec06c4d46f5ff9ee936a78d8b077cd,48288f3ec2832850282f95d4e38d10e1,c44ec79872ab10cbe7336182f183ff60,cccfd5ff480e281556e2210cd0e5c4b5,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="SPESOLIMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Spesolimab is an IL-36R antagonist targeting IL36RN, in early clinical development
Spesolimab is an anti-IL-36R antibody tested in a rare form of pustular psoriasis and explored for atopic dermatitis
Spesolimab is a biologic injection targeting IL-36R used in the treatment of atopic dermatitis
A treatment targeting IL-36R, effective in treating a rare type of psoriasis
Spesolimab is a biologic agent targeting interleukin-36R in atopic dermatitis treatment</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,6309eeea565f06479830cec32938abc9,849e0980ffd6a7e1cf0b8d3d1fbacd98,c44ec79872ab10cbe7336182f183ff60,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="FSH">
      <data key="d0">PROTEIN</data>
      <data key="d1">FSH is a protein known as follicle-stimulating hormone, involved in reproductive processesFSH is a hormone involved in reproductive processes</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="HCG">
      <data key="d0">PROTEIN</data>
      <data key="d1">HCG is a hormone involved in pregnancyHCG is a protein known as human chorionic gonadotropin, involved in pregnancy</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="LH">
      <data key="d0">PROTEIN</data>
      <data key="d1">LH is a protein known as luteinizing hormone, involved in reproductive processesLH is a hormone involved in reproductive processes</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="VILOBELIMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Vilobelimab is a C5&#945; inhibitor targeting C5, in early clinical development</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="C5">
      <data key="d0">GENE</data>
      <data key="d1">C5 is a gene encoding complement component 5, involved in immune response</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="IL-17A">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-17A is a cytokine involved in inflammatory responses
IL-17A is a cytokine involved in immune responses and has a lesser contribution to the inflammatory responses in HS
Interleukin-17A is an inflammatory cytokine with enriched signals in HS
IL-17A is a pro-inflammatory cytokine involved in the immune response
A key Th17-related cytokine involved in the pathogenesis of atopic dermatitis
IL-17A (Interleukin-17A) is a cytokine involved in the immune response and inflammation
IL-17A is a cytokine involved in the immune response and inflammation
IL-17A is a cytokine involved in the immune response, targeted by secukinumab</data>
      <data key="d2">1d0c4a4cd555b7ecd0b9d7b0310e9fe9,2cec06c4d46f5ff9ee936a78d8b077cd,411a4d246f0a9321e52971446a5a0606,41ccc4b41bd57cf2bda4dbb6c7ae4198,523bbfee1ae3b4ecabf9b11d10eea9ff,c44ec79872ab10cbe7336182f183ff60,e340a83f7cba0ea5be731b1f682ea7c7,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="IL-17F">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-17F is a cytokine involved in inflammatory responses</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="IL-17R">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-17R is a receptor for IL-17 cytokines, involved in inflammatory responses</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="IL-36R">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-36R is a receptor for IL-36 cytokines, involved in inflammatory responses
IL-36R (Interleukin-36 receptor) is a protein involved in the immune response and inflammation
Interleukin-36 receptor, involved in inflammation</data>
      <data key="d2">849e0980ffd6a7e1cf0b8d3d1fbacd98,c44ec79872ab10cbe7336182f183ff60,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="C5&#913;">
      <data key="d0">PROTEIN</data>
      <data key="d1">C5&#945; is a component of the complement system involved in immune responses</data>
      <data key="d2">c44ec79872ab10cbe7336182f183ff60</data>
    </node>
    <node id="JAK">
      <data key="d0">PROTEIN</data>
      <data key="d1">JAK is a family of tyrosine kinases involved in cytokine signaling
JAK family of tyrosine kinases includes JAK1, JAK2, JAK3, and TYK2, involved in cytokine receptor signaling
Janus kinase, involved in signaling pathways for immune response
Janus Kinase (JAK) is a protein involved in the JAK/STAT signaling pathway for cytokines like IL-4, IL-13, and IL-31
Janus Kinases (JAK) are enzymes involved in cytokine signaling, targeted by JAK inhibitors
JAK is a receptor involved in the pathophysiology of AD</data>
      <data key="d2">286730b1c1f680ac465cc21d522fda0c,2cec06c4d46f5ff9ee936a78d8b077cd,3df8535e965efb96f5094169610507ff,849e0980ffd6a7e1cf0b8d3d1fbacd98,c44ec79872ab10cbe7336182f183ff60,c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </node>
    <node id="IL-12">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-12 is a cytokine involved in immune responses
Interleukin-12, a cytokine involved in inflammatory responses
A cytokine upregulated in atopic dermatitis lesions, driving Th1 cell differentiation</data>
      <data key="d2">1d0c4a4cd555b7ecd0b9d7b0310e9fe9,c44ec79872ab10cbe7336182f183ff60,e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="IL-23">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-23 is a cytokine involved in immune responses
Interleukin-23, a cytokine involved in inflammatory responses
A cytokine upregulated in atopic dermatitis lesions, driving Th17 cell differentiation
IL-23 is a cytokine involved in the immune response and related to psoriasis
IL-23 is a cytokine involved in the IL-23&#8211;IL-17 axis, implicated in psoriasis and AD
IL-23 (Interleukin-23) is a cytokine involved in the immune response and inflammation
IL-23 is a cytokine involved in the immune response and inflammation</data>
      <data key="d2">1d0c4a4cd555b7ecd0b9d7b0310e9fe9,41ccc4b41bd57cf2bda4dbb6c7ae4198,48288f3ec2832850282f95d4e38d10e1,6309eeea565f06479830cec32938abc9,c44ec79872ab10cbe7336182f183ff60,e95d4d15e4f3110c91a3d3fcb5910d06,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="OX40">
      <data key="d0">GENE</data>
      <data key="d1">OX40 is a checkpoint molecule that potentiates pro-inflammatory T-cell responses
OX40 is a co-stimulatory immune checkpoint molecule involved in T-cell activation and survival
OX40 is a protein targeted by rocatinlimab, involved in T-cell activation
OX40 is a protein involved in the costimulatory pathway of T-cells
OX40 is a protein involved in the immune response and T-cell functioning
OX40 is a co-stimulatory T-cell receptor expressed predominantly on effector and regulatory T-cells
OX40 is a protein involved in the immune response and is a target for inhibitors in atopic dermatitis treatment
OX40 is a gene involved in T-cell costimulatory pathways
OX40 is a protein involved in the regulation of T-cell function
OX40 is a tumour necrosis factor receptor family member whose expression is increased in AD lesions and affects T-cell proliferation, survival, and memory cell formation
OX40 is a costimulatory molecule and member of the TNF receptor family involved in T cell activation
OX40 is a protein involved in the immune response, particularly in T cell subsets
A protein involved in the immune response, particularly in the Th2 pathway
OX40 is a costimulatory receptor and member of the TNF receptor superfamily involved in T-cell activation
OX40 is a costimulatory receptor and a member of the TNF receptor superfamily, expressed when T-cells are stimulated
OX40 is a co-stimulatory T-cell receptor involved in the pathogenesis of Atopic Dermatitis
OX40, a protein analyzed on the cell surface of PBMCs from patients with AD and HC
OX40 is a protein highly expressed by skin-homing T cells and monocytes in atopic dermatitis
OX40 is a gene that encodes a protein involved in T cell costimulation and immune response modulation
OX40 is a gene involved in the immune response and is part of the TNF receptor superfamily
OX40 is a member of the TNF receptor superfamily that generates a potent costimulatory signal
OX40 is involved in positive costimulatory pathways
OX40 is a protein involved in T cell costimulation
OX40 is a protein expressed on CD4+ and CD8+ T cells, providing a costimulatory signal
OX40, also known as TNFRSF4 or CD134, is a marker of T-cell activation and promotes T-cell survival, proliferation, and cytokine secretion
OX40 is a gene involved in T-cell receptor signaling and modulates activated T-cell activity
OX40 is a receptor for OX40L, also known as CD134, ACT35, TXGP1L
OX40 is a costimulatory molecule involved in immune responses and targeted by monoclonal antibodies in clinical trials</data>
      <data key="d2">100dd7646c10899301b3c0631183da16,1412a7a7fef5f18cc09a030b97b18e13,1b656cfce91ff9ccec4223703489dab3,2cec06c4d46f5ff9ee936a78d8b077cd,2e0cdefd62bed7c674d7fb93ef336c2b,2e9a8d71f6bd251a0b13458c39e69746,3287c502f10f4651d2f56bf39ee7bb7a,3df8535e965efb96f5094169610507ff,44f2592262cac835560b4c149fee8d2b,475995d7d211bbfde6d8ba52f324d688,4842292208575bd45b2b5998513dd087,4d0e8ae9371a435885994b4161126bc3,6309eeea565f06479830cec32938abc9,68015074236b0144899baa38d01ae467,691cb2e23ac3c6e591129d16714f8ef8,6b099960b0a39866e3aa6b908f1886e4,78e26c66107dba37ac4bab65406b43a0,7c13f41d7349d9d2e56c36e00c0ca2d9,849e0980ffd6a7e1cf0b8d3d1fbacd98,855c455b4c9592746834ee3a4e0e6b81,89dbac0da39e4de2b602052cd792b90d,8ce8c356713490cd2c680f505bcd050b,b201c6ff3e22b2475c8c59260a0eb6a7,b876251511f570468eb5b6ee6a239cc6,c95d22c2a90e77cd22bd0d280d55b26a,dc905ba8b6eb7d84cf2776303211010d,e075bccd45593ae008b2ce7f9ed8ff6c,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </node>
    <node id="OX40L">
      <data key="d0">GENE</data>
      <data key="d1">OX40L is a checkpoint molecule that binds to OX40 to potentiate pro-inflammatory T-cell responses
OX40L is the ligand for OX40 and plays a role in T-cell activation and survival
OX40L is a protein that binds to OX40 and is involved in the costimulatory pathway of T-cells
OX40L is a protein that binds to OX40 and is involved in the immune response and T-cell functioning
OX40L is a ligand expressed on activated antigen-presenting cells and endothelial cells, playing a central role in pro-inflammatory T-cell responses
OX40L is the binding partner of OX40 and is involved in the immune response, targeted by inhibitors in atopic dermatitis treatment
OX40L is a protein that binds to OX40 and is involved in T-cell activation
OX40L is the ligand for OX40 and is involved in T-cell proliferation, survival, and memory cell formation
OX40L is the ligand for OX40, expressed on DCs and involved in T cell activation
OX40L is a protein that interacts with OX40 and is involved in the immune response
OX40L (OX40 ligand) is a protein involved in the immune response and inflammation
OX40L, or OX40 ligand, is a protein involved in the regulation of immune responses
OX40L is a ligand for OX40 produced by antigen-presenting cells during inflammation
OX40L is a ligand for OX40, produced by antigen-presenting cells during inflammation
OX40L is the ligand for OX40, playing a central role in the pathogenesis of Atopic Dermatitis
OX40L, a protein analyzed on the cell surface of PBMCs from patients with AD and HC
OX40L is a protein targeted by monoclonal mouse antibodies for analysis
OX40L is a protein highly expressed by monocytes and co-localized with OX40 in the skin of AD patients
OX40L is a gene that encodes a ligand for OX40, involved in T cell costimulation and immune response modulation
OX40L is a gene that encodes a ligand for OX40, playing a role in immune response modulation
OX40L is a costimulatory protein in immune response modulation
OX40L is the binding partner of OX40 and enhances T cell survival and B cell proliferation
OX40L is a costimulatory protein in immune response modulation
OX40 ligand, involved in positive costimulatory pathways
OX40L is a protein involved in T cell costimulation, also known as OX40 ligand
OX40L is a T cell costimulatory molecule encoded by the TNFSF4 gene
OX40L is a protein encoded by TNFSF4 and is involved in T cell proliferation, survival, and cytokine production
OX40L, also known as TNFSF4 or CD252, is the ligand for OX40 and is expressed on antigen-presenting cells
OX40L, also known as TNFSF4 or CD252, is a ligand for OX40 and is involved in co-stimulatory signaling
OX40L is a ligand in the TNF superfamily, also known as CD252, CD134L, Gp34, TXGP1
OX40L is a costimulatory molecule involved in immune responses and targeted by monoclonal antibodies in clinical trials</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14,100dd7646c10899301b3c0631183da16,1412a7a7fef5f18cc09a030b97b18e13,1b656cfce91ff9ccec4223703489dab3,2cec06c4d46f5ff9ee936a78d8b077cd,2e9a8d71f6bd251a0b13458c39e69746,3287c502f10f4651d2f56bf39ee7bb7a,348f2797841cbef27311b03f2cd788dd,3df8535e965efb96f5094169610507ff,44f2592262cac835560b4c149fee8d2b,4842292208575bd45b2b5998513dd087,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,6309eeea565f06479830cec32938abc9,68015074236b0144899baa38d01ae467,691cb2e23ac3c6e591129d16714f8ef8,6b099960b0a39866e3aa6b908f1886e4,78e26c66107dba37ac4bab65406b43a0,7c13f41d7349d9d2e56c36e00c0ca2d9,855c455b4c9592746834ee3a4e0e6b81,89dbac0da39e4de2b602052cd792b90d,8ce8c356713490cd2c680f505bcd050b,9867d43adab0ba5db44961fae4863eee,b201c6ff3e22b2475c8c59260a0eb6a7,b876251511f570468eb5b6ee6a239cc6,c95d22c2a90e77cd22bd0d280d55b26a,dc905ba8b6eb7d84cf2776303211010d,e075bccd45593ae008b2ce7f9ed8ff6c,e9841b88c9fab58c5175af409653da50,f14a13d54127c3baadeb0b34d40928c9,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </node>
    <node id="ROCATINLIMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Rocatinlimab is an anti-OX40 antibody being developed for the treatment of atopic dermatitis
Rocatinlimab is a fully human, non-fucosylated, IgG1 anti-OX40 monoclonal antibody investigated for the treatment of AD
Rocatinlimab, formerly known as AMG 451/KHK4083, is a fully human, non-fucosylated, immunoglobulin G1 (IgG1) anti-OX40 monoclonal antibody currently under investigation for the treatment of moderate-to-severe atopic dermatitis
Rocatinlimab is a drug being evaluated in a phase 3 trial for its efficacy in treating head and neck disease
Rocatinlimab is an anti-OX40 monoclonal antibody used in the treatment of atopic dermatitis
Rocatinlimab is a fully human anti-OX40 monoclonal antibody that selectively depletes sOX40+ activated T-cells
Rocatinlimab is a drug being tested in clinical trials for atopic dermatitis
Rocatinlimab (KHK4083) is a monoclonal antibody against OX40 that yielded positive results in a phase-II experiment
Rocatinlimab is a biologic drug targeting OX-40</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd,3287c502f10f4651d2f56bf39ee7bb7a,475995d7d211bbfde6d8ba52f324d688,4842292208575bd45b2b5998513dd087,b201c6ff3e22b2475c8c59260a0eb6a7,b876251511f570468eb5b6ee6a239cc6,cccfd5ff480e281556e2210cd0e5c4b5,dc905ba8b6eb7d84cf2776303211010d,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </node>
    <node id="AMLITELIMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Amlitelimab is an anti-OX40L antibody being developed for the treatment of atopic dermatitis
Amlitelimab, also known as KY1005/SAR445229, is an OX40-OX40L pathway inhibitor with a different mechanism of action
Amlitelimab is a monoclonal antibody targeting the OX40-OX40L pathway, used in the treatment of moderate-to-severe atopic dermatitis
Amlitelimab is a non-depleting IgG4 human anti-OX40L monoclonal antibody that blocks interaction with OX40
Amlitelimab is an anti-OX40L monoclonal antibody that reduces IL-22 serum levels</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd,b201c6ff3e22b2475c8c59260a0eb6a7,b876251511f570468eb5b6ee6a239cc6,dc905ba8b6eb7d84cf2776303211010d,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </node>
    <node id="ATOPIC DERMATITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Atopic dermatitis is a chronically relapsing, inflammatory skin disease with a great impact on the patient&#8217;s quality of life
Atopic Dermatitis is a chronic inflammatory skin disease
Atopic Dermatitis, also known as AD, is a chronic inflammatory skin disease
Atopic Dermatitis (AD) is a chronic, systemic, inflammatory disease that affects the skin and is characterized by persistent itch and marked redness
Atopic dermatitis, also known as AD, is a chronic inflammatory skin disease characterized by itchy and inflamed skin
Atopic Dermatitis (AD) is a common chronic inflammatory skin disease with a complex pathophysiology and a wide spectrum of clinical phenotypes
Atopic dermatitis, also referred to as AD, a chronic inflammatory skin disease
Atopic Dermatitis (AD) is a chronic inflammatory skin disease
Atopic Dermatitis (AD) is a chronic inflammatory skin disease characterized by itchy and inflamed skin
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by itching and redness
Atopic dermatitis is a chronic inflammatory skin condition characterized by itchy and inflamed skin
Atopic Dermatitis (AD) is an inflammatory skin condition that frequently develops before the onset of allergic rhinitis or asthma. It is characterized by skin irritation, redness, and eczematous lesions.
Atopic dermatitis (AD) is a chronic inflammatory skin disease
Atopic Dermatitis is a chronic inflammatory skin disease
Atopic Dermatitis (AD) is a chronic, or chronically relapsing, inflammatory skin disease associated with asthma and allergic rhinitis, dominated by Th2 cells
Atopic Dermatitis (AD) is a chronic inflammatory skin disease
Atopic dermatitis is a type of skin fibrosis
Atopic dermatitis, also known as eczema, is a condition that makes the skin red and itchy
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by itchy, red, swollen, and cracked skin
Atopic dermatitis, a chronic skin condition characterized by itchy and inflamed skin
Atopic dermatitis is a chronic inflammatory skin condition</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,08e39958b85d84950ab7173daab9111b,1596d061dbe1a1c9e8f31a02a21e5524,2e0cdefd62bed7c674d7fb93ef336c2b,348f2797841cbef27311b03f2cd788dd,3dfbb4c51838e0951f53ce951395225f,48288f3ec2832850282f95d4e38d10e1,5f37466ca41c9b8b06ed8be0303d49f2,68015074236b0144899baa38d01ae467,691cb2e23ac3c6e591129d16714f8ef8,693a2aac101eaaadf92614317a1e4da8,6ada075e562abd7bd445164e9fc309b4,83eb9003d42977bb83fea1d123dd5ab9,b28eeca0ff01a7715947d55a04978a43,b2aae16813e647959b783a39ef9a19a7,cccfd5ff480e281556e2210cd0e5c4b5,df74aa1b86eeeb811ca5586767ae3a71,e075bccd45593ae008b2ce7f9ed8ff6c,e9841b88c9fab58c5175af409653da50,f1897c89e321a3a80924fd72a56e90df,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </node>
    <node id="PRURITUS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Pruritus is a severe itching sensation that significantly impacts the quality of life of atopic dermatitis patients
Pruritus is the medical term for itching, often associated with inflammatory skin conditions
Pruritus, or itching, was measured using the NRS score in patients treated with rocatinlimab
Pruritus is a symptom characterized by severe itching
Pruritus is a medical term for itching
Pruritus is a symptom characterized by severe itching
Pruritus, or itching, is a common symptom in atopic dermatitis
Severe itching associated with atopic dermatitis
Pruritus, commonly known as itching, is a symptom often associated with atopic dermatitis
Pruritus is the medical term for itching, often seen in AD
Pruritus is a symptom of atopic dermatitis characterized by severe itching
Pruritus is a symptom characterized by severe itching
Severe itching, a common symptom in AD
Pruritus is severe itching of the skin
Severe itching of the skin
Pruritus is the medical term for itching, a common symptom in atopic dermatitis
Pruritus is the medical term for itching
Pruritus is severe itching of the skin
Pruritus, or itching, is a common symptom associated with Atopic Dermatitis
Pruritus is the sensation of itching that leads to scratching
Pruritus is a symptom characterized by severe itching, often seen in AD
Pruritus is intense itching, a symptom of Atopic Dermatitis</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,08e39958b85d84950ab7173daab9111b,143d2dc302af5606656797bff162e23e,1596d061dbe1a1c9e8f31a02a21e5524,1d0c4a4cd555b7ecd0b9d7b0310e9fe9,28f548554737fcc026b968db6bbafa30,3287c502f10f4651d2f56bf39ee7bb7a,3ce96e927d65736b305f792977fed4b9,3df8535e965efb96f5094169610507ff,3ea70e257330c812b52334ca1f90d807,442e7fad2fab75fa2449309783294d89,475995d7d211bbfde6d8ba52f324d688,4842292208575bd45b2b5998513dd087,6309eeea565f06479830cec32938abc9,691cb2e23ac3c6e591129d16714f8ef8,90f4809673ca34628b0e607908f0bf0b,a867a1e73cef039eb3f28e072463b838,b201c6ff3e22b2475c8c59260a0eb6a7,b876251511f570468eb5b6ee6a239cc6,e075bccd45593ae008b2ce7f9ed8ff6c,f1897c89e321a3a80924fd72a56e90df,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </node>
    <node id="TOPICAL CORTICOSTEROIDS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Topical corticosteroids are part of the topical therapy used in the treatment of atopic dermatitis
A class of steroid hormones used to reduce inflammation in skin diseases
Topical corticosteroids (TCSs) are anti-inflammatory medications used to treat AD flares
Topical corticosteroids are used in the treatment of AD
Topical corticosteroids are used in combination with tralokinumab for treating AD</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,1d0c4a4cd555b7ecd0b9d7b0310e9fe9,2cec06c4d46f5ff9ee936a78d8b077cd,8246ea974dfb00cb5e3d984004e21a9e,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </node>
    <node id="CALCINEURIN INHIBITORS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Calcineurin inhibitors are part of the topical therapy used in the treatment of atopic dermatitis
Calcineurin inhibitors, such as pimecrolimus and tacrolimus, are used as topical treatments for Atopic Dermatitis
Calcineurin Inhibitors are medications used to suppress the immune system and reduce inflammation</data>
      <data key="d2">693a2aac101eaaadf92614317a1e4da8,c46e8b6ee0c29e37b7f18c42558d7a3e,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </node>
    <node id="CRISABOROLE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Crisaborole is a topical therapy used in the treatment of atopic dermatitis
Crisaborole is a topical phosphodiesterase-4 inhibitor approved for the treatment of Atopic Dermatitis
A topical PDE-4 inhibitor approved for the treatment of mild-to-moderate AD
Crisaborole is a phosphodiesterase 4 (PDE4) inhibitor used to treat AD
Crisaborole is a topical PDE4 inhibitor approved for the treatment of mild to moderate atopic dermatitis
Crisaborole is a topical PDE4 inhibitor approved for the treatment of Atopic Dermatitis
Crisaborole is a topical ointment for treating AD</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,286730b1c1f680ac465cc21d522fda0c,442e7fad2fab75fa2449309783294d89,693a2aac101eaaadf92614317a1e4da8,90f4809673ca34628b0e607908f0bf0b,e075bccd45593ae008b2ce7f9ed8ff6c,e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="PHOTOTHERAPY">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Phototherapy is a treatment option for atopic dermatitis
Phototherapy is a treatment approach for Atopic Dermatitis that involves the use of ultraviolet light</data>
      <data key="d2">693a2aac101eaaadf92614317a1e4da8,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </node>
    <node id="IMMUNOSUPPRESSANTS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Conventional systemic immunosuppressants are used in the treatment of atopic dermatitis but may have limited efficacy and long-term toxicity
Immunosuppressants are systemic agents used in the treatment of Atopic Dermatitis, though they present tolerability issues</data>
      <data key="d2">693a2aac101eaaadf92614317a1e4da8,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </node>
    <node id="TRALOKINUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Tralokinumab is an IL-13 inhibitor used in the treatment of atopic dermatitis
Tralokinumab is an anti-IL-13 antibody used to treat atopic dermatitis
Tralokinumab is an anti&#8211;IL&#8208;13 monoclonal antibody in advanced-stage trials for Atopic Dermatitis
Tralokinumab is an antibody targeting IL-13, under development for AD treatment
Tralokinumab is an IgG4&#955; anti&#8211;IL-13 monoclonal antibody that prevents IL-13 from binding to IL-13R&#945;1 and IL-13R&#945;2
Tralokinumab is a biologic targeting IL-13, currently in clinical studies for atopic dermatitis
A biologic drug targeting IL-13, used in the treatment of atopic dermatitis
Tralokinumab is an anti-IL-13 inhibitor approved for the treatment of AD
Tralokinumab is a fully humanized antibody targeting IL-13
A monoclonal antibody targeting IL-13, used in the treatment of atopic dermatitis
Tralokinumab is a monoclonal antibody that targets IL-13, used in the treatment of atopic dermatitis
Tralokinumab is a biologic injection targeting IL-13 used in the treatment of atopic dermatitis
Tralokinumab is an IgG4k IL-13 antagonist that prevents IL-13 from interacting with its receptors
Tralokinumab is a biological drug that targets IL-13, used for treating AD
Tralokinumab is a biological drug that specifically targets IL-13 and has shown safety and efficacy, particularly when used with topical corticosteroids
Tralokinumab is a biologic agent targeting interleukin-13 in atopic dermatitis treatment
Tralokinumab is a biologic drug targeting Interleukin-13Ra1
Tralokinumab is a medication inhibiting the cytokine IL-13</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,0ba9fbea14e0c2c1d01a12ffaacfda9b,104cc78517b2eca2e9cb7e00de1fe4b0,1596d061dbe1a1c9e8f31a02a21e5524,286730b1c1f680ac465cc21d522fda0c,28f548554737fcc026b968db6bbafa30,2cec06c4d46f5ff9ee936a78d8b077cd,3df8535e965efb96f5094169610507ff,3dfbb4c51838e0951f53ce951395225f,48de7eebab3f3b418feb35a152df38fd,693a2aac101eaaadf92614317a1e4da8,78e26c66107dba37ac4bab65406b43a0,8246ea974dfb00cb5e3d984004e21a9e,96e553a44a27e728c27c4892045ec5c2,cccfd5ff480e281556e2210cd0e5c4b5,dc905ba8b6eb7d84cf2776303211010d,e075bccd45593ae008b2ce7f9ed8ff6c,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="ABROCITINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Abrocitinib is a JAK1 inhibitor used in the treatment of atopic dermatitis
Abrocitinib is a JAK inhibitor used to treat atopic dermatitis
Abrocitinib is a JAK1-selective inhibitor used in the treatment of autoimmune diseases
Abrocitinib is a small molecule drug developed by Pfizer, targeting JAK1
Abrocitinib is a Janus kinase (JAK) inhibitor used as a targeted therapy for Atopic Dermatitis.
Abrocitinib is a JAK inhibitor licensed for treating AD
Abrocitinib is a JAK inhibitor used for treating moderate to severe AD
Abrocitinib is a small molecule drug targeting JAK1</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd,3df8535e965efb96f5094169610507ff,6ada075e562abd7bd445164e9fc309b4,a867a1e73cef039eb3f28e072463b838,cccfd5ff480e281556e2210cd0e5c4b5,dc905ba8b6eb7d84cf2776303211010d,e075bccd45593ae008b2ce7f9ed8ff6c,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="BARICITINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Baricitinib is a JAK1/2 inhibitor used in the treatment of atopic dermatitis
Baricitinib is a JAK inhibitor used to treat atopic dermatitis
An oral JAK1/JAK2 inhibitor used in the treatment of moderate-to-severe AD
Baricitinib is a JAK1/2 inhibitor approved for the treatment of AD
Baricitinib is an oral JAK1/JAK2 inhibitor approved for treating moderate to severe AD
Baricitinib is a JAK1/JAK2 inhibitor used in the treatment of autoimmune diseases
Baricitinib is a JAK1/JAK2 inhibitor used in the treatment of rheumatoid arthritis and being studied for atopic dermatitis
Baricitinib is a small molecule drug developed by Lilly, targeting JAK1/JAK2
Baricitinib is a Janus kinase (JAK) inhibitor used as a targeted therapy for Atopic Dermatitis.
Baricitinib is a JAK inhibitor licensed for treating AD
Baricitinib is a JAK inhibitor used for treating moderate to severe AD</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,1596d061dbe1a1c9e8f31a02a21e5524,2cec06c4d46f5ff9ee936a78d8b077cd,3df8535e965efb96f5094169610507ff,6ada075e562abd7bd445164e9fc309b4,a867a1e73cef039eb3f28e072463b838,c46e8b6ee0c29e37b7f18c42558d7a3e,dc905ba8b6eb7d84cf2776303211010d,e075bccd45593ae008b2ce7f9ed8ff6c,e95d4d15e4f3110c91a3d3fcb5910d06,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="LEBRIKIZUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Lebrikizumab is an IL-13 inhibitor in an advanced stage of clinical development for the treatment of atopic dermatitis
Lebrikizumab is an anti&#8211;IL&#8208;13 monoclonal antibody in advanced-stage trials for Atopic Dermatitis
Lebrikizumab is an antibody targeting IL-13, under development for AD treatment
Lebrikizumab is a humanized IgG4&#954; monoclonal antibody that binds soluble IL-13 with high affinity
A monoclonal antibody used in the treatment of asthma and potentially AD
Lebrikizumab is a monoclonal antibody used in the treatment of asthma
Lebrikizumab is a biologic targeting IL-13, currently in clinical studies for atopic dermatitis
A biologic drug targeting IL-13, used in the treatment of atopic dermatitis
A monoclonal antibody targeting IL-13, used in the treatment of atopic dermatitis
Lebrikizumab is a monoclonal antibody that targets IL-13, used in the treatment of atopic dermatitis
Lebrikizumab is a biologic injection targeting IL-13 used in the treatment of atopic dermatitis
Lebrikizumab is an IgG4k monoclonal antibody that selectively binds to IL-13, blocking its signaling
Lebrikizumab is a biologic agent targeting interleukin-13 in atopic dermatitis treatment
Lebrikizumab is a biologic drug targeting Interleukin-13</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,0ba9fbea14e0c2c1d01a12ffaacfda9b,104cc78517b2eca2e9cb7e00de1fe4b0,28f548554737fcc026b968db6bbafa30,3df8535e965efb96f5094169610507ff,3dfbb4c51838e0951f53ce951395225f,48de7eebab3f3b418feb35a152df38fd,693a2aac101eaaadf92614317a1e4da8,96e553a44a27e728c27c4892045ec5c2,b19f42c9497f71b231222cd953036d6b,cccfd5ff480e281556e2210cd0e5c4b5,e075bccd45593ae008b2ce7f9ed8ff6c,e95d4d15e4f3110c91a3d3fcb5910d06,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="NEMOLIZUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Nemolizumab is an IL-31 inhibitor in an advanced stage of clinical development for the treatment of atopic dermatitis

Nemolizumab is a humanized IgG2&#954;, anti-IL-31R&#945; monoclonal antibody that mitigates IL-31&#8211;dependent processes by antagonizing its cognate receptor
Nemolizumab is an anti-IL-31R&#945; antibody used to reduce pruritus in atopic dermatitis
Nemolizumab is a biologic drug developed by Galderma, targeting the IL-31 receptor
Nemolizumab is a humanized monoclonal antibody that targets IL-31RA to control AD inflammation and pruritus
Nemolizumab is a biologic drug targeting Interleukin-31</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b,1d0c4a4cd555b7ecd0b9d7b0310e9fe9,3df8535e965efb96f5094169610507ff,cccfd5ff480e281556e2210cd0e5c4b5,e075bccd45593ae008b2ce7f9ed8ff6c,f14a13d54127c3baadeb0b34d40928c9,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </node>
    <node id="TH2">
      <data key="d0">CELL</data>
      <data key="d1">Th2 cells are involved in the immune response and are modulated in the acute phase of atopic dermatitis
Th2 cells are a subset of T-helper cells involved in the immune response, particularly in atopic dermatitis
Th2 is a type of T-helper cell pathway involved in the immune response
Th2 cells are a subset of T-helper cells involved in the immune response, particularly in atopic dermatitis
Th2 cells are a type of T cell involved in the immune response
A subset of T helper cells involved in humoral immunity and allergic responses
Th2 cells are a subset of T-helper cells involved in the immune response and associated with allergic reactions
T helper 2 cells are involved in immune polarization and play a key role in atopic dermatitis
T helper 2 cells, a type of immune cell involved in allergic responses
TH2 cells are a subset of T helper cells involved in immune responses
TH2 immune response is a pathway leading to cutaneous inflammation in atopic dermatitis
T-helper 2 cells, a subset of T cells involved in the immune response
TH2 cells are a subset of T helper cells involved in the immune response
Th2 cells are a subset of T helper cells involved in the immune response
TH2 cells are a subset of T helper cells involved in the immune response
TH2 cells are a subset of T helper cells involved in the immune response and inflammation
T helper 2 (TH2) cells are involved in the adaptive immune response in atopic dermatitis, leading to IgE sensitization
Th2 cells are a type of T-helper cell involved in the immune response and associated with cytokine production in Atopic Dermatitis.
Th2 cells are a subtype of T helper cells involved in the immune response and inflammation
Th2 cells are a subset of T cells involved in the immune response and are influenced by IL-4 and IL-13
Th2 cells are a subset of T-cells involved in the immune response, particularly in central memory cell growth
TH2 cells are a subset of T helper cells involved in the immune response
T helper type 2 cells, playing a central role in M2 macrophage polarization
T helper 2 cells are a subset of T cells that produce cytokines and are involved in the immune response
Th2 cells are a type of T helper cell involved in allergic airway inflammation
Th2 cells are a subset of T helper cells involved in the immune response against extracellular parasites and in allergic reactions
Th2 cells are a subset of T helper cells involved in the immune response, particularly in producing interleukin-4 and interleukin-13</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,05c97152fe02249153103be341d65b67,0829313703a7d2bae5436a9ee542334d,143d2dc302af5606656797bff162e23e,1596d061dbe1a1c9e8f31a02a21e5524,1d0c4a4cd555b7ecd0b9d7b0310e9fe9,2cec06c4d46f5ff9ee936a78d8b077cd,2e0cdefd62bed7c674d7fb93ef336c2b,3df8535e965efb96f5094169610507ff,3ea70e257330c812b52334ca1f90d807,41ccc4b41bd57cf2bda4dbb6c7ae4198,44f2592262cac835560b4c149fee8d2b,475995d7d211bbfde6d8ba52f324d688,48288f3ec2832850282f95d4e38d10e1,5ec1ebf4e260eb1f8fda8acdf06cd39e,5f37466ca41c9b8b06ed8be0303d49f2,6309eeea565f06479830cec32938abc9,6ada075e562abd7bd445164e9fc309b4,78e26c66107dba37ac4bab65406b43a0,83eb9003d42977bb83fea1d123dd5ab9,855c455b4c9592746834ee3a4e0e6b81,8ce8c356713490cd2c680f505bcd050b,a867a1e73cef039eb3f28e072463b838,b201c6ff3e22b2475c8c59260a0eb6a7,c46e8b6ee0c29e37b7f18c42558d7a3e,dc905ba8b6eb7d84cf2776303211010d,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </node>
    <node id="TH22">
      <data key="d0">CELL</data>
      <data key="d1">Th22 cells are involved in the immune response and are modulated in the acute phase of atopic dermatitis
Th22 cells are a subset of T-helper cells involved in the immune response
Th22 cells are a subset of T-cells involved in pro-inflammatory responses
Th22 is a type of T-helper cell pathway involved in the immune response
Th22 cells are a subset of T-helper cells involved in immune responses
Th22 cells are a subset of T-helper cells involved in the immune response and associated with skin diseases
T helper 22 cells are involved in immune responses and are implicated in atopic dermatitis
Th22 cells are a subset of T helper cells involved in the immune response
T helper 22 (TH22) cells are part of the adaptive immune response in atopic dermatitis
Th22 cells are a subtype of T helper cells involved in the immune response and inflammation
Th22 cells are a subset of T-cells involved in the immune response, particularly in the Th22 pathway</data>
      <data key="d2">143d2dc302af5606656797bff162e23e,1596d061dbe1a1c9e8f31a02a21e5524,2cec06c4d46f5ff9ee936a78d8b077cd,41ccc4b41bd57cf2bda4dbb6c7ae4198,475995d7d211bbfde6d8ba52f324d688,83eb9003d42977bb83fea1d123dd5ab9,b201c6ff3e22b2475c8c59260a0eb6a7,b876251511f570468eb5b6ee6a239cc6,c46e8b6ee0c29e37b7f18c42558d7a3e,dc905ba8b6eb7d84cf2776303211010d,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </node>
    <node id="TH1">
      <data key="d0">CELL</data>
      <data key="d1">Th1 cells are involved in the immune response and are activated in the chronic phase of atopic dermatitis
Th1 cells are a subset of T-helper cells involved in the immune response
Th1 cells are a subset of T-cells involved in pro-inflammatory responses
Th1 is a type of T-helper cell pathway involved in the immune response
Th1 cells are a subset of T-helper cells involved in cellular immunity
A subset of T helper cells involved in cellular immune responses
Th1 cells are a subset of T-helper cells involved in the immune response and associated with inflammation
TH1 cells are a subset of T helper cells involved in the immune response
T helper 1 (TH1) cells are part of the adaptive immune response in atopic dermatitis
Th1 cells are a subtype of T helper cells involved in the immune response and inflammation
T helper 1 cells are a subset of T cells that produce cytokines and are involved in the immune response
Th1 cells are a type of T helper cell whose differentiation is inhibited by impaired TNF/TNFR2 signaling
Th1 cells are a subset of T helper cells involved in the immune response against intracellular pathogens
Th1 cells are a subset of T helper cells involved in the immune response, particularly in producing interferon-gamma</data>
      <data key="d2">05c97152fe02249153103be341d65b67,1596d061dbe1a1c9e8f31a02a21e5524,1d0c4a4cd555b7ecd0b9d7b0310e9fe9,41ccc4b41bd57cf2bda4dbb6c7ae4198,475995d7d211bbfde6d8ba52f324d688,48288f3ec2832850282f95d4e38d10e1,5ec1ebf4e260eb1f8fda8acdf06cd39e,5f37466ca41c9b8b06ed8be0303d49f2,83eb9003d42977bb83fea1d123dd5ab9,8ce8c356713490cd2c680f505bcd050b,b201c6ff3e22b2475c8c59260a0eb6a7,b876251511f570468eb5b6ee6a239cc6,dc905ba8b6eb7d84cf2776303211010d,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </node>
    <node id="FILAGGRIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Filaggrin is a protein involved in skin barrier function and is downregulated in atopic dermatitis
Filaggrin is a protein involved in the formation of the epidermal barrier
Filaggrin is a terminal marker of epidermal differentiation suppressed in chronic atopic dermatitis
Filaggrin is a protein important for skin barrier function, reduced in AD lesions
Filaggrin is a protein involved in skin barrier function
Filaggrin is a protein involved in epidermal barrier function, reduced by IL-4
Filaggrin is a protein that plays a crucial role in the formation and maintenance of the skin barrier
Filaggrin is a protein involved in the formation of the skin barrier
Filaggrin (FLG) is a gene encoding structural elements of the epidermis, mutations of which are implicated in atopic dermatitis
FLG, a protein encoded by genes that are mutated in AD, affecting epidermal barrier function
Filaggrin is a protein involved in skin barrier function, downregulated by IL-22 in keratinocytes
Filaggrin is a protein that binds to keratin fibers in epithelial cells
Filaggrin (FLG) is an essential membrane protein with the greatest genetic association with Atopic Dermatitis.
Filaggrin (FLG) is a gene whose expression is restored by coal tar binding to AhR</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,143d2dc302af5606656797bff162e23e,1596d061dbe1a1c9e8f31a02a21e5524,28f548554737fcc026b968db6bbafa30,3ea70e257330c812b52334ca1f90d807,48288f3ec2832850282f95d4e38d10e1,4842292208575bd45b2b5998513dd087,48de7eebab3f3b418feb35a152df38fd,6059a6e2710b7df94c6a09e5eb7b024a,6ada075e562abd7bd445164e9fc309b4,b19f42c9497f71b231222cd953036d6b,e075bccd45593ae008b2ce7f9ed8ff6c,f2aa3fd6ae3f1853347874c50afb60ea,f66eb51473925a8084dad1745be63b78</data>
    </node>
    <node id="LORICRIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Loricrin is a protein involved in skin barrier function and is downregulated in atopic dermatitis
Loricrin is a protein involved in the formation of the epidermal barrier
Loricrin is a terminal marker of epidermal differentiation suppressed in chronic atopic dermatitis
Loricrin is a protein important for epidermal barrier integrity, downregulated by IL-4 and IL-13
Loricrin is a protein involved in skin barrier function
Loricrin is a protein involved in epidermal barrier function, reduced by IL-4
Loricrin is a protein involved in the formation of the skin barrier
Loricrin is a major protein component of the cornified cell envelope in the epidermis</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,1596d061dbe1a1c9e8f31a02a21e5524,28f548554737fcc026b968db6bbafa30,4842292208575bd45b2b5998513dd087,48de7eebab3f3b418feb35a152df38fd,b19f42c9497f71b231222cd953036d6b,e075bccd45593ae008b2ce7f9ed8ff6c,f66eb51473925a8084dad1745be63b78</data>
    </node>
    <node id="TSLP">
      <data key="d0">PROTEIN</data>
      <data key="d1">TSLP (thymic stromal lymphopoietin) is an epidermis-derived alarmin cytokine involved in the immune response in atopic dermatitis
Thymic stromal lymphopoietin (TSLP) is a cytokine involved in the activation of dendritic cells
Thymic stromal lymphopoietin (TSLP) is highly expressed in skin epithelial cells in AD and has roles in generating type 2 immune responses and inducing itch
Thymic stromal lymphopoietin, a keratinocyte-derived alarmin involved in AD
Thymic stromal lymphopoietin, a cytokine involved in the immune response
Thymic stromal lymphopoietin is a cytokine involved in the pathogenesis of atopic dermatitis
TSLP (Thymic stromal lymphopoietin) is a protein involved in the immune response and inflammation
Thymic stromal lymphopoietin (TSLP) is a cytokine involved in the immune response and inflammation
Thymic stromal lymphopoietin, involved in Th2 cell activation
Thymic Stromal Lymphopoietin (TSLP) is a cytokine that activates antigen-presenting cells and increases T-cell adhesion and migrationThymic Stromal Lymphopoietin (TSLP) is a cytokine involved in the activation of antigen-presenting cells
TSLP is a cytokine that activates antigen-presenting cells, including endothelial cells and DCs, during inflammation
Thymic stromal lymphopoietin (TSLP) is a cytokine that shows a considerable reduction with the topical administration of PLG-based nanoparticles
Thymic stromal lymphopoietin (TSLP) is a cytokine involved in the regulation of immune responses
TSLP is a cytokine involved in the pathogenesis of AD
Thymic stromal lymphopoietin is a cytokine implicated in EoE pathogenesis</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,27a7e95c7d3ad59a948aa46741fee456,286730b1c1f680ac465cc21d522fda0c,2cec06c4d46f5ff9ee936a78d8b077cd,3df8535e965efb96f5094169610507ff,3ea70e257330c812b52334ca1f90d807,41ccc4b41bd57cf2bda4dbb6c7ae4198,4842292208575bd45b2b5998513dd087,6309eeea565f06479830cec32938abc9,849e0980ffd6a7e1cf0b8d3d1fbacd98,bddc3b1a7f098e71f0aa64adec047124,d4797ed1483e5057bcd8301eaa509d5e,e075bccd45593ae008b2ce7f9ed8ff6c,e9841b88c9fab58c5175af409653da50,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </node>
    <node id="IL-25">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-25 is an epidermis-derived alarmin cytokine involved in the immune response in atopic dermatitis
IL-25 is a cytokine involved in the activation of type 2 immune responses
Interleukin-25, a keratinocyte-derived alarmin involved in AD
IL-25 is a cytokine involved in the initiation of the skin-derived immune response
IL-25 is a cytokine involved in the immune response and associated with Atopic Dermatitis.
IL-25 is a cytokine involved in the immune response and inflammationIL-25 is a cytokine that plays a role in the immune response and inflammation
Interleukin-25, involved in Th2 cell activation
Interleukin-25 (IL-25) is a cytokine produced by mast cells, central to the pathogenesis of Atopic Dermatitis</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807,41ccc4b41bd57cf2bda4dbb6c7ae4198,4842292208575bd45b2b5998513dd087,6309eeea565f06479830cec32938abc9,691cb2e23ac3c6e591129d16714f8ef8,6ada075e562abd7bd445164e9fc309b4,849e0980ffd6a7e1cf0b8d3d1fbacd98,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </node>
    <node id="IL-33">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-33 is an epidermis-derived alarmin cytokine involved in the immune response in atopic dermatitis
IL-33 is a cytokine produced by barrier-disrupted keratinocytes that stimulates type 2 immune responses
IL-33 is an IL-1 family member that enhances type 2 responses through the induction of IL-5 and IL-13 in ILC2, type 1 responses through induction of IFN-&#947;, and contributes to epidermal barrier dysfunction by downregulation of filaggrin expression
Interleukin-33, a keratinocyte-derived alarmin involved in AD
IL-33 is a cytokine involved in the innate immune response
IL-33 (Interleukin-33) is a cytokine involved in the immune response and inflammation
IL-33 is a cytokine involved in the immune response and inflammation
Interleukin-33, involved in inflammation and Th2 responses
IL-33 is a cytokine involved in immune response and inflammation</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807,41ccc4b41bd57cf2bda4dbb6c7ae4198,4842292208575bd45b2b5998513dd087,6309eeea565f06479830cec32938abc9,849e0980ffd6a7e1cf0b8d3d1fbacd98,a10787d7fbb1307be263e86dc7b33a51,e075bccd45593ae008b2ce7f9ed8ff6c,e9841b88c9fab58c5175af409653da50,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </node>
    <node id="IGE">
      <data key="d0">PROTEIN</data>
      <data key="d1">IgE is an immunoglobulin involved in the immune response and stimulated by IL-4 and IL-13 in atopic dermatitis
IgE is an antibody that plays a crucial role in allergic reactions and is produced by plasma cells
Immunoglobulin E, produced by plasma cells in response to IL-4 and IL-13
Immunoglobulin E, an antibody involved in allergic reactions and regulated by IL-4
Immunoglobulin E (IgE) is an antibody commonly detected at increased levels in AD patients, though its role in pathophysiology is not clear
IgE is an antibody involved in allergic reactions and sensitization in atopic dermatitis
Immunoglobulin E, an antibody involved in allergic reactions
Immunoglobulin E, an antibody involved in allergic reactions
IgE is an immunoglobulin involved in allergic reactions and is a hallmark of TH2 immune response
IgE is an immunoglobulin involved in allergic reactions and expressed on Langerhans cells and inflammatory dendritic epidermal cells
Immunoglobulin E is an antibody associated with allergic reactions
Immunoglobulin E (IgE) is involved in sensitization to environmental allergens in atopic dermatitis
IgE (Immunoglobulin E) is an antibody that plays a crucial role in allergies and is involved in the immune response to parasites
Immunoglobulin E (IgE) is an antibody involved in allergic reactions and immune responses
Immunoglobulin E, involved in allergic reactions and Th2 immune response
Immunoglobulin E (IgE) is an antibody associated with allergic reactions
Immunoglobulin E (IgE) is an antibody associated with allergic reactions
Immunoglobulin E (IgE) is an antibody associated with allergic reactions
IgE is an antibody that is elevated in up to 80% of patients with Atopic Dermatitis
IgE is an immunoglobulin associated with allergic reactions and measured in atopic dermatitis patients
Immunoglobulin E, an antibody measured in the study but not correlated with OX40 expression
Immunoglobulin E (IgE) is an antibody associated with allergic reactions
Immunoglobulin E (IgE) is an antibody associated with allergic reactions</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,0829313703a7d2bae5436a9ee542334d,143d2dc302af5606656797bff162e23e,27a7e95c7d3ad59a948aa46741fee456,28f548554737fcc026b968db6bbafa30,348f2797841cbef27311b03f2cd788dd,3dfbb4c51838e0951f53ce951395225f,41ccc4b41bd57cf2bda4dbb6c7ae4198,48288f3ec2832850282f95d4e38d10e1,4842292208575bd45b2b5998513dd087,48de7eebab3f3b418feb35a152df38fd,6309eeea565f06479830cec32938abc9,691cb2e23ac3c6e591129d16714f8ef8,6aef5adb1be227170f66c76a292c25e5,6b099960b0a39866e3aa6b908f1886e4,83eb9003d42977bb83fea1d123dd5ab9,849e0980ffd6a7e1cf0b8d3d1fbacd98,89dbac0da39e4de2b602052cd792b90d,c46e8b6ee0c29e37b7f18c42558d7a3e,d2c44662af9752fc9f82c86121ede7c0,e075bccd45593ae008b2ce7f9ed8ff6c,e9841b88c9fab58c5175af409653da50,f2aa3fd6ae3f1853347874c50afb60ea</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="PLASMA CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Plasma cells produce IgE in response to IL-4 and IL-13 stimulation in atopic dermatitis
Plasma cells are a type of white blood cell that produces antibodies, including IgE
Plasma cells are a type of white blood cell that produces antibodies and are involved in the pathogenesis of HS
Plasma cells are a type of immune cell found in the skin
Plasma cells are differentiated B cells that produce large volumes of antibodies
Plasma cells are a type of white blood cell that produce antibodies and are predominant in HS skin
Plasma cells are a type of B cell that produce antibodies and are identified as a potential therapeutic target in HS
Plasma cells produce immunoglobulin E in response to IL-4 and IL-13
Plasma cells are a type of white blood cell that produces antibodies
Plasma cells are differentiated B cells that produce antibodies</data>
      <data key="d2">05c97152fe02249153103be341d65b67,2e0cdefd62bed7c674d7fb93ef336c2b,411a4d246f0a9321e52971446a5a0606,4842292208575bd45b2b5998513dd087,48de7eebab3f3b418feb35a152df38fd,4cf23e218b6aab3c77115173b5c7c2fd,523bbfee1ae3b4ecabf9b11d10eea9ff,b62ecc47bf54393bc78dd65986b949d6,bae090d8a29c15868ba1c4f29ae79e99,e075bccd45593ae008b2ce7f9ed8ff6c</data>
      <data key="d3">CELL</data>
    </node>
    <node id="HISTAMINE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Histamine is involved in pruritus and is amplified by IL-31 in atopic dermatitis

Histamine is a compound involved in local immune responses and allergic reactions
Histamine is a compound involved in local immune responses</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,3dfbb4c51838e0951f53ce951395225f,4842292208575bd45b2b5998513dd087,e075bccd45593ae008b2ce7f9ed8ff6c</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="EASI">
      <data key="d0">SYMPTOM</data>
      <data key="d1">EASI (Eczema Area and Severity Index) is a measure used to assess the severity of atopic dermatitis
Eczema Area and Severity Index (EASI) is a tool used to measure the extent and severity of atopic dermatitis
Eczema Area and Severity Index (EASI) is a tool used to measure the extent and severity of eczema
Eczema Area and Severity Index, a tool used to measure the severity of atopic dermatitis
Eczema Area and Severity Index (EASI) is a tool used to measure the extent and severity of eczema
Eczema Area and Severity Index (EASI) is a tool used to measure the severity of eczema
Eczema Area and Severity Index, a tool used to measure the extent and severity of atopic dermatitis
Eczema Area and Severity Index, a tool used to measure the extent and severity of eczema
Eczema Area and Severity Index (EASI) is a tool used to measure the extent and severity of eczema
Eczema Area and Severity Index, a tool used to measure the extent and severity of eczema
The Eczema Area Severity Index is a tool for assessing the severity of atopic dermatitis
Eczema Area and Severity Index, a tool used to measure the extent and severity of eczema
Eczema Area and Severity Index, a tool used to measure the extent and severity of eczema
Eczema Area and Severity Index, a tool used to measure the severity of eczema
Eczema Area and Severity Index (EASI) is a tool used to measure the extent and severity of eczema
Eczema Area and Severity Index, a tool used to measure the extent and severity of eczema
EASI is a scoring system used to measure the extent and severity of eczema
Eczema Area and Severity Index (EASI) is a tool used to measure the extent and severity of eczema
Eczema Area and Severity Index, a tool used to measure the severity of atopic dermatitis
Eczema Area and Severity Index (EASI) is a tool used to measure the extent and severity of eczema
Eczema Area and Severity Index is a tool used to measure the extent and severity of eczema
Eczema Area and Severity Index, a measure of eczema severity
EASI is a clinical tool used to assess the severity of AD
Eczema Area and Severity Index, a measure used to evaluate disease severity in AD
Eczema Area and Severity Index (EASI) is a tool used to measure the severity of eczema
Eczema Area and Severity Index is a tool used to measure the extent and severity of eczema</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,0829313703a7d2bae5436a9ee542334d,0ba9fbea14e0c2c1d01a12ffaacfda9b,100dd7646c10899301b3c0631183da16,104cc78517b2eca2e9cb7e00de1fe4b0,143d2dc302af5606656797bff162e23e,1d0c4a4cd555b7ecd0b9d7b0310e9fe9,28f548554737fcc026b968db6bbafa30,2cec06c4d46f5ff9ee936a78d8b077cd,3287c502f10f4651d2f56bf39ee7bb7a,3ea70e257330c812b52334ca1f90d807,442e7fad2fab75fa2449309783294d89,475995d7d211bbfde6d8ba52f324d688,48288f3ec2832850282f95d4e38d10e1,6309eeea565f06479830cec32938abc9,78e26c66107dba37ac4bab65406b43a0,8246ea974dfb00cb5e3d984004e21a9e,849e0980ffd6a7e1cf0b8d3d1fbacd98,89dbac0da39e4de2b602052cd792b90d,b201c6ff3e22b2475c8c59260a0eb6a7,b876251511f570468eb5b6ee6a239cc6,c46e8b6ee0c29e37b7f18c42558d7a3e,dc905ba8b6eb7d84cf2776303211010d,e075bccd45593ae008b2ce7f9ed8ff6c,f1897c89e321a3a80924fd72a56e90df,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </node>
    <node id="IL-31">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-31 is a cytokine involved in the immune response and pruritus in atopic dermatitis
IL-31 is a cytokine produced by Th2 cells that is involved in inflammation and immune response
IL-31 is a type 2 cytokine involved in the pathophysiology of atopic dermatitis and is associated with itch
IL-31 is a cytokine involved in the immune response and associated with AD
IL-31 is a cytokine involved in immune response and inflammation
A cytokine produced by Th2 cells and mature dendritic cells, evoking itch and altering barrier protein expression
IL-31 is a cytokine produced by Th2 cells and mature dendritic cells, known to evoke itch and alter the expression of barrier proteins
Interleukin-31, a cytokine produced by T helper 2 cells that is associated with pruritus in atopic dermatitis
IL-31 (Interleukin-31) is a cytokine involved in the inflammatory response
IL-31 (Interleukin-31) is a cytokine involved in the immune response and inflammation
IL-31 is a cytokine involved in the regulation of immune responses and itching
IL-31 is a cytokine involved in the immune response and associated with Atopic Dermatitis.
IL-31 is a cytokine involved in the immune response and inflammation
Interleukin-31, involved in inflammation and immune response
IL-31 is a cytokine known as the "itch cytokine" that induces pruritus in AD patients
IL-31 is a cytokine involved in the immune response and inflammation
IL-31 is a cytokine involved in the pathogenesis of AD</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b,1d0c4a4cd555b7ecd0b9d7b0310e9fe9,286730b1c1f680ac465cc21d522fda0c,2cec06c4d46f5ff9ee936a78d8b077cd,3df8535e965efb96f5094169610507ff,41ccc4b41bd57cf2bda4dbb6c7ae4198,4842292208575bd45b2b5998513dd087,48de7eebab3f3b418feb35a152df38fd,6ada075e562abd7bd445164e9fc309b4,849e0980ffd6a7e1cf0b8d3d1fbacd98,a867a1e73cef039eb3f28e072463b838,b19f42c9497f71b231222cd953036d6b,e075bccd45593ae008b2ce7f9ed8ff6c,e9841b88c9fab58c5175af409653da50,f14a13d54127c3baadeb0b34d40928c9,f2aa3fd6ae3f1853347874c50afb60ea,f66eb51473925a8084dad1745be63b78</data>
    </node>
    <node id="IL-4R&#913;">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-4R&#945; is the receptor subunit targeted by dupilumab in the treatment of atopic dermatitis
IL-4R&#945; is the receptor for IL-4, targeted by the antibody dupilumab in the treatment of Atopic Dermatitis
IL-4R&#945; is a subunit of the type 2 IL-4 receptor involved in IL-4 and IL-13 signaling
IL-4R&#945; is a receptor subunit involved in IL-4 and IL-13 signaling
IL-4R&#945; is a receptor subunit involved in IL-4 and IL-13 signaling
IL-4 receptor alpha, a component of both type 1 and type 2 heterodimeric receptors for IL-4 and IL-13
IL-4 receptor alpha, a subunit of the interleukin-4 receptor complex
IL-4R&#945; is a receptor for interleukin-4, involved in immune response modulation
IL-4R&#945; is a receptor chain common to type I and type II receptors for IL-4 and IL-13
Interleukin-4 receptor alpha, a component of the IL-4 receptor
IL-4R&#945; (Interleukin-4 receptor alpha) is a protein that mediates the effects of interleukin-4 and interleukin-13, playing a role in the immune response
IL-4R&#945;, or &#945;-chain of the IL-4 receptor, is a protein involved in the regulation of immune responses
IL-4R&#945; is a receptor involved in the signaling pathway of IL-4 and IL-13</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,104cc78517b2eca2e9cb7e00de1fe4b0,1596d061dbe1a1c9e8f31a02a21e5524,28f548554737fcc026b968db6bbafa30,3df8535e965efb96f5094169610507ff,48de7eebab3f3b418feb35a152df38fd,693a2aac101eaaadf92614317a1e4da8,78e26c66107dba37ac4bab65406b43a0,96e553a44a27e728c27c4892045ec5c2,b19f42c9497f71b231222cd953036d6b,e075bccd45593ae008b2ce7f9ed8ff6c,e9841b88c9fab58c5175af409653da50,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="TH2 CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Th2 cells are a type of T-helper cell involved in the immune response in atopic dermatitis
Th2 cells are a subset of T-helper cells involved in the immune response, particularly in the production of cytokines like IL-4, IL-13, and IL-31
Th2 cells are involved in the immune response and their development is stimulated by IL-4 and IL-13
Th2 cells are a subset of T cells involved in the immune response, particularly in the production of cytokines like IL-31
T helper 2 cells, a subset of T cells involved in the immune response and associated with allergic reactions
Th2 cells are a subtype of T helper cells involved in the immune response and inflammation
Th2 cells are a type of T-helper cell involved in the immune response, dominating in Atopic Dermatitis
Th2 cells are a subset of T helper cells involved in the immune response and known to play a role in fibrosis
Th2 cells are a subset of T cells involved in the immune response, affected by OX40-OX40L signaling</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b,1b656cfce91ff9ccec4223703489dab3,41ccc4b41bd57cf2bda4dbb6c7ae4198,4842292208575bd45b2b5998513dd087,48de7eebab3f3b418feb35a152df38fd,691cb2e23ac3c6e591129d16714f8ef8,7c13f41d7349d9d2e56c36e00c0ca2d9,e075bccd45593ae008b2ce7f9ed8ff6c,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </node>
    <node id="TH22 CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Th22 cells are a type of T-helper cell involved in the immune response in atopic dermatitis
Th22 cells are a subtype of T helper cells involved in the immune response and inflammation</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </node>
    <node id="TH17 CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Th17 cells are a type of T-helper cell variably involved in the immune response in atopic dermatitis
Th17 cells are a subtype of T helper cells involved in the immune response and inflammation</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </node>
    <node id="TH1 CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Th1 cells are a type of T-helper cell involved in the immune response in chronic atopic dermatitis
Th1 cells are a subset of T-cells involved in the immune response, particularly in the production of cytokines like IFN-&#947;
Th1 cells are a subtype of T helper cells involved in the immune response and inflammation
Th1 cells are a subset of T helper cells involved in the immune response and known to play a role in inflammation</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198,4842292208575bd45b2b5998513dd087,7c13f41d7349d9d2e56c36e00c0ca2d9,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </node>
    <node id="INTERCELLULAR LIPIDS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Intercellular lipids are involved in skin barrier function and are disrupted in atopic dermatitis</data>
      <data key="d2">e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </node>
    <node id="TIGHT JUNCTIONS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Tight junctions are involved in skin barrier function and are disrupted in atopic dermatitis</data>
      <data key="d2">e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </node>
    <node id="EPIDERMIS">
      <data key="d0">TISSUE</data>
      <data key="d1">The epidermis is the outer layer of the skin affected by atopic dermatitis
The epidermis is the outer layer of the skin, separated during sample preparation for scRNA-Seq
The outermost layer of the skin
The epidermis is the outermost layer of the skin affected by atopic dermatitis
The outermost layer of the skin, involved in barrier function and affected in atopic dermatitis
The epidermis is the outermost layer of the skin, involved in the barrier function
The epidermis is the outermost layer of skin, affected in conditions like AD
The epidermis is the outermost layer of skin that provides a barrier to infection and regulates water loss
The epidermis is the outermost layer of the skin
The epidermis is the outermost layer of skin
The epidermis is the outermost layer of the skin, involved in barrier function
The epidermis is a layer of skin where higher TAC levels were observed with PLG-based nanoparticles
The epidermis is the outermost layer of the skin, providing a barrier to infection and regulating water loss</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,1596d061dbe1a1c9e8f31a02a21e5524,1d0c4a4cd555b7ecd0b9d7b0310e9fe9,27a7e95c7d3ad59a948aa46741fee456,3ce96e927d65736b305f792977fed4b9,41ccc4b41bd57cf2bda4dbb6c7ae4198,442e7fad2fab75fa2449309783294d89,48288f3ec2832850282f95d4e38d10e1,b62ecc47bf54393bc78dd65986b949d6,bddc3b1a7f098e71f0aa64adec047124,c46e8b6ee0c29e37b7f18c42558d7a3e,e075bccd45593ae008b2ce7f9ed8ff6c,f66eb51473925a8084dad1745be63b78</data>
    </node>
    <node id="ALARMIN CYTOKINES">
      <data key="d0">PROTEIN</data>
      <data key="d1">Alarmin cytokines are rapidly released by keratinocytes in response to tissue damage in atopic dermatitis</data>
      <data key="d2">e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </node>
    <node id="T-HELPER (TH)2 CELLS">
      <data key="d0">CELL</data>
      <data key="d1">T-helper (Th)2 cells are a subset of T-cells involved in the immune response, particularly in the production of cytokines like IL-4, IL-13, and IL-31</data>
      <data key="d2">4842292208575bd45b2b5998513dd087</data>
    </node>
    <node id="EPIDERMAL BARRIER">
      <data key="d0">TISSUE</data>
      <data key="d1">The epidermal barrier is the outermost layer of the skin that protects against environmental damage
The epidermal barrier is the outermost layer of the skin, which is dysfunctional in Atopic Dermatitis
The epidermal barrier is disrupted in atopic dermatitis, contributing to disease pathophysiology
The epidermal barrier is affected by IL-4 and IL-13, leading to dysfunction in AD
The epidermal barrier is the outermost layer of the skin, which is dysfunctional in AD
The epidermal barrier is the outermost layer of the skin, which is compromised in atopic dermatitis
The epidermal barrier is the outermost layer of the skin that protects against environmental damage
The epidermal barrier is the outermost layer of the skin that protects against environmental damage
The epidermal barrier is the outermost layer of the skin that protects against environmental damage and is compromised in Atopic Dermatitis.
The epidermal barrier is a tissue structure targeted for restoration in AD treatment</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,143d2dc302af5606656797bff162e23e,1596d061dbe1a1c9e8f31a02a21e5524,3ce96e927d65736b305f792977fed4b9,4842292208575bd45b2b5998513dd087,48de7eebab3f3b418feb35a152df38fd,6059a6e2710b7df94c6a09e5eb7b024a,693a2aac101eaaadf92614317a1e4da8,6ada075e562abd7bd445164e9fc309b4,f66eb51473925a8084dad1745be63b78</data>
      <data key="d3">TISSUE</data>
    </node>
    <node id="IL-22">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-22 is a cytokine involved in immune response and inflammation, particularly in the skin
IL-22 is a cytokine involved in the pathogenesis of atopic dermatitis
IL-22 is a cytokine involved in the pathogenesis of atopic dermatitis and its serum levels correlate with disease severity
IL-22 is a cytokine involved in the pathophysiology of atopic dermatitis, particularly in chronic lesions
IL-22 is a cytokine involved in immune response and inflammation
A type 22 cytokine contributing to epidermal hyperplasia and inhibiting keratinocyte differentiation
IL-22 is a cytokine involved in the immune response and related to psoriasis
IL-22 is a cytokine involved in inflammatory responses and is part of the transcriptomic signature in AD
IL-22 (Interleukin-22) is a cytokine involved in the inflammatory response
IL-22 (Interleukin-22) is a cytokine involved in the immune response and inflammation
IL-22 is a cytokine involved in the immune response and associated with Atopic Dermatitis.
IL-22 is a cytokine involved in immune responses and inflammation
Interleukin-22, involved in inflammation and immune response
IL-22 is a cytokine involved in immune responses and is being explored in clinical studies for conditions like psoriasis
IL-22 is a cytokine involved in the proliferation and downregulation of FLG in keratinocytes
IL-22 is a cytokine involved in the pathogenesis of AD</data>
      <data key="d2">1d0c4a4cd555b7ecd0b9d7b0310e9fe9,286730b1c1f680ac465cc21d522fda0c,2cec06c4d46f5ff9ee936a78d8b077cd,3df8535e965efb96f5094169610507ff,41ccc4b41bd57cf2bda4dbb6c7ae4198,48288f3ec2832850282f95d4e38d10e1,4842292208575bd45b2b5998513dd087,6309eeea565f06479830cec32938abc9,6ada075e562abd7bd445164e9fc309b4,849e0980ffd6a7e1cf0b8d3d1fbacd98,a867a1e73cef039eb3f28e072463b838,b19f42c9497f71b231222cd953036d6b,b876251511f570468eb5b6ee6a239cc6,dc905ba8b6eb7d84cf2776303211010d,e9841b88c9fab58c5175af409653da50,f66eb51473925a8084dad1745be63b78</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="AD">
      <data key="d0">DISEASE</data>
      <data key="d1">Atopic Dermatitis is a chronic inflammatory skin disease characterized by pruritus and epidermal barrier dysfunction
Atopic dermatitis, a chronic inflammatory skin disease
Atopic Dermatitis, a chronic inflammatory skin disease
Atopic dermatitis, an autoimmune disease characterized by chronic inflammation of the skin
Atopic dermatitis is a chronic inflammatory skin disease
Atopic dermatitis, also known as AD, is a chronic inflammatory skin disease
Atopic Dermatitis (AD) is a chronic skin condition characterized by itchy and inflamed skin
Atopic Dermatitis, also known as AD, is a chronic inflammatory skin disease
Atopic Dermatitis, a chronic inflammatory skin disease characterized by itchy and inflamed skin
Atopic dermatitis, an autoimmune disease characterized by chronic eczematous skin lesions
Atopic Dermatitis, a chronic inflammatory skin disease
Atopic Dermatitis, a chronic inflammatory skin disease
Atopic Dermatitis, an autoimmune disease characterized by dysfunction in multiple immune pathways
Atopic dermatitis, a chronic inflammatory skin disease
Atopic dermatitis, an autoimmune disease characterized by chronic inflammation and skin lesions
Atopic dermatitis, a chronic inflammatory skin disease
Atopic dermatitis, also known as AD, is a chronic inflammatory skin disease characterized by itchy and inflamed skin
Atopic dermatitis, also known as AD, is a chronic inflammatory skin disease
Atopic Dermatitis, an autoimmune disease characterized by chronic inflammation and itch-scratch cycles
Atopic dermatitis, a chronic inflammatory skin disease
Atopic Dermatitis, a chronic inflammatory skin disease characterized by dry, sensitive, and highly permeable skin
Atopic Dermatitis, a chronic inflammatory skin disease
Atopic dermatitis (AD) is a chronic inflammatory skin disease
Atopic dermatitis, a chronic inflammatory skin disease
Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by itchy and inflamed skin
Atopic Dermatitis, a chronic inflammatory skin disease
Atopic Dermatitis, a chronic inflammatory skin disease characterized by itchy and inflamed skin
Atopic Dermatitis is a chronic inflammatory skin condition characterized by itchy and inflamed skin
Atopic dermatitis is a chronic inflammatory skin disorder
Atopic dermatitis, a chronic inflammatory skin disease
Atopic Dermatitis, a complex disorder with systemic impact and comorbidities
Atopic Dermatitis, an autoimmune disease characterized by skin inflammation and barrier dysfunction
Atopic dermatitis (AD) is an autoimmune disease characterized by inflammation of the skin
Atopic Dermatitis, a chronic inflammatory skin condition
Atopic Dermatitis, an autoimmune disease characterized by inflammation and pruritus
Atopic Dermatitis (AD) is a chronic inflammatory skin disease
Atopic Dermatitis, a chronic skin condition that impacts quality of life
Atopic Dermatitis, a chronic inflammatory skin disease
Atopic Dermatitis is a dermatological illness that can be treated with various formulations
Atopic dermatitis is a chronic inflammatory skin condition characterized by itchy and inflamed skin
Atopic Dermatitis, also known as AD, is a skin condition treated by various drugs
Atopic Dermatitis, a chronic inflammatory skin condition
Atopic Dermatitis, a chronic inflammatory skin disease
Atopic Dermatitis, an inflammatory skin condition often associated with atopic comorbidities
Atopic Dermatitis is a chronic inflammatory skin disease characterized by itchy and inflamed skin
Atopic Dermatitis is a chronic inflammatory skin disease characterized by itchy and inflamed skin</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,0829313703a7d2bae5436a9ee542334d,0ba9fbea14e0c2c1d01a12ffaacfda9b,100dd7646c10899301b3c0631183da16,104cc78517b2eca2e9cb7e00de1fe4b0,1412a7a7fef5f18cc09a030b97b18e13,143d2dc302af5606656797bff162e23e,1d0c4a4cd555b7ecd0b9d7b0310e9fe9,27a7e95c7d3ad59a948aa46741fee456,286730b1c1f680ac465cc21d522fda0c,28f548554737fcc026b968db6bbafa30,2cec06c4d46f5ff9ee936a78d8b077cd,2e9a8d71f6bd251a0b13458c39e69746,3287c502f10f4651d2f56bf39ee7bb7a,3ce96e927d65736b305f792977fed4b9,3df8535e965efb96f5094169610507ff,3ea70e257330c812b52334ca1f90d807,41ccc4b41bd57cf2bda4dbb6c7ae4198,442e7fad2fab75fa2449309783294d89,475995d7d211bbfde6d8ba52f324d688,4842292208575bd45b2b5998513dd087,48de7eebab3f3b418feb35a152df38fd,6059a6e2710b7df94c6a09e5eb7b024a,6309eeea565f06479830cec32938abc9,6aef5adb1be227170f66c76a292c25e5,6b099960b0a39866e3aa6b908f1886e4,78e26c66107dba37ac4bab65406b43a0,8246ea974dfb00cb5e3d984004e21a9e,849e0980ffd6a7e1cf0b8d3d1fbacd98,89dbac0da39e4de2b602052cd792b90d,90f4809673ca34628b0e607908f0bf0b,96e553a44a27e728c27c4892045ec5c2,a867a1e73cef039eb3f28e072463b838,b19f42c9497f71b231222cd953036d6b,b201c6ff3e22b2475c8c59260a0eb6a7,b28eeca0ff01a7715947d55a04978a43,b62ecc47bf54393bc78dd65986b949d6,b876251511f570468eb5b6ee6a239cc6,bddc3b1a7f098e71f0aa64adec047124,c46e8b6ee0c29e37b7f18c42558d7a3e,dc905ba8b6eb7d84cf2776303211010d,e30574e513dd250992d637d808759c34,e95d4d15e4f3110c91a3d3fcb5910d06,f1897c89e321a3a80924fd72a56e90df,f2aa3fd6ae3f1853347874c50afb60ea,f66eb51473925a8084dad1745be63b78</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="MOUSE MODELS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Mouse models are used in research to study the mechanisms and treatments of diseases, including AD</data>
      <data key="d2">4842292208575bd45b2b5998513dd087</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="IMMUNE CHECKPOINT MOLECULES">
      <data key="d0">PROTEIN</data>
      <data key="d1">Immune checkpoint molecules are proteins that regulate immune responses, including co-stimulatory and co-inhibitory signals</data>
      <data key="d2">4842292208575bd45b2b5998513dd087</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="TNFSF">
      <data key="d0">PROTEIN</data>
      <data key="d1">The tumor necrosis factor superfamily (TNFSF) includes proteins involved in immune regulation
The tumor necrosis super family (TNFSF) members are involved in inflammation and cell death and are now considered therapeutic targets for fibrotic diseases
TNFSF refers to the tumor necrosis factor superfamily, which includes various members involved in immune responses and fibrosis</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,4842292208575bd45b2b5998513dd087,68015074236b0144899baa38d01ae467</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="TNFRSF">
      <data key="d0">PROTEIN</data>
      <data key="d1">The tumor necrosis factor receptor superfamily (TNFRSF) includes receptors for TNFSF proteins</data>
      <data key="d2">4842292208575bd45b2b5998513dd087</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="EFFECTOR T-CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Effector T-cells are activated T-cells that perform immune functions such as cytokine production
Effector T-cells are activated T-cells that actively respond to a stimulus, such as a pathogen
Effector T-cells are a type of T-cell that actively responds to a stimulus, such as a pathogen</data>
      <data key="d2">3df8535e965efb96f5094169610507ff,4842292208575bd45b2b5998513dd087,b201c6ff3e22b2475c8c59260a0eb6a7</data>
      <data key="d3">CELL</data>
    </node>
    <node id="REGULATORY T-CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Regulatory T-cells are a subset of T-cells that modulate the immune response to prevent autoimmunity
Regulatory T-cells are a component of the immune system that suppress immune responses of other cells
Regulatory T-cells (Tregs) are a type of T-cell involved in suppressing immune responses</data>
      <data key="d2">3df8535e965efb96f5094169610507ff,4842292208575bd45b2b5998513dd087,b201c6ff3e22b2475c8c59260a0eb6a7</data>
      <data key="d3">CELL</data>
    </node>
    <node id="DENDRITIC CELLS (DCS)">
      <data key="d0">CELL</data>
      <data key="d1">Dendritic cells are antigen-presenting cells that activate T-cells</data>
      <data key="d2">4842292208575bd45b2b5998513dd087</data>
      <data key="d3">CELL</data>
    </node>
    <node id="ENDOTHELIAL CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Endothelial cells line blood vessels and are involved in various functions, including immune response
Endothelial cells line the interior surface of blood vessels and lymphatic vessels
Endothelial cells are a type of cell found in the skin
Endothelial cells line the interior surface of blood vessels and lymphatic vessels, playing a key role in vascular biology
Endothelial Cells are cells that line the blood vessels and are involved in inflammation and immune responsesEndothelial Cells are antigen-presenting cells activated by TSLP to produce OX40L
Endothelial cells are a type of antigen-presenting cell activated by TSLP
Endothelial cells line the interior surface of blood vessels
Endothelial cells line the interior surface of blood vessels and lymphatic vessels
Endothelial cells line the interior surface of blood vessels and lymphatic vessels</data>
      <data key="d2">05c97152fe02249153103be341d65b67,2cec06c4d46f5ff9ee936a78d8b077cd,2e0cdefd62bed7c674d7fb93ef336c2b,3df8535e965efb96f5094169610507ff,4842292208575bd45b2b5998513dd087,7c13f41d7349d9d2e56c36e00c0ca2d9,b201c6ff3e22b2475c8c59260a0eb6a7,bae090d8a29c15868ba1c4f29ae79e99,df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">CELL</data>
    </node>
    <node id="MACROPHAGES">
      <data key="d0">CELL</data>
      <data key="d1">Macrophages are immune cells that engulf and digest pathogens and cellular debris
Macrophages are immune cells that engulf and digest cellular debris and pathogens
Macrophages are immune cells that express IL-31RA and are involved in inflammation
Macrophages are immune cells involved in the detection and destruction of bacteria and other harmful organisms
Macrophages are a type of cell that produces TNF
Macrophages are cells involved in the detection, phagocytosis, and destruction of bacteria and other harmful organisms
Macrophages are immune cells involved in detecting, engulfing, and destroying pathogens and apoptotic cells
Macrophages are immune cells involved in inflammation and express TACI
Macrophages are immune cells that engulf and digest cellular debris and pathogens
Macrophages are a type of white blood cell that engulfs and digests cellular debris and pathogens
Macrophages are immune cells involved in the detection and destruction of pathogens
Macrophages are immune cells that LIGHT and TL1A can act upon</data>
      <data key="d2">05c97152fe02249153103be341d65b67,080b1dc5fcc0eee3645a06983a0de603,3df8535e965efb96f5094169610507ff,41ccc4b41bd57cf2bda4dbb6c7ae4198,4842292208575bd45b2b5998513dd087,516e41e96d2e72d45bf1e2c69da7f18a,68015074236b0144899baa38d01ae467,7c13f41d7349d9d2e56c36e00c0ca2d9,9867d43adab0ba5db44961fae4863eee,c525762bb827485bceeb9f09bb4bcfe0,d2c44662af9752fc9f82c86121ede7c0,df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">CELL</data>
    </node>
    <node id="B-CELLS">
      <data key="d0">CELL</data>
      <data key="d1">B-cells are a type of white blood cell that produces antibodies</data>
      <data key="d2">4842292208575bd45b2b5998513dd087</data>
      <data key="d3">CELL</data>
    </node>
    <node id="CD86">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD86 is a co-stimulatory molecule involved in T-cell activation
CD86 is a protein that binds to CD28 to provide a costimulatory signal for T-cell activation
CD86 is a protein that binds to CTLA-4 and CD28, involved in T cell activation
CD86 is a protein that interacts with CD28 to provide costimulatory signals for T-cell activation
CD86 is involved in positive costimulatory pathways
CD86 is a protein involved in T cell activation, also known as B7-2</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b,4842292208575bd45b2b5998513dd087,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,855c455b4c9592746834ee3a4e0e6b81,9867d43adab0ba5db44961fae4863eee</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="CD28">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD28 is a co-stimulatory molecule involved in T-cell activation
CD28 is a gene involved in T-cell costimulatory pathways
CD28 is a costimulatory protein involved in T-cell immune responses
CD28 is a costimulatory protein involved in T-cell immune responses
CD28 is a costimulatory protein involved in T-cell immune responses
CD28 is a costimulatory protein involved in T-cell immune responses
CD28 is involved in positive costimulatory pathways

CD28 is a costimulatory protein involved in T-cell immune responses</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,1b656cfce91ff9ccec4223703489dab3,2e0cdefd62bed7c674d7fb93ef336c2b,44f2592262cac835560b4c149fee8d2b,4842292208575bd45b2b5998513dd087,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,855c455b4c9592746834ee3a4e0e6b81,9867d43adab0ba5db44961fae4863eee</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="MEMORY T-CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Memory T-cells are long-lived T-cells that provide a faster response upon re-exposure to an antigen</data>
      <data key="d2">4842292208575bd45b2b5998513dd087</data>
      <data key="d3">CELL</data>
    </node>
    <node id="EFFECTOR MEMORY T-CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Effector memory T-cells are a subset of memory T-cells that rapidly respond to re-exposure to an antigen</data>
      <data key="d2">4842292208575bd45b2b5998513dd087</data>
      <data key="d3">CELL</data>
    </node>
    <node id="TYPE 2 INNATE LYMPHOID CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Type 2 innate lymphoid cells are involved in the immune response and produce type 2 cytokines
Type 2 innate lymphoid (ILC2) cells are involved in the inappropriate activation in Atopic Dermatitis</data>
      <data key="d2">4842292208575bd45b2b5998513dd087,693a2aac101eaaadf92614317a1e4da8</data>
      <data key="d3">CELL</data>
    </node>
    <node id="PERIPHERAL BLOOD MONONUCLEAR CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Peripheral blood mononuclear cells are blood cells with a single round nucleus, including lymphocytes and monocytes
Peripheral Blood Mononuclear Cells (PBMCs) are blood cells with a single round nucleus, used in flow cytometry analysis
Peripheral blood mononuclear cells are blood cells with a single round nucleus, including lymphocytes and monocytes</data>
      <data key="d2">348f2797841cbef27311b03f2cd788dd,4842292208575bd45b2b5998513dd087,89dbac0da39e4de2b602052cd792b90d</data>
      <data key="d3">CELL</data>
    </node>
    <node id="GBR 830">
      <data key="d0">CHEMICAL</data>
      <data key="d1">GBR 830 is a humanized monoclonal antibody against OX40, investigated for the treatment of AD
GBR 830 is a drug mentioned in the context of the study, but no further studies have been developed with it
GBR 830 is a monoclonal antibody against OX40 that was investigated for the treatment of atopic dermatitis
GBR 830 is a humanized anti-OX40 monoclonal antibody
GBR 830 is an antibody directed against OX40 used in clinical studies for atopic dermatitis
GBR 830, also known as ISB 830, is a biologic injection targeting OX40 used in the treatment of atopic dermatitis</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688,4842292208575bd45b2b5998513dd087,6309eeea565f06479830cec32938abc9,dc905ba8b6eb7d84cf2776303211010d,e9841b88c9fab58c5175af409653da50,f2aa3fd6ae3f1853347874c50afb60ea</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="ECZEMA AREA AND SEVERITY INDEX (EASI)">
      <data key="d0">SYMPTOM</data>
      <data key="d1">The Eczema Area and Severity Index (EASI) is a tool used to measure the severity of eczema</data>
      <data key="d2">4842292208575bd45b2b5998513dd087</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="MRNA">
      <data key="d0">CHEMICAL</data>
      <data key="d1">mRNA is a type of RNA that carries genetic information from DNA to the ribosome for protein synthesis
mRNA expression levels were analyzed to assess the impact of rocatinlimab treatment
mRNA is a type of RNA that conveys genetic information from DNA to the ribosome
Messenger ribonucleic acid, involved in the expression of IL-4 and IL-13</data>
      <data key="d2">28f548554737fcc026b968db6bbafa30,2a0384addc6e7fd709e0508b83496cd7,475995d7d211bbfde6d8ba52f324d688,4842292208575bd45b2b5998513dd087</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="CCL11">
      <data key="d0">PROTEIN</data>
      <data key="d1">CCL11 is a chemokine involved in the recruitment of eosinophils
Chemokine ligand 11 (CCL11) is a chemokine involved in the immune response and inflammation
CCL11 is a chemokine ligand that ascends in the skin during inflammation and promotes the attraction of inflammatory T cells and DC subtypes
CCL11 is a cytokine implicated in EoE pathogenesis</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198,4842292208575bd45b2b5998513dd087,6059a6e2710b7df94c6a09e5eb7b024a,d4797ed1483e5057bcd8301eaa509d5e</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="CCL17">
      <data key="d0">PROTEIN</data>
      <data key="d1">CCL17 is a chemokine involved in the recruitment of T-cells
CCL17 (TARC) is a chemokine that binds to CCR4 and is produced in high amounts in AD
Chemokine ligand 17 (CCL17) is a chemokine involved in the immune response and inflammation
CCL17 is a chemokine ligand that ascends in the skin during inflammation and promotes the attraction of inflammatory T cells and DC subtypes</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9,41ccc4b41bd57cf2bda4dbb6c7ae4198,4842292208575bd45b2b5998513dd087,6059a6e2710b7df94c6a09e5eb7b024a</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="S100">
      <data key="d0">PROTEIN</data>
      <data key="d1">S100 is a family of proteins involved in the regulation of a variety of cellular processes</data>
      <data key="d2">4842292208575bd45b2b5998513dd087</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="AMG 451">
      <data key="d0">CHEMICAL</data>
      <data key="d1">AMG 451 is another name for Rocatinlimab, an anti-OX40 monoclonal antibody
AMG 451 is another name for rocatinlimab, used in clinical trials</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688,4842292208575bd45b2b5998513dd087</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="KHK4083">
      <data key="d0">CHEMICAL</data>
      <data key="d1">KHK4083 is another name for Rocatinlimab, an anti-OX40 monoclonal antibody
KHK4083 is another name for rocatinlimab, used in clinical trials
KHK4083 is a fully human, non-fucosylated IgG1, anti-OX40 monoclonal antibody
KHK4083 is an antibody directed against OX40 used in clinical studies for atopic dermatitis
KHK4083 is a compound tested in a phase Ib trial for its effects on EASI score reduction in patients
KHK4083 is a biologic injection targeting OX40 used in the treatment of atopic dermatitis</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688,4842292208575bd45b2b5998513dd087,6309eeea565f06479830cec32938abc9,78e26c66107dba37ac4bab65406b43a0,e9841b88c9fab58c5175af409653da50,f2aa3fd6ae3f1853347874c50afb60ea</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="T-CELLS">
      <data key="d0">CELL</data>
      <data key="d1">T-cells are immune cells that are selectively depleted by rocatinlimab
T-cells, including effector and regulatory T-cells (Tregs), express OX40 when stimulated</data>
      <data key="d2">3df8535e965efb96f5094169610507ff,475995d7d211bbfde6d8ba52f324d688</data>
    </node>
    <node id="PYREXIA">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Pyrexia, or fever, was a common infusion reaction reported in patients treated with rocatinlimab
Pyrexia, or fever, is a common side effect observed after the first administration of rocatinlimab
Pyrexia is a medical term for fever</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688,b201c6ff3e22b2475c8c59260a0eb6a7,dc905ba8b6eb7d84cf2776303211010d</data>
    </node>
    <node id="CHILLS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Chills were a common infusion reaction reported in patients treated with rocatinlimab
Chills are a common side effect observed after the first administration of rocatinlimab
Chills are sensations of coldness often accompanied by shivering</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688,b201c6ff3e22b2475c8c59260a0eb6a7,dc905ba8b6eb7d84cf2776303211010d</data>
    </node>
    <node id="APHTHOUS ULCERS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Aphthous ulcers, or canker sores, were reported in patients treated with rocatinlimab</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688</data>
    </node>
    <node id="BLOOD URIC ACID">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Blood uric acid levels increased in some patients treated with rocatinlimab</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688</data>
    </node>
    <node id="NASOPHARYNGITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Nasopharyngitis, or the common cold, was reported in patients treated with rocatinlimab
Nasopharyngitis is an inflammation of the nasopharynx, often referred to as the common cold
Nasopharyngitis is an inflammation of the nasal passages and pharynx</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688,a867a1e73cef039eb3f28e072463b838,b201c6ff3e22b2475c8c59260a0eb6a7</data>
    </node>
    <node id="ERYTHEMA">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Erythema, or skin redness, was reported in patients treated with rocatinlimab
Erythema is redness of the skin caused by increased blood flow, often seen in AD
Erythema is a clinical sign of atopic dermatitis characterized by redness of the skin
Erythema is poorly defined redness of the skin, often seen in infantile Atopic Dermatitis.
Erythema is redness of the skin caused by increased blood flow
Erythema is redness of the skin caused by increased blood flow to the capillaries</data>
      <data key="d2">143d2dc302af5606656797bff162e23e,1596d061dbe1a1c9e8f31a02a21e5524,27a7e95c7d3ad59a948aa46741fee456,3dfbb4c51838e0951f53ce951395225f,475995d7d211bbfde6d8ba52f324d688,6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="HORDEOLUM">
      <data key="d0">DISEASE</data>
      <data key="d1">Hordeolum, or stye, was reported in patients treated with rocatinlimab</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688</data>
    </node>
    <node id="POLYMERASE CHAIN REACTION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Polymerase chain reaction (PCR) is a technique used to amplify and analyze DNA and RNA sequences</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688</data>
    </node>
    <node id="SERUM">
      <data key="d0">TISSUE</data>
      <data key="d1">Serum samples were collected to analyze proteomic profiles in AD patients
Serum is the component of blood that can contain biomarkers for atopic dermatitis
Serum biomarkers are used to assess the severity of AD
The liquid part of blood used in biomarker analyses
Serum is the liquid part of blood used for measuring levels of sOX40 and sOX40L
Serum is the liquid part of blood that remains after clotting, used in various diagnostic tests
Serum is the liquid part of blood that remains after clotting, containing various proteins and antibodies
Serum is a tissue where increased expression levels of costimulatory molecules are observed in SSc
Serum is the liquid part of blood that remains after clotting
Serum is the liquid part of blood that remains after clotting, containing various proteins and antibodies
Serum is the liquid part of blood that remains after clotting</data>
      <data key="d2">05c97152fe02249153103be341d65b67,104cc78517b2eca2e9cb7e00de1fe4b0,348f2797841cbef27311b03f2cd788dd,44f2592262cac835560b4c149fee8d2b,475995d7d211bbfde6d8ba52f324d688,48de7eebab3f3b418feb35a152df38fd,4cf23e218b6aab3c77115173b5c7c2fd,4d0e8ae9371a435885994b4161126bc3,855c455b4c9592746834ee3a4e0e6b81,89dbac0da39e4de2b602052cd792b90d,f66eb51473925a8084dad1745be63b78</data>
    </node>
    <node id="HEAD AND NECK">
      <data key="d0">TISSUE</data>
      <data key="d1">Head and neck regions were specifically evaluated for EASI score improvements in AD patients
The head and neck region is a specific area of the body being evaluated in the study</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688,b876251511f570468eb5b6ee6a239cc6</data>
    </node>
    <node id="TEAE">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Treatment-emergent adverse events (TEAE) were reported in patients treated with rocatinlimab
Treatment-Emergent Adverse Events (TEAEs) are adverse events that occur during treatment</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688,b876251511f570468eb5b6ee6a239cc6</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="NRS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Numeric Rating Scale (NRS) is used to measure the severity of pruritus in AD patients
Numeric Rating Scale (NRS) is a tool used to measure the intensity of pruritus
Numerical Rating Scale (NRS) is a tool used to measure the intensity of pruritus
Numeric Rating Scale, used to measure pruritus in atopic dermatitis
Numeric rating scale used to measure pruritus severity
Numerical Rating Scale, used to measure the intensity of pruritus
Numeric Rating Scale, a tool used to measure the intensity of pruritus
NRS (Numeric Rating Scale) is a tool used to measure the intensity of pruritus</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,1d0c4a4cd555b7ecd0b9d7b0310e9fe9,28f548554737fcc026b968db6bbafa30,3287c502f10f4651d2f56bf39ee7bb7a,3ce96e927d65736b305f792977fed4b9,475995d7d211bbfde6d8ba52f324d688,6309eeea565f06479830cec32938abc9,b876251511f570468eb5b6ee6a239cc6</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="TH2/TH22">
      <data key="d0">CELL</data>
      <data key="d1">Th2/Th22 cells are subsets of T-helper cells involved in the immune response, particularly in atopic dermatitis</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688</data>
      <data key="d3">CELL</data>
    </node>
    <node id="PROTEOMIC ANALYSIS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Proteomic analysis was conducted to study protein expression changes in AD patients treated with rocatinlimab
Proteomic analysis is the large-scale study of proteins, particularly their structures and functions</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b,475995d7d211bbfde6d8ba52f324d688</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="GENOMIC PROFILE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Genomic profile analysis was conducted to study gene expression changes in AD patients treated with rocatinlimab
The genomic profile of AD can be affected by treatment</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd,475995d7d211bbfde6d8ba52f324d688</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="TRANSCRIPTOMIC PROFILE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Transcriptomic profile analysis was conducted to study RNA expression changes in AD patients treated with rocatinlimab</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="EASI75">
      <data key="d0">PATHWAY</data>
      <data key="d1">EASI75 is a measure indicating a 75% improvement in the Eczema Area and Severity Index score
75% improvement in Eczema Area and Severity Index from baseline
EASI75 is a clinical endpoint indicating a 75% improvement in the Eczema Area and Severity Index
EASI75 is a measure indicating a 75% improvement in the Eczema Area and Severity Index
EASI75 is a measure of the severity of eczema, indicating a 75% improvement in symptoms</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9,475995d7d211bbfde6d8ba52f324d688,6309eeea565f06479830cec32938abc9,78e26c66107dba37ac4bab65406b43a0,f1897c89e321a3a80924fd72a56e90df</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="PLACEBO">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Placebo was used as a control in clinical trials evaluating rocatinlimab
Placebo is a substance with no therapeutic effect used as a control in testing new drugs
A substance with no therapeutic effect used as a control in testing new drugs
Placebo is a substance with no therapeutic effect, used as a control in testing new drugs
Placebo is a substance with no therapeutic effect used as a control in testing new drugs
Placebo is a substance with no therapeutic effect used as a control in testing new drugs
Placebo is a substance with no therapeutic effect used as a control in testing new drugs
Placebo is a substance with no therapeutic effect used as a control in testing new drugs
Placebo is a substance with no therapeutic effect used as a control in clinical trials</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3,1d0c4a4cd555b7ecd0b9d7b0310e9fe9,423195c6b63ad0a6773374364ebf3612,475995d7d211bbfde6d8ba52f324d688,68015074236b0144899baa38d01ae467,7f559ad7372a4e35e90b43cc67047b0f,8e5a1be9981340d419f7b3ad27076009,b876251511f570468eb5b6ee6a239cc6,c95d22c2a90e77cd22bd0d280d55b26a</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="PHASE 1">
      <data key="d0">PATHWAY</data>
      <data key="d1">Phase 1 clinical trial evaluated the safety and dosage of rocatinlimab in AD patients</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="PHASE 2B">
      <data key="d0">PATHWAY</data>
      <data key="d1">Phase 2b clinical trial evaluated the efficacy and safety of rocatinlimab in AD patients</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="PHASE 3">
      <data key="d0">PATHWAY</data>
      <data key="d1">Phase 3 clinical trial is planned to further evaluate rocatinlimab in AD patients
Phase 3 is a stage in clinical trials to assess the effectiveness and safety of a drug</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3,475995d7d211bbfde6d8ba52f324d688</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IGG1">
      <data key="d0">PROTEIN</data>
      <data key="d1">IgG1 is a subclass of immunoglobulin G, which rocatinlimab belongs to
IgG1 is a subclass of immunoglobulin G involved in the immune response
Immunoglobulin G1, a subclass of antibodies</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688,b28eeca0ff01a7715947d55a04978a43,e4d25b1cd44df240a29591bc46a875ab</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="MONOCLONAL ANTIBODY">
      <data key="d0">PROTEIN</data>
      <data key="d1">Monoclonal antibody is a type of protein that rocatinlimab is classified as</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="TH2-DRIVEN CONDITIONS">
      <data key="d0">DISEASE</data>
      <data key="d1">Th2-driven conditions are immune responses primarily mediated by Th2 cells, often associated with allergies and atopic dermatitis</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="CLONAL T-CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Clonal T-cells are a population of T-cells that expand from a single cell, targeted by rocatinlimab</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688</data>
      <data key="d3">CELL</data>
    </node>
    <node id="INFUSION REACTIONS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Infusion reactions are adverse effects that occur during or after the administration of a drug, such as rocatinlimab</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="EASI SCORE">
      <data key="d0">PATHWAY</data>
      <data key="d1">EASI score is a measure used to assess the severity of atopic dermatitis</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="PRURITUS NRS SCORE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Pruritus NRS score is a measure used to assess the severity of itching in atopic dermatitis patients</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="SKIN BIOPSY">
      <data key="d0">TISSUE</data>
      <data key="d1">Skin biopsy specimens were collected to analyze the effects of rocatinlimab on gene and protein expression</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688</data>
      <data key="d3">TISSUE</data>
    </node>
    <node id="SERUM SAMPLES">
      <data key="d0">TISSUE</data>
      <data key="d1">Serum samples were collected to analyze the effects of rocatinlimab on protein expression</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688</data>
      <data key="d3">TISSUE</data>
    </node>
    <node id="HEAD AND NECK EASI SCORE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Head and neck EASI score is a measure used to assess the severity of atopic dermatitis in the head and neck regions</data>
      <data key="d2">475995d7d211bbfde6d8ba52f324d688</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="CATINLIMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Catinlimab is a drug being evaluated for its efficacy in treating head and neck disease</data>
      <data key="d2">b876251511f570468eb5b6ee6a239cc6</data>
    </node>
    <node id="T-CELL">
      <data key="d0">CELL</data>
      <data key="d1">T-cells are a type of immune cell involved in the body's immune response
T-cells are a type of immune cell involved in the body's defense mechanisms
T-cells are a type of lymphocyte that play a central role in cell-mediated immunity
T-cells are a type of lymphocyte involved in the immune response, implicated in AD
T-cells, including effector and regulatory T-cells (Tregs), are involved in the immune response and express OX40 when stimulated</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,2cec06c4d46f5ff9ee936a78d8b077cd,b201c6ff3e22b2475c8c59260a0eb6a7,b876251511f570468eb5b6ee6a239cc6,dc905ba8b6eb7d84cf2776303211010d</data>
      <data key="d3">CELL</data>
    </node>
    <node id="VIGA">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Validated Investigator&#8217;s Global Assessment (vIGA) is a scale used to assess the severity of atopic dermatitis
Validated Investigator Global Assessment, a tool used to measure the severity of atopic dermatitis
The validated Investigator Global Assessment is a measure for evaluating the severity of atopic dermatitis
Validated Investigator's Global Assessment, a tool used to assess the severity of atopic dermatitis</data>
      <data key="d2">143d2dc302af5606656797bff162e23e,b876251511f570468eb5b6ee6a239cc6,dc905ba8b6eb7d84cf2776303211010d,f1897c89e321a3a80924fd72a56e90df</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="HYPERSENSITIVITY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Hypersensitivity is an exaggerated immune response to a substance</data>
      <data key="d2">b876251511f570468eb5b6ee6a239cc6</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="SCORAD">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Scoring Atopic Dermatitis (SCORAD) is a clinical tool used to assess the severity of atopic dermatitis
Scoring Atopic Dermatitis, a clinical tool used to assess the extent and severity of atopic dermatitis
Scoring Atopic Dermatitis, a tool used to assess the severity of atopic dermatitis
Scoring of Atopic Dermatitis, a clinical tool used to assess the severity of atopic dermatitis
Scoring of Atopic Dermatitis, a clinical tool used to assess the severity of atopic dermatitis
The Scoring of Atopic Dermatitis is a tool for assessing the intensity and extent of atopic dermatitis
Scoring of Atopic Dermatitis, a tool used to assess the extent and severity of atopic dermatitis
Scoring Atopic Dermatitis, a tool used to measure the extent and severity of atopic dermatitis
SCORAD is a clinical tool used to assess the severity of atopic dermatitis
SCORing Atopic Dermatitis (SCORAD) is a clinical tool used to assess the severity of atopic dermatitis
Scoring Atopic Dermatitis, a clinical tool used to assess the severity of atopic dermatitis
SCORAD is a clinical tool used to assess the severity of atopic dermatitis
SCORAD is a clinical tool used to assess the severity of AD
SCORing Atopic Dermatitis index (SCORAD) is a clinical tool used to assess the severity of Atopic Dermatitis
SCORAD is a scoring system used to assess the severity of atopic dermatitis
SCORAD index, a clinical tool used to assess the severity of atopic dermatitis</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,0829313703a7d2bae5436a9ee542334d,0ba9fbea14e0c2c1d01a12ffaacfda9b,104cc78517b2eca2e9cb7e00de1fe4b0,143d2dc302af5606656797bff162e23e,1d0c4a4cd555b7ecd0b9d7b0310e9fe9,28f548554737fcc026b968db6bbafa30,2cec06c4d46f5ff9ee936a78d8b077cd,348f2797841cbef27311b03f2cd788dd,442e7fad2fab75fa2449309783294d89,48288f3ec2832850282f95d4e38d10e1,691cb2e23ac3c6e591129d16714f8ef8,6b099960b0a39866e3aa6b908f1886e4,b876251511f570468eb5b6ee6a239cc6,dc905ba8b6eb7d84cf2776303211010d,f1897c89e321a3a80924fd72a56e90df</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="NCT05398445">
      <data key="d0">PATHWAY</data>
      <data key="d1">NCT05398445 is the identifier for the clinical trial ROCKET-IGNITE</data>
      <data key="d2">b876251511f570468eb5b6ee6a239cc6</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="NCT03161288">
      <data key="d0">PATHWAY</data>
      <data key="d1">NCT03161288 is the identifier for the phase 1 clinical trial evaluating amlitelimab
NCT03161288 is a clinical trial identifier for a study on amlitelimab in healthy subjects</data>
      <data key="d2">b201c6ff3e22b2475c8c59260a0eb6a7,b876251511f570468eb5b6ee6a239cc6</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="NCT03754309">
      <data key="d0">PATHWAY</data>
      <data key="d1">NCT03754309 is the identifier for the phase 2a clinical trial evaluating amlitelimab
NCT03754309 is a clinical trial identifier for a phase 2a study on amlitelimab in moderate-to-severe atopic dermatitis</data>
      <data key="d2">b201c6ff3e22b2475c8c59260a0eb6a7,b876251511f570468eb5b6ee6a239cc6</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="NCT05131477">
      <data key="d0">PATHWAY</data>
      <data key="d1">A Phase 2b study evaluating the impact of amlitelimab in patients with moderate-to-severe atopic dermatitis</data>
      <data key="d2">dc905ba8b6eb7d84cf2776303211010d</data>
    </node>
    <node id="NCT05492578">
      <data key="d0">PATHWAY</data>
      <data key="d1">A single group, phase 2, long-term extension study characterizing the safety and efficacy of amlitelimab in treated adult participants with moderate-to-severe atopic dermatitis</data>
      <data key="d2">dc905ba8b6eb7d84cf2776303211010d</data>
    </node>
    <node id="NCT05421598">
      <data key="d0">PATHWAY</data>
      <data key="d1">A study evaluating amlitelimab for the treatment of moderate-to-severe asthma</data>
      <data key="d2">dc905ba8b6eb7d84cf2776303211010d</data>
    </node>
    <node id="ASTHMA">
      <data key="d0">DISEASE</data>
      <data key="d1">A chronic inflammatory disease of the airways
A chronic inflammatory disease of the airways
Asthma is a chronic inflammatory disease of the airways
A chronic inflammatory disease of the airways
Asthma is a chronic respiratory condition characterized by airway inflammation and constriction
Asthma is a chronic respiratory condition characterized by airway inflammation and hyperreactivity
Asthma is a respiratory condition that children with Atopic Dermatitis may develop.
Asthma is a chronic respiratory condition often associated with atopic diseases
Asthma is a chronic inflammatory disease of the airways associated with Atopic Dermatitis
Asthma is a common comorbidity in patients with atopic dermatitis
Asthma, a respiratory condition that is an atopic comorbidity in patients with AD
Asthma is a chronic respiratory disease characterized by airway inflammation and hyperreactivity
Asthma is a condition in which airways narrow and swell, producing extra mucus
Asthma is a chronic inflammatory disease of the airways characterized by variable and recurring symptoms, airflow obstruction, and bronchospasm
Asthma is a chronic inflammatory disease of the airways
Asthma is a chronic inflammatory disease of the airways</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,05c97152fe02249153103be341d65b67,0829313703a7d2bae5436a9ee542334d,348f2797841cbef27311b03f2cd788dd,3ce96e927d65736b305f792977fed4b9,3df8535e965efb96f5094169610507ff,5f37466ca41c9b8b06ed8be0303d49f2,68015074236b0144899baa38d01ae467,691cb2e23ac3c6e591129d16714f8ef8,6ada075e562abd7bd445164e9fc309b4,6b099960b0a39866e3aa6b908f1886e4,89dbac0da39e4de2b602052cd792b90d,b19f42c9497f71b231222cd953036d6b,dc905ba8b6eb7d84cf2776303211010d,df74aa1b86eeeb811ca5586767ae3a71,e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="SYSTEMIC CORTICOSTEROIDS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Systemic corticosteroids are medications used to reduce inflammation in various conditions, including atopic dermatitis
Systemic corticosteroids are used in severe cases of AD</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd,dc905ba8b6eb7d84cf2776303211010d</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="AZATHIOPRINE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Azathioprine is an immunosuppressant drug used to treat atopic dermatitis
Azathioprine is an immunosuppressant used in the systemic treatment of Atopic Dermatitis
Azathioprine is an immunosuppressant used to treat severe forms of AD
Azathioprine is a drug used in systemic therapy for AD</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,2cec06c4d46f5ff9ee936a78d8b077cd,693a2aac101eaaadf92614317a1e4da8,dc905ba8b6eb7d84cf2776303211010d</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="ANTIGEN-PRESENTING CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Antigen-presenting cells are immune cells that present antigens to T-cells to initiate an immune response
Antigen-presenting cells are cells that display antigens to T-cells, initiating an immune response
Antigen-presenting cells (APCs) are immune cells that present antigens to T cells
Antigen-presenting Cells (APCs) are immune cells that process and present antigens to T-cells</data>
      <data key="d2">3df8535e965efb96f5094169610507ff,41ccc4b41bd57cf2bda4dbb6c7ae4198,b201c6ff3e22b2475c8c59260a0eb6a7,dc905ba8b6eb7d84cf2776303211010d</data>
    </node>
    <node id="FDA">
      <data key="d0">PATHWAY</data>
      <data key="d1">The Food and Drug Administration, a regulatory body that approves drugs for clinical use
The FDA is the U.S. Food and Drug Administration, responsible for approving drugs for medical use
The Food and Drug Administration, a regulatory body that approves drugs for clinical use
Food and Drug Administration, a regulatory agency responsible for approving drugs and treatments
The Food and Drug Administration (FDA) is a federal agency responsible for protecting public health by ensuring the safety and efficacy of drugs, vaccines, and other medical products
The FDA is the regulatory body that approved dupilumab for AD treatment
The Food and Drug Administration (FDA) is responsible for approving TNF antagonists for therapeutic use
Food and Drug Administration, a regulatory agency</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,104cc78517b2eca2e9cb7e00de1fe4b0,27a7e95c7d3ad59a948aa46741fee456,286730b1c1f680ac465cc21d522fda0c,48de7eebab3f3b418feb35a152df38fd,5ec1ebf4e260eb1f8fda8acdf06cd39e,dc905ba8b6eb7d84cf2776303211010d,e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="PHASE 3 TRIAL">
      <data key="d0">PATHWAY</data>
      <data key="d1">A clinical trial phase that evaluates the efficacy and safety of a treatment in a larger patient population</data>
      <data key="d2">dc905ba8b6eb7d84cf2776303211010d</data>
    </node>
    <node id="SKIN TRANSCRIPTOMIC ANALYSIS">
      <data key="d0">PATHWAY</data>
      <data key="d1">A method used to study gene expression in skin tissue</data>
      <data key="d2">dc905ba8b6eb7d84cf2776303211010d</data>
    </node>
    <node id="INTERFERON-&#915;">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interferon-&#947; is a cytokine critical for innate and adaptive immunity</data>
      <data key="d2">b201c6ff3e22b2475c8c59260a0eb6a7</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="VIRUS-SPECIFIC ANTIBODY">
      <data key="d0">PROTEIN</data>
      <data key="d1">Virus-specific antibodies are produced in response to viral infections</data>
      <data key="d2">b201c6ff3e22b2475c8c59260a0eb6a7</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="CYTOTOXIC T-CELL">
      <data key="d0">CELL</data>
      <data key="d1">Cytotoxic T-cells are immune cells that kill cancer cells, cells that are infected (particularly with viruses), or cells that are damaged in other ways</data>
      <data key="d2">b201c6ff3e22b2475c8c59260a0eb6a7</data>
      <data key="d3">CELL</data>
    </node>
    <node id="SOX40">
      <data key="d0">PROTEIN</data>
      <data key="d1">sOX40 is a form of OX40 expressed on activated T-cells
Soluble OX40 (sOX40) is a form of OX40 with anti-inflammatory effects when binding to membrane-bound OX40L
Soluble OX40, a protein measured in serum from patients with AD and HC
sOX40 is a soluble form of the OX40 protein, measured in serum of atopic dermatitis patients
Soluble OX40, a protein associated with atopic comorbidities and disease activity in children with AD
sOX40 is the soluble form of OX40, involved in immune response modulation</data>
      <data key="d2">2e9a8d71f6bd251a0b13458c39e69746,348f2797841cbef27311b03f2cd788dd,691cb2e23ac3c6e591129d16714f8ef8,6b099960b0a39866e3aa6b908f1886e4,89dbac0da39e4de2b602052cd792b90d,b201c6ff3e22b2475c8c59260a0eb6a7</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="APC">
      <data key="d0">CELL</data>
      <data key="d1">Antigen-presenting cells are cells that process and present antigens to T-cells
</data>
      <data key="d2">691cb2e23ac3c6e591129d16714f8ef8,b201c6ff3e22b2475c8c59260a0eb6a7</data>
      <data key="d3">CELL</data>
    </node>
    <node id="NCT03096223">
      <data key="d0">PATHWAY</data>
      <data key="d1">NCT03096223 is a clinical trial identifier for a study on rocatinlimab in moderate-to-severe atopic dermatitis</data>
      <data key="d2">b201c6ff3e22b2475c8c59260a0eb6a7</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="NCT03703102">
      <data key="d0">PATHWAY</data>
      <data key="d1">NCT03703102 is a clinical trial identifier for a phase 2b study on rocatinlimab in moderate-to-severe atopic dermatitis</data>
      <data key="d2">b201c6ff3e22b2475c8c59260a0eb6a7</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="HEADACHE">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Headache is a pain or discomfort in the head or face area
Headache is a common symptom characterized by pain in the head</data>
      <data key="d2">a867a1e73cef039eb3f28e072463b838,b201c6ff3e22b2475c8c59260a0eb6a7</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="VITAL SIGNS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Vital signs are clinical measurements that indicate the state of a patient's essential body functions</data>
      <data key="d2">b201c6ff3e22b2475c8c59260a0eb6a7</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="LABORATORY SAFETY DATA">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Laboratory safety data includes results from tests that monitor the safety of a treatment</data>
      <data key="d2">b201c6ff3e22b2475c8c59260a0eb6a7</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="ANTI-VIRAL ANTIBODY">
      <data key="d0">PROTEIN</data>
      <data key="d1">Anti-viral antibodies are produced by the immune system to neutralize viruses</data>
      <data key="d2">b201c6ff3e22b2475c8c59260a0eb6a7</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="VIRAL DNA">
      <data key="d0">PROTEIN</data>
      <data key="d1">Viral DNA is the genetic material of a virus</data>
      <data key="d2">b201c6ff3e22b2475c8c59260a0eb6a7</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="CYTOKINES">
      <data key="d0">PROTEIN</data>
      <data key="d1">Cytokines are small proteins important in cell signaling, especially in immune responses
Cytokines are signaling proteins involved in immune responses, such as IFN-&#947;, IL-36, TNF, and IL-17A in HS
Cytokines are signaling proteins, including IL-13 and IL-4, that are involved in tissue inflammation and epidermal barrier dysfunction in Atopic Dermatitis
Cytokines are signaling proteins involved in immune responses, targeted by various biologics
Proteins that are key effectors in immune responses and inflammation
Cytokines are small proteins important in cell signaling, especially in immune responses
Cytokines are involved in the inflammatory response in atopic dermatitis and are targeted by biologics
Cytokines are signaling proteins that mediate and regulate immunity, inflammation, and hematopoiesis
Cytokines are signaling proteins that regulate immune and inflammatory responses
Cytokines are immunological signals modified by methotrexate</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456,286730b1c1f680ac465cc21d522fda0c,41ccc4b41bd57cf2bda4dbb6c7ae4198,523bbfee1ae3b4ecabf9b11d10eea9ff,693a2aac101eaaadf92614317a1e4da8,83eb9003d42977bb83fea1d123dd5ab9,96e553a44a27e728c27c4892045ec5c2,a867a1e73cef039eb3f28e072463b838,b201c6ff3e22b2475c8c59260a0eb6a7,e95d4d15e4f3110c91a3d3fcb5910d06</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="ELECTROCARDIOGRAMS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Electrocardiograms are tests that measure the electrical activity of the heart</data>
      <data key="d2">b201c6ff3e22b2475c8c59260a0eb6a7</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="EASI-75">
      <data key="d0">SYMPTOM</data>
      <data key="d1">EASI-75 is a measure indicating a 75% improvement in the Eczema Area and Severity Index</data>
      <data key="d2">b201c6ff3e22b2475c8c59260a0eb6a7</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="B CELLS">
      <data key="d0">CELL</data>
      <data key="d1">B cells are a type of white blood cell that plays a role in the immune response and are involved in the pathogenesis of HS
B cells are a type of immune cell with significant signatures in HS skin
B cells are a type of white blood cell that plays a vital role in the humoral immune response by producing antibodies
B cells are a type of white blood cell involved in the immune response and are predominant in HS skin
B cells are a type of white blood cell involved in the immune response and are identified as a potential therapeutic target in HS
B cells are increased in the circulation and skin tissue of patients with Atopic Dermatitis
B cells are haematopoietic cells involved in immune responses and affected by IL-4 signaling
B cells are a type of lymphocyte involved in the production of antibodies
B cells are involved in the immune response in atopic dermatitis
B cells are a type of white blood cell involved in the production of antibodies
B cells are a type of cell that can express TNF
B cells are a type of lymphocyte involved in the adaptive immune response
B cells are professional antigen presenting cells that express OX40L when activated
B cells are immune cells that BAFF can act upon</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,1b656cfce91ff9ccec4223703489dab3,2e0cdefd62bed7c674d7fb93ef336c2b,411a4d246f0a9321e52971446a5a0606,48de7eebab3f3b418feb35a152df38fd,516e41e96d2e72d45bf1e2c69da7f18a,523bbfee1ae3b4ecabf9b11d10eea9ff,693a2aac101eaaadf92614317a1e4da8,7c13f41d7349d9d2e56c36e00c0ca2d9,83eb9003d42977bb83fea1d123dd5ab9,89dbac0da39e4de2b602052cd792b90d,b62ecc47bf54393bc78dd65986b949d6,bae090d8a29c15868ba1c4f29ae79e99,f2aa3fd6ae3f1853347874c50afb60ea</data>
      <data key="d3">CELL</data>
    </node>
    <node id="IFN-&#915;">
      <data key="d0">PROTEIN</data>
      <data key="d1">IFN-&#947; is a cytokine involved in immune responses and is implicated in the inflammatory responses in HS
IFN-&#947; is a type II interferon with significant response in HS lesional skin
IFN-&#947; is a cytokine critical for innate and adaptive immunity against viral and intracellular bacterial infections
IFN-&#947; is a cytokine involved in the immune response
Interferon-gamma, a cytokine critical for innate and adaptive immunity against viral and intracellular bacterial infections and for tumor control
IFN-&#947; is a type 1 cytokine involved in the pathophysiology of chronic atopic dermatitis lesions
Interferon-gamma, a cytokine involved in inflammatory responses
IFN-&#947; is a type 1 cytokine involved in immune response
Interferon-gamma (IFN-&#947;) is a cytokine involved in type 1 immune responses and has roles in inflammation and immune regulation
Interferon-gamma (IFN-&#947;) is a cytokine involved in the immune response and inflammation
Interferon-gamma (IFN-&#947;) is a cytokine involved in the immune response
Interferon-gamma (IFN-&#947;) is a cytokine involved in immune responses and inflammation
IFN-&#947; is a proinflammatory cytokine involved in immune response
IFN-&#947; is a proinflammatory cytokine induced by ICOS in activated T cells</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,27a7e95c7d3ad59a948aa46741fee456,2e0cdefd62bed7c674d7fb93ef336c2b,3dfbb4c51838e0951f53ce951395225f,41ccc4b41bd57cf2bda4dbb6c7ae4198,44f2592262cac835560b4c149fee8d2b,503107475d2e9dac49abd8ebcbadd9f5,523bbfee1ae3b4ecabf9b11d10eea9ff,b19f42c9497f71b231222cd953036d6b,bae090d8a29c15868ba1c4f29ae79e99,e340a83f7cba0ea5be731b1f682ea7c7,e95d4d15e4f3110c91a3d3fcb5910d06,f2aa3fd6ae3f1853347874c50afb60ea,f66eb51473925a8084dad1745be63b78</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="BRUTON&#8217;S TYROSINE KINASE">
      <data key="d0">PROTEIN</data>
      <data key="d1">Bruton&#8217;s Tyrosine Kinase (BTK) is involved in B cell signaling and is a potential therapeutic target in HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="SPLEEN TYROSINE KINASE">
      <data key="d0">PROTEIN</data>
      <data key="d1">Spleen Tyrosine Kinase (SYK) is involved in B cell signaling and is a potential therapeutic target in HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="ABSCESS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Abscess formation is a characteristic symptom of HS, involving localized collections of pus</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="SINUS TRACTS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Sinus tracts are abnormal channels that develop in the skin, commonly seen in HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="COMPLEMENT ACTIVATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Complement activation is a part of the immune response implicated in the pathogenesis of HS
Complement activation is a biological process enriched among increased DEGs in HS
Complement activation is part of the immune response that enhances the ability of antibodies and phagocytic cells to clear pathogens
Complement activation is a part of the immune response that enhances the ability of antibodies and phagocytic cells to clear pathogens</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b,523bbfee1ae3b4ecabf9b11d10eea9ff,bae090d8a29c15868ba1c4f29ae79e99,e4d25b1cd44df240a29591bc46a875ab</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="C5A">
      <data key="d0">PROTEIN</data>
      <data key="d1">C5a is a complement fragment that acts as a chemoattractant for neutrophils and is elevated in HS
C5a is a protein fragment released during complement activation and acts as a neutrophil chemoattractant</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff,e340a83f7cba0ea5be731b1f682ea7c7</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="NETOSIS">
      <data key="d0">PATHWAY</data>
      <data key="d1">NETosis is a process where neutrophils release neutrophil extracellular traps (NETs), observed in HS
NETosis is a form of cell death in which neutrophils release extracellular traps to capture pathogens</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff,e340a83f7cba0ea5be731b1f682ea7c7</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="PLASMACYTOID DENDRITIC CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Plasmacytoid dendritic cells (pDCs) are involved in type I IFN responses and are activated in HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">CELL</data>
    </node>
    <node id="CD19">
      <data key="d0">GENE</data>
      <data key="d1">CD19 is a gene associated with B cell responses and is upregulated in HS skin
CD19 is a gene with a 33-fold increased expression in the study</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b,523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">GENE</data>
    </node>
    <node id="CD79A">
      <data key="d0">GENE</data>
      <data key="d1">CD79a is a gene associated with B cell responses and is upregulated in HS skin
CD79a is a gene with a 32-fold increased expression in the study</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b,523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">GENE</data>
    </node>
    <node id="IGLV3-27">
      <data key="d0">GENE</data>
      <data key="d1">IGLV3-27 is an immunoglobulin gene that is upregulated in HS skin</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">GENE</data>
    </node>
    <node id="PBMCS">
      <data key="d0">CELL</data>
      <data key="d1">Peripheral blood mononuclear cells (PBMCs) are blood cells that have a round nucleus, including lymphocytes, monocytes, and macrophages, and are used in HS studies

Peripheral blood mononuclear cells, a type of blood cell that is critical in immune response
Peripheral Blood Mononuclear Cells, used for immunophenotyping in AD patients</data>
      <data key="d2">2e9a8d71f6bd251a0b13458c39e69746,523bbfee1ae3b4ecabf9b11d10eea9ff,691cb2e23ac3c6e591129d16714f8ef8,6b099960b0a39866e3aa6b908f1886e4</data>
      <data key="d3">CELL</data>
    </node>
    <node id="NOTCH SIGNALING">
      <data key="d0">PATHWAY</data>
      <data key="d1">Notch signaling is a pathway involved in cell differentiation and is hypothesized to be involved in HS pathogenesis
Notch signaling is a fundamental pathway involved in cell differentiation and development</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff,e340a83f7cba0ea5be731b1f682ea7c7</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="GAMMA-SECRETASE COMPLEX">
      <data key="d0">PROTEIN</data>
      <data key="d1">Gamma-secretase complex is involved in Notch signaling and has genetic mutations associated with HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="TYPE I IFN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Type I interferons (IFNs) are cytokines involved in antiviral responses and are increased in HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="IMMUNOGLOBULINS">
      <data key="d0">PROTEIN</data>
      <data key="d1">Immunoglobulins are antibodies produced by plasma cells and are increased in HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="AFRICAN AMERICANS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">African Americans are an ethnic group with a higher incidence of HS compared to Caucasians</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="CAUCASIANS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Caucasians are an ethnic group with a lower incidence of HS compared to African Americans</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="HORMONAL COMPONENT">
      <data key="d0">PATHWAY</data>
      <data key="d1">Hormonal components are factors that influence the development and progression of HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="QUALITY OF LIFE">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Quality of life is significantly affected in patients with HS
Quality of life is a patient-reported outcome affected by atopic dermatitis
Quality of life refers to the general well-being of individuals and societies
Quality of life is improved by effective AD treatments
Quality of life refers to the general well-being of individuals and societies, encompassing both physical and mental health</data>
      <data key="d2">143d2dc302af5606656797bff162e23e,2cec06c4d46f5ff9ee936a78d8b077cd,48288f3ec2832850282f95d4e38d10e1,523bbfee1ae3b4ecabf9b11d10eea9ff,e30574e513dd250992d637d808759c34</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="RNA-SEQ">
      <data key="d0">PATHWAY</data>
      <data key="d1">RNA sequencing (RNA-Seq) is a technique used to analyze the transcriptome and was used in HS studies
RNA-Seq is a technique used to analyze the transcriptomic characteristics of HS
RNA sequencing is a technique used to analyze the quantity and sequences of RNA in a sample
RNA-Seq is a sequencing technique used to study the transcriptome
RNA-Seq is a technique used to analyze the transcriptome of an organism
RNA sequencing, a technique used to analyze the quantity and sequences of RNA in a sample
RNA sequencing is a technique used to analyze the transcriptome of SSc patients</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,2a0384addc6e7fd709e0508b83496cd7,2e0cdefd62bed7c674d7fb93ef336c2b,411a4d246f0a9321e52971446a5a0606,523bbfee1ae3b4ecabf9b11d10eea9ff,b28eeca0ff01a7715947d55a04978a43,d4797ed1483e5057bcd8301eaa509d5e</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="CYTOMETRY BY TIME OF FLIGHT">
      <data key="d0">PATHWAY</data>
      <data key="d1">Cytometry by time of flight (CyTOF) is an imaging technique used to analyze cell populations in HS studies</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNE COMPLEX DEPOSITION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune complex deposition is the accumulation of immune complexes in tissues, contributing to HSImmune complex deposition is a process where immune complexes accumulate in tissues and is implicated in HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNOPATHOGENESIS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immunopathogenesis refers to the development of disease due to immune system dysfunction, as seen in HS
Immunopathogenesis is the process by which an immune response contributes to the development of disease</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff,7b454335c2f5651d86f712037a0dc0ff</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="SINGLE-CELL RNA-SEQUENCING">
      <data key="d0">PATHWAY</data>
      <data key="d1">Single-cell RNA sequencing is a technique used to analyze the transcriptome at the single-cell level and was used in HS studies</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="BULK RNA-SEQUENCING">
      <data key="d0">PATHWAY</data>
      <data key="d1">Bulk RNA sequencing is a technique used to analyze the transcriptome of a population of cells and was used in HS studies</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="PRINCIPAL COMPONENTS ANALYSIS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Principal components analysis (PCA) is a statistical technique used to reduce the dimensionality of data and was used in HS studies</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="DIFFERENTIALLY EXPRESSED GENES">
      <data key="d0">GENE</data>
      <data key="d1">Differentially expressed genes (DEGs) are genes that show significant differences in expression levels between conditions, such as HS and healthy controls</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">GENE</data>
    </node>
    <node id="FALSE DISCOVERY RATE">
      <data key="d0">PATHWAY</data>
      <data key="d1">False discovery rate (FDR) is a statistical method used to correct for multiple comparisons in gene expression studies
False discovery rate is the expected proportion of false discoveries among the rejected hypotheses</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff,8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="FOLD CHANGE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Fold change is a measure of the change in expression level of a gene between conditions, such as HS and healthy controls</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="CHEMOATTRACTANT">
      <data key="d0">PATHWAY</data>
      <data key="d1">Chemoattractants are substances that attract cells, such as C5a attracting neutrophils in HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="NEUTROPHIL EXTRACELLULAR TRAPS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Neutrophil extracellular traps (NETs) are networks of extracellular fibers released by neutrophils during NETosis, observed in HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="AUTOSOMAL DOMINANT">
      <data key="d0">PATHWAY</data>
      <data key="d1">Autosomal dominant is a pattern of inheritance where a single copy of a mutated gene can cause a disease, such as certain forms of HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="GENETIC MUTATIONS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Genetic mutations are changes in DNA sequence that can contribute to diseases like HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="COMORBIDITIES">
      <data key="d0">PATHWAY</data>
      <data key="d1">Comorbidities are additional diseases or conditions that occur along with a primary disease, such as obesity with HS
Comorbidities are additional diseases or conditions that occur with Atopic Dermatitis</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff,90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="PROTEOMIC APPROACHES">
      <data key="d0">PATHWAY</data>
      <data key="d1">Proteomic approaches involve the large-scale study of proteins and were used to characterize inflammatory responses in HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="TRANSCRIPTOMIC APPROACHES">
      <data key="d0">PATHWAY</data>
      <data key="d1">Transcriptomic approaches involve the study of RNA transcripts and were used to characterize inflammatory responses in HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="PRECLINICAL EVIDENCE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Preclinical evidence refers to data obtained from laboratory studies that support the potential effectiveness of a treatment, such as targeting BTK and SYK in HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="CLINICAL TRIALS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Clinical trials are research studies conducted with patients to evaluate the effectiveness of new treatments, such as those targeting BTK and SYK in HS
Clinical trials are research studies conducted to evaluate the efficacy and safety of medical treatments, including those for AD

Clinical trials are research studies that explore the efficacy and safety of new treatments, including those for Atopic Dermatitis.</data>
      <data key="d2">1d0c4a4cd555b7ecd0b9d7b0310e9fe9,48de7eebab3f3b418feb35a152df38fd,523bbfee1ae3b4ecabf9b11d10eea9ff,6ada075e562abd7bd445164e9fc309b4</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="THERAPEUTIC TARGETS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Therapeutic targets are specific molecules or pathways that can be targeted for treatment, such as B cells and plasma cells in HS
Therapeutic targets are specific molecules or pathways identified for drug development in Atopic Dermatitis
Therapeutic targets are specific molecules or pathways in the body that are targeted by drugs to treat diseases, including AD</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff,90f4809673ca34628b0e607908f0bf0b,e30574e513dd250992d637d808759c34</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="THERAPEUTIC DEVELOPMENT">
      <data key="d0">PATHWAY</data>
      <data key="d1">Therapeutic development involves the process of discovering and developing new treatments for diseases, such as HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="INFLAMMATORY PATHWAYS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Inflammatory pathways are biological pathways involved in inflammation, which are dysregulated in HS
Inflammatory pathways are involved in the immune response and pathogenesis of Atopic Dermatitis</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff,90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNE RESPONSES">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune responses are the body's defense mechanisms against pathogens, which are dysregulated in HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="ANTIBODIES">
      <data key="d0">PROTEIN</data>
      <data key="d1">Antibodies are proteins produced by plasma cells that help neutralize pathogens and are increased in HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="COMPLEMENT FRAGMENT">
      <data key="d0">PROTEIN</data>
      <data key="d1">Complement fragments are parts of the complement system involved in immune responses, such as C5a in HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="CHEMOATTRACTANTS">
      <data key="d0">PROTEIN</data>
      <data key="d1">Chemoattractants are substances that attract immune cells, such as C5a attracting neutrophils in HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="IMMUNE COMPLEXES">
      <data key="d0">PROTEIN</data>
      <data key="d1">Immune complexes are formed when antibodies bind to antigens and can deposit in tissues, contributing to HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="INFLAMMATORY RESPONSES">
      <data key="d0">PATHWAY</data>
      <data key="d1">Inflammatory responses are the body's reactions to harmful stimuli, which are dysregulated in HS</data>
      <data key="d2">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </node>
    <node id="V3-27">
      <data key="d0">GENE</data>
      <data key="d1">V3-27 is a gene with a 100-fold increased expression in the study</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b</data>
    </node>
    <node id="SPRR2F">
      <data key="d0">GENE</data>
      <data key="d1">SPRR2F is an antimicrobial gene dysregulated in lesional skin of HS, psoriasis, and atopic dermatitis</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b</data>
    </node>
    <node id="CD177">
      <data key="d0">GENE</data>
      <data key="d1">CD177 is an antimicrobial gene dysregulated in lesional skin of HS, psoriasis, and atopic dermatitis</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b</data>
    </node>
    <node id="TCN1">
      <data key="d0">GENE</data>
      <data key="d1">TCN1 is an antimicrobial gene dysregulated in lesional skin of HS, psoriasis, and atopic dermatitis</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b</data>
    </node>
    <node id="IL17C">
      <data key="d0">GENE</data>
      <data key="d1">IL17C is a gene with overall decreased expression in HS</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b</data>
    </node>
    <node id="CD4+">
      <data key="d0">CELL</data>
      <data key="d1">CD4+ cells are a type of T cell involved in the immune response</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b</data>
    </node>
    <node id="CD8+">
      <data key="d0">CELL</data>
      <data key="d1">CD8+ cells are a type of T cell involved in the immune response</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b</data>
    </node>
    <node id="MELANOCYTES">
      <data key="d0">CELL</data>
      <data key="d1">Melanocytes are a type of cell found in the skin
Melanocytes are cells in the skin responsible for producing melanin, the pigment that gives skin its color</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b,bae090d8a29c15868ba1c4f29ae79e99</data>
      <data key="d3">CELL</data>
    </node>
    <node id="FIBROBLASTS">
      <data key="d0">CELL</data>
      <data key="d1">Fibroblasts are a type of cell found in the skin
Fibroblasts are cells that synthesize the extracellular matrix and collagen, playing a critical role in wound healing
Fibroblasts are involved in fibrotic skin remodeling in AD
Fibroblasts are responsible for collagen and extracellular matrix protein deposition in fibrosis
Fibroblasts are cells that express type 1 collagen after TNF-co-stimulation of SSc patient T cells
Fibroblasts are cells that produce collagen and other fibers
Fibroblasts are cells that synthesize the extracellular matrix and collagen
Fibroblasts are cells that synthesize the extracellular matrix and collagen, playing a critical role in wound healing and fibrosis
Fibroblasts are cells that produce collagen and other fibers
Fibroblasts are structural cells that express OX40L in fibrotic tissues
Fibroblasts are cells that produce extracellular matrix and collagen
Fibroblasts are structural cells involved in the formation of connective tissue and fibrosis
Fibroblasts are structural cells that LIGHT, TL1A, and BAFF can act upon</data>
      <data key="d2">05c97152fe02249153103be341d65b67,080b1dc5fcc0eee3645a06983a0de603,1b656cfce91ff9ccec4223703489dab3,2e0cdefd62bed7c674d7fb93ef336c2b,48de7eebab3f3b418feb35a152df38fd,4cf23e218b6aab3c77115173b5c7c2fd,516e41e96d2e72d45bf1e2c69da7f18a,5ec1ebf4e260eb1f8fda8acdf06cd39e,5f37466ca41c9b8b06ed8be0303d49f2,68015074236b0144899baa38d01ae467,a10787d7fbb1307be263e86dc7b33a51,bae090d8a29c15868ba1c4f29ae79e99,df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">CELL</data>
    </node>
    <node id="SMOOTH MUSCLE CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Smooth muscle cells are a type of cell found in the skin
Smooth muscle cells are responsible for the contractility of hollow organs such as blood vessels and the gastrointestinal tract
Smooth muscle cells are involved in the process of fibrosis
Smooth muscle cells are cells found in the walls of hollow organs like blood vessels and the intestines
Smooth muscle cells are responsible for the contractility of hollow organs such as blood vessels and the gastrointestinal tract
Smooth muscle cells are found in the walls of hollow organs and are involved in involuntary movements
Smooth muscle cells are structural cells that LIGHT can act upon</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,2e0cdefd62bed7c674d7fb93ef336c2b,516e41e96d2e72d45bf1e2c69da7f18a,5f37466ca41c9b8b06ed8be0303d49f2,68015074236b0144899baa38d01ae467,bae090d8a29c15868ba1c4f29ae79e99,df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">CELL</data>
    </node>
    <node id="T CELLS">
      <data key="d0">CELL</data>
      <data key="d1">T cells are a type of immune cell found in the skin
T cells are a type of lymphocyte that plays a central role in cell-mediated immunity
T cells are increased in the circulation and skin tissue of patients with Atopic Dermatitis
T cells are haematopoietic cells involved in immune responses and affected by IL-4 signaling
T cells are a type of immune cell involved in adaptive immunity
T cells are a type of lymphocyte that play a central role in cell-mediated immunity
T cells are a type of lymphocyte that play a central role in cell-mediated immunity
T cells are effectors in the inflammatory reaction in atopic dermatitis
T cells are immune system cells in the skin targeted by methotrexate
T cells, specifically skin-homing memory-prone CLA+ T cells, which express OX40 in AD patients
T cells are a type of lymphocyte involved in the immune response, expressing OX40 in AD
T cells are a type of immune cell involved in the body's immune response
T cells are a type of cell that can express TNF
T cells are a type of immune cell involved in the pathogenesis of systemic sclerosis
T cells are a type of lymphocyte involved in the immune responseT cells are a type of lymphocyte involved in immune response
T cells are a type of lymphocyte that play a central role in cell-mediated immunity
T cells are modulated by OX40-OX40L signaling, promoting their survival, proliferation, and cytokine secretion
T cells are a type of lymphocyte involved in the immune response
T cells are immune cells that TL1A can act upon</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,0ba9fbea14e0c2c1d01a12ffaacfda9b,1b656cfce91ff9ccec4223703489dab3,286730b1c1f680ac465cc21d522fda0c,2e0cdefd62bed7c674d7fb93ef336c2b,44f2592262cac835560b4c149fee8d2b,48de7eebab3f3b418feb35a152df38fd,516e41e96d2e72d45bf1e2c69da7f18a,5ec1ebf4e260eb1f8fda8acdf06cd39e,68015074236b0144899baa38d01ae467,693a2aac101eaaadf92614317a1e4da8,6b099960b0a39866e3aa6b908f1886e4,83eb9003d42977bb83fea1d123dd5ab9,89dbac0da39e4de2b602052cd792b90d,b19f42c9497f71b231222cd953036d6b,bae090d8a29c15868ba1c4f29ae79e99,c525762bb827485bceeb9f09bb4bcfe0,df74aa1b86eeeb811ca5586767ae3a71,f2aa3fd6ae3f1853347874c50afb60ea</data>
      <data key="d3">CELL</data>
    </node>
    <node id="MYELOID CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Myeloid cells are a type of immune cell found in the skin
Myeloid cells are a group of cells derived from bone marrow progenitors, including monocytes, macrophages, and neutrophils</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b,bae090d8a29c15868ba1c4f29ae79e99</data>
      <data key="d3">CELL</data>
    </node>
    <node id="MAST CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Mast cells are a type of immune cell found in the skin
Mast cells are immune cells that play a key role in allergic reactions and inflammation
Mast cells are immune cells that play a role in allergic reactions and inflammation
Mast cells express high-affinity receptors for IgE and are involved in the immune response in atopic dermatitis
Mast cells are a type of white blood cell that are elevated in the skin of Atopic Dermatitis patients.
Mast cells are immune cells that release histamine and other substances during inflammatory and allergic reactions
Mast cells express OX40L and are involved in immediate hypersensitivity reactions and production of Th2 driving cytokines in Atopic Dermatitis
Mast cells, identified by positive tryptase staining and expressing OX40L in AD skin
Mast cells are immune cells involved in allergic reactions and inflammation, expressing OX40L in AD
Mast cells are a type of cell that can express TNF</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,2e0cdefd62bed7c674d7fb93ef336c2b,41ccc4b41bd57cf2bda4dbb6c7ae4198,691cb2e23ac3c6e591129d16714f8ef8,6ada075e562abd7bd445164e9fc309b4,6b099960b0a39866e3aa6b908f1886e4,83eb9003d42977bb83fea1d123dd5ab9,89dbac0da39e4de2b602052cd792b90d,bae090d8a29c15868ba1c4f29ae79e99,f2aa3fd6ae3f1853347874c50afb60ea</data>
      <data key="d3">CELL</data>
    </node>
    <node id="PPAR SIGNALING PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">PPAR signaling pathway is a biological process enriched among decreased DEGs in HS</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="STEROID BIOSYNTHESIS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Steroid biosynthesis is a biological process enriched among decreased DEGs in HS</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="CHOLESTEROL BIOSYNTHETIC PROCESS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Cholesterol biosynthetic process is a KEGG pathway among decreased DEGs in HS</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="LIPID METABOLIC PROCESS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Lipid metabolic process is a KEGG pathway among decreased DEGs in HS</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNE RESPONSE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune response is a biological process enriched among increased DEGs in HS
The immune response involves the body's defense mechanisms, which are dysregulated in AD
The immune response involves the body's defense mechanisms against pathogens and is implicated in atopic dermatitis
Immune response is the body's defense mechanism against infections and diseases
The immune response is a critical pathway in the pathogenesis and treatment of Atopic Dermatitis
The immune response is involved in the pathogenesis and treatment of AD
The immune response is the body's defense mechanism against pathogens, involving various cells and proteins</data>
      <data key="d2">143d2dc302af5606656797bff162e23e,1596d061dbe1a1c9e8f31a02a21e5524,2cec06c4d46f5ff9ee936a78d8b077cd,2e0cdefd62bed7c674d7fb93ef336c2b,3ce96e927d65736b305f792977fed4b9,44f2592262cac835560b4c149fee8d2b,90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="REGULATION OF IMMUNE RESPONSE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Regulation of immune response is a biological process enriched among increased DEGs in HS</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="FC-GAMMA RECEPTOR SIGNALING PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Fc-gamma receptor signaling pathway is a biological process enriched among increased DEGs in HS</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="INNATE IMMUNE RESPONSE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Innate immune response is a biological process enriched among increased DEGs in HS
Innate immune response is the body's first line of defense against pathogens</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b,6309eeea565f06479830cec32938abc9</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="B CELL RECEPTOR SIGNALING">
      <data key="d0">PATHWAY</data>
      <data key="d1">B cell receptor signaling is a biological process enriched among increased DEGs in HS</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="NEUTROPHIL CHEMOTAXIS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Neutrophil chemotaxis is a biological process enriched among increased DEGs in HS
Neutrophil chemotaxis is the movement of neutrophils towards the site of infection or inflammation</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b,bae090d8a29c15868ba1c4f29ae79e99</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="SCRNA-SEQ">
      <data key="d0">CHEMICAL</data>
      <data key="d1">scRNA-Seq is a technique used to outline the cellular composition of HS
Single-cell RNA sequencing, a method used to examine the gene expression of individual cells</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,2e0cdefd62bed7c674d7fb93ef336c2b</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="CTLA-4">
      <data key="d0">GENE</data>
      <data key="d1">CTLA-4 is a gene involved in T-cell costimulatory pathways
CTLA-4 is a protein associated with immune response regulation
Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is a protein involved in the immune response
CTLA-4 is a protein associated with immune response regulation
CTLA-4 is a T cell inhibitory molecule that binds to CD80/86, reducing IL-2 production and T cell proliferation
CTLA-4 is a protein associated with immune response regulation
Cytotoxic T-lymphocyte-associated protein 4, involved in negative costimulatory pathways
CTLA-4 is a protein involved in immune response regulation, also known as cytotoxic T-lymphocyte-associated protein 4
CTLA-4 is a protein associated with immune response regulation</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,1b656cfce91ff9ccec4223703489dab3,2e0cdefd62bed7c674d7fb93ef336c2b,41ccc4b41bd57cf2bda4dbb6c7ae4198,44f2592262cac835560b4c149fee8d2b,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,855c455b4c9592746834ee3a4e0e6b81,9867d43adab0ba5db44961fae4863eee</data>
    </node>
    <node id="ICOS">
      <data key="d0">GENE</data>
      <data key="d1">ICOS is a gene involved in T-cell costimulatory pathways
Inducible T-cell COStimulator, a protein involved in T-cell activation and survival
ICOS is a member of the CD28 superfamily and is highly expressed in activated T cells
ICOS is a protein that induces proinflammatory and pro-fibrotic cytokine synthesis in activated T cells
Inducible T-cell costimulator, involved in positive costimulatory pathways
ICOS is a protein involved in T cell costimulation, also known as inducible co-stimulatory molecule
ICOS is a costimulatory protein involved in T-cell immune responses</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,1b656cfce91ff9ccec4223703489dab3,2e0cdefd62bed7c674d7fb93ef336c2b,44f2592262cac835560b4c149fee8d2b,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="CD70">
      <data key="d0">GENE</data>
      <data key="d1">CD70 is a gene involved in T-cell costimulatory pathways
CD70 is a protein involved in the activation of T cells and B cells
CD70 is a protein involved in the CD70-CD27 costimulatory pathway
CD70 is a protein involved in T cell activation
CD70 is a ligand for CD27, involved in T and B cell signaling
CD70 is a protein that interacts with CD27 to provide stimulatory signals for T and B cell activation
CD70 is a ligand in the TNF superfamily, also known as CD27L</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,1b656cfce91ff9ccec4223703489dab3,2e0cdefd62bed7c674d7fb93ef336c2b,4cf23e218b6aab3c77115173b5c7c2fd,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="CD27">
      <data key="d0">GENE</data>
      <data key="d1">CD27 is a gene involved in T-cell costimulatory pathways
CD27 is a protein found on the surface of T cells and is involved in T cell activation and survival
CD27 is a protein that plays a role in the regulation of B-cell and T-cell function
CD27 is a protein involved in the CD70-CD27 costimulatory pathway
CD27 is a protein involved in T cell activation
CD27 is a member of the TNFRSF that acts as a costimulatory signal for T cells
CD27 is a receptor for CD70, involved in T and B cell signaling
CD27 is a protein involved in the costimulatory pathway important for T and B cell activation
CD27 is a receptor for CD70, also known as S152, Tp55</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,1b656cfce91ff9ccec4223703489dab3,2e0cdefd62bed7c674d7fb93ef336c2b,4cf23e218b6aab3c77115173b5c7c2fd,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,7c13f41d7349d9d2e56c36e00c0ca2d9,b28eeca0ff01a7715947d55a04978a43,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="CD40">
      <data key="d0">GENE</data>
      <data key="d1">CD40 is a gene involved in T-cell costimulatory pathways
CD40 is a protein that plays a role in the activation of immune responses
CD40 is a protein involved in the CD40-CD154 costimulatory pathway
CD40 is a member of the TNF receptor superfamily involved in immune and inflammatory responses
CD40 is involved in positive costimulatory pathways
CD40 is a protein involved in immune response regulation
CD40 is a costimulatory protein involved in immune responses</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,1b656cfce91ff9ccec4223703489dab3,2e0cdefd62bed7c674d7fb93ef336c2b,44f2592262cac835560b4c149fee8d2b,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="CD154">
      <data key="d0">GENE</data>
      <data key="d1">CD154 is a gene involved in T-cell costimulatory pathways
CD154 is a protein that binds to CD40 and is involved in immune responses
CD154 is a protein involved in the CD40-CD154 costimulatory pathway
CD154, also known as CD40L, binds to CD40 and activates antigen-presenting cells
CD154 is involved in positive costimulatory pathways
CD154 is a protein involved in immune response regulation, also known as CD40 ligand
CD154 is a ligand for CD40, involved in immune responses</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,1b656cfce91ff9ccec4223703489dab3,2e0cdefd62bed7c674d7fb93ef336c2b,44f2592262cac835560b4c149fee8d2b,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="B CELL">
      <data key="d0">CELL</data>
      <data key="d1">B cells are a type of immune cell involved in the immune response
B cells are a type of white blood cell involved in the adaptive immune response
B cells are a type of white blood cell involved in the adaptive immune response
B cells are a type of white blood cell involved in the immune response, particularly in antibody production
B cells are a type of white blood cell involved in the immune response
B cells are lymphocytes that play a role in the immune response by producing antibodies
B cells are involved in the immune response and are affected in systemic sclerosis
B cell proliferation and differentiation are enhanced by OX40/OX40L interaction
B cells are a type of immune cell involved in the production of antibodies
B cells are a type of lymphocyte involved in antibody production
B cells are a type of white blood cell involved in the immune response</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,2a0384addc6e7fd709e0508b83496cd7,2e0cdefd62bed7c674d7fb93ef336c2b,44f2592262cac835560b4c149fee8d2b,48288f3ec2832850282f95d4e38d10e1,503107475d2e9dac49abd8ebcbadd9f5,8ce8c356713490cd2c680f505bcd050b,9867d43adab0ba5db44961fae4863eee,b2aae16813e647959b783a39ef9a19a7,e340a83f7cba0ea5be731b1f682ea7c7,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="T CELL">
      <data key="d0">CELL</data>
      <data key="d1">T cells are a type of immune cell involved in the immune response
T cells are a type of white blood cell involved in the adaptive immune response
T cells are a type of white blood cell that play a central role in cell-mediated immunity
T cells are immune cells involved in the pathophysiology of atopic dermatitis
T cells are a type of lymphocyte that play a central role in cell-mediated immunity
T cells are a type of immune cell involved in the inflammatory response in AD
T cells are immune cells that are attracted to the skin during inflammation in AD patients
T cells are a type of lymphocyte that play a central role in cell-mediated immunity
T cells are involved in the immune response and are affected in systemic sclerosis
T cells are a type of immune cell involved in the body's immune response
T cells are a type of lymphocyte involved in the immune response
T cells are a type of lymphocyte that play a central role in cell-mediated immunity</data>
      <data key="d2">100dd7646c10899301b3c0631183da16,1412a7a7fef5f18cc09a030b97b18e13,2a0384addc6e7fd709e0508b83496cd7,2e0cdefd62bed7c674d7fb93ef336c2b,3ce96e927d65736b305f792977fed4b9,442e7fad2fab75fa2449309783294d89,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,6059a6e2710b7df94c6a09e5eb7b024a,8ce8c356713490cd2c680f505bcd050b,9867d43adab0ba5db44961fae4863eee,f66eb51473925a8084dad1745be63b78</data>
    </node>
    <node id="CD4+ NAIVE CELLS">
      <data key="d0">CELL</data>
      <data key="d1">CD4+ naive cells are a type of T cell involved in the immune response</data>
      <data key="d2">2e0cdefd62bed7c674d7fb93ef336c2b</data>
    </node>
    <node id="NOTCH SIGNALING PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">The Notch signaling pathway is involved in cell differentiation, proliferation, and apoptosis</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="CCL20">
      <data key="d0">PROTEIN</data>
      <data key="d1">CCL20 is a chemokine involved in immunoregulatory and inflammatory processes</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="B CELL ACTIVATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">B cell activation is the process by which B cells respond to antigens and produce antibodies</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="ANTIBACTERIAL HUMORAL RESPONSE">
      <data key="d0">PATHWAY</data>
      <data key="d1">The antibacterial humoral response involves the production of antibodies to neutralize bacterial pathogens</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="B CELL RECEPTOR SIGNALING PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">The B cell receptor signaling pathway is crucial for B cell development and activation</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="IFN-&#915; MEDIATED SIGNALING PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">The IFN-&#947; mediated signaling pathway is involved in the immune response to pathogens</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="INFLAMMATORY RESPONSE">
      <data key="d0">PATHWAY</data>
      <data key="d1">The inflammatory response is the body's reaction to infection or injury, involving immune cells, blood vessels, and molecular mediators
The inflammatory response is the body's reaction to injury or infection, involving immune cells and molecules
The inflammatory response is part of the immune system's reaction to injury or infection, playing a role in atopic dermatitis
Inflammatory response is the body's reaction to injury or infection, involving immune cells and mediators</data>
      <data key="d2">143d2dc302af5606656797bff162e23e,1596d061dbe1a1c9e8f31a02a21e5524,3ce96e927d65736b305f792977fed4b9,bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="T CELL RECEPTOR SIGNALING PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">The T cell receptor signaling pathway is essential for T cell activation and function</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="T CELL COSTIMULATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">T cell costimulation is a secondary signal required for T cell activation and survival</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="TNF-MEDIATED SIGNALING">
      <data key="d0">PATHWAY</data>
      <data key="d1">TNF-mediated signaling is involved in inflammation and apoptosis</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="CYTOF">
      <data key="d0">TECHNIQUE</data>
      <data key="d1">CyTOF is a mass cytometry technique used to analyze cell populationsCyTOF (Cytometry by Time-Of-Flight) is a mass cytometry technique used to analyze cell populations based on protein expression
CyTOF is a mass cytometry technique used for high-dimensional single-cell analysis
Cytometry by Time-Of-Flight, a technique used to measure the properties of cells, including protein expression</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,b28eeca0ff01a7715947d55a04978a43,bae090d8a29c15868ba1c4f29ae79e99</data>
      <data key="d3">TECHNIQUE</data>
    </node>
    <node id="T-SNE">
      <data key="d0">TECHNIQUE</data>
      <data key="d1">t-SNE (t-Distributed Stochastic Neighbor Embedding) is a technique for visualizing high-dimensional data by reducing it to two or three dimensionst-SNE is a dimensionality reduction technique used for visualizing high-dimensional data
t-SNE is a dimensionality reduction algorithm used for visualizing high-dimensional data
t-distributed Stochastic Neighbor Embedding, a machine learning algorithm for dimensionality reduction</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,b28eeca0ff01a7715947d55a04978a43,bae090d8a29c15868ba1c4f29ae79e99</data>
      <data key="d3">TECHNIQUE</data>
    </node>
    <node id="MONOCYTES">
      <data key="d0">CELL</data>
      <data key="d1">Monocytes are a type of white blood cell that can differentiate into macrophages and dendritic cells
Monocytes are a type of white blood cell that plays a role in immune defense and inflammation
Monocytes are hyperactive inflammatory cells calmed down by methotrexate
Monocytes, which express high levels of OX40L in both AD patients and healthy controls
Monocytes are a type of white blood cell that can differentiate into macrophages and dendritic cells, involved in immune responses
Monocytes are a type of cell that produces TNF
Monocytes are immune cells that differentiate into macrophages and express receptors for APRIL and BAFF
Monocytes are a type of white blood cell that primarily express TRAIL</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,27a7e95c7d3ad59a948aa46741fee456,286730b1c1f680ac465cc21d522fda0c,6b099960b0a39866e3aa6b908f1886e4,89dbac0da39e4de2b602052cd792b90d,bae090d8a29c15868ba1c4f29ae79e99,c525762bb827485bceeb9f09bb4bcfe0,d4797ed1483e5057bcd8301eaa509d5e</data>
      <data key="d3">CELL</data>
    </node>
    <node id="LEUKOCYTES">
      <data key="d0">CELL</data>
      <data key="d1">Leukocytes are white blood cells involved in protecting the body against infections</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
      <data key="d3">CELL</data>
    </node>
    <node id="STROMAL CELLS">
      <data key="d0" />
      <data key="d1">
Stromal cells are connective tissue cells that support the function of the parenchymal cells</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51,bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="GENES">
      <data key="d0">GENE</data>
      <data key="d1">Genes are units of heredity that contribute to the characteristics and functions of an organism</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="TRANSCRIPTS">
      <data key="d0">GENE</data>
      <data key="d1">Transcripts are RNA molecules transcribed from DNA, representing gene expression</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="CELLPHONEDB">
      <data key="d0">TECHNIQUE</data>
      <data key="d1">CellPhoneDB is a computational tool used to analyze cell-cell communication via ligand-receptor interactions
CellPhoneDB is a database used for analyzing cell-cell communication</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7,bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="LIGAND">
      <data key="d0">PROTEIN</data>
      <data key="d1">A ligand is a molecule that binds to a specific receptor to initiate a biological response</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">A receptor is a protein on the cell surface or within cells that binds to specific ligands to trigger a response</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="CIRCOS PLOT">
      <data key="d0">TECHNIQUE</data>
      <data key="d1">A Circos plot is a graphical representation used to visualize complex data, such as interactions between entities</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="IL-36G">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-36G is a cytokine involved in inflammatory responses
IL-36G is a cytokine involved in the immune response</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99,e340a83f7cba0ea5be731b1f682ea7c7</data>
    </node>
    <node id="UMAP">
      <data key="d0">TECHNIQUE</data>
      <data key="d1">UMAP (Uniform Manifold Approximation and Projection) is a dimensionality reduction technique used for visualizing high-dimensional data
Uniform Manifold Approximation and Projection, a dimension reduction technique</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="ANTIMICROBIAL GENES">
      <data key="d0">GENE</data>
      <data key="d1">Antimicrobial genes encode proteins that help protect against microbial infections</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="LEUKOCYTE INFILTRATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Leukocyte infiltration refers to the accumulation of white blood cells in a tissue, often indicative of inflammation or infection</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="INFLAMMATORY BURDEN">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Inflammatory burden refers to the extent of inflammation present in a tissue or organism</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="INFLAMMATORY SIGNATURE">
      <data key="d0">SYMPTOM</data>
      <data key="d1">An inflammatory signature is a pattern of gene or protein expression indicative of inflammation</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="INFLAMMATORY STIMULI">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Inflammatory stimuli are factors that trigger an inflammatory response</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="CYTOKINE RESPONSE">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Cytokine response refers to the production and action of cytokines in response to a stimulus</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="MARKER GENES">
      <data key="d0">GENE</data>
      <data key="d1">Marker genes are genes used to identify specific cell types or states</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="SUBCLUSTERS">
      <data key="d0">CELL</data>
      <data key="d1">Subclusters are smaller groups within a larger cell population, identified through clustering analysis</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="DIMENSIONAL REDUCTION">
      <data key="d0">TECHNIQUE</data>
      <data key="d1">Dimensional reduction is a process used to reduce the number of variables in a dataset while preserving important information</data>
      <data key="d2">bae090d8a29c15868ba1c4f29ae79e99</data>
    </node>
    <node id="MONOCYTE/MACROPHAGES">
      <data key="d0">CELL</data>
      <data key="d1">Monocytes and macrophages are types of white blood cells involved in the immune response and are present in HS skin</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606</data>
    </node>
    <node id="CD8+ T CELLS">
      <data key="d0">CELL</data>
      <data key="d1">CD8+ T cells are a type of white blood cell involved in the immune response and are present in HS skin
CD8+ T cells, a subset of T cells expressing OX40 in AD patients
CD8+ T cells are a subset of T cells involved in the immune response</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606,44f2592262cac835560b4c149fee8d2b,6b099960b0a39866e3aa6b908f1886e4</data>
    </node>
    <node id="IMMUNOGLOBULIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Immunoglobulins are antibodies produced by plasma cells and are increased in HS skin
Immunoglobulins are antibodies produced by B cells that play a crucial role in identifying and neutralizing pathogens
Immunoglobulins are antibodies produced by B cells that play a crucial role in the immune response
Immunoglobulins are antibodies produced by B cells that play a key role in immune responses</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,411a4d246f0a9321e52971446a5a0606,44f2592262cac835560b4c149fee8d2b,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="COMPLEMENT">
      <data key="d0">PROTEIN</data>
      <data key="d1">Complement proteins are part of the immune system and are activated in HS skin
Complement is a part of the immune system that enhances the ability of antibodies and phagocytic cells to clear microbes and damaged cells</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,411a4d246f0a9321e52971446a5a0606</data>
    </node>
    <node id="BCR">
      <data key="d0">GENE</data>
      <data key="d1">B cell receptor gene segments are involved in the immune response and are increased in HS skin
B-cell receptor (BCR) is a molecule found on the surface of B cells that is responsible for recognizing antigens
B cell receptor, a molecule on the surface of B cells that binds to specific antigens
B cell receptor, involved in B cell activation and signaling</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,411a4d246f0a9321e52971446a5a0606,b28eeca0ff01a7715947d55a04978a43,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="TCR">
      <data key="d0">GENE</data>
      <data key="d1">T cell receptor gene segments are involved in the immune response and show less pronounced shifts in HS
T-cell receptor (TCR) is a molecule found on the surface of T cells that is responsible for recognizing antigens
T cell receptor, involved in T cell activation and signaling
T cell receptor, involved in the binding to a major histocompatibility complex molecule carrying a peptide antigen</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606,855c455b4c9592746834ee3a4e0e6b81,b28eeca0ff01a7715947d55a04978a43,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="C1Q">
      <data key="d0">PROTEIN</data>
      <data key="d1">C1q is a component of the complement system and is prominently expressed in HS skin
C1q is a protein involved in the complement system of the immune response
C1q is a protein involved in the complement system and immune response
C1q is a protein involved in the complement pathway</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7,411a4d246f0a9321e52971446a5a0606,b28eeca0ff01a7715947d55a04978a43,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="C3B">
      <data key="d0">PROTEIN</data>
      <data key="d1">C3b is a breakdown product of the complement system and is prominently expressed in HS skin
C3b is a protein involved in the complement system and opsonization
C3b is a breakdown product of the complement component C3</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7,411a4d246f0a9321e52971446a5a0606,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="C4D">
      <data key="d0">PROTEIN</data>
      <data key="d1">C4d is a breakdown product of the complement system and is prominently expressed in HS skin
C4d is a protein involved in the complement system and immune response
C4d is a breakdown product of the complement component C4</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7,411a4d246f0a9321e52971446a5a0606,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="CR1">
      <data key="d0">PROTEIN</data>
      <data key="d1">Complement receptor 1 is increased in HS skin
CR1 (CD35) is a protein involved in the immune response and is found on the surface of various cells
Complement receptor 1, involved in the immune response</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606,b28eeca0ff01a7715947d55a04978a43,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="CR2">
      <data key="d0">PROTEIN</data>
      <data key="d1">Complement receptor 2 is increased in HS skin
CR2 (CD21) is a protein involved in the immune response and is found on the surface of B cells
Complement receptor 2, involved in the immune response</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606,b28eeca0ff01a7715947d55a04978a43,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="IGG">
      <data key="d0">PROTEIN</data>
      <data key="d1">IgG is an immunoglobulin that forms immune complexes and is deposited in HS skin
Immunoglobulin G, a type of antibody
Immunoglobulin G, the most common type of antibody found in blood circulation
Immunoglobulin G, a type of antibody
IgG is an antibody used as a control in studies of TL1A-driven inflammation
IgG is an antibody that plays a crucial role in the immune response</data>
      <data key="d2">104cc78517b2eca2e9cb7e00de1fe4b0,411a4d246f0a9321e52971446a5a0606,4cf23e218b6aab3c77115173b5c7c2fd,c525762bb827485bceeb9f09bb4bcfe0,e340a83f7cba0ea5be731b1f682ea7c7,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="SYK">
      <data key="d0">PROTEIN</data>
      <data key="d1">Spleen tyrosine kinase is involved in B cell receptor signaling and is a potential therapeutic target in HS
Spleen tyrosine kinase, a gene involved in immune cell signaling
SYK is a protein involved in B cell signaling and is a potential therapeutic target in HS
SYK is a protein involved in signal transduction in immune cells
Spleen tyrosine kinase, a protein involved in B cell signaling
SYK is a spleen tyrosine kinase involved in T cell activation and signaling for IgE receptors
SYK, or spleen tyrosine kinase, is a protein involved in the regulation of immune responses</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7,411a4d246f0a9321e52971446a5a0606,b62ecc47bf54393bc78dd65986b949d6,c46e8b6ee0c29e37b7f18c42558d7a3e,e340a83f7cba0ea5be731b1f682ea7c7,e4d25b1cd44df240a29591bc46a875ab,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="GRANZYME B">
      <data key="d0">PROTEIN</data>
      <data key="d1">Granzyme B is a serine protease with enriched signals in HS</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606</data>
    </node>
    <node id="CCR5">
      <data key="d0">PROTEIN</data>
      <data key="d1">CCR5 is a chemokine receptor with enriched signals in HS</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606</data>
    </node>
    <node id="ACALABRUTINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Acalabrutinib is a BTK inhibitor used as a potential therapeutic in HS
Acalabrutinib is a BTK inhibitor used in the treatment of certain cancers and autoimmune diseases
Acalabrutinib is a BTK inhibitor shown to prevent plasma cell generation in HS
Acalabrutinib is a chemical inhibitor used in B cell stimulation experiments
Acalabrutinib is a BTK inhibitor used in the treatment of certain cancers</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7,411a4d246f0a9321e52971446a5a0606,b62ecc47bf54393bc78dd65986b949d6,e340a83f7cba0ea5be731b1f682ea7c7,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="IBRUTINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Ibrutinib is a BTK inhibitor used as a potential therapeutic in HS
Ibrutinib is a BTK inhibitor used in the treatment of certain cancers and autoimmune diseases
Ibrutinib is a BTK inhibitor shown to prevent plasma cell generation in HS
Ibrutinib is a chemical inhibitor used in B cell stimulation experiments
Ibrutinib is a BTK inhibitor used in the treatment of certain cancers</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7,411a4d246f0a9321e52971446a5a0606,b62ecc47bf54393bc78dd65986b949d6,e340a83f7cba0ea5be731b1f682ea7c7,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="CCL4">
      <data key="d0">PROTEIN</data>
      <data key="d1">CCL4 is a monocyte chemokine involved in the immune response in HS
CCL4 is a chemokine involved in the recruitment of immune cells to sites of inflammation
CCL4 is a proinflammatory mediator whose expression is decreased by B cell targeting in HS
Carbon tetrachloride, a chemical used to induce liver fibrosis in experimental models
Carbon tetrachloride is a chemical used to induce liver fibrosis and cirrhosis in experimental models</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606,a10787d7fbb1307be263e86dc7b33a51,b62ecc47bf54393bc78dd65986b949d6,d4797ed1483e5057bcd8301eaa509d5e,e340a83f7cba0ea5be731b1f682ea7c7</data>
    </node>
    <node id="CD3+ T CELLS">
      <data key="d0">CELL</data>
      <data key="d1">CD3+ T cells are a type of white blood cell involved in the immune response and are present in HS skin</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606</data>
    </node>
    <node id="CD20+ B CELLS">
      <data key="d0">CELL</data>
      <data key="d1">CD20+ B cells are a type of white blood cell involved in the immune response and are present in HS skin</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606</data>
    </node>
    <node id="CD138+ PLASMA CELLS">
      <data key="d0">CELL</data>
      <data key="d1">CD138+ plasma cells are a type of white blood cell involved in the immune response and are present in HS skin</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606</data>
    </node>
    <node id="PHOSPHO-BTK">
      <data key="d0">PROTEIN</data>
      <data key="d1">Phosphorylated Bruton&#8217;s tyrosine kinase is involved in B cell receptor signaling and is increased in HS
Phospho-BTK is a phosphorylated form of BTK protein involved in B cell receptor signaling
Phospho-BTK is the phosphorylated form of BTK, involved in B cell receptor signaling
Phosphorylated Bruton's tyrosine kinase, an activated form of BTK</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7,411a4d246f0a9321e52971446a5a0606,b28eeca0ff01a7715947d55a04978a43,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="PHOSPHO-SYK">
      <data key="d0">PROTEIN</data>
      <data key="d1">Phosphorylated spleen tyrosine kinase is involved in B cell receptor signaling and is increased in HS
Phospho-SYK is a phosphorylated form of SYK protein involved in signal transduction in immune cells
Phospho-SYK is the phosphorylated form of SYK, involved in signal transduction in immune cells
Phosphorylated spleen tyrosine kinase, an activated form of SYK</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7,411a4d246f0a9321e52971446a5a0606,b28eeca0ff01a7715947d55a04978a43,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="LEUKOCYTE">
      <data key="d0">CELL</data>
      <data key="d1">Leukocytes are white blood cells involved in the immune response and are clustered in HS skin
White blood cells involved in protecting the body against infectious disease and foreign invaders
Leukocytes, or white blood cells, are cells of the immune system involved in protecting the body against infections
Leukocytes are white blood cells involved in the immune response</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,411a4d246f0a9321e52971446a5a0606,442e7fad2fab75fa2449309783294d89,7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="CD20">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD20 is a protein marker found on the surface of B cells
CD20 is a protein found on B cells, targeted by the therapeutic agent rituximabCD20 is a marker for B cells, targeted by rituximab
CD20 is a protein found on the surface of B cells and is involved in B cell activation and proliferation
CD20 is a protein expressed on the surface of B cells and involved in B cell activation
CD20 is a protein expressed on the surface of B cells</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7,411a4d246f0a9321e52971446a5a0606,b28eeca0ff01a7715947d55a04978a43,b62ecc47bf54393bc78dd65986b949d6,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="CD138">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD138 is a protein marker found on the surface of plasma cells
CD138 is a marker for plasma cellsCD138 is a marker found on plasma cells, which are involved in TNF expression in HS
CD138 is a protein found on the surface of plasma cells and is involved in cell adhesion
CD138 is a protein expressed on plasma cells and involved in cell adhesion
CD138 is a protein expressed on the surface of plasma cells</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7,411a4d246f0a9321e52971446a5a0606,b28eeca0ff01a7715947d55a04978a43,b62ecc47bf54393bc78dd65986b949d6,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="CD8">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD8 is a protein marker found on the surface of CD8+ T cells
CD8 is a protein found on the surface of cytotoxic T cells and is involved in the immune response
CD8, a protein marker used in flow cytometry for T cells
CD8 is a glycoprotein found on the surface of cytotoxic T cells</data>
      <data key="d2">2e9a8d71f6bd251a0b13458c39e69746,411a4d246f0a9321e52971446a5a0606,89dbac0da39e4de2b602052cd792b90d,b28eeca0ff01a7715947d55a04978a43</data>
    </node>
    <node id="CD3">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD3 is a protein marker found on the surface of T cells
CD3 is a marker for T cells
CD3 is a protein complex and T cell co-receptor involved in activating both the cytotoxic T cell and T helper cellsCD3 is a protein complex found on the surface of T cells and is involved in T cell activation
CD3 is a protein complex and T cell co-receptor involved in activating T cells
CD3 is a protein complex and T cell co-receptor involved in activating both the cytotoxic T cell and T helper cells</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7,411a4d246f0a9321e52971446a5a0606,b28eeca0ff01a7715947d55a04978a43,b62ecc47bf54393bc78dd65986b949d6,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="IGM">
      <data key="d0">PROTEIN</data>
      <data key="d1">IgM is an immunoglobulin involved in the immune response
Immunoglobulin M, a type of antibody
Immunoglobulin M, a basic antibody that is produced by B cells</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606,e340a83f7cba0ea5be731b1f682ea7c7,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="SHANNON INDEX">
      <data key="d0">METRIC</data>
      <data key="d1">The Shannon index is a measure of diversity in a population</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606</data>
    </node>
    <node id="JACCARD DISTANCE">
      <data key="d0">METRIC</data>
      <data key="d1">The Jaccard distance is a measure of dissimilarity between sample sets</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606</data>
    </node>
    <node id="PCOA">
      <data key="d0">TECHNIQUE</data>
      <data key="d1">Principal coordinates analysis is a technique used to visualize similarities or dissimilarities of data
PCoA is a method for visualizing dissimilarities between samples
Principal coordinates analysis, a method for visualizing similarities or dissimilarities in data</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606,b28eeca0ff01a7715947d55a04978a43,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="IHC">
      <data key="d0">TECHNIQUE</data>
      <data key="d1">Immunohistochemistry is a technique used to visualize the presence and location of proteins in tissue sections
Immunohistochemistry, a method for detecting specific antigens in cells or tissues</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="GEPS">
      <data key="d0">TECHNIQUE</data>
      <data key="d1">Gene Pattern Search is a literature-based network analysis tool
GePS is a version of Genomatix software used for creating biological literature-based networks
Genomatix-Pathway System, a tool for analyzing signal transduction networks</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7,411a4d246f0a9321e52971446a5a0606,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="BCR SIGNALING">
      <data key="d0">PATHWAY</data>
      <data key="d1">B cell receptor signaling is a pathway involved in B cell activation and function</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606</data>
    </node>
    <node id="SYK SIGNALING">
      <data key="d0">PATHWAY</data>
      <data key="d1">Spleen tyrosine kinase signaling is a pathway involved in immune cell activation</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606</data>
    </node>
    <node id="BTK SIGNALING">
      <data key="d0">PATHWAY</data>
      <data key="d1">Bruton&#8217;s tyrosine kinase signaling is a pathway involved in B cell activation and function</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606</data>
    </node>
    <node id="COMPLEMENT PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">The complement pathway is part of the immune system that enhances the ability to clear pathogens
A part of the immune system that enhances the ability of antibodies and phagocytic cells to clear microbes and damaged cells</data>
      <data key="d2">411a4d246f0a9321e52971446a5a0606,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="GAMMA-SECRETASE">
      <data key="d0">PROTEIN</data>
      <data key="d1">Gamma-secretase is an enzyme complex involved in the regulation of Notch signaling</data>
      <data key="d2">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </node>
    <node id="NCSTN">
      <data key="d0">GENE</data>
      <data key="d1">NCSTN is a gene encoding a component of the gamma-secretase complex</data>
      <data key="d2">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </node>
    <node id="PSENEN">
      <data key="d0">GENE</data>
      <data key="d1">PSENEN is a gene encoding a component of the gamma-secretase complex</data>
      <data key="d2">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </node>
    <node id="PSEN1">
      <data key="d0">GENE</data>
      <data key="d1">PSEN1 is a gene encoding a component of the gamma-secretase complex</data>
      <data key="d2">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </node>
    <node id="NEUTROPHIL">
      <data key="d0">CELL</data>
      <data key="d1">Neutrophils are a type of white blood cell involved in the innate immune response
Neutrophils are a type of white blood cell involved in the immune response</data>
      <data key="d2">6309eeea565f06479830cec32938abc9,e340a83f7cba0ea5be731b1f682ea7c7</data>
    </node>
    <node id="CD4+ T CELL">
      <data key="d0">CELL</data>
      <data key="d1">CD4+ T cells are a type of immune cell involved in orchestrating the immune response
CD4+ T cells are a type of immune cell that produce IL-4 and IL-13
CD4+ T cells are a type of T cell that play a key role in the immune system</data>
      <data key="d2">28f548554737fcc026b968db6bbafa30,8ce8c356713490cd2c680f505bcd050b,e340a83f7cba0ea5be731b1f682ea7c7</data>
    </node>
    <node id="TYPE I IFNS">
      <data key="d0">PROTEIN</data>
      <data key="d1">Type I interferons are a group of cytokines involved in the antiviral response</data>
      <data key="d2">e340a83f7cba0ea5be731b1f682ea7c7</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="MX1">
      <data key="d0">GENE</data>
      <data key="d1">MX1 is a gene encoding a protein involved in the antiviral response
MX1 is a protein involved in antiviral response</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b,e340a83f7cba0ea5be731b1f682ea7c7</data>
      <data key="d3">GENE</data>
    </node>
    <node id="IFI27">
      <data key="d0">GENE</data>
      <data key="d1">IFI27 is a gene encoding a protein involved in the interferon response
IFI27 is a gene that is proposed to be driven by NETs interacting with infiltrating pDCs in lesional HS skin</data>
      <data key="d2">b62ecc47bf54393bc78dd65986b949d6,e340a83f7cba0ea5be731b1f682ea7c7</data>
      <data key="d3">GENE</data>
    </node>
    <node id="PDC">
      <data key="d0">CELL</data>
      <data key="d1">Plasmacytoid dendritic cells are a type of immune cell involved in the production of interferons</data>
      <data key="d2">e340a83f7cba0ea5be731b1f682ea7c7</data>
      <data key="d3">CELL</data>
    </node>
    <node id="IL-36A">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-36A is a cytokine involved in the immune response</data>
      <data key="d2">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </node>
    <node id="NETS">
      <data key="d0">PROTEIN</data>
      <data key="d1">Neutrophil extracellular traps (NETs) are structures released by neutrophils that can interact with pDCs in lesional HS skin</data>
      <data key="d2">b62ecc47bf54393bc78dd65986b949d6</data>
    </node>
    <node id="PDCS">
      <data key="d0">CELL</data>
      <data key="d1">Plasmacytoid dendritic cells (pDCs) are immune cells that interact with NETs in lesional HS skin</data>
      <data key="d2">b62ecc47bf54393bc78dd65986b949d6</data>
    </node>
    <node id="IFN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interferons (IFNs) are proteins involved in the immune response, including type I and type II IFNs
Interferon, a group of signaling proteins involved in the immune response</data>
      <data key="d2">104cc78517b2eca2e9cb7e00de1fe4b0,b62ecc47bf54393bc78dd65986b949d6</data>
    </node>
    <node id="LCK">
      <data key="d0">PROTEIN</data>
      <data key="d1">LCK is a protein involved in B cell signaling and is a potential therapeutic target in HS
LCK is a protein tyrosine kinase involved in T cell receptor signaling
Lymphocyte-specific protein tyrosine kinase, involved in T cell signaling</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7,b62ecc47bf54393bc78dd65986b949d6,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="DERMIS">
      <data key="d0">TISSUE</data>
      <data key="d1">The dermis is the inner layer of the skin, separated during sample preparation for scRNA-Seq
The dermis is the layer of skin beneath the epidermis, containing connective tissue, blood vessels, and nerves
The dermis is the layer of skin beneath the epidermis that contains connective tissue, blood vessels, and nerves
The dermis is the layer of skin beneath the epidermis
The dermis is the layer of skin beneath the epidermis
The dermis is a layer of skin where higher TAC levels were observed with PLG-based nanoparticles
The dermis is a layer of skin where OX40+ and OX40L+ cells are co-located in Atopic Dermatitis
The dermis is the layer of skin beneath the epidermis, containing connective tissue, blood vessels, and cells</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,3ce96e927d65736b305f792977fed4b9,442e7fad2fab75fa2449309783294d89,691cb2e23ac3c6e591129d16714f8ef8,6aef5adb1be227170f66c76a292c25e5,89dbac0da39e4de2b602052cd792b90d,b62ecc47bf54393bc78dd65986b949d6,bddc3b1a7f098e71f0aa64adec047124</data>
      <data key="d3">TISSUE</data>
    </node>
    <node id="MICE">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Mice are a model organism used in preclinical studies, although no animal models exist for HS
Mice are a model organism used in immunogenetics studies
Mice are a model organism used in biological experiments
Mice are a model organism used to study the effects of IL-4 and IL-13 in atopic dermatitis
Mice are a model organism used to study the effects of Staphylococcus aureus on skin inflammation
Mice are a model organism used in biomedical research
Mice are a model organism used to study the effects of oxidative stress
Mice are a model organism used to study the effects of various treatments and conditions
Mice are a model organism used in experimental studies of liver fibrosis and cardiovascular diseases
Mice are a model organism used to study the effects of TL1A on inflammation and fibrosis
Mice possess two TRAIL decoy receptors and a single TRAIL death receptor (mDR5) similar to human DR5</data>
      <data key="d2">28f548554737fcc026b968db6bbafa30,2a0384addc6e7fd709e0508b83496cd7,3dfbb4c51838e0951f53ce951395225f,41ccc4b41bd57cf2bda4dbb6c7ae4198,44f2592262cac835560b4c149fee8d2b,9867d43adab0ba5db44961fae4863eee,a10787d7fbb1307be263e86dc7b33a51,b28eeca0ff01a7715947d55a04978a43,b62ecc47bf54393bc78dd65986b949d6,c525762bb827485bceeb9f09bb4bcfe0,d4797ed1483e5057bcd8301eaa509d5e</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="HANK&#8217;S BALANCED SALINE SOLUTION">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Hank&#8217;s Balanced Saline Solution is used in the preparation of single-cell suspensions for scRNA-Seq</data>
      <data key="d2">b62ecc47bf54393bc78dd65986b949d6</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="TRYPSIN-EDTA">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Trypsin-EDTA is used to digest the epidermis during sample preparation for scRNA-Seq</data>
      <data key="d2">b62ecc47bf54393bc78dd65986b949d6</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="DNASE I">
      <data key="d0">CHEMICAL</data>
      <data key="d1">DNase I is used to digest DNA during sample preparation for scRNA-Seq</data>
      <data key="d2">b62ecc47bf54393bc78dd65986b949d6</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="FBS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Fetal Bovine Serum (FBS) is used to quench trypsin activity during sample preparation for scRNA-Seq</data>
      <data key="d2">b62ecc47bf54393bc78dd65986b949d6</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="COLLAGENASE II">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Collagenase II is used to digest the dermis during sample preparation for scRNA-Seq</data>
      <data key="d2">b62ecc47bf54393bc78dd65986b949d6</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="COLLAGENASE V">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Collagenase V is used to digest the dermis during sample preparation for scRNA-Seq</data>
      <data key="d2">b62ecc47bf54393bc78dd65986b949d6</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="10X GENOMICS CHROMIUM SYSTEM">
      <data key="d0">CHEMICAL</data>
      <data key="d1">The 10x Genomics Chromium system is used for constructing single-cell RNA sequencing libraries</data>
      <data key="d2">b62ecc47bf54393bc78dd65986b949d6</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="ILLUMINA NOVASEQ 6000">
      <data key="d0">CHEMICAL</data>
      <data key="d1">The Illumina NovaSeq 6000 is a sequencer used to generate paired-end reads for scRNA-Seq
Illumina NovaSeq 6000 is a sequencing platform used for high-throughput sequencing</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7,b62ecc47bf54393bc78dd65986b949d6</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="SEURAT">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Seurat is a software used for normalization, data integration, and clustering analysis in scRNA-Seq</data>
      <data key="d2">b62ecc47bf54393bc78dd65986b949d6</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="RNALATER">
      <data key="d0">CHEMICAL</data>
      <data key="d1">RNAlater is a solution used to preserve RNA in skin biopsy samples</data>
      <data key="d2">b62ecc47bf54393bc78dd65986b949d6</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="ILLUMINA NEXTSEQ">
      <data key="d0">CHEMICAL</data>
      <data key="d1">The Illumina NextSeq is a platform used for RNA sequencing
Illumina NextSeq is a sequencing platform used for RNA sequencing</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43,b62ecc47bf54393bc78dd65986b949d6</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="STAR">
      <data key="d0">CHEMICAL</data>
      <data key="d1">STAR is a software used for mapping RNA-Seq reads to the human genome</data>
      <data key="d2">b62ecc47bf54393bc78dd65986b949d6</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="GRCH37">
      <data key="d0">CHEMICAL</data>
      <data key="d1">GRCh37 is a human genome build used for mapping RNA-Seq reads
GRCh37 is a human genome build used as a reference for mapping sequence reads</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43,b62ecc47bf54393bc78dd65986b949d6</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="GENCODE V24">
      <data key="d0">CHEMICAL</data>
      <data key="d1">GENCODE v24 is a gene annotation used for quantifying gene expression levels in RNA-Seq</data>
      <data key="d2">b62ecc47bf54393bc78dd65986b949d6</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="CD123">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD123 is a marker for plasmacytoid dendritic cells (pDCs)</data>
      <data key="d2">b62ecc47bf54393bc78dd65986b949d6</data>
    </node>
    <node id="CD303">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD303 is a marker for plasmacytoid dendritic cells (pDCs)</data>
      <data key="d2">b62ecc47bf54393bc78dd65986b949d6</data>
    </node>
    <node id="RNA">
      <data key="d0">CHEMICAL</data>
      <data key="d1">RNA is a molecule essential for various biological roles, including coding, decoding, regulation, and expression of genes
RNA is a nucleic acid involved in gene expression and regulation
RNA is a molecule involved in the synthesis of proteins in cells</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,2a0384addc6e7fd709e0508b83496cd7,b28eeca0ff01a7715947d55a04978a43</data>
    </node>
    <node id="HTSEQ">
      <data key="d0">CHEMICAL</data>
      <data key="d1">HTSeq is a software used for analyzing high-throughput sequencing data</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43</data>
    </node>
    <node id="DESEQ2">
      <data key="d0">CHEMICAL</data>
      <data key="d1">DESeq2 is a software package used for differential gene expression analysis based on RNA-Seq data</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43</data>
    </node>
    <node id="MIXCR">
      <data key="d0">CHEMICAL</data>
      <data key="d1">MiXCR is a software used for extracting TCR and BCR CDR3 sequences from RNA-Seq data</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43</data>
    </node>
    <node id="IMGT">
      <data key="d0">CHEMICAL</data>
      <data key="d1">International ImMunoGeneTics (IMGT) is a database and nomenclature system for immunogenetics</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43</data>
    </node>
    <node id="CD14">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD14 is a protein expressed on the surface of macrophages and is involved in the recognition of bacterial lipopolysaccharides
CD14, a protein marker used in flow cytometry for monocytes</data>
      <data key="d2">2e9a8d71f6bd251a0b13458c39e69746,b28eeca0ff01a7715947d55a04978a43</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="CD16">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD16 is a protein found on the surface of natural killer cells and some T cells, involved in antibody-dependent cellular cytotoxicity</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="CD68">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD68 is a protein highly expressed by macrophages and is used as a marker for these cells</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="CD15">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD15 is a protein expressed on the surface of neutrophils and some other cells, involved in cell adhesion</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="CD31">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD31 is a protein found on the surface of endothelial cells and is involved in leukocyte transmigration</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="CD45">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD45 is a protein tyrosine phosphatase found on the surface of all nucleated hematopoietic cells
CD45 is a protein tyrosine phosphatase receptor type C, involved in T and B cell receptor signaling</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43,df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="E-CADHERIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">E-Cadherin is a protein involved in cell-cell adhesion in epithelial tissues</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="COLLAGEN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Collagen is a structural protein found in connective tissues
Collagen is deposited by fibroblasts during fibrotic skin remodeling in AD
Collagen is a structural protein found in the skin and other connective tissues
Collagen is a structural protein involved in the formation of connective tissue
Collagen is a structural protein that is a major component of connective tissues and is involved in fibrosis
Collagen is a structural protein found in connective tissues
Collagen is a structural protein whose deposition is increased in fibrosis and reduced by anti-TL1A treatment
Collagen is a structural protein in connective tissues
Collagen is a structural protein found in the extracellular matrix
Collagen is a protein whose deposition is measured to assess fibrosis</data>
      <data key="d2">05c97152fe02249153103be341d65b67,1596d061dbe1a1c9e8f31a02a21e5524,48de7eebab3f3b418feb35a152df38fd,4cf23e218b6aab3c77115173b5c7c2fd,5f37466ca41c9b8b06ed8be0303d49f2,a10787d7fbb1307be263e86dc7b33a51,b28eeca0ff01a7715947d55a04978a43,b2aae16813e647959b783a39ef9a19a7,c525762bb827485bceeb9f09bb4bcfe0,d4797ed1483e5057bcd8301eaa509d5e</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="CD103">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD103 is a protein found on the surface of certain T cells and is involved in cell adhesion</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="PAN-ACTIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Pan-actin is a protein involved in cell structure and motility</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="INTERCALATOR-IR">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Intercalator-Ir is a chemical used for staining cells in CyTOF imaging</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43</data>
    </node>
    <node id="HYPERION IMAGING SYSTEM">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Hyperion Imaging System is a platform used for high-dimensional imaging of tissues</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43</data>
    </node>
    <node id="CELLPROFILER">
      <data key="d0">CHEMICAL</data>
      <data key="d1">CellProfiler is a software used for cell image analysis</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43</data>
    </node>
    <node id="PHENOGRAPH">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Phenograph is an unsupervised clustering algorithm used for high-dimensional single-cell data analysis
Phenograph is a computational method for identifying cell populations in high-dimensional single-cell data</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,b28eeca0ff01a7715947d55a04978a43</data>
    </node>
    <node id="HISTOCAT">
      <data key="d0">CHEMICAL</data>
      <data key="d1">HistoCAT is a software used for high-dimensional single-cell data analysis</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43</data>
    </node>
    <node id="SHANNON DIVERSITY INDEX">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Shannon diversity index is a measure of diversity that incorporates both evenness and richness
A measure of diversity in a community, used here to describe BCR gene segment diversity</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43,e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="JACCARD DISTANCES">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Jaccard distances are a measure of dissimilarity between sample sets</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43</data>
    </node>
    <node id="INTERNAL ORGANS">
      <data key="d0">TISSUE</data>
      <data key="d1">Internal organs are tissues that can be affected by systemic diseases
Internal organs are the organs inside the body, such as the heart, liver, and lungs</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43,c46e8b6ee0c29e37b7f18c42558d7a3e</data>
      <data key="d3">TISSUE</data>
    </node>
    <node id="CDR3">
      <data key="d0">PROTEIN</data>
      <data key="d1">CDR3 is the third complementarity-determining region of the TCR and BCR, crucial for antigen specificity
Complementarity-determining region 3, a part of the variable chains in immunoglobulins and T cell receptors that contributes to the specificity of antigen binding</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,b28eeca0ff01a7715947d55a04978a43</data>
    </node>
    <node id="CD35">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD35, also known as CR1, is a protein involved in the immune response and found on the surface of various cells</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43</data>
    </node>
    <node id="CD21">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD21, also known as CR2, is a protein involved in the immune response and found on the surface of B cells</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43</data>
    </node>
    <node id="FORMALIN-FIXED, PARAFFIN-EMBEDDED TISSUE">
      <data key="d0">TISSUE</data>
      <data key="d1">Formalin-fixed, paraffin-embedded tissue is a method of preserving tissue samples for analysis
Formalin-fixed, paraffin-embedded tissue is a method of preserving tissue samples for histological analysis</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7,b28eeca0ff01a7715947d55a04978a43</data>
    </node>
    <node id="HEALTHY CONTROL SKIN">
      <data key="d0">TISSUE</data>
      <data key="d1">Healthy control skin is used as a reference tissue in comparative studies</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43</data>
    </node>
    <node id="HIDRADENITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Hidradenitis is a chronic skin condition characterized by inflamed and swollen lumps</data>
      <data key="d2">b28eeca0ff01a7715947d55a04978a43</data>
    </node>
    <node id="DMSO">
      <data key="d0">CHEMICAL</data>
      <data key="d1">DMSO is a solvent used in biological experiments</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
    </node>
    <node id="FOSTAMATINIB DISODIUM">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Fostamatinib disodium is a chemical inhibitor used in B cell stimulation experiments</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
    </node>
    <node id="DAPI">
      <data key="d0">CHEMICAL</data>
      <data key="d1">DAPI is a fluorescent stain that binds strongly to DNA
DAPI is a fluorescent stain that binds strongly to A-T rich regions in DNA</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7,348f2797841cbef27311b03f2cd788dd</data>
    </node>
    <node id="HUMAN">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Humans are the species from which the tissue samples were obtained</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
    </node>
    <node id="GRCH38">
      <data key="d0">GENE</data>
      <data key="d1">GRCh38 is a reference genome assembly used for mapping reads in RNA-Seq experiments</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">GENE</data>
    </node>
    <node id="DESEQ">
      <data key="d0">GENE</data>
      <data key="d1">DESeq is a software tool used for differential expression analysis in RNA-Seq data</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">GENE</data>
    </node>
    <node id="SCIDAP">
      <data key="d0">PATHWAY</data>
      <data key="d1">SciDAP is a platform used for scientific data analysis, including RNA-Seq data</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="TRIM GALORE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Trim Galore is a software tool used for trimming adapters in RNA-Seq data</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
    </node>
    <node id="PCA">
      <data key="d0">PATHWAY</data>
      <data key="d1">PCA is a statistical method used for principal component analysis in gene expression data
Principal Component Analysis, a statistical procedure used to convert observations of possibly correlated variables into a set of values of linearly uncorrelated variables</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="FDR">
      <data key="d0">PATHWAY</data>
      <data key="d1">FDR is a statistical method used to control the false discovery rate in multiple testing
False Discovery Rate, a method used in multiple hypothesis testing to correct for multiple comparisons</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="STUDENT&#8217;S T TEST">
      <data key="d0">PATHWAY</data>
      <data key="d1">Student&#8217;s t test is a statistical test used to compare the means of two groups
A statistical test used to compare the means of two groups</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="MANN-WHITNEY U TEST">
      <data key="d0">PATHWAY</data>
      <data key="d1">Mann-Whitney U test is a non-parametric test used to compare differences between two independent groups
A nonparametric test used to determine whether there is a difference between two independent groups</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="ALEXA FLUOR 488">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Alexa Fluor 488 is a fluorescent dye used for labeling antibodies</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="ALEXA FLUOR 594">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Alexa Fluor 594 is a fluorescent dye used for labeling antibodies</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="DONKEY SERUM">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Donkey serum is used as a blocking agent in immunofluorescence experiments
Donkey Serum, used to block slides before staining</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7,2e9a8d71f6bd251a0b13458c39e69746</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="PBS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">PBS is a buffer solution used in biological experiments
PBS is a buffer solution used in biological research</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3,2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="NEW ENGLAND BIOLABS">
      <data key="d0">PATHWAY</data>
      <data key="d1">New England Biolabs is a company that provides reagents for molecular biology experiments</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="QIAGEN">
      <data key="d0">PATHWAY</data>
      <data key="d1">QIAGEN is a company that provides reagents for nucleic acid isolation and purification</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="VECTASHIELD">
      <data key="d0">CHEMICAL</data>
      <data key="d1">VECTASHIELD is an antifade mounting medium used in microscopy</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="EASYSEP">
      <data key="d0">PATHWAY</data>
      <data key="d1">EasySep is a kit used for isolating specific cell types from blood</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="LYMPHOPREP">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Lymphoprep is a reagent used for isolating lymphocytes from blood</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="GOAT F(AB&#8242;)2 ANTI-HUMAN IGM">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Goat F(ab&#8242;)2 Anti-Human IgM is an antibody used for stimulating B cells</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="GOAT F(AB&#8242;)2 ANTI-HUMAN IGG">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Goat F(ab&#8242;)2 Anti-Human IgG is an antibody used for stimulating B cells</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="4&#8242;,6-DIAMIDINO-2-PHENYLINDOLE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">4&#8242;,6-diamidino-2-phenylindole (DAPI) is a fluorescent stain that binds strongly to DNA</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="ZEISS AXIOSKOP 2">
      <data key="d0">PATHWAY</data>
      <data key="d1">Zeiss Axioskop 2 is a microscope used for imaging biological samples</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">National Center for Biotechnology Information is a database for storing biological data</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="GSE154775">
      <data key="d0">PATHWAY</data>
      <data key="d1">GSE154775 is an accession number for a transcriptomic data set in the Gene Expression Omnibus database</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="GSE154773">
      <data key="d0">PATHWAY</data>
      <data key="d1">GSE154773 is an accession number for a transcriptomic data set in the Gene Expression Omnibus database</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="GENOMATIX">
      <data key="d0">PATHWAY</data>
      <data key="d1">Genomatix is a software tool used for creating biological literature-based networks</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNOFLUORESCENCE">
      <data key="d0" />
      <data key="d1">
Immunofluorescence is a technique used to show the co-location of OX40+ and OX40L+ cells within the dermis in Atopic Dermatitis</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7,691cb2e23ac3c6e591129d16714f8ef8</data>
    </node>
    <node id="DONKEY ANTI-RABBIT IGG">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Donkey anti-rabbit IgG is a secondary antibody used in immunofluorescence experiments</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
    </node>
    <node id="DONKEY ANTI-MOUSE IGG">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Donkey anti-mouse IgG is a secondary antibody used in immunofluorescence experiments</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
    </node>
    <node id="BUFFY COAT">
      <data key="d0">TISSUE</data>
      <data key="d1">Buffy coat is a fraction of blood containing most of the white blood cells and platelets</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
    </node>
    <node id="POLY(A)">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Poly(A) is a sequence of adenine nucleotides added to RNA molecules</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
    </node>
    <node id="STRANDED MRNA LIBRARIES">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Stranded mRNA libraries are collections of mRNA sequences used for sequencing</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
    </node>
    <node id="TRIM GALORE RNA-SEQ PIPELINE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Trim Galore RNA-Seq pipeline is a software tool used for trimming adapters in RNA-Seq data</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7</data>
    </node>
    <node id="TISSUE">
      <data key="d0" />
      <data key="d1">
Tissue refers to a group of cells that perform a specific function, often affected in fibrotic diseases</data>
      <data key="d2">2a0384addc6e7fd709e0508b83496cd7,516e41e96d2e72d45bf1e2c69da7f18a</data>
    </node>
    <node id="KERATINOCYTE">
      <data key="d0">CELL</data>
      <data key="d1">Keratinocytes are the predominant cell type in the epidermis, the outermost layer of the skin, and are involved in forming a barrier against environmental damage
Keratinocytes are skin cells that can be damaged by IL-4, leading to reduced expression of filaggrin, loricrin, and involucrin
A type of cell that makes up the outer layer of the skin and is involved in skin barrier function
Keratinocytes are the primary cell type in the epidermis, involved in the skin barrier function
Keratinocytes are skin cells that can be damaged in atopic dermatitis, contributing to barrier dysfunction
Keratinocytes are the primary cell type in the epidermis, responsible for forming the barrier against environmental damage
A type of cell that makes up the outer layer of the skin</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,143d2dc302af5606656797bff162e23e,1596d061dbe1a1c9e8f31a02a21e5524,1d0c4a4cd555b7ecd0b9d7b0310e9fe9,28f548554737fcc026b968db6bbafa30,3ce96e927d65736b305f792977fed4b9,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </node>
    <node id="ERASMUS MC">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Erasmus University Medical Center, a medical institution involved in the study and treatment of various diseases</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13</data>
    </node>
    <node id="DECLARATION OF HELSINKI">
      <data key="d0">PATHWAY</data>
      <data key="d1">A set of ethical principles for medical research involving human subjects</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="INSTITUTIONAL REVIEW BOARD">
      <data key="d0">PATHWAY</data>
      <data key="d1">A committee that reviews and approves research involving human subjects to ensure ethical standards are met</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="BIOPSY">
      <data key="d0">PATHWAY</data>
      <data key="d1">A medical test involving the extraction of sample cells or tissues for examination</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="ABDOMINOPLASTY">
      <data key="d0">PATHWAY</data>
      <data key="d1">A surgical procedure to remove excess skin and fat from the abdomen</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="SURGERY">
      <data key="d0">PATHWAY</data>
      <data key="d1">A medical procedure involving an incision with instruments to treat a condition or injury</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="PROINFLAMMATORY CYTOKINE">
      <data key="d0">PROTEIN</data>
      <data key="d1">Cytokines that promote systemic inflammation</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="DEG">
      <data key="d0">GENE</data>
      <data key="d1">Differentially Expressed Genes, genes that show statistically significant differences in expression levels between different conditions</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13</data>
      <data key="d3">GENE</data>
    </node>
    <node id="RECEPTOR-LIGAND">
      <data key="d0">PROTEIN</data>
      <data key="d1">Molecules that bind to specific receptors to initiate a cellular response</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="PLASMA CELL">
      <data key="d0">CELL</data>
      <data key="d1">A type of white blood cell that produces antibodies
Plasma cells are a type of white blood cell that produces antibodies</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,e4d25b1cd44df240a29591bc46a875ab</data>
      <data key="d3">CELL</data>
    </node>
    <node id="B7RP1">
      <data key="d0">PROTEIN</data>
      <data key="d1">B7-related protein 1, involved in T-cell activation
B7RP1 is a protein involved in the ICOS-B7RP1 costimulatory pathway
B7-related protein 1, involved in positive costimulatory pathways
B7RP1 is a protein involved in T cell costimulation, also known as B7-related protein-1</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="DERMATOLOGY">
      <data key="d0">PATHWAY</data>
      <data key="d1">The branch of medicine dealing with the skin and its diseases</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="INFLAMMATORY INFILTRATE">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Accumulation of inflammatory cells in tissue</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="STROMAL TISSUE">
      <data key="d0">TISSUE</data>
      <data key="d1">The connective tissue cells that support the function of the parenchymal cells of an organ</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13</data>
      <data key="d3">TISSUE</data>
    </node>
    <node id="ERASMUS UNIVERSITY MEDICAL CENTER">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Erasmus University Medical Center, a medical institution involved in the study and treatment of various diseases</data>
      <data key="d2">1412a7a7fef5f18cc09a030b97b18e13</data>
    </node>
    <node id="JUN">
      <data key="d0">PROTEIN</data>
      <data key="d1">JUN is a protein that is part of the AP-1 transcription factor complex</data>
      <data key="d2">e4d25b1cd44df240a29591bc46a875ab</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="STAT1">
      <data key="d0">PROTEIN</data>
      <data key="d1">Signal transducer and activator of transcription 1, involved in cytokine signaling</data>
      <data key="d2">e4d25b1cd44df240a29591bc46a875ab</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="BCR CDR3">
      <data key="d0">PROTEIN</data>
      <data key="d1">B cell receptor complementarity-determining region 3, a critical part of the BCR involved in antigen binding</data>
      <data key="d2">e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="BCR GENE SEGMENT">
      <data key="d0">GENE</data>
      <data key="d1">Segments of the B cell receptor gene involved in the diversity of the immune response</data>
      <data key="d2">e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="TCR V/J GENE SEGMENT">
      <data key="d0">GENE</data>
      <data key="d1">Segments of the T cell receptor gene involved in the diversity of the immune response</data>
      <data key="d2">e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="B CELL SIGNALING">
      <data key="d0">PATHWAY</data>
      <data key="d1">A signaling pathway involved in the activation and function of B cells</data>
      <data key="d2">e4d25b1cd44df240a29591bc46a875ab</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="INFLAMMATORY NODES">
      <data key="d0">PATHWAY</data>
      <data key="d1">Critical points in signaling pathways that regulate inflammation</data>
      <data key="d2">e4d25b1cd44df240a29591bc46a875ab</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="SIGNAL TRANSDUCTION NETWORKS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Networks of molecular signals that control cellular responses</data>
      <data key="d2">e4d25b1cd44df240a29591bc46a875ab</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="JACCARD DISSIMILARITIES">
      <data key="d0">PATHWAY</data>
      <data key="d1">A measure of how dissimilar two sets are, used in PCoA</data>
      <data key="d2">e4d25b1cd44df240a29591bc46a875ab</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="CLONAL ABUNDANCE">
      <data key="d0">PATHWAY</data>
      <data key="d1">The frequency of specific clones of cells, used here to describe BCR and TCR repertoires</data>
      <data key="d2">e4d25b1cd44df240a29591bc46a875ab</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IG HEAVY CHAIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">The heavy chain of an immunoglobulin molecule, part of the antibody structure</data>
      <data key="d2">e4d25b1cd44df240a29591bc46a875ab</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="&#922; LIGHT CHAIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Kappa light chain, one of the two types of light chains in antibodies</data>
      <data key="d2">e4d25b1cd44df240a29591bc46a875ab</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="&#923; LIGHT CHAIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Lambda light chain, one of the two types of light chains in antibodies</data>
      <data key="d2">e4d25b1cd44df240a29591bc46a875ab</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="BCR CDR3 EXPRESSION">
      <data key="d0">PROTEIN</data>
      <data key="d1">B cell receptor complementarity-determining region 3 expression, involved in antigen binding and immune response</data>
      <data key="d2">e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="BCR GENE SEGMENT EXPRESSION">
      <data key="d0">GENE</data>
      <data key="d1">Expression of gene segments of the B cell receptor, contributing to immune diversity</data>
      <data key="d2">e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="TCR V/J GENE SEGMENT EXPRESSION">
      <data key="d0">GENE</data>
      <data key="d1">Expression of gene segments of the T cell receptor, contributing to immune diversity</data>
      <data key="d2">e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="C4">
      <data key="d0">PROTEIN</data>
      <data key="d1">Complement component 4, a protein involved in the complement system</data>
      <data key="d2">e4d25b1cd44df240a29591bc46a875ab</data>
    </node>
    <node id="TYPE 2 T HELPER CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Type 2 T helper (Th2) cells are involved in the inappropriate activation in Atopic Dermatitis</data>
      <data key="d2">693a2aac101eaaadf92614317a1e4da8</data>
    </node>
    <node id="CORTICOSTEROIDS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Corticosteroids are systemic agents used in the treatment of Atopic Dermatitis, though they present tolerability issues
Corticosteroids are systemic immunosuppressants used to treat AD
Corticosteroids are anti-inflammatory drugs used in the treatment of AD</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd,48de7eebab3f3b418feb35a152df38fd,693a2aac101eaaadf92614317a1e4da8</data>
    </node>
    <node id="PIMECROLIMUS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Pimecrolimus is a topical calcineurin inhibitor approved for the treatment of Atopic Dermatitis
Pimecrolimus is a topical calcineurin inhibitor used to treat AD
Pimecrolimus is a topical calcineurin inhibitor used to treat inflammatory skin conditions
Pimecrolimus is an immunosuppressive drug used to treat eczema and other inflammatory skin conditions</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,27a7e95c7d3ad59a948aa46741fee456,442e7fad2fab75fa2449309783294d89,693a2aac101eaaadf92614317a1e4da8</data>
    </node>
    <node id="TACROLIMUS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Tacrolimus is a topical calcineurin inhibitor approved for the treatment of Atopic Dermatitis
Tacrolimus is a topical calcineurin inhibitor used to treat AD
Tacrolimus is an immunosuppressive drug used in nanotechnology-based therapeutic approaches
Tacrolimus is an immunosuppressive drug used to treat eczema and other inflammatory skin conditions</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,27a7e95c7d3ad59a948aa46741fee456,693a2aac101eaaadf92614317a1e4da8,cccfd5ff480e281556e2210cd0e5c4b5</data>
    </node>
    <node id="STAPHYLOCOCCUS AUREUS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Staphylococcus aureus is a bacterium that patients with Atopic Dermatitis are at increased risk of infection from
Staphylococcus aureus is a bacterium that may trigger atopic dermatitis
A bacterium that can produce toxins and is targeted by Staphylococcus hominis A9
Staphylococcus aureus (S.a.) is a bacterium that overgrows in the skin of atopic dermatitis patients</data>
      <data key="d2">143d2dc302af5606656797bff162e23e,693a2aac101eaaadf92614317a1e4da8,83eb9003d42977bb83fea1d123dd5ab9,f1897c89e321a3a80924fd72a56e90df</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="HERPES SIMPLEX TYPE 1 VIRUS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Herpes simplex type 1 virus is a virus that patients with Atopic Dermatitis are at increased risk of infection from</data>
      <data key="d2">693a2aac101eaaadf92614317a1e4da8</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="CARDIOVASCULAR DISEASES">
      <data key="d0">DISEASE</data>
      <data key="d1">Cardiovascular diseases are comorbidities associated with Atopic Dermatitis</data>
      <data key="d2">693a2aac101eaaadf92614317a1e4da8</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="NEUROPSYCHIATRIC DISEASES">
      <data key="d0">DISEASE</data>
      <data key="d1">Neuropsychiatric diseases are comorbidities associated with Atopic Dermatitis</data>
      <data key="d2">693a2aac101eaaadf92614317a1e4da8</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="MALIGNANT DISEASES">
      <data key="d0">DISEASE</data>
      <data key="d1">Malignant diseases are comorbidities associated with Atopic Dermatitis</data>
      <data key="d2">693a2aac101eaaadf92614317a1e4da8</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="ANXIETY">
      <data key="d0">DISEASE</data>
      <data key="d1">Anxiety is a mental health disorder more common in patients with Atopic Dermatitis
Anxiety is a mental health disorder characterized by feelings of worry, anxiety, or fear</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,693a2aac101eaaadf92614317a1e4da8</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="DEPRESSION">
      <data key="d0">DISEASE</data>
      <data key="d1">Depression is a mental health disorder more common in patients with Atopic Dermatitis
Depression is a side effect of corticosteroids
Depression is a mental health disorder characterized by persistently depressed mood or loss of interest in activities</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,48de7eebab3f3b418feb35a152df38fd,693a2aac101eaaadf92614317a1e4da8</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="ATTENTION-DEFICIT/HYPERACTIVITY DISORDER">
      <data key="d0">DISEASE</data>
      <data key="d1">Attention-deficit/hyperactivity disorder (ADHD) is a mental health disorder more common in patients with Atopic Dermatitis</data>
      <data key="d2">693a2aac101eaaadf92614317a1e4da8</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="ITCH">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Persistent itch is a primary symptom of Atopic Dermatitis
Itch is a common symptom of atopic dermatitis, often associated with cytokines like IL-31
Itch is a common symptom in atopic dermatitis, contributing to the itch-scratch cycle
Itch is a subjective symptom considered in the SCORAD assessment
Itch is a key symptom in AD, leading to the itch-scratch cycle
Itch is an uncomfortable sensation on the skin that provokes the urge to scratch
Itch is a common symptom associated with atopic dermatitis
Itch is a common symptom in AD, often leading to scratching and further skin damage</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b,143d2dc302af5606656797bff162e23e,3ce96e927d65736b305f792977fed4b9,6059a6e2710b7df94c6a09e5eb7b024a,693a2aac101eaaadf92614317a1e4da8,83eb9003d42977bb83fea1d123dd5ab9,f1897c89e321a3a80924fd72a56e90df,f66eb51473925a8084dad1745be63b78</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="REDNESS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Marked redness is a primary symptom of Atopic Dermatitis</data>
      <data key="d2">693a2aac101eaaadf92614317a1e4da8</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="CRACKING">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Cracking of the skin is a symptom of Atopic Dermatitis
Cracking is one of the symptoms assessed in the POEM tool</data>
      <data key="d2">693a2aac101eaaadf92614317a1e4da8,f1897c89e321a3a80924fd72a56e90df</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="DRYNESS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Dryness of the skin is a symptom of Atopic Dermatitis
Dryness is a clinical sign of atopic dermatitis characterized by lack of moisture in the skin</data>
      <data key="d2">143d2dc302af5606656797bff162e23e,693a2aac101eaaadf92614317a1e4da8</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="EMOLLIENTS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Emollients are topical therapies used in the treatment of Atopic Dermatitis to moisturize and soothe the skin
Substances that soften and moisturize the skin</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807,693a2aac101eaaadf92614317a1e4da8</data>
    </node>
    <node id="PHOSPHODIESTERASE-4">
      <data key="d0">PROTEIN</data>
      <data key="d1">Phosphodiesterase-4 is an enzyme targeted by crisaborole in the treatment of Atopic Dermatitis</data>
      <data key="d2">693a2aac101eaaadf92614317a1e4da8</data>
    </node>
    <node id="T HELPER CELLS">
      <data key="d0">CELL</data>
      <data key="d1">T helper cells, including Th2 cells, are involved in the immune response in Atopic Dermatitis</data>
      <data key="d2">693a2aac101eaaadf92614317a1e4da8</data>
    </node>
    <node id="INNATE LYMPHOID CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Innate lymphoid cells, including ILC2 cells, are involved in the immune response in Atopic Dermatitis</data>
      <data key="d2">693a2aac101eaaadf92614317a1e4da8</data>
    </node>
    <node id="TH2 CELL">
      <data key="d0">CELL</data>
      <data key="d1">Th2 cells are a type of T helper cell involved in the immune response, particularly in atopic dermatitis
T helper cell type 2, involved in the differentiation and development of immune responses
TH2 cells are a subset of T cells involved in the immune response and are important in the pathogenesis of atopic dermatitis
TH2 cells are a subset of T cells that play a significant role in the inflammation of AD
A type of T cell involved in the immune response</data>
      <data key="d2">28f548554737fcc026b968db6bbafa30,3ce96e927d65736b305f792977fed4b9,442e7fad2fab75fa2449309783294d89,849e0980ffd6a7e1cf0b8d3d1fbacd98,f66eb51473925a8084dad1745be63b78</data>
    </node>
    <node id="ILC2">
      <data key="d0">CELL</data>
      <data key="d1">ILC2 cells are innate lymphoid cells involved in the immune response in atopic dermatitis
Innate lymphoid cells type 2 are immune cells involved in the production of cytokines and regulation of inflammation
ILC2 are innate lymphoid cells activated by TL1A and involved in inflammation</data>
      <data key="d2">05c97152fe02249153103be341d65b67,c525762bb827485bceeb9f09bb4bcfe0,f66eb51473925a8084dad1745be63b78</data>
    </node>
    <node id="IL-5">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-5 is a type 2 cytokine involved in the pathophysiology of atopic dermatitis
IL-5 is a cytokine involved in the growth and differentiation of eosinophils
IL-5 is a cytokine involved in the activation and growth of eosinophils, playing a role in type 2 immune responses
IL-5 is a cytokine involved in the immune response and TH2 polarization
IL-5 is a cytokine involved in the TH2 immune response
Interleukin-5, a cytokine involved in the growth and activation of eosinophils
IL-5 (Interleukin-5) is a cytokine involved in the inflammatory response
IL-5 is a cytokine involved in the immune response and inflammation
Interleukin-5, involved in Th2 cell activation and immune response
IL-5 is a cytokine that causes eosinophils to migrate and is important in atopic diseases
Interleukin-5 (IL-5) is a cytokine whose levels are reduced in an AD animal model treated with CsA-loaded nanoparticles
Interleukin-5 (IL-5) is a cytokine involved in the immune response
IL-5 is a cytokine involved in the pathogenesis of AD
Interleukin-5 is a cytokine that is the major driver of allergen-induced EoE
IL-5 is a cytokine involved in the immune response</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,286730b1c1f680ac465cc21d522fda0c,3df8535e965efb96f5094169610507ff,3dfbb4c51838e0951f53ce951395225f,41ccc4b41bd57cf2bda4dbb6c7ae4198,6309eeea565f06479830cec32938abc9,78e26c66107dba37ac4bab65406b43a0,849e0980ffd6a7e1cf0b8d3d1fbacd98,a867a1e73cef039eb3f28e072463b838,b19f42c9497f71b231222cd953036d6b,bddc3b1a7f098e71f0aa64adec047124,c95d22c2a90e77cd22bd0d280d55b26a,d4797ed1483e5057bcd8301eaa509d5e,f2aa3fd6ae3f1853347874c50afb60ea,f66eb51473925a8084dad1745be63b78</data>
    </node>
    <node id="K16">
      <data key="d0">PROTEIN</data>
      <data key="d1">Keratin 16 is a marker of epidermal proliferation increased in atopic dermatitis lesions
K16 is a type of keratin involved in skin structure</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b,f66eb51473925a8084dad1745be63b78</data>
    </node>
    <node id="KI67">
      <data key="d0">PROTEIN</data>
      <data key="d1">Ki67 is a marker of cell proliferation increased in atopic dermatitis lesions
Ki67 is a protein associated with cell proliferation</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b,f66eb51473925a8084dad1745be63b78</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="PERIPLAKIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Periplakin is a terminal marker of epidermal differentiation suppressed in chronic atopic dermatitis</data>
      <data key="d2">f66eb51473925a8084dad1745be63b78</data>
    </node>
    <node id="DC">
      <data key="d0">CELL</data>
      <data key="d1">Dendritic cells, including mature and inflammatory dendritic epidermal cells, are involved in the pathophysiology of atopic dermatitis
Dendritic cells, involved in antigen presentation and immune response
Dendritic cells, antigen-presenting cells involved in the immune response
Dendritic cells (DCs) are immune cells that are attracted to the skin during inflammation in AD patients
Dendritic cells, involved in immune response and residence in the epidermis
DCs are unleashed after T-reg cell inactivation, allowing them to induce an adaptive immune response</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,44f2592262cac835560b4c149fee8d2b,6059a6e2710b7df94c6a09e5eb7b024a,6309eeea565f06479830cec32938abc9,849e0980ffd6a7e1cf0b8d3d1fbacd98,f66eb51473925a8084dad1745be63b78</data>
    </node>
    <node id="MYELOID CELL">
      <data key="d0">CELL</data>
      <data key="d1">Myeloid cells are immune cells involved in the pathophysiology of atopic dermatitis</data>
      <data key="d2">f66eb51473925a8084dad1745be63b78</data>
    </node>
    <node id="SPONGIOSIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Spongiosis is the presence of intercellular edema in the epidermis, seen in atopic dermatitis</data>
      <data key="d2">f66eb51473925a8084dad1745be63b78</data>
    </node>
    <node id="EPIDERMAL THICKNESS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Epidermal thickness is increased in atopic dermatitis lesions
Increased epidermal thickness is a characteristic of AD</data>
      <data key="d2">48de7eebab3f3b418feb35a152df38fd,f66eb51473925a8084dad1745be63b78</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="EPIDERMAL HYPERPLASIA">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Epidermal hyperplasia is characterized by increased cell proliferation in the epidermis, seen in atopic dermatitis
Epidermal hyperplasia is the thickening of the epidermis, often seen in inflammatory skin conditions</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,f66eb51473925a8084dad1745be63b78</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="LESION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Lesions are areas of damaged skin seen in atopic dermatitis</data>
      <data key="d2">f66eb51473925a8084dad1745be63b78</data>
    </node>
    <node id="CHRONIC LESION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Chronic lesions are long-lasting areas of skin damage in atopic dermatitis, characterized by increased inflammation and cytokine expression</data>
      <data key="d2">f66eb51473925a8084dad1745be63b78</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="ACUTE LESION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Acute lesions are short-term areas of skin damage in atopic dermatitis, characterized by significant increases in type 2 and type 22 cytokines</data>
      <data key="d2">f66eb51473925a8084dad1745be63b78</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="BIOMARKER">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Biomarkers are measurable indicators of the severity or presence of atopic dermatitis</data>
      <data key="d2">f66eb51473925a8084dad1745be63b78</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="HISTOLOGIC PROFILING">
      <data key="d0">PATHWAY</data>
      <data key="d1">Histologic profiling involves studying the tissue structure and cellular composition in atopic dermatitis lesions</data>
      <data key="d2">f66eb51473925a8084dad1745be63b78</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="TYPE 2 PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">The type 2 pathway involves cytokines like IL-4, IL-5, IL-13, and IL-31, playing a key role in atopic dermatitis
Type 2 pathway involves IL-4 and IL-13 signaling, contributing to AD pathophysiology
Type 2 pathway involves cytokines like IL-4, IL-13, and IL-31</data>
      <data key="d2">48de7eebab3f3b418feb35a152df38fd,b19f42c9497f71b231222cd953036d6b,f66eb51473925a8084dad1745be63b78</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="TYPE 22 PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">The type 22 pathway involves cytokines like IL-22, playing a role in chronic atopic dermatitis
Type 22 pathway involves cytokines like IL-22 and IL-32</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b,f66eb51473925a8084dad1745be63b78</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="TYPE 1 PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">The type 1 pathway involves cytokines like IFN-&#947;, playing a role in chronic atopic dermatitis
Type 1 pathway involves cytokines like IFN-&#947; and IL-1&#946;</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b,f66eb51473925a8084dad1745be63b78</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="TYPE 17 PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">The type 17 pathway involves cytokines like IL-17, playing a role in atopic dermatitis
Type 17 pathway involves cytokines like IL-17 and IL-23</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b,f66eb51473925a8084dad1745be63b78</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="TYPE 9 PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">The type 9 pathway involves cytokines like IL-9, playing a role in atopic dermatitis</data>
      <data key="d2">f66eb51473925a8084dad1745be63b78</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IL-9">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-9 is a cytokine involved in the pathophysiology of atopic dermatitis, particularly in pediatric cases</data>
      <data key="d2">f66eb51473925a8084dad1745be63b78</data>
    </node>
    <node id="IL-13R&#913;1">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-13R&#945;1 is a subunit of the type 2 IL-4 receptor involved in IL-4 and IL-13 signaling
IL-13R&#945;1 is a receptor subunit that forms a heterodimer with IL-4R&#945; for type 2 receptor signaling
IL-13R&#945;1 is a receptor subunit involved in IL-13 signaling
IL-13 receptor alpha 1, a component of the type 2 heterodimeric receptor for IL-13
IL-13 receptor alpha 1, a subunit of the interleukin-13 receptor complex
IL-13R&#945;1 is a receptor chain involved in the type II receptor for IL-4 and IL-13
Interleukin-13 receptor alpha 1, a component of the IL-13 receptor
IL-13R&#945;1 (Interleukin-13 receptor alpha 1) is a protein that binds interleukin-13 and is involved in the immune response
IL-13R&#945;1, or &#945;1 chain of the IL-13 receptor, is a protein involved in the regulation of immune responses
IL-13R&#945;1 is a receptor subunit that forms part of the IL-13 receptor complex involved in signaling</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,104cc78517b2eca2e9cb7e00de1fe4b0,28f548554737fcc026b968db6bbafa30,3df8535e965efb96f5094169610507ff,48de7eebab3f3b418feb35a152df38fd,78e26c66107dba37ac4bab65406b43a0,96e553a44a27e728c27c4892045ec5c2,b19f42c9497f71b231222cd953036d6b,e9841b88c9fab58c5175af409653da50,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="STAT6">
      <data key="d0">PROTEIN</data>
      <data key="d1">STAT6 is a transcription factor activated by IL-4 and IL-13 signaling
Signal transducer and activator of transcription 6 (STAT6) is a protein involved in the immune response
STAT6 is a gene that acts as an activator of transcription and is responsible for the development of atopic dermatitis (AD)</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198,48de7eebab3f3b418feb35a152df38fd,6059a6e2710b7df94c6a09e5eb7b024a</data>
    </node>
    <node id="TYPE 1 IL-4 RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Type 1 IL-4 receptor is composed of IL-4R&#945; and the common gamma chain, expressed on haematopoietic cells</data>
      <data key="d2">48de7eebab3f3b418feb35a152df38fd</data>
    </node>
    <node id="INVOLUCRIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Involucrin is a protein important for epidermal barrier integrity, downregulated by IL-4 and IL-13
Involucrin is a protein involved in skin barrier function
Involucrin is a protein involved in epidermal barrier function, reduced by IL-4
Involucrin is a protein involved in the formation of the skin barrier</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,28f548554737fcc026b968db6bbafa30,48de7eebab3f3b418feb35a152df38fd,b19f42c9497f71b231222cd953036d6b</data>
    </node>
    <node id="FIBROCYTES">
      <data key="d0">CELL</data>
      <data key="d1">Fibrocytes are recruited to inflamed skin lesions in AD, contributing to fibrosis</data>
      <data key="d2">48de7eebab3f3b418feb35a152df38fd</data>
    </node>
    <node id="SENSORY NEURONS">
      <data key="d0">CELL</data>
      <data key="d1">Sensory neurons are activated by type 2 cytokines, causing chronic itch in AD</data>
      <data key="d2">48de7eebab3f3b418feb35a152df38fd</data>
    </node>
    <node id="MURINE MODELS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Mouse models are used to study AD and the effects of IL-4 and IL-13</data>
      <data key="d2">48de7eebab3f3b418feb35a152df38fd</data>
    </node>
    <node id="DORSAL ROOT GANGLIA">
      <data key="d0">TISSUE</data>
      <data key="d1">Dorsal root ganglia are involved in sensory neuron activation and chronic itch in AD</data>
      <data key="d2">48de7eebab3f3b418feb35a152df38fd</data>
    </node>
    <node id="GLUCOSE INTOLERANCE">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Glucose intolerance is a side effect of corticosteroids</data>
      <data key="d2">48de7eebab3f3b418feb35a152df38fd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="HEADACHES">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Headaches are a side effect of corticosteroids and cyclosporine A</data>
      <data key="d2">48de7eebab3f3b418feb35a152df38fd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="NEPHROTOXICITY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Nephrotoxicity is a side effect of cyclosporine A</data>
      <data key="d2">48de7eebab3f3b418feb35a152df38fd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="HYPERTENSION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Hypertension is a side effect of cyclosporine A
Hypertension, also known as high blood pressure
Hypertension is a condition characterized by consistently high blood pressure</data>
      <data key="d2">48de7eebab3f3b418feb35a152df38fd,d2c44662af9752fc9f82c86121ede7c0,df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="ANAEMIA">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Anaemia is a side effect of methotrexate</data>
      <data key="d2">48de7eebab3f3b418feb35a152df38fd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="LEUKOPENIA">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Leukopenia is a side effect of methotrexate</data>
      <data key="d2">48de7eebab3f3b418feb35a152df38fd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="HEPATOTOXICITY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Hepatotoxicity is a side effect of methotrexate</data>
      <data key="d2">48de7eebab3f3b418feb35a152df38fd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="HAEMATOPOIETIC CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Haematopoietic cells, including T cells and B cells, are involved in immune responses and affected by IL-4 signaling</data>
      <data key="d2">48de7eebab3f3b418feb35a152df38fd</data>
    </node>
    <node id="TYPE 2 IL-4 RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Type 2 IL-4 receptor is a heterodimeric receptor composed of IL-13R&#945;1 and IL-4R&#945;, involved in IL-4 and IL-13 signaling</data>
      <data key="d2">48de7eebab3f3b418feb35a152df38fd</data>
    </node>
    <node id="CHRONIC ITCH">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Chronic itch is a symptom of AD, caused by activation of sensory neurons by type 2 cytokines</data>
      <data key="d2">48de7eebab3f3b418feb35a152df38fd</data>
    </node>
    <node id="BIOLOGICS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Biologics are therapeutic agents targeting specific components of the immune system, used in AD treatment
Biological drugs used to target specific mechanistic pathways in diseases like AD
Biologics are drugs with a slow but pathway-specific mode of action used for long-term control and disease modification in Atopic Dermatitis
Biologics are a category of drugs derived from living organisms used to treat various diseases, including AD</data>
      <data key="d2">48de7eebab3f3b418feb35a152df38fd,90f4809673ca34628b0e607908f0bf0b,e30574e513dd250992d637d808759c34,e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="EUROPE">
      <data key="d0">GEOGRAPHIC_LOCATION</data>
      <data key="d1">Europe is a region where cyclosporine A is approved for AD treatment
Europe is a region where cost-effectiveness considerations impact drug development for Atopic Dermatitis</data>
      <data key="d2">48de7eebab3f3b418feb35a152df38fd,90f4809673ca34628b0e607908f0bf0b</data>
    </node>
    <node id="IL-13R&#913;2">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-13R&#945;2 is a receptor with a short cytoplasmic tail, thought to have an anti-inflammatory, decoy function
IL-13R&#945;2 is a receptor subunit involved in IL-13 signaling
IL-13R&#945;2 is a receptor chain involved in the binding of IL-13
Interleukin-13 receptor alpha 2, a component of the IL-13 receptor
IL-13R&#945;2 is a receptor subunit that forms part of the IL-13 receptor complex involved in signaling</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,3df8535e965efb96f5094169610507ff,78e26c66107dba37ac4bab65406b43a0,96e553a44a27e728c27c4892045ec5c2,b19f42c9497f71b231222cd953036d6b</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="IMA-638">
      <data key="d0">CHEMICAL</data>
      <data key="d1">IMA-638 is an anti-human IL-13 monoclonal antibody that prevents the IL-13/IL-13R&#945;1 complex from accessing IL-4R&#945;</data>
      <data key="d2">96e553a44a27e728c27c4892045ec5c2</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="IMA-026">
      <data key="d0">CHEMICAL</data>
      <data key="d1">IMA-026 is an anti-human IL-13 monoclonal antibody that interferes with IL-13 binding to IL-13R&#945;1 and IL-13R&#945;2</data>
      <data key="d2">96e553a44a27e728c27c4892045ec5c2</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="MOUSE MODEL">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Mouse model used to study cutaneous inflammation and the effects of IL-13 decoy receptor loss
Mouse model is used to study the effects of colonization with S. aureus on IL-36R- and IL-1R-dependent inflammation</data>
      <data key="d2">6309eeea565f06479830cec32938abc9,96e553a44a27e728c27c4892045ec5c2</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="TCS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Topical corticosteroid, used in combination therapy studies for AD
Topical corticosteroids, used in combination therapy studies for atopic dermatitis
Topical corticosteroids, a class of steroid medications applied to the skin to reduce inflammation
Topical corticosteroids, commonly used in the treatment of atopic dermatitis
Topical corticosteroids (TCS) are used to reduce inflammation in skin conditions
Topical Corticosteroids (TCS) are medications used to reduce inflammation in skin conditions
Topical corticosteroids, used in treating inflammatory skin conditions</data>
      <data key="d2">104cc78517b2eca2e9cb7e00de1fe4b0,28f548554737fcc026b968db6bbafa30,48288f3ec2832850282f95d4e38d10e1,6309eeea565f06479830cec32938abc9,849e0980ffd6a7e1cf0b8d3d1fbacd98,96e553a44a27e728c27c4892045ec5c2,c46e8b6ee0c29e37b7f18c42558d7a3e</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="CYTOKINE RECEPTORS">
      <data key="d0">PROTEIN</data>
      <data key="d1">Cytokine receptors are proteins that bind cytokines and mediate their effects, targeted by various biologics
Receptors that bind cytokines and mediate their effects</data>
      <data key="d2">96e553a44a27e728c27c4892045ec5c2,e95d4d15e4f3110c91a3d3fcb5910d06</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="PF-04965842">
      <data key="d0">CHEMICAL</data>
      <data key="d1">An oral JAK1 inhibitor under investigation for the treatment of moderate-to-severe AD</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="PDE-4">
      <data key="d0">PROTEIN</data>
      <data key="d1">Phosphodiesterase-4, an enzyme involved in chronic inflammatory pathways</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="CAMP">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Cyclic adenosine monophosphate, a molecule that mediates downstream events in inflammatory pathways
Cyclic adenosine monophosphate (cAMP) is increased by PDE4 inhibitors to generate anti-inflammatory cytokines in atopic dermatitis</data>
      <data key="d2">83eb9003d42977bb83fea1d123dd5ab9,e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="PERIOSTIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">A protein induced by type 2 cytokines IL-4 and IL-13, used as a biomarker in asthma
Periostin is a protein induced by type 2 cytokines IL-4 and IL-13
Periostin is a protein involved in tissue repair and remodeling, often associated with type II inflammatory responses</data>
      <data key="d2">5f37466ca41c9b8b06ed8be0303d49f2,b19f42c9497f71b231222cd953036d6b,e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="FEV1">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Forced expiratory volume in one second, a measure of lung function
Forced expiratory volume in one second, a measure of lung function</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b,e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="TYPE 1 IMMUNE PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">An immune response pathway involving type 1 cytokines</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="TYPE 2 IMMUNE PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">An immune response pathway involving type 2 cytokines</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="TYPE 17 IMMUNE PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">An immune response pathway involving type 17 cytokines</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="TYPE 22 IMMUNE PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">An immune response pathway involving type 22 cytokines</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="INTRINSIC AD">
      <data key="d0">DISEASE</data>
      <data key="d1">A subtype of atopic dermatitis with no detectable allergen-specific IgE
Intrinsic Atopic Dermatitis is a subtype of AD that may involve the IL-23&#8211;IL-17 axis</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1,e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="EXTRINSIC AD">
      <data key="d0">DISEASE</data>
      <data key="d1">A subtype of atopic dermatitis with detectable allergen-specific IgE</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="ADULT AD">
      <data key="d0">DISEASE</data>
      <data key="d1">Atopic dermatitis occurring in adults</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="PAEDIATRIC AD">
      <data key="d0">DISEASE</data>
      <data key="d1">Atopic dermatitis occurring in children</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="ETHNIC ORIGIN AD">
      <data key="d0">DISEASE</data>
      <data key="d1">Atopic dermatitis with variations in prevalence and clinical features based on ethnic origin</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="ENDOTYPES">
      <data key="d0">DISEASE</data>
      <data key="d1">Subsets of patients with common underlying mechanisms of disease</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="NCT02925117">
      <data key="d0">STUDY</data>
      <data key="d1">A phase 2b, 88-week, randomized controlled trial for upadacitinib in AD</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="NCT03569293">
      <data key="d0">STUDY</data>
      <data key="d1">A phase 3, randomized controlled trial for upadacitinib monotherapy in AD</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="NCT03607422">
      <data key="d0">STUDY</data>
      <data key="d1">A phase 3, randomized controlled trial for upadacitinib monotherapy in AD</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="NCT03568318">
      <data key="d0">STUDY</data>
      <data key="d1">A phase 3, randomized controlled trial for upadacitinib with topical corticosteroids in AD</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="NCT02576938">
      <data key="d0">STUDY</data>
      <data key="d1">A phase 2 trial for baricitinib in AD</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="BREEZE-AD1">
      <data key="d0">STUDY</data>
      <data key="d1">A phase 3, 16-week randomized controlled trial for baricitinib in AD</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="BREEZE-AD2">
      <data key="d0">STUDY</data>
      <data key="d1">A phase 3, 16-week randomized controlled trial for baricitinib in AD</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="BREEZE-AD3">
      <data key="d0">STUDY</data>
      <data key="d1">A phase 3, 52-week long-term safety and efficacy study for baricitinib in AD</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="BREEZE-AD5">
      <data key="d0">STUDY</data>
      <data key="d1">A phase 3, 16-week randomized controlled trial for baricitinib in AD</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="BREEZE-AD6">
      <data key="d0">STUDY</data>
      <data key="d1">A phase 3, 116-week open-label extension study for baricitinib in AD</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="BREEZE-AD4">
      <data key="d0">STUDY</data>
      <data key="d1">A phase 3, randomized controlled trial for baricitinib in AD patients with inadequate response to cyclosporine</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="NCT03428100">
      <data key="d0">STUDY</data>
      <data key="d1">A phase 3, randomized controlled trial for baricitinib in AD patients with inadequate response to cyclosporine</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="NCT02780167">
      <data key="d0">STUDY</data>
      <data key="d1">A phase 2 study for PF-04965842 in AD</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="JADE MONO-1">
      <data key="d0">STUDY</data>
      <data key="d1">A phase 3, 12-week randomized controlled trial for PF-04965842 in AD</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="JADE MONO-2">
      <data key="d0">STUDY</data>
      <data key="d1">A phase 3, 12-week randomized controlled trial for PF-04965842 in AD</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="JADE EXTEND">
      <data key="d0">STUDY</data>
      <data key="d1">A phase 3, 96-week long-term extension study for PF-04965842 in AD</data>
      <data key="d2">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </node>
    <node id="CCL5">
      <data key="d0">PROTEIN</data>
      <data key="d1">CCL5 is a chemokine involved in immune cell recruitment
Chemokine ligand 5 (CCL5) is a chemokine involved in the immune response and inflammation
CCL5 is a chemokine ligand that ascends in the skin during inflammation and promotes the attraction of inflammatory T cells and DC subtypes</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198,6059a6e2710b7df94c6a09e5eb7b024a,b19f42c9497f71b231222cd953036d6b</data>
    </node>
    <node id="CCL13">
      <data key="d0">PROTEIN</data>
      <data key="d1">CCL13 is a chemokine involved in immune cell recruitment</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b</data>
    </node>
    <node id="IL-32">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-32 is a cytokine involved in immune response and inflammation</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b</data>
    </node>
    <node id="CXCL9">
      <data key="d0">PROTEIN</data>
      <data key="d1">CXCL9 is a chemokine involved in immune cell recruitment</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b</data>
    </node>
    <node id="IL-23P19">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-23p19 is a subunit of the cytokine IL-23</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b</data>
    </node>
    <node id="IL-23P40">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-23p40 is a subunit of the cytokine IL-23</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b</data>
    </node>
    <node id="ILC2S">
      <data key="d0">CELL</data>
      <data key="d1">ILC2s are a type of innate lymphoid cell involved in immune response
Type 2 innate lymphoid cells (ILC2s) are involved in the immune response and inflammation
ILC2s are immune cells that TL1A can act upon</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198,516e41e96d2e72d45bf1e2c69da7f18a,b19f42c9497f71b231222cd953036d6b</data>
    </node>
    <node id="DCS">
      <data key="d0">CELL</data>
      <data key="d1">Dendritic cells are antigen-presenting cells involved in immune response
Dendritic cells, resident in the epidermis and expressing AhR, involved in AD
Dendritic cells, antigen-presenting cells that play a crucial role in the initiation of immune responses
Dendritic Cells (DCs) are antigen-presenting cells that express IL-31RA and are involved in immune responses
Dendritic cells (DCs) are antigen-presenting cells activated by TSLP
DCs, or dendritic cells, are antigen-presenting cells that play a crucial role in initiating immune responses</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b,2cec06c4d46f5ff9ee936a78d8b077cd,3df8535e965efb96f5094169610507ff,3ea70e257330c812b52334ca1f90d807,7c13f41d7349d9d2e56c36e00c0ca2d9,b19f42c9497f71b231222cd953036d6b</data>
    </node>
    <node id="IDECS">
      <data key="d0">CELL</data>
      <data key="d1">Inflammatory dendritic epidermal cells are a type of dendritic cell involved in skin inflammation</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b</data>
    </node>
    <node id="PPL">
      <data key="d0">PROTEIN</data>
      <data key="d1">Periplakin is a protein involved in skin barrier function</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b</data>
    </node>
    <node id="IVL">
      <data key="d0">PROTEIN</data>
      <data key="d1">Involucrin is a protein involved in skin barrier function</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b</data>
    </node>
    <node id="ELAFIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Elafin is a protein involved in skin inflammation</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b</data>
    </node>
    <node id="&#915;C">
      <data key="d0">PROTEIN</data>
      <data key="d1">&#947;c is a common gamma chain receptor subunit involved in cytokine signaling</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b</data>
    </node>
    <node id="IL-13R&#913;">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-13R&#945; is a receptor subunit involved in IL-13 signaling</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b</data>
    </node>
    <node id="IL-4R&#913; AND &#915;C">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-4R&#945; and &#947;c form a heterodimeric receptor for IL-4 signaling</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b</data>
    </node>
    <node id="IL-4R&#913; AND IL-13R&#913;">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-4R&#945; and IL-13R&#945; form a heterodimeric receptor for IL-4 and IL-13 signaling</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b</data>
    </node>
    <node id="TYPE 1 RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Type 1 receptor is a heterodimeric receptor involving IL-4R&#945; and &#947;c</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b</data>
    </node>
    <node id="TYPE 2 RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Type 2 receptor is a heterodimeric receptor involving IL-4R&#945; and IL-13R&#945;</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b</data>
    </node>
    <node id="IL-13R&#913;1 AND IL-13R&#913;2">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-13R&#945;1 and IL-13R&#945;2 form a heterodimeric receptor for IL-13 signalingIL-13R&#945;1 and IL-13R&#945;2 are receptor subunits involved in IL-13 signaling</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="IL-13R&#913;1 AND IL-4R&#913;">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-13R&#945;1 and IL-4R&#945; form a heterodimeric receptor for IL-13 signaling</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b</data>
    </node>
    <node id="IL-13R&#913;2 AND IL-4R&#913;">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-13R&#945;2 and IL-4R&#945; form a heterodimeric receptor for IL-13 signaling</data>
      <data key="d2">b19f42c9497f71b231222cd953036d6b</data>
    </node>
    <node id="CD8+ T CELL">
      <data key="d0">CELL</data>
      <data key="d1">CD8+ T cells are a type of immune cell that produce IL-4 and IL-13
CD8+ T cells are a type of T cell that are involved in the direct killing of infected cells</data>
      <data key="d2">28f548554737fcc026b968db6bbafa30,8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">CELL</data>
    </node>
    <node id="MAST CELL">
      <data key="d0">CELL</data>
      <data key="d1">Mast cells are immune cells that produce IL-4 and IL-13
Mast cells are involved in allergic reactions and release histamine and other mediators
A type of immune cell involved in allergic reactions
Mast cell infiltration is decreased in DNCB-induced AD skin lesions treated with NIC-CS-NPs
Mast cells are immune cells involved in allergic reactions and inflammation
Mast cells are immune cells involved in the inflammation of the esophagus in EoE</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,28f548554737fcc026b968db6bbafa30,6aef5adb1be227170f66c76a292c25e5,8246ea974dfb00cb5e3d984004e21a9e,849e0980ffd6a7e1cf0b8d3d1fbacd98,d4797ed1483e5057bcd8301eaa509d5e</data>
      <data key="d3">CELL</data>
    </node>
    <node id="BASOPHIL">
      <data key="d0">CELL</data>
      <data key="d1">Basophils are immune cells that produce IL-4 and IL-13</data>
      <data key="d2">28f548554737fcc026b968db6bbafa30</data>
      <data key="d3">CELL</data>
    </node>
    <node id="EOSINOPHIL">
      <data key="d0">CELL</data>
      <data key="d1">Eosinophils are immune cells that produce IL-4 and IL-13
Eosinophils are a type of white blood cell involved in allergic reactions and inflammation</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,28f548554737fcc026b968db6bbafa30</data>
      <data key="d3">CELL</data>
    </node>
    <node id="ILC">
      <data key="d0">CELL</data>
      <data key="d1">Innate lymphoid cells, a type of immune cell that produce IL-13
Innate lymphoid cell, a type of immune cell involved in the body's defense mechanisms</data>
      <data key="d2">104cc78517b2eca2e9cb7e00de1fe4b0,28f548554737fcc026b968db6bbafa30</data>
      <data key="d3">CELL</data>
    </node>
    <node id="INKT">
      <data key="d0">CELL</data>
      <data key="d1">Invariant natural killer T cells, a type of immune cell that produce IL-13</data>
      <data key="d2">28f548554737fcc026b968db6bbafa30</data>
      <data key="d3">CELL</data>
    </node>
    <node id="SOLO 1">
      <data key="d0">TRIAL</data>
      <data key="d1">SOLO 1 is a phase 3 clinical trial of Dupilumab monotherapy in adult patients with moderate to severe atopic dermatitis</data>
      <data key="d2">28f548554737fcc026b968db6bbafa30</data>
      <data key="d3">TRIAL</data>
    </node>
    <node id="SOLO 2">
      <data key="d0">TRIAL</data>
      <data key="d1">SOLO 2 is a phase 3 clinical trial of Dupilumab monotherapy in adult patients with moderate to severe atopic dermatitis</data>
      <data key="d2">28f548554737fcc026b968db6bbafa30</data>
      <data key="d3">TRIAL</data>
    </node>
    <node id="ARBAN">
      <data key="d0">TRIAL</data>
      <data key="d1">ARBAN is a phase 2 open-label, monotherapy study of Lebrikizumab in adult patients with moderate to severe atopic dermatitis</data>
      <data key="d2">28f548554737fcc026b968db6bbafa30</data>
      <data key="d3">TRIAL</data>
    </node>
    <node id="CHRONOS">
      <data key="d0">TRIAL</data>
      <data key="d1">CHRONOS is a phase 3 randomized, double-blind study of Dupilumab plus TCS versus placebo plus TCS in adult patients with moderate to severe atopic dermatitis</data>
      <data key="d2">28f548554737fcc026b968db6bbafa30</data>
      <data key="d3">TRIAL</data>
    </node>
    <node id="TREBLE">
      <data key="d0">TRIAL</data>
      <data key="d1">TREBLE is a phase 2 randomized, double-blind study of Lebrikizumab plus TCS in adult patients with moderate to severe atopic dermatitis</data>
      <data key="d2">28f548554737fcc026b968db6bbafa30</data>
      <data key="d3">TRIAL</data>
    </node>
    <node id="TCI">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Topical calcineurin inhibitors, used as rescue therapy in combination therapy studies for atopic dermatitis</data>
      <data key="d2">28f548554737fcc026b968db6bbafa30</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="IGA">
      <data key="d0">SCORE</data>
      <data key="d1">Investigator's Global Assessment, a tool used to measure the severity of atopic dermatitis
Investigator's Global Assessment, a scale used to assess the severity of atopic dermatitis
Investigator's Global Assessment, a tool used to assess the severity of atopic dermatitis
Investigator's Global Assessment (IGA) is a scale used to assess the severity of a disease
Immunoglobulin A, a type of antibody that plays a crucial role in the immune function of mucous membranes
Investigator's Global Assessment, a scale used to assess the overall severity of atopic dermatitis
Investigator's Global Assessment (IGA) is a scale used to assess the severity of skin conditions
Immunoglobulin A is an antibody that plays a critical role in mucosal immunity
Investigator's Global Assessment, a measure of disease severity</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,0ba9fbea14e0c2c1d01a12ffaacfda9b,1d0c4a4cd555b7ecd0b9d7b0310e9fe9,28f548554737fcc026b968db6bbafa30,78e26c66107dba37ac4bab65406b43a0,849e0980ffd6a7e1cf0b8d3d1fbacd98,a867a1e73cef039eb3f28e072463b838,c46e8b6ee0c29e37b7f18c42558d7a3e,f1897c89e321a3a80924fd72a56e90df</data>
      <data key="d3">SCORE</data>
    </node>
    <node id="VAS">
      <data key="d0">SCORE</data>
      <data key="d1">Visual Analog Scale, used to measure pruritus in atopic dermatitis
Visual analogue scale used to measure pruritus severity
Visual analogue scale, a tool used to measure the intensity of pain or other symptoms</data>
      <data key="d2">104cc78517b2eca2e9cb7e00de1fe4b0,1d0c4a4cd555b7ecd0b9d7b0310e9fe9,28f548554737fcc026b968db6bbafa30</data>
      <data key="d3">SCORE</data>
    </node>
    <node id="BSA">
      <data key="d0">SCORE</data>
      <data key="d1">Body Surface Area, used to measure the extent of atopic dermatitis
Body surface area affected by atopic dermatitis
Body Surface Area, a measure used to assess the extent of skin involvement in dermatological conditions</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b,1d0c4a4cd555b7ecd0b9d7b0310e9fe9,28f548554737fcc026b968db6bbafa30</data>
      <data key="d3">SCORE</data>
    </node>
    <node id="IL-17C">
      <data key="d0">PROTEIN</data>
      <data key="d1">A member of the IL-17 family of cytokines involved in the pathogenesis of atopic dermatitis</data>
      <data key="d2">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </node>
    <node id="MOR106">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A human IgG1, anti-IL-17C monoclonal antibody used in the treatment of moderate-to-severe atopic dermatitis</data>
      <data key="d2">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </node>
    <node id="FEZAKINUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">An intravenous, human IgG1&#955;, anti-IL-22 monoclonal antibody used in the treatment of moderate-to-severe atopic dermatitis
Fezakinumab is a monoclonal antibody used in the treatment of autoimmune diseases, including atopic dermatitis
Fezakinumab is an anti-IL-22 antibody investigated for the treatment of moderate to severe AD
Fezakinumab is a biologic injection targeting IL-22 used in the treatment of atopic dermatitis
Fezakinumab is an anti-IL-22 antibody used for the downregulation of IL-22</data>
      <data key="d2">1d0c4a4cd555b7ecd0b9d7b0310e9fe9,2cec06c4d46f5ff9ee936a78d8b077cd,48288f3ec2832850282f95d4e38d10e1,e9841b88c9fab58c5175af409653da50,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </node>
    <node id="DENDRITIC CELL">
      <data key="d0">CELL</data>
      <data key="d1">An immune cell that processes antigen material and presents it to T cells
Dendritic cells are antigen-presenting cells that play a crucial role in the immune response
Dendritic cells are antigen-presenting cells that process antigen material and present it to T cells</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,1d0c4a4cd555b7ecd0b9d7b0310e9fe9,8ce8c356713490cd2c680f505bcd050b</data>
    </node>
    <node id="ANKYLOSING SPONDYLITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">A type of arthritis that affects the spine and large joints
Ankylosing spondylitis, a disease treated with TNF inhibitorsAnkylosing spondylitis is a type of arthritis that affects the spine and large joints</data>
      <data key="d2">1d0c4a4cd555b7ecd0b9d7b0310e9fe9,516e41e96d2e72d45bf1e2c69da7f18a</data>
    </node>
    <node id="TOPICAL CALCINEURIN INHIBITOR">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A class of drugs used to treat inflammatory skin diseases by inhibiting calcineurin</data>
      <data key="d2">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </node>
    <node id="TREATMENT-EMERGENT ADVERSE EVENT">
      <data key="d0">SYMPTOM</data>
      <data key="d1">An adverse event that emerges during treatment with a drug</data>
      <data key="d2">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </node>
    <node id="INTERLEUKIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">A group of cytokines that play important roles in the immune system</data>
      <data key="d2">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </node>
    <node id="IGG1&#922;">
      <data key="d0">PROTEIN</data>
      <data key="d1">A subtype of immunoglobulin G used in monoclonal antibodies for therapeutic purposes</data>
      <data key="d2">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </node>
    <node id="IGG1&#923;">
      <data key="d0">PROTEIN</data>
      <data key="d1">A subtype of immunoglobulin G used in monoclonal antibodies for therapeutic purposes</data>
      <data key="d2">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </node>
    <node id="IMMUNE SYSTEM">
      <data key="d0" />
      <data key="d1">
The immune system is the body's defense system against infections and diseases
The immune system is a complex network of cells, tissues, and organs that work together to defend the body against harmful invaders
The immune system plays a significant role in the pathogenesis of Atopic Dermatitis, involving dysregulation that contributes to the disease.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,1d0c4a4cd555b7ecd0b9d7b0310e9fe9,442e7fad2fab75fa2449309783294d89,6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="MONOCLONAL ANTIBODIES">
      <data key="d0" />
      <data key="d1" />
      <data key="d2">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </node>
    <node id="DENDRITIC CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Dendritic cells are antigen-presenting cells that play a crucial role in the initiation of the immune response
Dendritic cells are immune cells that activate the adaptive immune response, involved in atopic dermatitis
Dendritic cells express high-affinity receptors for IgE and are involved in the immune response in atopic dermatitis
Dendritic cells are antigen-presenting cells that are key regulators of the immune system
Dendritic cells (DCs) are antigen-presenting cells that initiate immune responses
Dendritic cells are antigen-presenting cells of the immune system
Dendritic cells are professional antigen presenting cells that express OX40L</data>
      <data key="d2">143d2dc302af5606656797bff162e23e,1b656cfce91ff9ccec4223703489dab3,41ccc4b41bd57cf2bda4dbb6c7ae4198,83eb9003d42977bb83fea1d123dd5ab9,df74aa1b86eeeb811ca5586767ae3a71,e9841b88c9fab58c5175af409653da50,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </node>
    <node id="ANB020">
      <data key="d0">CHEMICAL</data>
      <data key="d1">ANB020 is a humanized IgG1, anti&#8211;IL-33 monoclonal antibody</data>
      <data key="d2">f2aa3fd6ae3f1853347874c50afb60ea</data>
    </node>
    <node id="PF-06817024">
      <data key="d0">CHEMICAL</data>
      <data key="d1">PF-06817024 is an anti&#8211;IL-33 monoclonal antibody</data>
      <data key="d2">f2aa3fd6ae3f1853347874c50afb60ea</data>
    </node>
    <node id="TSLPR">
      <data key="d0">PROTEIN</data>
      <data key="d1">TSLPR is the cognate receptor for TSLP, expressed on multiple immune cells including T cells, B cells, dendritic cells, mast cells, basophils, and eosinophils</data>
      <data key="d2">f2aa3fd6ae3f1853347874c50afb60ea</data>
    </node>
    <node id="TEZEPELUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Tezepelumab is a human IgG2&#955;, anti-TSLP monoclonal antibody
AMG 157, an anti-TSLP antibody showing results in allergic asthma and AD
Tezepelumab (AMG 157) is an anti-TSLP antibody used in the treatment of severe and uncontrolled allergic asthma
Tezepelumab is a biologic injection targeting TSLP used in the treatment of atopic dermatitis
An anti-TSLP antibody used in treating allergic asthma
Tezepelumab is a biologic agent targeting TSLP in atopic dermatitis treatment</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,3ea70e257330c812b52334ca1f90d807,6309eeea565f06479830cec32938abc9,849e0980ffd6a7e1cf0b8d3d1fbacd98,e9841b88c9fab58c5175af409653da50,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </node>
    <node id="BASOPHILS">
      <data key="d0">CELL</data>
      <data key="d1">Basophils are a type of white blood cell involved in immune responses, particularly in allergic reactions
A type of white blood cell involved in the immune response
Basophils are white blood cells that play a role in immune responses and inflammation
Basophils are immune cells that express IL-31RA and are involved in allergic reactions</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,3df8535e965efb96f5094169610507ff,41ccc4b41bd57cf2bda4dbb6c7ae4198,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </node>
    <node id="EOSINOPHILS">
      <data key="d0">CELL</data>
      <data key="d1">Eosinophils are a type of white blood cell involved in combating multicellular parasites and certain infections, and play a role in allergic responses
A type of white blood cell involved in the immune response
Eosinophils are a type of white blood cell that are elevated in the skin of Atopic Dermatitis patients.
Eosinophils are white blood cells involved in the immune response and inflammation
Eosinophils are a type of white blood cell involved in allergic reactions and atopic diseases
Eosinophils are a type of white blood cell involved in the response to allergens and asthma
Eosinophils are a type of white blood cell involved in allergic reactions and parasitic infections</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,3df8535e965efb96f5094169610507ff,41ccc4b41bd57cf2bda4dbb6c7ae4198,4cf23e218b6aab3c77115173b5c7c2fd,6ada075e562abd7bd445164e9fc309b4,df74aa1b86eeeb811ca5586767ae3a71,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </node>
    <node id="IL">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin, a group of cytokines that play important roles in the immune system</data>
      <data key="d2">104cc78517b2eca2e9cb7e00de1fe4b0</data>
    </node>
    <node id="TH">
      <data key="d0">CELL</data>
      <data key="d1">T helper cell, a type of T cell that plays an important role in the immune system</data>
      <data key="d2">104cc78517b2eca2e9cb7e00de1fe4b0</data>
    </node>
    <node id="JAK/STAT PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">A signaling pathway involved in the transmission of information from chemical signals outside the cell to the cell nucleus</data>
      <data key="d2">104cc78517b2eca2e9cb7e00de1fe4b0</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="NCT02300701">
      <data key="d0">DISEASE</data>
      <data key="d1">A phase 4 study ongoing in children with severe recalcitrant atopic eczema</data>
      <data key="d2">104cc78517b2eca2e9cb7e00de1fe4b0</data>
    </node>
    <node id="IL-4RA">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-4Ra is a receptor for interleukin-4, involved in immune response modulation
IL-4Ra is a biologic target and inhibitor for producing IL-4/IL-13</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,286730b1c1f680ac465cc21d522fda0c</data>
    </node>
    <node id="JAK1/2">
      <data key="d0">PROTEIN</data>
      <data key="d1">JAK1/2 are Janus kinases involved in signal transduction pathways linked to cytokine receptors</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="ECZEMATOUS LESIONS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Eczematous lesions are inflamed, itchy, and scaly patches of skin commonly seen in AD</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="ITCHING">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Itching is a severe sensation often accompanying eczematous lesions in AD
Itching is a common symptom of Atopic Dermatitis, often leading to scratching and skin damage.
Itching is a common symptom of AD that treatments aim to eliminate</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,2cec06c4d46f5ff9ee936a78d8b077cd,6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="IMMUNOGLOBULIN E">
      <data key="d0">PROTEIN</data>
      <data key="d1">Immunoglobulin E (IgE) is an antibody involved in allergic reactions and is elevated in atopic diseases
Immunoglobulin E (IgE) levels are increased in Atopic Dermatitis patients.
Immunoglobulin E, an antibody involved in allergic reactions</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,6ada075e562abd7bd445164e9fc309b4,cccfd5ff480e281556e2210cd0e5c4b5</data>
    </node>
    <node id="CICLOSPORIN A">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Ciclosporin A is an immunosuppressant used to treat severe forms of AD</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="SKIN MICROBIOME">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">The skin microbiome consists of microorganisms living on the skin, which can influence AD
The skin microbiome is the community of microorganisms living on the skin, which can influence atopic dermatitis
Skin microbiome is the collection of microorganisms living on the skin</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b,1596d061dbe1a1c9e8f31a02a21e5524,83eb9003d42977bb83fea1d123dd5ab9</data>
    </node>
    <node id="ITCH-SCRATCH CYCLE">
      <data key="d0">PATHWAY</data>
      <data key="d1">The itch-scratch cycle is a feedback loop where itching leads to scratching, worsening AD symptoms</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="ALLERGIC RHINO-CONJUNCTIVITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Allergic rhino-conjunctivitis is an atopic disorder that can be a comorbidity of AD
Allergic rhino-conjunctivitis is an allergic reaction affecting the eyes and nose</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b,1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="CARDIOVASCULAR DISORDERS">
      <data key="d0">DISEASE</data>
      <data key="d1">Cardiovascular disorders are potential comorbidities of AD
Cardiovascular disorders are diseases that involve the heart or blood vessels
Cardiovascular disorders are significant comorbidities associated with Atopic Dermatitis.</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,1596d061dbe1a1c9e8f31a02a21e5524,6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="NEUROPSYCHIATRIC DISORDERS">
      <data key="d0">DISEASE</data>
      <data key="d1">Neuropsychiatric disorders are potential comorbidities of AD
Neuropsychiatric disorders are significant comorbidities associated with Atopic Dermatitis.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="JANUS KINASE">
      <data key="d0">PROTEIN</data>
      <data key="d1">Janus Kinase (JAK) is a family of enzymes involved in cytokine receptor signaling
Janus Kinase (JAK) is a family of enzymes that are targeted by inhibitors like Baricitinib, Upadacitinib, and Abrocitinib for the treatment of Atopic Dermatitis.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="PHOSPHODIESTERASE 4">
      <data key="d0">PROTEIN</data>
      <data key="d1">Phosphodiesterase 4 (PDE4) is an enzyme involved in the breakdown of cyclic AMP, targeted by crisaborole
Phosphodiesterase 4 (PDE4) is targeted by inhibitors to increase cellular levels of cAMP and reduce inflammation in atopic dermatitis
Phosphodiesterase 4 (PDE4) is an enzyme that increases cellular levels of cAMP and contributes to anti-inflammatory cytokine generation
Phosphodiesterase 4 is an enzyme that breaks down cyclic AMP</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b,1596d061dbe1a1c9e8f31a02a21e5524,83eb9003d42977bb83fea1d123dd5ab9,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="CALCINEURIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Calcineurin is a protein phosphatase involved in T-cell activation, targeted by tacrolimus and pimecrolimus</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="B-CELL">
      <data key="d0">CELL</data>
      <data key="d1">B-cells are a type of lymphocyte involved in the immune response, implicated in AD</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="FIBROBLAST">
      <data key="d0">CELL</data>
      <data key="d1">Fibroblasts are cells that synthesize the extracellular matrix and collagen, involved in skin repair
Fibroblasts are cells that synthesize the extracellular matrix and collagen
Fibroblasts are cells that produce extracellular matrix and collagen, playing a role in fibrosis
Fibroblasts are cells that synthesize the extracellular matrix and collagen
Fibroblasts are activated by M2 macrophages leading to excessive extracellular matrix production
Fibroblasts are cells that produce collagen and are involved in fibrosis
Fibroblasts are cells that synthesize the extracellular matrix and collagen
Fibroblasts are cells that produce collagen and other fibers</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,3dfbb4c51838e0951f53ce951395225f,44f2592262cac835560b4c149fee8d2b,503107475d2e9dac49abd8ebcbadd9f5,5ec1ebf4e260eb1f8fda8acdf06cd39e,855c455b4c9592746834ee3a4e0e6b81,b2aae16813e647959b783a39ef9a19a7,df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="MACROPHAGE">
      <data key="d0">CELL</data>
      <data key="d1">Macrophages are immune cells that engulf and digest cellular debris and pathogens
Macrophages are cells involved in the detection, phagocytosis, and destruction of bacteria and other harmful organisms</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,8ce8c356713490cd2c680f505bcd050b</data>
    </node>
    <node id="INTERLEUKIN-4">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-4 (IL-4) is a cytokine involved in the differentiation of Th2 cells</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="INTERLEUKIN-13">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-13 (IL-13) is a cytokine involved in the immune response and inflammation
Interleukin-13, a cytokine involved in immune response</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,cccfd5ff480e281556e2210cd0e5c4b5</data>
    </node>
    <node id="INTERLEUKIN-31">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-31 (IL-31) is a cytokine involved in the immune response and associated with itching
Interleukin-31, a cytokine involved in immune response</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,cccfd5ff480e281556e2210cd0e5c4b5</data>
    </node>
    <node id="INTERLEUKIN-22">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-22 (IL-22) is a cytokine involved in the immune response and skin barrier function
Interleukin-22, a cytokine involved in immune response</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,cccfd5ff480e281556e2210cd0e5c4b5</data>
    </node>
    <node id="INTERLEUKIN-17">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-17 (IL-17) is a cytokine involved in the immune response and inflammation</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="INTERLEUKIN-1">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-1 (IL-1) is a cytokine involved in the immune response and inflammation</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="INTERLEUKIN-6">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-6 (IL-6) is a cytokine involved in the immune response and inflammation</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="INTERLEUKIN-10">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-10 (IL-10) is a cytokine involved in the immune response and inflammation</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="INTERLEUKIN-12">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-12 (IL-12) is a cytokine involved in the immune response and inflammation</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="INTERLEUKIN-23">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-23 (IL-23) is a cytokine involved in the immune response and inflammation
Interleukin-23, a cytokine involved in immune response</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,cccfd5ff480e281556e2210cd0e5c4b5</data>
    </node>
    <node id="INTERLEUKIN-33">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-33 (IL-33) is a cytokine involved in the immune response and inflammation</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="TUMOR NECROSIS FACTOR-ALPHA">
      <data key="d0">PROTEIN</data>
      <data key="d1">Tumor Necrosis Factor-alpha (TNF-&#945;) is a cytokine involved in systemic inflammation</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="INTERFERON-GAMMA">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interferon-gamma (IFN-&#947;) is a cytokine involved in the immune response and inflammation</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="TRANSFORMING GROWTH FACTOR-BETA">
      <data key="d0">PROTEIN</data>
      <data key="d1">Transforming Growth Factor-beta (TGF-&#946;) is a cytokine involved in cell growth and differentiation</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="PROSTAGLANDIN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Prostaglandins are lipid compounds involved in inflammation and immune responses</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="LEUKOTRIENE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Leukotrienes are lipid compounds involved in inflammation and allergic reactions</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="CORTICOSTEROID">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Corticosteroids are a class of steroid hormones used to reduce inflammation</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="CALCINEURIN INHIBITOR">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Calcineurin inhibitors are drugs that suppress the immune system by inhibiting calcineurin
Calcineurin inhibitors are drugs that suppress the immune system by inhibiting the activity of calcineurin</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,442e7fad2fab75fa2449309783294d89</data>
    </node>
    <node id="PHOSPHODIESTERASE INHIBITOR">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Phosphodiesterase inhibitors are drugs that block the degradation of cyclic AMP</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="JANUS KINASE INHIBITOR">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Janus kinase inhibitors are drugs that block the activity of Janus kinases</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="BIOLOGIC THERAPY">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Biologic therapies are treatments derived from living organisms used to target specific components of the immune system</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="SMALL MOLECULE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Small molecules are low molecular weight compounds used in drug development</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="PRECISION MEDICINE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Precision medicine is an approach to patient care that allows for tailored treatments based on individual characteristics
Precision medicine is an approach to patient care that allows for more personalized treatment based on individual variability</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="IMMUNE PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune pathways are the series of interactions between immune cells and molecules that lead to an immune response</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="SIGNAL TRANSDUCTION PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Signal transduction pathways are the processes by which a cell converts a signal from outside the cell into a functional response</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="EPIDERMAL BARRIER DYSFUNCTION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Epidermal barrier dysfunction is a condition where the skin barrier is compromised, leading to increased permeability and susceptibility to irritants
Epidermal Barrier Dysfunction is a symptom of Atopic Dermatitis causing dry skin and inflammation</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,691cb2e23ac3c6e591129d16714f8ef8</data>
    </node>
    <node id="CHRONIC INFLAMMATORY REACTION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Chronic inflammatory reaction is a prolonged inflammatory response that can lead to tissue damage</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="DRY SKIN">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Dry skin is a condition where the skin lacks moisture, often seen in AD
Dry skin is a symptom of Atopic Dermatitis caused by skin inflammation and epidermal barrier dysfunction</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,691cb2e23ac3c6e591129d16714f8ef8</data>
    </node>
    <node id="SENSITIVE SKIN">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Sensitive skin is a condition where the skin reacts easily to irritants, often seen in AD
Sensitive skin is prone to irritation and adverse reactions to environmental factors and products</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="SEVERE ITCHING">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Severe itching is an intense itching sensation often seen in AD</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="LOCALIZED LESIONS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Localized lesions are specific areas of inflamed skin seen in AD</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="DISSEMINATED LESIONS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Disseminated lesions are widespread areas of inflamed skin seen in AD</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="EDEMA">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Edema is swelling caused by excess fluid in tissues, often seen in AD
Edema is swelling of the skin, often seen in infantile Atopic Dermatitis.
Edema is swelling caused by excess fluid trapped in the body's tissues</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,6ada075e562abd7bd445164e9fc309b4,6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="LICHENIFICATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Lichenification is thickening of the skin with exaggerated skin markings, often seen in chronic AD
Lichenification is a clinical sign of atopic dermatitis characterized by thickened skin
Lichenification is the thickening of the skin due to chronic scratching, often seen in childhood Atopic Dermatitis.</data>
      <data key="d2">143d2dc302af5606656797bff162e23e,1596d061dbe1a1c9e8f31a02a21e5524,6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="EXCORIATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Excoriation is the act of scratching or scraping the skin, often seen in AD
Excoriation is a clinical sign of atopic dermatitis characterized by skin picking or scratching</data>
      <data key="d2">143d2dc302af5606656797bff162e23e,1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="HYPERPIGMENTATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Hyperpigmentation is darkening of the skin, often seen in AD</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="HYPOPIGMENTATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Hypopigmentation is lightening of the skin, often seen in AD</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="XEROSIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Xerosis is the medical term for dry skin, often seen in AD
Xerosis is increased dryness of the skin, often seen in childhood Atopic Dermatitis.
Xerosis is a symptom characterized by dry skin, often seen in AD</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,3df8535e965efb96f5094169610507ff,6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="SUBCUTANEOUS TISSUE">
      <data key="d0">TISSUE</data>
      <data key="d1">Subcutaneous tissue is the layer of tissue beneath the dermis, containing fat and connective tissue</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="LYMPH NODE">
      <data key="d0">TISSUE</data>
      <data key="d1">Lymph nodes are small, bean-shaped structures that filter lymph and store white blood cells
Lymph nodes are small, bean-shaped structures that filter lymph and store white blood cells</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="BLOOD VESSEL">
      <data key="d0">TISSUE</data>
      <data key="d1">Blood vessels are tubular structures that carry blood throughout the body</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="NERVE">
      <data key="d0">TISSUE</data>
      <data key="d1">Nerves are bundles of fibers that transmit electrical signals between the brain and the rest of the body</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="SWEAT GLAND">
      <data key="d0">TISSUE</data>
      <data key="d1">Sweat glands are structures in the skin that produce sweat</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="SEBACEOUS GLAND">
      <data key="d0">TISSUE</data>
      <data key="d1">Sebaceous glands are structures in the skin that produce sebum, an oily substance</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="STRATUM CORNEUM">
      <data key="d0">TISSUE</data>
      <data key="d1">The stratum corneum is the outermost layer of the epidermis, involved in the barrier function
The Stratum Corneum (SC) is the outermost layer of the skin, crucial for skin barrier function and keratin buildup.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="STRATUM GRANULOSUM">
      <data key="d0">TISSUE</data>
      <data key="d1">The stratum granulosum is a layer of the epidermis involved in the formation of the skin barrier</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="STRATUM SPINOSUM">
      <data key="d0">TISSUE</data>
      <data key="d1">The stratum spinosum is a layer of the epidermis involved in the strength and flexibility of the skin</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="STRATUM BASALE">
      <data key="d0">TISSUE</data>
      <data key="d1">The stratum basale is the deepest layer of the epidermis, involved in the production of new skin cells</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="BASEMENT MEMBRANE">
      <data key="d0">TISSUE</data>
      <data key="d1">The basement membrane is a thin layer of extracellular matrix that separates the epidermis from the dermis</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="ELASTIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Elastin is a protein in connective tissue that allows tissues to resume their shape after stretching
Elastin is a protein in connective tissue that allows tissues to resume their shape after stretching or contracting</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="FIBRONECTIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Fibronectin is a glycoprotein involved in cell adhesion and wound healing
Fibronectin is a high-molecular-weight glycoprotein involved in cell adhesion and wound healing
Fibronectin is a glycoprotein involved in cell adhesion and wound healing
Fibronectin is a glycoprotein that helps in cell adhesion and wound healing</data>
      <data key="d2">05c97152fe02249153103be341d65b67,1596d061dbe1a1c9e8f31a02a21e5524,4cf23e218b6aab3c77115173b5c7c2fd,a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="LAMININ">
      <data key="d0">PROTEIN</data>
      <data key="d1">Laminin is a protein in the basement membrane involved in cell adhesion</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="INTEGRIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Integrins are proteins that mediate the attachment between a cell and its surroundings</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="CADHERIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Cadherins are proteins involved in cell-cell adhesion</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="CLAUDIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Claudins are proteins involved in the formation of tight junctions between cells</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="OCCLUDIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Occludin is a protein involved in the formation of tight junctions between cells</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="DESMOGLEIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Desmogleins are proteins involved in cell-cell adhesion in the epidermis</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="DESMOCOLLIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Desmocollins are proteins involved in cell-cell adhesion in the epidermis</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="KERATIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Keratin is a structural protein in the skin, hair, and nails
Keratin is a structural protein in the skin, and its buildup is crucial for the formation of the stratum corneum, which is affected in Atopic Dermatitis.</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="S100 PROTEIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">S100 proteins are a family of proteins involved in the regulation of a variety of cellular processes</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="DEFENSIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Defensins are antimicrobial peptides involved in the immune response</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="CATHELICIDIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Cathelicidins are antimicrobial peptides involved in the immune response</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="PSORIASIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Psoriasin is an antimicrobial peptide involved in the immune response</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="HISTONE">
      <data key="d0">PROTEIN</data>
      <data key="d1">Histones are proteins involved in the packaging of DNA in the cell nucleus</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="DNA">
      <data key="d0">PROTEIN</data>
      <data key="d1">DNA is the molecule that carries genetic information in cells</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="MICRORNA">
      <data key="d0">PROTEIN</data>
      <data key="d1">MicroRNAs are small non-coding RNAs involved in the regulation of gene expression</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="LONG NON-CODING RNA">
      <data key="d0">PROTEIN</data>
      <data key="d1">Long non-coding RNAs are RNA molecules involved in the regulation of gene expression</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="EPIGENETIC">
      <data key="d0">PATHWAY</data>
      <data key="d1">Epigenetics is the study of changes in gene expression that do not involve changes to the DNA sequence
Epigenetic mechanisms refer to changes in gene expression that do not involve alterations to the DNA sequence, potentially involved in atopic dermatitis
Epigenetic refers to changes in gene expression that do not involve changes to the underlying DNA sequence</data>
      <data key="d2">143d2dc302af5606656797bff162e23e,1596d061dbe1a1c9e8f31a02a21e5524,4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="GENETIC">
      <data key="d0">PATHWAY</data>
      <data key="d1">Genetics is the study of genes and heredity</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="EXPOSOME">
      <data key="d0">PATHWAY</data>
      <data key="d1">The exposome is the measure of all the exposures of an individual in a lifetime and how those exposures relate to health</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="MICROBIOME">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">The microbiome is the collection of microorganisms living in a particular environment, such as the skin
The community of microorganisms living on the skin, which can be modulated to treat atopic dermatitis
The microbiome consists of the microorganisms that live in a particular environment, including the body
The microbiome, including skin and gut microbiomes, plays a role in the pathogenesis and treatment of Atopic Dermatitis</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,1596d061dbe1a1c9e8f31a02a21e5524,90f4809673ca34628b0e607908f0bf0b,f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="ALLERGIC REACTION">
      <data key="d0">PATHWAY</data>
      <data key="d1">An allergic reaction is an immune response to a substance that is not harmful to most people</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="CHRONIC DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">A chronic disease is a long-lasting condition that can be controlled but not cured</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="INFLAMMATORY DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">An inflammatory disease is a condition characterized by inflammation</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="SKIN DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">A skin disease is a condition that affects the skin</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="ALLERGIC DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">An allergic disease is a condition caused by an allergic reaction
Allergic diseases are conditions caused by an overreaction of the immune system to allergens</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="COMORBIDITY">
      <data key="d0">DISEASE</data>
      <data key="d1">A comorbidity is the presence of one or more additional conditions co-occurring with a primary condition</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </node>
    <node id="PATHOPHYSIOLOGY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Pathophysiology is the study of the functional changes that occur in the body as a result of a disease
Pathophysiology refers to the functional changes associated with or resulting from disease or injury, particularly in AD</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,e30574e513dd250992d637d808759c34</data>
    </node>
    <node id="PHARMACOLOGICAL INTERVENTION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Pharmacological intervention is the use of drugs to treat a disease or condition
Pharmacological intervention involves using drugs to treat or prevent Atopic Dermatitis and its comorbidities</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,90f4809673ca34628b0e607908f0bf0b</data>
    </node>
    <node id="THERAPEUTIC TARGET">
      <data key="d0">PATHWAY</data>
      <data key="d1">A therapeutic target is a
A therapeutic target is a molecule or pathway that can be modulated by treatment to achieve a therapeutic effect</data>
      <data key="d2">1596d061dbe1a1c9e8f31a02a21e5524,44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="SCRATCH">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Scratching is a response to itch, exacerbating the condition in atopic dermatitis</data>
      <data key="d2">143d2dc302af5606656797bff162e23e</data>
    </node>
    <node id="LANGERHANS CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Langerhans cells are epidermal dendritic cells involved in educating the adaptive immune system, defective in atopic dermatitis
A type of dendritic cell found in the skin
Langerhans Cells are dendritic cells in the epidermis involved in immune responses</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,143d2dc302af5606656797bff162e23e,c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </node>
    <node id="OEDEMA">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Oedema is a clinical sign of atopic dermatitis characterized by swelling</data>
      <data key="d2">143d2dc302af5606656797bff162e23e</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="INDURATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Induration is a clinical sign of atopic dermatitis characterized by hardening of the skin</data>
      <data key="d2">143d2dc302af5606656797bff162e23e</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="PAPULATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Papulation is a clinical sign of atopic dermatitis characterized by raised bumps on the skin</data>
      <data key="d2">143d2dc302af5606656797bff162e23e</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="OOZING">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Oozing is a clinical sign of atopic dermatitis characterized by fluid discharge from the skin</data>
      <data key="d2">143d2dc302af5606656797bff162e23e</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="SLEEPLESSNESS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Sleeplessness is a symptom of atopic dermatitis caused by pruritus
Sleeplessness is a subjective symptom considered in the SCORAD assessment</data>
      <data key="d2">143d2dc302af5606656797bff162e23e,f1897c89e321a3a80924fd72a56e90df</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="DISEASE CONTROL">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Disease control is a patient-reported outcome in the management of atopic dermatitis</data>
      <data key="d2">143d2dc302af5606656797bff162e23e</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="ADAPTIVE IMMUNE SYSTEM">
      <data key="d0">PATHWAY</data>
      <data key="d1">The adaptive immune system is responsible for long-term immunity and is involved in atopic dermatitis</data>
      <data key="d2">143d2dc302af5606656797bff162e23e</data>
    </node>
    <node id="TH2 RESPONSE">
      <data key="d0">PATHWAY</data>
      <data key="d1">TH2 response is an immune pathway involving T helper 2 cells, playing a key role in atopic dermatitis</data>
      <data key="d2">143d2dc302af5606656797bff162e23e</data>
    </node>
    <node id="TH17 RESPONSE">
      <data key="d0">PATHWAY</data>
      <data key="d1">TH17 response is an immune pathway involving T helper 17 cells, implicated in atopic dermatitis</data>
      <data key="d2">143d2dc302af5606656797bff162e23e</data>
    </node>
    <node id="TH22 RESPONSE">
      <data key="d0">PATHWAY</data>
      <data key="d1">TH22 response is an immune pathway involving T helper 22 cells, implicated in atopic dermatitis</data>
      <data key="d2">143d2dc302af5606656797bff162e23e</data>
    </node>
    <node id="NEURO-IMMUNOLOGICAL">
      <data key="d0">PATHWAY</data>
      <data key="d1">Neuro-immunological mechanisms involve interactions between the nervous and immune systems, relevant in atopic dermatitis</data>
      <data key="d2">143d2dc302af5606656797bff162e23e</data>
    </node>
    <node id="KERATINOCYTE DAMAGE">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Keratinocyte damage refers to injury to skin cells, contributing to barrier dysfunction in atopic dermatitis</data>
      <data key="d2">143d2dc302af5606656797bff162e23e</data>
    </node>
    <node id="DENDRITIC CELL ACTIVATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Dendritic cell activation refers to the stimulation of dendritic cells, which play a role in the immune response in atopic dermatitis</data>
      <data key="d2">143d2dc302af5606656797bff162e23e</data>
    </node>
    <node id="EASI90">
      <data key="d0">SYMPTOM</data>
      <data key="d1">90% improvement in Eczema Area and Severity Index from baseline</data>
      <data key="d2">f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="OSCORAD">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Objective Scoring of Atopic Dermatitis, a version of SCORAD excluding subjective symptoms</data>
      <data key="d2">f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="SCORAD75">
      <data key="d0">SYMPTOM</data>
      <data key="d1">75% improvement in Scoring of Atopic Dermatitis from baseline</data>
      <data key="d2">f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="PP-NRS-11">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Peak Pruritus Numerical Rating Scale, a tool used to measure peak itch sensation</data>
      <data key="d2">f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="DLQI">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Dermatology Life Quality Index, a questionnaire used to measure the impact of skin diseases on quality of life
Dermatology Life Quality Index, a measure used to evaluate the impact of skin diseases on quality of life</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e,f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="POEM">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Patient-Oriented Eczema Measure, a tool used for self-assessment of eczema symptoms</data>
      <data key="d2">f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="RECAP">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Recap of Atopic Eczema, a tool used to measure disease control in atopic dermatitis</data>
      <data key="d2">f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="ADCT">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Atopic Dermatitis Control Tool, a tool used to measure disease control in atopic dermatitis</data>
      <data key="d2">f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="ROSEOMONAS MUCOSA">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">A Gram-negative bacterium found in healthy skin microbiome</data>
      <data key="d2">f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="FB-401">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A product combining three strains of Roseomonas mucosa, developed for therapeutic activity in atopic dermatitis
FB-401 is a drug being tested in clinical trials for the treatment of atopic dermatitis in children and adults
FB-401 is a bacterial replacement therapy that has anti-inflammatory effects via TLR5 and TNFR activation
FB-401 is a mucosal erythrocyte series with therapeutic capabilities including activating tissue healing and inhibiting TLR5 signaling and TNFR
FB-401 is a therapeutic agent targeting TNFR activation and bacterial substitution</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,6059a6e2710b7df94c6a09e5eb7b024a,83eb9003d42977bb83fea1d123dd5ab9,e9841b88c9fab58c5175af409653da50,f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="TLR5">
      <data key="d0">PROTEIN</data>
      <data key="d1">Toll-like receptor 5, involved in tissue repair and anti-inflammatory activity
TLR5 (Toll-like receptor 5) is a protein involved in the immune response to bacterial flagellin
Toll-like receptor 5 (TLR5) is a protein involved in immune response signaling</data>
      <data key="d2">6059a6e2710b7df94c6a09e5eb7b024a,e9841b88c9fab58c5175af409653da50,f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="TNFR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Tumor necrosis factor receptor, involved in tissue repair and anti-inflammatory activity
TNFR (Tumor necrosis factor receptor) is a protein involved in the immune response and inflammation
Tumor necrosis factor receptor (TNFR) is a protein involved in immune response signaling</data>
      <data key="d2">6059a6e2710b7df94c6a09e5eb7b024a,e9841b88c9fab58c5175af409653da50,f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="STAPHYLOCOCCUS HOMINIS A9">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">A strain of bacteria with dual activity of killing Staphylococcus aureus and inhibiting its toxin production
Staphylococcus hominis A9 (ShA9) is a bacterium used in a bacteriotherapeutic approach to kill S. aureus and inhibit its toxins</data>
      <data key="d2">6059a6e2710b7df94c6a09e5eb7b024a,f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="SHA9">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A lyophilized strain of Staphylococcus hominis A9 used for microbiome recovery in atopic dermatitis
ShA9 is a targeted microbiome transplant used in the treatment of atopic dermatitis
ShA9 is a microbiota selected for transplant in atopic dermatitis treatment</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,e9841b88c9fab58c5175af409653da50,f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="NITRIC OXIDE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">An important mediator with beneficial metabolic and potential anti-inflammatory properties</data>
      <data key="d2">f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="NITROSOMONAS EUTROPHA">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">An ammonia-oxidizing bacterium able to produce nitric oxide
Nitrosomonas eutropha (B244) is a bacterium that produces nitric oxide by oxidizing ammonia and is used to treat AD</data>
      <data key="d2">6059a6e2710b7df94c6a09e5eb7b024a,f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="B244">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A product containing Nitrosomonas eutropha, used in clinical development for atopic dermatitis
An ammonia-oxidizing bacterium in clinical development for AD
B244 is a nitric oxide donor used in the treatment of atopic dermatitis
B244 is a bacterial strain used for microbiome modulation in atopic dermatitis treatment</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,3ea70e257330c812b52334ca1f90d807,e9841b88c9fab58c5175af409653da50,f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="CLINICAL SIGNS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Clinical signs are used to stratify patients according to severity in atopic dermatitis</data>
      <data key="d2">f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="BLEEDING">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Bleeding is one of the symptoms assessed in the POEM tool
Bleeding can occur in Atopic Dermatitis patients due to intense scratching.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4,f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="WEEPING/OOZING">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Weeping/oozing is one of the symptoms assessed in the POEM tool</data>
      <data key="d2">f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="FLAKING">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Flaking is one of the symptoms assessed in the POEM tool</data>
      <data key="d2">f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="DRYNESS OF THE SKIN">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Dryness of the skin is one of the symptoms assessed in the POEM tool</data>
      <data key="d2">f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="SKIN LESIONS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Skin lesions are measured by EASI and SCORAD in atopic dermatitis</data>
      <data key="d2">f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="INFLAMMATORY REACTION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Inflammatory reaction is a response measured in clinical trials for atopic dermatitis</data>
      <data key="d2">f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="MSB-01">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A topical product in clinical development for modulating the skin microbiome
MSB-01 is a clinical trial product used to investigate microbiome transplantation and bacterial modulation in AD</data>
      <data key="d2">6059a6e2710b7df94c6a09e5eb7b024a,f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="DB-001">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A topical product in clinical development for modulating the skin microbiome
DB-001 is a clinical trial product used to investigate microbiome transplantation and bacterial modulation in AD</data>
      <data key="d2">6059a6e2710b7df94c6a09e5eb7b024a,f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="AOBIOME">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">A company involved in the development of B244 for atopic dermatitis
AOBiome is a company conducting clinical trials for pruritus associated with Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b,f1897c89e321a3a80924fd72a56e90df</data>
    </node>
    <node id="S. AUREUS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Staphylococcus aureus, a bacterium that can colonize the skin and exacerbate AD
Staphylococcus aureus, a bacterium that can induce IL-36R- and IL-1R-dependent inflammation
Staphylococcus aureus is a bacterium often found on the skin of AD patients
Staphylococcus aureus (S. aureus) is a bacterium whose toxins are inhibited by ShA9
Staphylococcus aureus, a bacterium that can cause skin infections
Staphylococcus aureus, a bacterium that causes infections enhanced by IL-4 and IL-13 in AD</data>
      <data key="d2">3df8535e965efb96f5094169610507ff,3ea70e257330c812b52334ca1f90d807,41ccc4b41bd57cf2bda4dbb6c7ae4198,6059a6e2710b7df94c6a09e5eb7b024a,6309eeea565f06479830cec32938abc9,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </node>
    <node id="NICLOSAMIDE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">ATx201, a chemical that inhibits bacterial growth and is used for decolonization of S. aureus
Niclosamide is a small molecule used in atopic dermatitis treatment</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,3ea70e257330c812b52334ca1f90d807</data>
    </node>
    <node id="OMIGANAN PENTACHLORIDE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">CLS-001, a synthetic antimicrobial cationic peptide in clinical development for controlling dysbiosis in AD</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807</data>
    </node>
    <node id="EDP1815">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A microbiome modulator in phase I clinical trials for oral application
EDP1815 is an oral bacterial strain that modulates systemic inflammation
EDP1815 is a microbiome modifier designed for oral use currently in phase I trials for AD treatment
EDP1815 is a bacterial strain used for systemic inflammation regulation</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,3ea70e257330c812b52334ca1f90d807,6059a6e2710b7df94c6a09e5eb7b024a,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="STMC-103H">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A microbiome modulator in phase I clinical trials for oral application
STMC-103H is an oral bacterial strain that modulates the immune system via microbiome manipulation
STMC-103H is a microbiome modifier designed for oral use currently in phase I trials for AD treatment
STMC-103H is a bacterial strain used for microbiome modulation in atopic dermatitis treatment</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,3ea70e257330c812b52334ca1f90d807,6059a6e2710b7df94c6a09e5eb7b024a,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="KBL697">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A microbiome modulator in phase I clinical trials for oral application</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807</data>
    </node>
    <node id="PETROLATUM">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A simple product used to modulate antimicrobial and epidermal barrier function in AD</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807</data>
    </node>
    <node id="AHR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Aryl-hydrocarbon receptor, a ligand-activated transcriptional factor involved in the pathophysiology of AD
AhR (Aryl hydrocarbon receptor) is a protein involved in the regulation of biological responses to planar aromatic (aryl) hydrocarbons
AhR, or aryl-hydrocarbon receptor, is a protein involved in the regulation of biological responses to environmental toxins
Aryl-hydrocarbon receptor (AhR) is a ligand-activated transcriptional factor involved in the development of skin inflammation, including AD
Aryl hydrocarbon receptor, involved in keratinocyte expression and epidermal DCs&#8217; residence</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807,6059a6e2710b7df94c6a09e5eb7b024a,849e0980ffd6a7e1cf0b8d3d1fbacd98,e9841b88c9fab58c5175af409653da50,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="COAL TAR">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A substance that binds to AhR and restores filaggrin expression
A substance that binds to AhR and restores FLG expression</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </node>
    <node id="TAPINAROF">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Benvitimod, a natural AhR agonist reducing inflammatory responses in AD and psoriasis
Tapinarof, also known as benvitimod, is a small molecule AhR agonist used in the treatment of atopic dermatitis
Tapinarof (benvitimod) is a natural agonist of AhR that decreases inflammatory reactions when topically administered
A natural agonist of AhR, decreases inflammatory reactions when topically administered
Tapinarof is a biologic agent used as an Ahr agonist in atopic dermatitis treatment</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,3ea70e257330c812b52334ca1f90d807,6059a6e2710b7df94c6a09e5eb7b024a,849e0980ffd6a7e1cf0b8d3d1fbacd98,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="SPINK5">
      <data key="d0">GENE</data>
      <data key="d1">A gene with mutations or variants that favor allergen-independent inflammation in AD
A gene prevalent in keratinocytes and associated with skin differentiation</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </node>
    <node id="EASI50">
      <data key="d0">SYMPTOM</data>
      <data key="d1">A clinical endpoint indicating a 50% improvement in the Eczema Area and Severity IndexEczema Area and Severity Index 50, a clinical endpoint in AD studies
EASI50 is a clinical endpoint indicating a 50% improvement in the Eczema Area and Severity Index</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807,6309eeea565f06479830cec32938abc9</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="RCT">
      <data key="d0">PATHWAY</data>
      <data key="d1">Randomized Controlled Trial, a type of scientific experiment used in clinical trials</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807</data>
    </node>
    <node id="PHASE IIA">
      <data key="d0">PATHWAY</data>
      <data key="d1">A phase in clinical trials where the efficacy and side effects of a drug are studied</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807</data>
    </node>
    <node id="PHASE IB">
      <data key="d0">PATHWAY</data>
      <data key="d1">A phase in clinical trials focusing on the safety and dosage of a drug in a small group of patients</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807</data>
    </node>
    <node id="PHASE IIB">
      <data key="d0">PATHWAY</data>
      <data key="d1">A phase in clinical trials focusing on the efficacy and side effects of a drug in a larger group of patients</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807</data>
    </node>
    <node id="HISTOLOGICAL MODIFICATIONS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Changes in tissue structure observed under a microscope</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807</data>
    </node>
    <node id="TRANSCRIPTIONAL MODIFICATIONS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Changes in gene expression levels</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807</data>
    </node>
    <node id="BARRIER FUNCTION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">The ability of the skin to act as a barrier to protect against environmental factors</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807</data>
    </node>
    <node id="DYSBIOSIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">An imbalance in the microbial communities, often associated with disease</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807</data>
    </node>
    <node id="EPIDERMAL BARRIER FUNCTION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">The protective function of the outermost layer of the skin</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807</data>
    </node>
    <node id="MOISTURIZERS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Products used to hydrate and protect the skin</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807</data>
    </node>
    <node id="ADAPTIVE IMMUNE RESPONSE">
      <data key="d0">PATHWAY</data>
      <data key="d1">The body's specific immune response to pathogens, involving memory cells
Adaptive immune response is the body's targeted defense against specific pathogens
Adaptive immune response is the body's targeted immune response involving T and B cells
</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807,48288f3ec2832850282f95d4e38d10e1,6309eeea565f06479830cec32938abc9,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </node>
    <node id="INVESTIGATOR GLOBAL ASSESSMENT (IGA)">
      <data key="d0">SYMPTOM</data>
      <data key="d1">A clinical endpoint used to assess the overall severity of a disease</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807</data>
    </node>
    <node id="ALARMINS">
      <data key="d0">PROTEIN</data>
      <data key="d1">Proteins that signal tissue damage and initiate immune responses
Alarmins are proteins targeted for intervention in the early stages of atopic dermatitis
Alarmins are proinflammatory cytokines and danger signals produced during the innate immune response</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b,3ea70e257330c812b52334ca1f90d807,83eb9003d42977bb83fea1d123dd5ab9</data>
    </node>
    <node id="SEVERE AND UNCONTROLLED ALLERGIC ASTHMA">
      <data key="d0">DISEASE</data>
      <data key="d1">A chronic inflammatory disease of the airways characterized by severe and uncontrolled symptoms</data>
      <data key="d2">3ea70e257330c812b52334ca1f90d807</data>
    </node>
    <node id="ETOKIMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Etokimab (ANB020) is an anti-IL-33 antibody used in clinical studies for atopic dermatitis
Etokimab is a drug that failed to meet the primary endpoint in a phase 2b clinical trial for Atopic Dermatitis
Etokimab is a biologic injection targeting IL-33 used in the treatment of atopic dermatitis
A humanized anti-IL-33 monoclonal antibody
Etokimab is a biologic agent targeting interleukin-33 in atopic dermatitis treatment</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,6309eeea565f06479830cec32938abc9,849e0980ffd6a7e1cf0b8d3d1fbacd98,90f4809673ca34628b0e607908f0bf0b,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="CXCR1">
      <data key="d0">PROTEIN</data>
      <data key="d1">CXCR1 is a receptor involved in neutrophil migration</data>
      <data key="d2">6309eeea565f06479830cec32938abc9</data>
    </node>
    <node id="ASTEGOLIMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Astegolimab (MSTT1041A/AMG282) is an anti-IL-33 antibody in clinical development
Astegolimab is a biologic injection targeting IL-33 used in the treatment of atopic dermatitis
Astegolimab is a biologic agent targeting interleukin-33 in atopic dermatitis treatment</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,6309eeea565f06479830cec32938abc9,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="MEDI3506">
      <data key="d0">CHEMICAL</data>
      <data key="d1">MEDI3506 is an anti-IL-33 antibody in clinical development
MEDI3506 is a biologic injection targeting IL-33 used in the treatment of atopic dermatitis
MEDI3506 is a biologic agent targeting interleukin-33 in atopic dermatitis treatment</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,6309eeea565f06479830cec32938abc9,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="REGN3500">
      <data key="d0">CHEMICAL</data>
      <data key="d1">REGN3500 is an anti-IL-33 antibody in clinical development
REGN3500 is a biologic injection targeting IL-33 used in the treatment of atopic dermatitis
REGN3500 is a biologic agent targeting interleukin-33 in atopic dermatitis treatment</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,6309eeea565f06479830cec32938abc9,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="IL-1&#913;">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-1&#945; is a proinflammatory cytokine released by keratinocytes after injury and by skin dysbiosis
IL-1&#945; (Interleukin-1 alpha) is a cytokine involved in the immune response and inflammation</data>
      <data key="d2">6309eeea565f06479830cec32938abc9,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="BERMEKIMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Bermekimab (MABp1) is an anti-IL-1&#945; antibody initially developed for oncological indications and recently for hidradenitis suppurativa
Bermekimab is a biologic injection targeting IL-1&#945; used in the treatment of atopic dermatitis
An anti-IL-1 monoclonal antibody used in treating inflammatory conditions
Bermekimab is a biologic agent targeting interleukin-1a in atopic dermatitis treatment</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,6309eeea565f06479830cec32938abc9,849e0980ffd6a7e1cf0b8d3d1fbacd98,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="IGA 0/1">
      <data key="d0">SYMPTOM</data>
      <data key="d1">IGA 0/1 is a clinical endpoint indicating clear or almost clear skin</data>
      <data key="d2">6309eeea565f06479830cec32938abc9</data>
    </node>
    <node id="KY1005">
      <data key="d0">CHEMICAL</data>
      <data key="d1">KY1005 is a non-depleting anti-OX40L biologic used in clinical studies for atopic dermatitis
KY1005 is a non-depleting anti-OX40L biologic antibody that inhibits effector T cell response and maintains regulatory T cell activity
KY1005 is a drug that completed phase 2a clinical trials for Atopic Dermatitis
KY1005 is a drug that has shown positive phase 2a results for the treatment of moderate to severe atopic dermatitis
KY1005 is a biologic injection targeting OX40L used in the treatment of atopic dermatitis
KY1005 is a monoclonal antibody used in clinical trials for immune system diseases</data>
      <data key="d2">6309eeea565f06479830cec32938abc9,68015074236b0144899baa38d01ae467,78e26c66107dba37ac4bab65406b43a0,83eb9003d42977bb83fea1d123dd5ab9,90f4809673ca34628b0e607908f0bf0b,e9841b88c9fab58c5175af409653da50</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="PHASE IIA STUDY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Phase IIa study is a clinical trial phase to assess efficacy and side effects
Phase IIa study is a clinical study phase to test the efficacy and side effects of a drug
Phase IIa study is an early phase clinical trial to assess efficacy and safety of a treatment
Phase IIa study is an early phase of clinical trials to assess the efficacy and side effects of a drug</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b,48288f3ec2832850282f95d4e38d10e1,6309eeea565f06479830cec32938abc9,78e26c66107dba37ac4bab65406b43a0</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="PHASE IIB TRIAL">
      <data key="d0">PATHWAY</data>
      <data key="d1">Phase IIb trial is a clinical trial phase to assess efficacy and side effects in a larger group
Phase IIb trial is a clinical study phase to test the efficacy and optimal dosing of a drug</data>
      <data key="d2">6309eeea565f06479830cec32938abc9,78e26c66107dba37ac4bab65406b43a0</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="ANTIGEN PRESENTATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Antigen presentation is a crucial process in the adaptive immune response leading to inflammation</data>
      <data key="d2">6309eeea565f06479830cec32938abc9</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="SEVERE ALLERGIC ASTHMA">
      <data key="d0">DISEASE</data>
      <data key="d1">Severe allergic asthma is a chronic inflammatory disease of the airways</data>
      <data key="d2">6309eeea565f06479830cec32938abc9</data>
    </node>
    <node id="TEFF CELL">
      <data key="d0">CELL</data>
      <data key="d1">Effector T cells (Teff cells) are a type of T cell involved in the immune response</data>
      <data key="d2">78e26c66107dba37ac4bab65406b43a0</data>
    </node>
    <node id="TREG CELL">
      <data key="d0">CELL</data>
      <data key="d1">Regulatory T cells (Treg cells) are a type of T cell that modulates the immune system
Treg cells are regulatory T cells involved in maintaining immune tolerance
Treg cells are a type of T cell that help regulate the immune system and maintain tolerance to self-antigens
Regulatory T cells, also known as Treg cells, are a component of the immune system that suppress immune responses of other cells</data>
      <data key="d2">442e7fad2fab75fa2449309783294d89,48288f3ec2832850282f95d4e38d10e1,78e26c66107dba37ac4bab65406b43a0,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="IL-2R&#915;">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-2R&#947; is a receptor chain involved in the type I receptor for IL-4</data>
      <data key="d2">78e26c66107dba37ac4bab65406b43a0</data>
    </node>
    <node id="CBP-201">
      <data key="d0">CHEMICAL</data>
      <data key="d1">CBP-201 is an IL-4R&#945; antagonist with a faster onset of action compared to dupilumab
CBP-201 is a biologic injection targeting IL-4R&#945; used in the treatment of atopic dermatitis
CBP-201 is a biologic agent targeting interleukin-4Ra in atopic dermatitis treatment</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,78e26c66107dba37ac4bab65406b43a0,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="AK120">
      <data key="d0">CHEMICAL</data>
      <data key="d1">AK120 is an antibody directed against IL-4R&#945; currently in phase Ib studies
AK120 is a biologic injection targeting IL-4R&#945; used in the treatment of atopic dermatitis</data>
      <data key="d2">78e26c66107dba37ac4bab65406b43a0,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="ASLAN004">
      <data key="d0">CHEMICAL</data>
      <data key="d1">ASLAN004 is a fully humanized antibody directed against IL-13R&#945;1
A monoclonal antibody targeting IL-4 and IL-13, used in the treatment of atopic dermatitis
ASLAN004 is a drug undergoing multiple ascending dose studies for the treatment of atopic dermatitis
ASLAN004 is a biologic injection targeting IL-13R&#945;1 used in the treatment of atopic dermatitis
ASLAN004 is a biologic agent targeting interleukin-13Ra1 in atopic dermatitis treatment
ASLAN004 is a biologic drug targeting Interleukin-4Ra</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,3dfbb4c51838e0951f53ce951395225f,78e26c66107dba37ac4bab65406b43a0,83eb9003d42977bb83fea1d123dd5ab9,cccfd5ff480e281556e2210cd0e5c4b5,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="EMA">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">European Medicines Agency (EMA) is a regulatory body that provides opinions on drug approvals
The European Medicines Agency is responsible for the approval of drugs like crisaborole in Europe</data>
      <data key="d2">78e26c66107dba37ac4bab65406b43a0,90f4809673ca34628b0e607908f0bf0b</data>
    </node>
    <node id="ECZTRA1">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">ECZTRA1 is a phase III pivotal monotherapy study for tralokinumab
A clinical study evaluating the efficacy of tralokinumab in patients</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,78e26c66107dba37ac4bab65406b43a0</data>
    </node>
    <node id="ECZTRA2">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">ECZTRA2 is a phase III pivotal monotherapy study for tralokinumab
A clinical study evaluating the efficacy of tralokinumab in patients</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,78e26c66107dba37ac4bab65406b43a0</data>
    </node>
    <node id="CONJUNCTIVITIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Conjunctivitis is an eye disorder that can develop as a side effect of dupilumab
Inflammation of the conjunctiva of the eye
Conjunctivitis is an inflammation or infection of the outer membrane of the eyeball and the inner eyelid</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,3df8535e965efb96f5094169610507ff,78e26c66107dba37ac4bab65406b43a0</data>
    </node>
    <node id="PHASE IB TRIAL">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Phase Ib trial is a clinical study phase to test the safety and efficacy of a drug</data>
      <data key="d2">78e26c66107dba37ac4bab65406b43a0</data>
    </node>
    <node id="PHASE III PROGRAMME">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Phase III programme is a clinical study phase to confirm the efficacy and monitor side effects of a drug</data>
      <data key="d2">78e26c66107dba37ac4bab65406b43a0</data>
    </node>
    <node id="TYPE I RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Type I receptor is a receptor complex involving IL-4R&#945; and IL-2R&#947;</data>
      <data key="d2">78e26c66107dba37ac4bab65406b43a0</data>
    </node>
    <node id="TYPE II RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Type II receptor is a receptor complex involving IL-4R&#945; and IL-13R&#945;1</data>
      <data key="d2">78e26c66107dba37ac4bab65406b43a0</data>
    </node>
    <node id="EYE DISORDERS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Eye disorders, such as conjunctivitis, can be side effects of certain treatments
Adverse events such as conjunctivitis, keratoconjunctivitis, and keratitis</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,78e26c66107dba37ac4bab65406b43a0</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="CHILDREN">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Children are a population group often included in clinical studies for pediatric indications</data>
      <data key="d2">78e26c66107dba37ac4bab65406b43a0</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="ADULTS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Adults are a population group often included in clinical studies for adult indications</data>
      <data key="d2">78e26c66107dba37ac4bab65406b43a0</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="PATIENTS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Patients are individuals receiving medical treatment or participating in clinical studies</data>
      <data key="d2">78e26c66107dba37ac4bab65406b43a0</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="PLACEBO GROUP">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Placebo group is a control group in clinical studies receiving a placebo treatment
Placebo group refers to the group of patients receiving a placebo in a clinical trial</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1,78e26c66107dba37ac4bab65406b43a0</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="MODERATE-TO-SEVERE AD">
      <data key="d0">DISEASE</data>
      <data key="d1">Moderate-to-severe atopic dermatitis is a more severe form of atopic dermatitis requiring intensive treatment</data>
      <data key="d2">78e26c66107dba37ac4bab65406b43a0</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="HEALTHY SUBJECTS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Healthy subjects are individuals without the disease being studied, often included in clinical trials for comparison</data>
      <data key="d2">78e26c66107dba37ac4bab65406b43a0</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="EMA/CHMP/202204/2021">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">EMA/CHMP/202204/2021 is a document reference for the European Medicines Agency's positive opinion on tralokinumab</data>
      <data key="d2">78e26c66107dba37ac4bab65406b43a0</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="KYMAB">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Kymab is a biopharmaceutical company involved in the development of KY1005
Kymab is a company that has shown positive phase 2a results for KY1005 in atopic dermatitis
Kymab is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b,78e26c66107dba37ac4bab65406b43a0,83eb9003d42977bb83fea1d123dd5ab9</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="ASLAN">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">ASLAN is a biopharmaceutical company involved in the development of ASLAN004</data>
      <data key="d2">78e26c66107dba37ac4bab65406b43a0</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="USA">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">USA is a country where clinical studies for dupilumab are being conducted</data>
      <data key="d2">78e26c66107dba37ac4bab65406b43a0</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="EU">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">EU is a region where clinical studies for dupilumab are being conducted</data>
      <data key="d2">78e26c66107dba37ac4bab65406b43a0</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="KERATOCONJUNCTIVITIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Inflammation of the cornea and conjunctiva of the eye</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41</data>
    </node>
    <node id="KERATITIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Inflammation of the cornea of the eye</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41</data>
    </node>
    <node id="EOSINOPHIL-DERIVED NEUROTOXIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">A protein released by eosinophils that is involved in the immune response</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="EOSINOPHIL CATIONIC PROTEIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">A protein released by eosinophils that is involved in the immune response</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="MEPOLIZUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A monoclonal antibody targeting IL-5, used in the treatment of eosinophilic asthma
Mepolizumab is a monoclonal antibody used to treat severe eosinophilic asthma
Mepolizumab is an IgG1k IL-5 inhibitor that reduces peripheral blood eosinophils
Mepolizumab is reserved for treating AD cases unresponsive to standard therapies
Mepolizumab is a biologic drug targeting Interleukin-5</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,0829313703a7d2bae5436a9ee542334d,3df8535e965efb96f5094169610507ff,8246ea974dfb00cb5e3d984004e21a9e,cccfd5ff480e281556e2210cd0e5c4b5</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="TARC">
      <data key="d0">PROTEIN</data>
      <data key="d1">Thymus and activation-regulated chemokine, a biomarker for atopic dermatitis severity</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="BENRALIZUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A monoclonal antibody targeting IL-5R&#945;, used in the treatment of eosinophilic asthma
Benralizumab is a biologic injection targeting IL-5R&#945; used in the treatment of atopic dermatitis
Benralizumab is a monoclonal antibody that inhibits IL-5 by targeting IL5R
Benralizumab is a biologic drug targeting Interleukin-5Ra</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,3df8535e965efb96f5094169610507ff,cccfd5ff480e281556e2210cd0e5c4b5,e9841b88c9fab58c5175af409653da50</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="IL-5R&#913;">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-5 receptor alpha, a component of the IL-5 receptor
IL-5R&#945; (Interleukin-5 receptor alpha) is a protein that binds interleukin-5 and is involved in the growth and differentiation of eosinophils
IL-5R&#945;, or &#945;-chain of the IL-5 receptor, is a protein involved in the regulation of immune responses</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41,e9841b88c9fab58c5175af409653da50,f14a13d54127c3baadeb0b34d40928c9</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="ADAPT">
      <data key="d0">STUDY</data>
      <data key="d1">Atopic Dermatitis Anti-IgE study, designed to verify the role of IgE in the paediatric population with atopic dermatitis</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41</data>
      <data key="d3">STUDY</data>
    </node>
    <node id="NASAL POLYPOSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">A condition characterized by the growth of polyps in the nasal cavity</data>
      <data key="d2">0007aca7507e3e422ad87a90c0fd2c41</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="MIGE">
      <data key="d0">PROTEIN</data>
      <data key="d1">Membrane-bound IgE (mIgE) is a form of IgE expressed on B cells
mIgE (Membrane form of Immunoglobulin E) is a protein involved in the immune response and inflammation</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="ANTI-C&#917;MX (FB825)">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Anti-C&#949;mX (FB825) is an antibody directed against mIgE to deplete IgE-committed B cells</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="IL-22R">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-22R is the receptor for IL-22, involved in mediating its biological activities</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="IL-22R1">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-22R1 is a subunit of the IL-22 receptor complexIL-22R1 is a receptor subunit that binds IL-22 and forms a complex with IL-10R2
IL-22R1 (Interleukin-22 receptor 1) is a protein that binds interleukin-22 and is involved in the immune response
IL-22R1, or IL-22 receptor 1, is a protein involved in the regulation of immune responses</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1,e9841b88c9fab58c5175af409653da50,f14a13d54127c3baadeb0b34d40928c9</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="IL-10R2">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-10R2 is a subunit of the IL-22 receptor complex that heterodimerizes with IL-22R1</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="IL-20">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-20 is a cytokine that binds to IL-22R1 and IL-20R2 receptor complexes</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="IL-24">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-24 is a cytokine that binds to IL-22R1 and IL-20R2 receptor complexes</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="LEO 138559">
      <data key="d0">CHEMICAL</data>
      <data key="d1">LEO 138559 is an antibody directed against IL-22R1, currently in phase I studies
LEO 138559 is a biologic injection targeting IL-22R1 used in the treatment of atopic dermatitis</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="RISANKIZUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Risankizumab is an anti-IL-23 antibody investigated for the treatment of AD
Risankizumab is a biologic injection targeting IL-23 used in the treatment of atopic dermatitis
Risankizumab is a biologic drug targeting Interleukin-23</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1,cccfd5ff480e281556e2210cd0e5c4b5,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="IL-2">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-2 is a cytokine involved in T cell proliferation and activation
IL-2 is a cytokine that plays a central role in the activation and proliferation of T cells
Interleukin-2 (IL-2) is a cytokine whose expression is reduced by TAC-loaded PLG-based nanoparticles
Interleukin-2 (IL-2) is a cytokine that plays a role in the activation and proliferation of T cells
IL-2 is a cytokine that promotes T-cell proliferation
IL-2 production is upregulated by the interaction between OX40 and OX40L
</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456,442e7fad2fab75fa2449309783294d89,44f2592262cac835560b4c149fee8d2b,48288f3ec2832850282f95d4e38d10e1,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,bddc3b1a7f098e71f0aa64adec047124</data>
    </node>
    <node id="LY3471851">
      <data key="d0">CHEMICAL</data>
      <data key="d1">LY3471851 is a pegylated recombinant human IL-2 designed to target the IL-2 receptor complex on T cells
LY3471851 is a biologic injection targeting rhIL-2 to Treg cells used in the treatment of atopic dermatitis</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="ULCERATIVE COLITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Ulcerative Colitis is a chronic inflammatory bowel disease
Ulcerative colitis is a chronic inflammatory bowel disease causing inflammation and ulcers in the digestive tract
Ulcerative colitis is a type of gastrointestinal tract fibrosis
Ulcerative colitis is an inflammatory disease treated with TNF antagonists
Ulcerative colitis is an inflammatory bowel disease treated with anti-TL1A antibody to reduce fibrosis
Ulcerative colitis is an inflammatory bowel disease
Ulcerative Colitis is a chronic inflammatory bowel disease causing inflammation and ulcers in the colon

Ulcerative colitis is an inflammatory bowel disease that causes long-lasting inflammation and ulcers in the digestive tract
Ulcerative colitis is a chronic inflammatory bowel disease that causes inflammation and ulcers in the digestive tract</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,423195c6b63ad0a6773374364ebf3612,442e7fad2fab75fa2449309783294d89,48288f3ec2832850282f95d4e38d10e1,516e41e96d2e72d45bf1e2c69da7f18a,5ec1ebf4e260eb1f8fda8acdf06cd39e,68015074236b0144899baa38d01ae467,7f559ad7372a4e35e90b43cc67047b0f,c525762bb827485bceeb9f09bb4bcfe0,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="ANTI-IGE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Anti-IgE refers to biologics that target IgE to treat allergic conditions</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="IMMUNOADSORPTION">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Immunoadsorption is a process used to remove specific antibodies from the blood</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="IL-20R2">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-20R2 is a receptor subunit that forms complexes with IL-22R1 and IL-20R1</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="IL-20R1">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-20R1 is a receptor subunit that forms complexes with IL-20R2</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="ASIAN PATIENTS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Asian patients are a demographic group studied in the context of AD and the IL-23&#8211;IL-17 axis</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="LYMPHOBLASTS">
      <data key="d0">CELL</data>
      <data key="d1">Lymphoblasts are immature lymphocytes involved in the immune response</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="STAPHYLOCOCCAL EXOTOXINS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Staphylococcal exotoxins are toxins produced by Staphylococcus bacteria that induce cytokine production</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="RECEPTOR COMPLEX">
      <data key="d0">PROTEIN</data>
      <data key="d1">Receptor complex refers to the combination of receptor subunits that mediate cytokine signaling</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="TRANSCRIPTOMIC SIGNATURE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Transcriptomic signature refers to the pattern of gene expression associated with a specific condition, such as AD</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="IMMUNE POLARIZATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune polarization refers to the skewing of the immune response towards a specific type, such as TH2 in allergies</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="ALLERGIC REACTIONS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Allergic reactions are immune responses to allergens, often involving IgE</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="POLYSENSITIZATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Polysensitization refers to being allergic to multiple allergens</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="OLIGOSENSITIZATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Oligosensitization refers to being allergic to a few specific allergens</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="ENVIRONMENTAL ALLERGENS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Environmental allergens are substances in the environment that can cause allergic reactions</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="AUTOIMMUNE DISORDERS">
      <data key="d0">DISEASE</data>
      <data key="d1">Autoimmune disorders are conditions where the immune system attacks the body's own tissues</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="ALLERGIC DISEASES">
      <data key="d0">DISEASE</data>
      <data key="d1">Allergic diseases are conditions caused by hypersensitivity of the immune system to allergens</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="RECOMBINANT HUMAN IL-2">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Recombinant human IL-2 is a lab-produced form of IL-2 used in therapies
Recombinant human IL-2 is a synthetic form of interleukin-2 used in immunotherapy</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b,48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="PEGYLATED">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Pegylated refers to the modification of a molecule with polyethylene glycol to improve its properties</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="PHASE I STUDIES">
      <data key="d0">PATHWAY</data>
      <data key="d1">Phase I studies are initial clinical trials to assess the safety of a treatment</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="PROOF-OF-CONCEPT STUDY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Proof-of-concept study is a preliminary study to evaluate the feasibility of a treatment</data>
      <data key="d2">48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="CLINICAL IMPROVEMENT">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Clinical improvement refers to the positive change in a patient's condition due to treatment
Clinical improvement refers to the positive changes in a patient's condition as a result of treatment
Clinical improvement refers to the positive change in a patient's condition as a result of treatment</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,44f2592262cac835560b4c149fee8d2b,48288f3ec2832850282f95d4e38d10e1</data>
    </node>
    <node id="RHIL-2">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Recombinant human IL-2 (rhIL-2; LY3471851) is a pegylated form designed to target the IL-2 receptor complex on T cells
rhIL-2 (recombinant human Interleukin-2) is a cytokine used to stimulate the growth of immune cells
rhIL-2, or recombinant human IL-2, is a protein involved in the regulation of immune responses</data>
      <data key="d2">442e7fad2fab75fa2449309783294d89,e9841b88c9fab58c5175af409653da50,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="PDE4">
      <data key="d0">PROTEIN</data>
      <data key="d1">Phosphodiesterase 4 (PDE4) is an enzyme involved in the breakdown of cyclic AMP and is a target for anti-inflammatory drugs
PDE4, or phosphodiesterase 4, is an enzyme involved in the breakdown of cyclic AMP
PDE4 is an enzymatic monoclonal antibody that helps immune cells release various cytokines</data>
      <data key="d2">286730b1c1f680ac465cc21d522fda0c,442e7fad2fab75fa2449309783294d89,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="LOTAMILAST">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Lotamilast (RVT-501/E6005) is a PDE4 inhibitor in development for the treatment of atopic dermatitis
Lotamilast (RVT-501/E6005) is a small molecule drug developed by Dermavant, targeting the PDE4 enzyme</data>
      <data key="d2">442e7fad2fab75fa2449309783294d89,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="DIFAMILAST">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Difamilast (OPA-15406/MM36) is a PDE4 inhibitor in development for the treatment of atopic dermatitis
Difamilast (OPA-15406) is a drug candidate for atopic dermatitis, currently in phase 3 studies in Japan
Difamilast (OPA-15406/MM36) is a small molecule drug developed by Otsuka, targeting the PDE4 enzyme
Difamilast is a novel selective phosphodiesterase 4 (PDE4) inhibitor undergoing phase-3 trials</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd,442e7fad2fab75fa2449309783294d89,83eb9003d42977bb83fea1d123dd5ab9,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="ROFLUMILAST">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Roflumilast (AQR-151) is a PDE4 inhibitor tested for the treatment of atopic dermatitis
Roflumilast is a small molecule drug developed by AstraZeneca, targeting the PDE4 enzyme</data>
      <data key="d2">442e7fad2fab75fa2449309783294d89,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="LEO 29102">
      <data key="d0">CHEMICAL</data>
      <data key="d1">LEO 29102 is a PDE inhibitor with selectivity for the PDE4D isoform
LEO 29102 is a small molecule drug developed by LEO Pharma, targeting the PDE4 enzyme</data>
      <data key="d2">442e7fad2fab75fa2449309783294d89,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="HISTAMINE H4 RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Histamine H4 receptor (H4R) is a G protein-coupled receptor involved in immunoregulatory activities on leukocytes</data>
      <data key="d2">442e7fad2fab75fa2449309783294d89</data>
    </node>
    <node id="JNJ-7777120">
      <data key="d0">CHEMICAL</data>
      <data key="d1">JNJ-7777120 is a reference compound for selective H4R antagonists</data>
      <data key="d2">442e7fad2fab75fa2449309783294d89</data>
    </node>
    <node id="ADRIFORANT">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Adriforant (formerly ZPL-389) is an H4R antagonist tested for inflammatory skin disorders
Adriforant is a small molecule targeting H4R used in the treatment of atopic dermatitis
Adriforant is a small molecule drug developed by Novartis, targeting the H4R receptor</data>
      <data key="d2">442e7fad2fab75fa2449309783294d89,e9841b88c9fab58c5175af409653da50,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="LEO 152020">
      <data key="d0">CHEMICAL</data>
      <data key="d1">LEO 152020 is an oral H4R antagonist currently in phase I clinical trials
LEO 152020, also known as JW1601, is a small molecule targeting H4R used in the treatment of atopic dermatitis</data>
      <data key="d2">442e7fad2fab75fa2449309783294d89,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="PATIENT-ORIENTED ECZEMA MEASURE">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Patient-Oriented Eczema Measure (POEM) is a tool used to assess the severity of eczema from the patient's perspective</data>
      <data key="d2">442e7fad2fab75fa2449309783294d89</data>
    </node>
    <node id="VISUAL ANALOGUE SCALE">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Visual analogue scale (VAS) is a tool used to measure the intensity of pruritus</data>
      <data key="d2">442e7fad2fab75fa2449309783294d89</data>
    </node>
    <node id="IL-2 RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-2 receptor is a protein complex on T cells that binds IL-2, leading to T cell activation and proliferation</data>
      <data key="d2">442e7fad2fab75fa2449309783294d89</data>
    </node>
    <node id="PDE4 INHIBITOR">
      <data key="d0">CHEMICAL</data>
      <data key="d1">PDE4 inhibitors are compounds that inhibit the activity of phosphodiesterase 4, reducing inflammation</data>
      <data key="d2">442e7fad2fab75fa2449309783294d89</data>
    </node>
    <node id="H1R">
      <data key="d0">PROTEIN</data>
      <data key="d1">Histamine H1 receptor (H1R) is a G protein-coupled receptor involved in allergic responses and pruritus</data>
      <data key="d2">442e7fad2fab75fa2449309783294d89</data>
    </node>
    <node id="H2R">
      <data key="d0">PROTEIN</data>
      <data key="d1">Histamine H2 receptor (H2R) is a G protein-coupled receptor involved in regulating smooth muscle relaxation in the gastrointestinal tract</data>
      <data key="d2">442e7fad2fab75fa2449309783294d89</data>
    </node>
    <node id="H3R">
      <data key="d0">PROTEIN</data>
      <data key="d1">Histamine H3 receptor (H3R) is a G protein-coupled receptor involved in the central nervous system, regulating histamine synthesis</data>
      <data key="d2">442e7fad2fab75fa2449309783294d89</data>
    </node>
    <node id="ANTIGEN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Antigens are molecules capable of inducing an immune response
Antigen is a substance that induces an immune response
A substance that induces an immune response, particularly in the adaptive immune system</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9,442e7fad2fab75fa2449309783294d89,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </node>
    <node id="CHEMOTACTIC MEDIATOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Chemotactic mediators are substances that attract cells to the site of inflammation or infection</data>
      <data key="d2">442e7fad2fab75fa2449309783294d89</data>
    </node>
    <node id="GASTROINTESTINAL TRACT">
      <data key="d0">TISSUE</data>
      <data key="d1">The gastrointestinal tract is the organ system responsible for digestion and absorption of nutrients
The gastrointestinal tract is one of the organs affected by fibrosis
The gastrointestinal tract is a system of organs involved in digestion and affected by TL1A-driven fibrosis
The gastrointestinal tract is a series of hollow organs involved in digestion and can be affected by fibrotic diseases</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,442e7fad2fab75fa2449309783294d89,68015074236b0144899baa38d01ae467,c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="CENTRAL NERVOUS SYSTEM">
      <data key="d0">TISSUE</data>
      <data key="d1">The central nervous system consists of the brain and spinal cord, responsible for processing and transmitting information</data>
      <data key="d2">442e7fad2fab75fa2449309783294d89</data>
    </node>
    <node id="H4R">
      <data key="d0" />
      <data key="d1">
H4R is a histamine receptor involved in immune response and inflammation
H4R, or type 4 histamine receptor, is a protein involved in immune response modulation</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9,442e7fad2fab75fa2449309783294d89,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="152020">
      <data key="d0">CHEMICAL</data>
      <data key="d1">152020 is an oral H4R antagonist currently in phase I clinical trials</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="PROSTAGLANDIN D2">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Prostaglandin D2 is a mediator involved in the generation of inflammation</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="CRTH2">
      <data key="d0">PROTEIN</data>
      <data key="d1">CRTH2 is a receptor for Prostaglandin D2, involved in TH2-mediated inflammation in AD</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="FEVIPIPRANT">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Fevipiprant (QAW039) is a CRTH2 antagonist that failed to significantly improve AD in phase II studies</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="TEMAPIPRANT">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Temapiprant (OC000459) is a CRTH2 antagonist that failed to significantly improve AD in phase II studies</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="RANTES">
      <data key="d0">PROTEIN</data>
      <data key="d1">RANTES is a chemokine that binds to CCR4 and is produced in high amounts in AD</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="MCP1">
      <data key="d0">PROTEIN</data>
      <data key="d1">MCP1 is a chemokine that binds to CCR4 and is produced in high amounts in AD</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="CCL22">
      <data key="d0">PROTEIN</data>
      <data key="d1">CCL22 (MDC) is a chemokine that binds to CCR4 and is produced in high amounts in AD
Chemokine ligand 22 (CCL22) is a chemokine involved in the immune response and inflammation
CCL22 is a chemokine ligand that ascends in the skin during inflammation and promotes the attraction of inflammatory T cells and DC subtypes</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9,41ccc4b41bd57cf2bda4dbb6c7ae4198,6059a6e2710b7df94c6a09e5eb7b024a</data>
    </node>
    <node id="RPT193">
      <data key="d0">CHEMICAL</data>
      <data key="d1">RPT193 is a small-molecule CCR4 antagonist that blocks the recruitment of TH2 cells in allergic diseases
RPT193 is a drug being tested in a phase 1b trial for the treatment of atopic dermatitis
RPT193 is a small molecule targeting CCR4 used in the treatment of atopic dermatitis
RPT193 is a small molecule drug developed by RAPT Therapeutics, targeting the CCR4 receptor</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9,83eb9003d42977bb83fea1d123dd5ab9,e9841b88c9fab58c5175af409653da50,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="S1P">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Sphingosine 1-phosphate (S1P) is an active terminal derivative of sphingosine metabolism involved in immune cell migration
Sphingosine-1-phosphate, a signaling lipid that regulates immune cell trafficking and vascular development</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b,3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="S1PR1">
      <data key="d0">PROTEIN</data>
      <data key="d1">S1PR1 is a receptor for S1P, expressed on T cells and DCs, involved in immune cell migration
S1PR1 (Sphingosine-1-phosphate receptor 1) is a protein involved in the immune response and inflammation
S1PR1, or sphingosine 1-phosphate receptor 1, is a protein involved in immune cell migration</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9,e9841b88c9fab58c5175af409653da50,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="S1PR3">
      <data key="d0">PROTEIN</data>
      <data key="d1">S1PR3 is a receptor for S1P, expressed on DCs, involved in immune cell migration</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="S1PR4">
      <data key="d0">PROTEIN</data>
      <data key="d1">S1PR4 is a receptor for S1P, expressed on T cells and DCs, involved in immune cell migration
S1PR4, or sphingosine 1-phosphate receptor 4, is a protein involved in immune cell migration</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="S1PR5">
      <data key="d0">PROTEIN</data>
      <data key="d1">S1PR5 is a receptor for S1P, involved in immune cell migration
S1PR5, or sphingosine 1-phosphate receptor 5, is a protein involved in immune cell migration</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="FINGOLIMOD">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Fingolimod is an S1PR1,3&#8211;5 agonist approved for the therapy of multiple sclerosis</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="SIPONIMOD">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Siponimod is an S1PR1,5 agonist approved for the therapy of multiple sclerosis</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="ETRASIMOD">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Etrasimod (APD334) is a next-generation S1PR agonist that induces sustained internalization of the S1PR1 receptor
Etrasimod is a drug advancing into phase 3 clinical trials for Atopic Dermatitis
Etrasimod is a drug being advanced into phase 3 clinical trials for the treatment of atopic dermatitis
Etrasimod is a small molecule targeting S1PR1 used in the treatment of atopic dermatitis
Etrasimod is a small molecule drug developed by Arena Pharma, targeting S1PR1, S1PR4, and S1PR5 receptors</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9,83eb9003d42977bb83fea1d123dd5ab9,90f4809673ca34628b0e607908f0bf0b,e9841b88c9fab58c5175af409653da50,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="SCD-044">
      <data key="d0">CHEMICAL</data>
      <data key="d1">SCD-044 is a selective S1PR1 agonist in development for AD and/or psoriasis
SCD-044 is a small molecule drug developed by Sun Pharma, targeting the S1PR1 receptor</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="LC51-0255">
      <data key="d0">CHEMICAL</data>
      <data key="d1">LC51-0255 is a selective S1PR1 agonist in development for AD and/or psoriasis
LC51-0255 is a small molecule drug developed by LG Chem, targeting the S1PR1 receptor</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="BMS-986166">
      <data key="d0">CHEMICAL</data>
      <data key="d1">BMS-986166 is a selective S1PR1 agonist in development for AD and/or psoriasis
BMS-986166 is a small molecule drug developed by Bristol Myers Squibb, targeting the S1PR1 receptor</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="KT-474">
      <data key="d0">CHEMICAL</data>
      <data key="d1">KT-474 is a selective S1PR1 agonist in development for AD and/or psoriasis
KT-474 is a small molecule drug developed by Kymera, targeting the S1PR1 receptor</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="AKP-11">
      <data key="d0">CHEMICAL</data>
      <data key="d1">AKP-11 is a highly selective S1PR1 agonist in clinical development for psoriasis and AD</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="CHEMOTACTIC MEDIATORS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Chemotactic mediators are substances that attract cells to sites of inflammation</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="MEMORY TH2 CELL">
      <data key="d0">CELL</data>
      <data key="d1">Memory TH2 cells are a subset of T cells that remember past infections and are involved in allergic responses</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="LYMPHATIC TISSUE">
      <data key="d0">TISSUE</data>
      <data key="d1">Lymphatic tissue is part of the immune system and includes lymph nodes and other structures</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="LYMPHOCYTE">
      <data key="d0">CELL</data>
      <data key="d1">Lymphocytes are a type of white blood cell involved in the immune response</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="PERIPHERAL LYMPHOCYTE">
      <data key="d0">CELL</data>
      <data key="d1">Peripheral lymphocytes are white blood cells found in the bloodstream and tissues</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL">
      <data key="d0">CELL</data>
      <data key="d1">Immune cells are cells involved in the body's defense against infections and diseases</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="CARDIOVASCULAR TOXICITY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Cardiovascular toxicity refers to harmful effects on the heart and blood vessels</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="SPHINGOSINE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Sphingosine is a type of lipid involved in cell signaling and metabolism</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="SPHINGOSINE METABOLISM">
      <data key="d0">PATHWAY</data>
      <data key="d1">Sphingosine metabolism is the process by which sphingosine is broken down and converted into other molecules</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="MULTIPLE SCLEROSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Multiple sclerosis is a chronic autoimmune disease affecting the central nervous system
Multiple sclerosis is a disease in which the immune system eats away at the protective covering of nerves
Multiple sclerosis is a chronic autoimmune disease affecting the central nervous system</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9,423195c6b63ad0a6773374364ebf3612,8ce8c356713490cd2c680f505bcd050b</data>
    </node>
    <node id="NEURODEGENERATION">
      <data key="d0">DISEASE</data>
      <data key="d1">Neurodegeneration refers to the progressive loss of structure or function of neurons</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="PNEUMONIA">
      <data key="d0">DISEASE</data>
      <data key="d1">Pneumonia is an infection that inflames the air sacs in one or both lungs</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="ALLERGIC INFLAMMATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Allergic inflammation is the immune system's response to allergens, causing redness, swelling, and itching
Allergic inflammation is an immune response to allergens, characterized by symptoms such as swelling and redness</data>
      <data key="d2">05c97152fe02249153103be341d65b67,3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE MODULATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune modulation refers to the alteration of the immune response to achieve a desired therapeutic effect</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL MIGRATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell migration is the movement of immune cells to sites of infection or inflammationImmune cell migration is the movement of immune cells to sites of infection or injury</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="LYMPHOCYTE TRAFFICKING">
      <data key="d0">PATHWAY</data>
      <data key="d1">Lymphocyte trafficking is the movement of lymphocytes within the body to perform immune functions</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL RECRUITMENT">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell recruitment is the process by which immune cells are attracted to sites of infection or injuryImmune cell recruitment is the process of attracting immune cells to sites of infection or inflammation</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNE CELL ACTIVATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell activation is the process by which immune cells are stimulated to respond to infections or diseases</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNE CELL EMIGRATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell emigration is the movement of immune cells from lymphatic sites to other parts of the body</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL INFILTRATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell infiltration is the movement of immune cells into tissues, often associated with inflammationImmune cell infiltration is the process by which immune cells enter tissues</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNE CELL SEGREGATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell segregation is the separation of immune cells into different compartments or tissues</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL PROLIFERATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell proliferation is the rapid increase in the number of immune cells in response to infection or disease</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL DIFFERENTIATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell differentiation is the process by which immune cells develop into specialized types</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL FUNCTION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell function refers to the various activities performed by immune cells to protect the body</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL SIGNALING">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell signaling is the communication between immune cells through chemical signals</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL INTERACTION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell interaction refers to the interactions between different types of immune cells</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL REGULATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell regulation is the control of immune cell activities to maintain immune homeostasis</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL SUPPRESSION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell suppression is the inhibition of immune cell activities to prevent excessive immune responses</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL DEACTIVATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell deactivation is the process by which immune cells are turned off or suppressed</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL APOPTOSIS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell apoptosis is the programmed cell death of immune cells</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL SURVIVAL">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell survival refers to the ability of immune cells to remain alive and functional</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL HOMEOSTASIS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell homeostasis is the maintenance of a stable number and function of immune cells</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL METABOLISM">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell metabolism refers to the biochemical processes that occur within immune cells</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL ENERGY PRODUCTION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell energy production is the generation of energy within immune cells to support their functions</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL NUTRIENT UPTAKE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell nutrient uptake is the absorption of nutrients by immune cells to support their functions</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL WASTE REMOVAL">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell waste removal is the elimination of waste products by immune cells</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL DETOXIFICATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell detoxification is the process by which immune cells neutralize and eliminate toxins</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL REPAIR">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell repair is the process by which immune cells fix damage to their structures or functions</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL REGENERATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell regeneration is the process by which immune cells are renewed or replaced</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL ADAPTATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell adaptation is the ability of immune cells to adjust to changes in their environment</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL PLASTICITY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell plasticity is the ability of immune cells to change their function or phenotype</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL MEMORY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell memory is the ability of immune cells to remember past infections and respond more effectively</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL TOLERANCE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell tolerance is the ability of immune cells to avoid attacking the body's own tissues</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL EXHAUSTION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell exhaustion is the state of reduced function and responsiveness in immune cells</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL SENESCENCE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell senescence is the process by which immune cells age and lose their function</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL REJUVENATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell rejuvenation is the process by which aged immune cells regain their function</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL REPROGRAMMING">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell reprogramming is the process by which immune cells are genetically or epigenetically modified</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL ENGINEERING">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell engineering is the process of designing and creating immune cells with specific functions</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL THERAPY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell therapy is the use of immune cells to treat diseases</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL TRANSPLANTATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell transplantation is the transfer of immune cells from one individual to another</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL INFUSION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell infusion is the administration of immune cells into the bloodstream</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL INJECTION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell injection is the administration of immune cells into tissues</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL DELIVERY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell delivery is the process of transporting immune cells to specific sites in the body</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL TARGETING">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell targeting is the process of directing immune cells to specific cells or tissues</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL HOMING">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell homing is the process by which immune cells migrate to specific tissues</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNE CELL LOCALIZATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell localization is the process by which immune cells are positioned within tissues</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNE CELL RETENTION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell retention is the process by which immune cells remain in specific tissues</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNE CELL RELEASE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell release is the process by which immune cells are released from tissues</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNE CELL MOBILIZATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell mobilization is the process by which immune cells are activated and moved to sites of infection or injury</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNE CELL ADHESION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell adhesion is the process by which immune cells stick to other cells or tissues</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNE CELL DETACHMENT">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell detachment is the process by which immune cells separate from other cells or tissues</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNE CELL INVASION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell invasion is the process by which immune cells penetrate tissues</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNE CELL EXTRAVASATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell extravasation is the process by which immune cells move out of blood vessels into tissues</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNE CELL ACCUMULATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell accumulation is the buildup of immune cells in tissues</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNE CELL CLEARANCE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell clearance is the removal of immune cells from tissues</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNE CELL TURNOVER">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell turnover is the replacement of old immune cells with new ones</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNE CELL LIFESPAN">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell lifespan is the duration of time that immune cells remain functional</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNE CELL DEATH">
      <data key="d0">PATHWAY</data>
      <data key="d1">ImmuneImmune cell death is the process by which immune cells die</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNE CELL NECROSIS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell necrosis is the death of immune cells due to injury or disease</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL AUTOPHAGY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell autophagy is the process by which immune cells degrade and recycle their own components</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL PHAGOCYTOSIS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell phagocytosis is the process by which immune cells engulf and digest pathogens or debris</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL ENDOCYTOSIS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell endocytosis is the process by which immune cells take in substances from their environment</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL EXOCYTOSIS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell exocytosis is the process by which immune cells release substances into their environment</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL SECRETION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell secretion is the process by which immune cells produce and release substances</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL EXCRETION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell excretion is the process by which immune cells eliminate waste products</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL ABSORPTION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell absorption is the process by which immune cells take in nutrients or other substances</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL TRANSPORT">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell transport is the movement of immune cells within the body</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL TRAFFICKING">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell trafficking is the movement of immune cells to different parts of the body</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="IMMUNE CELL CIRCULATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune cell circulation is the movement of immune cells through the bloodstream</data>
      <data key="d2">3ce96e927d65736b305f792977fed4b9</data>
    </node>
    <node id="EPIDERMAL KERATINOCYTES">
      <data key="d0">CELL</data>
      <data key="d1">Epidermal keratinocytes are the primary type of cell found in the epidermis, the outermost layer of the skin
Epidermal Keratinocytes are skin cells that express IL-31RA and are involved in inflammation</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b,3df8535e965efb96f5094169610507ff</data>
      <data key="d3">CELL</data>
    </node>
    <node id="PERIPHERAL SENSORY NEURONS">
      <data key="d0">CELL</data>
      <data key="d1">Peripheral sensory neurons are nerve cells responsible for transmitting sensory information from the periphery to the central nervous system</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
      <data key="d3">CELL</data>
    </node>
    <node id="IL-31R&#913;">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-31 receptor alpha, a receptor that mediates the effects of IL-31</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="OSMR&#914;">
      <data key="d0">PROTEIN</data>
      <data key="d1">Oncostatin M receptor beta, a receptor subunit that pairs with IL-31R&#945; to mediate IL-31 signaling
OSMR&#946;, or oncostatin M receptor-&#946;, is a protein involved in the regulation of inflammation and immune responses</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b,f14a13d54127c3baadeb0b34d40928c9</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="TCSS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Topical corticosteroids, a class of steroid medications applied to the skin to reduce inflammation</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="PP-NRS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Peak Pruritus Numerical Rating Scale, a tool used to measure the intensity of itch
Peak Pruritus Numerical Rating Scale (PP-NRS) is a tool used to measure the intensity of itch
Pruritus Patient-Reported Outcome Numeric Rating Scale is a measure of itch severity</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b,a867a1e73cef039eb3f28e072463b838,c46e8b6ee0c29e37b7f18c42558d7a3e</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="PRURIGO NODULARIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Prurigo nodularis is a chronic skin condition characterized by itchy nodules
Prurigo Nodularis is a chronic skin disease characterized by itchy nodules</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b,c46e8b6ee0c29e37b7f18c42558d7a3e</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="VIXARELIMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Vixarelimab is a fully human antibody targeting OSMR&#946;, used to reduce pruritus in atopic dermatitis
Vixarelimab is a biologic drug developed by Kiniksa Pharma, targeting the OSMR&#946; receptor</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b,f14a13d54127c3baadeb0b34d40928c9</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="SUBSTANCE P">
      <data key="d0">PROTEIN</data>
      <data key="d1">Substance P is a neuropeptide involved in the transmission of pain and itch signals</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="NK1R">
      <data key="d0">PROTEIN</data>
      <data key="d1">Neurokinin 1 receptor, a receptor for substance P involved in the transmission of pain and itch signals
NK1R (Neurokinin 1 receptor) is a protein involved in the immune response and inflammation
NK1R, or neurokinin 1 receptor, is a protein involved in the regulation of pain and inflammation</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b,e9841b88c9fab58c5175af409653da50,f14a13d54127c3baadeb0b34d40928c9</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="MRGPRS">
      <data key="d0">PROTEIN</data>
      <data key="d1">Mas-related G protein-coupled receptors, involved in the transmission of itch signals</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="SERLOPITANT">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Serlopitant is a NK1R antagonist used to reduce pruritus in prurigo nodularis
Serlopitant is a small molecule drug developed by Menlo, targeting the NK1R receptor</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b,f14a13d54127c3baadeb0b34d40928c9</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="TRADIPITANT">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Tradipitant is a NK1R antagonist used to reduce pruritus in atopic dermatitis
Tradipitant is a small molecule drug developed by Vanda, targeting the NK1R receptor</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b,f14a13d54127c3baadeb0b34d40928c9</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="P2XR3">
      <data key="d0">PROTEIN</data>
      <data key="d1">P2X purinoreceptor 3, a cation channel involved in sensory neuron activation and associated with itch</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="BLU-5937">
      <data key="d0">CHEMICAL</data>
      <data key="d1">BLU-5937 is a selective P2X3 antagonist in development to treat chronic cough and pruritus
BLU-5937 is a small molecule drug developed by Bellus, targeting the P2X3 receptor</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b,f14a13d54127c3baadeb0b34d40928c9</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="JAK FAMILY">
      <data key="d0" />
      <data key="d1" />
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </node>
    <node id="NEURONS">
      <data key="d0">CELL</data>
      <data key="d1">Neurons are nerve cells that transmit information through electrical and chemical signals</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </node>
    <node id="NERVE ENDINGS">
      <data key="d0">CELL</data>
      <data key="d1">Nerve endings are the terminal parts of neurons where signals are transmitted to other cells</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </node>
    <node id="PHASE I TRIAL">
      <data key="d0">PATHWAY</data>
      <data key="d1">Phase I trial is the first stage of clinical testing of a new drug in humans</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </node>
    <node id="PHASE III STUDY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Phase III study is a late-stage clinical trial to confirm the effectiveness and monitor adverse reactions of a drug</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </node>
    <node id="PHASE IB STUDY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Phase Ib study is a clinical trial phase to evaluate the safety and biological activity of a drug</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </node>
    <node id="ATOMIK STUDY">
      <data key="d0">PATHWAY</data>
      <data key="d1">ATOMIK study is a clinical trial to evaluate the efficacy of a drug in patients with atopic dermatitis</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </node>
    <node id="EPIONE STUDY">
      <data key="d0">PATHWAY</data>
      <data key="d1">EPIONE study is a clinical trial to evaluate the efficacy of a drug in reducing pruritus</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </node>
    <node id="BLUEPRINT TRIAL">
      <data key="d0">PATHWAY</data>
      <data key="d1">BLUEPRINT trial is a clinical trial to explore the effect of a drug on pruritus in patients with atopic dermatitis</data>
      <data key="d2">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </node>
    <node id="SARS-COV-2">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">SARS-CoV-2 is the virus responsible for the COVID-19 pandemic</data>
      <data key="d2">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="INFLAMMATORY DENDRITIC EPIDERMAL CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Inflammatory Dendritic Epidermal Cells are involved in immune responses in the skin</data>
      <data key="d2">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
      <data key="d3">CELL</data>
    </node>
    <node id="VITILIGO">
      <data key="d0">DISEASE</data>
      <data key="d1">Vitiligo is a condition characterized by loss of skin pigmentation</data>
      <data key="d2">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="CUTANEOUS LUPUS">
      <data key="d0">DISEASE</data>
      <data key="d1">Cutaneous Lupus is a form of lupus affecting the skin</data>
      <data key="d2">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="BREPOCITINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Brepocitinib is a JAK1/TYK2 inhibitor in clinical development for treating AD
Brepocitinib is a small molecule drug developed by Pfizer, targeting JAK1/TYK2
Brepocitinib is a selective JAK inhibitor used in AD therapy
Brepocitinib is a small molecule drug targeting JAK1</data>
      <data key="d2">3df8535e965efb96f5094169610507ff,c46e8b6ee0c29e37b7f18c42558d7a3e,cccfd5ff480e281556e2210cd0e5c4b5,f14a13d54127c3baadeb0b34d40928c9</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="JAKTINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Jaktinib is a pan-JAK inhibitor in clinical development for treating AD
Jaktinib is a small molecule drug developed by Suzhou Zeigen Biopharma, targeting Pan-JAK</data>
      <data key="d2">c46e8b6ee0c29e37b7f18c42558d7a3e,f14a13d54127c3baadeb0b34d40928c9</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="ATI-1777">
      <data key="d0">CHEMICAL</data>
      <data key="d1">ATI-1777 is a JAK1/JAK3 inhibitor in clinical development for treating AD
ATI-1777 is a small molecule drug developed by Aclaris, targeting JAK1/JAK3</data>
      <data key="d2">c46e8b6ee0c29e37b7f18c42558d7a3e,f14a13d54127c3baadeb0b34d40928c9</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="CEE321">
      <data key="d0">CHEMICAL</data>
      <data key="d1">CEE321 is a pan-JAK inhibitor in clinical development for treating AD
CEE321 is a small molecule drug developed by Novartis, targeting Pan-JAK</data>
      <data key="d2">c46e8b6ee0c29e37b7f18c42558d7a3e,f14a13d54127c3baadeb0b34d40928c9</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="SHR0302">
      <data key="d0">CHEMICAL</data>
      <data key="d1">SHR0302 is a JAK1 inhibitor in clinical development for treating AD
SHR0302 is a JAK1-selective inhibitor currently in development for the treatment of atopic dermatitis
SHR0302 is a small molecule drug developed by Reistone Biopharma, targeting JAK1</data>
      <data key="d2">a867a1e73cef039eb3f28e072463b838,c46e8b6ee0c29e37b7f18c42558d7a3e,f14a13d54127c3baadeb0b34d40928c9</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="ECZEMA HERPETICUM">
      <data key="d0">DISEASE</data>
      <data key="d1">Eczema Herpeticum is a severe skin infection caused by the herpes simplex virus
Eczema herpeticum is a severe skin infection caused by the herpes simplex virus</data>
      <data key="d2">a867a1e73cef039eb3f28e072463b838,c46e8b6ee0c29e37b7f18c42558d7a3e</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="HAEMATOPOIESIS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Haematopoiesis is the process of forming blood cellular components</data>
      <data key="d2">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="CHRONIC HAND ECZEMA">
      <data key="d0" />
      <data key="d1" />
      <data key="d2">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </node>
    <node id="ALOPECIA AREATA">
      <data key="d0">DISEASE</data>
      <data key="d1">Alopecia Areata is an autoimmune disorder that causes hair loss
An autoimmune disease causing hair loss</data>
      <data key="d2">849e0980ffd6a7e1cf0b8d3d1fbacd98,c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </node>
    <node id="CYTOKINE STORM">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Cytokine Storm is a severe immune reaction in which the body releases too many cytokines into the blood too quickly</data>
      <data key="d2">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </node>
    <node id="COLONY-STIMULATING FACTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Colony-Stimulating Factors are proteins that stimulate the production of blood cells</data>
      <data key="d2">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </node>
    <node id="HORMONE RECEPTORS">
      <data key="d0">PROTEIN</data>
      <data key="d1">Hormone Receptors are proteins that bind to specific hormones and mediate their effects</data>
      <data key="d2">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </node>
    <node id="INTERFERON">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interferons are proteins released by host cells in response to the presence of pathogens</data>
      <data key="d2">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </node>
    <node id="TYPE I CYTOKINE RECEPTORS">
      <data key="d0">PROTEIN</data>
      <data key="d1">Type I Cytokine Receptors are receptors involved in the immune response</data>
      <data key="d2">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </node>
    <node id="TYPE II CYTOKINE RECEPTORS">
      <data key="d0">PROTEIN</data>
      <data key="d1">Type II Cytokine Receptors are receptors involved in the immune response</data>
      <data key="d2">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </node>
    <node id="HAND">
      <data key="d0">TISSUE</data>
      <data key="d1">The hand is the terminal part of the human arm used for grasping and holding</data>
      <data key="d2">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </node>
    <node id="VENOUS THROMBOSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Venous thrombosis is the formation of blood clots within a vein</data>
      <data key="d2">a867a1e73cef039eb3f28e072463b838</data>
    </node>
    <node id="GM-CSF">
      <data key="d0">PROTEIN</data>
      <data key="d1">GM-CSF (Granulocyte-macrophage colony-stimulating factor) is a protein involved in haematopoiesis</data>
      <data key="d2">a867a1e73cef039eb3f28e072463b838</data>
    </node>
    <node id="G-CSF">
      <data key="d0">PROTEIN</data>
      <data key="d1">G-CSF (Granulocyte colony-stimulating factor) is a protein that stimulates the bone marrow to produce granulocytes and stem cells</data>
      <data key="d2">a867a1e73cef039eb3f28e072463b838</data>
    </node>
    <node id="EPO">
      <data key="d0">PROTEIN</data>
      <data key="d1">EPO (Erythropoietin) is a hormone that regulates red blood cell production</data>
      <data key="d2">a867a1e73cef039eb3f28e072463b838</data>
    </node>
    <node id="PROS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Patient-related outcomes are measures of a patient's health status</data>
      <data key="d2">a867a1e73cef039eb3f28e072463b838</data>
    </node>
    <node id="UPPER RESPIRATORY TRACT INFECTIONS">
      <data key="d0">DISEASE</data>
      <data key="d1">Upper respiratory tract infections are infections in the upper part of the respiratory system
Upper Respiratory Tract Infections are infections that affect the nose, throat, and airways</data>
      <data key="d2">3df8535e965efb96f5094169610507ff,a867a1e73cef039eb3f28e072463b838</data>
    </node>
    <node id="TRKS">
      <data key="d0">PROTEIN</data>
      <data key="d1">Tropomyosin receptor kinases are proteins that bind neurotrophins and are involved in skin inflammation</data>
      <data key="d2">a867a1e73cef039eb3f28e072463b838</data>
    </node>
    <node id="BEN2293">
      <data key="d0">CHEMICAL</data>
      <data key="d1">BEN2293 is a TRK inhibitor in development for the treatment of atopic dermatitis
BEN2293 is a TRK inhibitor currently in a phase I/II proof-of-concept study for mild to moderate forms of atopic dermatitis
BEN2293 is a small molecule drug developed by BenevolentiAI, targeting the TRK receptor</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,a867a1e73cef039eb3f28e072463b838,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="TAUREOXYCHOLIC ACID">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Taureoxycholic acid (HY209) is an agonist of G protein-coupled receptor 19
Taureoxycholic acid (HY209) is an agonist of G protein-coupled receptor 19</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,a867a1e73cef039eb3f28e072463b838</data>
    </node>
    <node id="G PROTEIN-COUPLED RECEPTOR 19">
      <data key="d0">PROTEIN</data>
      <data key="d1">G protein-coupled receptor 19 is a receptor involved in various cellular responses
G protein-coupled receptor 19 is a receptor that HY209 acts upon</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,a867a1e73cef039eb3f28e072463b838</data>
    </node>
    <node id="NF-&#922;B">
      <data key="d0">PROTEIN</data>
      <data key="d1">NF-&#954;B (Nuclear factor kappa-light-chain-enhancer of activated B cells) is a protein complex involved in cellular responses to stimuli
Nuclear factor &#954;B is a protein complex that controls transcription of DNA, cytokine production, and cell survival
NF-&#954;B is a protein involved in the pathophysiology of AD
NF-&#954;B is a protein complex that controls transcription of DNA, cytokine production, and cell survival</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,286730b1c1f680ac465cc21d522fda0c,5ec1ebf4e260eb1f8fda8acdf06cd39e,a867a1e73cef039eb3f28e072463b838</data>
    </node>
    <node id="P38 KINASE">
      <data key="d0">PROTEIN</data>
      <data key="d1">P38 kinase is a protein involved in cellular responses to stress and inflammation
p38 kinase is a type of mitogen-activated protein kinase involved in cellular responses to stress and inflammation</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,a867a1e73cef039eb3f28e072463b838</data>
    </node>
    <node id="ANIMAL MODEL">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Animal models are non-human species used in research to understand biological processes</data>
      <data key="d2">a867a1e73cef039eb3f28e072463b838</data>
    </node>
    <node id="TH2 INFLAMMATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">TH2 inflammation is a type of immune response associated with allergic reactions and asthma</data>
      <data key="d2">a867a1e73cef039eb3f28e072463b838</data>
    </node>
    <node id="JAKI">
      <data key="d0">CHEMICAL</data>
      <data key="d1">JAK inhibitors are a class of medication that inhibit Janus kinases, used in the treatment of autoimmune diseases
Janus kinase inhibitors are a type of medication that inhibits the activity of one or more of the Janus kinase family of enzymes
JAK inhibitors are small molecules used for rapid relief in pruritus and inflammation in Atopic Dermatitis</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,90f4809673ca34628b0e607908f0bf0b,a867a1e73cef039eb3f28e072463b838</data>
    </node>
    <node id="JOINTS">
      <data key="d0">TISSUE</data>
      <data key="d1">Joints are the connections between bones that allow for movement and flexibility</data>
      <data key="d2">a867a1e73cef039eb3f28e072463b838</data>
    </node>
    <node id="ANTI-INFLAMMATORY COMPOUNDS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Anti-inflammatory compounds are substances that reduce inflammation</data>
      <data key="d2">a867a1e73cef039eb3f28e072463b838</data>
    </node>
    <node id="ANTITUMOUR DEFENCE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Antitumour defence mechanisms are biological processes that protect the body from cancer</data>
      <data key="d2">a867a1e73cef039eb3f28e072463b838</data>
    </node>
    <node id="DRUG&#8211;DRUG INTERACTIONS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Drug&#8211;drug interactions occur when the effects of one drug are altered by the presence of another drug
Drug&#8211;drug interactions occur when one drug affects the activity of another drug, potentially causing adverse effects</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,a867a1e73cef039eb3f28e072463b838</data>
    </node>
    <node id="POST-AUTHORIZATION SAFETY STUDIES">
      <data key="d0">PATHWAY</data>
      <data key="d1">Post-authorization safety studies are conducted to monitor the safety of a drug after it has been approved for use</data>
      <data key="d2">a867a1e73cef039eb3f28e072463b838</data>
    </node>
    <node id="REAL-WORLD REGISTRIES">
      <data key="d0">PATHWAY</data>
      <data key="d1">Real-world registries collect data on the use and outcomes of drugs in routine clinical practice</data>
      <data key="d2">a867a1e73cef039eb3f28e072463b838</data>
    </node>
    <node id="NEUROTROPHINS">
      <data key="d0">PROTEIN</data>
      <data key="d1">Neurotrophins are a family of proteins that promote the survival, development, and function of neurons</data>
      <data key="d2">a867a1e73cef039eb3f28e072463b838</data>
    </node>
    <node id="TRK">
      <data key="d0">PROTEIN</data>
      <data key="d1">TRK is a family of tyrosine kinase receptors involved in the development and function of the nervous system
TRK, or tropomyosin receptor kinase, is a family of receptors involved in neurotrophin signaling</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="HY209">
      <data key="d0">CHEMICAL</data>
      <data key="d1">HY209 is an agonist of G protein-coupled receptor 19, also known as Taureoxycholic acid
HY209 is a small molecule drug developed by Shaperon, targeting the GPCR19 receptor</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="CCL17/TARC">
      <data key="d0">PROTEIN</data>
      <data key="d1">CCL17, also known as TARC (thymus and activation-regulated chemokine), is a chemokine involved in the pathogenesis of atopic dermatitis</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
    </node>
    <node id="LXR&#913;">
      <data key="d0">PROTEIN</data>
      <data key="d1">Liver X receptor alpha is a nuclear receptor involved in the regulation of lipid metabolism and inflammation</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
    </node>
    <node id="LXR&#914;">
      <data key="d0">PROTEIN</data>
      <data key="d1">Liver X receptor beta is a nuclear receptor involved in the regulation of lipid metabolism and inflammation</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
    </node>
    <node id="VTP-38543">
      <data key="d0">CHEMICAL</data>
      <data key="d1">VTP-38543 is an LXR&#946; agonist used in a phase I/II study for atopic dermatitis
VTP-38543 is a small molecule drug developed by Vitae Pharma, targeting the Liver X receptor-&#946;</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="ALX 101">
      <data key="d0">CHEMICAL</data>
      <data key="d1">ALX 101 is an LXR&#946; agonist currently being tested in a phase IIb study for atopic dermatitis
ALX 101 is a small molecule drug developed by Ralexar, targeting the Liver X receptor</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="BREAST CANCER">
      <data key="d0">DISEASE</data>
      <data key="d1">Breast cancer is a type of cancer that forms in the cells of the breasts</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
    </node>
    <node id="TAPE-STRIP">
      <data key="d0">TISSUE</data>
      <data key="d1">Tape-strip specimens are non-invasive samples collected from the skin surface</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
    </node>
    <node id="TRANSCUTOLP">
      <data key="d0">CHEMICAL</data>
      <data key="d1">TranscutolP is a penetration enhancer used in topical formulations</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
    </node>
    <node id="PHASE I/II STUDY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Phase I/II study is a clinical trial phase that assesses the safety, efficacy, and optimal dosing of a drug</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
    </node>
    <node id="PHASE II TRIAL">
      <data key="d0">PATHWAY</data>
      <data key="d1">Phase II trial is a clinical trial phase that focuses on the efficacy of a drug and further evaluates its safety</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
    </node>
    <node id="PHASE IIB STUDY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Phase IIb study is a clinical trial phase that focuses on the efficacy and optimal dosing of a drug</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
    </node>
    <node id="PHASE III TRIALS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Phase III trials are clinical trial phases that confirm the efficacy of a drug, monitor side effects, and compare it to commonly used treatments</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
    </node>
    <node id="ATOPIC MARCH">
      <data key="d0">DISEASE</data>
      <data key="d1">Atopic march refers to the progression of allergic diseases such as atopic dermatitis, allergic rhinitis, and asthma
The atopic march refers to the progression of allergic diseases, which can be impacted by early intervention in Atopic Dermatitis</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,90f4809673ca34628b0e607908f0bf0b</data>
    </node>
    <node id="NEUROPSYCHIATRIC COMORBIDITIES">
      <data key="d0">DISEASE</data>
      <data key="d1">Neuropsychiatric comorbidities include mental health disorders such as anxiety and depression</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
    </node>
    <node id="NON-ATOPIC COMORBIDITIES">
      <data key="d0">DISEASE</data>
      <data key="d1">Non-atopic comorbidities are additional conditions that are not related to allergies but occur alongside atopic dermatitisNon-atopic comorbidities include conditions such as cardiovascular disorders that are not related to allergies</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="GENOTYPE">
      <data key="d0">GENE</data>
      <data key="d1">Genotype refers to the genetic constitution of an individual organism</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
    </node>
    <node id="FLUID BLOOD SAMPLES">
      <data key="d0">TISSUE</data>
      <data key="d1">Fluid blood samples are collected for analysis of various biomarkers and cells
Fluid blood samples are collected for research in Atopic Dermatitis</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">TISSUE</data>
    </node>
    <node id="SKIN BIOPSY SAMPLES">
      <data key="d0">TISSUE</data>
      <data key="d1">Skin biopsy samples are collected for histological and molecular analysis</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
    </node>
    <node id="CELLULAR SAMPLES">
      <data key="d0">TISSUE</data>
      <data key="d1">Cellular samples are collected for analysis of cell types and functions
Cellular samples are collected for research in Atopic Dermatitis</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">TISSUE</data>
    </node>
    <node id="BIOREPOSITORIES">
      <data key="d0">TISSUE</data>
      <data key="d1">Biorepositories are facilities that collect, store, and manage biological samples for research
Biorepositories collect samples like microbiome, cellular, and fluid blood samples for research in Atopic DermatitisBiorepositories collect and store biological samples for research in Atopic Dermatitis</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,90f4809673ca34628b0e607908f0bf0b</data>
    </node>
    <node id="MICROBIOME SAMPLES">
      <data key="d0">TISSUE</data>
      <data key="d1">Microbiome samples are collected to study the microorganisms present in a particular environment</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
    </node>
    <node id="TAPE-STRIP SPECIMENS">
      <data key="d0">TISSUE</data>
      <data key="d1">Tape-strip specimens are non-invasive samples collected from the skin surface for analysis
Tape-strip specimens are non-invasive samples collected for research in Atopic Dermatitis</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">TISSUE</data>
    </node>
    <node id="REGULATORY GRADE PATIENT REGISTRIES">
      <data key="d0">PATHWAY</data>
      <data key="d1">Regulatory grade patient registries are high-quality databases that collect detailed patient information for research and regulatory purposes</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
    </node>
    <node id="HIGH-QUALITY BIOREPOSITORIES">
      <data key="d0">PATHWAY</data>
      <data key="d1">High-quality biorepositories are facilities that collect, store, and manage biological samples for research</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="LONGITUDINAL PATIENT REGISTRIES">
      <data key="d0">PATHWAY</data>
      <data key="d1">Longitudinal patient registries collect patient data over an extended period to study disease progression and treatment outcomes</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
    </node>
    <node id="MULTIDIMENSIONAL MODEL">
      <data key="d0">PATHWAY</data>
      <data key="d1">Multidimensional model refers to a comprehensive framework that integrates various data types to understand complex diseases</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="NEW DRUG TARGETS">
      <data key="d0">PATHWAY</data>
      <data key="d1">New drug targets are specific molecules or pathways identified for the development of new therapies</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="THERAPEUTIC RESPONSE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Therapeutic response refers to the reaction of a patient to a particular treatmentTherapeutic response refers to</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="ADVERSE EVENTS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Adverse events are unwanted side effects or reactions to a treatment</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="BODY SURFACE AREA">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Body surface area is a measurement used to assess the extent of skin involvement in diseases like atopic dermatitis</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="TREATMENT-RELATED ADVERSE EVENTS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Treatment-related adverse events are side effects or reactions directly linked to a treatment</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="ENVIRONMENTAL INFLUENCES">
      <data key="d0">PATHWAY</data>
      <data key="d1">Environmental influences are external factors that can affect the development and progression of diseases
Environmental influences are external factors that can affect the onset and severity of Atopic Dermatitis.</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,6ada075e562abd7bd445164e9fc309b4</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="DYNAMIC IMMUNE RESPONSE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Dynamic immune response refers to the changing activity of the immune system in response to various stimuli</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="DISEASE-MODIFYING PREVENTION STRATEGY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Disease-modifying prevention strategy aims to alter the course of a disease to prevent its onset or progression</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="RISK MITIGATION STRATEGIES">
      <data key="d0">PATHWAY</data>
      <data key="d1">Risk mitigation strategies are approaches to reduce the likelihood or impact of adverse events</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="AGE OF DISEASE ONSET">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Age of disease onset refers to the age at which a patient first develops symptoms of a disease</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="CLINICAL PHENOTYPE">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Clinical phenotype refers to the observable characteristics or traits of a disease in a patient</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="ETHNIC BACKGROUNDS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Ethnic backgrounds refer to the diverse genetic and cultural heritage of patient populations</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="GENETICALLY DRIVEN EPIDERMAL BARRIER DYSFUNCTION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Genetically driven epidermal barrier dysfunction refers to skin barrier issues caused by genetic factors</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="SENSITIVE AND PERMEABLE SKIN">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Sensitive and permeable skin is a characteristic of atopic dermatitis, making it more prone to irritation and infection</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="INFANCY">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Infancy is the early stage of human development, often considered from birth to one year of age</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="PAEDIATRIC PATIENTS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Paediatric patients are children and adolescents receiving medical care</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="ELDERLY">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Elderly refers to older adults, typically aged 65 and above</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="COMPLEX GENOTYPE">
      <data key="d0">GENE</data>
      <data key="d1">Complex genotype refers to the intricate genetic makeup that contributes to the development of diseases</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">GENE</data>
    </node>
    <node id="MICROBIOME-DERIVED SIGNALS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Microbiome-derived signals are biochemical messages from the microbiome that influence host physiology and disease</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="COMPLEX PHENOTYPES">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Complex phenotypes are the diverse and multifaceted characteristics of a disease</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="ENDOTYPE-BASED STRATIFICATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Endotype-based stratification is the classification of patients based on specific biological markers to tailor treatments</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="OPTIMAL RISK&#8211;BENEFIT RATIO">
      <data key="d0">PATHWAY</data>
      <data key="d1">Optimal risk&#8211;benefit ratio refers to the balance between the positive effects of a treatment and its potential risks</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="SKIN CARE PRODUCTS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Skin care products are formulations designed to improve and protect the skin</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="PERMEABLE SKIN">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Permeable skin has a compromised barrier function, allowing easier penetration of substances</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="EARLY IDENTIFICATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Early identification refers to the timely detection of disease risk factors or early symptoms</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="DISEASE-MODIFYING PREVENTION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Disease-modifying prevention aims to alter the course of a disease to prevent its onset or progression</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="RISK FACTORS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Risk factors are characteristics or conditions that increase the likelihood of developing a disease</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="ATOPIC COMORBIDITIES">
      <data key="d0">DISEASE</data>
      <data key="d1">Atopic comorbidities are additional allergic conditions that occur alongside atopic dermatitis</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="PREVENTION STRATEGIES">
      <data key="d0">PATHWAY</data>
      <data key="d1">Prevention strategies are approaches to reduce the risk of developing a disease</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="RISK MITIGATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Risk mitigation refers to strategies to reduce the likelihood or impact of adverse events</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="LONGITUDINAL ANALYSIS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Longitudinal analysis involves studying data collected over an extended period to observe changes and trends</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="REGULATORY GRADE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Regulatory grade refers to the high-quality standards required for data and samples used in regulatory submissions</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="PATIENT REGISTRIES">
      <data key="d0">PATHWAY</data>
      <data key="d1">Patient registries are databases that collect detailed information about patients for research and clinical purposes
Patient registries collect data on patients for research and drug development in Atopic Dermatitis</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="SKIN TISSUE">
      <data key="d0">TISSUE</data>
      <data key="d1">Skin tissue is collected for histological and molecular analysis
Skin tissue is collected for research in Atopic Dermatitis</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d,90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">TISSUE</data>
    </node>
    <node id="INTEGRATED TECHNOLOGICAL PLATFORMS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Integrated technological platforms combine various technologies to facilitate research and discovery</data>
      <data key="d2">0829313703a7d2bae5436a9ee542334d</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="GUT MICROBIOME">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">The gut microbiome is involved in the pathogenesis and treatment of Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="EPITHELIAL EVENTS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Epithelial events are dynamic processes involved in the immune response in Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="ARENA PHARMACEUTICALS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Arena Pharmaceuticals is advancing etrasimod into phase 3 clinical trials for Atopic Dermatitis
Arena Pharmaceuticals is a company advancing etrasimod into phase 3 clinical trials for atopic dermatitis</data>
      <data key="d2">83eb9003d42977bb83fea1d123dd5ab9,90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="JAPAN">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Japan is a country where delgocitinib was approved for Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="HEALTH TECHNOLOGY ASSESSMENT AGENCIES">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Health technology assessment agencies influence drug development and market access in dermatology</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="THIRD-PARTY PAYERS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Third-party payers are entities that impact drug development and patient access in dermatology</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="PHARMACOVIGILANCE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Pharmacovigilance is the process of monitoring the benefit-risk ratio of drugs like JAK inhibitors in Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="PREDICTIVE BIOMARKERS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Predictive biomarkers are used for innovative molecular taxonomy and companion diagnostics in Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="PROGNOSTIC BIOMARKERS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Prognostic biomarkers are used for predicting disease outcomes and guiding treatment in Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="DRUG TARGETS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Drug targets are specific molecules or pathways identified for therapeutic intervention in Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="THERAPEUTICS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Therapeutics are drugs or treatments developed for managing Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="TRANSLATIONAL EFFORTS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Translational efforts convert scientific knowledge into drug discovery and development for Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="PRECLINICAL DEVELOPMENT">
      <data key="d0">PATHWAY</data>
      <data key="d1">Preclinical development involves testing new drugs in the lab before clinical trials in Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="CLINICAL DEVELOPMENT">
      <data key="d0">PATHWAY</data>
      <data key="d1">Clinical development involves testing new drugs in human trials for Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="COMPANION DIAGNOSTICS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Companion diagnostics are tests used alongside therapeutics to guide treatment decisions in Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="MARKET ACCESS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Market access involves the process of making new drugs available to patients, influenced by cost-effectiveness considerations</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="COST-EFFECTIVENESS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Cost-effectiveness is a consideration for third-party payers when evaluating new drugs for Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="REAL-WORLD DATA">
      <data key="d0">PATHWAY</data>
      <data key="d1">Real-world data provides evidence from actual patient experiences to support drug development in Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="PATIENT ADVOCACY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Patient advocacy involves efforts by patients to influence drug development and access in Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="SYSTEMIC THERAPY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Systemic therapy involves using drugs that affect the entire body to treat Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="TOPICAL THERAPY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Topical therapy involves applying drugs directly to the skin to treat Atopic Dermatitis
Topical therapy is used to treat AD</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd,90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="SEVERITY SCALES">
      <data key="d0">PATHWAY</data>
      <data key="d1">Severity scales are used to define the severity of Atopic Dermatitis and guide treatment decisions</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="DISEASE MODIFICATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Disease modification involves altering the course of Atopic Dermatitis to prevent progression and comorbidities</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="PHARMACEUTICAL COMPANIES">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Pharmaceutical companies develop and market new drugs for Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="DRUG DISCOVERY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Drug discovery involves identifying new compounds for treating Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="DRUG DEVELOPMENT">
      <data key="d0">PATHWAY</data>
      <data key="d1">Drug development involves the process of bringing new drugs to market for Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="EPITHELIAL PATHWAYS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Epithelial pathways are involved in the immune response and pathogenesis of Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="IMMUNOLOGICAL PATHWAYS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immunological pathways are involved in the immune response and pathogenesis of Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="MOLECULAR TAXONOMY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Molecular taxonomy involves classifying diseases based on molecular characteristics for targeted treatment in Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="TAILORED THERAPEUTICS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Tailored therapeutics are drugs specifically designed for individual patients based on molecular characteristics in Atopic Dermatitis</data>
      <data key="d2">90f4809673ca34628b0e607908f0bf0b</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="STAPHYLOCOCCUS HOMINIS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Staphylococcus hominis (S.h.) is a commensal bacterium that can help in the recovery of skin microbiome in atopic dermatitis</data>
      <data key="d2">83eb9003d42977bb83fea1d123dd5ab9</data>
    </node>
    <node id="STAPHYLOCOCCUS EPIDERMIDIS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Staphylococcus epidermidis (S.e.) is a commensal bacterium that can help in the recovery of skin microbiome in atopic dermatitis</data>
      <data key="d2">83eb9003d42977bb83fea1d123dd5ab9</data>
    </node>
    <node id="ARYL-HYDROCARBON RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Aryl-hydrocarbon receptor (AhR) is a protein targeted for intervention in the early stages of atopic dermatitis
Aryl-hydrocarbon receptor (AhR) is a ligand-activated transcriptional factor involved in the development of skin inflammation, including AD</data>
      <data key="d2">6059a6e2710b7df94c6a09e5eb7b024a,83eb9003d42977bb83fea1d123dd5ab9</data>
    </node>
    <node id="SPHINGOSINE 1-PHOSPHATE RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Sphingosine 1-phosphate receptor (S1PR) is involved in the migratory activity of T cells in atopic dermatitis</data>
      <data key="d2">83eb9003d42977bb83fea1d123dd5ab9</data>
    </node>
    <node id="C-C CHEMOKINE RECEPTOR 4">
      <data key="d0">PROTEIN</data>
      <data key="d1">C-C chemokine receptor 4 (CCR4) is involved in the migration of T cells into the skin in atopic dermatitis</data>
      <data key="d2">83eb9003d42977bb83fea1d123dd5ab9</data>
    </node>
    <node id="JANUS KINASES">
      <data key="d0">PROTEIN</data>
      <data key="d1">Janus kinases (JAKs) are involved in the signal transduction of cytokine receptors and are targeted by JAK inhibitors in atopic dermatitis</data>
      <data key="d2">83eb9003d42977bb83fea1d123dd5ab9</data>
    </node>
    <node id="TROPOMYOSIN RECEPTOR KINASE">
      <data key="d0">PROTEIN</data>
      <data key="d1">Tropomyosin receptor kinase (TRK) is involved in pathways related to nerve growth factor in atopic dermatitis
Tropomyosin receptor kinase is a receptor involved in neurotrophic signaling</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b,83eb9003d42977bb83fea1d123dd5ab9</data>
    </node>
    <node id="BRUTON TYROSINE KINASE">
      <data key="d0">PROTEIN</data>
      <data key="d1">Bruton tyrosine kinase (BTK) is involved in the signal transduction of the B cell receptor in atopic dermatitis</data>
      <data key="d2">83eb9003d42977bb83fea1d123dd5ab9</data>
    </node>
    <node id="HISTAMINE RECEPTOR 4">
      <data key="d0">PROTEIN</data>
      <data key="d1">Histamine receptor 4 (H4R) is involved in immunomodulatory mechanisms in atopic dermatitis
Histamine receptor 4 (H4R) is involved in immunomodulatory mechanisms and is widely expressed</data>
      <data key="d2">83eb9003d42977bb83fea1d123dd5ab9,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="SENSING NEURONS">
      <data key="d0">CELL</data>
      <data key="d1">Sensing neurons in the skin can be activated by multiple mediators generated during the inflammatory reaction in atopic dermatitis</data>
      <data key="d2">83eb9003d42977bb83fea1d123dd5ab9</data>
      <data key="d3">CELL</data>
    </node>
    <node id="ASAN PHARMACEUTICALS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Asan Pharmaceuticals is a company conducting studies on ASLAN004 for atopic dermatitis</data>
      <data key="d2">83eb9003d42977bb83fea1d123dd5ab9</data>
    </node>
    <node id="FORTE BIOSCIENCES">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Forte Biosciences is a company conducting clinical trials of FB-401 for atopic dermatitis</data>
      <data key="d2">83eb9003d42977bb83fea1d123dd5ab9</data>
    </node>
    <node id="OTSUKA">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Otsuka is a company conducting phase 3 studies on difamilast for atopic dermatitis</data>
      <data key="d2">83eb9003d42977bb83fea1d123dd5ab9</data>
    </node>
    <node id="RAPT THERAPEUTICS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">RAPT Therapeutics is a company conducting a phase 1b trial of RPT193 for atopic dermatitis</data>
      <data key="d2">83eb9003d42977bb83fea1d123dd5ab9</data>
    </node>
    <node id="INNATE IMMUNITY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Innate immunity is the first line of defense activated in atopic dermatitis
Innate immunity is the body's first line of defense against pathogens, involving non-specific immune responses
Innate immunity is the immune response involving non-specific defense mechanisms</data>
      <data key="d2">05c97152fe02249153103be341d65b67,83eb9003d42977bb83fea1d123dd5ab9,c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="ADAPTIVE IMMUNITY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Adaptive immunity is activated following innate immunity in atopic dermatitis, involving TH2, TH1, TH17, and TH22 responses
Adaptive immunity is the body's specific immune response to pathogens, involving the activation of lymphocytes
Adaptive immunity is the immune response involving lymphocytes</data>
      <data key="d2">05c97152fe02249153103be341d65b67,83eb9003d42977bb83fea1d123dd5ab9,c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="IMMUNOLOGICAL MARCH">
      <data key="d0">PATHWAY</data>
      <data key="d1">The immunological march is a model describing the progression of immune responses in atopic dermatitis
Immunological march is the sequence of events leading to different types of immune responses</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b,83eb9003d42977bb83fea1d123dd5ab9</data>
    </node>
    <node id="SPHINGOSINE 1-PHOSPHATE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Sphingosine 1-phosphate is a signaling molecule involved in the migration of T cells in atopic dermatitis</data>
      <data key="d2">83eb9003d42977bb83fea1d123dd5ab9</data>
    </node>
    <node id="C-C CHEMOKINE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">C-C chemokine is involved in the migration of T cells into the skin in atopic dermatitis</data>
      <data key="d2">83eb9003d42977bb83fea1d123dd5ab9</data>
    </node>
    <node id="JANUS KINASE INHIBITORS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Janus kinase inhibitors (JAKi) are used to target JAKs involved in cytokine receptor signal transduction in atopic dermatitis</data>
      <data key="d2">83eb9003d42977bb83fea1d123dd5ab9</data>
    </node>
    <node id="B CELL RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">B cell receptor is involved in the immune response in atopic dermatitis</data>
      <data key="d2">83eb9003d42977bb83fea1d123dd5ab9</data>
    </node>
    <node id="HIGH-AFFINITY IGE RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">High-affinity IgE receptor is expressed in mast cells and dendritic cells in atopic dermatitis</data>
      <data key="d2">83eb9003d42977bb83fea1d123dd5ab9</data>
    </node>
    <node id="ANTI-INFLAMMATORY CYTOKINES">
      <data key="d0">PROTEIN</data>
      <data key="d1">Anti-inflammatory cytokines are generated by increasing cAMP levels through PDE4 inhibitors in atopic dermatitis
Anti-inflammatory cytokines like IL-37 are involved in reducing inflammation in AD</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd,83eb9003d42977bb83fea1d123dd5ab9</data>
    </node>
    <node id="IL-31 RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-31 receptor (IL-31R) is involved in the generation of itching during inflammatory reactions</data>
      <data key="d2">e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="NEUROKININ 1 RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Neurokinin 1 receptor (NK1R) is involved in the generation of itching during inflammatory reactions
Neurokinin 1 receptor is a protein involved in various physiological processes</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="PURINORECEPTOR 3">
      <data key="d0">PROTEIN</data>
      <data key="d1">Purinoreceptor 3 (P2X3) is involved in the generation of itching during inflammatory reactions
Purinoreceptor 3 is a receptor involved in the response to extracellular ATP</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="LIVER X RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Liver X receptor (LXR) is involved in cholesterol metabolism and inflammation
</data>
      <data key="d2">e9841b88c9fab58c5175af409653da50,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="MEMBRANE FORM OF IGE">
      <data key="d0">PROTEIN</data>
      <data key="d1">Membrane form of IgE (mIgE) is involved in allergic reactions</data>
      <data key="d2">e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="OX40 LIGAND">
      <data key="d0">PROTEIN</data>
      <data key="d1">OX40 ligand (OX40L) is a costimulatory molecule involved in T cell activation
OX40 ligand is a costimulatory molecule involved in T cell activation</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="T HELPER CELL">
      <data key="d0">CELL</data>
      <data key="d1">T helper cell (TH cell) is a type of T cell that plays a crucial role in the immune response</data>
      <data key="d2">e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="THYMIC STROMAL LYMPHOPOIETIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Thymic stromal lymphopoietin (TSLP) is involved in the initiation of allergic inflammation
Thymic stromal lymphopoietin is a cytokine involved in the development of allergic inflammation
Thymic stromal lymphopoietin (TSLP) is a cytokine involved in the regulation of immune responses and inflammation</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b,5f37466ca41c9b8b06ed8be0303d49f2,e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="CLS-001">
      <data key="d0">CHEMICAL</data>
      <data key="d1">CLS-001, also known as omiganan, is a cell membrane enhancer used in the treatment of atopic dermatitis
CLS-001 is a small molecule with omiganan activity used in atopic dermatitis treatment</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,e9841b88c9fab58c5175af409653da50</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="ATX201">
      <data key="d0">CHEMICAL</data>
      <data key="d1">ATx201, also known as niclosamide, has protonophore activity and is used in the treatment of atopic dermatitis
Atx201 is a small molecule with niclosamide activity used in atopic dermatitis treatment</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,e9841b88c9fab58c5175af409653da50</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="FB825">
      <data key="d0">CHEMICAL</data>
      <data key="d1">FB825, also known as anti-C&#949;mX, is a biologic injection targeting mIgE used in the treatment of atopic dermatitis</data>
      <data key="d2">e9841b88c9fab58c5175af409653da50</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="TREG CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Treg cells (Regulatory T cells) are a type of T cell involved in maintaining immune tolerance and preventing autoimmune disease</data>
      <data key="d2">e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="P2X3">
      <data key="d0">PROTEIN</data>
      <data key="d1">P2X3 (Purinoreceptor 3) is a protein involved in the immune response and inflammation
P2X3, or purinoreceptor 3, is a protein involved in the regulation of pain and inflammation</data>
      <data key="d2">e9841b88c9fab58c5175af409653da50,f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="LXR">
      <data key="d0">PROTEIN</data>
      <data key="d1">LXR (Liver X receptor) is a protein involved in the regulation of cholesterol, fatty acid, and glucose homeostasis</data>
      <data key="d2">e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="TH CELL">
      <data key="d0">CELL</data>
      <data key="d1">TH cell (T helper cell) is a type of T cell involved in the immune response and inflammation</data>
      <data key="d2">e9841b88c9fab58c5175af409653da50</data>
    </node>
    <node id="LEO 152020/JW1601">
      <data key="d0">CHEMICAL</data>
      <data key="d1">LEO 152020/JW1601 is a small molecule drug developed by LEO Pharma, targeting the H4R receptor</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="AKP-19">
      <data key="d0">CHEMICAL</data>
      <data key="d1">AKP-19 is a small molecule drug developed by Akaal Pharma, targeting the S1PR1 receptor</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="DRM02">
      <data key="d0">CHEMICAL</data>
      <data key="d1">DRM02 is a small molecule drug developed by Dermira, targeting the PDE4 enzyme</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="HEMAY-808">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Hemay-808 is a small molecule drug developed by Tianjin Hemay Pharmaceutical, targeting the PDE4 enzyme</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="PF-07038124">
      <data key="d0">CHEMICAL</data>
      <data key="d1">PF-07038124 is a small molecule drug developed by Pfizer, targeting the PDE4 enzyme</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="GPCR19">
      <data key="d0">PROTEIN</data>
      <data key="d1">GPCR19, or G protein-coupled receptor 19, is a protein involved in various cellular signaling pathways</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="LIVER X RECEPTOR-&#914;">
      <data key="d0">PROTEIN</data>
      <data key="d1">Liver X receptor-&#946; is a nuclear receptor involved in the regulation of cholesterol, fatty acid, and glucose homeostasis</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="PAN-JAK">
      <data key="d0">PROTEIN</data>
      <data key="d1">Pan-JAK refers to the family of Janus kinases involved in the regulation of immune responses</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT04081350">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving Treg cells</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT03517566">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving Adriforant</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT04203836">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving LEO 152020/JW1601</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT04271514">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving RPT193</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT04162769">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving Etrasimod</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT04684485">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving SCD-044</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT03038711">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving BMS-986166</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT04772885">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving KT-474</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT03394677">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving Lotamilast</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT02950922">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving Lotamilast</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT02945657">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving Difamilast</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT01993420">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving DRM02</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT01037881">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving LEO 29102</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT04156191">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving Roflumilast</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT04352595">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving Hemay-808</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT04664153">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving PF-07038124</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT04737304">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving BEN2293</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT04530643">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving HY209</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT02655679">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving VTP-38543</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT03859986">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving ALX 101</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT03989349">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving Nemolizumab</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT03985943">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving Nemolizumab</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT03816891">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving Vixarelimab</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT02975206">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving Serlopitant</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT03568331">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving Tradipitant</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT04693195">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving BLU-5937</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT03725722">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving Delgocitinib</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT03745638">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving Ruxolitinib</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT03745651">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving Ruxolitinib</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT03903822">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving Brepocitinib</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT04598269">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving ATI-1777</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT04612062">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving CEE321</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT04539639">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving Jaktinib</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT04717310">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving SHR0302</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT03952559">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving Baricitinib</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT03646604">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving Upadacitinib</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT03627767">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving Abrocitinib</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="NCT04162899">
      <data key="d0">DISEASE</data>
      <data key="d1">Clinical trial identifier for a study involving SHR0302</data>
      <data key="d2">f14a13d54127c3baadeb0b34d40928c9</data>
    </node>
    <node id="ONCOSTATIN M RECEPTOR-&#914;">
      <data key="d0">PROTEIN</data>
      <data key="d1">Oncostatin M receptor-&#946; is a protein involved in the signaling of oncostatin M</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="SPHINGOSINE 1-PHOSPHATE RECEPTOR 1">
      <data key="d0">PROTEIN</data>
      <data key="d1">Sphingosine 1-phosphate receptor 1 is a receptor involved in immune cell trafficking</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="REGULATORY T CELL">
      <data key="d0">CELL</data>
      <data key="d1">Regulatory T cell is a type of T cell involved in maintaining immune tolerance</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
      <data key="d3">CELL</data>
    </node>
    <node id="BIOLOGIC THERAPIES">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Biologic therapies are treatments using antibodies or other biological products to target specific pathways</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="EXPOSOMAL FACTORS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Exposomal factors are exogenous and environmental factors that influence the human body and immune system</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="BACTERIOTHERAPY">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Bacteriotherapy is the use of living bacteria to influence the microbiome composition</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="CATIONIC HOST DEFENCE PEPTIDES">
      <data key="d0">PROTEIN</data>
      <data key="d1">Cationic host defence peptides are short peptides with antibacterial, antifungal, and antiviral properties</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="EOSINOPHILIC ASTHMA">
      <data key="d0">DISEASE</data>
      <data key="d1">Eosinophilic asthma is a subtype of asthma characterized by eosinophilic infiltration of the lungs</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="AEROALLERGENS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Aeroallergens are airborne particles that can cause allergic reactions</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="EXOTOXINS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Exotoxins are toxins released by bacteria that can affect other bacteria or the host</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="CHEMOTACTIC FACTORS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Chemotactic factors are mediators that lead to the migration and attraction of cellsChemotactic factors are mediators that lead to the migration and attraction of cells)&lt;|COMPLETE|&gt;</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="ABBVIE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">AbbVie is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="ALLMIRAL">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Allmiral is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="ANAPTYSBIO">
      <data key="d0">CHEMICAL</data>
      <data key="d1">AnaptysBio is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="ARENA">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Arena is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="ASANA BIOSCIENCES">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Asana Biosciences is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="BAYER HEALTH">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Bayer Health is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="BIOVERSYS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">BioVerSys is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="B&#214;HRINGER-INGELHEIM">
      <data key="d0">CHEMICAL</data>
      <data key="d1">B&#246;hringer-Ingelheim is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="BRISTOL MYERS SQUIBB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Bristol Myers Squibb is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="DOMAIN THERAPEUTICS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Domain Therapeutics is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="GALAPAGOS/MORPHOSYS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Galapagos/MorphoSys is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="GALDERMA">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Galderma is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="GLENMARK">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Glenmark is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="GSK">
      <data key="d0">CHEMICAL</data>
      <data key="d1">GSK is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="INCYTE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Incyte is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="IQVIA">
      <data key="d0">CHEMICAL</data>
      <data key="d1">IQVIA is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="JANSSEN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Janssen is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="KIRIN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Kirin is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="LEO PHARMA">
      <data key="d0">CHEMICAL</data>
      <data key="d1">LEO Pharma is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="LG CHEM">
      <data key="d0">CHEMICAL</data>
      <data key="d1">LG Chem is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="LILLY">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Lilly is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="L&#8217;OR&#201;AL">
      <data key="d0">CHEMICAL</data>
      <data key="d1">L&#8217;Or&#233;al is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="MENLOTX">
      <data key="d0">CHEMICAL</data>
      <data key="d1">MenloTx is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="NOVARTIS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Novartis is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="VIFOR PHARMA">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Vifor Pharma is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="PFIZER">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Pfizer is a pharmaceutical company involved in the development of biologic therapies
Pfizer is a pharmaceutical company involved in the development and testing of new drugs</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b,423195c6b63ad0a6773374364ebf3612</data>
    </node>
    <node id="PIERRE FABRE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Pierre Fabre is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="SANOFI/REGENERON">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Sanofi/Regeneron is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="UCB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">UCB is a pharmaceutical company involved in the development of biologic therapies</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="DAVOS BIOSCIENCES">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Davos Biosciences is a non-profit biotech company within the International K&#252;hne Foundation</data>
      <data key="d2">08e39958b85d84950ab7173daab9111b</data>
    </node>
    <node id="LYMPHOCYTES">
      <data key="d0">CELL</data>
      <data key="d1">Lymphocytes are a type of white blood cell that infiltrate the skin in Atopic Dermatitis patients.
Lymphocytes are a type of white blood cell involved in the immune response
Lymphocytes are white blood cells involved in the adaptive immune response
Lymphocytes are a type of white blood cell that primarily express TRAIL</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e,6ada075e562abd7bd445164e9fc309b4,c525762bb827485bceeb9f09bb4bcfe0,d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="RASH">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Rash is a common symptom of Atopic Dermatitis, characterized by red, inflamed skin.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="EROSIONS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Erosions are areas of skin damage that can occur in Atopic Dermatitis patients due to scratching.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="PLAQUES">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Plaques are thickened areas of skin that are common in Atopic Dermatitis patients.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="ELBOWS">
      <data key="d0">TISSUE</data>
      <data key="d1">The elbows are one of the common sites affected by Atopic Dermatitis plaques.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="KNEES">
      <data key="d0">TISSUE</data>
      <data key="d1">The knees are one of the common sites affected by Atopic Dermatitis plaques.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="FACE">
      <data key="d0">TISSUE</data>
      <data key="d1">The face is one of the common sites affected by Atopic Dermatitis plaques.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="NECK">
      <data key="d0">TISSUE</data>
      <data key="d1">The neck is one of the common sites affected by Atopic Dermatitis plaques.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="WRISTS">
      <data key="d0">TISSUE</data>
      <data key="d1">The wrists are one of the common sites affected by Atopic Dermatitis plaques.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="FOOD ALLERGIES">
      <data key="d0">DISEASE</data>
      <data key="d1">Food Allergies are conditions that children with Atopic Dermatitis may develop.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="COMMON COLD">
      <data key="d0">DISEASE</data>
      <data key="d1">The common cold is a condition that children with Atopic Dermatitis have a 75% risk of developing.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="VESICLES">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Vesicles are small blisters seen in infantile Atopic Dermatitis.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="EXCORIATIONS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Excoriations are scratch marks seen in infantile Atopic Dermatitis.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="SEROUS EXUDATE">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Serous Exudate is a clear fluid discharge seen in infantile Atopic Dermatitis.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="CHEEKS">
      <data key="d0">TISSUE</data>
      <data key="d1">The cheeks are one of the common sites affected by infantile Atopic Dermatitis.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="SCALP">
      <data key="d0">TISSUE</data>
      <data key="d1">The scalp is one of the common sites affected by infantile Atopic Dermatitis.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="HANDS">
      <data key="d0">TISSUE</data>
      <data key="d1">The hands are commonly affected by chronic hand eczema in adult Atopic Dermatitis.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="HEAD&#8211;NECK DERMATITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Head&#8211;Neck Dermatitis is a form of Atopic Dermatitis affecting the upper trunk, shoulders, and scalp in adults.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="PRO-FLG">
      <data key="d0">PROTEIN</data>
      <data key="d1">Pro-FLG is a polymer that is dephosphorylated and proteolytically cleaved to form FLG monomers.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="INFANTILE ATOPIC DERMATITIS">
      <data key="d0" />
      <data key="d1" />
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="CHILDHOOD ATOPIC DERMATITIS">
      <data key="d0" />
      <data key="d1" />
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="ADULT ATOPIC DERMATITIS">
      <data key="d0" />
      <data key="d1" />
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="GENETICS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Genetics refers to the study of genes and their roles in inheritance, which is a factor in the onset and severity of Atopic Dermatitis.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="SKIN BARRIER">
      <data key="d0">PATHWAY</data>
      <data key="d1">The skin barrier is a critical component in the pathophysiology of Atopic Dermatitis, involving abnormalities that contribute to the disease.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="INTERLEUKINS">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukins are a group of cytokines that play a role in the immune response and are involved in the pathophysiology of Atopic Dermatitis.
Interleukins are cytokines controlled by cibinqo</data>
      <data key="d2">286730b1c1f680ac465cc21d522fda0c,6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="BIOLOGIC MEDICATIONS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Biologic medications are a class of drugs derived from living organisms, used in various stages of approval or development for treating Atopic Dermatitis.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="SMALL MOLECULES">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Small molecules are a type of non-biologic targeted therapy that have emerged as treatment options for Atopic Dermatitis.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="PERSONALIZED MEDICINE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Personalized medicine involves tailoring medical treatment to the individual characteristics of each patient, which is a potential approach for Atopic Dermatitis.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="PSYCHOLOGICAL FACTORS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Psychological factors are elements that can influence the onset and severity of Atopic Dermatitis.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="DRUGS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Drugs refer to substances used to treat or manage Atopic Dermatitis, including both biologic and non-biologic therapies.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="DNA METHYLATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">DNA methylation is an epigenetic mechanism that can influence gene expression, including the FLG gene associated with Atopic Dermatitis.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="FLG GENE">
      <data key="d0">GENE</data>
      <data key="d1">The FLG gene encodes the protein filaggrin, which is crucial for skin barrier function and is associated with Atopic Dermatitis.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="FLG NULL MUTATIONS">
      <data key="d0">GENE</data>
      <data key="d1">FLG null mutations are genetic alterations that result in a lack of functional filaggrin protein, increasing the risk of Atopic Dermatitis.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="FLG COPY NUMBER VARIATIONS">
      <data key="d0">GENE</data>
      <data key="d1">FLG copy number variations are changes in the number of copies of the FLG gene, which can affect filaggrin levels and Atopic Dermatitis risk.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="SKIN MICROORGANISMS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Skin microorganisms are part of the skin's microbiome and can influence the development and severity of Atopic Dermatitis.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="TOPICAL TREATMENTS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Topical treatments are medications applied directly to the skin to manage Atopic Dermatitis symptoms.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="SYSTEMIC TREATMENTS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Systemic treatments are medications that affect the entire body and are used to manage Atopic Dermatitis symptoms.
Systemic treatments are part of the treatment strategy for AD</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd,6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="STRATUM CORNEUM FORMATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Stratum corneum formation is the process of creating the outermost layer of the skin, which is crucial for barrier function and is affected in Atopic Dermatitis.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="EPIDERMAL COMPLEX">
      <data key="d0">TISSUE</data>
      <data key="d1">The epidermal complex includes various components of the skin's outer layer, which are crucial for barrier function and are affected in Atopic Dermatitis.</data>
      <data key="d2">6ada075e562abd7bd445164e9fc309b4</data>
    </node>
    <node id="FLG">
      <data key="d0">PROTEIN</data>
      <data key="d1">FLG, or filaggrin, is a protein crucial for the development and maintenance of the skin barrier
Filaggrin (FLG) is a gene whose expression is restored by coal tar binding to AhR
Filaggrin gene, involved in skin barrier function
Filaggrin (FLG) is a protein downregulated by IL-22 in keratinocytes</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd,41ccc4b41bd57cf2bda4dbb6c7ae4198,6059a6e2710b7df94c6a09e5eb7b024a,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </node>
    <node id="SPINK">
      <data key="d0">PROTEIN</data>
      <data key="d1">SPINK, or serine protease inhibitor Kazal-type, is a protein involved in skin barrier function</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </node>
    <node id="CLAUDINS">
      <data key="d0">PROTEIN</data>
      <data key="d1">Claudins are proteins that play a role in the formation of tight junctions in the skin barrier</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </node>
    <node id="&#916;-TOXIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">&#948;-toxin is a toxin produced by Staphylococcus aureus that can trigger mast cells</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </node>
    <node id="&#913;-TOXIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">&#945;-toxin is a toxin produced by Staphylococcus aureus that can damage host cells</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </node>
    <node id="IL-8">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-8 is a cytokine involved in the immune response and inflammation
Interleukin-8 (IL-8) is a pro-inflammatory cytokine whose levels are reduced by PLGA-based nanoparticles loaded with CsA
IL-8 is a chemokine involved in the recruitment of neutrophils to sites of inflammation</data>
      <data key="d2">05c97152fe02249153103be341d65b67,41ccc4b41bd57cf2bda4dbb6c7ae4198,bddc3b1a7f098e71f0aa64adec047124</data>
    </node>
    <node id="MIP-1&#913;">
      <data key="d0">PROTEIN</data>
      <data key="d1">Macrophage inflammatory protein-1&#945; (MIP-1&#945;) is a chemokine involved in the immune response and inflammation</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </node>
    <node id="MIP-1&#914;">
      <data key="d0">PROTEIN</data>
      <data key="d1">Macrophage inflammatory protein-1&#946; (MIP-1&#946;) is a chemokine involved in the immune response and inflammation</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </node>
    <node id="MCP-1">
      <data key="d0">PROTEIN</data>
      <data key="d1">Monocyte chemoattractant protein-1 (MCP-1) is a chemokine involved in the immune response and inflammation
Monocyte chemoattractant protein-1, involved in the recruitment of monocytes to sites of injury and inflammation</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198,a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="KLK7">
      <data key="d0">PROTEIN</data>
      <data key="d1">Kallikrein 7 (KLK7) is a serine protease involved in skin barrier function</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </node>
    <node id="STAT 6">
      <data key="d0">PROTEIN</data>
      <data key="d1">Signal transducer and activator of transcription 6 (STAT 6) is a protein involved in the immune response</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </node>
    <node id="CTLA4">
      <data key="d0">PROTEIN</data>
      <data key="d1">Cytotoxic T-lymphocyte-associated protein 4 (CTLA4) is a protein involved in the immune response
CTLA4 is a gene that encodes the cytotoxic T-lymphocyte-associated protein 4, involved in the development of atopic dermatitis (AD)</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198,6059a6e2710b7df94c6a09e5eb7b024a</data>
    </node>
    <node id="POLLUTION">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Pollution refers to harmful substances in the environment that can affect health</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </node>
    <node id="SOAP">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Soap is a chemical substance used for cleaning that can affect the skin barrier</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </node>
    <node id="PERIPHERAL BLOOD LYMPHOCYTES">
      <data key="d0">CELL</data>
      <data key="d1">Peripheral blood lymphocytes are immune cells found in the bloodstream</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </node>
    <node id="NA&#207;VE T CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Na&#239;ve T cells are immature T cells that have not yet encountered an antigen
Na&#239;ve T cells are immature T cells that are primed by CD27:CD70 signaling
Na&#239;ve T cells are T lymphocytes that have not yet encountered their specific antigen</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3,41ccc4b41bd57cf2bda4dbb6c7ae4198,4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="SERINE PROTEASE">
      <data key="d0">PROTEIN</data>
      <data key="d1">Serine protease is an enzyme that cleaves peptide bonds in proteins</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </node>
    <node id="KALLIKREIN 7">
      <data key="d0">PROTEIN</data>
      <data key="d1">Kallikrein 7 (KLK7) is a serine protease involved in skin barrier function</data>
      <data key="d2">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </node>
    <node id="ROSEMONAS MUCOSA">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Rosemonas mucosa is a Gram-negative bacterium found in the skin microbiome of AD patients</data>
      <data key="d2">6059a6e2710b7df94c6a09e5eb7b024a</data>
    </node>
    <node id="OMEGANAN PENTACHLORIDE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Omeganan pentachloride (CLS-001) is a synthetic antimicrobial cationic peptide undergoing clinical testing as a topical treatment for managing dysbiosis in AD</data>
      <data key="d2">6059a6e2710b7df94c6a09e5eb7b024a</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="KBL69">
      <data key="d0">CHEMICAL</data>
      <data key="d1">KBL69 is a microbiome modifier designed for oral use currently in phase I trials for AD treatment</data>
      <data key="d2">6059a6e2710b7df94c6a09e5eb7b024a</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="IMMUNE CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Various types of immune cells work together in specific locations and at specific times in the inflamed skin of AD patients</data>
      <data key="d2">6059a6e2710b7df94c6a09e5eb7b024a</data>
    </node>
    <node id="NATURAL KILLER CELL">
      <data key="d0">CELL</data>
      <data key="d1">A type of immune cell involved in the body's defense against tumors and virally infected cells</data>
      <data key="d2">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </node>
    <node id="IL-1R">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-1 receptor, involved in inflammation and immune response</data>
      <data key="d2">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </node>
    <node id="ITCHINESS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">A common symptom in inflammatory skin conditions</data>
      <data key="d2">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </node>
    <node id="ITEPEKIMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">An IL-33 inhibitor</data>
      <data key="d2">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </node>
    <node id="IL-37">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-37, involved in inflammation and immune response
IL-37 is an anti-inflammatory cytokine within the IL-1 family, with lower levels observed in children with AD</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="IL-4R">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-4 receptor, a common receptor chain between IL-13 and IL-4
IL-4R is a receptor that encourages the signaling of IL-4 and IL-13
IL-4R is a receptor involved in the pathophysiology of AD</data>
      <data key="d2">286730b1c1f680ac465cc21d522fda0c,2cec06c4d46f5ff9ee936a78d8b077cd,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="FOLLICULITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Inflammation of hair follicles, often resulting in red, bumpy skin</data>
      <data key="d2">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </node>
    <node id="UPPER-RESPIRATORY-TRACT INFECTIONS">
      <data key="d0">DISEASE</data>
      <data key="d1">Infections affecting the upper respiratory tract, including the nose, throat, and sinuses</data>
      <data key="d2">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </node>
    <node id="TH1 CELL">
      <data key="d0">CELL</data>
      <data key="d1">A type of T cell involved in the immune response, particularly in the formation of Th17 and Th2 cells</data>
      <data key="d2">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </node>
    <node id="PAIN">
      <data key="d0">SYMPTOM</data>
      <data key="d1">A common symptom in inflammatory skin conditions</data>
      <data key="d2">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </node>
    <node id="IL-13R1">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-13R1 is a receptor for IL-13 involved in the signaling pathway</data>
      <data key="d2">3df8535e965efb96f5094169610507ff</data>
    </node>
    <node id="IL-13R2">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-13R2 is a receptor for IL-13 involved in the signaling pathway</data>
      <data key="d2">3df8535e965efb96f5094169610507ff</data>
    </node>
    <node id="EOSINOPHILIC ESOPHAGITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Eosinophilic Esophagitis is an atopic disease characterized by eosinophil accumulation in the esophagus
Eosinophilic esophagitis is a type of gastrointestinal tract fibrosis
Eosinophilic esophagitis is a chronic immune system disease in which eosinophils build up in the esophagus
Eosinophilic esophagitis (EoE) is a chronic immune system disease in which eosinophils build up in the esophagus, leading to inflammation and difficulty swallowing</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,3df8535e965efb96f5094169610507ff,5f37466ca41c9b8b06ed8be0303d49f2,df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="IL5R">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL5R is a receptor for IL-5 involved in the signaling pathway</data>
      <data key="d2">3df8535e965efb96f5094169610507ff</data>
    </node>
    <node id="CUTANEOUS PERIPHERAL NERVES">
      <data key="d0">TISSUE</data>
      <data key="d1">Cutaneous Peripheral Nerves are nerves in the skin that express IL-31RA and are involved in pruritus</data>
      <data key="d2">3df8535e965efb96f5094169610507ff</data>
    </node>
    <node id="IL-31RA">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-31RA is a receptor for IL-31 involved in the signaling pathway</data>
      <data key="d2">3df8535e965efb96f5094169610507ff</data>
    </node>
    <node id="JAK/STAT">
      <data key="d0">PATHWAY</data>
      <data key="d1">JAK/STAT is a signaling pathway involved in immune function and homeostasis</data>
      <data key="d2">3df8535e965efb96f5094169610507ff</data>
    </node>
    <node id="ECZEMATOUS PLAQUES">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Eczematous Plaques are areas of inflamed, itchy, and red skin, often seen in eczema and AD</data>
      <data key="d2">3df8535e965efb96f5094169610507ff</data>
    </node>
    <node id="TREGS">
      <data key="d0">CELL</data>
      <data key="d1">Regulatory T-cells (Tregs) are a subset of T-cells involved in maintaining immune tolerance
Regulatory T cells (Tregs) are a component of the immune system that suppress immune responses of other cells
Tregs, or regulatory T cells, are a subset of T cells that maintain immune tolerance and prevent autoimmune disease</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd,7c13f41d7349d9d2e56c36e00c0ca2d9,d2c44662af9752fc9f82c86121ede7c0</data>
      <data key="d3">CELL</data>
    </node>
    <node id="GBR830">
      <data key="d0">CHEMICAL</data>
      <data key="d1">GBR830 is an anti-OX40 monoclonal IgG1 antibody that has passed phase IIa testing</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="IL-18R&#913;">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-18R&#945; is a receptor with high affinity for IL-18</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="TOPICAL CALCINEURIN INHIBITORS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Topical calcineurin inhibitors (TCIs) are used for anti-inflammatory therapy in AD</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="PLAQUE PSORIASIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Plaque psoriasis is a chronic autoimmune skin disease treated with secukinumab
Plaque psoriasis is a chronic autoimmune condition that causes raised, red, scaly patches on the skinPlaque psoriasis, a disease treated with TNF inhibitors</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd,516e41e96d2e72d45bf1e2c69da7f18a</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="NANOPARTICLE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Nanoparticles are used in novel drug delivery systems for AD treatment</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="LIPOSOME">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Liposomes are used in novel drug delivery systems for AD treatment</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="PATCH">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Patches are used in novel drug delivery systems for AD treatment</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="NANOTECHNOLOGY">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Nanotechnology is used to develop novel drug delivery systems for AD treatment
Nanotechnology offers a method for treating various skin conditions, including AD, psoriasis, eczema, and cancer</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd,8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="BIOLOGICAL AGENTS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Biological agents are used in systemic therapy for AD</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="SYNTHETIC ANTI-INFLAMMATORY CYTOKINES">
      <data key="d0">PROTEIN</data>
      <data key="d1">Synthetic anti-inflammatory cytokines are potential future treatments for AD</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="IMMUNE PATHWAYS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune pathways are involved in the development and treatment of AD</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="INFLAMMATORY PROCESSES">
      <data key="d0">PATHWAY</data>
      <data key="d1">Inflammatory processes are targeted in the treatment of AD</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="SKIN INFECTIONS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Skin infections are a complication of AD that require treatment</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="PREVENTIVE MEASURES">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Preventive measures are part of the treatment strategy for AD</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="SKINCARE ROUTINES">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Skincare routines are part of the treatment strategy for AD</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="TOPICAL SOLUTIONS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Topical solutions are part of the treatment strategy for AD</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="COMBINED THERAPY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Combined therapy is used to improve treatment efficacy and safety in ADCombined therapy is used to improve AD treatment</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="FORMULATION EFFICACY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Formulation efficacy is an important consideration in AD treatmentFormulation efficacy is a focus in developing AD treatments</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="ADVERSE EFFECTS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Adverse effects are minimized in developing AD treatmentsAdverse effects are minimized in AD treatment</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="TREATMENT SAFETY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Treatment safety is a focus in developing AD treatmentsTreatment safety is an important consideration in AD management</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="MULTI-TARGETED STRATEGY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">A multi-targeted strategy is used in the management and therapy of ADA multi-targeted strategy is used in AD management</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="CARETAKER AWARENESS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Caretaker awareness is important in AD managementCaretaker awareness is important in the management of AD</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="PATIENT AWARENESS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Patient awareness is important in the management of ADPatient awareness is important in AD management</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="ECONOMIC IMPACT">
      <data key="d0">SYMPTOM</data>
      <data key="d1">The economic impact of AD treatments is a significant considerationThe economic impact of AD treatments is an important consideration</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="AFFORDABILITY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Affordability of AD treatments is a significant considerationAffordability of AD treatments is an important consideration</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="CHRONIC NATURE">
      <data key="d0">SYMPTOM</data>
      <data key="d1">The chronic nature of AD affects treatment strategies and considerationsThe chronic nature of AD affects treatment strategies</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="LONG-TERM SAFETY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Long-term safety data are needed for AD treatments</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="RAPID ITCH RELIEF">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Rapid itch relief is a benefit of JAK inhibitors in AD treatment</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="CLINICAL IMPROVEMENTS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Clinical improvements are measured in AD treatment studies</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="PHASE-3 TRIALS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Phase-3 trials are conducted to test the efficacy and safety of AD treatments</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="PHASE-II EXPERIMENT">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Phase-II experiments are conducted to test the efficacy and safety of AD treatments</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="PHASE IIA TESTING">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Phase IIa testing is conducted to test the efficacy and safety of AD treatments</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="FDA AUTHORIZATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">FDA authorization is required for the use of new AD treatments</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="MANUFACTURING AND MARKETING APPROVAL">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Manufacturing and marketing approval is required for new AD treatments</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="BASELINE SERUM LEVELS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Baseline serum levels are measured in AD treatment studies</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="RESPONDER">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Responders are patients who show improvement with AD treatment</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="NONRESPONDER">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Nonresponders are patients who do not show improvement with AD treatment</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="THERAPEUTIC APPROACH">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Therapeutic approaches are strategies used to treat AD</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="TREATMENT STRATEGIES">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Treatment strategies are plans for managing and treating AD</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="NOVEL DRUG DELIVERY SYSTEM">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Novel drug delivery systems are used to improve AD treatment</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="SPECIFIC DELIVERY SYSTEMS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Specific delivery systems are used to improve AD treatment</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="CONVENTIONAL SYSTEMIC THERAPIES">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Conventional systemic therapies are used to treat AD</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="NOVEL SYSTEMIC MEDICATIONS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Novel systemic medications are used to treat AD</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="BIOLOGICAL DRUGS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Biological drugs are used to treat AD</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="MODERATE TO SEVERE AD">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Moderate to severe AD requires more intensive treatment</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="SAFETY PROFILE">
      <data key="d0">SYMPTOM</data>
      <data key="d1">The safety profile of AD treatments is an important consideration</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="EFFICACY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">The efficacy of AD treatments is an important consideration</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="COST">
      <data key="d0">SYMPTOM</data>
      <data key="d1">The cost of AD treatments is an important consideration</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="ACCESS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Access to AD treatments is an important consideration</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="TREATMENT PLANS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Treatment plans are strategies for managing and treating AD</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="TREATMENT EFFICACY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Treatment efficacy is an important consideration in AD management</data>
      <data key="d2">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </node>
    <node id="PRURITUS/ITCH NUMERIC RATING SCALE">
      <data key="d0">SYMPTOM</data>
      <data key="d1">A scale used to evaluate the severity of itching in skin conditions</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="CANCER">
      <data key="d0">DISEASE</data>
      <data key="d1">Cancer is a condition that can be treated using nanotechnology</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="CERAMIDE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Ceramide levels drop in AD, leading to increased trans-epidermal water loss and compromised skin barrier</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="LIPOSOMES">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Liposomes are nanosized systems developed to improve the deep absorption of drugs into the skin</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="SOLID LIPID NANOPARTICLES (SLNS)">
      <data key="d0">CHEMICAL</data>
      <data key="d1">SLNs are lipid nanoparticles that showed potential for cutaneous application</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="NANOSTRUCTURED LIPID CARRIERS (NLCS)">
      <data key="d0">CHEMICAL</data>
      <data key="d1">NLCs are lipid nanoparticles that showed potential for cutaneous application</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="CHITOSAN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Chitosan is a polysaccharide used in tissue engineering and targeted medication delivery
Chitosan is a biopolymer used in drug delivery systems
Chitosan is used in gel formulations to enhance drug accumulation and minimize systemic toxicity
Chitosan is a biopolymer used in nanoparticle formulations for drug delivery</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,6aef5adb1be227170f66c76a292c25e5,8246ea974dfb00cb5e3d984004e21a9e,bddc3b1a7f098e71f0aa64adec047124</data>
    </node>
    <node id="TACROLIMUS (FK506)">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Tacrolimus is a drug used in chitosan-based nanoparticles for treating AD</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="NICOTINAMIDE (NIC)">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Nicotinamide is used as a hydrotropic agent in chitosan-based nanoparticles for treating AD</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="SPRAGUE DAWLEY RATS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Sprague Dawley rats are used in in vivo studies for sustained skin permeation</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="BABL/C MICE">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">BABL/c mice are used in studies for DNCB-induced AD-like skin lesions</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="DNCB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">DNCB is used to induce AD-like skin lesions in mice</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="SPLEEN">
      <data key="d0">TISSUE</data>
      <data key="d1">The spleen is an organ where weight and index are measured in AD studies</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="PROTOPIC">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Protopic is a treatment compared to NIC-CS-NPs loaded with FK506 in AD studies</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="HYALURONIC ACID (HA)">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Hyaluronic Acid is used to decorate TAC-loaded nanoparticles for treating AD</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="NIOSOMES">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Niosomes are nonionic, drug-containing vesicular systems used for drug delivery</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="BETAMETHASONE VALERATE (BMV)">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Betamethasone Valerate is loaded into chitosan nanoparticles for treating AD</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="CARBOPOL&#174;980">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Carbopol&#174;980 is used as a gel in nanocarriers for drug delivery
Carbopol&#174;980 is a gel used in various formulations for drug delivery</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5,8246ea974dfb00cb5e3d984004e21a9e</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="PHYTOCERAMIDES">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Phytoceramides are produced from oats and included in nanocarriers for skin absorption
Phytoceramides are plant-derived ceramides used in skincare for their moisturizing properties</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5,8246ea974dfb00cb5e3d984004e21a9e</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="STARCH">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Starch is used in nanocarriers for drug delivery
Starch is a carbohydrate used in drug delivery systems
Starch is a polysaccharide used as a drug delivery agent</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,6aef5adb1be227170f66c76a292c25e5,8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="LECITHIN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Lecithin is used in nanocarriers for drug delivery
Lecithin is a fatty substance used in drug delivery systems</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5,8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="MICROEMULSIONS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Microemulsions are used in nanocarriers for drug delivery
Microemulsions are colloidal dispersions used to enhance drug delivery</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5,8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="NIC-CS-NPS">
      <data key="d0" />
      <data key="d1">NIC-CS-NPs are chitosan-based nanoparticles containing tacrolimus and nicotinamide for treating AD</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="TAC-LOADED NANOPARTICLES">
      <data key="d0" />
      <data key="d1" />
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="NANOPARTICLES">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Nanoparticles are used in drug delivery systems to enhance drug delivery to the skin</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="POLYMERIC PARTICULATES">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Polymeric particulates are used as carriers in drug delivery systems for skin conditions</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="DENDRIMERS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Dendrimers are used as carriers in drug delivery systems for skin conditions</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="DENDRITIC-CORE MULTI-SHELL NANO TRANSPORTERS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Dendritic-core multi-shell nano transporters are used as carriers in drug delivery systems for skin conditions</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="LIPID NANOPARTICLES">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Lipid nanoparticles serve as carriers in drug delivery systems for skin conditions</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="CHITOSAN-BASED NANOPARTICLES">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Chitosan-based nanoparticles are used for drug delivery in treating AD</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="EAR SKIN">
      <data key="d0">TISSUE</data>
      <data key="d1">Ear skin thickness is measured in AD studies</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="SPLEEN INDEX">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Spleen index is measured to assess immune activation in AD studies</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="HISTOPATHOLOGY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Histopathology is used to examine DNCB-induced AD skin lesions
Histopathology is the microscopic examination of tissue to study the manifestations of disease</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5,8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="HYALURONIC ACID (HA)-DECORATED TAC-LOADED NPS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Hyaluronic Acid (HA)-decorated TAC-loaded NPs are nanoparticles used for treating AD</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="POLYMERIC NANOPARTICLES">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Polymeric nanoparticles are used for the topical administration of medicinal compounds</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="BETAMETHASONE VALERATE (BMV)-LOADED CHITOSAN NPS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Betamethasone Valerate (BMV)-loaded chitosan NPs are nanoparticles used for treating AD</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="STARCH-BASED MICROEMULSIONS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Starch-based microemulsions are used in nanocarriers for drug delivery</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="LECITHIN-BASED MICROEMULSIONS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Lecithin-based microemulsions are used in nanocarriers for drug delivery</data>
      <data key="d2">8246ea974dfb00cb5e3d984004e21a9e</data>
    </node>
    <node id="OATS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Oats are a species of cereal grain used in various formulations for their beneficial properties</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="NPS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Nanoparticles (NPs) are tiny particles used in drug delivery systems
Nanoparticles (NPs) are used for drug delivery in various formulations</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="SC">
      <data key="d0">TISSUE</data>
      <data key="d1">Stratum Corneum (SC) is the outermost layer of the skin
Stratum corneum (SC) is the outermost layer of the skin where higher TAC levels were observed with PLG-based nanoparticles</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5,bddc3b1a7f098e71f0aa64adec047124</data>
    </node>
    <node id="PIOGLITAZONE (PGZ)">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Pioglitazone (PGZ) is a drug recognized for its anti-diabetic properties and potential in modulating inflammatory responses</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="CLOBETASOL PROPIONATE (CP)">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Clobetasol Propionate (CP) is a corticosteroid used to treat skin diseases</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="BMV">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Betamethasone Valerate (BMV) is a corticosteroid used to treat inflammatory skin conditions
Betamethasone valerate (BMV) is a drug encapsulated in PLGA or lecithin/chitosan-based nanoparticles</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5,bddc3b1a7f098e71f0aa64adec047124</data>
    </node>
    <node id="DIFLUCORTOLONE VALERATE (DFV)">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Diflucortolone Valerate (DFV) is a corticosteroid used to treat skin conditions</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="ALBINO WISTAR RATS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Albino Wistar Rats are a common model organism used in biomedical research</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="TEWL">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Transepidermal Water Loss (TEWL) is a measure of the water loss through the skin
Transepidermal water loss (TEWL) is reduced in an AD animal model treated with CsA-loaded nanoparticles
Transepidermal water loss (TEWL) is a measure of the skin's barrier function
Transepidermal water loss (TEWL) is the loss of water through the epidermis, indicating skin barrier function</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456,3dfbb4c51838e0951f53ce951395225f,6aef5adb1be227170f66c76a292c25e5,bddc3b1a7f098e71f0aa64adec047124</data>
    </node>
    <node id="NICOTINAMIDE (VITAMIN B3)">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Nicotinamide (Vitamin B3) is a form of vitamin B3 used in skincare for its anti-inflammatory properties</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="GLYCYRRHIZIC ACID (GA)">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Glycyrrhizic Acid (GA) is a compound derived from licorice root with anti-inflammatory properties</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="BALB/C MICE">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">BALB/c Mice are a common inbred strain of laboratory mice used in research
BALB/c mice are used in in vivo skin irritation tests
BALB/c mice are a genetic background model used to study the effects of OX40L signaling</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3,6aef5adb1be227170f66c76a292c25e5,bddc3b1a7f098e71f0aa64adec047124</data>
    </node>
    <node id="CYCLOSPORINE A (CSA)">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Cyclosporine A (CsA) is an immunosuppressive medication used in the treatment of autoimmune diseases</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="HUMAN EPIDERMIS">
      <data key="d0">TISSUE</data>
      <data key="d1">The human epidermis is the outermost layer of the skin</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="TAC">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Tacrolimus (TAC) is an immunosuppressive drug used in the treatment of skin conditions
Tacrolimus (TAC) is a drug used in dermatological treatments to improve skin penetration
Tacrolimus (TAC) is an immunosuppressive drug used to treat eczema and other inflammatory skin conditions
Transverse aortic constriction (TAC) is a surgical model used to study cardiac hypertrophy and heart failure</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456,6aef5adb1be227170f66c76a292c25e5,bddc3b1a7f098e71f0aa64adec047124,d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="RABBITS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Rabbits are used as model organisms in biomedical research</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="BETAMETHASONE DIPROPIONATE (BMD)">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Betamethasone Dipropionate (BMD) is a corticosteroid used to treat inflammatory skin conditions</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="VITAMIN E (VE)">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Vitamin E (VE) is a fat-soluble antioxidant used in skincare for its moisturizing properties</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="TESSEMA">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Tessema is a researcher involved in the study of phytoceramides in nanocarriers</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="ESPINOZA">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Espinoza is a researcher who developed a nanoemulsion of pioglitazone for topical application</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="INFLAMMATORY CYTOKINES">
      <data key="d0">PROTEIN</data>
      <data key="d1">Inflammatory cytokines are signaling molecules involved in the inflammatory response</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="ALAM">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Alam is a researcher who designed a nanoemulsion for topical application using clobetasol propionate</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="EROGLU">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Eroglu is a researcher who studied the effects of liposomes encapsulating BMV and DFV in chitosan gel</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="EL-MENSHAWE">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">El-Menshawe is a researcher who designed thermally sensitive ethosomal gels for topical nicotinamide delivery</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="CHAUHAN">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Chauhan is a researcher who developed a transfersome loaded with glycyrrhizic acid for the treatment of AD</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="CARRERAS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Carreras is a researcher who developed ultra-flexible lipid vesicles for the topical administration of cyclosporine A</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="KANG">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Kang is a researcher who investigated the use of thermosensitive solid lipid nanoparticles for TAC delivery</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="NAGAICH">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Nagaich is a researcher who developed nanostructured lipid carriers for delivering betamethasone dipropionate</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="EIRAS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Eiras is a researcher who developed nanostructured lipid carriers incorporating vitamin E into hydrogel</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="FERREIRA">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Ferreira is a researcher who developed methotrexate formulations</data>
      <data key="d2">6aef5adb1be227170f66c76a292c25e5</data>
    </node>
    <node id="NLCS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Nanostructured lipid carriers (NLCs) are well-known systems that demonstrate effectiveness in improving skin moisture and are recommended for cosmetic and dermatological usage
Nanostructured lipid carriers (NLCs) are used for drug delivery, enhancing drug permeation and controlled release</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456,bddc3b1a7f098e71f0aa64adec047124</data>
    </node>
    <node id="HG-NLCVE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">HG-NLCVE is a formulation that could be utilized in cosmetic applications or treating dermatological illnesses</data>
      <data key="d2">bddc3b1a7f098e71f0aa64adec047124</data>
    </node>
    <node id="METHOTREXATE (MTX)">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Methotrexate (MTX) is a drug used to enhance bioavailability and dermal penetration in treatments</data>
      <data key="d2">bddc3b1a7f098e71f0aa64adec047124</data>
    </node>
    <node id="BECLOMETHASONE DIPROPIONATE (BDP)">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Beclomethasone dipropionate (BDP) is a topical medication used as an anti-inflammatory agent for treating AD</data>
      <data key="d2">bddc3b1a7f098e71f0aa64adec047124</data>
    </node>
    <node id="MOUSE">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Mouse is a model organism used in skin penetration studies
Mouse is a model organism used in scientific research</data>
      <data key="d2">bddc3b1a7f098e71f0aa64adec047124,d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="HA">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Hyaluronic acid (HA) is used in polymeric nanoparticles to improve skin penetration</data>
      <data key="d2">bddc3b1a7f098e71f0aa64adec047124</data>
    </node>
    <node id="CHOLESTEROL">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Cholesterol is used in polymeric nanoparticles to improve skin penetration</data>
      <data key="d2">bddc3b1a7f098e71f0aa64adec047124</data>
    </node>
    <node id="NIC">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Nicotinamide (NIC) is used to improve solubility and skin penetration in nanoparticle formulations</data>
      <data key="d2">bddc3b1a7f098e71f0aa64adec047124</data>
    </node>
    <node id="HACAT CELLS">
      <data key="d0">CELL</data>
      <data key="d1">HaCaT cells are a type of human keratinocyte cell line used in cell uptake experiments</data>
      <data key="d2">bddc3b1a7f098e71f0aa64adec047124</data>
    </node>
    <node id="C6">
      <data key="d0">CHEMICAL</data>
      <data key="d1">C6 is a fluorescent marker used in confocal laser scanning microscopy</data>
      <data key="d2">bddc3b1a7f098e71f0aa64adec047124</data>
    </node>
    <node id="PLA">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Polylactic acid (PLA) is used in nanoparticle formulations for anti-inflammatory purposes</data>
      <data key="d2">bddc3b1a7f098e71f0aa64adec047124</data>
    </node>
    <node id="PLG">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Polylactide-co-glycerol (PLG) is used in nanoparticles for topical delivery of TAC</data>
      <data key="d2">bddc3b1a7f098e71f0aa64adec047124</data>
    </node>
    <node id="PLGA">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Poly(lactic-co-glycolic acid) (PLGA) is used in nanoparticles for topical drug delivery</data>
      <data key="d2">bddc3b1a7f098e71f0aa64adec047124</data>
    </node>
    <node id="CSA">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Cyclosporine A (CsA) is a drug used in PLGA-based nanoparticles for anti-inflammatory effects</data>
      <data key="d2">bddc3b1a7f098e71f0aa64adec047124</data>
    </node>
    <node id="INF-&#915;">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interferon-gamma (INF-&#947;) is a cytokine whose levels are reduced in an AD animal model treated with CsA-loaded nanoparticles</data>
      <data key="d2">bddc3b1a7f098e71f0aa64adec047124</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="OVA-IGE">
      <data key="d0">PROTEIN</data>
      <data key="d1">Ovalbumin-specific IgE (OVA-IgE) is a serum level reduced in an AD animal model treated with CsA-loaded nanoparticles</data>
      <data key="d2">bddc3b1a7f098e71f0aa64adec047124</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="HYDROCORTISONE (HC)">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Hydrocortisone (HC) is a corticosteroid used in chitosan-based nanoparticles for topical administration</data>
      <data key="d2">bddc3b1a7f098e71f0aa64adec047124</data>
    </node>
    <node id="HYDROXYTYROSOL (HT)">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Hydroxytyrosol (HT) is used in chitosan-based nanoparticles for topical administration</data>
      <data key="d2">bddc3b1a7f098e71f0aa64adec047124</data>
    </node>
    <node id="HYDROCORTISONE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Hydrocortisone (HC) is a corticosteroid used to reduce inflammation
Hydrocortisone is a corticosteroid used to reduce inflammation and treat various skin conditions</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456,3dfbb4c51838e0951f53ce951395225f</data>
    </node>
    <node id="HYDROXYTYROSOL">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Hydroxytyrosol (HT) is a phenolic compound with antioxidant properties
Hydroxytyrosol is a phenolic compound with antioxidant properties</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456,3dfbb4c51838e0951f53ce951395225f</data>
    </node>
    <node id="DERMATITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Dermatitis is an inflammatory condition of the skin
Dermatitis is a general term for inflammation of the skin</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456,3dfbb4c51838e0951f53ce951395225f</data>
    </node>
    <node id="IL-12P70">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-12p70 (IL-12p70) is a cytokine involved in the immune response</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f</data>
    </node>
    <node id="PROSTAGLANDIN-E2">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Prostaglandin-E2 (PGE2) is a lipid compound involved in inflammation</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f</data>
    </node>
    <node id="VEGF-&#913;">
      <data key="d0">PROTEIN</data>
      <data key="d1">Vascular endothelial growth factor-alpha (VEGF-&#945;) is a protein involved in angiogenesis</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="ELASTIC FIBER">
      <data key="d0">CELL</data>
      <data key="d1">Elastic fibers are components of the extracellular matrix that provide elasticity to tissues</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f</data>
      <data key="d3">CELL</data>
    </node>
    <node id="FUCOIDAN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Fucoidan is a sulfated polysaccharide found in brown seaweed</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="MTX">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Methotrexate (MTX) is a medication used to treat inflammatory diseases
MTX (methotrexate) is a medication used to treat autoimmune diseases and certain types of cancer
MTX (Methotrexate) is a medication used to treat autoimmune diseases and cancer</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f,423195c6b63ad0a6773374364ebf3612,8e5a1be9981340d419f7b3ad27076009</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="HNE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Human neutrophil elastase (HNE) is an enzyme involved in the breakdown of elastin</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="ER143">
      <data key="d0">CHEMICAL</data>
      <data key="d1">ER143 is a synthetic inhibitor of human neutrophil elastase (HNE)
ER143 is a human neutrophil elastase inhibitor used to reduce inflammation</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456,3dfbb4c51838e0951f53ce951395225f</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="DESONIDE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Desonide (DES) is a corticosteroid used to treat inflammation
Desonide is a corticosteroid used to treat inflammation and itching caused by skin conditions</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456,3dfbb4c51838e0951f53ce951395225f</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="ACAI OIL">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Acai oil (AO) is an oil extracted from the acai berry, used in formulations for its antioxidant properties</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="MEDIUM-CHAIN TRIGLYCERIDES">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Medium-chain triglycerides (MCT) are fats used in drug formulations</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="BDP">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Beclomethasone dipropionate (BDP) is a corticosteroid used to treat inflammation</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="HPMC">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Hydroxypropyl methylcellulose (HPMC) is a polymer used in drug formulations</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="CD-1 MOUSE">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">CD-1 mouse is a strain of laboratory mouse used in research</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="OMIGANAN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Omiganan is a small molecule used in atopic dermatitis treatment</data>
      <data key="d2">3dfbb4c51838e0951f53ce951395225f</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="EUDRAGIT&#174; RL100">
      <data key="d0" />
      <data key="d1" />
      <data key="d2">3dfbb4c51838e0951f53ce951395225f</data>
    </node>
    <node id="INTERLEUKIN-4RA">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-4 receptor alpha, involved in immune response modulation</data>
      <data key="d2">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </node>
    <node id="INTERLEUKIN-13RA1">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-13 receptor alpha 1, involved in immune response modulation</data>
      <data key="d2">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </node>
    <node id="INTERLEUKIN-5RA">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-5 receptor alpha, involved in immune response modulation</data>
      <data key="d2">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </node>
    <node id="FB825/ANTI-C&#917;MX">
      <data key="d0">CHEMICAL</data>
      <data key="d1">FB825/anti-C&#949;mX is a biologic drug targeting Immunoglobulin E</data>
      <data key="d2">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </node>
    <node id="FEZAKIMUAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Fezakimuab is a biologic drug targeting Interleukin-22</data>
      <data key="d2">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </node>
    <node id="INTERLEUKIN-17A">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-17a, a cytokine involved in immune response</data>
      <data key="d2">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </node>
    <node id="INTERLEUKIN-5">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interleukin-5, a cytokine involved in immune response</data>
      <data key="d2">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </node>
    <node id="AMDITELIMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Amditelimab is a biologic drug targeting OX-40</data>
      <data key="d2">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </node>
    <node id="OX-40">
      <data key="d0">PROTEIN</data>
      <data key="d1">OX-40, a protein involved in T-cell costimulation</data>
      <data key="d2">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </node>
    <node id="BACRICITINIB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Bacricitinib is a small molecule drug targeting JAK1</data>
      <data key="d2">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </node>
    <node id="HYALURONIC ACID">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Hyaluronic acid is a substance used in nanotechnology-based therapeutic approaches</data>
      <data key="d2">cccfd5ff480e281556e2210cd0e5c4b5</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="BETAMETHASONE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Betamethasone is a corticosteroid used in nanotechnology-based therapeutic approaches</data>
      <data key="d2">cccfd5ff480e281556e2210cd0e5c4b5</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="OAT-CERAMIDES">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Oat-ceramides are used in nanotechnology-based therapeutic approaches</data>
      <data key="d2">cccfd5ff480e281556e2210cd0e5c4b5</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="PIOGLITAZONE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Pioglitazone is a drug used in nanotechnology-based therapeutic approaches</data>
      <data key="d2">cccfd5ff480e281556e2210cd0e5c4b5</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="CLOBETASOL PROPIONATE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Clobetasol propionate is a corticosteroid used in nanotechnology-based therapeutic approaches</data>
      <data key="d2">cccfd5ff480e281556e2210cd0e5c4b5</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="DIFLUCORTOLONE VALERATE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Diflucortolone valerate is a corticosteroid used in nanotechnology-based therapeutic approaches</data>
      <data key="d2">cccfd5ff480e281556e2210cd0e5c4b5</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="GLYCYRRHIZIC ACID">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Glycyrrhizic acid is a compound used in nanotechnology-based therapeutic approaches</data>
      <data key="d2">cccfd5ff480e281556e2210cd0e5c4b5</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="VITAMIN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Vitamin is used in nanotechnology-based therapeutic approaches</data>
      <data key="d2">cccfd5ff480e281556e2210cd0e5c4b5</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="BETAMETHASONE VALERATE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Betamethasone valerate is a corticosteroid used to reduce inflammation and treat various skin conditions</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
    </node>
    <node id="BETAMETHASONE DIPROPIONATE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Betamethasone dipropionate is a corticosteroid used to treat inflammation and skin conditions</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
    </node>
    <node id="AURAPTENE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Auraptene is a natural compound with anti-inflammatory properties</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
    </node>
    <node id="MIZOLASTINE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Mizolastine is an antihistamine used to treat allergic conditions</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
    </node>
    <node id="LEVOCETIRIZINE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Levocetirizine is an antihistamine used to treat allergy symptoms</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
    </node>
    <node id="LYMPHOMA">
      <data key="d0">DISEASE</data>
      <data key="d1">Lymphoma is a type of cancer that affects the lymphatic system
A type of cancer treated with pembrolizumab</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456,855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="SKIN CANCER">
      <data key="d0">DISEASE</data>
      <data key="d1">Skin cancer is a type of cancer that develops in the skin cells</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
    </node>
    <node id="CELL PROLIFERATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Cell proliferation is the process by which cells divide and multiply</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="SKIN THICKENING">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Skin thickening is an increase in the thickness of the skin, often due to chronic inflammation or other conditions</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="SWELLING">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Swelling is an abnormal enlargement of a body part, often due to inflammation or fluid accumulation</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="BLANCHING">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Blanching is the whitening of the skin due to reduced blood flow</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="SKIN RETENTION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Skin retention refers to the ability of the skin to retain substances, such as drugs, within its layers</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="PERMEATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Permeation is the process by which a substance passes through a barrier, such as the skin</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="FLUX">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Flux refers to the rate of flow of a substance through a barrier, such as the skin</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="NON-FICKIAN DIFFUSION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Non-Fickian diffusion is a type of diffusion where the rate of drug release is not solely dependent on concentration gradients</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="CONTROLLED RELEASE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Controlled release is a drug delivery method that allows for the gradual release of a drug over time</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="SUSTAINED RELEASE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Sustained release is a drug delivery method that maintains a consistent drug concentration over an extended period</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="BIOCOMPATIBILITY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Biocompatibility refers to the ability of a material to be compatible with living tissue without causing an immune response</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="NON-TOXICITY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Non-toxicity refers to the property of a substance being non-toxic or not harmful to living organisms</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="ANTI-INFLAMMATORY ACTION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Anti-inflammatory action refers to the ability of a substance to reduce inflammation</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="INHIBITION OF CELL PROLIFERATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Inhibition of cell proliferation refers to the process of preventing or slowing down the multiplication of cells</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="INHIBITION OF IL-2 SECRETION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Inhibition of IL-2 secretion refers to the process of preventing or reducing the release of interleukin-2</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="INHIBITION OF TSLP">
      <data key="d0">PATHWAY</data>
      <data key="d1">Inhibition of TSLP refers to the process of preventing or reducing the release of thymic stromal lymphopoietin</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="PREVENTION OF SKIN THICKENING">
      <data key="d0">PATHWAY</data>
      <data key="d1">Prevention of skin thickening refers to the process of stopping or reducing the increase in skin thickness</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="PRESERVATION OF SKIN INTEGRITY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Preservation of skin integrity refers to maintaining the skin's structure and function</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="REDUCTION OF SWELLING">
      <data key="d0">PATHWAY</data>
      <data key="d1">Reduction of swelling refers to the process of decreasing abnormal enlargement of a body part</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="REDUCTION OF ERYTHEMA">
      <data key="d0">PATHWAY</data>
      <data key="d1">Reduction of erythema refers to the process of decreasing redness of the skin</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="REDUCTION OF TEWL">
      <data key="d0">PATHWAY</data>
      <data key="d1">Reduction of transepidermal water loss refers to the process of decreasing water loss through the epidermis</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="REDUCTION OF DERMATITIS INDEX">
      <data key="d0">PATHWAY</data>
      <data key="d1">Reduction of dermatitis index refers to the process of decreasing the severity of dermatitis</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="REDUCTION OF EAR THICKNESS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Reduction of ear thickness refers to the process of decreasing the thickness of the ear, often used as a measure in inflammation studies</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="SUPPRESSION OF CELL INFILTRATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Suppression of cell infiltration refers to the process of preventing or reducing the movement of cells into a tissue, often related to inflammation</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="SUPPRESSION OF IMMUNOGLOBULIN E">
      <data key="d0">PATHWAY</data>
      <data key="d1">Suppression of immunoglobulin E refers to the process of preventing or reducing the production of IgE, an antibody associated with allergic reactions</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="INCREASE IN DRUG ACCUMULATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Increase in drug accumulation refers to the process of enhancing the concentration of a drug within a specific area, such as the skin</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="INCREASE IN SKIN RETENTION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Increase in skin retention refers to the process of enhancing the ability of the skin to retain substances, such as drugs, within its layers</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="INCREASE IN SKIN PERMEATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Increase in skin permeation refers to the process of enhancing the passage of substances through the skin</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="INCREASE IN ANTI-INFLAMMATORY PROPERTIES">
      <data key="d0">PATHWAY</data>
      <data key="d1">Increase in anti-inflammatory properties refers to the process of enhancing the ability of a substance to reduce inflammation</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="INCREASE IN ERYTHEMA INHIBITION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Increase in erythema inhibition refers to the process of enhancing the ability to reduce skin redness</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="INCREASE IN INHIBITION OF CELL PROLIFERATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Increase in inhibition of cell proliferation refers to the process of enhancing the ability to prevent or slow down the multiplication of cells</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="INCREASE IN INHIBITION OF IL-2 SECRETION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Increase in inhibition of IL-2 secretion refers to the process of enhancing the ability to prevent or reduce the release of interleukin-2</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="INCREASE IN INHIBITION OF TSLP">
      <data key="d0">PATHWAY</data>
      <data key="d1">IncreaseIncrease in inhibition of TSLP refers to the process of enhancing the ability to prevent or reduce the release of thymic stromal lymphopoietin</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="INCREASE IN SKIN LAYER PENETRATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Increase in skin layer penetration refers to the process of enhancing the ability of a substance to penetrate deeper layers of the skin</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="INCREASE IN PERMEATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Increase in permeation refers to the process of enhancing the passage of substances through a barrier, such as the skin</data>
      <data key="d2">27a7e95c7d3ad59a948aa46741fee456</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="CIBINQO">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Cibinqo, also known as abrocitinib, is a JAK1 inhibitor approved for AD treatment</data>
      <data key="d2">286730b1c1f680ac465cc21d522fda0c</data>
    </node>
    <node id="JADE TEEN">
      <data key="d0">STUDY</data>
      <data key="d1">JADE TEEN is a Phase III clinical trial supporting cibinqo label expansion</data>
      <data key="d2">286730b1c1f680ac465cc21d522fda0c</data>
    </node>
    <node id="SANOFI">
      <data key="d0">ORGANIZATION</data>
      <data key="d1">Sanofi is a company that produces dupilumab</data>
      <data key="d2">286730b1c1f680ac465cc21d522fda0c</data>
    </node>
    <node id="REGENERON">
      <data key="d0">ORGANIZATION</data>
      <data key="d1">Regeneron is a company that produces dupilumab</data>
      <data key="d2">286730b1c1f680ac465cc21d522fda0c</data>
    </node>
    <node id="ADBRY">
      <data key="d0">CHEMICAL</data>
      <data key="d1">ADBRY is a medication approved for AD treatment</data>
      <data key="d2">286730b1c1f680ac465cc21d522fda0c</data>
    </node>
    <node id="OPZELURA">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Opzelura is a cream approved as the first topical JAK inhibitor for AD treatment</data>
      <data key="d2">286730b1c1f680ac465cc21d522fda0c</data>
    </node>
    <node id="IL-13R">
      <data key="d0">PROTEIN</data>
      <data key="d1">IL-13R is a receptor involved in the pathophysiology of AD</data>
      <data key="d2">286730b1c1f680ac465cc21d522fda0c</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="NOS2">
      <data key="d0">PROTEIN</data>
      <data key="d1">NOS2 is a biomarker used to monitor the severity of AD</data>
      <data key="d2">286730b1c1f680ac465cc21d522fda0c</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="INOS">
      <data key="d0">PROTEIN</data>
      <data key="d1">iNOS is a biomarker used to monitor the severity of AD</data>
      <data key="d2">286730b1c1f680ac465cc21d522fda0c</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="BIOLOGICAL THERAPIES">
      <data key="d0">TREATMENT</data>
      <data key="d1">Biological therapies are advanced treatments for dermatological conditions like AD</data>
      <data key="d2">286730b1c1f680ac465cc21d522fda0c</data>
      <data key="d3">TREATMENT</data>
    </node>
    <node id="NANOCARRIERS">
      <data key="d0">TREATMENT</data>
      <data key="d1">Nanocarriers are innovative therapeutic delivery systems for AD treatment
Nanocarriers are nanoscale vehicles designed for targeted drug delivery</data>
      <data key="d2">286730b1c1f680ac465cc21d522fda0c,e30574e513dd250992d637d808759c34</data>
      <data key="d3">TREATMENT</data>
    </node>
    <node id="BIOLOGICAL PHARMACEUTICALS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Biological pharmaceuticals are drugs derived from living organisms used in the treatment of various diseases, including AD</data>
      <data key="d2">e30574e513dd250992d637d808759c34</data>
    </node>
    <node id="NANOPARTICLE SYSTEMS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Nanoparticle systems are engineered particles at the nanoscale used for drug delivery and therapeutic purposes</data>
      <data key="d2">e30574e513dd250992d637d808759c34</data>
    </node>
    <node id="NANOMEDICINE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Nanomedicine involves the application of nanotechnology for medical purposes, including drug delivery and therapy</data>
      <data key="d2">e30574e513dd250992d637d808759c34</data>
    </node>
    <node id="MYELOFIBROSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Myelofibrosis is a rare bone marrow cancer that disrupts the body's normal production of blood cells</data>
      <data key="d2">e30574e513dd250992d637d808759c34</data>
    </node>
    <node id="BIOTHERAPEUTICS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Biotherapeutics are therapeutic materials produced using biological processes, often involving recombinant DNA technology</data>
      <data key="d2">e30574e513dd250992d637d808759c34</data>
    </node>
    <node id="PATHWAYS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Pathways refer to the series of actions among molecules in a cell that leads to a certain product or change in the cell, often implicated in disease mechanisms</data>
      <data key="d2">e30574e513dd250992d637d808759c34</data>
    </node>
    <node id="THERAPEUTIC STRATEGIES">
      <data key="d0">PATHWAY</data>
      <data key="d1">Therapeutic strategies refer to the methods and plans designed to treat diseases, including AD</data>
      <data key="d2">e30574e513dd250992d637d808759c34</data>
    </node>
    <node id="DRUG DELIVERY MECHANISMS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Drug delivery mechanisms are methods or processes of administering a pharmaceutical compound to achieve a therapeutic effect</data>
      <data key="d2">e30574e513dd250992d637d808759c34</data>
    </node>
    <node id="PRECLINICAL RESEARCH">
      <data key="d0">PATHWAY</data>
      <data key="d1">Preclinical research involves studies that test a drug, procedure, or other medical treatment in animals before it is tested in humans</data>
      <data key="d2">e30574e513dd250992d637d808759c34</data>
    </node>
    <node id="CLINICAL RESEARCH">
      <data key="d0">PATHWAY</data>
      <data key="d1">Clinical research involves studies or trials that test the safety and effectiveness of drugs, procedures, or other medical treatments in humans</data>
      <data key="d2">e30574e513dd250992d637d808759c34</data>
    </node>
    <node id="MULTIDISCIPLINARY APPROACH">
      <data key="d0">PATHWAY</data>
      <data key="d1">A multidisciplinary approach involves integrating multiple fields of study to address complex issues, such as the management of AD</data>
      <data key="d2">e30574e513dd250992d637d808759c34</data>
    </node>
    <node id="THERAPY COMPLIANCE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Therapy compliance refers to the degree to which a patient correctly follows medical advice and treatment plans</data>
      <data key="d2">e30574e513dd250992d637d808759c34</data>
    </node>
    <node id="SEVERE AD">
      <data key="d0">DISEASE</data>
      <data key="d1">Severe AD refers to a more intense and debilitating form of atopic dermatitis</data>
      <data key="d2">e30574e513dd250992d637d808759c34</data>
    </node>
    <node id="TRADITIONAL TREATMENTS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Traditional treatments refer to conventional methods of treating diseases, which may include medications, therapies, and procedures</data>
      <data key="d2">e30574e513dd250992d637d808759c34</data>
    </node>
    <node id="NANOTECHNOLOGY-BASED DRUG DELIVERY SYSTEMS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Nanotechnology-based drug delivery systems use nanoscale materials to deliver drugs more effectively to specific sites in the body</data>
      <data key="d2">e30574e513dd250992d637d808759c34</data>
    </node>
    <node id="MEMORY T CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Memory T cells are believed to be central for the chronicity of Atopic Dermatitis
Memory T cells are a type of T cell involved in long-term immune response, affected by CD27:CD70 signaling</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3,691cb2e23ac3c6e591129d16714f8ef8</data>
    </node>
    <node id="ANTIGEN-PRESENTING CELLS (APC)">
      <data key="d0">CELL</data>
      <data key="d1">APCs express OX40L and are involved in the immune response in Atopic Dermatitis</data>
      <data key="d2">691cb2e23ac3c6e591129d16714f8ef8</data>
    </node>
    <node id="PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS)">
      <data key="d0">CELL</data>
      <data key="d1">PBMCs are blood cells that are critical in the immune response and are isolated for research in Atopic Dermatitis</data>
      <data key="d2">691cb2e23ac3c6e591129d16714f8ef8</data>
    </node>
    <node id="PLASMA">
      <data key="d0">TISSUE</data>
      <data key="d1">Plasma is the liquid component of blood, collected for research in Atopic Dermatitis
Plasma, the liquid component of blood collected from patients with AD and HC</data>
      <data key="d2">2e9a8d71f6bd251a0b13458c39e69746,691cb2e23ac3c6e591129d16714f8ef8</data>
    </node>
    <node id="HEALTHY CONTROLS (HC)">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Healthy Controls (HC) are individuals without Atopic Dermatitis or other systemic inflammatory diseases, used as a comparison group in research</data>
      <data key="d2">691cb2e23ac3c6e591129d16714f8ef8</data>
    </node>
    <node id="ENZYME-LINKED IMMUNOASSAY (ELISA)">
      <data key="d0">PATHWAY</data>
      <data key="d1">ELISA is a laboratory technique used to measure the concentration of soluble OX40 in blood samples from patients with Atopic Dermatitis</data>
      <data key="d2">691cb2e23ac3c6e591129d16714f8ef8</data>
    </node>
    <node id="FLOW CYTOMETRY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Flow Cytometry is a technique used to analyze the expression of OX40 by activated skin-homing CD4+ T cells in Atopic Dermatitis
Flow cytometry is a technique used to analyze the physical and chemical characteristics of cells</data>
      <data key="d2">348f2797841cbef27311b03f2cd788dd,691cb2e23ac3c6e591129d16714f8ef8</data>
    </node>
    <node id="ANTIGEN-ACTIVATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Antigen-Activation is the process that triggers T-cell expression of OX40 and APC expression of OX40L in Atopic Dermatitis</data>
      <data key="d2">691cb2e23ac3c6e591129d16714f8ef8</data>
    </node>
    <node id="MAST CELL DEGRANULATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Mast Cell Degranulation is inhibited by soluble OX40, reducing the inflammatory response in Atopic Dermatitis</data>
      <data key="d2">691cb2e23ac3c6e591129d16714f8ef8</data>
    </node>
    <node id="HANIFIN &amp; RAJKA CRITERIA">
      <data key="d0">PATHWAY</data>
      <data key="d1">Hanifin &amp; Rajka Criteria are used to diagnose patients with Atopic Dermatitis</data>
      <data key="d2">691cb2e23ac3c6e591129d16714f8ef8</data>
    </node>
    <node id="FICOLL-PAQUE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Ficoll-Paque is a chemical used for density gradient centrifugation to isolate PBMCs in research on Atopic Dermatitis
Ficoll-Paque, a chemical used for density gradient centrifugation to isolate PBMCs</data>
      <data key="d2">2e9a8d71f6bd251a0b13458c39e69746,691cb2e23ac3c6e591129d16714f8ef8</data>
    </node>
    <node id="HC">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Healthy Controls, individuals without atopic diseases or systemic inflammatory diseases
Healthy Controls, used as a comparison group in the study
Healthy Controls are individuals without the disease, used as a comparison group in studies</data>
      <data key="d2">2e9a8d71f6bd251a0b13458c39e69746,6b099960b0a39866e3aa6b908f1886e4,89dbac0da39e4de2b602052cd792b90d</data>
    </node>
    <node id="SOX40L">
      <data key="d0">PROTEIN</data>
      <data key="d1">Soluble OX40L, a protein measured in serum from patients with AD and HC
sOX40L is a soluble form of the OX40L protein, measured in serum of atopic dermatitis patients
Soluble OX40L, a protein with no significant differences observed between groups in the study
sOX40L is the soluble form of OX40L, involved in immune response modulation</data>
      <data key="d2">2e9a8d71f6bd251a0b13458c39e69746,348f2797841cbef27311b03f2cd788dd,6b099960b0a39866e3aa6b908f1886e4,89dbac0da39e4de2b602052cd792b90d</data>
    </node>
    <node id="CD4">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD4, a protein marker used in flow cytometry for T cells
CD4 is a glycoprotein found on the surface of immune cells such as T helper cells
CD4 is a protein marker on T cells, involved in the immune response and affected by OX40-OX40L signaling</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3,2e9a8d71f6bd251a0b13458c39e69746,89dbac0da39e4de2b602052cd792b90d</data>
    </node>
    <node id="CD45RO">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD45RO, a protein marker used in flow cytometry for memory T cells
CD45RO is an isoform of the CD45 protein, expressed on memory T cells</data>
      <data key="d2">2e9a8d71f6bd251a0b13458c39e69746,89dbac0da39e4de2b602052cd792b90d</data>
    </node>
    <node id="CD56">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD56, a protein marker used in flow cytometry for natural killer cells</data>
      <data key="d2">2e9a8d71f6bd251a0b13458c39e69746</data>
    </node>
    <node id="CLA">
      <data key="d0">PROTEIN</data>
      <data key="d1">Cutaneous Lymphocyte Antigen, a protein marker used in flow cytometry
Cutaneous lymphocyte-associated antigen (CLA) is a protein expressed on T cells, involved in skin homing</data>
      <data key="d2">2e9a8d71f6bd251a0b13458c39e69746,89dbac0da39e4de2b602052cd792b90d</data>
    </node>
    <node id="FORMALDEHYDE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Formaldehyde, a chemical used for fixing cells and tissuesFormaldehyde, used to fix cells in flow cytometry</data>
      <data key="d2">2e9a8d71f6bd251a0b13458c39e69746</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="TRYPTASE">
      <data key="d0">PROTEIN</data>
      <data key="d1">Tryptase, a protein analyzed in skin biopsies
Tryptase is a protein targeted by monoclonal rabbit antibodies for analysis
Tryptase, a marker used to confirm mast cells expressing OX40L in AD skin
Tryptase is a protease enzyme found in mast cells, used as a marker for mast cell activation</data>
      <data key="d2">2e9a8d71f6bd251a0b13458c39e69746,348f2797841cbef27311b03f2cd788dd,6b099960b0a39866e3aa6b908f1886e4,89dbac0da39e4de2b602052cd792b90d</data>
    </node>
    <node id="MOUSE IGG">
      <data key="d0">PROTEIN</data>
      <data key="d1">Mouse IgG, used to block unspecific binding in flow cytometry</data>
      <data key="d2">2e9a8d71f6bd251a0b13458c39e69746</data>
    </node>
    <node id="BOVINE SERUM ALBUMIN (BSA)">
      <data key="d0">PROTEIN</data>
      <data key="d1">Bovine Serum Albumin, used in wash buffer for flow cytometry</data>
      <data key="d2">2e9a8d71f6bd251a0b13458c39e69746</data>
    </node>
    <node id="SODIUM AZIDE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Sodium Azide, used in wash buffer for flow cytometry</data>
      <data key="d2">2e9a8d71f6bd251a0b13458c39e69746</data>
    </node>
    <node id="PARAFFIN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Paraffin, used to embed skin biopsies</data>
      <data key="d2">2e9a8d71f6bd251a0b13458c39e69746</data>
    </node>
    <node id="CITRATE-PHOSPHATE BUFFER">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Citrate-Phosphate Buffer, used for heat-induced antigen retrieval</data>
      <data key="d2">2e9a8d71f6bd251a0b13458c39e69746</data>
    </node>
    <node id="ALEXA 488">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Alexa 488, a fluorescent dye used for staining in confocal microscopy</data>
      <data key="d2">2e9a8d71f6bd251a0b13458c39e69746</data>
    </node>
    <node id="RHINITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Rhinitis is a common comorbidity in patients with atopic dermatitis</data>
      <data key="d2">348f2797841cbef27311b03f2cd788dd</data>
    </node>
    <node id="MONOCLONAL RABBIT ANTI-TRYPTASE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Monoclonal rabbit anti-tryptase is an antibody used for targeting tryptase in immunohistochemistry</data>
      <data key="d2">348f2797841cbef27311b03f2cd788dd</data>
    </node>
    <node id="MONOCLONAL MOUSE ANTI-OX40L">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Monoclonal mouse anti-OX40L is an antibody used for targeting OX40L in immunohistochemistry</data>
      <data key="d2">348f2797841cbef27311b03f2cd788dd</data>
    </node>
    <node id="DONKEY ANTI-MOUSE ALEXA 488">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Donkey anti-mouse Alexa 488 is a secondary antibody used for fluorescence detection</data>
      <data key="d2">348f2797841cbef27311b03f2cd788dd</data>
    </node>
    <node id="DONKEY ANTI-RABBIT ALEXA 647">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Donkey anti-rabbit Alexa 647 is a secondary antibody used for fluorescence detection</data>
      <data key="d2">348f2797841cbef27311b03f2cd788dd</data>
    </node>
    <node id="MOUSE IGG1 ISOTYPE CONTROL">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Mouse IgG1 isotype control is used as a negative control for unspecific binding in immunohistochemistry</data>
      <data key="d2">348f2797841cbef27311b03f2cd788dd</data>
    </node>
    <node id="MOUNTING MEDIUM">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Mounting Medium is used to fix tissue sections for microscopy analysis</data>
      <data key="d2">348f2797841cbef27311b03f2cd788dd</data>
    </node>
    <node id="PRISM 6">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Prism 6 is a software used for statistical analysis and graphing</data>
      <data key="d2">348f2797841cbef27311b03f2cd788dd</data>
    </node>
    <node id="MANN-WHITNEY RANK SUM TEST">
      <data key="d0">PATHWAY</data>
      <data key="d1">Mann-Whitney rank sum test is a non-parametric test used for comparing unpaired data</data>
      <data key="d2">348f2797841cbef27311b03f2cd788dd</data>
    </node>
    <node id="WILCOXON SIGNED-RANK TEST">
      <data key="d0">PATHWAY</data>
      <data key="d1">Wilcoxon signed-rank test is a non-parametric test used for comparing paired data</data>
      <data key="d2">348f2797841cbef27311b03f2cd788dd</data>
    </node>
    <node id="SPEARMAN&#8217;S RHO">
      <data key="d0">PATHWAY</data>
      <data key="d1">Spearman&#8217;s rho is a statistical measure used to test correlations</data>
      <data key="d2">348f2797841cbef27311b03f2cd788dd</data>
    </node>
    <node id="ENZYME-LINKED IMMUNOASSAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Enzyme-linked immunoassay (ELISA) is a technique used to measure levels of sOX40 and sOX40L in serum</data>
      <data key="d2">348f2797841cbef27311b03f2cd788dd</data>
    </node>
    <node id="CHILDREN WITH AD">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Children with atopic dermatitis are a group studied for serum levels of sOX40 and sOX40L</data>
      <data key="d2">348f2797841cbef27311b03f2cd788dd</data>
    </node>
    <node id="ADULTS WITH AD">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Adults with atopic dermatitis are a group studied for serum levels of sOX40 and sOX40L</data>
      <data key="d2">348f2797841cbef27311b03f2cd788dd</data>
    </node>
    <node id="TISSUE SECTIONS">
      <data key="d0" />
      <data key="d1" />
      <data key="d2">348f2797841cbef27311b03f2cd788dd</data>
    </node>
    <node id="STATISTICAL ANALYSIS">
      <data key="d0" />
      <data key="d1" />
      <data key="d2">348f2797841cbef27311b03f2cd788dd</data>
    </node>
    <node id="UNPAIRED DATA">
      <data key="d0" />
      <data key="d1" />
      <data key="d2">348f2797841cbef27311b03f2cd788dd</data>
    </node>
    <node id="PAIRED DATA">
      <data key="d0" />
      <data key="d1" />
      <data key="d2">348f2797841cbef27311b03f2cd788dd</data>
    </node>
    <node id="CORRELATION">
      <data key="d0" />
      <data key="d1" />
      <data key="d2">348f2797841cbef27311b03f2cd788dd</data>
    </node>
    <node id="CLA+ T CELLS">
      <data key="d0">CELL</data>
      <data key="d1">CLA+ T cells are skin-homing memory-prone T cells expressing OX40 in AD patients</data>
      <data key="d2">6b099960b0a39866e3aa6b908f1886e4</data>
    </node>
    <node id="CLA- T CELLS">
      <data key="d0">CELL</data>
      <data key="d1">CLA- T cells are a subset of T cells expressing OX40 in AD patients</data>
      <data key="d2">6b099960b0a39866e3aa6b908f1886e4</data>
    </node>
    <node id="CD4+CD45RO+CLA+ T CELLS">
      <data key="d0">CELL</data>
      <data key="d1">CD4+CD45RO+CLA+ T cells are a subset of T cells expressing the highest amount of OX40 in AD patients
A subset of T cells expressing CD4, CD45RO, and cutaneous lymphocyte-associated antigen (CLA), involved in immune responses in AD</data>
      <data key="d2">6b099960b0a39866e3aa6b908f1886e4,89dbac0da39e4de2b602052cd792b90d</data>
    </node>
    <node id="CD4+CD45RO+CLA- T CELLS">
      <data key="d0">CELL</data>
      <data key="d1">CD4+CD45RO+CLA- T cells are a subset of T cells expressing OX40 in AD patients</data>
      <data key="d2">6b099960b0a39866e3aa6b908f1886e4</data>
    </node>
    <node id="CD8+CD45RO+CLA+ T CELLS">
      <data key="d0">CELL</data>
      <data key="d1">CD8+CD45RO+CLA+ T cells are a subset of T cells expressing OX40 in AD patients</data>
      <data key="d2">6b099960b0a39866e3aa6b908f1886e4</data>
    </node>
    <node id="CD8+CD45RO+CLA- T CELLS">
      <data key="d0">CELL</data>
      <data key="d1">CD8+CD45RO+CLA- T cells are a subset of T cells expressing OX40 in AD patients</data>
      <data key="d2">6b099960b0a39866e3aa6b908f1886e4</data>
    </node>
    <node id="MURINE ASTHMA MODELS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Murine asthma models are mouse models used to study asthma and allergic reactions</data>
      <data key="d2">89dbac0da39e4de2b602052cd792b90d</data>
    </node>
    <node id="LUNG">
      <data key="d0">TISSUE</data>
      <data key="d1">The lung is a respiratory organ involved in gas exchange, affected in asthma
The lung is another tissue affected by systemic sclerosis, particularly in the context of fibrosis
Lungs are affected by interstitial lung disease in SSc
The lung is an organ involved in respiration and gas exchange
The lung is a tissue where TL1A-driven inflammation and fibrosis have been observed
The lung is an organ involved in respiration
The lung is an organ involved in respiration and is affected in pulmonary fibrosis</data>
      <data key="d2">05c97152fe02249153103be341d65b67,44f2592262cac835560b4c149fee8d2b,7c13f41d7349d9d2e56c36e00c0ca2d9,855c455b4c9592746834ee3a4e0e6b81,89dbac0da39e4de2b602052cd792b90d,b2aae16813e647959b783a39ef9a19a7,c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="ATOPIC DISEASES">
      <data key="d0">DISEASE</data>
      <data key="d1">Atopic diseases are a group of diseases characterized by a tendency to develop allergic reactions</data>
      <data key="d2">100dd7646c10899301b3c0631183da16</data>
    </node>
    <node id="SKIN THICKNESS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Skin thickness is a measure often used to assess the severity of skin conditions like atopic dermatitis</data>
      <data key="d2">100dd7646c10899301b3c0631183da16</data>
    </node>
    <node id="SYSTEMIC SCLEROSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Systemic sclerosis (SSc) is an autoimmune T-cell disease characterized by pathological fibrosis of the skin and internal organs
Systemic sclerosis, also referred to as SSc, involves the fibrosis of skin and internal organs
Systemic sclerosis (SSc) is an idiopathic autoimmune disease that presents with fibrosis mainly in the skin but also in visceral organs including the lungs and heart
Systemic sclerosis (SSc) is an autoimmune disease characterized by fibrosis of the skin and internal organs
Systemic sclerosis is an autoimmune disease characterized by fibrosis of the skin and internal organs
Systemic Sclerosis is an autoimmune disease characterized by fibrosis of the skin and internal organs</data>
      <data key="d2">423195c6b63ad0a6773374364ebf3612,503107475d2e9dac49abd8ebcbadd9f5,5ec1ebf4e260eb1f8fda8acdf06cd39e,5f37466ca41c9b8b06ed8be0303d49f2,8e5a1be9981340d419f7b3ad27076009,d8a485eb1e9435b083d5ef6a17f06ea5</data>
    </node>
    <node id="SSC">
      <data key="d0">DISEASE</data>
      <data key="d1">Systemic sclerosis, also referred to as SSc, involves the fibrosis of skin and internal organs
Systemic sclerosis, where OX40 levels are found significantly increased in patients
Systemic sclerosis is an autoimmune disease causing fibrosis
Systemic sclerosis is a very severe autoimmune disease characterized by fibrosis of the skin and internal organs
Systemic sclerosis is an autoimmune disease causing fibrosis of the skin and internal organs
Systemic sclerosis, also known as scleroderma, is a chronic multisystem disease characterized by progressive fibrosis in the skin and internal organs
Systemic sclerosis, an autoimmune disease causing fibrosis
Systemic sclerosis, a clinically heterogeneous autoimmune disease characterized by fibrosis of the skin and internal organs
Systemic sclerosis, a disease associated with TNFSF4 and SNPs rs2205960 and rs855648
Systemic sclerosis, a disease associated with TNFSF4 and various SNPs
Systemic sclerosis, an autoimmune disease causing fibrosis
Systemic sclerosis, an autoimmune disease characterized by fibrosis of the skin and internal organs
Systemic sclerosis, also referred to as SSc, involves the fibrosis of skin and internal organs
Systemic sclerosis, an autoimmune disease causing fibrosis
Systemic sclerosis is an autoimmune disease characterized by fibrosis of the skin and internal organs
Systemic sclerosis, an autoimmune disease causing fibrosis of the skin and internal organs
Systemic sclerosis is an autoimmune disease characterized by fibrosis and is associated with OX40-OX40L signaling
Systemic sclerosis is an autoimmune disease characterized by fibrosis of the skin and internal organs
Systemic sclerosis is an autoimmune disease characterized by fibrosis of the skin and internal organs</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14,05c97152fe02249153103be341d65b67,1b656cfce91ff9ccec4223703489dab3,40ad2241836485e0bf264bdfb62fd789,44f2592262cac835560b4c149fee8d2b,4cf23e218b6aab3c77115173b5c7c2fd,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,5ec1ebf4e260eb1f8fda8acdf06cd39e,7b454335c2f5651d86f712037a0dc0ff,855c455b4c9592746834ee3a4e0e6b81,8ce8c356713490cd2c680f505bcd050b,9867d43adab0ba5db44961fae4863eee,b2aae16813e647959b783a39ef9a19a7,c69c7fb997f95c56cc077b3975f41923,d4797ed1483e5057bcd8301eaa509d5e,d8a485eb1e9435b083d5ef6a17f06ea5,df74aa1b86eeeb811ca5586767ae3a71,f9c444698bb08349abe4244fb771c1ee</data>
    </node>
    <node id="RA">
      <data key="d0">DISEASE</data>
      <data key="d1">Rheumatoid arthritis is an autoimmune disease affecting joints
Rheumatoid arthritis, a rheumatic disease where abatacept has a well-documented safety profile
Rheumatoid arthritis is an autoimmune disease causing inflammation of the joints
Rheumatoid arthritis, an autoimmune disease
Rheumatoid arthritis, an autoimmune disease</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,855c455b4c9592746834ee3a4e0e6b81,8ce8c356713490cd2c680f505bcd050b</data>
    </node>
    <node id="SLE">
      <data key="d0">DISEASE</data>
      <data key="d1">Systemic lupus erythematosus is an autoimmune disease
Systemic lupus erythematosus, where OX40 levels are compared to those in SSc patients
Systemic lupus erythematosus, an autoimmune disease
Systemic lupus erythematosus, an autoimmune disease
Systemic lupus erythematosus, an autoimmune disease
Systemic lupus erythematosus is an autoimmune disease associated with OX40-OX40L signaling</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14,1b656cfce91ff9ccec4223703489dab3,44f2592262cac835560b4c149fee8d2b,503107475d2e9dac49abd8ebcbadd9f5,8ce8c356713490cd2c680f505bcd050b,f9c444698bb08349abe4244fb771c1ee</data>
    </node>
    <node id="SJ&#214;GREN'S SYNDROME">
      <data key="d0">DISEASE</data>
      <data key="d1">Sj&#246;gren's syndrome is an autoimmune disease affecting moisture-producing glands</data>
      <data key="d2">503107475d2e9dac49abd8ebcbadd9f5</data>
    </node>
    <node id="POLYMYOSITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Polymyositis is an autoimmune disease causing muscle inflammation</data>
      <data key="d2">503107475d2e9dac49abd8ebcbadd9f5</data>
    </node>
    <node id="DCSSC">
      <data key="d0">DISEASE</data>
      <data key="d1">Diffuse cutaneous systemic sclerosis is a subtype of systemic sclerosis
Early diffuse cutaneous systemic sclerosis, a subtype of systemic sclerosis characterized by rapid skin thickening and involvement of internal organs
Diffuse cutaneous systemic sclerosis is a severe form of systemic sclerosis affecting the skin
Diffuse cutaneous systemic sclerosis, a subtype of systemic sclerosis
Diffuse cutaneous systemic sclerosis is a subtype of systemic sclerosis characterized by widespread skin involvement</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,855c455b4c9592746834ee3a4e0e6b81,9867d43adab0ba5db44961fae4863eee</data>
    </node>
    <node id="ASSET TRIAL">
      <data key="d0">PATHWAY</data>
      <data key="d1">ASSET trial (NCT02161406) is a phase II clinical trial assessing the efficacy of abatacept in SSc
Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis, a randomized placebo-controlled double-blind phase 2 trial</data>
      <data key="d2">503107475d2e9dac49abd8ebcbadd9f5,855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="CTLA4-B7">
      <data key="d0">PATHWAY</data>
      <data key="d1">CTLA4-B7 is a negative costimulatory pathway that restrains adaptive immune response</data>
      <data key="d2">503107475d2e9dac49abd8ebcbadd9f5</data>
    </node>
    <node id="PD1-PDL1/2">
      <data key="d0">PATHWAY</data>
      <data key="d1">PD1-PDL1/2 is a negative costimulatory pathway that restrains adaptive immune response</data>
      <data key="d2">503107475d2e9dac49abd8ebcbadd9f5</data>
    </node>
    <node id="IL-2 SECRETION">
      <data key="d0">PATHWAY</data>
      <data key="d1">IL-2 secretion is induced by CD28 binding to CD80 and CD86, promoting T-cell proliferation</data>
      <data key="d2">503107475d2e9dac49abd8ebcbadd9f5</data>
    </node>
    <node id="INFLAMMATION-DRIVEN DERMAL FIBROSIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Inflammation-driven dermal fibrosis is a symptom of systemic sclerosis</data>
      <data key="d2">503107475d2e9dac49abd8ebcbadd9f5</data>
    </node>
    <node id="DIGESTIVE INVOLVEMENT">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Digestive involvement is a symptom of systemic sclerosis</data>
      <data key="d2">503107475d2e9dac49abd8ebcbadd9f5</data>
    </node>
    <node id="LUNG FIBROSIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Lung fibrosis is a symptom of systemic sclerosis
Lung fibrosis is a type of fibrosis affecting the lungs, associated with OX40-OX40L signaling</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3,503107475d2e9dac49abd8ebcbadd9f5</data>
    </node>
    <node id="PULMONARY HYPERTENSION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Pulmonary hypertension is a symptom of systemic sclerosis
Pulmonary hypertension is a condition characterized by high blood pressure in the lungs
Pulmonary hypertension is a clinical manifestation observed in SSc
Pulmonary hypertension, a condition characterized by high blood pressure in the lungs</data>
      <data key="d2">503107475d2e9dac49abd8ebcbadd9f5,855c455b4c9592746834ee3a4e0e6b81,9867d43adab0ba5db44961fae4863eee,c69c7fb997f95c56cc077b3975f41923</data>
    </node>
    <node id="INFLAMMATORY JOINT INVOLVEMENT">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Inflammatory joint involvement is a symptom of systemic sclerosis</data>
      <data key="d2">503107475d2e9dac49abd8ebcbadd9f5</data>
    </node>
    <node id="PLACEBO-CONTROLLED RANDOMIZED TRIAL">
      <data key="d0">PATHWAY</data>
      <data key="d1">A placebo-controlled randomized trial is a type of clinical trial used to assess the efficacy of treatments</data>
      <data key="d2">503107475d2e9dac49abd8ebcbadd9f5</data>
    </node>
    <node id="NCT02161406">
      <data key="d0">PATHWAY</data>
      <data key="d1">NCT02161406 is the clinical trial identifier for the ASSET trial assessing abatacept in SSc</data>
      <data key="d2">503107475d2e9dac49abd8ebcbadd9f5</data>
    </node>
    <node id="T CELL RECEPTOR (TCR)">
      <data key="d0">PROTEIN</data>
      <data key="d1">T cell receptor (TCR) is involved in the recognition of antigens by T cells</data>
      <data key="d2">503107475d2e9dac49abd8ebcbadd9f5</data>
    </node>
    <node id="NAIVE T CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Naive T cells require costimulatory signals for activation and proliferation</data>
      <data key="d2">503107475d2e9dac49abd8ebcbadd9f5</data>
    </node>
    <node id="EXTRACELLULAR MATRIX">
      <data key="d0">TISSUE</data>
      <data key="d1">Extracellular matrix is produced by fibroblasts and is involved in tissue structure and fibrosis
The extracellular matrix is a network of proteins and other molecules that provide structural and biochemical support to surrounding cells
Extracellular matrix is a network of proteins and other molecules outside cells that provide structural and biochemical support
Extracellular matrix is a network of non-cellular components present within tissues and organs
The extracellular matrix is a network of proteins and other molecules that provide structural support to cells
The extracellular matrix is a network of proteins and other molecules that provide structural and biochemical support to surrounding cells</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14,44f2592262cac835560b4c149fee8d2b,4cf23e218b6aab3c77115173b5c7c2fd,503107475d2e9dac49abd8ebcbadd9f5,b2aae16813e647959b783a39ef9a19a7,df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="PD1">
      <data key="d0" />
      <data key="d1">
Programmed cell death protein 1, involved in negative costimulatory pathways
PD1 is a protein involved in immune response regulation, also known as programmed death 1</data>
      <data key="d2">4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="T-REG CELL">
      <data key="d0">CELL</data>
      <data key="d1">T-reg cell function is inactivated by OX40, unleashing nearby DCs</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="DERMAL FIBROBLASTS">
      <data key="d0">CELL</data>
      <data key="d1">Dermal fibroblasts are fibroblasts located in the skin

Dermal fibroblasts are cells in the skin that produce extracellular matrix and collagen, playing a critical role in wound healing and fibrosis</data>
      <data key="d2">05c97152fe02249153103be341d65b67,44f2592262cac835560b4c149fee8d2b,5f37466ca41c9b8b06ed8be0303d49f2</data>
    </node>
    <node id="MMP">
      <data key="d0">PROTEIN</data>
      <data key="d1">Matrix metalloproteinases are enzymes that break down proteins in the extracellular matrix
MMP is a family of enzymes involved in the proteolytic cleavage of CD27 from cells</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3,44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="MMP-2">
      <data key="d0">PROTEIN</data>
      <data key="d1">MMP-2 is a specific type of matrix metalloproteinase involved in the breakdown of extracellular matrix proteins
Matrix metalloproteinase-2 (MMP-2) is an enzyme involved in the breakdown of extracellular matrix proteins</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b,d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="PAH">
      <data key="d0">DISEASE</data>
      <data key="d1">Pulmonary arterial hypertension, a vascular complication associated with systemic sclerosis
Pulmonary arterial hypertension is a disease characterized by severe pulmonary hypertension and fibrosis</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3,44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="DIGITAL ULCERS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Digital ulcers are sores that occur on the fingers or toes, often associated with systemic sclerosis
Digital ulcers are a clinical manifestation observed in SSc</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b,855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="PERIPHERAL MICROANGIOPATHY">
      <data key="d0">DISEASE</data>
      <data key="d1">Peripheral microangiopathy is a condition involving small blood vessel damage, often assessed by nailfold videocapillaroscopy</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="IMATINIB MESYLATE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Imatinib Mesylate is a drug used in the treatment of certain cancers and has shown clinical improvement in systemic sclerosis</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="DNAM-1">
      <data key="d0">PROTEIN</data>
      <data key="d1">DNAX accessory molecule 1 is a regulator of adhesion and costimulation of T cells
DNAM-1 is a gene involved in immune cell signaling
DNAM-1 is a protein involved in immune response modulation, also known as CD226</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b,4d0e8ae9371a435885994b4161126bc3,9867d43adab0ba5db44961fae4863eee</data>
    </node>
    <node id="CD226">
      <data key="d0">GENE</data>
      <data key="d1">CD226 encodes DNAM-1 and is associated with genetic susceptibility to systemic sclerosis</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="PD-1">
      <data key="d0">PROTEIN</data>
      <data key="d1">Programmed cell death protein 1 is an immune checkpoint protein that regulates immune responses
PD-1 is an inhibitory molecule that regulates T cell tolerance
Programmed cell death protein 1, a protein targeted by pembrolizumab</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b,855c455b4c9592746834ee3a4e0e6b81,9867d43adab0ba5db44961fae4863eee</data>
    </node>
    <node id="PD-L1">
      <data key="d0">PROTEIN</data>
      <data key="d1">Programmed cell death ligand 1 is a protein that binds to PD-1 and plays a role in immune regulation
PD-L1 is a ligand of PD-1 that antagonizes T cell responses</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b,9867d43adab0ba5db44961fae4863eee</data>
    </node>
    <node id="SCTLA-4">
      <data key="d0">PROTEIN</data>
      <data key="d1">Soluble CTLA-4 is a form of CTLA-4 found in the serum, associated with disease severity in systemic sclerosis
sCTLA-4 is a soluble form of CTLA-4 that may inhibit early T-cell activation by blocking CD80/CD86&#8212;CD28 interaction</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b,9867d43adab0ba5db44961fae4863eee</data>
    </node>
    <node id="CD40L">
      <data key="d0" />
      <data key="d1" />
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="CD80/86">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD80 and CD86 are proteins that bind to CTLA-4 and CD28, involved in T cell activation</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="NAILFOLD VIDEOCAPILLAROSCOPY">
      <data key="d0">TISSUE</data>
      <data key="d1">Nailfold videocapillaroscopy is a technique used to assess peripheral microangiopathy</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="MEMORY B CELL">
      <data key="d0">CELL</data>
      <data key="d1">Memory B cells are a type of B cell that retains information about pathogens for faster response upon re-exposure</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="GERMINAL CENTER">
      <data key="d0">TISSUE</data>
      <data key="d1">Germinal centers are sites within lymph nodes where mature B cells proliferate, differentiate, and mutate their antibody genes</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="EPIGENETIC MODIFICATIONS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Epigenetic modifications are changes in gene expression without altering the DNA sequence, such as demethylation of regulatory elements</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="SOLUBLE CD40L">
      <data key="d0">PROTEIN</data>
      <data key="d1">Soluble CD40L is a form of CD40L found in the serum, associated with vascular complications in systemic sclerosis</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="MULTIANALYTE SIGNATURE">
      <data key="d0">PATHWAY</data>
      <data key="d1">A multianalyte signature is a combination of multiple biomarkers used to predict clinical outcomes</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="IMMUNE CHECKPOINT INHIBITORS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Immune checkpoint inhibitors are drugs that block proteins like PD-1 and CTLA-4 to boost the immune response against cancer</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="IMMUNE-RELATED ADVERSE EVENTS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Immune-related adverse events are side effects that occur when immune checkpoint inhibitors cause the immune system to attack normal tissues</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="NEOPLASTIC CONDITIONS">
      <data key="d0">DISEASE</data>
      <data key="d1">Neoplastic conditions are diseases that involve the growth of abnormal tissue, such as cancer</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="IMMUNE CHECKPOINT">
      <data key="d0">PROTEIN</data>
      <data key="d1">Immune checkpoints are proteins that regulate the immune response to maintain self-tolerance and prevent autoimmunity</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="ADHESION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Adhesion is the process by which cells interact and attach to neighboring cells through specialized molecules on their surface</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="COSTIMULATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Costimulation is a secondary signal that immune cells require to fully activate and respond to pathogens</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="T CELL PROLIFERATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">T cell proliferation is the process of T cells rapidly dividing and increasing in number in response to an antigen</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="T CELL ACTIVATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">T cell activation is the process by which T cells are primed to respond to pathogens</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="DISEASE SEVERITY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Disease severity refers to the extent and seriousness of a disease's impact on the body</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="DISEASE ACTIVITY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Disease activity refers to the current level of disease manifestation and progression</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="GENETIC SUSCEPTIBILITY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Genetic susceptibility refers to the increased likelihood of developing a disease due to genetic factors</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="IMMUNOLOGIC HOMEOSTASIS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immunologic homeostasis is the balance of immune responses to maintain health and prevent autoimmunity</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="IMMUNE CHECKPOINT BLOCKADE THERAPY">
      <data key="d0">PATHWAY</data>
      <data key="d1">Immune checkpoint blockade therapy is a treatment that inhibits immune checkpoints to enhance the immune response against cancer</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="T CELL INHIBITORY MOLECULE">
      <data key="d0">PROTEIN</data>
      <data key="d1">T cell inhibitory molecules are proteins that downregulate T cell activity to prevent overactivation</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="SERUM SOLUBLE CTLA-4">
      <data key="d0">PROTEIN</data>
      <data key="d1">Serum soluble CTLA-4 is a form of CTLA-4 found in the serum, associated with disease severity in systemic sclerosis</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="META-ANALYSIS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Meta-analysis is a statistical analysis that combines the results of multiple scientific studies</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="PUBLISHED DATA">
      <data key="d0">PATHWAY</data>
      <data key="d1">Published data refers to information that has been made publicly available through scientific publications</data>
      <data key="d2">44f2592262cac835560b4c149fee8d2b</data>
    </node>
    <node id="M2 MACROPHAGES">
      <data key="d0">CELL</data>
      <data key="d1">M2 macrophages are a profibrotic phenotype of macrophages that may perpetuate systemic sclerosis
Profibrotic type 2 macrophages induced by T helper cell cytokines</data>
      <data key="d2">855c455b4c9592746834ee3a4e0e6b81,9867d43adab0ba5db44961fae4863eee</data>
      <data key="d3">CELL</data>
    </node>
    <node id="PD-L2">
      <data key="d0">PROTEIN</data>
      <data key="d1">PD-L2 is a ligand of PD-1 that antagonizes T cell responses</data>
      <data key="d2">9867d43adab0ba5db44961fae4863eee</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="BLEOMYCIN MOUSE MODEL">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">The Bleomycin mouse model is used to study dermal fibrosis
Bleomycin mouse model is used to study dermal fibrosis and the effects of OX40L signaling</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3,9867d43adab0ba5db44961fae4863eee</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="INTERSTITIAL LUNG DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">Interstitial lung disease is a group of lung disorders affecting the interstitium
Interstitial lung disease is a type of lung fibrosis
Interstitial Lung Disease is a group of lung disorders causing progressive scarring of lung tissue</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,7f559ad7372a4e35e90b43cc67047b0f,9867d43adab0ba5db44961fae4863eee</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="FRA-2 TRANSGENIC MOUSE MODEL">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">The Fra-2 transgenic mouse model is used to study inflammatory infiltrates and vasculopathy</data>
      <data key="d2">9867d43adab0ba5db44961fae4863eee</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="CGVHD">
      <data key="d0">DISEASE</data>
      <data key="d1">Chronic graft-vs.-host disease is a condition that occurs after a stem cell or bone marrow transplant</data>
      <data key="d2">9867d43adab0ba5db44961fae4863eee</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="LIVER">
      <data key="d0">TISSUE</data>
      <data key="d1">The liver is an organ involved in various metabolic processes
The liver is one of the organs affected by fibrosis
The liver is an organ involved in metabolism, detoxification, and protein synthesis
The liver is an organ involved in metabolism, detoxification, and protein synthesis
The liver is a tissue where TL1A has been implicated in fibrosis
The liver is an organ involved in metabolism and detoxification
The liver is an organ involved in metabolism and detoxification, affected in liver cirrhosis
The liver is an organ involved in metabolism and detoxification and can be affected by fibrotic diseases</data>
      <data key="d2">05c97152fe02249153103be341d65b67,080b1dc5fcc0eee3645a06983a0de603,68015074236b0144899baa38d01ae467,7c13f41d7349d9d2e56c36e00c0ca2d9,9867d43adab0ba5db44961fae4863eee,a10787d7fbb1307be263e86dc7b33a51,b2aae16813e647959b783a39ef9a19a7,c525762bb827485bceeb9f09bb4bcfe0</data>
      <data key="d3">TISSUE</data>
    </node>
    <node id="COLON">
      <data key="d0">TISSUE</data>
      <data key="d1">The colon is part of the large intestine involved in water absorption and feces formation</data>
      <data key="d2">9867d43adab0ba5db44961fae4863eee</data>
      <data key="d3">TISSUE</data>
    </node>
    <node id="RODNAN SKIN SCORE">
      <data key="d0">SYMPTOM</data>
      <data key="d1">The Rodnan skin score is a measure of skin thickness used in systemic sclerosis</data>
      <data key="d2">9867d43adab0ba5db44961fae4863eee</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="EUSTAR">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">The European League Against Rheumatism Scleroderma Trials and Research group is a cohort used for studying systemic sclerosis
European League Against Rheumatism Scleroderma Trials and Research group, a cohort used for studying SSc</data>
      <data key="d2">855c455b4c9592746834ee3a4e0e6b81,9867d43adab0ba5db44961fae4863eee</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="MONOCYTE">
      <data key="d0">CELL</data>
      <data key="d1">Monocytes are a type of white blood cell that can differentiate into macrophages and dendritic cells</data>
      <data key="d2">9867d43adab0ba5db44961fae4863eee</data>
    </node>
    <node id="PROINFLAMMATORY CYTOKINES">
      <data key="d0">PROTEIN</data>
      <data key="d1">Proinflammatory cytokines are signaling molecules that promote inflammation
Proinflammatory cytokines are signaling molecules that promote inflammation</data>
      <data key="d2">05c97152fe02249153103be341d65b67,9867d43adab0ba5db44961fae4863eee</data>
    </node>
    <node id="PROFIBROTIC CYTOKINES">
      <data key="d0">PROTEIN</data>
      <data key="d1">Profibrotic cytokines are signaling molecules that promote fibrosis
Profibrotic cytokines are signaling molecules that promote fibrosis</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e,9867d43adab0ba5db44961fae4863eee</data>
    </node>
    <node id="TIGHT SKIN-1 MOUSE MODEL">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">The Tight skin-1 mouse model is used to study non-inflammatory dermal fibrosis</data>
      <data key="d2">9867d43adab0ba5db44961fae4863eee</data>
    </node>
    <node id="GASTROINTESTINAL INVOLVEMENT">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Gastrointestinal involvement refers to the impact of a disease on the digestive system</data>
      <data key="d2">9867d43adab0ba5db44961fae4863eee</data>
    </node>
    <node id="CARDIAC HEMODYNAMIC IMPAIRMENT">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Cardiac hemodynamic impairment refers to the dysfunction of blood flow dynamics in the heart</data>
      <data key="d2">9867d43adab0ba5db44961fae4863eee</data>
    </node>
    <node id="FIBROGENIC MARKERS">
      <data key="d0">PROTEIN</data>
      <data key="d1">Fibrogenic markers are indicators of fibrosis in tissues</data>
      <data key="d2">9867d43adab0ba5db44961fae4863eee</data>
    </node>
    <node id="T-CELL PROLIFERATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">T-cell proliferation refers to the rapid increase in the number of T cells</data>
      <data key="d2">9867d43adab0ba5db44961fae4863eee</data>
    </node>
    <node id="M1 MACROPHAGES">
      <data key="d0">CELL</data>
      <data key="d1">M1 macrophages are a proinflammatory phenotype of macrophages</data>
      <data key="d2">9867d43adab0ba5db44961fae4863eee</data>
    </node>
    <node id="MRSS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Modified Rodnan Skin Score, a measure used to assess skin fibrosis in SSc patients
Modified-Rodnan skin score is a measure of skin thickness used in systemic sclerosis</data>
      <data key="d2">4d0e8ae9371a435885994b4161126bc3,855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="PEMBROLIZUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Pembrolizumab is a PD-1 inhibitor approved for the treatment of advanced melanoma, selected lymphomas, and advanced non-small cell lung cancer</data>
      <data key="d2">855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="NON-SMALL CELL LUNG CANCER">
      <data key="d0">DISEASE</data>
      <data key="d1">A type of lung cancer treated with pembrolizumab</data>
      <data key="d2">855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="CYCLOPHOSPHAMIDE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Cyclophosphamide is a standard therapy drug used in the treatment of SSc</data>
      <data key="d2">855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="MHC">
      <data key="d0">PROTEIN</data>
      <data key="d1">Major histocompatibility complex, involved in presenting peptide antigens to T cells</data>
      <data key="d2">855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="DNAM">
      <data key="d0">PROTEIN</data>
      <data key="d1">DNAX accessory molecule, involved in positive costimulatory pathways</data>
      <data key="d2">855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="CD112">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD112 is involved in positive costimulatory pathways
CD112 is a protein involved in immune response modulation, also known as Nectin-2</data>
      <data key="d2">4d0e8ae9371a435885994b4161126bc3,855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="CD115">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD115 is involved in positive costimulatory pathways</data>
      <data key="d2">855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="PDL1">
      <data key="d0">PROTEIN</data>
      <data key="d1">Programmed death-ligand 1, involved in negative costimulatory pathways</data>
      <data key="d2">855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="PDL2">
      <data key="d0">PROTEIN</data>
      <data key="d1">Programmed death-ligand 2, involved in negative costimulatory pathways</data>
      <data key="d2">855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="IFN&#915;">
      <data key="d0">PROTEIN</data>
      <data key="d1">Interferon gamma, a cytokine involved in T helper cell responses</data>
      <data key="d2">855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="TREG">
      <data key="d0">CELL</data>
      <data key="d1">Regulatory T cells, promoting M2 macrophage polarization and activation</data>
      <data key="d2">855c455b4c9592746834ee3a4e0e6b81</data>
      <data key="d3">CELL</data>
    </node>
    <node id="TGF&#914;">
      <data key="d0">PROTEIN</data>
      <data key="d1">Transforming growth factor beta, secreted by Treg cells to promote M2 macrophage activation
Transforming growth factor-beta (TGF&#946;) is a central fibrogenic cytokine involved in fibrosis pathogenesis
TGF&#946; is a protein whose mRNA expression is reduced by TAPI-1 treatment
TGF&#946; is a cytokine that plays a crucial role in cell growth, differentiation, and fibrosis
Transforming growth factor-beta is a cytokine involved in cell growth, proliferation, and differentiation
Transforming growth factor-beta is a cytokine implicated in EoE pathogenesis</data>
      <data key="d2">05c97152fe02249153103be341d65b67,080b1dc5fcc0eee3645a06983a0de603,5ec1ebf4e260eb1f8fda8acdf06cd39e,5f37466ca41c9b8b06ed8be0303d49f2,855c455b4c9592746834ee3a4e0e6b81,d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="MMPS">
      <data key="d0">PROTEIN</data>
      <data key="d1">Metalloproteinases, stimulating antigen-presenting cells to upregulate positive costimulatory molecules</data>
      <data key="d2">855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="APCS">
      <data key="d0">CELL</data>
      <data key="d1">Antigen-presenting cells, upregulated by MMPs to express positive costimulatory molecules</data>
      <data key="d2">855c455b4c9592746834ee3a4e0e6b81</data>
      <data key="d3">CELL</data>
    </node>
    <node id="JOINT">
      <data key="d0">TISSUE</data>
      <data key="d1">Joints are affected by inflammatory involvement in SSc</data>
      <data key="d2">855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="NVC PATTERN">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Nailfold videocapillaroscopy pattern, used to assess microvascular changes in SSc</data>
      <data key="d2">855c455b4c9592746834ee3a4e0e6b81</data>
    </node>
    <node id="ILD">
      <data key="d0">DISEASE</data>
      <data key="d1">Interstitial lung disease, a condition associated with SSc
Interstitial lung disease is a group of lung disorders affecting the interstitium
Interstitial lung disease, a group of lung disorders causing scarring of lung tissue</data>
      <data key="d2">4d0e8ae9371a435885994b4161126bc3,855c455b4c9592746834ee3a4e0e6b81,b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="CD155">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD155 is a protein involved in immune response modulation, also known as PVR</data>
      <data key="d2">4d0e8ae9371a435885994b4161126bc3</data>
    </node>
    <node id="DERMAL FIBROSIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Dermal fibrosis is characterized by excessive scarring of the skin
Dermal fibrosis is a type of fibrosis affecting the skin, associated with OX40-OX40L signaling</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3,4d0e8ae9371a435885994b4161126bc3</data>
    </node>
    <node id="PD1-L">
      <data key="d0">PROTEIN</data>
      <data key="d1">PD1-L is a ligand for PD1, involved in immune response regulation</data>
      <data key="d2">4d0e8ae9371a435885994b4161126bc3</data>
    </node>
    <node id="PH">
      <data key="d0">DISEASE</data>
      <data key="d1">Pulmonary hypertension is a condition characterized by high blood pressure in the lungs</data>
      <data key="d2">4d0e8ae9371a435885994b4161126bc3</data>
    </node>
    <node id="NVC">
      <data key="d0">PATHWAY</data>
      <data key="d1">Nailfold vascular capillaroscopy is a diagnostic technique used to examine capillaries</data>
      <data key="d2">4d0e8ae9371a435885994b4161126bc3</data>
    </node>
    <node id="AUTOIMMUNITY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Autoimmunity is a condition where the immune system attacks the body's own tissues
Autoimmunity is a condition in which the immune system attacks the body's own tissues</data>
      <data key="d2">4d0e8ae9371a435885994b4161126bc3,8ce8c356713490cd2c680f505bcd050b</data>
    </node>
    <node id="ANIMAL MODELS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Animal models are used in research to study disease mechanisms and test treatments</data>
      <data key="d2">4d0e8ae9371a435885994b4161126bc3</data>
    </node>
    <node id="RS1234314">
      <data key="d0">SNP</data>
      <data key="d1">Single nucleotide polymorphism rs1234314 in the TNFSF4 gene region is associated with systemic sclerosis susceptibility
Single nucleotide polymorphism rs1234314 in the TNFSF4 gene region
Single nucleotide polymorphism rs1234314 of the TNFSF4 gene is associated with systemic sclerosis
Single nucleotide polymorphism rs1234314 of the TNFSF4 gene is associated with systemic sclerosis
Single nucleotide polymorphism rs1234314 of the TNFSF4 gene is linked to systemic sclerosis</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14,40ad2241836485e0bf264bdfb62fd789,c69c7fb997f95c56cc077b3975f41923,d8a485eb1e9435b083d5ef6a17f06ea5,f9c444698bb08349abe4244fb771c1ee</data>
      <data key="d3">SNP</data>
    </node>
    <node id="RS2205960">
      <data key="d0">SNP</data>
      <data key="d1">Single nucleotide polymorphism rs2205960 in the TNFSF4 gene region is associated with systemic sclerosis susceptibility
Single nucleotide polymorphism rs2205960 in the TNFSF4 gene region
Single nucleotide polymorphism rs2205960 of the TNFSF4 gene is associated with systemic sclerosis
Single nucleotide polymorphism rs2205960 of the TNFSF4 gene is linked to systemic sclerosis
Single nucleotide polymorphism rs2205960 of the TNFSF4 gene is associated with systemic sclerosis
Single nucleotide polymorphism rs2205960 of the TNFSF4 gene is linked to systemic sclerosis</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14,40ad2241836485e0bf264bdfb62fd789,8ce8c356713490cd2c680f505bcd050b,c69c7fb997f95c56cc077b3975f41923,d8a485eb1e9435b083d5ef6a17f06ea5,f9c444698bb08349abe4244fb771c1ee</data>
      <data key="d3">SNP</data>
    </node>
    <node id="RS844648">
      <data key="d0">SNP</data>
      <data key="d1">Single nucleotide polymorphism rs844648 in the TNFSF4 gene region is associated with systemic sclerosis susceptibility
Single nucleotide polymorphism rs844648 in the TNFSF4 gene region
Single nucleotide polymorphism rs844648 of the TNFSF4 gene is associated with systemic sclerosis
Single nucleotide polymorphism rs844648 of the TNFSF4 gene is associated with systemic sclerosis
Single nucleotide polymorphism rs844648 of the TNFSF4 gene is associated with systemic sclerosis</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14,40ad2241836485e0bf264bdfb62fd789,c69c7fb997f95c56cc077b3975f41923,d8a485eb1e9435b083d5ef6a17f06ea5,f9c444698bb08349abe4244fb771c1ee</data>
      <data key="d3">SNP</data>
    </node>
    <node id="RS844644">
      <data key="d0">SNP</data>
      <data key="d1">Single nucleotide polymorphism rs844644 in the TNFSF4 gene region is protective against systemic sclerosis
Single nucleotide polymorphism rs844644 in the TNFSF4 gene region
Single nucleotide polymorphism rs844644 of the TNFSF4 gene is associated with systemic sclerosis
Single nucleotide polymorphism rs844644 of the TNFSF4 gene is associated with systemic sclerosis
Single nucleotide polymorphism rs844644 of the TNFSF4 gene is associated with systemic sclerosis</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14,40ad2241836485e0bf264bdfb62fd789,c69c7fb997f95c56cc077b3975f41923,d8a485eb1e9435b083d5ef6a17f06ea5,f9c444698bb08349abe4244fb771c1ee</data>
      <data key="d3">SNP</data>
    </node>
    <node id="PTPN22">
      <data key="d0">GENE</data>
      <data key="d1">PTPN22 is a gene associated with the development of multiple autoimmune diseases including type I diabetes mellitus, rheumatoid arthritis, and systemic lupus erythematosus
PTPN22 is a gene associated with autoimmune diseases</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14,8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">GENE</data>
    </node>
    <node id="TIDM">
      <data key="d0">DISEASE</data>
      <data key="d1">Type I diabetes mellitus, an autoimmune disease</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="STAT4">
      <data key="d0">GENE</data>
      <data key="d1">STAT4 is a susceptibility gene for the development of systemic lupus erythematosus and rheumatoid arthritis
STAT4 is a gene involved in the signaling pathways of the immune system</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14,8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">GENE</data>
    </node>
    <node id="IRF5">
      <data key="d0">GENE</data>
      <data key="d1">IRF5 is a gene associated with polymorphisms linked to systemic lupus erythematosus and systemic sclerosis
IRF5 is a gene involved in the regulation of the immune response</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14,8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">GENE</data>
    </node>
    <node id="FAS">
      <data key="d0">GENE</data>
      <data key="d1">FAS is a gene associated with polymorphisms linked to systemic lupus erythematosus and systemic sclerosis
FAS is a gene involved in the regulation of programmed cell death</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14,8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">GENE</data>
    </node>
    <node id="CREST">
      <data key="d0">SYMPTOM</data>
      <data key="d1">CREST syndrome includes Calcinosis, Raynaud&#8217;s phenomenon, Esophageal dysfunction, Sclerodactyly, and Telangiectasias</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="CALCINOSIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Calcinosis is the formation of calcium deposits in the skin</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="RAYNAUD&#8217;S PHENOMENON">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Raynaud&#8217;s phenomenon is a condition where blood flow to extremities is reduced, often in response to cold or stress</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="ESOPHAGEAL DYSFUNCTION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Esophageal dysfunction involves problems with the esophagus, such as difficulty swallowing</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="SCLERODACTYLY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Sclerodactyly is the thickening and tightening of the skin on the fingers and hands</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="TELANGIECTASIAS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Telangiectasias are small, widened blood vessels on the skin</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="MYOSITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Myositis is an inflammation of the muscles
Myositis, an inflammatory disease causing muscle weakness</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14,f9c444698bb08349abe4244fb771c1ee</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="SJOGREN'S SYNDROME">
      <data key="d0">DISEASE</data>
      <data key="d1">Sjogren's syndrome is an autoimmune disease characterized by dry eyes and dry mouth
Sjogren's syndrome, an autoimmune disease affecting moisture-producing glands</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14,f9c444698bb08349abe4244fb771c1ee</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="NORTH AMERICAN CAUCASIAN">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">North American Caucasian refers to the population group involved in the study</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="GENISOS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">GENISOS stands for Genetics versus Environment in Scleroderma Outcomes Study</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="AMERICAN COLLEGE OF RHEUMATOLOGY">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">American College of Rheumatology is an organization that provides criteria for disease classification</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="SCLERODERMA FAMILY REGISTRY AND DNA REPOSITORY">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Scleroderma Family Registry and DNA Repository is a resource for genetic and clinical data on scleroderma</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="UNIVERSITY OF TEXAS RHEUMATOLOGY DIVISION">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">University of Texas Rheumatology Division is an institution involved in the study</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="PERIPHERAL BLOOD CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Peripheral blood cells are blood cells circulating in the bloodstream</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14</data>
      <data key="d3">CELL</data>
    </node>
    <node id="TYPE I INTERFERON">
      <data key="d0">PROTEIN</data>
      <data key="d1">Type I interferon is a protein involved in the immune response
Type I interferons are a group of cytokines involved in the regulation of the immune response</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14,8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="ANTINUCLEAR ANTIBODIES">
      <data key="d0">PROTEIN</data>
      <data key="d1">Antinuclear antibodies are autoantibodies that bind to contents of the cell nucleus
Antinuclear antibodies, detected using indirect immunofluorescence</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14,f9c444698bb08349abe4244fb771c1ee</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="VASCULOPATHY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Vasculopathy is a disease affecting blood vessels</data>
      <data key="d2">04bc518ea94163a4c2e74dcf1f885d14</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="HEP-2 CELLS">
      <data key="d0">CELL</data>
      <data key="d1">HEp-2 cells, used as an antigen substrate in immunofluorescence assays</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
    </node>
    <node id="ANTI-CENTROMERE ANTIBODIES">
      <data key="d0">PROTEIN</data>
      <data key="d1">Autoantibodies identified by their distinctive IIF pattern on HEp-2 cellsAnti-centromere antibodies, identified by their distinctive IIF pattern</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="TOPOISOMERASE I">
      <data key="d0">PROTEIN</data>
      <data key="d1">Topoisomerase I, targeted by autoantibodies in passive immunodiffusion</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
    </node>
    <node id="ANTI-RNA POLYMERASE III ANTIBODIES">
      <data key="d0">PROTEIN</data>
      <data key="d1">Autoantibodies detected by enzyme-linked immunoassayAnti-RNA polymerase III antibodies, detected by enzyme-linked immunoassay</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="RS1234315">
      <data key="d0">SNP</data>
      <data key="d1">Single nucleotide polymorphism rs1234315 in the TNFSF4 gene region</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
    </node>
    <node id="RS12039904">
      <data key="d0">SNP</data>
      <data key="d1">Single nucleotide polymorphism rs12039904 in the TNFSF4 gene region</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
    </node>
    <node id="RS2795288">
      <data key="d0">SNP</data>
      <data key="d1">Single nucleotide polymorphism rs2795288 in the TNFSF4 gene region</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
    </node>
    <node id="RS844665">
      <data key="d0">SNP</data>
      <data key="d1">Single nucleotide polymorphism rs844665 in the TNFSF4 gene region
Single nucleotide polymorphism rs844665 of the TNFSF4 gene is not significantly associated with systemic sclerosis
Single nucleotide polymorphism rs844665 of the TNFSF4 gene is associated with systemic sclerosis</data>
      <data key="d2">c69c7fb997f95c56cc077b3975f41923,d8a485eb1e9435b083d5ef6a17f06ea5,f9c444698bb08349abe4244fb771c1ee</data>
    </node>
    <node id="RS10912580">
      <data key="d0">SNP</data>
      <data key="d1">Single nucleotide polymorphism rs10912580 in the TNFSF4 gene region</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
    </node>
    <node id="PERIPHERAL BLOOD">
      <data key="d0">TISSUE</data>
      <data key="d1">Blood from which genomic DNA was extracted for SNP genotypingPeripheral blood, used for genomic DNA extraction</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
      <data key="d3">TISSUE</data>
    </node>
    <node id="GENOMIC DNA">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Genomic DNA, extracted from peripheral blood for SNP genotyping</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
    </node>
    <node id="CAUCASIAN">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Caucasian, the population used in the candidate gene association studyPopulation used in the candidate gene association study
Caucasian refers to a population group used in genetic studies</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b,f9c444698bb08349abe4244fb771c1ee</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="HAPMAP">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Resource used for allele call validationHapMap, a resource used for allele call validation</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="CEPH">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Centre d&#8217;Etude du Polymorphisme Humain, used as positive controls in genotyping assays</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="HWE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Hardy&#8211;Weinberg equilibrium, a principle used in genetic studies</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="LD">
      <data key="d0">PATHWAY</data>
      <data key="d1">Linkage disequilibrium, a measure of association between genetic variants</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="OMNIBUS TEST">
      <data key="d0">PATHWAY</data>
      <data key="d1">Omnibus test, used to detect differences in haplotype frequency profiles</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="CART">
      <data key="d0">PATHWAY</data>
      <data key="d1">Classification and regression tree analysis, used to explore interactions between SNPs
Classification and regression tree analysis is a statistical method used to explore the relationship between variables</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b,f9c444698bb08349abe4244fb771c1ee</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="ACR">
      <data key="d0">PATHWAY</data>
      <data key="d1">American College of Rheumatology criteria, used for diagnosing SLE</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
    </node>
    <node id="ANTI-TOPOISOMERASE I ANTIBODIES">
      <data key="d0">PROTEIN</data>
      <data key="d1">Autoantibodies targeting topoisomerase I, detected by passive immunodiffusion</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
    </node>
    <node id="PUREGENE GENOMIC DNA ISOLATION KIT">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Kit used for extracting genomic DNA from peripheral blood</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
    </node>
    <node id="ABI TAQMAN SNP GENOTYPING ASSAY">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Assay used for genotyping SNPs</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
    </node>
    <node id="ABI 7900HT">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Real-time thermocycler used for plate reading in SNP genotyping</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
    </node>
    <node id="SAS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Software used for statistical analysis</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
    </node>
    <node id="HAPLOVIEW">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Software used for determining linkage disequilibrium</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
    </node>
    <node id="SALFORD SYSTEMS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Software used for classification and regression tree analysis</data>
      <data key="d2">f9c444698bb08349abe4244fb771c1ee</data>
    </node>
    <node id="LSSC">
      <data key="d0">DISEASE</data>
      <data key="d1">Limited systemic sclerosis, a subset of systemic sclerosis with limited cutaneous involvement
Limited systemic sclerosis, a subset of systemic sclerosis</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b,c69c7fb997f95c56cc077b3975f41923</data>
    </node>
    <node id="DSSC">
      <data key="d0">DISEASE</data>
      <data key="d1">Diffuse systemic sclerosis, a subset of systemic sclerosis with extensive cutaneous involvement
Diffuse systemic sclerosis, a subset of systemic sclerosis</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b,c69c7fb997f95c56cc077b3975f41923</data>
    </node>
    <node id="ACA">
      <data key="d0">PROTEIN</data>
      <data key="d1">Anticentromere antibodies, associated with a subset of systemic sclerosis</data>
      <data key="d2">c69c7fb997f95c56cc077b3975f41923</data>
    </node>
    <node id="ATA">
      <data key="d0">PROTEIN</data>
      <data key="d1">Anti-topoisomerase antibodies, associated with a subset of systemic sclerosis</data>
      <data key="d2">c69c7fb997f95c56cc077b3975f41923</data>
    </node>
    <node id="ARA">
      <data key="d0">PROTEIN</data>
      <data key="d1">Anti-RNA polymerase III antibodies, associated with a subset of systemic sclerosis</data>
      <data key="d2">c69c7fb997f95c56cc077b3975f41923</data>
    </node>
    <node id="PULMONARY FIBROSIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Pulmonary fibrosis, a condition characterized by scarring of the lung tissue
Pulmonary fibrosis is a type of lung fibrosis
Pulmonary fibrosis is a condition characterized by the thickening and scarring of lung tissuePulmonary fibrosis is a condition studied using bleomycin-induced mouse models
Pulmonary fibrosis is a lung disease characterized by damaged and scarred lung tissue
Pulmonary Fibrosis is a lung disease that occurs when lung tissue becomes damaged and scarred</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,5ec1ebf4e260eb1f8fda8acdf06cd39e,7c13f41d7349d9d2e56c36e00c0ca2d9,7f559ad7372a4e35e90b43cc67047b0f,c69c7fb997f95c56cc077b3975f41923</data>
    </node>
    <node id="RS855648">
      <data key="d0">SNP</data>
      <data key="d1">Single nucleotide polymorphism rs855648 of the TNFSF4 gene is associated with systemic sclerosis
Single nucleotide polymorphism rs855648 of the TNFSF4 gene is associated with systemic sclerosis</data>
      <data key="d2">c69c7fb997f95c56cc077b3975f41923,d8a485eb1e9435b083d5ef6a17f06ea5</data>
    </node>
    <node id="ANTI-CENTROMERE">
      <data key="d0">PROTEIN</data>
      <data key="d1">Anti-centromere antibodies are associated with systemic sclerosis
Antibodies against centromere proteins, associated with systemic sclerosis</data>
      <data key="d2">40ad2241836485e0bf264bdfb62fd789,d8a485eb1e9435b083d5ef6a17f06ea5</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="ANTI-TOPOISOMERASE I">
      <data key="d0">PROTEIN</data>
      <data key="d1">Anti-topoisomerase I antibodies are associated with systemic sclerosis
Antibodies against topoisomerase I, associated with systemic sclerosis</data>
      <data key="d2">40ad2241836485e0bf264bdfb62fd789,d8a485eb1e9435b083d5ef6a17f06ea5</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="ANTI-RNA POLYMERASE III">
      <data key="d0">PROTEIN</data>
      <data key="d1">Anti-RNA polymerase III antibodies are associated with systemic sclerosis
Antibodies against RNA polymerase III, associated with systemic sclerosis</data>
      <data key="d2">40ad2241836485e0bf264bdfb62fd789,d8a485eb1e9435b083d5ef6a17f06ea5</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="LIMITED SYSTEMIC SCLEROSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">A subtype of systemic sclerosis characterized by limited skin involvement</data>
      <data key="d2">40ad2241836485e0bf264bdfb62fd789</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="DIFFUSE SYSTEMIC SCLEROSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">A subtype of systemic sclerosis characterized by widespread skin involvement</data>
      <data key="d2">40ad2241836485e0bf264bdfb62fd789</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="SNP">
      <data key="d0">SNP</data>
      <data key="d1">Single nucleotide polymorphism, a variation in a single nucleotide that occurs at a specific position in the genome</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
    </node>
    <node id="RS944648">
      <data key="d0">SNP</data>
      <data key="d1">Single nucleotide polymorphism rs944648 of the TNFSF4 gene is associated with systemic sclerosis</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
    </node>
    <node id="NK CELL">
      <data key="d0">CELL</data>
      <data key="d1">Natural killer cells are a type of lymphocyte that can kill tumor cells and virus-infected cells</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
    </node>
    <node id="ENDOTHELIAL CELL">
      <data key="d0">CELL</data>
      <data key="d1">Endothelial cells form the lining of blood vessels and play a role in vascular biology</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">CELL</data>
    </node>
    <node id="SMOOTH MUSCLE CELL">
      <data key="d0">CELL</data>
      <data key="d1">Smooth muscle cells are found in the walls of hollow organs and are involved in involuntary movements</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">CELL</data>
    </node>
    <node id="FOXP3+ REGULATORY T CELL">
      <data key="d0">CELL</data>
      <data key="d1">Foxp3+ regulatory T cells are a subset of T cells involved in maintaining immune tolerance</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">CELL</data>
    </node>
    <node id="C57/BL6">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">C57/BL6 is a common inbred strain of laboratory mouse</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="NON-OBESE DIABETIC MOUSE">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Non-obese diabetic mouse is a model organism used to study autoimmune diabetes</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Experimental autoimmune encephalomyelitis is a model for multiple sclerosis</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="MHC CLASS II">
      <data key="d0">GENE</data>
      <data key="d1">Major histocompatibility complex class II is a gene involved in the immune response</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">GENE</data>
    </node>
    <node id="AIF1">
      <data key="d0">GENE</data>
      <data key="d1">AIF1 is a gene associated with immune response regulation</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">GENE</data>
    </node>
    <node id="AUTOANTIBODY">
      <data key="d0">PROTEIN</data>
      <data key="d1">Autoantibodies are antibodies that mistakenly target and react with a person's own tissues</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="GENE&#8211;GENE INTERACTION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Gene&#8211;gene interaction refers to the interaction between different genes that can affect the development of diseases</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="GENE&#8211;ENVIRONMENT INTERACTION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Gene&#8211;environment interaction refers to the interaction between genetic predisposition and environmental factors in the development of diseases</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="BENJAMINI AND HOCHBERG METHOD">
      <data key="d0">PATHWAY</data>
      <data key="d1">Benjamini and Hochberg method is a statistical method used to control the false discovery rate in multiple hypothesis testing</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="&#935;2">
      <data key="d0">PATHWAY</data>
      <data key="d1">Chi-squared test is a statistical test used to determine if there is a significant association between two categorical variables</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="LOGISTIC REGRESSION">
      <data key="d0">PATHWAY</data>
      <data key="d1">Logistic regression is a statistical method used to model the relationship between a dependent variable and one or more independent variables</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="D&#8217;">
      <data key="d0">PATHWAY</data>
      <data key="d1">Disequilibrium coefficient D&#8217; is a measure of linkage disequilibrium between genetic markers</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="R">
      <data key="d0">PATHWAY</data>
      <data key="d1">Correlation coefficient r is a measure of the strength and direction of the relationship between two variables</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="HAPLOTYPE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Haplotype is a group of genes within an organism that was inherited together from a single parent</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="LINKAGE DISEQUILIBRIUM">
      <data key="d0">PATHWAY</data>
      <data key="d1">Linkage disequilibrium is the non-random association of alleles at different loci in a given population</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="HAPLOTYPE BLOCK">
      <data key="d0">PATHWAY</data>
      <data key="d1">Haplotype block is a region of the genome where genetic variations are inherited together</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
      <data key="d3">PATHWAY</data>
    </node>
    <node id="PFDR">
      <data key="d0">PATHWAY</data>
      <data key="d1">Corrected p values using Benjamini and Hochberg false discovery rate method</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
    </node>
    <node id="PU">
      <data key="d0">PATHWAY</data>
      <data key="d1">Raw &#967;2 p values</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
    </node>
    <node id="DIABETES">
      <data key="d0">DISEASE</data>
      <data key="d1">Diabetes is a disease characterized by high blood sugar levels</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
    </node>
    <node id="GENDER">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Gender is a demographic variable often controlled for in genetic studies</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
    </node>
    <node id="NORTH AMERICAN">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">North American refers to a population group used in genetic studies</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
    </node>
    <node id="CAUCASIAN WOMEN">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Caucasian women refers to a specific demographic group used in genetic studies</data>
      <data key="d2">8ce8c356713490cd2c680f505bcd050b</data>
    </node>
    <node id="SNPS">
      <data key="d0">SNP</data>
      <data key="d1">Single nucleotide polymorphisms within the promoter region of the TNFSF4 gene, associated with SSc susceptibility</data>
      <data key="d2">7b454335c2f5651d86f712037a0dc0ff</data>
    </node>
    <node id="UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON MEDICAL SCHOOL IRB">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">The institutional review board that approved the study</data>
      <data key="d2">7b454335c2f5651d86f712037a0dc0ff</data>
    </node>
    <node id="ODDS RATIOS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Odds ratios are statistical measures used to determine the strength of association between two events</data>
      <data key="d2">7b454335c2f5651d86f712037a0dc0ff</data>
    </node>
    <node id="GENOTYPING">
      <data key="d0">PATHWAY</data>
      <data key="d1">Genotyping is a process used to determine differences in the genetic make-up or genotype of an individual by examining their DNA sequence</data>
      <data key="d2">7b454335c2f5651d86f712037a0dc0ff</data>
    </node>
    <node id="DNA SEQUENCING">
      <data key="d0">PATHWAY</data>
      <data key="d1">DNA sequencing is the process of determining the precise order of nucleotides within a DNA molecule</data>
      <data key="d2">7b454335c2f5651d86f712037a0dc0ff</data>
    </node>
    <node id="PROMOTER REGION">
      <data key="d0">TISSUE</data>
      <data key="d1">The promoter region is a sequence of DNA needed to turn a gene on or off</data>
      <data key="d2">7b454335c2f5651d86f712037a0dc0ff</data>
    </node>
    <node id="GENETIC STRUCTURE">
      <data key="d0">PATHWAY</data>
      <data key="d1">Genetic structure refers to the organization of and interaction between genes within a genome</data>
      <data key="d2">7b454335c2f5651d86f712037a0dc0ff</data>
    </node>
    <node id="LUNGS">
      <data key="d0">TISSUE</data>
      <data key="d1">The lungs are one of the organs affected by fibrosis
The lungs are visceral organs affected by systemic sclerosisThe lungs are organs affected by pulmonary fibrosis
The lungs are respiratory organs that can be affected by fibrotic diseases</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,5ec1ebf4e260eb1f8fda8acdf06cd39e,68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="HEART">
      <data key="d0">TISSUE</data>
      <data key="d1">The heart is one of the organs affected by fibrosis
The heart is an organ affected by systemic sclerosisThe heart is a visceral organ affected by systemic sclerosis
The heart is an organ responsible for pumping blood throughout the body
The heart is a muscular organ that can be affected by fibrotic diseases</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,5ec1ebf4e260eb1f8fda8acdf06cd39e,68015074236b0144899baa38d01ae467,a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="KIDNEY">
      <data key="d0">TISSUE</data>
      <data key="d1">The kidney is one of the organs affected by fibrosis
The kidney is an organ involved in filtering blood, removing waste, and regulating fluid balance</data>
      <data key="d2">05c97152fe02249153103be341d65b67,080b1dc5fcc0eee3645a06983a0de603</data>
    </node>
    <node id="MYOFIBROBLASTS">
      <data key="d0">CELL</data>
      <data key="d1">Myofibroblasts are differentiated fibroblasts responsible for collagen and extracellular matrix protein deposition and smooth muscle hypertrophy in fibrosis
Myofibroblasts are cells whose numbers are reduced by TAPI-1 treatment
Myofibroblasts are specialized cells involved in wound healing and fibrosis
Myofibroblasts are differentiated fibroblasts that produce collagen and are induced by TL1A in the lung
Myofibroblasts are structural cells that express OX40L in fibrotic tissues</data>
      <data key="d2">05c97152fe02249153103be341d65b67,080b1dc5fcc0eee3645a06983a0de603,1b656cfce91ff9ccec4223703489dab3,5ec1ebf4e260eb1f8fda8acdf06cd39e,c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="TNFR1">
      <data key="d0">PROTEIN</data>
      <data key="d1">TNF receptor I (TNFR1), also known as TNFR&#945;, p55, or CD120a, is a receptor for TNF involved in cell survival and death responses
TNFR1 is a receptor that can signal to induce NF-&#954;B activation and cell survival responses, and also has potential to induce cell death response
TNFR1 is a receptor for TNF involved in inflammation and fibrosis
TNFR1 is a receptor for tumor necrosis factor involved in inflammation and apoptosis
TNFR1 is a receptor for TNF, also known as CD120a, TNFAR, p55</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,5ec1ebf4e260eb1f8fda8acdf06cd39e,a10787d7fbb1307be263e86dc7b33a51,c95d22c2a90e77cd22bd0d280d55b26a,df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="TNFR2">
      <data key="d0">PROTEIN</data>
      <data key="d1">TNF receptor II (TNFR2), also known as TNFR&#946; or p75, is a receptor for TNF involved in cell survival responses
TNFR2 is a receptor that recruits TNFR-associated factor (TRAF) 1 and 2 proteins and signals to induce NF-&#954;B activation and cell survival responses
TNFR2 is a receptor for TNF that appears to be key for mediating fibrotic development
TNFR2 is another receptor for tumor necrosis factor involved in immune response regulation
TNFR2 is a receptor for TNF, also known as CD120b, TNFBR, p75</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,5ec1ebf4e260eb1f8fda8acdf06cd39e,a10787d7fbb1307be263e86dc7b33a51,c95d22c2a90e77cd22bd0d280d55b26a,df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="NK CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Natural killer (NK) cells are a type of cell that can express TNF
Natural killer (NK) cells are a type of lymphocyte critical to the innate immune system
NK cells, or natural killer cells, are a type of lymphocyte involved in the innate immune response
NK cells are a type of lymphocyte involved in the immune response, expressing CD27
Natural killer cells are a type of lymphocyte critical to the innate immune system</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,1b656cfce91ff9ccec4223703489dab3,4cf23e218b6aab3c77115173b5c7c2fd,7c13f41d7349d9d2e56c36e00c0ca2d9,d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="IDIOPATHIC PULMONARY FIBROSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Idiopathic pulmonary fibrosis is a type of lung fibrosis
Idiopathic pulmonary fibrosis is a chronic, progressive lung disease
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease characterized by fibrosis of the lung tissue
Idiopathic Pulmonary Fibrosis is a type of chronic lung disease characterized by a progressive and irreversible decline in lung function</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,5f37466ca41c9b8b06ed8be0303d49f2,7f559ad7372a4e35e90b43cc67047b0f,df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="ACUTE RESPIRATORY DISTRESS SYNDROME">
      <data key="d0">DISEASE</data>
      <data key="d1">Acute respiratory distress syndrome is a type of lung fibrosis
Acute respiratory distress syndrome (ARDS) is a severe lung condition characterized by rapid onset of widespread inflammation in the lungs</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,5f37466ca41c9b8b06ed8be0303d49f2</data>
    </node>
    <node id="CYSTIC FIBROSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Cystic fibrosis is a type of lung fibrosis</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603</data>
    </node>
    <node id="MYOCARDITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Myocarditis is a type of heart fibrosis
Myocarditis is inflammation of the heart muscle</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="ISCHEMIC MYOCARDIAL INFARCTION">
      <data key="d0">DISEASE</data>
      <data key="d1">Ischemic myocardial infarction is a type of heart fibrosis</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603</data>
    </node>
    <node id="NON-ISCHEMIC HYPERTROPHIC CARDIOMYOPATHY">
      <data key="d0">DISEASE</data>
      <data key="d1">Non-ischemic hypertrophic cardiomyopathy is a type of heart fibrosis</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603</data>
    </node>
    <node id="ATOPIC ECZEMA">
      <data key="d0">DISEASE</data>
      <data key="d1">Atopic eczema is a type of skin fibrosis
</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="DUPUYTREN&#8217;S DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">Dupuytren&#8217;s disease is a type of skin fibrosis
Dupuytren&#8217;s disease is a condition that affects the hands and fingers</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="ACUTE KIDNEY INJURY">
      <data key="d0">DISEASE</data>
      <data key="d1">Acute kidney injury is a type of kidney fibrosis
Acute kidney injury (AKI) is a sudden episode of kidney failure or kidney damage that happens within a few hours or a few days</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,5f37466ca41c9b8b06ed8be0303d49f2</data>
    </node>
    <node id="CHRONIC KIDNEY DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">Chronic kidney disease is a type of kidney fibrosis</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603</data>
    </node>
    <node id="NON-ALCOHOLIC STEATOHEPATITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Non-alcoholic steatohepatitis is a type of liver fibrosis</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603</data>
    </node>
    <node id="NON-ALCOHOLIC FATTY LIVER DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">Non-alcoholic fatty liver disease is a type of liver fibrosis
Non-alcoholic fatty liver disease is a condition where fat builds up in the liver
Non-alcoholic fatty liver disease (NAFLD) is a condition characterized by excess fat stored in the liver not due to alcohol use</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,5f37466ca41c9b8b06ed8be0303d49f2,df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="PRIMARY BILIARY CHOLANGITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Primary biliary cholangitis is a type of liver fibrosis
Primary biliary cholangitis is a chronic liver disease characterized by progressive destruction of the bile ducts</data>
      <data key="d2">080b1dc5fcc0eee3645a06983a0de603,b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="FR1">
      <data key="d0">PROTEIN</data>
      <data key="d1">FR1 contains a death domain (DD) and can recruit TNFR1-associated DD (TRADD)</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="TRADD">
      <data key="d0">PROTEIN</data>
      <data key="d1">TRADD is recruited by FR1 and is involved in signaling pathways</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="TRAF1">
      <data key="d0">PROTEIN</data>
      <data key="d1">TRAF1 is recruited by TNFR2 and is involved in signaling pathways</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="TRAF2">
      <data key="d0">PROTEIN</data>
      <data key="d1">TRAF2 is recruited by TNFR2 and is involved in signaling pathways</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="CERTOLIZUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Certolizumab is a TNF antagonist used in the treatment of inflammatory diseases</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="SPONDYLARTHROPATHIES">
      <data key="d0">DISEASE</data>
      <data key="d1">Spondylarthropathies are inflammatory diseases treated with TNF antagonists</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="TACE">
      <data key="d0">PROTEIN</data>
      <data key="d1">TACE processes pro-TNF and its receptors including soluble TNFR1
TNF-alpha-converting enzyme, involved in the cleavage of membrane-bound TNF</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e,a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="TAPI-1">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Tumor necrosis factor-alpha processing inhibitor-1 (TAPI-1) is used to block TACE</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="COL1A1">
      <data key="d0">GENE</data>
      <data key="d1">Col1a1 is a gene whose mRNA expression is reduced by TAPI-1 treatment
Col1a1 is a gene encoding collagen type I alpha 1 chain, involved in fibrosis</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e,a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="&#913;SMA">
      <data key="d0">PROTEIN</data>
      <data key="d1">Alpha smooth muscle actin (&#945;SMA) is a protein whose mRNA expression is reduced by TAPI-1 treatmentAlpha smooth muscle actin (&#945;SMA) is a protein involved in the contractile function of myofibroblasts
&#945;SMA is a protein whose expression is suppressed by TNF in human dermal fibroblasts
&#945;SMA (alpha-smooth muscle actin) is a protein marker of myofibroblast differentiation and fibrosis
Alpha-smooth muscle actin is a protein involved in the contractile function of myofibroblasts
Alpha-smooth muscle actin, a marker of myofibroblast differentiation
&#945;SMA is a protein marker found on myofibroblasts expressing OX40L in fibrotic skin
Alpha-smooth muscle actin is a protein used as a marker to measure fibrosis</data>
      <data key="d2">05c97152fe02249153103be341d65b67,1b656cfce91ff9ccec4223703489dab3,5ec1ebf4e260eb1f8fda8acdf06cd39e,5f37466ca41c9b8b06ed8be0303d49f2,a10787d7fbb1307be263e86dc7b33a51,b2aae16813e647959b783a39ef9a19a7,d4797ed1483e5057bcd8301eaa509d5e</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="DERMAL T CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Dermal T cells from patients with diffuse cutaneous SSc show upregulated TNFR1 and TNFR2</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="TYPE 1 COLLAGEN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Type 1 collagen expression is elevated in fibroblasts after TNF-co-stimulation of SSc patient T cells</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="IPF">
      <data key="d0">DISEASE</data>
      <data key="d1">Idiopathic pulmonary fibrosis (IPF) is a disease where sTNFR1 is increased in fibroblast supernatant</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="BLEOMYCIN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Bleomycin is used to induce pulmonary fibrosis in mouse models
Bleomycin is a medication used in chemotherapy that can induce pulmonary fibrosis in animal models
Bleomycin is a chemical used to induce cell injury and fibrosis in experimental models
Bleomycin is a chemical used to induce skin fibrosis in experimental models</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e,7c13f41d7349d9d2e56c36e00c0ca2d9,b2aae16813e647959b783a39ef9a19a7,d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="TNF-/-">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">TNF-/- mice are genetically modified to lack TNF expression</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="TNFTM/TM">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">TNFtm/tm mice only express membrane-bound TNF (mTNF)</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="WT">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Wild-type (WT) mice are used as controls in experiments
Wild-type, referring to the normal, non-mutated genotype</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e,a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="CD4+CD25+ T-CELL">
      <data key="d0">CELL</data>
      <data key="d1">CD4+CD25+ T-cell differentiation is inhibited by impaired TNF/TNFR2 signaling</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="BALF">
      <data key="d0">TISSUE</data>
      <data key="d1">Bronchoalveolar lavage fluid (BALF) is used to measure inflammatory cytokines
Bronchoalveolar lavage fluid, a sample of fluid from the lungs
Bronchoalveolar lavage fluid (BALF) is a sample of fluid from the lungs used for analysis in research</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e,7c13f41d7349d9d2e56c36e00c0ca2d9,b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="HYPERSENSITIVITY PNEUMONITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Hypersensitivity pneumonitis (HP) is a condition where TNFR2 signaling is elevated in fibrotic samples</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="HUMAN DERMAL FIBROBLASTS">
      <data key="d0">CELL</data>
      <data key="d1">Human dermal fibroblasts are cells where TNF suppresses &#945;SMA expression in vitroHuman dermal fibroblasts are cells that produce collagen and are involved in fibrosis
Human dermal fibroblasts are cells found in the dermis layer of the skin involved in wound healing and fibrosis</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e,a10787d7fbb1307be263e86dc7b33a51</data>
      <data key="d3">CELL</data>
    </node>
    <node id="PROFIBROTIC MACROPHAGES">
      <data key="d0">CELL</data>
      <data key="d1">Profibrotic macrophages are a type of immune cell that promotes fibrosisProfibrotic macrophages are cells whose numbers and programming status are affected by TNF</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
      <data key="d3">CELL</data>
    </node>
    <node id="VISCERAL ORGANS">
      <data key="d0">TISSUE</data>
      <data key="d1">Visceral organs including the lungs and heart are affected by systemic sclerosis</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
      <data key="d3">TISSUE</data>
    </node>
    <node id="CELL DEATH">
      <data key="d0" />
      <data key="d1" />
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="STNFR1">
      <data key="d0" />
      <data key="d1">Soluble TNFR1 is a form of TNFR1 that is increased in the fibroblast supernatant from IPF patients</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="TNF ANTAGONISTS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">TNF antagonists are drugs that inhibit the action of tumor necrosis factor and are used to treat inflammatory diseases</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="SOLUBLE TNFR1">
      <data key="d0">PROTEIN</data>
      <data key="d1">Soluble TNFR1 is a form of TNFR1 that is found in the serum and correlates with disease severity in SSc</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="BLEOMYCIN-INDUCED MURINE MODEL">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Bleomycin-induced murine model is a mouse model used to study systemic sclerosis and pulmonary fibrosis</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="MTNF">
      <data key="d0">PROTEIN</data>
      <data key="d1">Membrane-bound TNF (mTNF) is a form of TNF that is expressed on the cell surface</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="STNF">
      <data key="d0">PROTEIN</data>
      <data key="d1">Soluble TNF (sTNF) is a form of TNF that is found in the serum and is necessary for lymphocyte recruitment and TGF-&#946;1 expression
sTNF is the soluble form of TNF that is upregulated in non-fibrotic HP patients</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e,a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="TGF-&#914;1">
      <data key="d0">PROTEIN</data>
      <data key="d1">TGF-&#946;1 is a protein involved in the transition from pulmonary inflammation to fibrosis
Transforming growth factor-beta 1 is a cytokine that induces dermal myofibroblasts transdifferentiation</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e,d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="REDENTE ET AL.">
      <data key="d0">AUTHOR</data>
      <data key="d1">Redente et al. conducted research on the role of TNF in pulmonary fibrosis</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="LI ET AL.">
      <data key="d0">AUTHOR</data>
      <data key="d1">Li et al. conducted research on the role of TNF/TNFR2 signaling in allergic airway inflammation</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="ALLERGIC AIRWAY INFLAMMATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Allergic airway inflammation is characterized by the inflammation of the airways due to an allergic reaction</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="TH2 INFLAMMATORY CYTOKINES">
      <data key="d0">PROTEIN</data>
      <data key="d1">Th2 inflammatory cytokines are signaling molecules produced by Th2 cells that promote inflammation</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="TH17 INFLAMMATORY CYTOKINES">
      <data key="d0">PROTEIN</data>
      <data key="d1">Th17 inflammatory cytokines are signaling molecules produced by Th17 cells that promote inflammation</data>
      <data key="d2">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </node>
    <node id="HP">
      <data key="d0">DISEASE</data>
      <data key="d1">Hypersensitivity pneumonitis, a condition characterized by inflammation of the lungs</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="TGF&#914;1">
      <data key="d0">PROTEIN</data>
      <data key="d1">TGF&#946;1 is a cytokine that increases &#945;SMA expression and is involved in fibrosis</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="MYOFIBROBLAST">
      <data key="d0">CELL</data>
      <data key="d1">Myofibroblasts are cells that play a role in wound healing and fibrosis</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="DD">
      <data key="d0">DISEASE</data>
      <data key="d1">Dupuytren&#8217;s disease, a localized fibrotic condition of the hand</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="WNT SIGNALING">
      <data key="d0">PATHWAY</data>
      <data key="d1">Wnt signaling is a complex network of proteins known for its roles in cell development and disease</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="ST2">
      <data key="d0">PROTEIN</data>
      <data key="d1">ST2, also known as IL1RL1, is a receptor for IL-33 involved in immune response</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="INTESTINAL MYOFIBROBLASTS">
      <data key="d0">CELL</data>
      <data key="d1">Intestinal myofibroblasts are cells in the intestine involved in fibrosis and inflammation</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="TIMP-1">
      <data key="d0">PROTEIN</data>
      <data key="d1">TIMP-1 is a tissue inhibitor of metalloproteinases involved in the regulation of extracellular matrix</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="ERK1/2">
      <data key="d0">PROTEIN</data>
      <data key="d1">ERK1/2 are proteins involved in the MAPK/ERK signaling pathway, which regulates various cellular processes</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="LIVER FIBROSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Liver fibrosis is the excessive accumulation of extracellular matrix proteins in the liver
Liver fibrosis is a condition associated with elevated TL1A levels
Liver fibrosis is a condition characterized by excessive tissue scarring in the liver</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51,c525762bb827485bceeb9f09bb4bcfe0,d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="HEMOSIDERIN">
      <data key="d0">PROTEIN</data>
      <data key="d1">Hemosiderin is an iron-storage complex found within cells</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="NAFLD">
      <data key="d0">DISEASE</data>
      <data key="d1">Non-alcoholic fatty liver disease, a condition characterized by excess fat in the liver
Non-alcoholic fatty liver disease is a condition characterized by excess fat accumulation in the liver
Nonalcoholic fatty liver disease, a condition characterized by fat accumulation in the liver</data>
      <data key="d2">05c97152fe02249153103be341d65b67,a10787d7fbb1307be263e86dc7b33a51,b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="HFD">
      <data key="d0">CHEMICAL</data>
      <data key="d1">High-fat diet, used in experimental models to induce NAFLD</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="CARDIAC INFLAMMATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Cardiac inflammation is the inflammation of the heart tissue</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="CVD">
      <data key="d0">DISEASE</data>
      <data key="d1">Cardiovascular diseases, a class of diseases that involve the heart or blood vessels</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="MI">
      <data key="d0">DISEASE</data>
      <data key="d1">Myocardial infarction, commonly known as a heart attack
Myocardial infarction, commonly known as a heart attack, caused by the interruption of blood supply to a part of the heart
Myocardial infarction (MI) is a condition commonly known as a heart attack</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51,d2c44662af9752fc9f82c86121ede7c0,df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="HCM">
      <data key="d0">DISEASE</data>
      <data key="d1">Hypertrophic cardiomyopathy, a condition where the heart muscle becomes abnormally thick
Hypertrophic cardiomyopathy, a condition where the heart muscle becomes abnormally thick
Hypertrophic cardiomyopathy (HCM) is a condition where the heart muscle becomes abnormally thick</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51,d2c44662af9752fc9f82c86121ede7c0,df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="HF">
      <data key="d0">DISEASE</data>
      <data key="d1">Heart failure, a condition where the heart is unable to pump sufficiently to maintain blood flow
Heart failure, a condition where the heart is unable to pump sufficiently to maintain blood flow
Heart failure (HF) is a condition in which the heart is unable to pump sufficiently to maintain blood flow</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51,d2c44662af9752fc9f82c86121ede7c0,df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="LDLR">
      <data key="d0">GENE</data>
      <data key="d1">Low-density lipoprotein receptor, involved in cholesterol metabolism</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="LT&#913;3">
      <data key="d0">PROTEIN</data>
      <data key="d1">Lymphotoxin-alpha homotrimer, involved in inflammation and immune response</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="ANG II">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Angiotensin II, a peptide hormone that causes blood vessels to constrict</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="CD34+CD45+ MONOCYTIC CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Monocytic cells expressing CD34 and CD45 markers, involved in fibrosis</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="CARDIAC FIBROSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Cardiac fibrosis is the thickening and stiffening of the cardiac tissue
Cardiac fibrosis is the thickening and stiffening of the cardiac tissue due to excessive fibrous connective tissue
Cardiac fibrosis is the thickening and stiffening of the cardiac tissue due to excess fibrous connective tissue</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51,d2c44662af9752fc9f82c86121ede7c0,df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="TNFR1-KO">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">TNFR1 knockout, a model organism with the TNFR1 gene deleted</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="TNFR2-KO">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">TNFR2 knockout, a model organism with the TNFR2 gene deleted</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="DOUBLE RECEPTOR KNOCKOUT">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Model organism with both TNFR1 and TNFR2 genes deleted</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="INFLAMMATORY DISEASES">
      <data key="d0" />
      <data key="d1">Inflammatory diseases are conditions characterized by inflammation, such as arthritis and inflammatory bowel disease</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="PALM">
      <data key="d0">TISSUE</data>
      <data key="d1">The palm is the inner surface of the hand, affected in Dupuytren&#8217;s disease</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="RATS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Rats are a model organism used in experimental studies of liver cirrhosis</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="CARDIAC TISSUE">
      <data key="d0">TISSUE</data>
      <data key="d1">Cardiac tissue is the muscle tissue of the heart involved in contraction and relaxation</data>
      <data key="d2">a10787d7fbb1307be263e86dc7b33a51</data>
    </node>
    <node id="ANG-II">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Angiotensin II, a peptide hormone that causes blood vessels to constrict, leading to increased blood pressure
Angiotensin II (Ang-II) is a peptide hormone that causes blood vessels to constrict, and drives blood pressure up</data>
      <data key="d2">d2c44662af9752fc9f82c86121ede7c0,df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="CD34">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD34 is a cell surface glycoprotein and a marker of hematopoietic stem cells</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="M2-LIKE CELLS">
      <data key="d0">CELL</data>
      <data key="d1">M2-like cells are a type of macrophage involved in tissue repair and fibrosis</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="M1-LIKE CELLS">
      <data key="d0">CELL</data>
      <data key="d1">M1-like cells are a type of macrophage involved in pro-inflammatory responses</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="WT-BONE MARROW">
      <data key="d0">TISSUE</data>
      <data key="d1">Wild-type bone marrow, used in reconstitution experiments</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="AKT PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">AKT pathway is a signal transduction pathway that promotes survival and growth in response to extracellular signals</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="NF-&#922;B PATHWAY">
      <data key="d0">PATHWAY</data>
      <data key="d1">NF-&#954;B pathway is a protein complex that controls transcription of DNA, cytokine production, and cell survival</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="ISCHEMIC CARDIOMYOPATHY">
      <data key="d0">DISEASE</data>
      <data key="d1">Ischemic cardiomyopathy is a condition where the heart's ability to pump blood is decreased due to coronary artery diseaseIschemic cardiomyopathy is a condition where heart muscle is weakened due to inadequate blood supply</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="NON-ISCHEMIC CARDIOMYOPATHY">
      <data key="d0">DISEASE</data>
      <data key="d1">Non-ischemic cardiomyopathy is a condition where the heart's ability to pump blood is decreased due to factors other than coronary artery diseaseNon-ischemic cardiomyopathy is a condition where heart muscle is weakened not due to blood supply issues</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="CARDIOMYOCYTE">
      <data key="d0">CELL</data>
      <data key="d1">Cardiomyocytes are the muscle cells of the heart</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="NECROSIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Necrosis is the death of cells or tissues through injury or disease</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="AORTIC VALVE STENOSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Aortic valve stenosis is a condition where the aortic valve narrows, affecting blood flow from the heart</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="CARDIAC HYPERTROPHY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Cardiac hypertrophy is the thickening of the heart muscle, often due to increased workloadCardiac hypertrophy is the thickening of the heart muscle</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="VASCULAR RAREFACTION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Vascular rarefaction is the reduction in the density of blood vessels</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="POST-MI HF">
      <data key="d0">DISEASE</data>
      <data key="d1">Heart failure occurring after a myocardial infarction</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="LEFT CORONARY ARTERY">
      <data key="d0">TISSUE</data>
      <data key="d1">The left coronary artery supplies blood to the heart muscle</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="VENTRICULAR DILATATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Ventricular dilatation is the enlargement of the ventricles of the heartVentricular dilatation is the enlargement of the ventricles of the heart, often due to weakening of the heart muscle</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="LT&#913;">
      <data key="d0">PROTEIN</data>
      <data key="d1">Lymphotoxin alpha, a cytokine involved in the regulation of immune responses</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="LIGHT">
      <data key="d0">PROTEIN</data>
      <data key="d1">LIGHT is a cytokine involved in immune response and tissue fibrosisLIGHT is a cytokine involved in immune response and tissue fibrosis, also known as TNFSF14, HVEM-L, or CD258
LIGHT is a protein involved in immune response and fibrosis, acting through receptors such as HVEM and LT&#946;R
LIGHT is a protein involved in immune response and inflammation, known to promote fibrosis and inflammation in various tissues
LIGHT is a ligand in the TNF superfamily, also known as CD258, HVEM-L
LIGHT is a member of the TNF superfamily involved in immune response regulation
LIGHT (TNFSF14) is a cytokine involved in immune responses and fibrosis
LIGHT (TNFSF14) is a protein that can act on structural and immune cells to drive pro-fibrotic and anti-fibrotic effects</data>
      <data key="d2">05c97152fe02249153103be341d65b67,516e41e96d2e72d45bf1e2c69da7f18a,5f37466ca41c9b8b06ed8be0303d49f2,68015074236b0144899baa38d01ae467,7f559ad7372a4e35e90b43cc67047b0f,c95d22c2a90e77cd22bd0d280d55b26a,df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="HVEM">
      <data key="d0">PROTEIN</data>
      <data key="d1">Herpesvirus entry mediator, a receptor for LIGHT, involved in immune response regulationHerpesvirus entry mediator, a receptor for LIGHT
HVEM is a receptor for LIGHT involved in immune response and fibrosis
HVEM is a protein that acts as a receptor for LIGHT and is involved in immune response regulation
HVEM is a receptor for LIGHT, also known as CD270, ATAR, TR2</data>
      <data key="d2">05c97152fe02249153103be341d65b67,5f37466ca41c9b8b06ed8be0303d49f2,c95d22c2a90e77cd22bd0d280d55b26a,df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="LT&#914;R">
      <data key="d0">PROTEIN</data>
      <data key="d1">Lymphotoxin-beta receptor, a receptor for LIGHTLymphotoxin-beta receptor, a receptor for LIGHT, involved in immune response and tissue organization
LT&#946;R is a receptor for LIGHT involved in immune response and fibrosis
LT&#946;R is a protein that acts as a receptor for LIGHT and is involved in immune response regulation
LT&#946;R is a receptor in the TNF superfamily, also known as CD18, TNFCR
LT&#946;R (Lymphotoxin Beta Receptor) is a receptor involved in the regulation of immune responses</data>
      <data key="d2">05c97152fe02249153103be341d65b67,5f37466ca41c9b8b06ed8be0303d49f2,7f559ad7372a4e35e90b43cc67047b0f,c95d22c2a90e77cd22bd0d280d55b26a,df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="DCR3">
      <data key="d0">PROTEIN</data>
      <data key="d1">Decoy receptor 3, a soluble receptor for LIGHT, involved in immune response regulationDecoy receptor 3, a soluble receptor for LIGHT
Decoy receptor 3 is a soluble receptor that neutralizes TL1A signaling
DcR3 is a receptor in the TNF superfamily, also known as TR6, M68</data>
      <data key="d2">05c97152fe02249153103be341d65b67,c95d22c2a90e77cd22bd0d280d55b26a,df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="FIBROPROLIFERATIVE">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Fibroproliferative refers to the excessive formation of fibrous tissue</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="CONNECTIVE TISSUE">
      <data key="d0">TISSUE</data>
      <data key="d1">Connective tissue supports, binds, or separates other tissues or organs</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">TISSUE</data>
    </node>
    <node id="HVEM-L">
      <data key="d0">PROTEIN</data>
      <data key="d1">Herpesvirus entry mediator ligand, another name for LIGHT</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="CD258">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD258 is another name for LIGHT</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="TNFRSF3">
      <data key="d0">GENE</data>
      <data key="d1">TNFRSF3 is the gene encoding LT&#946;R
TNFRSF3 is the TNF receptor superfamily nomenclature for LT&#946;R</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a,df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">GENE</data>
    </node>
    <node id="TNFRSF14">
      <data key="d0">GENE</data>
      <data key="d1">TNFRSF14 is the gene encoding HVEM
TNFRSF14 is the TNF receptor superfamily nomenclature for HVEM</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a,df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">GENE</data>
    </node>
    <node id="TNFRSF6B">
      <data key="d0">GENE</data>
      <data key="d1">TNFRSF6B is the gene encoding DcR3
TNFRSF6B is the TNF receptor superfamily nomenclature for DcR3</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a,df74aa1b86eeeb811ca5586767ae3a71</data>
      <data key="d3">GENE</data>
    </node>
    <node id="MONOCYTIC INFILTRATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Monocytic infiltration refers to the accumulation of monocytes in tissue, often associated with inflammation</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="CARDIAC COLLAGEN DEPOSITION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Cardiac collagen deposition is the accumulation of collagen in the heart tissue, contributing to fibrosis</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="HEART FAILURE">
      <data key="d0">DISEASE</data>
      <data key="d1">Heart failure is a condition in which the heart is unable to pump blood effectively</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="MYOCARDIAL INFARCTION">
      <data key="d0">DISEASE</data>
      <data key="d1">Myocardial infarction, commonly known as a heart attack, occurs when blood flow to a part of the heart is blocked for a long enough time that part of the heart muscle is damaged or dies</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="CARDIOMYOCYTE NECROSIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Cardiomyocyte necrosis is the death of heart muscle cells, often due to ischemia</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="REPLACEMENT FIBROSIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Replacement fibrosis is the process where fibrous tissue replaces dead or damaged tissue, often seen after myocardial infarction</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="REACTIVE FIBROSIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Reactive fibrosis is the formation of fibrous tissue in response to chronic low-grade inflammation</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="CONTRACTILE DYSFUNCTION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Contractile dysfunction is the impaired ability of the heart muscle to contract and pump blood</data>
      <data key="d2">df74aa1b86eeeb811ca5586767ae3a71</data>
    </node>
    <node id="HOUSE DUST MITE">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">House dust mites (HDM) are common allergens that can induce allergic reactions and asthma in susceptible individuals</data>
      <data key="d2">5f37466ca41c9b8b06ed8be0303d49f2</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="ACUTE HYPOXIC RESPIRATORY FAILURE">
      <data key="d0">DISEASE</data>
      <data key="d1">Acute hypoxic respiratory failure (AHRF) is a condition where the lungs cannot provide enough oxygen to the body's tissues</data>
      <data key="d2">5f37466ca41c9b8b06ed8be0303d49f2</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="NASH">
      <data key="d0">DISEASE</data>
      <data key="d1">Non-alcoholic steatohepatitis (NASH) is a more severe form of NAFLD characterized by inflammation and damage to liver cells
Non-alcoholic steatohepatitis is a severe form of NAFLD characterized by inflammation and liver cell damage
Non-alcoholic steatohepatitis is a liver disease associated with elevated serum BAFF levels and fibrosis
Non-alcoholic steatohepatitis, a severe form of non-alcoholic fatty liver disease</data>
      <data key="d2">05c97152fe02249153103be341d65b67,5f37466ca41c9b8b06ed8be0303d49f2,b2aae16813e647959b783a39ef9a19a7,c525762bb827485bceeb9f09bb4bcfe0</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="SIMPLE STEATOSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Simple steatosis is a form of NAFLD characterized by the accumulation of fat in the liver without significant inflammation or damage
Simple steatosis is a liver condition that can be distinguished from NASH by serum BAFF levels</data>
      <data key="d2">5f37466ca41c9b8b06ed8be0303d49f2,c525762bb827485bceeb9f09bb4bcfe0</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="STEATOSIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Steatosis is the abnormal accumulation of fat in the liver
Steatosis is the abnormal retention of lipids within a cell, often seen in liver diseases</data>
      <data key="d2">05c97152fe02249153103be341d65b67,b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="HUH7">
      <data key="d0">CELL</data>
      <data key="d1">Huh7 cells are a human hepatoma cell line used in liver disease research</data>
      <data key="d2">05c97152fe02249153103be341d65b67</data>
    </node>
    <node id="H2O2">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Hydrogen peroxide is a reactive oxygen species involved in oxidative stress</data>
      <data key="d2">05c97152fe02249153103be341d65b67</data>
    </node>
    <node id="HEPATIC STEATOSIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Hepatic steatosis is the accumulation of fat in the liver
Hepatic steatosis is the accumulation of fat in the liver</data>
      <data key="d2">05c97152fe02249153103be341d65b67,b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="GI TRACT">
      <data key="d0">TISSUE</data>
      <data key="d1">The gastrointestinal tract is the organ system responsible for digestion and absorption of nutrients</data>
      <data key="d2">05c97152fe02249153103be341d65b67</data>
    </node>
    <node id="EOE">
      <data key="d0">DISEASE</data>
      <data key="d1">Eosinophilic esophagitis is a chronic immune system disease characterized by eosinophil accumulation in the esophagus
Eosinophilic esophagitis is a chronic immune system disease characterized by inflammation of the esophagus
Eosinophilic esophagitis, a disease involving esophageal remodeling</data>
      <data key="d2">05c97152fe02249153103be341d65b67,c95d22c2a90e77cd22bd0d280d55b26a,d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="ICAM-1">
      <data key="d0">PROTEIN</data>
      <data key="d1">Intercellular adhesion molecule 1 is a protein involved in the adhesion of leukocytes to endothelial cells</data>
      <data key="d2">05c97152fe02249153103be341d65b67</data>
    </node>
    <node id="CKD">
      <data key="d0">DISEASE</data>
      <data key="d1">Chronic kidney disease is a condition characterized by gradual loss of kidney function over time</data>
      <data key="d2">05c97152fe02249153103be341d65b67</data>
    </node>
    <node id="UUO">
      <data key="d0">DISEASE</data>
      <data key="d1">Unilateral ureteral obstruction is a condition where one of the ureters is blocked, leading to kidney damage</data>
      <data key="d2">05c97152fe02249153103be341d65b67</data>
    </node>
    <node id="LDO">
      <data key="d0">DISEASE</data>
      <data key="d1">Lacrimal duct obstruction is a condition where the tear ducts are blocked, leading to tear drainage issues</data>
      <data key="d2">05c97152fe02249153103be341d65b67</data>
    </node>
    <node id="MONONUCLEAR CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Mononuclear cells are immune cells with a single round nucleus, including lymphocytes and monocytes</data>
      <data key="d2">05c97152fe02249153103be341d65b67</data>
    </node>
    <node id="COLUMNAR EPITHELIAL CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Columnar epithelial cells are elongated cells found in the lining of the digestive tract and other organs</data>
      <data key="d2">05c97152fe02249153103be341d65b67</data>
      <data key="d3">CELL</data>
    </node>
    <node id="TL1A">
      <data key="d0">PROTEIN</data>
      <data key="d1">TL1A is a TNF-like ligand involved in immune response and inflammation
TL1A is a cytokine involved in severe bowel pathology and inflammation
TL1A is a ligand in the TNF superfamily, also known as VEGI, TL1
TL1A is a member of the TNF superfamily involved in immune response regulation
TL1A is a protein involved in inflammatory processes and is a target for monoclonal antibody therapies
TL1A (TNFSF15) is a cytokine involved in immune responses and fibrosis
TL1A (TNFSF15) is a protein that can act on structural and immune cells to drive pro-fibrotic and anti-fibrotic effects</data>
      <data key="d2">05c97152fe02249153103be341d65b67,423195c6b63ad0a6773374364ebf3612,516e41e96d2e72d45bf1e2c69da7f18a,68015074236b0144899baa38d01ae467,7f559ad7372a4e35e90b43cc67047b0f,c525762bb827485bceeb9f09bb4bcfe0,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="DR3">
      <data key="d0">PROTEIN</data>
      <data key="d1">Death receptor 3 is a receptor for TL1A involved in immune response regulation
DR3 is a receptor that interacts with TL1A to promote fibrosis
DR3 is a receptor for TL1A, also known as Apo-3, TRAMP, LARD, WS-1
DR3 (Death Receptor 3) is a receptor involved in the regulation of immune responses</data>
      <data key="d2">05c97152fe02249153103be341d65b67,7f559ad7372a4e35e90b43cc67047b0f,c525762bb827485bceeb9f09bb4bcfe0,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="NF-KB">
      <data key="d0">PATHWAY</data>
      <data key="d1">NF-kB is a protein complex involved in regulating immune response and inflammation</data>
      <data key="d2">05c97152fe02249153103be341d65b67</data>
    </node>
    <node id="COLITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Colitis is inflammation of the colon
Colitis is an inflammatory condition of the colon treated with anti-TL1A antibody
Colitis is inflammation of the colon</data>
      <data key="d2">05c97152fe02249153103be341d65b67,68015074236b0144899baa38d01ae467,c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="TRANSGENIC MICE">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Transgenic mice are genetically modified mice used in research to study gene function and disease</data>
      <data key="d2">05c97152fe02249153103be341d65b67</data>
    </node>
    <node id="SMALL INTESTINE">
      <data key="d0">TISSUE</data>
      <data key="d1">The small intestine is part of the gastrointestinal tract involved in nutrient absorption
The small intestine is a part of the gastrointestinal tract where T cells are primarily activated</data>
      <data key="d2">05c97152fe02249153103be341d65b67,c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="BOWEL">
      <data key="d0">TISSUE</data>
      <data key="d1">The bowel is part of the gastrointestinal tract involved in digestion and waste elimination
The bowel is part of the gastrointestinal tract affected by TL1A-driven pathology</data>
      <data key="d2">05c97152fe02249153103be341d65b67,c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="MURINE HEPATIC FIBROBLASTS">
      <data key="d0">CELL</data>
      <data key="d1">Murine hepatic fibroblasts are liver fibroblast cells derived from mice, involved in liver fibrosis research</data>
      <data key="d2">05c97152fe02249153103be341d65b67</data>
    </node>
    <node id="SPLENECTOMY">
      <data key="d0">TISSUE</data>
      <data key="d1">Splenectomy is the surgical removal of the spleen</data>
      <data key="d2">05c97152fe02249153103be341d65b67</data>
    </node>
    <node id="ESOPHAGEAL FIBROBLASTS">
      <data key="d0">CELL</data>
      <data key="d1">Esophageal fibroblasts are cells in the esophagus involved in tissue repair and fibrosis</data>
      <data key="d2">05c97152fe02249153103be341d65b67</data>
    </node>
    <node id="RENAL TISSUE">
      <data key="d0">TISSUE</data>
      <data key="d1">Renal tissue refers to the tissue of the kidneys</data>
      <data key="d2">05c97152fe02249153103be341d65b67</data>
    </node>
    <node id="LACRIMAL SAC">
      <data key="d0">TISSUE</data>
      <data key="d1">The lacrimal sac is part of the tear drainage system in the eye</data>
      <data key="d2">05c97152fe02249153103be341d65b67</data>
    </node>
    <node id="MONONUCLEAR CELL INFILTRATES">
      <data key="d0">CELL</data>
      <data key="d1">Mononuclear cell infiltrates are immune cells that have migrated into tissues during inflammation</data>
      <data key="d2">05c97152fe02249153103be341d65b67</data>
    </node>
    <node id="T LYMPHOCYTES">
      <data key="d0">CELL</data>
      <data key="d1">T lymphocytes are a type of white blood cell involved in the immune response
T lymphocytes are immune cells involved in cell-mediated immunity and express receptors for APRIL and BAFF
T lymphocytes are a type of white blood cell that plays a central role in cell-mediated immunity</data>
      <data key="d2">05c97152fe02249153103be341d65b67,4cf23e218b6aab3c77115173b5c7c2fd,c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="ANTI-TL1A ANTIBODY">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Anti-TL1A antibody is a therapeutic antibody used to block TL1A signaling
</data>
      <data key="d2">05c97152fe02249153103be341d65b67,c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="OXIDATIVE STRESS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Oxidative stress is an imbalance between free radicals and antioxidants in the body, leading to cell damage</data>
      <data key="d2">05c97152fe02249153103be341d65b67</data>
    </node>
    <node id="PATHOLOGY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Pathology refers to the study of diseases and the changes they cause in the body</data>
      <data key="d2">05c97152fe02249153103be341d65b67</data>
    </node>
    <node id="TISSUE REMODELING">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Tissue remodeling is the process of renewal and reconstruction of tissue architecture
Tissue remodeling involves changes in tissue structure and is driven by TNFSF members</data>
      <data key="d2">05c97152fe02249153103be341d65b67,516e41e96d2e72d45bf1e2c69da7f18a</data>
    </node>
    <node id="FIBROTIC DISORDERS">
      <data key="d0">DISEASE</data>
      <data key="d1">Fibrotic disorders are diseases characterized by excessive fibrosis or scarring of tissues
Fibrotic disorders are conditions characterized by excessive fibrosis or scarring of tissues</data>
      <data key="d2">05c97152fe02249153103be341d65b67,b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="LUNG INFLAMMATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Lung inflammation is the swelling and irritation of the lung tissue</data>
      <data key="d2">05c97152fe02249153103be341d65b67</data>
    </node>
    <node id="BOWEL PATHOLOGY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Bowel pathology refers to diseases and disorders affecting the bowel</data>
      <data key="d2">05c97152fe02249153103be341d65b67</data>
    </node>
    <node id="COLONIC FIBROBLASTS">
      <data key="d0">CELL</data>
      <data key="d1">Colonic fibroblasts are cells in the colon that contribute to fibrosis when activated by TL1A-DR3 signaling</data>
      <data key="d2">c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="MMP7">
      <data key="d0">PROTEIN</data>
      <data key="d1">MMP7 is a matrix metalloproteinase involved in the fibrotic pathway and reduced by anti-TL1A treatment</data>
      <data key="d2">c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="MMP10">
      <data key="d0">PROTEIN</data>
      <data key="d1">MMP10 is a matrix metalloproteinase involved in the fibrotic pathway and reduced by anti-TL1A treatment</data>
      <data key="d2">c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="HDM">
      <data key="d0">CHEMICAL</data>
      <data key="d1">HDM is an airway irritant used to study TL1A-driven inflammation and fibrosis in mice</data>
      <data key="d2">c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="MUCUS">
      <data key="d0">PROTEIN</data>
      <data key="d1">Mucus is produced in the lung and its production is increased by TL1A-driven IL-13 signaling</data>
      <data key="d2">c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="TACI">
      <data key="d0">PROTEIN</data>
      <data key="d1">TACI is a receptor for APRIL and BAFF involved in immune responses and fibrosis
TACI is a receptor for APRIL, also known as CD267, IGAD2</data>
      <data key="d2">c525762bb827485bceeb9f09bb4bcfe0,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="BCMA">
      <data key="d0">PROTEIN</data>
      <data key="d1">BCMA is a receptor for APRIL and BAFF involved in immune responses and fibrosis
BCMA is a receptor in the TNF superfamily, also known as CD269</data>
      <data key="d2">c525762bb827485bceeb9f09bb4bcfe0,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="BAFF-R">
      <data key="d0">PROTEIN</data>
      <data key="d1">BAFF-R is a receptor for BAFF involved in immune responses and fibrosis</data>
      <data key="d2">c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="B LYMPHOCYTES">
      <data key="d0">CELL</data>
      <data key="d1">B lymphocytes are immune cells involved in antibody production and express receptors for APRIL and BAFF
B lymphocytes are a type of white blood cell involved in the immune response</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd,c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="AUTOIMMUNE HEPATITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Autoimmune hepatitis is a liver disease associated with elevated BAFF levels and fibrosis
Autoimmune hepatitis is a chronic disease in which the body's immune system attacks liver cells</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7,c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="INTESTINAL INFLAMMATION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Intestinal inflammation is a condition associated with elevated TL1A levels</data>
      <data key="d2">c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="INTESTINAL FIBROSIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Intestinal fibrosis is a condition associated with elevated TL1A levels</data>
      <data key="d2">c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="MACROPHAGE RECRUITMENT">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Macrophage recruitment is a process involved in inflammation and fibrosis</data>
      <data key="d2">c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="M1 POLARIZATION">
      <data key="d0">PATHWAY</data>
      <data key="d1">M1 polarization is a process where macrophages adopt a pro-inflammatory phenotype</data>
      <data key="d2">c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="PATHOGENIC TISSUE REMODELING">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Pathogenic tissue remodeling is a process involving changes in tissue structure due to disease</data>
      <data key="d2">c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="SERUM BAFF LEVELS">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Serum BAFF levels are a biomarker associated with fibrosis severity</data>
      <data key="d2">c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="HEPATOCYTE BALLOONING">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Hepatocyte ballooning is a condition associated with elevated serum BAFF levels and liver fibrosis</data>
      <data key="d2">c525762bb827485bceeb9f09bb4bcfe0</data>
    </node>
    <node id="HEPATOCYTE">
      <data key="d0">CELL</data>
      <data key="d1">Hepatocytes are the main functional cells of the liver</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="BAFF-/- MICE">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">BAFF-/- mice are genetically modified mice lacking the BAFF protein</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="MIXED CONNECTIVE TISSUE DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">Mixed connective tissue disease is an autoimmune disorder with features of several connective tissue diseases</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="PF">
      <data key="d0">DISEASE</data>
      <data key="d1">Pulmonary fibrosis, a lung disease characterized by scarring of lung tissue</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="AE">
      <data key="d0">DISEASE</data>
      <data key="d1">Atopic eczema, a chronic skin condition similar to atopic dermatitis</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="BAFFR">
      <data key="d0">PROTEIN</data>
      <data key="d1">BAFFR is a receptor for BAFF, involved in B cell survival and maturation
BAFFR is a receptor for BAFF, also known as CD268</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="TSK/+ MICE">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Tight skin (TSK/+) mice are a model organism used to study skin fibrosis</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="PBMC">
      <data key="d0">CELL</data>
      <data key="d1">Peripheral blood mononuclear cells, a type of blood cell that is critical in immune response</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="ANTI-TOPO I ANTIBODIES">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Antibodies against topoisomerase I, associated with systemic sclerosis</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="TIMP1">
      <data key="d0">PROTEIN</data>
      <data key="d1">Tissue inhibitor of metalloproteinases 1, involved in the regulation of extracellular matrix</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="RANKL">
      <data key="d0">PROTEIN</data>
      <data key="d1">Receptor activator of nuclear factor kappa-B ligand, involved in bone metabolism and fibrosis
Receptor activator of nuclear factor kappa-&#914; ligand (RANKL) is a protein upregulated in multiple fibrotic liver diseases and plays a key role in pathogenesis
RANKL is a ligand in the TNF superfamily, also known as CD254, TRANCE, OPGL, ODF
RANKL is a protein involved in bone metabolism and targeted by monoclonal antibodies in clinical trials</data>
      <data key="d2">68015074236b0144899baa38d01ae467,b2aae16813e647959b783a39ef9a19a7,c95d22c2a90e77cd22bd0d280d55b26a,d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="RANK">
      <data key="d0">PROTEIN</data>
      <data key="d1">Receptor activator of nuclear factor kappa-B, a receptor for RANKL
Receptor activator of nuclear factor kappa-&#914; (RANK) is a receptor that interacts with RANKL
RANK is a receptor for RANKL, also known as CD265, ODFR, FEO
RANK (Receptor Activator of Nuclear Factor Kappa-&#914;) is a protein involved in bone metabolism and immune response</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3,b2aae16813e647959b783a39ef9a19a7,c95d22c2a90e77cd22bd0d280d55b26a,d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="OPG">
      <data key="d0">PROTEIN</data>
      <data key="d1">Osteoprotegerin, a decoy receptor for RANKL
Osteoprotegerin (OPG) is a protein that inhibits ECM degradation by blocking RANKL-RANK interactions
Osteoprotegerin is a secreted glycoprotein and TNF superfamily member that serves as a soluble decoy receptor for TRAIL
OPG is a receptor in the TNF superfamily, also known as OCIF, TR1</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7,c95d22c2a90e77cd22bd0d280d55b26a,d2c44662af9752fc9f82c86121ede7c0,d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="OSTEOCLAST">
      <data key="d0">CELL</data>
      <data key="d1">Osteoclasts are bone cells that break down bone tissue
Osteoclasts are bone cells that break down bone tissue</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7,d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="OSTEOBLAST">
      <data key="d0">CELL</data>
      <data key="d1">Osteoblasts are bone cells that form new bone tissue</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="ECM">
      <data key="d0">TISSUE</data>
      <data key="d1">Extracellular matrix, a network of proteins and other molecules that provide structural support to cells
Extracellular matrix (ECM) is a network of proteins and other molecules that provide structural and biochemical support to surrounding cells</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7,d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="PBC">
      <data key="d0">DISEASE</data>
      <data key="d1">Primary biliary cholangitis, a chronic liver disease
Primary biliary cholangitis (PBC) is a disease characterized by injury to the small intrahepatic bile ducts</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7,d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="BEFFS">
      <data key="d0">CELL</data>
      <data key="d1">Fibrotic B cells that produce IL-6</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="BREGS">
      <data key="d0">CELL</data>
      <data key="d1">Regulatory B cells that produce IL-10</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="FIBROSIS SCORE">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Fibrosis score is a measure of the extent of fibrosis in tissue</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="HIGH FAT DIET">
      <data key="d0">CHEMICAL</data>
      <data key="d1">A high fat diet is a diet that consists of a high proportion of fat, often used in research to induce metabolic disorders in animal models</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="SOLUBLE RECEPTOR">
      <data key="d0">PROTEIN</data>
      <data key="d1">A soluble receptor is a form of receptor that is not membrane-bound and can neutralize its ligand in the extracellular space</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="INFLAMMATORY DISORDERS">
      <data key="d0">DISEASE</data>
      <data key="d1">Inflammatory disorders are conditions characterized by inflammation, which can affect various tissues and organs</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="TNFRSF11A">
      <data key="d0">GENE</data>
      <data key="d1">TNFRSF11A is the gene encoding RANK, the receptor for RANKL
TNFRSF11A is the TNF receptor superfamily nomenclature for RANK</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="TNFRSF11B">
      <data key="d0">GENE</data>
      <data key="d1">TNFRSF11B is the gene encoding OPG, a decoy receptor for RANKL
TNFRSF11B is the TNF receptor superfamily nomenclature for OPG</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="BONE">
      <data key="d0">TISSUE</data>
      <data key="d1">Bone is a rigid organ that constitutes part of the vertebrate skeleton</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="BONE HOMEOSTASIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Bone homeostasis is the balance between bone formation and bone resorption</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="BONE RESORPTION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Bone resorption is the process by which osteoclasts break down bone tissue</data>
      <data key="d2">b2aae16813e647959b783a39ef9a19a7</data>
    </node>
    <node id="CHOLANGIOCYTES">
      <data key="d0">CELL</data>
      <data key="d1">Cholangiocytes are the epithelial cells of the bile duct</data>
      <data key="d2">d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="LIVER CIRRHOSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Liver cirrhosis is a disease characterized by significant fibrosis and complications such as low bone density and bone mass loss
Liver cirrhosis is a chronic liver disease characterized by fibrosis and impaired liver function</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9,d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="FIBROTIC LUNG DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">Fibrotic lung disease is a condition characterized by the formation of excess fibrous connective tissue in the lungs</data>
      <data key="d2">d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="SILICOSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Silicosis is a type of pulmonary fibrosis caused by inhalation of silica dust</data>
      <data key="d2">d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="MMP-12">
      <data key="d0">PROTEIN</data>
      <data key="d1">Matrix metalloproteinase-12 (MMP-12) is an enzyme involved in the breakdown of extracellular matrix proteins</data>
      <data key="d2">d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="AC-SDKP">
      <data key="d0">CHEMICAL</data>
      <data key="d1">N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) is a naturally occurring tetrapeptide with potential therapeutic roles</data>
      <data key="d2">d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="CF">
      <data key="d0">DISEASE</data>
      <data key="d1">Cystic fibrosis (CF) is a genetic disorder affecting the lungs and other organs, characterized by thick, sticky mucus</data>
      <data key="d2">d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="CFTR">
      <data key="d0">GENE</data>
      <data key="d1">Cystic fibrosis transmembrane conductance regulator (CFTR) is a gene that, when mutated, causes cystic fibrosis</data>
      <data key="d2">d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="OSTEOBLASTS">
      <data key="d0">CELL</data>
      <data key="d1">Osteoblasts are bone-forming cells</data>
      <data key="d2">d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="INTERSTITIAL FIBROSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Interstitial fibrosis is the formation of fibrous tissue in the interstitial spaces of organs</data>
      <data key="d2">d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="PERIVASCULAR FIBROSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Perivascular fibrosis is the formation of fibrous tissue around blood vessels</data>
      <data key="d2">d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="CARDIOMYOCYTES">
      <data key="d0">CELL</data>
      <data key="d1">Cardiomyocytes are the muscle cells of the heart</data>
      <data key="d2">d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="PROCOLLAGEN &#913;1">
      <data key="d0">PROTEIN</data>
      <data key="d1">Procollagen &#945;1 is a precursor of collagen, a major component of the extracellular matrix</data>
      <data key="d2">d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="FCERI">
      <data key="d0">PROTEIN</data>
      <data key="d1">Fc epsilon RI (FcERI) is a high-affinity receptor for the Fc region of immunoglobulin E (IgE)</data>
      <data key="d2">d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="NEONATAL CARDIOMYOCYTES">
      <data key="d0">CELL</data>
      <data key="d1">Neonatal cardiomyocytes are heart muscle cells from newborns</data>
      <data key="d2">d2c44662af9752fc9f82c86121ede7c0</data>
      <data key="d3">CELL</data>
    </node>
    <node id="CARDIAC FIBROBLAST">
      <data key="d0">CELL</data>
      <data key="d1">Cardiac fibroblasts are cells in the heart that produce extracellular matrix and collagen</data>
      <data key="d2">d2c44662af9752fc9f82c86121ede7c0</data>
      <data key="d3">CELL</data>
    </node>
    <node id="AORTIC STENOSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Aortic stenosis is a condition where the aortic valve narrows, reducing blood flow from the heart</data>
      <data key="d2">d2c44662af9752fc9f82c86121ede7c0</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="LEFT VENTRICULAR MASS INDEX">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Left ventricular mass index is a measure of the mass of the left ventricle of the heart</data>
      <data key="d2">d2c44662af9752fc9f82c86121ede7c0</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="MYOCARDIAL STIFFNESS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Myocardial stiffness is the rigidity of the heart muscle, affecting its ability to contract and relax</data>
      <data key="d2">d2c44662af9752fc9f82c86121ede7c0</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="HF WITH PRESERVED EJECTION FRACTION">
      <data key="d0">DISEASE</data>
      <data key="d1">Heart failure with preserved ejection fraction (HFpEF) is a type of heart failure where the heart muscle contracts normally but the ventricles do not relax as they should</data>
      <data key="d2">d2c44662af9752fc9f82c86121ede7c0</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="GITR">
      <data key="d0">PROTEIN</data>
      <data key="d1">Glucocorticoid-induced TNF receptor family related protein (GITR) is a type I transmembrane protein expressed by Tregs and other immune cells
GITR, also known as TNFRSF18, is a type I transmembrane protein constitutively expressed by Tregs and resting CD25-CD4+ T cells, with increased expression following T cell activation
GITR is a receptor for GITRL, also known as CD357, AITR</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9,c95d22c2a90e77cd22bd0d280d55b26a,d2c44662af9752fc9f82c86121ede7c0</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="CD25-CD4+ T CELLS">
      <data key="d0">CELL</data>
      <data key="d1">CD25-CD4+ T cells are a subset of T cells that express the CD4 receptor but not the CD25 receptor
CD25-CD4+ T cells are a subset of T cells with lower expression of GITR compared to Tregs</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9,d2c44662af9752fc9f82c86121ede7c0</data>
      <data key="d3">CELL</data>
    </node>
    <node id="TRAP">
      <data key="d0">PROTEIN</data>
      <data key="d1">Tartrate-resistant acid phosphatase (TRAP) is an enzyme expressed in osteoclasts and macrophages</data>
      <data key="d2">d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="MMP-1">
      <data key="d0">PROTEIN</data>
      <data key="d1">Matrix metalloproteinase-1 (MMP-1) is an enzyme involved in the breakdown of extracellular matrix proteins</data>
      <data key="d2">d2c44662af9752fc9f82c86121ede7c0</data>
    </node>
    <node id="TNFRSF18">
      <data key="d0">PROTEIN</data>
      <data key="d1">TNFRSF18 is another name for GITR, a type I transmembrane protein involved in T cell activation
TNFRSF18 is the TNF receptor superfamily nomenclature for GITR</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="GITRL">
      <data key="d0">PROTEIN</data>
      <data key="d1">GITRL, also known as TNFSF18, is the ligand for GITR and is mainly expressed on B cells, DCs, macrophages, and endothelial cells
GITRL is a ligand in the TNF superfamily, also known as TL6, AITRL</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="TNFSF18">
      <data key="d0">PROTEIN</data>
      <data key="d1">TNFSF18 is another name for GITRL, the ligand for GITR
TNFSF18 is the TNF superfamily nomenclature for GITRL</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="4-1BB">
      <data key="d0">PROTEIN</data>
      <data key="d1">4-1BB is a member of the TNFRSF that acts as a costimulatory signal for T cells</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="DTA-1">
      <data key="d0">CHEMICAL</data>
      <data key="d1">DTA-1 is an agonistic anti-GITR antibody used to stimulate GITR</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="FOXP3">
      <data key="d0">PROTEIN</data>
      <data key="d1">Foxp3 is the master transcription factor that drives Treg development and functionalization</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="FLS">
      <data key="d0">CELL</data>
      <data key="d1">Fibroblast-like synoviocytes are cells derived from the synovial membrane that play a role in arthritis</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="MLE-12 CELLS">
      <data key="d0">CELL</data>
      <data key="d1">MLE-12 cells are an immortalized mouse lung type II epithelial cell line used in research</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="MENSC">
      <data key="d0">CELL</data>
      <data key="d1">MenSC, or human menstrual blood-derived mesenchymal stem cells, are used in research for their regenerative properties</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="GITR-/- MICE">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">GITR-/- mice are genetically modified mice lacking the GITR gene, used in research to study GITR function</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="GITR+/+ MICE">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">GITR+/+ mice are wild-type mice with normal GITR expression, used as controls in research</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="FC-GITR FUSION PROTEIN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Fc-GITR fusion protein is a molecule used to disrupt GITRL/GITR signaling in experimental models</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="MPO">
      <data key="d0">PROTEIN</data>
      <data key="d1">Myeloperoxidase (MPO) is an enzyme found in neutrophils that is involved in the body's defense against pathogens</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="CD252">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD252 is another name for OX40L, the ligand for OX40
CD252, also known as OX40L or TNFSF4, is a gene encoding the OX40 ligand</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3,7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="CD134">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD134 is another name for OX40, a marker of T-cell activation</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="CD25+CD4+ T CELLS">
      <data key="d0">CELL</data>
      <data key="d1">CD25+CD4+ T cells, also known as regulatory T cells (Tregs), are a subset of T cells that maintain immune tolerance and prevent autoimmune disease</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="ARTHRITIC MOUSE">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Arthritic mouse is a model organism used to study arthritis and related immune responses</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="SYNOVIA">
      <data key="d0">TISSUE</data>
      <data key="d1">Synovia is the soft tissue found in joint cavities that produces synovial fluid</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="FIBROTIC MODELS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Fibrotic models are experimental models used to study fibrosis and related mechanisms</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="GRANULOCYTES">
      <data key="d0">CELL</data>
      <data key="d1">Granulocytes are a type of white blood cell involved in the immune response
Granulocytes are a type of white blood cell involved in the immune response
Granulocytes are immune cells that LIGHT can act upon</data>
      <data key="d2">516e41e96d2e72d45bf1e2c69da7f18a,68015074236b0144899baa38d01ae467,7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="TH2 CYTOKINE">
      <data key="d0">PROTEIN</data>
      <data key="d1">Th2 cytokine is a type of signaling molecule involved in the immune response and fibrosis</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="TH1 CYTOKINE">
      <data key="d0">PROTEIN</data>
      <data key="d1">Th1 cytokine is a type of signaling molecule involved in the immune response and inflammation</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="ANTIGEN PRESENTING CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Antigen presenting cells are immune cells that present antigens to T cells to initiate an immune response</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="LUNG INJURY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Lung injury refers to damage to the lung tissue, often associated with inflammation and fibrosis</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="CELL INJURY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Cell injury refers to damage to cells, which can lead to cell death and tissue damage</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="EPITHELIAL TO MESENCHYMAL TRANSITION (EMT)">
      <data key="d0">PATHWAY</data>
      <data key="d1">EMT is a biological process where epithelial cells transform into mesenchymal cells, often associated with fibrosis</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="CIRRHOSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Cirrhosis is a chronic liver disease characterized by fibrosis and impaired liver function
Cirrhosis is a chronic liver disease characterized by scarring and impaired liver function</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd,7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="HISTOLOGICAL SIGNS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Histological signs refer to microscopic changes in tissue structure, often used to diagnose diseases</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="PRO-INFLAMMATORY ENVIRONMENT">
      <data key="d0">SYMPTOM</data>
      <data key="d1">A pro-inflammatory environment is characterized by increased inflammation, which can lead to tissue damage and fibrosis</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="ANTI-INFLAMMATORY ENVIRONMENT">
      <data key="d0">SYMPTOM</data>
      <data key="d1">An anti-inflammatory environment is characterized by reduced inflammation, which can prevent tissue damage and fibrosis</data>
      <data key="d2">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </node>
    <node id="C57BL/6 MICE">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">C57BL/6 mice are a transgenic model used to study the effects of OX40L overexpression</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="CD90">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD90 is a protein marker found on cells expressing OX40L in fibrotic skin</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="LDLR-/- MICE">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">LDLR-/- mice are a model used to study atherosclerosis and the effects of OX40-OX40L signaling</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="GATA-3">
      <data key="d0">PROTEIN</data>
      <data key="d1">GATA-3 is a protein involved in Th2 cell promotion, reduced by OX40-OX40L signaling disruption</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="HYDROXYPROLINE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Hydroxyproline is a marker for collagen content, used to assess fibrosis</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="ANTI-OX40L ANTIBODY">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Anti-OX40L antibody is used to block OX40L signaling in research studies</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="SOLUBLE OX40L">
      <data key="d0">PROTEIN</data>
      <data key="d1">Soluble OX40L is a form of OX40L found in serum, used as a biomarker for fibrosis</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="INFLAMMATION-DRIVEN FIBROSIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Inflammation-driven fibrosis is a type of fibrosis caused by chronic inflammation</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="FIBROSING ALVEOLITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Fibrosing alveolitis is a lung disease characterized by inflammation and fibrosis</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="LUNG VESSEL REMODELING">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Lung vessel remodeling is a pathological change in lung blood vessels associated with fibrosis</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3</data>
    </node>
    <node id="WESTERN-TYPE DIET">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Western-type diet is used to induce atherosclerosis in research models</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="CHOW DIET">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Chow diet is a standard diet used in research models</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3</data>
      <data key="d3">CHEMICAL</data>
    </node>
    <node id="EFFECTOR T CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Effector T cells are a type of T cell involved in the immune response, affected by CD27:CD70 signaling</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3</data>
      <data key="d3">CELL</data>
    </node>
    <node id="HEMATOPOIETIC STEM CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Hematopoietic stem cells are progenitor cells that give rise to blood cells, expressing CD27
Hematopoietic stem cells are stem cells that give rise to other blood cells</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3,4cf23e218b6aab3c77115173b5c7c2fd</data>
      <data key="d3">CELL</data>
    </node>
    <node id="PULMONARY ARTERIOLE">
      <data key="d0">TISSUE</data>
      <data key="d1">Pulmonary arteriole is a small artery in the lung affected by PAH</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3</data>
      <data key="d3">TISSUE</data>
    </node>
    <node id="MEDIAL MUSCULAR HYPERTROPHY">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Medial muscular hypertrophy is a thickening of the muscular layer of blood vessels, associated with PAH</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="INTIMAL FIBROSIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Intimal fibrosis is the scarring of the innermost layer of blood vessels, associated with PAH</data>
      <data key="d2">1b656cfce91ff9ccec4223703489dab3</data>
      <data key="d3">SYMPTOM</data>
    </node>
    <node id="SCD27">
      <data key="d0">PROTEIN</data>
      <data key="d1">Soluble CD27 is a functionally active form of CD27 that is secreted after proteolytic cleavage</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="CD4 T CELLS">
      <data key="d0">CELL</data>
      <data key="d1">CD4 T cells are a type of T lymphocyte that assists other cells in the immune response</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="TEM">
      <data key="d0">CELL</data>
      <data key="d1">Effector-memory T cells are a subset of T cells that have previously encountered antigens and can quickly respond upon re-exposure</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="CHRONIC RENAL NEPHRITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Chronic renal nephritis is a long-term inflammation of the kidneys</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="INTRARENAL LYMPHOID FOLLICLE-LIKE STRUCTURES">
      <data key="d0">TISSUE</data>
      <data key="d1">These are structures found within the kidneys that resemble lymphoid follicles</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="TNF-BETA">
      <data key="d0">PROTEIN</data>
      <data key="d1">TNF-beta is a cytokine involved in systemic inflammation</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="CD95">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD95, also known as Fas, is a protein that mediates apoptosis</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="FASL">
      <data key="d0">PROTEIN</data>
      <data key="d1">Fas ligand is a protein that binds to Fas and induces apoptosis</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="ENDOTOXIN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Endotoxin is a toxin released by certain bacteria that can cause inflammation</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="EAM">
      <data key="d0">DISEASE</data>
      <data key="d1">Experimental autoimmune myocarditis is a model of heart inflammation used in research</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="CARDIAC NK CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Cardiac NK cells are natural killer cells found in the heart</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="TRAIL">
      <data key="d0">PROTEIN</data>
      <data key="d1">Tumor necrosis factor-related apoptosis-inducing ligand is a protein involved in inducing cell death
TRAIL, also known as TNFSF10, Apo-2 ligand, or CD253, is a Type II membrane protein involved in inducing apoptosis
TRAIL is a protein in the TNF superfamily involved in apoptosis and fibrotic disease therapy</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd,c95d22c2a90e77cd22bd0d280d55b26a,d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="DR4">
      <data key="d0">PROTEIN</data>
      <data key="d1">Death receptor 4 is a receptor that binds to TRAIL and induces apoptosis
Death receptor 4, also known as TRAIL-R1 or TNFRSF10A, is a receptor that TRAIL binds to, initiating apoptosis
DR4 is a receptor for TRAIL, also known as CD261, TRAILR1, Apo-2</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd,c95d22c2a90e77cd22bd0d280d55b26a,d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="DR5">
      <data key="d0">PROTEIN</data>
      <data key="d1">Death receptor 5 is another receptor that binds to TRAIL and induces apoptosis
Death receptor 5, also known as TRAIL-R2 or TNFRSF10B, is a receptor that TRAIL binds to, initiating apoptosis
DR5 is a receptor for TRAIL, also known as CD262, TRAILR2, KILLER</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd,c95d22c2a90e77cd22bd0d280d55b26a,d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="DCR1">
      <data key="d0">PROTEIN</data>
      <data key="d1">Decoy receptor 1 is a receptor that binds to TRAIL but does not induce apoptosis
Decoy receptor 1, also known as TRAIL-R3 or TNFRSF10C, is a receptor that lacks a death domain and binds TRAIL
DcR1 is a receptor in the TNF superfamily, also known as CD263, TRAILR3, LIT, TRID</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd,c95d22c2a90e77cd22bd0d280d55b26a,d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="DCR2">
      <data key="d0">PROTEIN</data>
      <data key="d1">Decoy receptor 2 is another receptor that binds to TRAIL but does not induce apoptosis
Decoy receptor 2, also known as TRAIL-R4 or TNFRSF10D, is a receptor with a truncated non-functional death domain that binds TRAIL
DcR2 is a receptor in the TNF superfamily, also known as CD264, TRAILR4, TRUNDD</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd,c95d22c2a90e77cd22bd0d280d55b26a,d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="MEMORY T LYMPHOCYTES">
      <data key="d0">CELL</data>
      <data key="d1">Memory T lymphocytes are T cells that have previously encountered an antigen and can quickly respond upon re-exposure</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="NA&#207;VE B CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Na&#239;ve B cells are B lymphocytes that have not yet encountered their specific antigen</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="MEMORY B LYMPHOCYTES">
      <data key="d0">CELL</data>
      <data key="d1">Memory B lymphocytes are B cells that have previously encountered an antigen and can quickly respond upon re-exposure</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="FIBROTIC DISEASES">
      <data key="d0">DISEASE</data>
      <data key="d1">Fibrotic diseases are conditions characterized by excessive tissue fibrosis</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="ACUTE INFLAMMATORY STATE">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Acute inflammatory state is a rapid onset of inflammation in response to injury or infection</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="RENAL DISEASES">
      <data key="d0">DISEASE</data>
      <data key="d1">Renal diseases are conditions that affect the kidneys</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="SYSTEMIC INFECTION">
      <data key="d0">DISEASE</data>
      <data key="d1">Systemic infection is an infection that affects the entire body</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="CARDIAC INFILTRATING EOSINOPHILS">
      <data key="d0">CELL</data>
      <data key="d1">Cardiac infiltrating eosinophils are eosinophils that have migrated into the heart tissue</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="CARDIAC FIBROBLASTS">
      <data key="d0">CELL</data>
      <data key="d1">Cardiac fibroblasts are fibroblasts found in the heart tissue</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="DISEASE PATHOGENESIS">
      <data key="d0">PATHWAY</data>
      <data key="d1">Disease pathogenesis is the process by which a disease develops and progresses</data>
      <data key="d2">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </node>
    <node id="FAS LIGAND">
      <data key="d0">PROTEIN</data>
      <data key="d1">Fas ligand is a protein that TRAIL bears high levels of homology to</data>
      <data key="d2">d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="NATURAL KILLER CELLS">
      <data key="d0">CELL</data>
      <data key="d1">Natural killer cells are a type of lymphocyte that primarily express TRAIL</data>
      <data key="d2">d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="FADD">
      <data key="d0">PROTEIN</data>
      <data key="d1">Fas-associated death domain is an adaptor protein recruited by DR4 and DR5 to form the death-inducing signaling complex</data>
      <data key="d2">d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="PROCASPASE-8">
      <data key="d0">PROTEIN</data>
      <data key="d1">Procaspase-8 is activated by FADD, leading to downstream signaling events that result in apoptosis</data>
      <data key="d2">d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="AHSCS">
      <data key="d0">CELL</data>
      <data key="d1">Activated hepatic stellate cells are the primary cell type responsible for liver fibrosis
Activated hepatic stellate cells, resistant to apoptosis but sensitive to TRAIL</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a,d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="DERMAL MYOFIBROBLASTS">
      <data key="d0">CELL</data>
      <data key="d1">Dermal myofibroblasts are the principal cell type responsible for fibrosis in scleroderma</data>
      <data key="d2">d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="TSK-1">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Tsk-1 is a genetic mouse model used to study systemic sclerosis</data>
      <data key="d2">d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="A FUMIGATUS">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Aspergillus fumigatus is a species of fungus used in a mouse model to study EoE</data>
      <data key="d2">d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="MID-1">
      <data key="d0">PROTEIN</data>
      <data key="d1">Midline-1 is an E3 ubiquitin-ligase whose downstream signaling events promote inflammation</data>
      <data key="d2">d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="PP2A">
      <data key="d0">PROTEIN</data>
      <data key="d1">Protein phosphatase 2A is an enzyme whose activity is inhibited by MID-1</data>
      <data key="d2">d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="CCL24">
      <data key="d0">PROTEIN</data>
      <data key="d1">CCL24 is a cytokine implicated in EoE pathogenesis</data>
      <data key="d2">d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="TNFSF10">
      <data key="d0">GENE</data>
      <data key="d1">TNFSF10 is another name for TRAIL, a Type II membrane protein involved in inducing apoptosis
TNFSF10 is the TNF superfamily nomenclature for TRAIL</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a,d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="CD253">
      <data key="d0">PROTEIN</data>
      <data key="d1">CD253 is another name for TRAIL, a Type II membrane protein involved in inducing apoptosis</data>
      <data key="d2">d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="TNFRSF10A">
      <data key="d0">GENE</data>
      <data key="d1">TNFRSF10A is another name for DR4, a receptor that TRAIL binds to, initiating apoptosis
TNFRSF10A is the TNF receptor superfamily nomenclature for DR4</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a,d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="TNFRSF10B">
      <data key="d0">GENE</data>
      <data key="d1">TNFRSF10B is another name for DR5, a receptor that TRAIL binds to, initiating apoptosis
TNFRSF10B is the TNF receptor superfamily nomenclature for DR5</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a,d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="TNFRSF10C">
      <data key="d0">GENE</data>
      <data key="d1">TNFRSF10C is another name for DcR1, a decoy receptor that binds TRAIL
TNFRSF10C is the TNF receptor superfamily nomenclature for DcR1</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a,d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="TNFRSF10D">
      <data key="d0">GENE</data>
      <data key="d1">TNFRSF10D is another name for DcR2, a decoy receptor that binds TRAIL
TNFRSF10D is the TNF receptor superfamily nomenclature for DcR2</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a,d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="PEGYLATED TRAIL">
      <data key="d0">CHEMICAL</data>
      <data key="d1">PEGylated TRAIL is a modified form of TRAIL used to treat liver fibrosis</data>
      <data key="d2">d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="SIRNA">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Small interfering RNA is used to target MID-1 in TRAIL deficient mice</data>
      <data key="d2">d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="ESOPHAGUS">
      <data key="d0">TISSUE</data>
      <data key="d1">The esophagus is the tissue affected in eosinophilic esophagitis</data>
      <data key="d2">d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="ESOPHAGEAL EOSINOPHIL">
      <data key="d0">CELL</data>
      <data key="d1">Esophageal eosinophils are immune cells involved in the inflammation of the esophagus in EoE</data>
      <data key="d2">d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="ESOPHAGEAL CIRCUMFERENCE">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Enlargement of the esophageal circumference is a symptom of EoE</data>
      <data key="d2">d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="ESOPHAGEAL REMODELING">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Esophageal remodeling is a histological change observed in EoE</data>
      <data key="d2">d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="CIRCULATION">
      <data key="d0">TISSUE</data>
      <data key="d1">Circulation refers to the blood flow system that can be affected by fibrosis</data>
      <data key="d2">d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="COLLAGEN DEPOSITION">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Collagen deposition is a marker of fibrosis</data>
      <data key="d2">d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="APOPTOSIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Apoptosis is the process of programmed cell death induced by TRAIL</data>
      <data key="d2">d4797ed1483e5057bcd8301eaa509d5e</data>
    </node>
    <node id="MFBS">
      <data key="d0">CELL</data>
      <data key="d1">Myofibroblasts, resistant to apoptosis but sensitive to TRAIL</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="LUMBAR SPINAL FIBROSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Lumbar spinal fibrosis is a condition involving fibrosis in the lumbar spine
Lumbar Spinal Fibrosis is a condition characterized by the thickening and scarring of connective tissue in the lumbar spine</data>
      <data key="d2">7f559ad7372a4e35e90b43cc67047b0f,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="ANTI-TNF THERAPY">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Anti-TNF therapy involves the use of antibodies to inhibit TNF activity</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="SALINE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Saline is a solution of salt in water, often used as a placebo in clinical trials
Saline is a solution of salt in water used as a placebo in clinical trials</data>
      <data key="d2">7f559ad7372a4e35e90b43cc67047b0f,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="TNF BLOCKER">
      <data key="d0">CHEMICAL</data>
      <data key="d1">TNF blocker is a drug that inhibits the activity of TNF
TNF blocker is a type of medication that inhibits the activity of TNF</data>
      <data key="d2">7f559ad7372a4e35e90b43cc67047b0f,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="IPAA">
      <data key="d0">PROCEDURE</data>
      <data key="d1">Ileal pouch-anal anastomosis is a surgical procedure for patients with ulcerative colitis</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="HAEMEK MEDICAL CENTER">
      <data key="d0">ORGANIZATION</data>
      <data key="d1">HaEmek Medical Center is a hospital in Israel</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="MOUNT SINAI HOSPITAL">
      <data key="d0">ORGANIZATION</data>
      <data key="d1">Mount Sinai Hospital is a hospital in Canada</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="UNIVERSITY OF TORONTO">
      <data key="d0">ORGANIZATION</data>
      <data key="d1">University of Toronto is a university in Canada
University of Toronto is an institution involved in clinical trials</data>
      <data key="d2">68015074236b0144899baa38d01ae467,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="UNIVERSITY OF OXFORD">
      <data key="d0">ORGANIZATION</data>
      <data key="d1">University of Oxford is a university in the United Kingdom</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="DEPARTMENT OF HEALTH, UNITED KINGDOM">
      <data key="d0">ORGANIZATION</data>
      <data key="d1">Department of Health is a government department in the United Kingdom</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="WELLCOME TRUST">
      <data key="d0">ORGANIZATION</data>
      <data key="d1">Wellcome Trust is a biomedical research charity in the United Kingdom</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="180 THERAPEUTICS LP">
      <data key="d0">ORGANIZATION</data>
      <data key="d1">180 Therapeutics LP is a biotechnology company</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="ASSISTANCE PUBLIQUE - H&#212;PITAUX DE PARIS">
      <data key="d0">ORGANIZATION</data>
      <data key="d1">Assistance Publique - H&#244;pitaux de Paris is a hospital network in France</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="NCT03747068">
      <data key="d0">CLINICAL_TRIAL</data>
      <data key="d1">Clinical trial targeting TNF for treating inflammatory bowel disease</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="NCT03180957">
      <data key="d0">CLINICAL_TRIAL</data>
      <data key="d1">Clinical trial repurposing anti-TNF for treating Dupuytren&#8217;s disease</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="NCT00385086">
      <data key="d0">CLINICAL_TRIAL</data>
      <data key="d1">Clinical trial targeting TNF for treating lumbar spinal fibrosis</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="TNFSF2">
      <data key="d0">PROTEIN</data>
      <data key="d1">TNFSF2 is the TNF superfamily nomenclature for TNF
TNFSF2 is another name for TNF&#945;, a cytokine involved in systemic inflammation</data>
      <data key="d2">68015074236b0144899baa38d01ae467,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="TNFRSF1B">
      <data key="d0">PROTEIN</data>
      <data key="d1">TNFRSF1B is the TNF receptor superfamily nomenclature for TNFR2</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="TNFSF15">
      <data key="d0">PROTEIN</data>
      <data key="d1">TNFSF15 is the TNF superfamily nomenclature for TL1A
TNFSF15 is another name for TL1A, a cytokine involved in immune responses and fibrosis
TNFSF15 is the gene encoding the protein TL1A</data>
      <data key="d2">516e41e96d2e72d45bf1e2c69da7f18a,68015074236b0144899baa38d01ae467,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="TNFRSF25">
      <data key="d0">PROTEIN</data>
      <data key="d1">TNFRSF25 is the TNF receptor superfamily nomenclature for DR3</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="TNFRSF13B">
      <data key="d0">PROTEIN</data>
      <data key="d1">TNFRSF13B is the TNF receptor superfamily nomenclature for TACI</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="TNFRSF13A">
      <data key="d0">PROTEIN</data>
      <data key="d1">TNFRSF13A is the TNF receptor superfamily nomenclature for BCMA</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="TNFRSF13C">
      <data key="d0">PROTEIN</data>
      <data key="d1">TNFRSF13C is the TNF receptor superfamily nomenclature for BAFFR</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="TNFSF7">
      <data key="d0">PROTEIN</data>
      <data key="d1">TNFSF7 is the TNF superfamily nomenclature for CD70</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="TNFRSF7">
      <data key="d0">PROTEIN</data>
      <data key="d1">TNFRSF7 is the TNF receptor superfamily nomenclature for CD27</data>
      <data key="d2">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </node>
    <node id="TNFR2-FC">
      <data key="d0">PROTEIN</data>
      <data key="d1">TNFR2-Fc is a soluble TNF receptor fusion protein used to inhibit TNF activity</data>
      <data key="d2">7f559ad7372a4e35e90b43cc67047b0f</data>
    </node>
    <node id="CBS001">
      <data key="d0">CHEMICAL</data>
      <data key="d1">CBS001 is an anti-LIGHT monoclonal antibody used in clinical trials</data>
      <data key="d2">7f559ad7372a4e35e90b43cc67047b0f</data>
    </node>
    <node id="NON-EOSINOPHILIC ASTHMA">
      <data key="d0">DISEASE</data>
      <data key="d1">Non-Eosinophilic Asthma is a type of asthma not characterized by high levels of eosinophils</data>
      <data key="d2">7f559ad7372a4e35e90b43cc67047b0f</data>
    </node>
    <node id="AVTX-002">
      <data key="d0">CHEMICAL</data>
      <data key="d1">AVTX-002 is an anti-LIGHT monoclonal antibody used in clinical trials</data>
      <data key="d2">7f559ad7372a4e35e90b43cc67047b0f</data>
    </node>
    <node id="COVID-19 PNEUMONIA">
      <data key="d0">DISEASE</data>
      <data key="d1">COVID-19 Pneumonia is a severe respiratory condition caused by the SARS-CoV-2 virus</data>
      <data key="d2">7f559ad7372a4e35e90b43cc67047b0f</data>
    </node>
    <node id="ACUTE LUNG INJURY">
      <data key="d0">DISEASE</data>
      <data key="d1">Acute Lung Injury is a condition characterized by rapid onset of widespread inflammation in the lungs</data>
      <data key="d2">7f559ad7372a4e35e90b43cc67047b0f</data>
    </node>
    <node id="ARDS">
      <data key="d0">DISEASE</data>
      <data key="d1">ARDS (Acute Respiratory Distress Syndrome) is a severe lung condition causing respiratory failure</data>
      <data key="d2">7f559ad7372a4e35e90b43cc67047b0f</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="CERC-002">
      <data key="d0">CHEMICAL</data>
      <data key="d1">CERC-002 is an anti-LIGHT monoclonal antibody used in clinical trials</data>
      <data key="d2">7f559ad7372a4e35e90b43cc67047b0f</data>
    </node>
    <node id="CROHN DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">Crohn Disease is a type of inflammatory bowel disease that affects the gastrointestinal tract
Crohn's disease is an inflammatory bowel disease that affects the gastrointestinal tract</data>
      <data key="d2">68015074236b0144899baa38d01ae467,7f559ad7372a4e35e90b43cc67047b0f</data>
    </node>
    <node id="MDGN-002">
      <data key="d0">CHEMICAL</data>
      <data key="d1">MDGN-002 is an anti-LIGHT monoclonal antibody used in clinical trials</data>
      <data key="d2">7f559ad7372a4e35e90b43cc67047b0f</data>
    </node>
    <node id="BAMINERCEPT">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Baminercept is a lymphotoxin-beta receptor fusion protein used in clinical trials</data>
      <data key="d2">7f559ad7372a4e35e90b43cc67047b0f</data>
    </node>
    <node id="PRIMARY SJ&#214;GREN&#8217;S SYNDROME">
      <data key="d0">DISEASE</data>
      <data key="d1">Primary Sj&#246;gren&#8217;s Syndrome is an autoimmune disease characterized by dry eyes and mouth</data>
      <data key="d2">7f559ad7372a4e35e90b43cc67047b0f</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="PRA023">
      <data key="d0">CHEMICAL</data>
      <data key="d1">PRA023 is an anti-TL1A monoclonal antibody used in clinical trials
PRA023 is a drug being tested for its efficacy in treating ulcerative colitis</data>
      <data key="d2">423195c6b63ad0a6773374364ebf3612,7f559ad7372a4e35e90b43cc67047b0f</data>
    </node>
    <node id="DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Diffuse Cutaneous Systemic Sclerosis is a form of systemic sclerosis characterized by skin thickening and fibrosis</data>
      <data key="d2">7f559ad7372a4e35e90b43cc67047b0f</data>
    </node>
    <node id="PTX-35">
      <data key="d0">CHEMICAL</data>
      <data key="d1">PTX-35 is an anti-DR3 monoclonal antibody used in clinical trials</data>
      <data key="d2">7f559ad7372a4e35e90b43cc67047b0f</data>
    </node>
    <node id="HEALTHY VOLUNTEER">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Healthy Volunteer refers to individuals participating in clinical trials who do not have the condition being studied</data>
      <data key="d2">7f559ad7372a4e35e90b43cc67047b0f</data>
    </node>
    <node id="POST OPERATIVE SCIATICA">
      <data key="d0">DISEASE</data>
      <data key="d1">Post Operative Sciatica is a condition characterized by pain along the sciatic nerve following surgery</data>
      <data key="d2">7f559ad7372a4e35e90b43cc67047b0f</data>
    </node>
    <node id="CHRONIC INFLAMMATORY DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">Chronic Inflammatory Disease is a condition characterized by long-term inflammation</data>
      <data key="d2">7f559ad7372a4e35e90b43cc67047b0f</data>
    </node>
    <node id="HEALTHY">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Healthy refers to individuals without any diagnosed diseases or conditions
Healthy refers to individuals without any diagnosed disease</data>
      <data key="d2">423195c6b63ad0a6773374364ebf3612,7f559ad7372a4e35e90b43cc67047b0f</data>
    </node>
    <node id="MODERATELY TO SEVERELY ACTIVE CROHN&#8217;S DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">Moderately to Severely Active Crohn&#8217;s Disease is a severe form of Crohn's Disease characterized by significant inflammation and symptoms</data>
      <data key="d2">7f559ad7372a4e35e90b43cc67047b0f</data>
    </node>
    <node id="MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Moderately to Severely Active Ulcerative Colitis is a severe form of Ulcerative Colitis characterized by significant inflammation and symptoms</data>
      <data key="d2">7f559ad7372a4e35e90b43cc67047b0f</data>
    </node>
    <node id="ALIMUMAB">
      <data key="d0" />
      <data key="d1" />
      <data key="d2">7f559ad7372a4e35e90b43cc67047b0f</data>
    </node>
    <node id="ANTI-TL1A MAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Anti-TL1A mAb is a monoclonal antibody targeting the TL1A protein</data>
      <data key="d2">423195c6b63ad0a6773374364ebf3612</data>
    </node>
    <node id="PF-06480605">
      <data key="d0">CHEMICAL</data>
      <data key="d1">PF-06480605 is a drug being tested for its efficacy in treating ulcerative colitis</data>
      <data key="d2">423195c6b63ad0a6773374364ebf3612</data>
    </node>
    <node id="TACI-FC FUSION PROTEIN">
      <data key="d0">CHEMICAL</data>
      <data key="d1">TACI-Fc fusion protein is a therapeutic agent targeting APRIL and BAFF
TACI-Fc fusion protein is a therapeutic agent designed to inhibit BAFF and APRIL, used in the treatment of autoimmune diseases
TACI-Fc fusion protein is a therapeutic agent targeting BAFF and APRIL</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3,423195c6b63ad0a6773374364ebf3612,8e5a1be9981340d419f7b3ad27076009</data>
    </node>
    <node id="IGA NEPHROPATHY">
      <data key="d0">DISEASE</data>
      <data key="d1">IgA nephropathy is a kidney disease caused by deposits of the protein immunoglobulin A in the kidneys
IgA Nephropathy is a kidney disease caused by the deposition of the IgA antibody in the glomerulus</data>
      <data key="d2">423195c6b63ad0a6773374364ebf3612,8e5a1be9981340d419f7b3ad27076009</data>
    </node>
    <node id="RELAPSING-REMITTING MULTIPLE SCLEROSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Relapsing-remitting multiple sclerosis is a form of multiple sclerosis characterized by periods of relapse and remission
Relapsing-remitting multiple sclerosis is a form of multiple sclerosis characterized by episodes of new or worsening symptoms followed by periods of remission</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3,423195c6b63ad0a6773374364ebf3612</data>
    </node>
    <node id="OCRELIZUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Ocrelizumab is a monoclonal antibody used to treat multiple sclerosis</data>
      <data key="d2">423195c6b63ad0a6773374364ebf3612</data>
    </node>
    <node id="CHRONIC OBSTRUCTIVE PULMONARY DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">Chronic obstructive pulmonary disease is a chronic inflammatory lung disease that causes obstructed airflow from the lungs</data>
      <data key="d2">423195c6b63ad0a6773374364ebf3612</data>
    </node>
    <node id="EMPHYSEMA">
      <data key="d0">DISEASE</data>
      <data key="d1">Emphysema is a type of chronic obstructive pulmonary disease characterized by damage to the alveoli in the lungs</data>
      <data key="d2">423195c6b63ad0a6773374364ebf3612</data>
    </node>
    <node id="PROMETHEUS BIOSCIENCES, INC.">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Prometheus Biosciences, Inc. is a biotechnology company involved in the development of drugs for autoimmune diseases</data>
      <data key="d2">423195c6b63ad0a6773374364ebf3612</data>
    </node>
    <node id="CELERION">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Celerion is a clinical research organization involved in the testing of new drugs</data>
      <data key="d2">423195c6b63ad0a6773374364ebf3612</data>
    </node>
    <node id="REMEGEN CO., LTD.">
      <data key="d0">CHEMICAL</data>
      <data key="d1">RemeGen Co., Ltd. is a biotechnology company involved in the development of drugs for autoimmune diseases</data>
      <data key="d2">423195c6b63ad0a6773374364ebf3612</data>
    </node>
    <node id="JOHNS HOPKINS UNIVERSITY">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Johns Hopkins University is an academic institution involved in clinical research</data>
      <data key="d2">423195c6b63ad0a6773374364ebf3612</data>
    </node>
    <node id="GLAXOSMITHKLINE">
      <data key="d0">CHEMICAL</data>
      <data key="d1">GlaxoSmithKline is a pharmaceutical company involved in the development and testing of new drugs
GlaxoSmithKline is a pharmaceutical company involved in clinical trials</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3,423195c6b63ad0a6773374364ebf3612</data>
    </node>
    <node id="HOSPITAL FOR SPECIAL SURGERY, NEW YORK">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Hospital for Special Surgery, New York is a medical institution involved in clinical research</data>
      <data key="d2">423195c6b63ad0a6773374364ebf3612</data>
    </node>
    <node id="UNIVERSITY OF ALABAMA AT BIRMINGHAM">
      <data key="d0">CHEMICAL</data>
      <data key="d1">University of Alabama at Birmingham is an academic institution involved in clinical research</data>
      <data key="d2">423195c6b63ad0a6773374364ebf3612</data>
    </node>
    <node id="VERA THERAPEUTICS, INC.">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Vera Therapeutics, Inc. is a biotechnology company involved in the development of drugs for autoimmune diseases</data>
      <data key="d2">423195c6b63ad0a6773374364ebf3612</data>
    </node>
    <node id="MMF">
      <data key="d0">CHEMICAL</data>
      <data key="d1">MMF (mycophenolate mofetil) is an immunosuppressive drug used to prevent organ rejection and treat autoimmune diseases</data>
      <data key="d2">423195c6b63ad0a6773374364ebf3612</data>
    </node>
    <node id="TABALUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Tabalumab is a monoclonal antibody targeting BAFF, used in the treatment of autoimmune diseases</data>
      <data key="d2">8e5a1be9981340d419f7b3ad27076009</data>
    </node>
    <node id="RC18">
      <data key="d0">CHEMICAL</data>
      <data key="d1">RC18 is a TACI-antibody fusion protein used in the treatment of autoimmune diseases</data>
      <data key="d2">8e5a1be9981340d419f7b3ad27076009</data>
    </node>
    <node id="ATACICEPT">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Atacicept is a fusion protein that inhibits BAFF and APRIL, used in the treatment of autoimmune diseases
Atacicept is a fusion protein used to inhibit BAFF and APRIL in autoimmune diseases</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3,8e5a1be9981340d419f7b3ad27076009</data>
    </node>
    <node id="ANTI-BAFF PEPTIBODY">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Anti-BAFF peptibody is a therapeutic agent targeting BAFF, used in the treatment of autoimmune diseases</data>
      <data key="d2">8e5a1be9981340d419f7b3ad27076009</data>
    </node>
    <node id="ANTI-BAFF MAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Anti-BAFF mAb is a monoclonal antibody targeting BAFF, used in the treatment of autoimmune diseases
Anti-BAFF monoclonal antibody is a therapeutic agent targeting BAFF</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3,8e5a1be9981340d419f7b3ad27076009</data>
    </node>
    <node id="ELI LILLY AND COMPANY">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Eli Lilly and Company is a pharmaceutical company involved in clinical trials</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="HUMAN GENOME SCIENCES INC.">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Human Genome Sciences Inc. is a biopharmaceutical company involved in clinical trials
Human Genome Sciences Inc. is a biotechnology company involved in clinical trials</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3,68015074236b0144899baa38d01ae467</data>
      <data key="d3">SPECIES_OR_MODEL</data>
    </node>
    <node id="EMD SERONO">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">EMD Serono is a biopharmaceutical company involved in clinical trials</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3</data>
    </node>
    <node id="MERCK KGAA">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Merck KGaA is a pharmaceutical company involved in clinical trials</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3</data>
    </node>
    <node id="PLACEBO Q2W">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Placebo Q2W is a placebo administered every two weeks in clinical trials</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3</data>
    </node>
    <node id="PLACEBO Q4W">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Placebo Q4W is a placebo administered every four weeks in clinical trials</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3</data>
    </node>
    <node id="NCT00931086">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">NCT00931086 is a clinical trial identifier for a study involving methotrexate and rheumatoid arthritis</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3</data>
    </node>
    <node id="NCT00882999">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">NCT00882999 is a clinical trial identifier for a study involving belimumab and rheumatoid arthritis</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3</data>
    </node>
    <node id="NCT00853762">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">NCT00853762 is a clinical trial identifier for a study involving LY2127399 and relapsing-remitting multiple sclerosis</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3</data>
    </node>
    <node id="NCT00837811">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">NCT00837811 is a clinical trial identifier for a study involving atacicept and relapsing multiple sclerosis</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3</data>
    </node>
    <node id="NCT00785928">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">NCT00785928 is a clinical trial identifier for a study involving LY2127399 and rheumatoid arthritis</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3</data>
    </node>
    <node id="NCT00689728">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">NCT00689728 is a clinical trial identifier for a study involving LY2127399 and rheumatoid arthritis</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3</data>
    </node>
    <node id="NCT00664521">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">NCT00664521 is a clinical trial identifier for a study involving atacicept and rheumatoid arthritis</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3</data>
    </node>
    <node id="NCT00642902">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">NCT00642902 is a clinical trial identifier for a study involving atacicept and rheumatoid arthritis</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3</data>
    </node>
    <node id="NCT00595413">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">NCT00595413 is a clinical trial identifier for a study involving atacicept and relapsing multiple sclerosis</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3</data>
    </node>
    <node id="NCT00583557">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">NCT00583557 is a clinical trial identifier for a study involving atacicept and rheumatoid arthritis</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3</data>
    </node>
    <node id="NCT00430495">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">NCT00430495 is a clinical trial identifier for a study involving belimumab and rheumatoid arthritis</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3</data>
    </node>
    <node id="NCT00308282">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">NCT00308282 is a clinical trial identifier for a study involving atacicept and rheumatoid arthritis</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3</data>
    </node>
    <node id="NCT00071812">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">NCT00071812 is a clinical trial identifier for a study involving belimumab and rheumatoid arthritis</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3</data>
    </node>
    <node id="NCT02321280">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">NCT02321280 is a clinical trial identifier for a study involving RANK</data>
      <data key="d2">0c7502a2bfe653785647d754ed10f4e3</data>
    </node>
    <node id="LYMPHOSTAT-B">
      <data key="d0">CHEMICAL</data>
      <data key="d1">LymphoStat-B is a monoclonal anti-BLyS antibody used in clinical trials for rheumatoid arthritis</data>
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="DENOSUMAB">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Denosumab is a monoclonal antibody used in clinical trials for Crohn's disease and osteoporosis</data>
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="CALCIFIC AORTIC STENOSIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Calcific aortic stenosis is a condition characterized by the narrowing of the aortic valve due to calcification</data>
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="ALENDRONIC ACID">
      <data key="d0">CHEMICAL</data>
      <data key="d1">Alendronic acid is a bisphosphonate drug used to treat osteoporosis</data>
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="DIGESTIVE SYSTEM DISEASES">
      <data key="d0">DISEASE</data>
      <data key="d1">Digestive system diseases encompass a range of conditions affecting the gastrointestinal tract</data>
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="GASTROINTESTINAL DISEASES">
      <data key="d0">DISEASE</data>
      <data key="d1">Gastrointestinal diseases affect the digestive tract</data>
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="INTESTINAL DISEASES">
      <data key="d0">DISEASE</data>
      <data key="d1">Intestinal diseases affect the intestines</data>
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="COLONIC DISEASES">
      <data key="d0">DISEASE</data>
      <data key="d1">Colonic diseases affect the colon</data>
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="ABDOMINAL PAIN">
      <data key="d0">SYMPTOM</data>
      <data key="d1">Abdominal pain is a common symptom in various gastrointestinal diseases</data>
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="TNF&#913;">
      <data key="d0">PROTEIN</data>
      <data key="d1">TNF&#945; (TNFSF2) is a cytokine involved in systemic inflammation and targeted by anti-TNF therapies</data>
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="KIDNEYS">
      <data key="d0">TISSUE</data>
      <data key="d1">The kidneys are organs that filter blood and can be affected by fibrotic diseases</data>
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="IMMUNE SYSTEM DISEASES">
      <data key="d0" />
      <data key="d1" />
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="UNIVERSITY OF MANITOBA">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">University of Manitoba is an institution involved in clinical trials</data>
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="MCMASTER UNIVERSITY">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">McMaster University is an institution involved in clinical trials</data>
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="UNIVERSITY OF EDINBURGH">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">University of Edinburgh is an institution involved in clinical trials</data>
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="BRITISH HEART FOUNDATION">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">British Heart Foundation is an organization involved in clinical trials</data>
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="NHS LOTHIAN">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">NHS Lothian is a healthcare organization involved in clinical trials</data>
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="GENENTECH, INC.">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Genentech, Inc. is a biotechnology company involved in clinical trials</data>
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="KYOWA KIRIN, INC.">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Kyowa Kirin, Inc. is a pharmaceutical company involved in clinical trials</data>
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="KYOWA KIRIN CO., LTD.">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Kyowa Kirin Co., Ltd. is a pharmaceutical company involved in clinical trials</data>
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="KYMAB LIMITED">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Kymab Limited is a biotechnology company involved in clinical trials</data>
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="ICHNOS SCIENCES SA">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Ichnos Sciences SA is a biotechnology company involved in clinical trials</data>
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="GLENMARK PHARMACEUTICALS S.A.">
      <data key="d0">SPECIES_OR_MODEL</data>
      <data key="d1">Glenmark Pharmaceuticals S.A. is a pharmaceutical company involved in clinical trials</data>
      <data key="d2">68015074236b0144899baa38d01ae467</data>
    </node>
    <node id="UC">
      <data key="d0">DISEASE</data>
      <data key="d1">Ulcerative colitis, a disease treated with TNF inhibitors</data>
      <data key="d2">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </node>
    <node id="JUVENILE IDIOPATHIC ARTHRITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Juvenile idiopathic arthritis is a type of arthritis that occurs in childrenJuvenile idiopathic arthritis, a disease treated with TNF inhibitors</data>
      <data key="d2">516e41e96d2e72d45bf1e2c69da7f18a</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS">
      <data key="d0">DISEASE</data>
      <data key="d1">Non-radiographic axial spondyloarthritis is a form of spondyloarthritis without visible changes on X-raysNon-radiographic axial spondyloarthritis, a disease treated with TNF inhibitors</data>
      <data key="d2">516e41e96d2e72d45bf1e2c69da7f18a</data>
      <data key="d3">DISEASE</data>
    </node>
    <node id="TNFSF MEMBERS">
      <data key="d0" />
      <data key="d1">TNFSF members are a group of proteins involved in inflammation, apoptosis, cell survival, fibrosis, and tissue remodeling</data>
      <data key="d2">516e41e96d2e72d45bf1e2c69da7f18a</data>
      <data key="d3">PROTEIN</data>
    </node>
    <node id="FIBROTIC DISEASE">
      <data key="d0">DISEASE</data>
      <data key="d1">Fibrotic disease involves excessive tissue scarring and remodeling</data>
      <data key="d2">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </node>
    <node id="END STAGE FIBROSIS">
      <data key="d0">SYMPTOM</data>
      <data key="d1">End stage fibrosis is a severe form of fibrosis where tissue function is significantly impaired</data>
      <data key="d2">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </node>
    <node id="ORGANS">
      <data key="d0">TISSUE</data>
      <data key="d1">Organs are collections of tissues that perform specific functions, often affected in fibrotic diseases</data>
      <data key="d2">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </node>
    <edge source="HIDRADENITIS SUPPURATIVA" target="ACNE INVERSA">
      <data key="d4">10.0</data>
      <data key="d5">Acne Inversa is another name for Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="ADALIMUMAB">
      <data key="d4">17.0</data>
      <data key="d5">Adalimumab is a drug approved for the treatment of Hidradenitis Suppurativa (HS).
Adalimumab is approved for the treatment of HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff,661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="HAIR FOLLICLE">
      <data key="d4">10.0</data>
      <data key="d5">The hair follicle is the tissue primarily affected in Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="KERATINOCYTES">
      <data key="d4">15.0</data>
      <data key="d5">Keratinocytes are involved in epithelial differentiation and inflammation in HS.
Keratinocytes produce cytokines like IL-6 and IL-1&#946; in HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff,661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="OBESITY">
      <data key="d4">13.0</data>
      <data key="d5">Obesity is considered an important risk factor for Hidradenitis Suppurativa (HS).
Obesity is a comorbidity associated with HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff,661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="METABOLIC SYNDROME">
      <data key="d4">7.0</data>
      <data key="d5">Metabolic Syndrome is considered an important risk factor for Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="INFLAMMATORY BOWEL DISEASE">
      <data key="d4">7.0</data>
      <data key="d5">Inflammatory Bowel Disease is a comorbid disorder associated with Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="ARTHRITIS">
      <data key="d4">7.0</data>
      <data key="d5">Arthritis is a comorbid disorder associated with Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="TYPE I DIABETES MELLITUS">
      <data key="d4">7.0</data>
      <data key="d5">Type I Diabetes Mellitus is a comorbid disorder associated with Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="ATHEROSCLEROSIS">
      <data key="d4">7.0</data>
      <data key="d5">Atherosclerosis is a comorbid disorder associated with Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="ADIPOGENESIS">
      <data key="d4">6.0</data>
      <data key="d5">Adipogenesis is a pathway involved in the comorbid disorders associated with Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="FOLLICULAR HYPERKERATOSIS">
      <data key="d4">8.0</data>
      <data key="d5">Follicular Hyperkeratosis is a consistent finding in Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="LYMPHOHISTIOCYTIC INFLAMMATION">
      <data key="d4">7.0</data>
      <data key="d5">Lymphohistiocytic Inflammation is an initial inflammatory response in Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="GRANULOMATOUS REACTION">
      <data key="d4">7.0</data>
      <data key="d5">Granulomatous Reaction is a type of inflammation associated with Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="SINUS TRACT FORMATION">
      <data key="d4">7.0</data>
      <data key="d5">Sinus Tract Formation is a symptom of Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="SCARRING">
      <data key="d4">14.0</data>
      <data key="d5">Scarring is a symptom of Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="EPITHELIAL SKIN CELLS">
      <data key="d4">8.0</data>
      <data key="d5">Epithelial Skin Cells are involved in the innate immunity response in Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="ADIPOSE TISSUE">
      <data key="d4">14.0</data>
      <data key="d5">Adipose Tissue is involved in Hidradenitis Suppurativa (HS).Adipose tissue is involved in Hidradenitis Suppurativa (HS) as shown in immune histochemical studies.</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="INVERSE VIRTUAL SCREENING">
      <data key="d4">12.0</data>
      <data key="d5">Inverse virtual screening is used to identify potential drugs for Hidradenitis Suppurativa (HS).Inverse Virtual Screening is used to identify potential drugs for Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="COMPUTATIONAL DRUG REPURPOSING">
      <data key="d4">12.0</data>
      <data key="d5">Computational Drug Repurposing is used to identify potential drugs for Hidradenitis Suppurativa (HS).Computational drug repurposing is used to identify potential drugs for Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="GENE EXPRESSION OMNIBUS">
      <data key="d4">5.0</data>
      <data key="d5">Gene Expression Omnibus is a database used for obtaining records related to Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="NATIONAL INSTITUTES OF HEALTH">
      <data key="d4">5.0</data>
      <data key="d5">National Institutes of Health is involved in the research of Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="TRANSCRIPTOME">
      <data key="d4">12.0</data>
      <data key="d5">Transcriptome studies are used to detect HS signature pathways.</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="PROTEOME">
      <data key="d4">12.0</data>
      <data key="d5">Proteome studies are used to detect HS signature pathways.</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="HUGO GENE NOMENCLATURE COMMITTEE">
      <data key="d4">2.0</data>
      <data key="d5">HUGO Gene Nomenclature Committee verifies gene nomenclature in studies related to Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="CHRONIC INFLAMMATION">
      <data key="d4">9.0</data>
      <data key="d5">Chronic inflammation is a major pathogenetic pathway of Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="DYSREGULATED EPITHELIAL DIFFERENTIATION">
      <data key="d4">9.0</data>
      <data key="d5">Dysregulated epithelial differentiation is a major pathogenetic pathway of Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="INFLAMMATION">
      <data key="d4">9.0</data>
      <data key="d5">Inflammation is a key component of the pathogenesis of Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="BACTERIAL COLONIZATION">
      <data key="d4">7.0</data>
      <data key="d5">Bacterial colonization is a possible secondary effect in Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="INNATE IMMUNITY RESPONSE">
      <data key="d4">8.0</data>
      <data key="d5">Innate immunity response is induced in epithelial skin cells in Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="IMPAIRED BARRIER FUNCTION">
      <data key="d4">8.0</data>
      <data key="d5">Impaired barrier function is detected at the follicular and epidermal keratinocyte level in Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="EPIDERMAL KERATINOCYTE">
      <data key="d4">8.0</data>
      <data key="d5">Epidermal keratinocytes are involved in the inflammatory process in Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="SKIN-GLAND LEVEL">
      <data key="d4">6.0</data>
      <data key="d5">The skin-gland level is involved to a minor degree in Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="APOCRINE GLAND">
      <data key="d4">7.0</data>
      <data key="d5">Apocrine glands are areas of the body commonly affected by Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="AXILLAE">
      <data key="d4">7.0</data>
      <data key="d5">The axillae are commonly affected areas in Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="INGUINAL REGION">
      <data key="d4">7.0</data>
      <data key="d5">The inguinal region is commonly affected in Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="ANOGENITAL REGION">
      <data key="d4">7.0</data>
      <data key="d5">The anogenital region is commonly affected in Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="FOLLICULAR RUPTURE">
      <data key="d4">8.0</data>
      <data key="d5">Follicular rupture is a consistent finding in Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="SINUS TRACT">
      <data key="d4">7.0</data>
      <data key="d5">Sinus tracts are formed as a result of Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="IMMUNE-RELATED DRIVERS">
      <data key="d4">8.0</data>
      <data key="d5">Immune-related drivers induce an innate immunity response in Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="DRUG REPURPOSING">
      <data key="d4">7.0</data>
      <data key="d5">Drug repurposing is a method used to find new treatments for Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="DRUG-GENE INTERACTION PROFILING">
      <data key="d4">7.0</data>
      <data key="d5">Drug-gene interaction profiling is used to identify potential drugs for Hidradenitis Suppurativa (HS).</data>
      <data key="d6">661a4cc53cee3ca36afa676952adc7fb</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="PLASMA CELLS">
      <data key="d4">9.0</data>
      <data key="d5">Plasma cells are involved in the pathogenesis of HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="B CELLS">
      <data key="d4">9.0</data>
      <data key="d5">B cells are involved in the pathogenesis of HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="IFN-&#915;">
      <data key="d4">8.0</data>
      <data key="d5">IFN-&#947; is implicated in the inflammatory responses in HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="IL-36">
      <data key="d4">8.0</data>
      <data key="d5">IL-36 is implicated in the inflammatory responses in HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="TNF">
      <data key="d4">8.0</data>
      <data key="d5">TNF is implicated in the inflammatory responses in HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="IL-17A">
      <data key="d4">6.0</data>
      <data key="d5">IL-17A has a lesser contribution to the inflammatory responses in HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="BRUTON&#8217;S TYROSINE KINASE">
      <data key="d4">7.0</data>
      <data key="d5">BTK is a potential therapeutic target in HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="SPLEEN TYROSINE KINASE">
      <data key="d4">7.0</data>
      <data key="d5">SYK is a potential therapeutic target in HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="SKIN">
      <data key="d4">10.0</data>
      <data key="d5">The skin is the primary tissue affected by HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="ABSCESS">
      <data key="d4">9.0</data>
      <data key="d5">Abscess formation is a characteristic symptom of HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="SINUS TRACTS">
      <data key="d4">9.0</data>
      <data key="d5">Sinus tracts are a characteristic symptom of HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="COMPLEMENT ACTIVATION">
      <data key="d4">8.0</data>
      <data key="d5">Complement activation is implicated in the pathogenesis of HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="C5A">
      <data key="d4">7.0</data>
      <data key="d5">C5a is elevated in HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="NEUTROPHILS">
      <data key="d4">8.0</data>
      <data key="d5">Neutrophils are prominent in HS skin</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="NETOSIS">
      <data key="d4">7.0</data>
      <data key="d5">NETosis is observed in HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="PLASMACYTOID DENDRITIC CELLS">
      <data key="d4">7.0</data>
      <data key="d5">Plasmacytoid dendritic cells are activated in HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="IL-6">
      <data key="d4">7.0</data>
      <data key="d5">IL-6 is involved in the inflammatory response in HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="IL-1&#914;">
      <data key="d4">7.0</data>
      <data key="d5">IL-1&#946; is involved in the inflammatory response in HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="CD19">
      <data key="d4">7.0</data>
      <data key="d5">CD19 is upregulated in HS skin</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="CD79A">
      <data key="d4">7.0</data>
      <data key="d5">CD79a is upregulated in HS skin</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="DEFB4A">
      <data key="d4">7.0</data>
      <data key="d5">DEFB4A is upregulated in HS skin</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="CXCL13">
      <data key="d4">7.0</data>
      <data key="d5">CXCL13 is upregulated in HS skin</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="IGLV3-27">
      <data key="d4">7.0</data>
      <data key="d5">IGLV3-27 is upregulated in HS skin</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="TNFRSF4">
      <data key="d4">7.0</data>
      <data key="d5">TNFRSF4 is upregulated in HS skin and blood</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="CCR4">
      <data key="d4">7.0</data>
      <data key="d5">CCR4 is upregulated in HS skin and blood</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="PBMCS">
      <data key="d4">6.0</data>
      <data key="d5">PBMCs are used in HS studies</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="NOTCH SIGNALING">
      <data key="d4">6.0</data>
      <data key="d5">Notch signaling is hypothesized to be involved in HS pathogenesis</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="GAMMA-SECRETASE COMPLEX">
      <data key="d4">6.0</data>
      <data key="d5">Gamma-secretase complex has genetic mutations associated with HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="TYPE I IFN">
      <data key="d4">7.0</data>
      <data key="d5">Type I IFNs are increased in HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="IMMUNOGLOBULINS">
      <data key="d4">7.0</data>
      <data key="d5">Immunoglobulins are increased in HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="AFRICAN AMERICANS">
      <data key="d4">6.0</data>
      <data key="d5">African Americans have a higher incidence of HS compared to Caucasians</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="CAUCASIANS">
      <data key="d4">6.0</data>
      <data key="d5">Caucasians have a lower incidence of HS compared to African Americans</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="HORMONAL COMPONENT">
      <data key="d4">6.0</data>
      <data key="d5">Hormonal components influence the development and progression of HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="QUALITY OF LIFE">
      <data key="d4">8.0</data>
      <data key="d5">Quality of life is significantly affected in patients with HS</data>
      <data key="d6">523bbfee1ae3b4ecabf9b11d10eea9ff</data>
    </edge>
    <edge source="HIDRADENITIS SUPPURATIVA" target="PRURITUS">
      <data key="d4">8.0</data>
      <data key="d5">Pruritus is a common symptom of hidradenitis suppurativa</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="ADALIMUMAB" target="HS">
      <data key="d4">10.0</data>
      <data key="d5">Adalimumab is used to treat HS
Adalimumab is the only registered drug for HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9,fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="ADALIMUMAB" target="TNF">
      <data key="d4">16.0</data>
      <data key="d5">Adalimumab inhibits TNF</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="ADALIMUMAB" target="DUPUYTREN&#8217;S DISEASE">
      <data key="d4">8.0</data>
      <data key="d5">Adalimumab is used to treat Dupuytren&#8217;s disease</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="ADALIMUMAB" target="ANTI-TNF THERAPY">
      <data key="d4">8.0</data>
      <data key="d5">Adalimumab is a drug used in anti-TNF therapy</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="ADALIMUMAB" target="NCT03180957">
      <data key="d4">14.0</data>
      <data key="d5">NCT03180957 is a clinical trial involving Adalimumab</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="ADALIMUMAB" target="RHEUMATOID ARTHRITIS">
      <data key="d4">16.0</data>
      <data key="d5">Adalimumab is used to treat rheumatoid arthritis</data>
      <data key="d6">0c7502a2bfe653785647d754ed10f4e3</data>
    </edge>
    <edge source="KERATINOCYTES" target="IL-17">
      <data key="d4">14.0</data>
      <data key="d5">IL-17 increases the expression of antimicrobial peptides in keratinocytes
IL-17 responses are heightened in keratinocytes</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99,fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="KERATINOCYTES" target="ATOPIC DERMATITIS">
      <data key="d4">16.0</data>
      <data key="d5">Keratinocytes release cytokines in response to tissue damage in atopic dermatitis</data>
      <data key="d6">e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="KERATINOCYTES" target="IL-22">
      <data key="d4">32.0</data>
      <data key="d5">IL-22 induces keratinocyte proliferation
IL-22 induces proliferation and downregulation of filaggrin expression in keratinocytes
IL-22 plays a role in the proliferation and downregulation of FLG in keratinocytes</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd,48288f3ec2832850282f95d4e38d10e1,4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="KERATINOCYTES" target="IL-33">
      <data key="d4">16.0</data>
      <data key="d5">IL-33 is produced by barrier-disrupted keratinocytes</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="KERATINOCYTES" target="HS">
      <data key="d4">7.0</data>
      <data key="d5">Keratinocytes show heightened inflammatory responses in HS</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="KERATINOCYTES" target="NOTCH SIGNALING PATHWAY">
      <data key="d4">6.0</data>
      <data key="d5">The Notch signaling pathway interacts with keratinocytes</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="KERATINOCYTES" target="IL18">
      <data key="d4">7.0</data>
      <data key="d5">IL18 is primarily derived from keratinocytes</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="KERATINOCYTES" target="IL-36">
      <data key="d4">7.0</data>
      <data key="d5">IL-36 responses are heightened in keratinocytes</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="KERATINOCYTES" target="DEFB4A">
      <data key="d4">7.0</data>
      <data key="d5">DEFB4A is highly expressed in keratinocytes</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="KERATINOCYTES" target="S100A7A">
      <data key="d4">7.0</data>
      <data key="d5">S100A7A is highly expressed in keratinocytes</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="KERATINOCYTES" target="IL36G">
      <data key="d4">7.0</data>
      <data key="d5">IL36G is highly expressed in keratinocytes</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="KERATINOCYTES" target="TNF">
      <data key="d4">7.0</data>
      <data key="d5">TNF responses are heightened in keratinocytes</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="KERATINOCYTES" target="IL-36G">
      <data key="d4">7.0</data>
      <data key="d5">IL-36G responses are heightened in keratinocytes</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="KERATINOCYTES" target="CYTOKINE">
      <data key="d4">7.0</data>
      <data key="d5">Cytokine responses are heightened in keratinocytes</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="KERATINOCYTES" target="ANTIMICROBIAL GENES">
      <data key="d4">7.0</data>
      <data key="d5">Antimicrobial genes are highly expressed in keratinocytes</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="KERATINOCYTES" target="INFLAMMATORY BURDEN">
      <data key="d4">7.0</data>
      <data key="d5">Keratinocytes show high inflammatory burden in HS</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="KERATINOCYTES" target="INFLAMMATORY SIGNATURE">
      <data key="d4">7.0</data>
      <data key="d5">Keratinocytes exhibit an inflammatory signature in HS</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="KERATINOCYTES" target="INFLAMMATORY STIMULI">
      <data key="d4">7.0</data>
      <data key="d5">Keratinocytes respond to inflammatory stimuli in HS</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="KERATINOCYTES" target="CYTOKINE RESPONSE">
      <data key="d4">7.0</data>
      <data key="d5">Keratinocytes exhibit cytokine responses in HS</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="KERATINOCYTES" target="IL-4">
      <data key="d4">16.0</data>
      <data key="d5">IL-4 reduces filaggrin expression in keratinocytes</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="KERATINOCYTES" target="IL-13">
      <data key="d4">16.0</data>
      <data key="d5">IL-13 reduces filaggrin expression in keratinocytes</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="KERATINOCYTES" target="AHR">
      <data key="d4">6.0</data>
      <data key="d5">AhR is expressed in keratinocytes</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="KERATINOCYTES" target="AD">
      <data key="d4">8.0</data>
      <data key="d5">Keratinocytes are involved in the immune response and inflammation in AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="KERATINOCYTES" target="FLG">
      <data key="d4">8.0</data>
      <data key="d5">Keratinocytes are involved in the proliferation and downregulation of FLG by IL-22</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </edge>
    <edge source="KERATINOCYTES" target="LIGHT">
      <data key="d4">16.0</data>
      <data key="d5">LIGHT acts on keratinocytes to promote skin fibrosis</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2</data>
    </edge>
    <edge source="KERATINOCYTES" target="HVEM">
      <data key="d4">16.0</data>
      <data key="d5">HVEM is expressed on keratinocytes and mediates LIGHT-induced skin fibrosis</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2</data>
    </edge>
    <edge source="INFLAMMATORY BOWEL DISEASE" target="HS">
      <data key="d4">7.0</data>
      <data key="d5">Inflammatory bowel disease pathway is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="INFLAMMATORY BOWEL DISEASE" target="IL19">
      <data key="d4">7.0</data>
      <data key="d5">IL19 is associated with Inflammatory bowel disease</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="INFLAMMATORY BOWEL DISEASE" target="IL22">
      <data key="d4">7.0</data>
      <data key="d5">IL22 is associated with Inflammatory bowel disease</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="INFLAMMATORY BOWEL DISEASE" target="IL23A">
      <data key="d4">8.0</data>
      <data key="d5">IL23A is associated with Inflammatory bowel disease</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="INFLAMMATORY BOWEL DISEASE" target="IL26">
      <data key="d4">7.0</data>
      <data key="d5">IL26 is associated with Inflammatory bowel disease</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="INFLAMMATORY BOWEL DISEASE" target="IL37">
      <data key="d4">7.0</data>
      <data key="d5">IL37 is associated with Inflammatory bowel disease</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="INFLAMMATORY BOWEL DISEASE" target="TRAIL">
      <data key="d4">7.0</data>
      <data key="d5">TRAIL is being explored as a therapy for inflammatory bowel disease</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="INFLAMMATORY BOWEL DISEASE" target="TNF">
      <data key="d4">8.0</data>
      <data key="d5">TNF is targeted in therapies for inflammatory bowel disease</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="INFLAMMATORY BOWEL DISEASE" target="ANTI-TNF THERAPY">
      <data key="d4">8.0</data>
      <data key="d5">Anti-TNF therapy is used to treat inflammatory bowel disease</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="INFLAMMATORY BOWEL DISEASE" target="NCT03747068">
      <data key="d4">7.0</data>
      <data key="d5">NCT03747068 is a clinical trial targeting inflammatory bowel disease</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="INFLAMMATORY BOWEL DISEASE" target="PRA023">
      <data key="d4">14.0</data>
      <data key="d5">PRA023 is used in clinical trials to treat Inflammatory Bowel Disease</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="ARTHRITIS" target="IL17A">
      <data key="d4">8.0</data>
      <data key="d5">IL17A is associated with Arthritis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="ARTHRITIS" target="IL17R">
      <data key="d4">7.0</data>
      <data key="d5">IL17R is associated with Arthritis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="ARTHRITIS" target="IL23A">
      <data key="d4">8.0</data>
      <data key="d5">IL23A is associated with Arthritis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="ARTHRITIS" target="TNIP1">
      <data key="d4">14.0</data>
      <data key="d5">TNIP1 is associated with arthritis</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="TYPE I DIABETES MELLITUS" target="HS">
      <data key="d4">14.0</data>
      <data key="d5">Type I diabetes mellitus pathway is associated with HS
Type I diabetes mellitus signaling is dysregulated in HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719,fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="ATHEROSCLEROSIS" target="HS">
      <data key="d4">7.0</data>
      <data key="d5">Atherosclerosis signaling is dysregulated in HS</data>
      <data key="d6">fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="ATHEROSCLEROSIS" target="HEART">
      <data key="d4">8.0</data>
      <data key="d5">Atherosclerosis affects the heart</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="ATHEROSCLEROSIS" target="TNFR1">
      <data key="d4">7.0</data>
      <data key="d5">TNFR1 signaling is involved in the control of atherosclerosis</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="ATHEROSCLEROSIS" target="ADAM17">
      <data key="d4">7.0</data>
      <data key="d5">ADAM17 deficiency favors overactivation of TNFR2 and atherosclerosis progression</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="ATHEROSCLEROSIS" target="OX40L">
      <data key="d4">16.0</data>
      <data key="d5">OX40L is implicated in atherosclerosis</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="ADIPOGENESIS" target="HS">
      <data key="d4">15.0</data>
      <data key="d5">Adipogenesis is associated with HS
Adipogenesis is linked to HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719,f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="SCARRING" target="TNFSF MEMBERS">
      <data key="d4">8.0</data>
      <data key="d5">TNFSF members are involved in driving scarring</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </edge>
    <edge source="ADIPOSE TISSUE" target="BAFF">
      <data key="d4">7.0</data>
      <data key="d5">BAFF-/- mice show reduced adipose tissue fibrosis</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="GENE EXPRESSION OMNIBUS" target="GSE154775">
      <data key="d4">7.0</data>
      <data key="d5">GSE154775 is a data set in the Gene Expression Omnibus</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="GENE EXPRESSION OMNIBUS" target="GSE154773">
      <data key="d4">7.0</data>
      <data key="d5">GSE154773 is a data set in the Gene Expression Omnibus</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="GENE EXPRESSION OMNIBUS" target="NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION">
      <data key="d4">16.0</data>
      <data key="d5">National Center for Biotechnology Information hosts the Gene Expression Omnibus</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="TRANSCRIPTOME" target="AD">
      <data key="d4">14.0</data>
      <data key="d5">Transcriptome analysis is used to study gene expression in atopic dermatitis</data>
      <data key="d6">f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="HUGO GENE NOMENCLATURE COMMITTEE" target="EUROPEAN BIOINFORMATICS INSTITUTE">
      <data key="d4">6.0</data>
      <data key="d5">The HUGO Gene Nomenclature Committee collaborates with the European Bioinformatics Institute</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="CHRONIC INFLAMMATION" target="ATOPIC DERMATITIS">
      <data key="d4">8.0</data>
      <data key="d5">Chronic inflammation is a symptom of Atopic Dermatitis</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="CHRONIC INFLAMMATION" target="CD27">
      <data key="d4">7.0</data>
      <data key="d5">Chronic inflammation is associated with a lack of CD27 expression</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="INFLAMMATION" target="HS">
      <data key="d4">25.0</data>
      <data key="d5">Inflammation is a key symptom in HS
HS is characterized by chronic inflammation</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13,f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="INFLAMMATION" target="AD">
      <data key="d4">44.0</data>
      <data key="d5">Inflammation is a key feature of atopic dermatitis
Inflammation is a common symptom in atopic dermatitis
Inflammation is a key feature of atopic dermatitis
Inflammation is a key symptom in Atopic Dermatitis and other comorbidities</data>
      <data key="d6">143d2dc302af5606656797bff162e23e,90f4809673ca34628b0e607908f0bf0b,a867a1e73cef039eb3f28e072463b838,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="SINUS TRACT" target="HS">
      <data key="d4">8.0</data>
      <data key="d5">Sinus tracts are associated with chronic inflammation in HS</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606</data>
    </edge>
    <edge source="HS" target="CXCL10">
      <data key="d4">24.0</data>
      <data key="d5">CXCL10 is one of the differentially expressed genes in Hidradenitis Suppurativa
CXCL10 expression is increased in HS</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9,b62ecc47bf54393bc78dd65986b949d6</data>
    </edge>
    <edge source="HS" target="IL6">
      <data key="d4">8.0</data>
      <data key="d5">IL6 is one of the differentially expressed genes in Hidradenitis Suppurativa</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="HS" target="IL17A">
      <data key="d4">24.0</data>
      <data key="d5">IL17A is one of the differentially expressed genes in Hidradenitis Suppurativa
IL17A has increased mRNA expression in HS</data>
      <data key="d6">2e0cdefd62bed7c674d7fb93ef336c2b,990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="HS" target="IL36A">
      <data key="d4">38.0</data>
      <data key="d5">IL36A is one of the differentially expressed genes in Hidradenitis Suppurativa
IL36A has increased mRNA expression in HS
IL36A expression is increased in HS</data>
      <data key="d6">2e0cdefd62bed7c674d7fb93ef336c2b,990bc0f89db6ad8683c7a06a3ab356d9,e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="HS" target="IL36G">
      <data key="d4">38.0</data>
      <data key="d5">IL36G is one of the differentially expressed genes in Hidradenitis Suppurativa
IL36G has increased mRNA expression in HS
IL36G expression is increased in HS</data>
      <data key="d6">2e0cdefd62bed7c674d7fb93ef336c2b,990bc0f89db6ad8683c7a06a3ab356d9,e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="HS" target="S100A8">
      <data key="d4">8.0</data>
      <data key="d5">S100A8 is one of the differentially expressed genes in Hidradenitis Suppurativa</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="HS" target="S100A9">
      <data key="d4">8.0</data>
      <data key="d5">S100A9 is one of the differentially expressed genes in Hidradenitis Suppurativa</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="HS" target="SKIN">
      <data key="d4">94.0</data>
      <data key="d5">The skin is a tissue affected by Hidradenitis Suppurativa
Skin is affected in HS, showing differences between lesional and non-lesional areas
HS affects the skin
HS primarily affects the skin
Formalin-fixed, paraffin-embedded tissue slides obtained from HS patients were used for CyTOF imaging
Lesional skin biopsies were collected from patients with HS
HS affects the skin</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13,411a4d246f0a9321e52971446a5a0606,990bc0f89db6ad8683c7a06a3ab356d9,b28eeca0ff01a7715947d55a04978a43,bae090d8a29c15868ba1c4f29ae79e99,e4d25b1cd44df240a29591bc46a875ab,f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="BLOOD">
      <data key="d4">35.0</data>
      <data key="d5">Blood is a tissue where differentially expressed genes and proteins are detected in Hidradenitis Suppurativa patients
Blood is used for biomarker studies in HS patients
Blood samples were collected from patients with HS</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13,990bc0f89db6ad8683c7a06a3ab356d9,f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="FIBROSIS">
      <data key="d4">7.0</data>
      <data key="d5">Fibrosis is a symptom often seen in chronic inflammatory diseases like Hidradenitis Suppurativa</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="HS" target="JAK-STAT SIGNALING PATHWAY">
      <data key="d4">16.0</data>
      <data key="d5">The JAK-STAT signaling pathway is associated with HS
JAK-STAT signaling pathway is involved in HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719,f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="RHEUMATOID ARTHRITIS">
      <data key="d4">7.0</data>
      <data key="d5">Rheumatoid arthritis pathway is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="TH17 CELL DIFFERENTIATION PATHWAY">
      <data key="d4">8.0</data>
      <data key="d5">Th17 cell differentiation pathway is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="LIPID AND ATHEROSCLEROSIS PATHWAY">
      <data key="d4">7.0</data>
      <data key="d5">Lipid and atherosclerosis pathway is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="TLR PATHWAY">
      <data key="d4">7.0</data>
      <data key="d5">TLR pathway is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="C-TYPE LEPTIN RECEPTOR SIGNALING PATHWAY">
      <data key="d4">7.0</data>
      <data key="d5">C-type leptin receptor signaling pathway is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="TNF SIGNALING PATHWAY">
      <data key="d4">7.0</data>
      <data key="d5">TNF signaling pathway is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="IL-17">
      <data key="d4">32.0</data>
      <data key="d5">IL-17 signaling is associated with HS
Anti-IL-17 compounds are proposed for HS treatment
IL-17 is implicated in HS pathogenesis</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719,e340a83f7cba0ea5be731b1f682ea7c7,f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="IL-4">
      <data key="d4">19.0</data>
      <data key="d5">IL-4 signaling is associated with HS
IL-4 has no significant response in HS lesional skin</data>
      <data key="d6">2e0cdefd62bed7c674d7fb93ef336c2b,4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="IL-13">
      <data key="d4">7.0</data>
      <data key="d5">IL-13 signaling is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="IL-10">
      <data key="d4">7.0</data>
      <data key="d5">IL-10 signaling is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="IL-20 FAMILY">
      <data key="d4">7.0</data>
      <data key="d5">IL-20 family signaling is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="IL-1 FAMILY">
      <data key="d4">7.0</data>
      <data key="d5">IL-1 family signaling is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="IL-18">
      <data key="d4">7.0</data>
      <data key="d5">IL-18 signaling is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="IL-36">
      <data key="d4">39.0</data>
      <data key="d5">IL-36 signaling is associated with HS
IL-36 has a significant response in HS lesional skin
IL-36 responses are prominent in HS keratinocytes</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13,2e0cdefd62bed7c674d7fb93ef336c2b,4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="IL-2 FAMILY">
      <data key="d4">7.0</data>
      <data key="d5">IL-2 family signaling is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="IL-21">
      <data key="d4">7.0</data>
      <data key="d5">IL-21 signaling is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="IL-12 FAMILY">
      <data key="d4">7.0</data>
      <data key="d5">IL-12 family signaling is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="EPIDERMAL GROWTH FACTOR RECEPTOR">
      <data key="d4">7.0</data>
      <data key="d5">Epidermal growth factor receptor signaling is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="IL-1 RECEPTOR">
      <data key="d4">7.0</data>
      <data key="d5">IL-1 receptor signaling is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="CORNIFIED ENVELOPE">
      <data key="d4">7.0</data>
      <data key="d5">Formation of the cornified envelope is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="ANTIMICROBIAL PEPTIDES">
      <data key="d4">7.0</data>
      <data key="d5">Antimicrobial peptides are associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="INNATE IMMUNE SYSTEM">
      <data key="d4">8.0</data>
      <data key="d5">Innate immune system is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="IFNG SIGNALING">
      <data key="d4">7.0</data>
      <data key="d5">IFNG signaling is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="SIGNAL TRANSDUCTION">
      <data key="d4">7.0</data>
      <data key="d5">Signal transduction is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="NUCLEAR RECEPTOR">
      <data key="d4">14.0</data>
      <data key="d5">Nuclear receptor signaling is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="GPCR">
      <data key="d4">14.0</data>
      <data key="d5">G protein-coupled receptors (GPCRs) are associated with HSGPCR signaling is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="LEPTIN">
      <data key="d4">14.0</data>
      <data key="d5">Leptin signaling is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="DEVELOPMENTAL BIOLOGY">
      <data key="d4">7.0</data>
      <data key="d5">Developmental biology pathways are associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="ABAT">
      <data key="d4">14.0</data>
      <data key="d5">ABAT is a druggable gene associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="ADRA1A">
      <data key="d4">14.0</data>
      <data key="d5">ADRA1A is a druggable gene associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="CYP3A4">
      <data key="d4">14.0</data>
      <data key="d5">CYP3A4 is a druggable gene associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="GRM4">
      <data key="d4">14.0</data>
      <data key="d5">GRM4 is a druggable gene associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="HRH1">
      <data key="d4">14.0</data>
      <data key="d5">HRH1 is a druggable gene associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="OPRD1">
      <data key="d4">14.0</data>
      <data key="d5">OPRD1 is a druggable gene associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="OPRM">
      <data key="d4">14.0</data>
      <data key="d5">OPRM is a druggable gene associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="PRKAB1">
      <data key="d4">14.0</data>
      <data key="d5">PRKAB1 is a druggable gene associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="PTGS1">
      <data key="d4">14.0</data>
      <data key="d5">PTGS1 is a druggable gene associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="PTGS2">
      <data key="d4">14.0</data>
      <data key="d5">PTGS2 is a druggable gene associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="SLC6A4">
      <data key="d4">14.0</data>
      <data key="d5">SLC6A4 is a druggable gene associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="CD4+ LYMPHOCYTES">
      <data key="d4">24.0</data>
      <data key="d5">CD4+ lymphocytes are involved in the pathogenesis of HS
CD4+ lymphocytes are involved in the pathogenesis of HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719,fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="HS" target="CD45+CD4+ T CELLS">
      <data key="d4">24.0</data>
      <data key="d5">CD45+CD4+ T cells are responsible for IL-17 production in HS
CD45+CD4+ T cells are responsible for IL-17 production in HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719,fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="HS" target="CD11C+CD1A-CD14+ DENDRITIC CELLS">
      <data key="d4">24.0</data>
      <data key="d5">CD11c+CD1a-CD14+ dendritic cells produce IL-1&#946; in HS
CD11c+CD1a-CD14+ dendritic cells produce IL-1&#946; in lesional HS skin</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719,fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="HS" target="IL-1&#914;">
      <data key="d4">45.0</data>
      <data key="d5">IL-1&#946; is produced in HSInterleukin-1 beta (IL-1&#946;) is produced in HS
IL-1&#946; is implicated in HS pathogenesis</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719,e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="HS" target="IL-17 CYTOKINE FAMILY">
      <data key="d4">10.0</data>
      <data key="d5">IL-17 cytokine family is involved in HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="DEGS">
      <data key="d4">32.0</data>
      <data key="d5">Differentially expressed genes (DEGs) are associated with HS
DEGs are differentially expressed in HS
DEGs were identified in HS
DEGs are prominently clustered around BTK and SYK nodes in HS</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,4a1ab1e50481cdd86d237db424a95719,e340a83f7cba0ea5be731b1f682ea7c7,f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="EGFR">
      <data key="d4">7.0</data>
      <data key="d5">Epidermal growth factor receptor (EGFR) signaling is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="TLRS">
      <data key="d4">7.0</data>
      <data key="d5">Toll-like receptors (TLRs) are associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="RESISTIN">
      <data key="d4">14.0</data>
      <data key="d5">Resistin signaling is associated with HS
Resistin signaling is dysregulated in HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719,fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="HS" target="IFNG">
      <data key="d4">39.0</data>
      <data key="d5">Interferon-gamma (IFNG) signaling is associated with HS
IFNG has increased mRNA expression in HS
IFNG expression is increased in HS</data>
      <data key="d6">2e0cdefd62bed7c674d7fb93ef336c2b,4a1ab1e50481cdd86d237db424a95719,b62ecc47bf54393bc78dd65986b949d6</data>
    </edge>
    <edge source="HS" target="CD4+ T CELLS">
      <data key="d4">8.0</data>
      <data key="d5">CD4+ T cells are involved in the pathogenesis of HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="CD11C+ DENDRITIC CELLS">
      <data key="d4">8.0</data>
      <data key="d5">CD11c+ dendritic cells are involved in the pathogenesis of HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="EXTRANUCLEAR SIGNALING">
      <data key="d4">7.0</data>
      <data key="d5">Extranuclear signaling is associated with HS</data>
      <data key="d6">4a1ab1e50481cdd86d237db424a95719</data>
    </edge>
    <edge source="HS" target="TH17">
      <data key="d4">8.0</data>
      <data key="d5">Th17 differentiation of CD4+ lymphocytes is activated in HS</data>
      <data key="d6">fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="HS" target="IL-1">
      <data key="d4">8.0</data>
      <data key="d5">IL-1 signaling pathway is prominent in HS</data>
      <data key="d6">fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="HS" target="PLIN1">
      <data key="d4">7.0</data>
      <data key="d5">PLIN1 is upregulated in HS</data>
      <data key="d6">fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="HS" target="PPAR&#915;">
      <data key="d4">15.0</data>
      <data key="d5">PPAR&#947; pathway is down-regulated in adipocytes of HS lesions
PPAR&#947; is involved in HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9,fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="HS" target="IGF">
      <data key="d4">7.0</data>
      <data key="d5">IGF transport and uptake of IGF-binding proteins pathway is dysregulated in HS</data>
      <data key="d6">fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="HS" target="LIPID">
      <data key="d4">7.0</data>
      <data key="d5">Lipid metabolism is dysregulated in HS</data>
      <data key="d6">fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="HS" target="C-TYPE LEPTIN RECEPTOR">
      <data key="d4">7.0</data>
      <data key="d5">C-type leptin receptor signaling is dysregulated in HS</data>
      <data key="d6">fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="HS" target="INFLAMMATORY BOWEL DISEASES">
      <data key="d4">8.0</data>
      <data key="d5">HS is associated with inflammatory bowel diseases</data>
      <data key="d6">fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="HS" target="CROHN&#8217;S DISEASE">
      <data key="d4">8.0</data>
      <data key="d5">HS is associated with Crohn&#8217;s disease</data>
      <data key="d6">fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="HS" target="AXIAL SPONDYLARTHRITIS">
      <data key="d4">8.0</data>
      <data key="d5">HS is associated with axial spondylarthritis</data>
      <data key="d6">fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="HS" target="PACHYONYCHIA CONGENITA">
      <data key="d4">8.0</data>
      <data key="d5">HS is associated with pachyonychia congenita</data>
      <data key="d6">fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="HS" target="STEATOCYSTOMA MULTIPLEX">
      <data key="d4">8.0</data>
      <data key="d5">HS is associated with steatocystoma multiplex</data>
      <data key="d6">fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="HS" target="DOWLING-DEGOS DISEASE">
      <data key="d4">8.0</data>
      <data key="d5">HS is associated with Dowling-Degos disease</data>
      <data key="d6">fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="HS" target="KERATITIS&#8211;ICHTHYOSIS&#8211;DEAFNESS SYNDROME">
      <data key="d4">8.0</data>
      <data key="d5">HS is associated with keratitis&#8211;ichthyosis&#8211;deafness syndrome</data>
      <data key="d6">fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="HS" target="DOWN SYNDROME">
      <data key="d4">8.0</data>
      <data key="d5">HS is associated with Down syndrome</data>
      <data key="d6">fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="HS" target="INFLAMMATORY BOWEL DISEASE PATHWAY">
      <data key="d4">8.0</data>
      <data key="d5">HS is associated with the inflammatory bowel disease pathway</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="RHEUMATOID ARTHRITIS PATHWAY">
      <data key="d4">8.0</data>
      <data key="d5">HS is associated with the rheumatoid arthritis pathway</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="TYPE I DIABETES MELLITUS SIGNALING">
      <data key="d4">8.0</data>
      <data key="d5">HS is associated with type I diabetes mellitus signaling</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="LIPID AND ATHEROSCLEROSIS">
      <data key="d4">8.0</data>
      <data key="d5">HS is associated with lipid and atherosclerosis</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="ADIPOGENESIS SIGNALING">
      <data key="d4">8.0</data>
      <data key="d5">HS is associated with adipogenesis signaling</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="JAK-STAT INHIBITORS">
      <data key="d4">8.0</data>
      <data key="d5">JAK-STAT inhibitors are proposed for HS treatment</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="PI3K INHIBITORS">
      <data key="d4">8.0</data>
      <data key="d5">PI3K inhibitors are proposed for HS treatment</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="MMP INHIBITORS">
      <data key="d4">8.0</data>
      <data key="d5">MMP inhibitors are proposed for HS treatment</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="GENTAMICIN">
      <data key="d4">7.0</data>
      <data key="d5">Gentamicin is reported as a repurposing drug for HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="IBUDILAST">
      <data key="d4">7.0</data>
      <data key="d5">Ibudilast is reported as a repurposing drug for HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="SPIRONOLACTONE">
      <data key="d4">7.0</data>
      <data key="d5">Spironolactone is reported as a repurposing drug for HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="TRASTUZUMAB">
      <data key="d4">7.0</data>
      <data key="d5">Trastuzumab is reported as a repurposing drug for HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="THALIDOMIDE">
      <data key="d4">7.0</data>
      <data key="d5">Thalidomide is reported as a repurposing drug for HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="APREMILAST">
      <data key="d4">7.0</data>
      <data key="d5">Apremilast is reported as a repurposing drug for HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="GLUCOSAMINE">
      <data key="d4">7.0</data>
      <data key="d5">Glucosamine is reported as a repurposing drug for HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="INTERFERON-A-2B">
      <data key="d4">7.0</data>
      <data key="d5">Interferon-a-2b is reported as a repurposing drug for HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="BINIMETINIB">
      <data key="d4">7.0</data>
      <data key="d5">Binimetinib is reported as a repurposing drug for HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="MIDOSTAURIN">
      <data key="d4">7.0</data>
      <data key="d5">Midostaurin is reported as a repurposing drug for HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="TYROSINE KINASE RECEPTOR INHIBITORS">
      <data key="d4">8.0</data>
      <data key="d5">Tyrosine kinase receptor inhibitors are proposed for HS treatment</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="TNF INHIBITORS">
      <data key="d4">8.0</data>
      <data key="d5">TNF inhibitors are proposed for HS treatment</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="CYCLOOXYGENASE INHIBITORS">
      <data key="d4">8.0</data>
      <data key="d5">Cyclooxygenase inhibitors are proposed for HS treatment</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="EGF RECEPTOR INHIBITORS">
      <data key="d4">8.0</data>
      <data key="d5">EGF receptor inhibitors are proposed for HS treatment</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="PPAR&#915; LIGANDS">
      <data key="d4">8.0</data>
      <data key="d5">PPAR&#947; ligands are proposed for HS treatment</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="EPITHELIAL CELL DIFFERENTIATION">
      <data key="d4">9.0</data>
      <data key="d5">Dysregulated epithelial cell differentiation is involved in HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="OBESITY SIGNALING">
      <data key="d4">8.0</data>
      <data key="d5">Obesity signaling is involved in HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="ADAM12">
      <data key="d4">14.0</data>
      <data key="d5">ADAM12 is upregulated in HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="ADIPOQ">
      <data key="d4">14.0</data>
      <data key="d5">ADIPOQ is downregulated in HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="AR">
      <data key="d4">14.0</data>
      <data key="d5">AR is upregulated in HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="BTK">
      <data key="d4">61.0</data>
      <data key="d5">BTK shows diversified regulation in HS
BTK is a potential therapeutic target in HS
BTK is a key node in the network analysis of HS
BTK is involved in B cell signaling and is a potential therapeutic target in HS
Increased expression of BTK in HS skin</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,b62ecc47bf54393bc78dd65986b949d6,e340a83f7cba0ea5be731b1f682ea7c7,e4d25b1cd44df240a29591bc46a875ab,f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="C3">
      <data key="d4">12.0</data>
      <data key="d5">C3 shows mixed regulation in HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="C5AR1">
      <data key="d4">14.0</data>
      <data key="d5">C5AR1 is upregulated in HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="CASP1">
      <data key="d4">14.0</data>
      <data key="d5">CASP1 is upregulated in HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="CCL18">
      <data key="d4">14.0</data>
      <data key="d5">CCL18 is upregulated in HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="CCL26">
      <data key="d4">14.0</data>
      <data key="d5">CCL26 is upregulated in HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="CCR4">
      <data key="d4">8.0</data>
      <data key="d5">CCR4 is upregulated in HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="KEGG GO">
      <data key="d4">7.0</data>
      <data key="d5">KEGG GO is used for pathway analysis in HS studies</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="IL-17 SIGNALING PATHWAY">
      <data key="d4">8.0</data>
      <data key="d5">IL-17 signaling pathway is involved in HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="RECEPTOR INTERACTION PATHWAY">
      <data key="d4">1.0</data>
      <data key="d5">Receptor interaction pathway is involved in HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="JAK INHIBITORS">
      <data key="d4">8.0</data>
      <data key="d5">JAK inhibitors are proposed for HS treatment</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="CYTOKINE INHIBITORS">
      <data key="d4">8.0</data>
      <data key="d5">Cytokine inhibitors are proposed for HS treatment</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="TYROSINE KINASE INHIBITORS">
      <data key="d4">8.0</data>
      <data key="d5">Tyrosine kinase inhibitors are proposed for HS treatment</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="TNF">
      <data key="d4">81.0</data>
      <data key="d5">TNF is involved in HS
TNF has no significant response in HS lesional skin
TNF is colocalized with plasma cells in HS
TNF is implicated in HS
TNF is a target for biologic treatment in HS
TNF responses are elevated in HS keratinocytes
TNF is primarily localized to plasma cells in HS skin</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13,2e0cdefd62bed7c674d7fb93ef336c2b,411a4d246f0a9321e52971446a5a0606,b62ecc47bf54393bc78dd65986b949d6,e340a83f7cba0ea5be731b1f682ea7c7,e4d25b1cd44df240a29591bc46a875ab,f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="CYCLOOXYGENASE">
      <data key="d4">8.0</data>
      <data key="d5">Cyclooxygenase is involved in HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="EGF RECEPTOR">
      <data key="d4">8.0</data>
      <data key="d5">EGF receptor is involved in HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="EPITHELIAL CELLS">
      <data key="d4">8.0</data>
      <data key="d5">Epithelial cells are involved in HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="HORMONES">
      <data key="d4">8.0</data>
      <data key="d5">Hormones are involved in HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="KEGG">
      <data key="d4">21.0</data>
      <data key="d5">KEGG is used for pathway analysis in HS studies
KEGG pathways were enriched in DEGs in HS skin</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13,f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="GO">
      <data key="d4">7.0</data>
      <data key="d5">GO is used for pathway analysis in HS studies</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="RECEPTOR INTERACTION">
      <data key="d4">8.0</data>
      <data key="d5">Receptor interaction pathway is involved in HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="IL-17 SIGNALING">
      <data key="d4">8.0</data>
      <data key="d5">IL-17 signaling pathway is involved in HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="JAK-STAT SIGNALING">
      <data key="d4">8.0</data>
      <data key="d5">JAK-STAT signaling pathway is involved in HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="TRANSCRIPTOMIC PROFILES">
      <data key="d4">8.0</data>
      <data key="d5">Transcriptomic profiles are used to study HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="PROTEIN EXPRESSION">
      <data key="d4">8.0</data>
      <data key="d5">Protein expression profiles are used to study HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="LESIONAL SKIN">
      <data key="d4">9.0</data>
      <data key="d5">Lesional skin is affected by HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="NON-LESIONAL SKIN">
      <data key="d4">9.0</data>
      <data key="d5">Non-lesional skin is not affected by HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="HEALTHY CONTROLS">
      <data key="d4">8.0</data>
      <data key="d5">Healthy controls are used as a comparison group in HS studies</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="BIOMARKERS">
      <data key="d4">8.0</data>
      <data key="d5">Biomarkers are used as indicators of HS</data>
      <data key="d6">f3b0f42501dbe75c224f7af44e0885f9</data>
    </edge>
    <edge source="HS" target="DEFB4A">
      <data key="d4">16.0</data>
      <data key="d5">DEFB4A is an antimicrobial gene with increased expression in HS</data>
      <data key="d6">2e0cdefd62bed7c674d7fb93ef336c2b</data>
    </edge>
    <edge source="HS" target="CXCL13">
      <data key="d4">16.0</data>
      <data key="d5">CXCL13 is a B cell chemoattractant gene with increased expression in HS</data>
      <data key="d6">2e0cdefd62bed7c674d7fb93ef336c2b</data>
    </edge>
    <edge source="HS" target="CXCL1">
      <data key="d4">16.0</data>
      <data key="d5">CXCL1 is a neutrophil chemokine gene with increased expression in HS</data>
      <data key="d6">2e0cdefd62bed7c674d7fb93ef336c2b</data>
    </edge>
    <edge source="HS" target="IL17F">
      <data key="d4">16.0</data>
      <data key="d5">IL17F has increased mRNA expression in HS</data>
      <data key="d6">2e0cdefd62bed7c674d7fb93ef336c2b</data>
    </edge>
    <edge source="HS" target="IL13">
      <data key="d4">14.0</data>
      <data key="d5">IL13 has decreased expression in HS</data>
      <data key="d6">2e0cdefd62bed7c674d7fb93ef336c2b</data>
    </edge>
    <edge source="HS" target="IL17C">
      <data key="d4">14.0</data>
      <data key="d5">IL17C has decreased expression in HS</data>
      <data key="d6">2e0cdefd62bed7c674d7fb93ef336c2b</data>
    </edge>
    <edge source="HS" target="IFN-&#915;">
      <data key="d4">54.0</data>
      <data key="d5">IFN-&#947; has a significant response in HS lesional skin
Increased IFN-&#947; levels are found in HS skinIFN-&#947; is implicated in HS pathogenesis
IFN-&#947; responses are prominent in HS keratinocytes</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13,2e0cdefd62bed7c674d7fb93ef336c2b,e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="HS" target="B CELLS">
      <data key="d4">51.0</data>
      <data key="d5">B cells have significant signatures in HS skin
B cells are involved in the immune response in HS
B cells are predominant in HS skin
B cells are identified as a potential therapeutic target in HS</data>
      <data key="d6">2e0cdefd62bed7c674d7fb93ef336c2b,411a4d246f0a9321e52971446a5a0606,b62ecc47bf54393bc78dd65986b949d6,bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="HS" target="TH2">
      <data key="d4">16.0</data>
      <data key="d5">Th2 cells have significant signatures in HS skin</data>
      <data key="d6">2e0cdefd62bed7c674d7fb93ef336c2b</data>
    </edge>
    <edge source="HS" target="CD4+">
      <data key="d4">16.0</data>
      <data key="d5">CD4+ cells have significant signatures in HS skin</data>
      <data key="d6">2e0cdefd62bed7c674d7fb93ef336c2b</data>
    </edge>
    <edge source="HS" target="CD8+">
      <data key="d4">16.0</data>
      <data key="d5">CD8+ cells have significant signatures in HS skin</data>
      <data key="d6">2e0cdefd62bed7c674d7fb93ef336c2b</data>
    </edge>
    <edge source="HS" target="RNA-SEQ">
      <data key="d4">38.0</data>
      <data key="d5">RNA-Seq was used to analyze the transcriptomic characteristics of HS
RNA-Seq was used to analyze gene expression in HS
RNA-Seq was used to characterize the inflammatory process in HS</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13,2e0cdefd62bed7c674d7fb93ef336c2b,411a4d246f0a9321e52971446a5a0606</data>
    </edge>
    <edge source="HS" target="SCRNA-SEQ">
      <data key="d4">18.0</data>
      <data key="d5">scRNA-Seq was used to outline the cellular composition of HS
scRNA-Seq was used to characterize the inflammatory cell composition in HS</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13,2e0cdefd62bed7c674d7fb93ef336c2b</data>
    </edge>
    <edge source="HS" target="PLASMA CELLS">
      <data key="d4">35.0</data>
      <data key="d5">Plasma cells are involved in the immune response in HS
Plasma cells are predominant in HS skin
Plasma cells are identified as a potential therapeutic target in HS</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,b62ecc47bf54393bc78dd65986b949d6,bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="HS" target="CYTOF">
      <data key="d4">26.0</data>
      <data key="d5">CyTOF imaging was used to identify and quantify infiltrating leukocytes in HS
CyTOF data demonstrated clear separation between HS and normal skin</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13,bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="HS" target="T-SNE">
      <data key="d4">24.0</data>
      <data key="d5">t-SNE was used to visualize leukocyte clustering in HS
t-SNE was used to analyze CyTOF data in HS</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13,bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="HS" target="MONOCYTES">
      <data key="d4">12.0</data>
      <data key="d5">Monocytes are part of the leukocyte infiltration in HS</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="HS" target="LEUKOCYTES">
      <data key="d4">2.0</data>
      <data key="d5">Leukocytes are increased in HS skin</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="HS" target="LEUKOCYTE INFILTRATION">
      <data key="d4">8.0</data>
      <data key="d5">Leukocyte infiltration is observed in HS skin</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="HS" target="MONOCYTE/MACROPHAGES">
      <data key="d4">8.0</data>
      <data key="d5">Monocytes and macrophages are present in HS skin</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606</data>
    </edge>
    <edge source="HS" target="CD8+ T CELLS">
      <data key="d4">8.0</data>
      <data key="d5">CD8+ T cells are present in HS skin</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606</data>
    </edge>
    <edge source="HS" target="NEUTROPHILS">
      <data key="d4">8.0</data>
      <data key="d5">Neutrophils are present in HS skin</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606</data>
    </edge>
    <edge source="HS" target="IMMUNOGLOBULIN">
      <data key="d4">23.0</data>
      <data key="d5">Immunoglobulin production is increased in HS skin
Increased immunoglobulin production in HS skin</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13,411a4d246f0a9321e52971446a5a0606</data>
    </edge>
    <edge source="HS" target="COMPLEMENT">
      <data key="d4">23.0</data>
      <data key="d5">Complement activation is increased in HS skin
Complement activation is increased in HS skin</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13,411a4d246f0a9321e52971446a5a0606</data>
    </edge>
    <edge source="HS" target="BCR">
      <data key="d4">38.0</data>
      <data key="d5">BCR gene segments are increased in HS skin
BCR diversity is increased in HS skin
Increased expression of BCR in HS skin</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13,411a4d246f0a9321e52971446a5a0606,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="TCR">
      <data key="d4">21.0</data>
      <data key="d5">TCR gene segments show less pronounced shifts in HS
Increased expression of TCR in HS skin</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="C1Q">
      <data key="d4">24.0</data>
      <data key="d5">C1q is prominently expressed in HS skin
C1q was used in immunohistochemistry of HS patient tissues
Increased levels of C1q in HS skin</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,b28eeca0ff01a7715947d55a04978a43,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="C3B">
      <data key="d4">22.0</data>
      <data key="d5">C3b is prominently expressed in HS skin
Increased levels of C3b in HS skin</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="C4D">
      <data key="d4">22.0</data>
      <data key="d5">C4d is prominently expressed in HS skin
Increased levels of C4d in HS skin</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="CR1">
      <data key="d4">34.0</data>
      <data key="d5">CR1 is increased in HS skin
CR1 was used in immunohistochemistry of HS patient tissues
Increased levels of CR1 in HS skin</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,b28eeca0ff01a7715947d55a04978a43,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="CR2">
      <data key="d4">34.0</data>
      <data key="d5">CR2 is increased in HS skin
CR2 was used in immunohistochemistry of HS patient tissues
Increased levels of CR2 in HS skin</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,b28eeca0ff01a7715947d55a04978a43,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="IGG">
      <data key="d4">22.0</data>
      <data key="d5">IgG immune complexes are deposited in HS skin
Overlap between gene expression in activated B cells treated with IgG and HS</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="SYK">
      <data key="d4">49.0</data>
      <data key="d5">SYK is a potential therapeutic target in HS
SYK is a key node in the network analysis of HS
SYK is involved in B cell signaling and is a potential therapeutic target in HS
Increased expression of SYK in HS skin</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,b62ecc47bf54393bc78dd65986b949d6,e340a83f7cba0ea5be731b1f682ea7c7,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="IL-17A">
      <data key="d4">16.0</data>
      <data key="d5">IL-17A has enriched signals in HS
Increased IL-17A levels are found in HS skin</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="HS" target="GRANZYME B">
      <data key="d4">8.0</data>
      <data key="d5">Granzyme B has enriched signals in HS</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606</data>
    </edge>
    <edge source="HS" target="CCR5">
      <data key="d4">8.0</data>
      <data key="d5">CCR5 has enriched signals in HS</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606</data>
    </edge>
    <edge source="HS" target="ACALABRUTINIB">
      <data key="d4">22.0</data>
      <data key="d5">Acalabrutinib is used as a potential therapeutic in HS
Overlap between gene expression in activated B cells treated with Acalabrutinib and HS</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="IBRUTINIB">
      <data key="d4">22.0</data>
      <data key="d5">Ibrutinib is used as a potential therapeutic in HS
Overlap between gene expression in activated B cells treated with Ibrutinib and HS</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="FOSTAMATINIB">
      <data key="d4">22.0</data>
      <data key="d5">Fostamatinib is used as a potential therapeutic in HS
Overlap between gene expression in activated B cells treated with Fostamatinib and HS</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="CCL4">
      <data key="d4">29.0</data>
      <data key="d5">CCL4 is involved in the immune response in HS
CCL4 is highly expressed in HS skin
CCL4 expression is decreased by B cell targeting in HS</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,b62ecc47bf54393bc78dd65986b949d6,e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="HS" target="CD3+ T CELLS">
      <data key="d4">8.0</data>
      <data key="d5">CD3+ T cells are present in HS skin</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606</data>
    </edge>
    <edge source="HS" target="CD20+ B CELLS">
      <data key="d4">8.0</data>
      <data key="d5">CD20+ B cells are present in HS skin</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606</data>
    </edge>
    <edge source="HS" target="CD138+ PLASMA CELLS">
      <data key="d4">8.0</data>
      <data key="d5">CD138+ plasma cells are present in HS skin</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606</data>
    </edge>
    <edge source="HS" target="PHOSPHO-BTK">
      <data key="d4">36.0</data>
      <data key="d5">Phospho-BTK is increased in HS
Phospho-BTK was used in immunohistochemistry of HS patient tissues
Activation of BTK in HS skin</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,b28eeca0ff01a7715947d55a04978a43,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="PHOSPHO-SYK">
      <data key="d4">29.0</data>
      <data key="d5">Phospho-SYK is increased in HS
Phospho-SYK was used in immunohistochemistry of HS patient tissues
Activation of SYK in HS skin</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,b28eeca0ff01a7715947d55a04978a43,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="LEUKOCYTE">
      <data key="d4">22.0</data>
      <data key="d5">Leukocytes are clustered in HS skin
Leukocytes are the dominant infiltrating cells in HS</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13,411a4d246f0a9321e52971446a5a0606</data>
    </edge>
    <edge source="HS" target="IGM">
      <data key="d4">22.0</data>
      <data key="d5">IgM is involved in the immune response in HS
Overlap between gene expression in activated B cells treated with IgM and HS</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="SHANNON INDEX">
      <data key="d4">7.0</data>
      <data key="d5">The Shannon index was used to measure BCR diversity in HS</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606</data>
    </edge>
    <edge source="HS" target="JACCARD DISTANCE">
      <data key="d4">7.0</data>
      <data key="d5">The Jaccard distance was used to measure dissimilarity in BCR sequences in HS</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606</data>
    </edge>
    <edge source="HS" target="PCOA">
      <data key="d4">21.0</data>
      <data key="d5">PCoA was used to visualize BCR diversity in HS
PCoA shows separation of BCR sequences in HS</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="IHC">
      <data key="d4">22.0</data>
      <data key="d5">IHC was used to validate findings in HS
IHC confirms the nature of the inflammatory infiltrate in HS</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="GEPS">
      <data key="d4">21.0</data>
      <data key="d5">GePS was used to analyze signal transduction networks in HS
GePS network analysis shows critical inflammatory nodes in HS</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="BCR SIGNALING">
      <data key="d4">9.0</data>
      <data key="d5">BCR signaling is enriched in HS</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606</data>
    </edge>
    <edge source="HS" target="SYK SIGNALING">
      <data key="d4">9.0</data>
      <data key="d5">SYK signaling is enriched in HS</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606</data>
    </edge>
    <edge source="HS" target="BTK SIGNALING">
      <data key="d4">9.0</data>
      <data key="d5">BTK signaling is enriched in HS</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606</data>
    </edge>
    <edge source="HS" target="COMPLEMENT PATHWAY">
      <data key="d4">17.0</data>
      <data key="d5">The complement pathway is activated in HS
Components of the complement pathway are increased in HS skin</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="C5A">
      <data key="d4">7.0</data>
      <data key="d5">C5a levels are elevated in HS</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="HS" target="NEUTROPHIL">
      <data key="d4">7.0</data>
      <data key="d5">Neutrophils are prominent in HS</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="HS" target="NETOSIS">
      <data key="d4">7.0</data>
      <data key="d5">NETosis is increased in HS</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="HS" target="CD4+ T CELL">
      <data key="d4">7.0</data>
      <data key="d5">Increased number of CD4+ T cells in HS</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="HS" target="IL-6">
      <data key="d4">21.0</data>
      <data key="d5">IL-6 is implicated in HS pathogenesis</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="HS" target="TYPE I IFNS">
      <data key="d4">14.0</data>
      <data key="d5">Type I IFNs are implicated in HS</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="HS" target="PDC">
      <data key="d4">14.0</data>
      <data key="d5">pDCs are implicated in HS</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="HS" target="IL-36A">
      <data key="d4">7.0</data>
      <data key="d5">Increased IL-36A expression is found in HS</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="HS" target="IL-36G">
      <data key="d4">7.0</data>
      <data key="d5">Increased IL-36G expression is found in HS</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="HS" target="LCK">
      <data key="d4">28.0</data>
      <data key="d5">LCK is involved in B cell signaling and is a potential therapeutic target in HS
Increased expression of LCK in HS skin</data>
      <data key="d6">b62ecc47bf54393bc78dd65986b949d6,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="MICE">
      <data key="d4">2.0</data>
      <data key="d5">No animal models exist for HS</data>
      <data key="d6">b62ecc47bf54393bc78dd65986b949d6</data>
    </edge>
    <edge source="HS" target="CD14">
      <data key="d4">12.0</data>
      <data key="d5">CD14 was one of the markers used in CyTOF imaging of HS patient tissues</data>
      <data key="d6">b28eeca0ff01a7715947d55a04978a43</data>
    </edge>
    <edge source="HS" target="CD16">
      <data key="d4">12.0</data>
      <data key="d5">CD16 was one of the markers used in CyTOF imaging of HS patient tissues</data>
      <data key="d6">b28eeca0ff01a7715947d55a04978a43</data>
    </edge>
    <edge source="HS" target="CD68">
      <data key="d4">12.0</data>
      <data key="d5">CD68 was one of the markers used in CyTOF imaging of HS patient tissues</data>
      <data key="d6">b28eeca0ff01a7715947d55a04978a43</data>
    </edge>
    <edge source="HS" target="CD15">
      <data key="d4">12.0</data>
      <data key="d5">CD15 was one of the markers used in CyTOF imaging of HS patient tissues</data>
      <data key="d6">b28eeca0ff01a7715947d55a04978a43</data>
    </edge>
    <edge source="HS" target="CD31">
      <data key="d4">12.0</data>
      <data key="d5">CD31 was one of the markers used in CyTOF imaging of HS patient tissues</data>
      <data key="d6">b28eeca0ff01a7715947d55a04978a43</data>
    </edge>
    <edge source="HS" target="CD45">
      <data key="d4">12.0</data>
      <data key="d5">CD45 was one of the markers used in CyTOF imaging of HS patient tissues</data>
      <data key="d6">b28eeca0ff01a7715947d55a04978a43</data>
    </edge>
    <edge source="HS" target="E-CADHERIN">
      <data key="d4">12.0</data>
      <data key="d5">E-Cadherin was one of the markers used in CyTOF imaging of HS patient tissues</data>
      <data key="d6">b28eeca0ff01a7715947d55a04978a43</data>
    </edge>
    <edge source="HS" target="CD20">
      <data key="d4">26.0</data>
      <data key="d5">CD20 was one of the markers used in CyTOF imaging of HS patient tissues
CD20 is expressed on B cells in HS skin</data>
      <data key="d6">b28eeca0ff01a7715947d55a04978a43,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="CD8">
      <data key="d4">12.0</data>
      <data key="d5">CD8 was one of the markers used in CyTOF imaging of HS patient tissues</data>
      <data key="d6">b28eeca0ff01a7715947d55a04978a43</data>
    </edge>
    <edge source="HS" target="COLLAGEN">
      <data key="d4">12.0</data>
      <data key="d5">Collagen was one of the markers used in CyTOF imaging of HS patient tissues</data>
      <data key="d6">b28eeca0ff01a7715947d55a04978a43</data>
    </edge>
    <edge source="HS" target="CD27">
      <data key="d4">12.0</data>
      <data key="d5">CD27 was one of the markers used in CyTOF imaging of HS patient tissues</data>
      <data key="d6">b28eeca0ff01a7715947d55a04978a43</data>
    </edge>
    <edge source="HS" target="CD103">
      <data key="d4">12.0</data>
      <data key="d5">CD103 was one of the markers used in CyTOF imaging of HS patient tissues</data>
      <data key="d6">b28eeca0ff01a7715947d55a04978a43</data>
    </edge>
    <edge source="HS" target="CD138">
      <data key="d4">26.0</data>
      <data key="d5">CD138 was one of the markers used in CyTOF imaging of HS patient tissues
CD138 is expressed on plasma cells in HS skin</data>
      <data key="d6">b28eeca0ff01a7715947d55a04978a43,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="PAN-ACTIN">
      <data key="d4">12.0</data>
      <data key="d5">Pan-actin was one of the markers used in CyTOF imaging of HS patient tissues</data>
      <data key="d6">b28eeca0ff01a7715947d55a04978a43</data>
    </edge>
    <edge source="HS" target="IGG1">
      <data key="d4">26.0</data>
      <data key="d5">IgG1 was used in immunohistochemistry of HS patient tissues
Increased levels of IgG1 in HS skin</data>
      <data key="d6">b28eeca0ff01a7715947d55a04978a43,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="CD3">
      <data key="d4">26.0</data>
      <data key="d5">CD3 was used in immunohistochemistry of HS patient tissues
CD3 is expressed in the inflammatory infiltrate in HS skin</data>
      <data key="d6">b28eeca0ff01a7715947d55a04978a43,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="B CELL">
      <data key="d4">32.0</data>
      <data key="d5">B cell responses are heightened in patients with HS
Increased immunoglobulin production and antibody diversity in HS skin</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="T CELL">
      <data key="d4">16.0</data>
      <data key="d5">T cell responses are enriched in the blood of patients with HS</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="PSORIASIS">
      <data key="d4">14.0</data>
      <data key="d5">Comparison of proinflammatory cytokine responses in HS skin with psoriasis</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="AD">
      <data key="d4">14.0</data>
      <data key="d5">Comparison of proinflammatory cytokine responses in HS skin with AD</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="KERATINOCYTE">
      <data key="d4">16.0</data>
      <data key="d5">Keratinocytes in HS skin show elevated inflammatory responses</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="ERASMUS MC">
      <data key="d4">12.0</data>
      <data key="d5">Patients with HS were recruited from Erasmus MC</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="CDR3">
      <data key="d4">14.0</data>
      <data key="d5">Increased BCR CDR3 expression in HS skin</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="PCA">
      <data key="d4">12.0</data>
      <data key="d5">PCA plots were used to analyze skin and blood samples in HS</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="PHENOGRAPH">
      <data key="d4">12.0</data>
      <data key="d5">Phenograph was used to identify cell populations in HS</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="MANN-WHITNEY U TEST">
      <data key="d4">10.0</data>
      <data key="d5">Mann-Whitney U test was used to analyze data in HS</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="STUDENT&#8217;S T TEST">
      <data key="d4">10.0</data>
      <data key="d5">Student&#8217;s t test was used to analyze data in HS</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="FDR">
      <data key="d4">10.0</data>
      <data key="d5">FDR was used to determine significance in RNA-Seq data in HS</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="DECLARATION OF HELSINKI">
      <data key="d4">10.0</data>
      <data key="d5">Study was conducted in accordance with Declaration of Helsinki principles</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="INSTITUTIONAL REVIEW BOARD">
      <data key="d4">10.0</data>
      <data key="d5">Study was approved by the Institutional Review Board</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="BIOPSY">
      <data key="d4">12.0</data>
      <data key="d5">Biopsies were collected from patients with HS</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="ABDOMINOPLASTY">
      <data key="d4">8.0</data>
      <data key="d5">Healthy controls were recruited from patients undergoing abdominoplasty</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="SURGERY">
      <data key="d4">12.0</data>
      <data key="d5">Patients with HS were undergoing surgery</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="PROINFLAMMATORY CYTOKINE">
      <data key="d4">14.0</data>
      <data key="d5">Proinflammatory cytokine responses were compared in HS</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="DEG">
      <data key="d4">14.0</data>
      <data key="d5">DEGs were identified in HS skin</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="RECEPTOR-LIGAND">
      <data key="d4">12.0</data>
      <data key="d5">Receptor-ligand interactions were mapped in HS</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="PLASMA CELL">
      <data key="d4">30.0</data>
      <data key="d5">Plasma cells interact with the HS microenvironment
Plasma cells are the predominant inflammatory infiltrate in HS skin</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13,e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="CD28">
      <data key="d4">14.0</data>
      <data key="d5">CD28 is overexpressed in patients with HS</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="CTLA-4">
      <data key="d4">14.0</data>
      <data key="d5">CTLA-4 is overexpressed in patients with HS</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="ICOS">
      <data key="d4">14.0</data>
      <data key="d5">ICOS is overexpressed in patients with HS</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="OX40L">
      <data key="d4">2.0</data>
      <data key="d5">OX40L is overexpressed in patients with HS</data>
      <data key="d6">1412a7a7fef5f18cc09a030b97b18e13</data>
    </edge>
    <edge source="HS" target="JUN">
      <data key="d4">14.0</data>
      <data key="d5">Increased expression of JUN in HS skin</data>
      <data key="d6">e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="STAT1">
      <data key="d4">14.0</data>
      <data key="d5">Increased expression of STAT1 in HS skin</data>
      <data key="d6">e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="BCR CDR3">
      <data key="d4">16.0</data>
      <data key="d5">Increased diversity of BCR CDR3 sequences in HS skin</data>
      <data key="d6">e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="BCR GENE SEGMENT">
      <data key="d4">16.0</data>
      <data key="d5">Increased diversity of BCR gene segments in HS skin</data>
      <data key="d6">e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="TCR V/J GENE SEGMENT">
      <data key="d4">14.0</data>
      <data key="d5">Increased expression of TCR V/J gene segments in HS skin</data>
      <data key="d6">e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="B CELL SIGNALING">
      <data key="d4">16.0</data>
      <data key="d5">B cell signaling pathways are enriched in HS skin</data>
      <data key="d6">e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="INFLAMMATORY NODES">
      <data key="d4">14.0</data>
      <data key="d5">Inflammatory nodes are critical in HS</data>
      <data key="d6">e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="SIGNAL TRANSDUCTION NETWORKS">
      <data key="d4">14.0</data>
      <data key="d5">Signal transduction networks are involved in HS</data>
      <data key="d6">e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="SHANNON DIVERSITY INDEX">
      <data key="d4">16.0</data>
      <data key="d5">Shannon diversity index shows increased BCR diversity in HS</data>
      <data key="d6">e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="JACCARD DISSIMILARITIES">
      <data key="d4">14.0</data>
      <data key="d5">Jaccard dissimilarities used in PCoA for HS</data>
      <data key="d6">e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="CLONAL ABUNDANCE">
      <data key="d4">14.0</data>
      <data key="d5">Clonal abundance analysis shows separation of HS from controls</data>
      <data key="d6">e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="IG HEAVY CHAIN">
      <data key="d4">14.0</data>
      <data key="d5">Ig heavy chain expression analyzed in HS</data>
      <data key="d6">e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="&#922; LIGHT CHAIN">
      <data key="d4">14.0</data>
      <data key="d5">&#954; light chain expression analyzed in HS</data>
      <data key="d6">e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="&#923; LIGHT CHAIN">
      <data key="d4">2.0</data>
      <data key="d5">&#955; light chain expression analyzed in HS</data>
      <data key="d6">e4d25b1cd44df240a29591bc46a875ab</data>
    </edge>
    <edge source="HS" target="BERMEKIMAB">
      <data key="d4">14.0</data>
      <data key="d5">Bermekimab was developed for hidradenitis suppurativa</data>
      <data key="d6">6309eeea565f06479830cec32938abc9</data>
    </edge>
    <edge source="CXCL10" target="C&#8211;C RECEPTOR INTERACTION PATHWAY">
      <data key="d4">14.0</data>
      <data key="d5">CXCL10 is involved in the cytokine-cytokine receptor interaction pathway</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="CXCL10" target="C-X-C MOTIF CHEMOKINE LIGAND 10">
      <data key="d4">9.0</data>
      <data key="d5">CXCL10 encodes C-X-C Motif Chemokine Ligand 10</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="CXCL10" target="TYPE I IFNS">
      <data key="d4">16.0</data>
      <data key="d5">CXCL10 is an interferon response gene</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="CXCL10" target="AD">
      <data key="d4">8.0</data>
      <data key="d5">CXCL10 is involved in the immune response in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="IL6" target="JAK-STAT SIGNALING PATHWAY">
      <data key="d4">14.0</data>
      <data key="d5">IL6 is involved in the JAK-STAT signaling pathway</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="IL6" target="INTERLEUKIN 6">
      <data key="d4">9.0</data>
      <data key="d5">IL6 encodes Interleukin 6</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="IL6" target="DUPILUMAB">
      <data key="d4">8.0</data>
      <data key="d5">Dupilumab is a receptor antagonist targeting IL6</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL6" target="CALCITRIOL">
      <data key="d4">7.0</data>
      <data key="d5">Calcitriol is involved in the regulation of IL6</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL6" target="SILTUXIMAB">
      <data key="d4">8.0</data>
      <data key="d5">Siltuximab is a receptor antagonist targeting IL6</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL6" target="TOCILIZUMAB">
      <data key="d4">8.0</data>
      <data key="d5">Tocilizumab is a receptor antagonist targeting IL6</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL6" target="SARILUMAB">
      <data key="d4">8.0</data>
      <data key="d5">Sarilumab is a receptor antagonist targeting IL6</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL6" target="SATRALIZUMAB">
      <data key="d4">8.0</data>
      <data key="d5">Satralizumab is a receptor antagonist targeting IL6</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL6" target="VITAMIN C">
      <data key="d4">6.0</data>
      <data key="d5">Vitamin C is involved in the regulation of IL6</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL6" target="VITAMIN E">
      <data key="d4">6.0</data>
      <data key="d5">Vitamin E is involved in the regulation of IL6</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL6" target="ANDROGRAPHOLIDE">
      <data key="d4">7.0</data>
      <data key="d5">Andrographolide inhibits IL6</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="IL6" target="INFLIXIMAB">
      <data key="d4">14.0</data>
      <data key="d5">Infliximab inhibits IL6</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="IL17A" target="IL-17 SIGNALING PATHWAY">
      <data key="d4">14.0</data>
      <data key="d5">IL17A is involved in the IL-17 signaling pathway</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="IL17A" target="ALLERGIC CONTACT DERMATITIS">
      <data key="d4">8.0</data>
      <data key="d5">IL17A is associated with Allergic contact dermatitis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL17A" target="BIMEKIZUMAB">
      <data key="d4">14.0</data>
      <data key="d5">Bimekizumab inhibits IL17A</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="IL17A" target="SECUKINUMAB">
      <data key="d4">7.0</data>
      <data key="d5">Secukinumab inhibits IL17A</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="IL17A" target="T CELLS">
      <data key="d4">8.0</data>
      <data key="d5">IL17A is expressed by T cells in HS skin</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="IL17A" target="IL-17A">
      <data key="d4">8.0</data>
      <data key="d5">IL17A encodes the cytokine IL-17A</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="IL36A" target="TH17 CELL DIFFERENTIATION PATHWAY">
      <data key="d4">14.0</data>
      <data key="d5">IL36A is involved in the Th17 cell differentiation pathway</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="IL36A" target="PSORIASIS">
      <data key="d4">8.0</data>
      <data key="d5">IL36A is associated with Psoriasis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL36G" target="TOLL-LIKE RECEPTOR PATHWAY">
      <data key="d4">14.0</data>
      <data key="d5">IL36G is involved in the Toll-like receptor pathway</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="IL36G" target="PSORIASIS">
      <data key="d4">8.0</data>
      <data key="d5">IL36G is associated with Psoriasis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL36G" target="ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS">
      <data key="d4">8.0</data>
      <data key="d5">IL36G is associated with Acute generalized exanthematous pustulosis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="S100A8" target="INFLAMMATORY BOWEL DISEASE PATHWAY">
      <data key="d4">14.0</data>
      <data key="d5">S100A8 is involved in the inflammatory bowel disease pathway</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="S100A8" target="BRODALUMAB">
      <data key="d4">14.0</data>
      <data key="d5">Brodalumab targets S100A8</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="S100A8" target="AD">
      <data key="d4">7.0</data>
      <data key="d5">S100A8 is upregulated in atopic dermatitis lesions</data>
      <data key="d6">f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="S100A9" target="RHEUMATOID ARTHRITIS PATHWAY">
      <data key="d4">14.0</data>
      <data key="d5">S100A9 is involved in the rheumatoid arthritis pathway</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="S100A9" target="LIPID AND ATHEROSCLEROSIS PATHWAY">
      <data key="d4">8.0</data>
      <data key="d5">S100A9 is involved in the lipid and atherosclerosis pathway</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="S100A9" target="BRODALUMAB">
      <data key="d4">14.0</data>
      <data key="d5">Brodalumab targets S100A9</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="S100A9" target="AD">
      <data key="d4">7.0</data>
      <data key="d5">S100A9 is upregulated in atopic dermatitis lesions</data>
      <data key="d6">f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="SKIN" target="ATOPIC DERMATITIS">
      <data key="d4">48.0</data>
      <data key="d5">The skin is the primary tissue affected by atopic dermatitis
Atopic Dermatitis affects the skin, causing inflammation and epidermal barrier dysfunction
The skin is the primary tissue affected by Atopic Dermatitis
Atopic Dermatitis affects the skin
Atopic dermatitis affects the skin</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603,693a2aac101eaaadf92614317a1e4da8,6ada075e562abd7bd445164e9fc309b4,cccfd5ff480e281556e2210cd0e5c4b5,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="SKIN" target="AD">
      <data key="d4">152.0</data>
      <data key="d5">Skin biopsy specimens were collected to analyze transcriptomic and proteomic profiles in AD patients
Atopic Dermatitis affects the skin
The skin is the primary tissue affected by atopic dermatitis
Atopic dermatitis affects the skin
The skin is the primary tissue affected in atopic dermatitis
Atopic dermatitis affects the skin
Atopic dermatitis (AD) affects the skin
The skin is affected in atopic dermatitis
The skin is affected in atopic dermatitis
The skin is a primary tissue affected by Atopic Dermatitis
The skin is affected by AD, requiring treatment to heal and reduce inflammation
Skin is the primary tissue affected in AD
Skin biopsies were collected from patients with AD
The skin is affected in AD</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d,104cc78517b2eca2e9cb7e00de1fe4b0,143d2dc302af5606656797bff162e23e,2cec06c4d46f5ff9ee936a78d8b077cd,2e9a8d71f6bd251a0b13458c39e69746,442e7fad2fab75fa2449309783294d89,475995d7d211bbfde6d8ba52f324d688,78e26c66107dba37ac4bab65406b43a0,8246ea974dfb00cb5e3d984004e21a9e,89dbac0da39e4de2b602052cd792b90d,90f4809673ca34628b0e607908f0bf0b,a867a1e73cef039eb3f28e072463b838,b62ecc47bf54393bc78dd65986b949d6,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="SKIN" target="PSORIASIS">
      <data key="d4">18.0</data>
      <data key="d5">Psoriasis affects the skin</data>
      <data key="d6">b62ecc47bf54393bc78dd65986b949d6</data>
    </edge>
    <edge source="SKIN" target="EPIDERMIS">
      <data key="d4">22.0</data>
      <data key="d5">The epidermis is the outer layer of the skin
The epidermis is the outermost layer of the skin</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9,b62ecc47bf54393bc78dd65986b949d6</data>
    </edge>
    <edge source="SKIN" target="DERMIS">
      <data key="d4">16.0</data>
      <data key="d5">The dermis is the inner layer of the skin</data>
      <data key="d6">b62ecc47bf54393bc78dd65986b949d6</data>
    </edge>
    <edge source="SKIN" target="HUMAN">
      <data key="d4">8.0</data>
      <data key="d5">Skin samples were obtained from human patients</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="SKIN" target="MICROBIOME">
      <data key="d4">7.0</data>
      <data key="d5">The skin microbiome can be modulated to treat atopic dermatitis</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="SKIN" target="PHYTOCERAMIDES">
      <data key="d4">8.0</data>
      <data key="d5">Phytoceramides enhance the absorption into the deeper layers of the skin</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="SKIN" target="BETAMETHASONE DIPROPIONATE (BMD)">
      <data key="d4">14.0</data>
      <data key="d5">Betamethasone Dipropionate (BMD) is used in nanostructured lipid carriers for skinBetamethasone Dipropionate (BMD) provides extended anti-inflammatory effects on the skin</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="SKIN" target="VITAMIN E (VE)">
      <data key="d4">2.0</data>
      <data key="d5">Vitamin E (VE) is used in nanostructured lipid carriers for skinVitamin E (VE) improves skin moisture</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="SKIN" target="PIOGLITAZONE (PGZ)">
      <data key="d4">7.0</data>
      <data key="d5">Pioglitazone (PGZ) is used in a nanoemulsion for treating skin diseases</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="SKIN" target="HISTOPATHOLOGY">
      <data key="d4">7.0</data>
      <data key="d5">Histopathology studies show improved structural features of the skin</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="SKIN" target="CLOBETASOL PROPIONATE (CP)">
      <data key="d4">7.0</data>
      <data key="d5">Clobetasol Propionate (CP) is used in a nanoemulsion for treating skin diseases</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="SKIN" target="BMV">
      <data key="d4">14.0</data>
      <data key="d5">BMV is used in liposomes for treating skin conditions
BMV-loaded chitosan gel formulations enhance drug accumulation in the skin</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5,bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="SKIN" target="DIFLUCORTOLONE VALERATE (DFV)">
      <data key="d4">7.0</data>
      <data key="d5">Diflucortolone Valerate (DFV) is used in liposomes for treating skin conditions</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="SKIN" target="CHITOSAN">
      <data key="d4">7.0</data>
      <data key="d5">Chitosan gel is used to deliver drugs to the skin</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="SKIN" target="ALBINO WISTAR RATS">
      <data key="d4">6.0</data>
      <data key="d5">Albino Wistar Rats are used to study skin conditions</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="SKIN" target="TEWL">
      <data key="d4">8.0</data>
      <data key="d5">TEWL is a measure of water loss through the skin</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="SKIN" target="MAST CELL">
      <data key="d4">7.0</data>
      <data key="d5">Mast cell activity is important in attenuating AD progression</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="SKIN" target="NICOTINAMIDE (VITAMIN B3)">
      <data key="d4">7.0</data>
      <data key="d5">Nicotinamide (Vitamin B3) is used in topical formulations for skin</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="SKIN" target="IGE">
      <data key="d4">7.0</data>
      <data key="d5">IgE levels are reduced in the skin</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="SKIN" target="GLYCYRRHIZIC ACID (GA)">
      <data key="d4">7.0</data>
      <data key="d5">Glycyrrhizic Acid (GA) is used in hydrogel for treating skin conditions</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="SKIN" target="CYCLOSPORINE A (CSA)">
      <data key="d4">7.0</data>
      <data key="d5">Cyclosporine A (CsA) is used in liposomal formulations for skin</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="SKIN" target="TAC">
      <data key="d4">14.0</data>
      <data key="d5">TAC is used in solid lipid nanoparticles for skin
TAC-loaded nanoparticles improve skin penetration</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5,bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="SKIN" target="NLCS">
      <data key="d4">8.0</data>
      <data key="d5">NLCs are used to improve skin moisture</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="SKIN" target="VITAMIN E">
      <data key="d4">7.0</data>
      <data key="d5">Vitamin E is used to increase skin hydration</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="SKIN" target="HG-NLCVE">
      <data key="d4">7.0</data>
      <data key="d5">HG-NLCVE could be utilized in cosmetic applications to improve skin hydration</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="SKIN" target="METHOTREXATE (MTX)">
      <data key="d4">7.0</data>
      <data key="d5">MTX-loaded NLCs enhance dermal penetration</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="SKIN" target="BECLOMETHASONE DIPROPIONATE (BDP)">
      <data key="d4">7.0</data>
      <data key="d5">BDP-loaded nanocrystals showed higher drug deposition through mouse skin</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="SKIN" target="HA">
      <data key="d4">7.0</data>
      <data key="d5">HA-based nanoparticles improve skin penetration</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="SKIN" target="CHOLESTEROL">
      <data key="d4">7.0</data>
      <data key="d5">Cholesterol-based nanoparticles improve skin penetration</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="SKIN" target="NIC">
      <data key="d4">7.0</data>
      <data key="d5">NIC improves skin penetration when incorporated into nanoparticles</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="SKIN" target="PLG">
      <data key="d4">7.0</data>
      <data key="d5">PLG-based nanoparticles are used for topical delivery to the skin</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="SKIN" target="PLGA">
      <data key="d4">7.0</data>
      <data key="d5">PLGA-based nanoparticles enhance drug penetration into deeper skin layers</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="SKIN" target="CSA">
      <data key="d4">7.0</data>
      <data key="d5">CsA-loaded nanoparticles enhance drug penetration into deeper skin layers</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="SKIN" target="HYDROCORTISONE (HC)">
      <data key="d4">7.0</data>
      <data key="d5">HC-loaded chitosan-based nanoparticles increase drug accumulation in the skin</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="SKIN" target="HYDROXYTYROSOL (HT)">
      <data key="d4">7.0</data>
      <data key="d5">HT-loaded chitosan-based nanoparticles increase drug accumulation in the skin</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="SKIN" target="HYDROCORTISONE">
      <data key="d4">14.0</data>
      <data key="d5">Hydrocortisone and hydroxytyrosol showed increased accumulation in the skin</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="SKIN" target="HYDROXYTYROSOL">
      <data key="d4">14.0</data>
      <data key="d5">Hydrocortisone and hydroxytyrosol showed increased accumulation in the skin</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="SKIN" target="MICE">
      <data key="d4">12.0</data>
      <data key="d5">Mice treated with NPs exhibited improved control over skin thickness</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="SKIN" target="ER143">
      <data key="d4">14.0</data>
      <data key="d5">ER143 exhibited high drug retention and penetration in pig skin</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="SKIN" target="DESONIDE">
      <data key="d4">14.0</data>
      <data key="d5">DES-loaded NPs provided effective topical AD treatment</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="SKIN" target="BDP">
      <data key="d4">14.0</data>
      <data key="d5">BDP-loaded PMs showed superior drug permeation and deposition in CD-1 mouse skin</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="SKIN" target="HC">
      <data key="d4">8.0</data>
      <data key="d5">Skin biopsies were collected from healthy controls</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="SKIN" target="FORMALDEHYDE">
      <data key="d4">7.0</data>
      <data key="d5">Formaldehyde was used to fix skin biopsies</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="SKIN" target="TRYPTASE">
      <data key="d4">1.0</data>
      <data key="d5">Tryptase was analyzed in skin biopsies</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="SKIN" target="PARAFFIN">
      <data key="d4">7.0</data>
      <data key="d5">Paraffin was used to embed skin biopsies</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="SKIN" target="CITRATE-PHOSPHATE BUFFER">
      <data key="d4">7.0</data>
      <data key="d5">Citrate-Phosphate Buffer was used for antigen retrieval in skin biopsies</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="SKIN" target="DONKEY SERUM">
      <data key="d4">7.0</data>
      <data key="d5">Donkey Serum was used to block slides before staining skin biopsies</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="SKIN" target="ALEXA 488">
      <data key="d4">1.0</data>
      <data key="d5">Alexa 488 was used for staining in skin biopsies</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="SKIN" target="OX40">
      <data key="d4">26.0</data>
      <data key="d5">OX40 is co-localized with OX40L in the skin of AD patients
OX40 is co-localized in the skin and plays a role in immune cell recruitment and activation</data>
      <data key="d6">100dd7646c10899301b3c0631183da16,6b099960b0a39866e3aa6b908f1886e4</data>
    </edge>
    <edge source="SKIN" target="OX40L">
      <data key="d4">41.0</data>
      <data key="d5">OX40L is co-localized with OX40 in the skin of AD patients
OX40L is co-localized in the skin and plays a role in immune cell recruitment and activation
OX40L expression is prominent in the skin of patients with diffuse systemic sclerosis
Increased expression of OX40L is observed in the skin of SSc patients</data>
      <data key="d6">100dd7646c10899301b3c0631183da16,44f2592262cac835560b4c149fee8d2b,6b099960b0a39866e3aa6b908f1886e4,855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="SKIN" target="T CELL">
      <data key="d4">8.0</data>
      <data key="d5">T cells are recruited to and activated in the skin</data>
      <data key="d6">100dd7646c10899301b3c0631183da16</data>
    </edge>
    <edge source="SKIN" target="SSC">
      <data key="d4">20.0</data>
      <data key="d5">The skin is affected by systemic sclerosis
The skin is affected by systemic sclerosis
Systemic sclerosis involves the fibrosis of the skin</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5,9867d43adab0ba5db44961fae4863eee,d8a485eb1e9435b083d5ef6a17f06ea5</data>
    </edge>
    <edge source="SKIN" target="ICOS">
      <data key="d4">7.0</data>
      <data key="d5">Increased expression of ICOS is observed in the skin of SSc patients</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="SKIN" target="CD112">
      <data key="d4">7.0</data>
      <data key="d5">Increased expression of CD112 is observed in the skin of SSc patients</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="SKIN" target="CD40">
      <data key="d4">7.0</data>
      <data key="d5">Increased expression of CD40 is observed in the skin of SSc patients</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="SKIN" target="FIBROSIS">
      <data key="d4">23.0</data>
      <data key="d5">Skin fibrosis is a clinical manifestation of SScSkin fibrosis is a hallmark of SSc
The skin can be affected by fibrosis</data>
      <data key="d6">68015074236b0144899baa38d01ae467,855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="SKIN" target="DIGITAL ULCERS">
      <data key="d4">7.0</data>
      <data key="d5">Digital ulcers are a clinical manifestation observed in the skin of SSc patients</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="SKIN" target="NVC PATTERN">
      <data key="d4">7.0</data>
      <data key="d5">Nailfold videocapillaroscopy pattern is used to assess microvascular changes in the skin of SSc patients</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="SKIN" target="DERMAL FIBROSIS">
      <data key="d4">9.0</data>
      <data key="d5">Dermal fibrosis affects the skin</data>
      <data key="d6">4d0e8ae9371a435885994b4161126bc3</data>
    </edge>
    <edge source="SKIN" target="SCLERODERMA">
      <data key="d4">8.0</data>
      <data key="d5">Scleroderma affects the skin</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="SKIN" target="ATOPIC ECZEMA">
      <data key="d4">8.0</data>
      <data key="d5">Atopic eczema affects the skin</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="SKIN" target="DUPUYTREN&#8217;S DISEASE">
      <data key="d4">8.0</data>
      <data key="d5">Dupuytren&#8217;s disease affects the skin</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="SKIN" target="SYSTEMIC SCLEROSIS">
      <data key="d4">16.0</data>
      <data key="d5">Systemic sclerosis presents with fibrosis mainly in the skin</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="SKIN" target="TAPI-1">
      <data key="d4">7.0</data>
      <data key="d5">TAPI-1 reduces skin thickness</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="SKIN" target="BAFF">
      <data key="d4">7.0</data>
      <data key="d5">BAFF mRNA expression is upregulated in the affected skin of SSc patients</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="SKIN" target="APRIL">
      <data key="d4">7.0</data>
      <data key="d5">APRIL is implicated in atopic skin diseases</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="BLOOD" target="HUMAN">
      <data key="d4">8.0</data>
      <data key="d5">Blood samples were obtained from human patients</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="BLOOD" target="BUFFY COAT">
      <data key="d4">8.0</data>
      <data key="d5">Buffy coat is a fraction of blood containing most of the white blood cells and platelets</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="FIBROSIS" target="IL-4">
      <data key="d4">14.0</data>
      <data key="d5">IL-4 triggers tissue fibrosis</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="FIBROSIS" target="IL-13">
      <data key="d4">30.0</data>
      <data key="d5">IL-13 triggers tissue fibrosis
IL-13 promotes fibrotic skin remodeling</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30,48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="FIBROSIS" target="SSC">
      <data key="d4">39.0</data>
      <data key="d5">Fibrosis is a symptom of systemic sclerosis
Fibrosis is a characteristic symptom of systemic sclerosis
Fibrosis is a key feature of systemic sclerosis
Fibrosis is a characteristic of systemic sclerosis
Systemic sclerosis is characterized by pathological fibrosis</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,7b454335c2f5651d86f712037a0dc0ff,9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="FIBROSIS" target="OX40L">
      <data key="d4">34.0</data>
      <data key="d5">OX40L links immunity directly to fibrosisOX40L is predictive of the worsening of dermal and lung fibrosis
OX40L is implicated in fibrosis</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3,44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="FIBROSIS" target="TNFSF">
      <data key="d4">9.0</data>
      <data key="d5">TNFSF members are involved in the process of fibrosis</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="FIBROSIS" target="FIBROBLASTS">
      <data key="d4">10.0</data>
      <data key="d5">Fibroblasts are responsible for collagen and extracellular matrix protein deposition in fibrosis</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="FIBROSIS" target="TGF&#914;">
      <data key="d4">10.0</data>
      <data key="d5">TGF&#946; is a central fibrogenic cytokine involved in fibrosis pathogenesis</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="FIBROSIS" target="MYOFIBROBLASTS">
      <data key="d4">10.0</data>
      <data key="d5">Myofibroblasts are responsible for collagen and extracellular matrix protein deposition and smooth muscle hypertrophy in fibrosis</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="FIBROSIS" target="TNF">
      <data key="d4">16.0</data>
      <data key="d5">TNF is involved in the process of fibrosis
TNF-mediated inflammation may prevent TGF&#946;1-driven fibrosis development</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603,a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="FIBROSIS" target="TNFR2">
      <data key="d4">8.0</data>
      <data key="d5">TNFR2 signaling appears to be key for mediating fibrotic development</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="FIBROSIS" target="MI">
      <data key="d4">16.0</data>
      <data key="d5">Myocardial infarction leads to replacement fibrosis</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="FIBROSIS" target="EXTRACELLULAR MATRIX">
      <data key="d4">16.0</data>
      <data key="d5">Extracellular matrix replaces dying cardiomyocytes in fibrosis</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="FIBROSIS" target="TNF INHIBITORS">
      <data key="d4">14.0</data>
      <data key="d5">TNF inhibitors are used in the treatment of fibrosis</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="FIBROSIS" target="LIGHT">
      <data key="d4">8.0</data>
      <data key="d5">LIGHT is a key regulator of fibrosis</data>
      <data key="d6">05c97152fe02249153103be341d65b67</data>
    </edge>
    <edge source="FIBROSIS" target="TL1A">
      <data key="d4">9.0</data>
      <data key="d5">TL1A-mediated inflammation leads to fibrosis</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="FIBROSIS" target="BAFF">
      <data key="d4">15.0</data>
      <data key="d5">Higher serum BAFF levels are associated with advanced fibrosisHigh BAFF levels serve as a marker for severe skin fibrosis in SSc</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="FIBROSIS" target="APRIL">
      <data key="d4">7.0</data>
      <data key="d5">Increased production of APRIL is associated with greater skin fibrosis</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="FIBROSIS" target="TREGS">
      <data key="d4">8.0</data>
      <data key="d5">Functional downregulation of Tregs can create a pro-inflammatory environment leading to fibrosis</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="FIBROSIS" target="TEM">
      <data key="d4">6.0</data>
      <data key="d5">Effector-memory T cells are associated with enhanced fibrosis</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="FIBROSIS" target="LIVER FIBROSIS">
      <data key="d4">7.0</data>
      <data key="d5">Fibrosis is a characteristic of liver fibrosis</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="FIBROSIS" target="TRAIL">
      <data key="d4">8.0</data>
      <data key="d5">TRAIL is involved in the amelioration and reversal of fibrosis</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="FIBROSIS" target="LUNGS">
      <data key="d4">7.0</data>
      <data key="d5">The lungs can be affected by fibrosis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="FIBROSIS" target="HEART">
      <data key="d4">7.0</data>
      <data key="d5">The heart can be affected by fibrosis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="FIBROSIS" target="KIDNEYS">
      <data key="d4">7.0</data>
      <data key="d5">The kidneys can be affected by fibrosis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="FIBROSIS" target="LIVER">
      <data key="d4">14.0</data>
      <data key="d5">The liver can be affected by fibrosis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="FIBROSIS" target="GASTROINTESTINAL TRACT">
      <data key="d4">2.0</data>
      <data key="d5">The gastrointestinal tract can be affected by fibrosis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="FIBROSIS" target="TNFSF MEMBERS">
      <data key="d4">9.0</data>
      <data key="d5">TNFSF members are implicated in driving fibrosis</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </edge>
    <edge source="NATIONAL CANCER INSTITUTE" target="G:PROFILER">
      <data key="d4">6.0</data>
      <data key="d5">The National Cancer Institute collaborates with g:Profiler</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="KYOTO ENCYCLOPEDIA OF GENES AND GENOMES (KEGG)" target="REACTOME">
      <data key="d4">6.0</data>
      <data key="d5">KEGG and Reactome are both databases used for pathway analysis</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="WIKIPATHWAYS" target="HUMAN PHENOTYPE ONTOLOGY (HP)">
      <data key="d4">6.0</data>
      <data key="d5">WikiPathways and Human Phenotype Ontology are both used for pathway and phenotype analysis</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="HUMAN PHENOTYPE ONTOLOGY (HP)" target="JACKSON LABORATORY FOR GENOMIC MEDICINE">
      <data key="d4">1.0</data>
      <data key="d5">The Jackson Laboratory for Genomic Medicine is involved in the Human Phenotype Ontology</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="THE DRUG REPURPOSING HUB" target="GENE CARDS">
      <data key="d4">6.0</data>
      <data key="d5">The Drug Repurposing Hub and Gene Cards are both used for drug and gene information</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="ELI AND EDY L. BROAD INSTITUTE" target="MIT">
      <data key="d4">6.0</data>
      <data key="d5">The Eli and Edy L. Broad Institute is affiliated with MIT</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="MIT" target="HARVARD UNIVERSITY">
      <data key="d4">6.0</data>
      <data key="d5">MIT and Harvard University collaborate on various research projects</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="WEIZMANN INSTITUTE OF SCIENCE" target="OREGON HEALTH AND SCIENCE UNIVERSITY">
      <data key="d4">6.0</data>
      <data key="d5">The Weizmann Institute of Science collaborates with Oregon Health and Science University</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="NEW YORK UNIVERSITY" target="ONTARIO INSTITUTE FOR CANCER RESEARCH">
      <data key="d4">6.0</data>
      <data key="d5">New York University collaborates with the Ontario Institute for Cancer Research</data>
      <data key="d6">990bc0f89db6ad8683c7a06a3ab356d9</data>
    </edge>
    <edge source="IL-17" target="HUMAN &#914;-DEFENSIN 2">
      <data key="d4">7.0</data>
      <data key="d5">IL-17 increases the expression of human &#946;-defensin 2</data>
      <data key="d6">fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="IL-17" target="PSORIASIN (S100A7)">
      <data key="d4">7.0</data>
      <data key="d5">IL-17 increases the expression of psoriasin (S100A7)</data>
      <data key="d6">fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="IL-17" target="CALPROTECTIN (S100A8/9)">
      <data key="d4">7.0</data>
      <data key="d5">IL-17 increases the expression of calprotectin (S100A8/9)</data>
      <data key="d6">fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="IL-17" target="AD">
      <data key="d4">23.0</data>
      <data key="d5">IL-17 is involved in the pathophysiology of chronic atopic dermatitis lesions
IL-17 is involved in the immune response in AD
IL-17 is involved in inflammation and immune response in AD</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98,b19f42c9497f71b231222cd953036d6b,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="IL-17" target="CAMP">
      <data key="d4">6.0</data>
      <data key="d5">cAMP mediates downstream events culminating in the inhibition of IL-17 secretion</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="IL-17" target="ATOPIC DERMATITIS">
      <data key="d4">14.0</data>
      <data key="d5">IL-17 is implicated in Atopic Dermatitis
IL-17 is a cytokine involved in the immune response and associated with Atopic Dermatitis</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1,6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="IL-17" target="IL-23">
      <data key="d4">8.0</data>
      <data key="d5">IL-23 is involved in the IL-23&#8211;IL-17 axis</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IL-17" target="SECUKINUMAB">
      <data key="d4">8.0</data>
      <data key="d5">Secukinumab is an anti-IL-17A antibody</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IL-17" target="SSC">
      <data key="d4">8.0</data>
      <data key="d5">IL-17 is a proinflammatory cytokine involved in systemic sclerosis</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="IL-17" target="ICOS">
      <data key="d4">8.0</data>
      <data key="d5">ICOS induces the synthesis of IL-17 in activated T cells</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="IL-17" target="TH2">
      <data key="d4">14.0</data>
      <data key="d5">IL-17 is a cytokine involved in T helper cell responses</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="IL-17" target="OX40L">
      <data key="d4">14.0</data>
      <data key="d5">OX40L interaction may negatively regulate interleukin 17 production</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="TH17 CELL" target="IL-1">
      <data key="d4">7.0</data>
      <data key="d5">IL-1 leads to the formation of Th17 cells</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="CYTOKINE" target="UMAP">
      <data key="d4">6.0</data>
      <data key="d5">UMAP is used to visualize cytokine response data</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="CYTOKINE" target="OX40">
      <data key="d4">8.0</data>
      <data key="d5">OX40 signaling promotes cytokine secretion</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="RHEUMATOID ARTHRITIS" target="IL22RA1">
      <data key="d4">7.0</data>
      <data key="d5">IL22RA1 is associated with Rheumatoid arthritis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="RHEUMATOID ARTHRITIS" target="TNIP1">
      <data key="d4">14.0</data>
      <data key="d5">TNIP1 is associated with rheumatoid arthritis</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="RHEUMATOID ARTHRITIS" target="JAK INHIBITORS">
      <data key="d4">22.0</data>
      <data key="d5">JAK inhibitors are in clinical development for treating rheumatoid arthritis
JAK inhibitors are initially employed for the treatment of rheumatoid arthritis</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e,e30574e513dd250992d637d808759c34</data>
    </edge>
    <edge source="RHEUMATOID ARTHRITIS" target="JOINTS">
      <data key="d4">8.0</data>
      <data key="d5">Joints are affected in rheumatoid arthritis</data>
      <data key="d6">a867a1e73cef039eb3f28e072463b838</data>
    </edge>
    <edge source="RHEUMATOID ARTHRITIS" target="ANTI-INFLAMMATORY COMPOUNDS">
      <data key="d4">7.0</data>
      <data key="d5">Anti-inflammatory compounds are used in the treatment of rheumatoid arthritis</data>
      <data key="d6">a867a1e73cef039eb3f28e072463b838</data>
    </edge>
    <edge source="RHEUMATOID ARTHRITIS" target="DRUG&#8211;DRUG INTERACTIONS">
      <data key="d4">7.0</data>
      <data key="d5">Patients with rheumatoid arthritis have a higher risk of drug&#8211;drug interactions</data>
      <data key="d6">a867a1e73cef039eb3f28e072463b838</data>
    </edge>
    <edge source="RHEUMATOID ARTHRITIS" target="ATOPIC DERMATITIS">
      <data key="d4">7.0</data>
      <data key="d5">Rheumatoid Arthritis is a condition that children with Atopic Dermatitis may develop</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="RHEUMATOID ARTHRITIS" target="TACI-FC FUSION PROTEIN">
      <data key="d4">16.0</data>
      <data key="d5">TACI-Fc fusion protein is being tested for its efficacy in treating rheumatoid arthritis
TACI-Fc fusion protein is used in the treatment of Rheumatoid Arthritis</data>
      <data key="d6">423195c6b63ad0a6773374364ebf3612,8e5a1be9981340d419f7b3ad27076009</data>
    </edge>
    <edge source="RHEUMATOID ARTHRITIS" target="MTX">
      <data key="d4">10.0</data>
      <data key="d5">MTX is used to treat rheumatoid arthritis
MTX is used to treat Rheumatoid Arthritis</data>
      <data key="d6">423195c6b63ad0a6773374364ebf3612,8e5a1be9981340d419f7b3ad27076009</data>
    </edge>
    <edge source="RHEUMATOID ARTHRITIS" target="TABALUMAB">
      <data key="d4">8.0</data>
      <data key="d5">Tabalumab is used in the treatment of Rheumatoid Arthritis</data>
      <data key="d6">8e5a1be9981340d419f7b3ad27076009</data>
    </edge>
    <edge source="RHEUMATOID ARTHRITIS" target="RC18">
      <data key="d4">8.0</data>
      <data key="d5">RC18 is used in the treatment of Rheumatoid Arthritis</data>
      <data key="d6">8e5a1be9981340d419f7b3ad27076009</data>
    </edge>
    <edge source="RHEUMATOID ARTHRITIS" target="PLACEBO">
      <data key="d4">14.0</data>
      <data key="d5">Placebo is used as a control in studies for Rheumatoid Arthritis
Placebo is used as a control in clinical trials for rheumatoid arthritis</data>
      <data key="d6">68015074236b0144899baa38d01ae467,8e5a1be9981340d419f7b3ad27076009</data>
    </edge>
    <edge source="RHEUMATOID ARTHRITIS" target="ANTI-BAFF MAB">
      <data key="d4">8.0</data>
      <data key="d5">Anti-BAFF mAb is used in the treatment of Rheumatoid Arthritis</data>
      <data key="d6">8e5a1be9981340d419f7b3ad27076009</data>
    </edge>
    <edge source="RHEUMATOID ARTHRITIS" target="LY2127399">
      <data key="d4">24.0</data>
      <data key="d5">LY2127399 is used in the treatment of Rheumatoid Arthritis
LY2127399 is used in clinical trials for treating rheumatoid arthritis</data>
      <data key="d6">0c7502a2bfe653785647d754ed10f4e3,8e5a1be9981340d419f7b3ad27076009</data>
    </edge>
    <edge source="RHEUMATOID ARTHRITIS" target="BELIMUMAB">
      <data key="d4">32.0</data>
      <data key="d5">Belimumab is used in the treatment of Rheumatoid Arthritis
Belimumab is used to treat rheumatoid arthritis
Belimumab is used in clinical trials for rheumatoid arthritis</data>
      <data key="d6">0c7502a2bfe653785647d754ed10f4e3,68015074236b0144899baa38d01ae467,8e5a1be9981340d419f7b3ad27076009</data>
    </edge>
    <edge source="RHEUMATOID ARTHRITIS" target="METHOTREXATE">
      <data key="d4">18.0</data>
      <data key="d5">Methotrexate is used to treat rheumatoid arthritis</data>
      <data key="d6">0c7502a2bfe653785647d754ed10f4e3</data>
    </edge>
    <edge source="RHEUMATOID ARTHRITIS" target="BAFF">
      <data key="d4">14.0</data>
      <data key="d5">BAFF is a target for therapeutic intervention in rheumatoid arthritis</data>
      <data key="d6">0c7502a2bfe653785647d754ed10f4e3</data>
    </edge>
    <edge source="RHEUMATOID ARTHRITIS" target="RITUXIMAB">
      <data key="d4">16.0</data>
      <data key="d5">Rituximab is used to treat rheumatoid arthritis</data>
      <data key="d6">0c7502a2bfe653785647d754ed10f4e3</data>
    </edge>
    <edge source="RHEUMATOID ARTHRITIS" target="RANK">
      <data key="d4">2.0</data>
      <data key="d5">RANK is involved in the pathogenesis of rheumatoid arthritis</data>
      <data key="d6">0c7502a2bfe653785647d754ed10f4e3</data>
    </edge>
    <edge source="RHEUMATOID ARTHRITIS" target="LYMPHOSTAT-B">
      <data key="d4">8.0</data>
      <data key="d5">LymphoStat-B is used in clinical trials for rheumatoid arthritis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="RHEUMATOID ARTHRITIS" target="HUMAN GENOME SCIENCES INC.">
      <data key="d4">6.0</data>
      <data key="d5">Human Genome Sciences Inc. is involved in clinical trials for rheumatoid arthritis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="RHEUMATOID ARTHRITIS" target="TNF INHIBITORS">
      <data key="d4">14.0</data>
      <data key="d5">TNF inhibitors are approved for the treatment of rheumatoid arthritis</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </edge>
    <edge source="IL-4" target="DUPILUMAB">
      <data key="d4">88.0</data>
      <data key="d5">Dupilumab targets the IL-4 receptor
Dupilumab blocks IL-4 signaling
Dupilumab targets IL-4
Dupilumab blocks IL-4
Dupilumab inhibits IL-4</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41,286730b1c1f680ac465cc21d522fda0c,28f548554737fcc026b968db6bbafa30,48de7eebab3f3b418feb35a152df38fd,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="IL-4" target="T-HELPER (TH)2 CELLS">
      <data key="d4">18.0</data>
      <data key="d5">Th2 cells produce IL-4</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="IL-4" target="FILAGGRIN">
      <data key="d4">46.0</data>
      <data key="d5">IL-4 downregulates filaggrin expression
IL-4 reduces filaggrin expression
IL-4 reduces filaggrin expression</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30,4842292208575bd45b2b5998513dd087,48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-4" target="LORICRIN">
      <data key="d4">44.0</data>
      <data key="d5">IL-4 downregulates loricrin expression
IL-4 downregulates loricrin
IL-4 reduces loricrin expression</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30,4842292208575bd45b2b5998513dd087,48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-4" target="IGE">
      <data key="d4">50.0</data>
      <data key="d5">IL-4 stimulates IgE production
IL-4 stimulates IgE production
IL-4 regulates IgE class switching</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30,4842292208575bd45b2b5998513dd087,48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-4" target="ATOPIC DERMATITIS">
      <data key="d4">9.0</data>
      <data key="d5">IL-4 is implicated in tissue inflammation and epidermal barrier dysfunction in Atopic Dermatitis</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="IL-4" target="AD">
      <data key="d4">53.0</data>
      <data key="d5">IL-4 is a key cytokine involved in the pathophysiology of atopic dermatitis
IL-4 is involved in the immune response in AD
IL-4 is involved in the pathogenesis of atopic dermatitis
IL-4 is involved in the immune response and inflammation in ADIL-4 is a Th2 cytokine that plays a pivotal role in AD</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30,41ccc4b41bd57cf2bda4dbb6c7ae4198,b19f42c9497f71b231222cd953036d6b,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="IL-4" target="IL-13">
      <data key="d4">61.0</data>
      <data key="d5">IL-4 and IL-13 share a receptor and have overlapping functions in AD
Both IL-4 and IL-13 are cytokines involved in immune response and share some signaling pathways
Both IL-4 and IL-13 utilize the IL-4R&#945; receptor for signaling
IL-4 and IL-13 are crucial in the pathophysiology of AD and enhance S. aureus infections</data>
      <data key="d6">104cc78517b2eca2e9cb7e00de1fe4b0,28f548554737fcc026b968db6bbafa30,3df8535e965efb96f5094169610507ff,48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-4" target="IL-13R&#913;1">
      <data key="d4">16.0</data>
      <data key="d5">IL-4 signals through a receptor that includes IL-13R&#945;1</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-4" target="IL-4R&#913;">
      <data key="d4">58.0</data>
      <data key="d5">IL-4 signals through a receptor that includes IL-4R&#945;
IL-4 signals through IL-4R&#945;
IL-4 binds to IL-4R&#945;, inducing receptor dimerization and signal transduction
IL-4 binds to IL-4R&#945;</data>
      <data key="d6">104cc78517b2eca2e9cb7e00de1fe4b0,28f548554737fcc026b968db6bbafa30,48de7eebab3f3b418feb35a152df38fd,78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="IL-4" target="JAK1">
      <data key="d4">14.0</data>
      <data key="d5">IL-4 signaling involves JAK1-mediated phosphorylation</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-4" target="STAT6">
      <data key="d4">14.0</data>
      <data key="d5">IL-4 signaling activates STAT6</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-4" target="TYPE 1 IL-4 RECEPTOR">
      <data key="d4">14.0</data>
      <data key="d5">IL-4 signals through the type 1 IL-4 receptor</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-4" target="T CELLS">
      <data key="d4">14.0</data>
      <data key="d5">IL-4 signals through the type 1 IL-4 receptor on T cells</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-4" target="B CELLS">
      <data key="d4">14.0</data>
      <data key="d5">IL-4 signals through the type 1 IL-4 receptor on B cells</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-4" target="PLASMA CELLS">
      <data key="d4">16.0</data>
      <data key="d5">IL-4 stimulates plasma cells to produce IgE</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-4" target="TH2 CELLS">
      <data key="d4">16.0</data>
      <data key="d5">IL-4 stimulates Th2 cell development</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-4" target="EPIDERMAL BARRIER">
      <data key="d4">16.0</data>
      <data key="d5">IL-4 contributes to epidermal barrier dysfunction</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-4" target="INVOLUCRIN">
      <data key="d4">28.0</data>
      <data key="d5">IL-4 downregulates involucrin
IL-4 reduces involucrin expression</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30,48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-4" target="FIBROCYTES">
      <data key="d4">14.0</data>
      <data key="d5">IL-4 recruits fibrocytes to inflamed skin lesions</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-4" target="SENSORY NEURONS">
      <data key="d4">14.0</data>
      <data key="d5">IL-4 activates sensory neurons</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-4" target="MURINE MODELS">
      <data key="d4">12.0</data>
      <data key="d5">IL-4 is studied in murine models of AD</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-4" target="DORSAL ROOT GANGLIA">
      <data key="d4">12.0</data>
      <data key="d5">IL-4 activates sensory neurons in dorsal root ganglia</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-4" target="PERIOSTIN">
      <data key="d4">15.0</data>
      <data key="d5">IL-4 induces the production of periostin
Periostin is induced by IL-4</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b,e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="IL-4" target="TH2 CELL">
      <data key="d4">14.0</data>
      <data key="d5">Th2 cells produce IL-4</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="IL-4" target="CD4+ T CELL">
      <data key="d4">14.0</data>
      <data key="d5">CD4+ T cells produce IL-4</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="IL-4" target="CD8+ T CELL">
      <data key="d4">14.0</data>
      <data key="d5">CD8+ T cells produce IL-4</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="IL-4" target="MAST CELL">
      <data key="d4">14.0</data>
      <data key="d5">Mast cells produce IL-4</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="IL-4" target="BASOPHIL">
      <data key="d4">14.0</data>
      <data key="d5">Basophils produce IL-4</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="IL-4" target="EOSINOPHIL">
      <data key="d4">14.0</data>
      <data key="d5">Eosinophils produce IL-4</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="IL-4" target="KERATINOCYTE">
      <data key="d4">14.0</data>
      <data key="d5">IL-4 promotes keratinocyte damage</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="IL-4" target="MICE">
      <data key="d4">14.0</data>
      <data key="d5">IL-4 overexpression in mice results in AD-like phenotype</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="IL-4" target="JAK/STAT PATHWAY">
      <data key="d4">8.0</data>
      <data key="d5">IL-4 signaling involves the JAK/STAT pathway</data>
      <data key="d6">104cc78517b2eca2e9cb7e00de1fe4b0</data>
    </edge>
    <edge source="IL-4" target="TH2">
      <data key="d4">54.0</data>
      <data key="d5">IL-4 is involved in the TH2 immune response
TH2 cells are involved in the immune response mediated by IL-4
IL-4 is a primary determinant of the Th2 immune axis
IL-4 is a cytokine involved in T helper cell responses</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41,3df8535e965efb96f5094169610507ff,78e26c66107dba37ac4bab65406b43a0,855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="IL-4" target="ASLAN004">
      <data key="d4">16.0</data>
      <data key="d5">ASLAN004 blocks IL-4</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41</data>
    </edge>
    <edge source="IL-4" target="PERIPHERAL SENSORY NEURONS">
      <data key="d4">14.0</data>
      <data key="d5">Peripheral sensory neurons express receptors for IL-4</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="IL-4" target="NEURONS">
      <data key="d4">7.0</data>
      <data key="d5">Neurons express receptors for IL-4</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="IL-4" target="TSLP">
      <data key="d4">7.0</data>
      <data key="d5">TSLP promotes the production of IL-4</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IL-4" target="IL-33">
      <data key="d4">7.0</data>
      <data key="d5">IL-33 increases the production of IL-4</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IL-4" target="IL-4R">
      <data key="d4">16.0</data>
      <data key="d5">IL-4R is a common receptor chain between IL-13 and IL-4
IL-4R encourages the signaling of IL-4</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IL-4" target="S. AUREUS">
      <data key="d4">14.0</data>
      <data key="d5">IL-4 enhances S. aureus infections</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="IL-4" target="PRURITUS">
      <data key="d4">12.0</data>
      <data key="d5">IL-4 is associated with pruritus in AD</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="IL-4" target="XEROSIS">
      <data key="d4">12.0</data>
      <data key="d5">IL-4 is associated with xerosis in AD</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="IL-4" target="JAK">
      <data key="d4">16.0</data>
      <data key="d5">JAK is involved in the signaling pathway of IL-4</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="IL-4" target="CSA">
      <data key="d4">14.0</data>
      <data key="d5">CsA-loaded nanoparticles reduce IL-4 levels</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="IL-4" target="HYDROCORTISONE">
      <data key="d4">14.0</data>
      <data key="d5">HC-NPs suppressed inflammatory cascades including IL-4</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="IL-4" target="MAST CELLS">
      <data key="d4">8.0</data>
      <data key="d5">Mast cells produce IL-4, central to the pathogenesis of Atopic Dermatitis</data>
      <data key="d6">691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="IL-4" target="SSC">
      <data key="d4">8.0</data>
      <data key="d5">IL-4 is a cytokine involved in promoting fibroblast activation in systemic sclerosis</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="IL-4" target="ICOS">
      <data key="d4">8.0</data>
      <data key="d5">ICOS induces the synthesis of IL-4 in activated T cells</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="IL-13" target="DUPILUMAB">
      <data key="d4">88.0</data>
      <data key="d5">Dupilumab targets the IL-13 receptor
Dupilumab blocks IL-13 signaling
Dupilumab targets IL-13
Dupilumab blocks IL-13
Dupilumab inhibits IL-13</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41,286730b1c1f680ac465cc21d522fda0c,28f548554737fcc026b968db6bbafa30,48de7eebab3f3b418feb35a152df38fd,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="IL-13" target="T-HELPER (TH)2 CELLS">
      <data key="d4">18.0</data>
      <data key="d5">Th2 cells produce IL-13</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="IL-13" target="FILAGGRIN">
      <data key="d4">32.0</data>
      <data key="d5">IL-13 downregulates filaggrin expression
IL-13 reduces filaggrin expression</data>
      <data key="d6">4842292208575bd45b2b5998513dd087,48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-13" target="LORICRIN">
      <data key="d4">30.0</data>
      <data key="d5">IL-13 downregulates loricrin expression
IL-13 downregulates loricrin</data>
      <data key="d6">4842292208575bd45b2b5998513dd087,48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-13" target="IGE">
      <data key="d4">34.0</data>
      <data key="d5">IL-13 stimulates IgE production
IL-13 stimulates IgE production</data>
      <data key="d6">4842292208575bd45b2b5998513dd087,48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-13" target="ATOPIC DERMATITIS">
      <data key="d4">9.0</data>
      <data key="d5">IL-13 is implicated in tissue inflammation and epidermal barrier dysfunction in Atopic Dermatitis</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="IL-13" target="AD">
      <data key="d4">68.0</data>
      <data key="d5">IL-13 is a key cytokine involved in the pathophysiology of atopic dermatitis
IL-13 is involved in the immune response in AD
IL-13 is involved in the pathogenesis of atopic dermatitis
IL-13 negatively impacts epidermal barrier function in AD
IL-13 is a cytokine involved in the inflammatory response in atopic dermatitis
IL-13 is a Th2 cytokine that plays a pivotal role in ADIL-13 is involved in the immune response and inflammation in AD</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30,3ea70e257330c812b52334ca1f90d807,41ccc4b41bd57cf2bda4dbb6c7ae4198,a867a1e73cef039eb3f28e072463b838,b19f42c9497f71b231222cd953036d6b,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="IL-13" target="IL-13R&#913;1">
      <data key="d4">50.0</data>
      <data key="d5">IL-13 signals through a receptor that includes IL-13R&#945;1
IL-13 signals through IL-13R&#945;1
IL-13 binds to IL-13R&#945;1, inducing receptor dimerization and signal transduction</data>
      <data key="d6">104cc78517b2eca2e9cb7e00de1fe4b0,28f548554737fcc026b968db6bbafa30,48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-13" target="IL-4R&#913;">
      <data key="d4">40.0</data>
      <data key="d5">IL-13 signals through a receptor that includes IL-4R&#945;
IL-13 signals through IL-4R&#945;
IL-13 binds to IL-4R&#945;</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30,48de7eebab3f3b418feb35a152df38fd,78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="IL-13" target="JAK1">
      <data key="d4">14.0</data>
      <data key="d5">IL-13 signaling involves JAK1-mediated phosphorylation</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-13" target="STAT6">
      <data key="d4">14.0</data>
      <data key="d5">IL-13 signaling activates STAT6</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-13" target="PLASMA CELLS">
      <data key="d4">16.0</data>
      <data key="d5">IL-13 stimulates plasma cells to produce IgE</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-13" target="TH2 CELLS">
      <data key="d4">16.0</data>
      <data key="d5">IL-13 stimulates Th2 cell development</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-13" target="EPIDERMAL BARRIER">
      <data key="d4">16.0</data>
      <data key="d5">IL-13 contributes to epidermal barrier dysfunction</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-13" target="INVOLUCRIN">
      <data key="d4">14.0</data>
      <data key="d5">IL-13 downregulates involucrin</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-13" target="FIBROCYTES">
      <data key="d4">14.0</data>
      <data key="d5">IL-13 recruits fibrocytes to inflamed skin lesions</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-13" target="FIBROBLASTS">
      <data key="d4">14.0</data>
      <data key="d5">IL-13 recruits fibroblasts for fibrotic skin remodeling</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-13" target="COLLAGEN">
      <data key="d4">14.0</data>
      <data key="d5">IL-13 promotes collagen deposition</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-13" target="SENSORY NEURONS">
      <data key="d4">14.0</data>
      <data key="d5">IL-13 activates sensory neurons</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-13" target="MURINE MODELS">
      <data key="d4">12.0</data>
      <data key="d5">IL-13 is studied in murine models of AD</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-13" target="DORSAL ROOT GANGLIA">
      <data key="d4">12.0</data>
      <data key="d5">IL-13 activates sensory neurons in dorsal root ganglia</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="IL-13" target="TRALOKINUMAB">
      <data key="d4">124.0</data>
      <data key="d5">Tralokinumab targets IL-13
Tralokinumab prevents IL-13 from binding to IL-13R&#945;1 and IL-13R&#945;2
Tralokinumab targets IL-13
Tralokinumab targets IL-13, showing potential efficacy in atopic dermatitis
Tralokinumab targets IL-13
Tralokinumab prevents IL-13 from interacting with its receptors
Tralokinumab targets IL-13 and is used for treating AD
Tralokinumab specifically targets IL-13
Tralokinumab inhibits IL-13</data>
      <data key="d6">104cc78517b2eca2e9cb7e00de1fe4b0,286730b1c1f680ac465cc21d522fda0c,28f548554737fcc026b968db6bbafa30,2cec06c4d46f5ff9ee936a78d8b077cd,3df8535e965efb96f5094169610507ff,48de7eebab3f3b418feb35a152df38fd,78e26c66107dba37ac4bab65406b43a0,8246ea974dfb00cb5e3d984004e21a9e,96e553a44a27e728c27c4892045ec5c2</data>
    </edge>
    <edge source="IL-13" target="LEBRIKIZUMAB">
      <data key="d4">96.0</data>
      <data key="d5">Lebrikizumab targets IL-13
Lebrikizumab binds soluble IL-13 with high affinity
Lebrikizumab targets IL-13
Lebrikizumab targets IL-13, showing potential efficacy in atopic dermatitis
Lebrikizumab targets IL-13
Lebrikizumab selectively binds to IL-13, blocking its signaling</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41,104cc78517b2eca2e9cb7e00de1fe4b0,28f548554737fcc026b968db6bbafa30,3df8535e965efb96f5094169610507ff,48de7eebab3f3b418feb35a152df38fd,96e553a44a27e728c27c4892045ec5c2</data>
    </edge>
    <edge source="IL-13" target="IL-13R&#913;2">
      <data key="d4">32.0</data>
      <data key="d5">IL-13R&#945;2 acts as a decoy receptor for IL-13
IL-13 binds to IL-13R&#945;2
IL-13R&#945;2 binds IL-13, but its biological role remains unclear</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41,78e26c66107dba37ac4bab65406b43a0,96e553a44a27e728c27c4892045ec5c2</data>
    </edge>
    <edge source="IL-13" target="IMA-638">
      <data key="d4">14.0</data>
      <data key="d5">IMA-638 prevents the IL-13/IL-13R&#945;1 complex from accessing IL-4R&#945;</data>
      <data key="d6">96e553a44a27e728c27c4892045ec5c2</data>
    </edge>
    <edge source="IL-13" target="IMA-026">
      <data key="d4">14.0</data>
      <data key="d5">IMA-026 interferes with IL-13 binding to IL-13R&#945;1 and IL-13R&#945;2</data>
      <data key="d6">96e553a44a27e728c27c4892045ec5c2</data>
    </edge>
    <edge source="IL-13" target="PERIOSTIN">
      <data key="d4">15.0</data>
      <data key="d5">IL-13 induces the production of periostin
Periostin is induced by IL-13</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b,e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="IL-13" target="TH2 CELL">
      <data key="d4">14.0</data>
      <data key="d5">Th2 cells produce IL-13</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="IL-13" target="CD4+ T CELL">
      <data key="d4">14.0</data>
      <data key="d5">CD4+ T cells produce IL-13</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="IL-13" target="CD8+ T CELL">
      <data key="d4">14.0</data>
      <data key="d5">CD8+ T cells produce IL-13</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="IL-13" target="MAST CELL">
      <data key="d4">14.0</data>
      <data key="d5">Mast cells produce IL-13</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="IL-13" target="BASOPHIL">
      <data key="d4">14.0</data>
      <data key="d5">Basophils produce IL-13</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="IL-13" target="EOSINOPHIL">
      <data key="d4">14.0</data>
      <data key="d5">Eosinophils produce IL-13</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="IL-13" target="ILC">
      <data key="d4">14.0</data>
      <data key="d5">ILCs produce IL-13</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="IL-13" target="INKT">
      <data key="d4">14.0</data>
      <data key="d5">iNKTs produce IL-13</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="IL-13" target="MICE">
      <data key="d4">14.0</data>
      <data key="d5">IL-13 overexpression in mice results in AD-like phenotype</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="IL-13" target="IL-33">
      <data key="d4">21.0</data>
      <data key="d5">IL-33 enhances type 2 responses through the induction of IL-13IL-33 induces the production of IL-13
IL-33 increases the production of IL-13</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="IL-13" target="JAK/STAT PATHWAY">
      <data key="d4">8.0</data>
      <data key="d5">IL-13 signaling involves the JAK/STAT pathway</data>
      <data key="d6">104cc78517b2eca2e9cb7e00de1fe4b0</data>
    </edge>
    <edge source="IL-13" target="TH2">
      <data key="d4">40.0</data>
      <data key="d5">IL-13 is involved in the TH2 immune response
TH2 cells are involved in the immune response mediated by IL-13
IL-13 is a primary determinant of the Th2 immune axis</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41,3df8535e965efb96f5094169610507ff,78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="IL-13" target="EYE DISORDERS">
      <data key="d4">14.0</data>
      <data key="d5">IL-13 blocking activity is attributed to the development of eye disorders</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41</data>
    </edge>
    <edge source="IL-13" target="ASLAN004">
      <data key="d4">16.0</data>
      <data key="d5">ASLAN004 blocks IL-13</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41</data>
    </edge>
    <edge source="IL-13" target="PERIPHERAL SENSORY NEURONS">
      <data key="d4">14.0</data>
      <data key="d5">Peripheral sensory neurons express receptors for IL-13</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="IL-13" target="NEURONS">
      <data key="d4">7.0</data>
      <data key="d5">Neurons express receptors for IL-13</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="IL-13" target="TSLP">
      <data key="d4">7.0</data>
      <data key="d5">TSLP promotes the production of IL-13</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IL-13" target="IL-4R">
      <data key="d4">9.0</data>
      <data key="d5">IL-4R is a common receptor chain between IL-13 and IL-4
IL-4R encourages the signaling of IL-13</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IL-13" target="S. AUREUS">
      <data key="d4">14.0</data>
      <data key="d5">IL-13 enhances S. aureus infections</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="IL-13" target="PRURITUS">
      <data key="d4">12.0</data>
      <data key="d5">IL-13 is associated with pruritus in AD</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="IL-13" target="XEROSIS">
      <data key="d4">12.0</data>
      <data key="d5">IL-13 is associated with xerosis in AD</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="IL-13" target="JAK">
      <data key="d4">16.0</data>
      <data key="d5">JAK is involved in the signaling pathway of IL-13</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="IL-13" target="HYDROCORTISONE">
      <data key="d4">14.0</data>
      <data key="d5">HC-NPs suppressed inflammatory cascades including IL-13</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="IL-13" target="LIGHT">
      <data key="d4">16.0</data>
      <data key="d5">LIGHT induces the expression of IL-13, a regulator of tissue remodeling</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2</data>
    </edge>
    <edge source="IL-13" target="TL1A">
      <data key="d4">16.0</data>
      <data key="d5">TL1A-driven inflammation is indicated by elevated IL-13
TL1A upregulates IL-13, indicating TL1A-driven inflammation</data>
      <data key="d6">05c97152fe02249153103be341d65b67,c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="IL-13" target="TRAIL">
      <data key="d4">1.0</data>
      <data key="d5">TRAIL is necessary for the production of IL-13</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="IL-13" target="IL-5">
      <data key="d4">7.0</data>
      <data key="d5">IL-13 plays a supporting role to IL-5</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="IL-10" target="AD">
      <data key="d4">22.0</data>
      <data key="d5">IL-10 is involved in the immune response in AD
IL-10 is a cytokine involved in the immune response and inflammation in ADIL-10 is involved in the immune response and inflammation in AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198,b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="IL-10" target="JAK2">
      <data key="d4">6.0</data>
      <data key="d5">IL-10 signaling is associated with JAK2</data>
      <data key="d6">a867a1e73cef039eb3f28e072463b838</data>
    </edge>
    <edge source="IL-10" target="SSC">
      <data key="d4">8.0</data>
      <data key="d5">IL-10 is an anti-inflammatory cytokine involved in systemic sclerosis</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="IL-10" target="TREG">
      <data key="d4">16.0</data>
      <data key="d5">IL-10 is secreted by Treg cells</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="IL-10" target="TNF">
      <data key="d4">14.0</data>
      <data key="d5">TNF-co-stimulation of SSc patient T cells results in decreased production of IL-10</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="IL-10" target="BAFF">
      <data key="d4">6.0</data>
      <data key="d5">BAFF antagonist inhibits IL-10 production in TSK/+ mice</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="IL-18" target="AD">
      <data key="d4">21.0</data>
      <data key="d5">IL-18 is involved in inflammation and immune response in AD
IL-18 is used to monitor the severity of AD</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IL-18" target="PSORIASIS">
      <data key="d4">7.0</data>
      <data key="d5">IL-18 is involved in inflammation and immune response in psoriasis</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IL-18" target="IL-18R&#913;">
      <data key="d4">8.0</data>
      <data key="d5">IL-18 provides a 50-fold-higher receptor affinity for IL-18R&#945;</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </edge>
    <edge source="IL-18" target="IL-37">
      <data key="d4">7.0</data>
      <data key="d5">IL-18 is relevant in relation to IL-37</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </edge>
    <edge source="IL-36" target="ATOPIC DERMATITIS">
      <data key="d4">7.0</data>
      <data key="d5">IL-36 is implicated in Atopic Dermatitis</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IL-36" target="AD">
      <data key="d4">7.0</data>
      <data key="d5">IL-36 is increased in the skin of AD patients</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IL-36" target="PSORIASIS">
      <data key="d4">14.0</data>
      <data key="d5">IL-36 is increased in the skin of psoriasis patientsIL-36 is involved in inflammation and immune response in psoriasis</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="INNATE IMMUNE SYSTEM" target="AD">
      <data key="d4">15.0</data>
      <data key="d5">The innate immune system is involved in the pathophysiology of atopic dermatitis
The innate immune system plays a role in the early phase of AD</data>
      <data key="d6">143d2dc302af5606656797bff162e23e,3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="LEPTIN" target="JAK2">
      <data key="d4">7.0</data>
      <data key="d5">Leptin signaling is dependent on JAK2</data>
      <data key="d6">a867a1e73cef039eb3f28e072463b838</data>
    </edge>
    <edge source="PRKAB1" target="METFORMIN">
      <data key="d4">14.0</data>
      <data key="d5">Metformin targets PRKAB1</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="PTGS1" target="BALSALAZIDE">
      <data key="d4">7.0</data>
      <data key="d5">Balsalazide inhibits PTGS1</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="PTGS2" target="BALSALAZIDE">
      <data key="d4">7.0</data>
      <data key="d5">Balsalazide inhibits PTGS2</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="IL-1&#914;" target="AD">
      <data key="d4">24.0</data>
      <data key="d5">IL-1&#946; is involved in the immune response in AD
IL-1&#946; is involved in the immune response and inflammation in ADIL-1&#946; is a cytokine involved in the immune response and inflammation in AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198,b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="IL-1&#914;" target="PIOGLITAZONE (PGZ)">
      <data key="d4">8.0</data>
      <data key="d5">Pioglitazone (PGZ) reduces the levels of inflammatory cytokine IL-1&#946;</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="IL-1&#914;" target="INFLAMMATORY CYTOKINES">
      <data key="d4">9.0</data>
      <data key="d5">IL-1&#946; is a type of inflammatory cytokine</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="IL-1&#914;" target="MTX">
      <data key="d4">14.0</data>
      <data key="d5">MTX-loaded NPs reduced levels of IL-1&#946;</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="IL-1&#914;" target="BAFF">
      <data key="d4">6.0</data>
      <data key="d5">BAFF inhibition reduces IL-1&#946; levels in a PF mouse model</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="DEGS" target="BTK">
      <data key="d4">8.0</data>
      <data key="d5">DEGs are prominently clustered around BTK nodes in HS</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="DEGS" target="SYK">
      <data key="d4">8.0</data>
      <data key="d5">DEGs are prominently clustered around SYK nodes in HS</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="EGFR" target="AG-490">
      <data key="d4">8.0</data>
      <data key="d5">AG-490 inhibits EGFR</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="EGFR" target="WHI-P154">
      <data key="d4">14.0</data>
      <data key="d5">WHI-P154 inhibits EGFR</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="TLRS" target="AD">
      <data key="d4">14.0</data>
      <data key="d5">TLRs are involved in the pathophysiology of AD</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="IFNG" target="INTERFERON &#915;">
      <data key="d4">9.0</data>
      <data key="d5">IFNG encodes Interferon &#947;</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="IFNG" target="3,3&#8217;-DIINDOLYLMETHANE">
      <data key="d4">6.0</data>
      <data key="d5">3,3&#8217;-Diindolylmethane regulates IFNG</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="IFNG" target="T CELLS">
      <data key="d4">8.0</data>
      <data key="d5">IFNG is expressed by T cells in HS skin</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="IFNG" target="IFN-&#915;">
      <data key="d4">8.0</data>
      <data key="d5">IFNG encodes the cytokine IFN-&#947;</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="CD4+ T CELLS" target="ATOPIC DERMATITIS">
      <data key="d4">8.0</data>
      <data key="d5">OX40 expression is increased on skin-homing CD4+ T cells in patients with Atopic Dermatitis</data>
      <data key="d6">691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="CD4+ T CELLS" target="OX40">
      <data key="d4">8.0</data>
      <data key="d5">CD4+ T cells in AD patients express OX40</data>
      <data key="d6">6b099960b0a39866e3aa6b908f1886e4</data>
    </edge>
    <edge source="CD4+ T CELLS" target="CD40">
      <data key="d4">14.0</data>
      <data key="d5">CD40 expression is increased in activated CD4+ T cells</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="CD4+ T CELLS" target="TCR">
      <data key="d4">16.0</data>
      <data key="d5">CD4+ T cells undergo expansion and differentiation during TCR binding</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="TH17" target="ATOPIC DERMATITIS">
      <data key="d4">21.0</data>
      <data key="d5">Th17 cells are variably involved in the immune response in atopic dermatitis
TH17 cells are involved in the adaptive immune response in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="TH17" target="ROCATINLIMAB">
      <data key="d4">14.0</data>
      <data key="d5">Th17-related genes were downregulated after rocatinlimab treatment</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="TH17" target="AMLITELIMAB">
      <data key="d4">14.0</data>
      <data key="d5">Amlitelimab blocks Th17 inflammation</data>
      <data key="d6">b876251511f570468eb5b6ee6a239cc6</data>
    </edge>
    <edge source="TH17" target="IL-17A">
      <data key="d4">8.0</data>
      <data key="d5">IL-17A is a key cytokine produced by Th17 cells</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </edge>
    <edge source="TH17" target="IL-17C">
      <data key="d4">7.0</data>
      <data key="d5">IL-17C is involved in the Th17-driven inflammatory response</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </edge>
    <edge source="TH17" target="IL-23">
      <data key="d4">8.0</data>
      <data key="d5">IL-23 drives the differentiation of Th17 cells</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </edge>
    <edge source="TH17" target="AD">
      <data key="d4">15.0</data>
      <data key="d5">T helper 17 cells are implicated in atopic dermatitis
Th17 cells are involved in the immune response and inflammation in AD</data>
      <data key="d6">143d2dc302af5606656797bff162e23e,41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="TH17" target="IL-22">
      <data key="d4">7.0</data>
      <data key="d5">IL-22 is induced by staphylococcal exotoxins in TH17 cells</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="TH17" target="TNFR2">
      <data key="d4">14.0</data>
      <data key="d5">Impaired TNF/TNFR2 signaling enhances Th17 polarization</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TH17" target="BALF">
      <data key="d4">14.0</data>
      <data key="d5">Inhibiting TNFR2 via antibody treatment led to increased expression of Th17 inflammatory cytokines in BALF</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TH17" target="LIGHT">
      <data key="d4">12.0</data>
      <data key="d5">LIGHT is associated with Th17 polarization in SSc</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2</data>
    </edge>
    <edge source="IL-1" target="AD">
      <data key="d4">7.0</data>
      <data key="d5">IL-1 expression is raised in AD</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IL-1" target="PSORIASIS">
      <data key="d4">7.0</data>
      <data key="d5">IL-1 expression is raised in psoriasis</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IL-1" target="TH2 CELL">
      <data key="d4">7.0</data>
      <data key="d5">IL-1 leads to the formation of Th2 cells</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IL-1" target="IL-1R">
      <data key="d4">8.0</data>
      <data key="d5">IL-1 and IL-1R are both highly produced in skin cells</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IL-1" target="ALOPECIA AREATA">
      <data key="d4">14.0</data>
      <data key="d5">IL-1 expression is raised in alopecia areata</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IL-1" target="BERMEKIMAB">
      <data key="d4">8.0</data>
      <data key="d5">Bermekimab is an anti-IL-1 monoclonal antibody</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IL-1" target="TH1 CELL">
      <data key="d4">7.0</data>
      <data key="d5">IL-1 increases Th1 cell expression</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IL1R1" target="ANAKINRA">
      <data key="d4">16.0</data>
      <data key="d5">Anakinra antagonizes IL1R1</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="IL32" target="CUTANEOUS DIPHTHERIA">
      <data key="d4">7.0</data>
      <data key="d5">IL32 is associated with Cutaneous diphtheria</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL36B" target="PERIOSTITIS">
      <data key="d4">7.0</data>
      <data key="d5">IL36B is associated with Periostitis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL36RN" target="SPESOLIMAB">
      <data key="d4">7.0</data>
      <data key="d5">Spesolimab antagonizes IL36RN</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="IL37" target="STILL&#8217;S DISEASE">
      <data key="d4">7.0</data>
      <data key="d5">IL37 is associated with Still&#8217;s disease</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="S100A7" target="AD">
      <data key="d4">15.0</data>
      <data key="d5">S100A7 is upregulated in atopic dermatitis lesions
S100A7 is involved in the immune response in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="S100A7A" target="BRODALUMAB">
      <data key="d4">14.0</data>
      <data key="d5">Brodalumab targets S100A7A</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="S100A12" target="AD">
      <data key="d4">8.0</data>
      <data key="d5">S100A12 is involved in the immune response in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="ADIPONECTIN" target="ADIPOQ">
      <data key="d4">7.0</data>
      <data key="d5">ADIPOQ encodes adiponectin</data>
      <data key="d6">fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="PPAR&#915;" target="THIAZOLIDINE DERIVATIVES">
      <data key="d4">7.0</data>
      <data key="d5">Thiazolidine derivatives act as PPAR&#947; agonists</data>
      <data key="d6">fa1f4687a5326fccd5d518845839e5f2</data>
    </edge>
    <edge source="INFLAMMATORY BOWEL DISEASES" target="JAK INHIBITORS">
      <data key="d4">16.0</data>
      <data key="d5">JAK inhibitors are in clinical development for treating inflammatory bowel diseases</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="CROHN&#8217;S DISEASE" target="IL26">
      <data key="d4">7.0</data>
      <data key="d5">IL26 is associated with Crohn&#8217;s disease</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="CROHN&#8217;S DISEASE" target="GASTROINTESTINAL TRACT">
      <data key="d4">8.0</data>
      <data key="d5">Crohn&#8217;s disease affects the gastrointestinal tract</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="CROHN&#8217;S DISEASE" target="TNF INHIBITORS">
      <data key="d4">14.0</data>
      <data key="d5">TNF inhibitors are approved for the treatment of Crohn&#8217;s disease</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </edge>
    <edge source="PACHYONYCHIA CONGENITA" target="KRT6A">
      <data key="d4">8.0</data>
      <data key="d5">KRT6A is associated with Pachyonychia congenita</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="PACHYONYCHIA CONGENITA" target="KRT16">
      <data key="d4">8.0</data>
      <data key="d5">KRT16 is associated with Pachyonychia congenita</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="NEUTROPHILS" target="ATOPIC DERMATITIS">
      <data key="d4">8.0</data>
      <data key="d5">Neutrophils are elevated in the skin of Atopic Dermatitis patients</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="NEUTROPHILS" target="METHOTREXATE">
      <data key="d4">14.0</data>
      <data key="d5">Methotrexate calms down hyperactive neutrophils</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="NEUTROPHILS" target="TNF">
      <data key="d4">1.0</data>
      <data key="d5">Neutrophils can express TNF</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="NEUTROPHILS" target="GITR">
      <data key="d4">8.0</data>
      <data key="d5">GITR may be found on activated neutrophils
GITR is expressed on activated neutrophils</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9,d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="INSULIN RESISTANCE" target="LIGHT">
      <data key="d4">7.0</data>
      <data key="d5">Genetic deletion of LIGHT results in reduced insulin resistance</data>
      <data key="d6">05c97152fe02249153103be341d65b67</data>
    </edge>
    <edge source="ADIPOCYTES" target="HVEM">
      <data key="d4">14.0</data>
      <data key="d5">HVEM is expressed on adipocytes</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="TNF-&#913;" target="TSLP">
      <data key="d4">7.0</data>
      <data key="d5">TSLP promotes the production of TNF-&#945;</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="TNF-&#913;" target="PIOGLITAZONE (PGZ)">
      <data key="d4">8.0</data>
      <data key="d5">Pioglitazone (PGZ) reduces the levels of inflammatory cytokine TNF-&#945;</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="TNF-&#913;" target="INFLAMMATORY CYTOKINES">
      <data key="d4">9.0</data>
      <data key="d5">TNF-&#945; is a type of inflammatory cytokine</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="TNF-&#913;" target="HYDROCORTISONE">
      <data key="d4">14.0</data>
      <data key="d5">HC-NPs suppressed inflammatory cascades including TNF-&#945;</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="TNF-&#913;" target="MTX">
      <data key="d4">14.0</data>
      <data key="d5">MTX-loaded NPs reduced levels of TNF-&#945;</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="TNF-&#913;" target="AD">
      <data key="d4">14.0</data>
      <data key="d5">TNF-&#945; is involved in the pathophysiology of AD</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="IL-6" target="TOCILIZUMAB">
      <data key="d4">16.0</data>
      <data key="d5">Tocilizumab targets IL-6</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="IL-6" target="AD">
      <data key="d4">16.0</data>
      <data key="d5">IL-6 is involved in the immune response and inflammation in ADIL-6 is a cytokine involved in the immune response and inflammation in AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="IL-6" target="PIOGLITAZONE (PGZ)">
      <data key="d4">8.0</data>
      <data key="d5">Pioglitazone (PGZ) reduces the levels of inflammatory cytokine IL-6</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="IL-6" target="INFLAMMATORY CYTOKINES">
      <data key="d4">9.0</data>
      <data key="d5">IL-6 is a type of inflammatory cytokine</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="IL-6" target="CSA">
      <data key="d4">7.0</data>
      <data key="d5">CsA-loaded nanoparticles reduce IL-6 levels</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="IL-6" target="HYDROCORTISONE">
      <data key="d4">14.0</data>
      <data key="d5">HC-NPs suppressed inflammatory cascades including IL-6</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="IL-6" target="MTX">
      <data key="d4">14.0</data>
      <data key="d5">MTX-loaded NPs reduced levels of IL-6</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="IL-6" target="SSC">
      <data key="d4">8.0</data>
      <data key="d5">IL-6 is a proinflammatory cytokine involved in systemic sclerosis</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="IL-6" target="TNFR1">
      <data key="d4">7.0</data>
      <data key="d5">TNFR1 is associated with reduced levels of IL-6 mRNA</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="IL-6" target="LIGHT">
      <data key="d4">14.0</data>
      <data key="d5">LIGHT increases IL-6 expression in dermal fibroblasts</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2</data>
    </edge>
    <edge source="IL-6" target="BAFF">
      <data key="d4">6.0</data>
      <data key="d5">BAFF antagonist inhibits IL-6 production in TSK/+ mice</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="TRASTUZUMAB" target="BREAST CANCER">
      <data key="d4">8.0</data>
      <data key="d5">Trastuzumab is used to treat breast cancer</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d</data>
    </edge>
    <edge source="APREMILAST" target="PSORIASIS">
      <data key="d4">9.0</data>
      <data key="d5">Apremilast is approved to treat moderate to severe forms of psoriasis</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="TNF INHIBITORS" target="UC">
      <data key="d4">7.0</data>
      <data key="d5">TNF inhibitors are approved for the treatment of ulcerative colitis</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </edge>
    <edge source="TNF INHIBITORS" target="PSORIATIC ARTHRITIS">
      <data key="d4">14.0</data>
      <data key="d5">TNF inhibitors are approved for the treatment of psoriatic arthritis</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </edge>
    <edge source="TNF INHIBITORS" target="ANKYLOSING SPONDYLITIS">
      <data key="d4">14.0</data>
      <data key="d5">TNF inhibitors are approved for the treatment of ankylosing spondylitis</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </edge>
    <edge source="TNF INHIBITORS" target="JUVENILE IDIOPATHIC ARTHRITIS">
      <data key="d4">14.0</data>
      <data key="d5">TNF inhibitors are approved for the treatment of juvenile idiopathic arthritis</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </edge>
    <edge source="TNF INHIBITORS" target="PLAQUE PSORIASIS">
      <data key="d4">14.0</data>
      <data key="d5">TNF inhibitors are approved for the treatment of plaque psoriasis</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </edge>
    <edge source="TNF INHIBITORS" target="NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS">
      <data key="d4">8.0</data>
      <data key="d5">TNF inhibitors are approved for the treatment of non-radiographic axial spondyloarthritis</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </edge>
    <edge source="TNF INHIBITORS" target="END STAGE FIBROSIS">
      <data key="d4">7.0</data>
      <data key="d5">TNF inhibitors are used to treat diseases presenting in end stage fibrosis</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </edge>
    <edge source="TNF INHIBITORS" target="ULCERATIVE COLITIS">
      <data key="d4">1.0</data>
      <data key="d5">TNF inhibitors are approved for the treatment of ulcerative colitis</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </edge>
    <edge source="AR" target="3,3&#8217;-DIINDOLYLMETHANE">
      <data key="d4">12.0</data>
      <data key="d5">3,3&#8217;-Diindolylmethane regulates AR</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="AR" target="CYPROTERONE ACETATE">
      <data key="d4">14.0</data>
      <data key="d5">Cyproterone acetate antagonizes AR</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="BTK" target="ACALABRUTINIB">
      <data key="d4">25.0</data>
      <data key="d5">Acalabrutinib is a BTK inhibitor used to treat HS
Acalabrutinib is a BTK inhibitor</data>
      <data key="d6">b62ecc47bf54393bc78dd65986b949d6,e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="BTK" target="IBRUTINIB">
      <data key="d4">25.0</data>
      <data key="d5">Ibrutinib is a BTK inhibitor used to treat HS
Ibrutinib is a BTK inhibitor</data>
      <data key="d6">b62ecc47bf54393bc78dd65986b949d6,e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="BTK" target="SYK">
      <data key="d4">8.0</data>
      <data key="d5">SYK and BTK are both involved in B cell receptor signaling</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="BTK" target="PHOSPHO-BTK">
      <data key="d4">8.0</data>
      <data key="d5">Phospho-BTK is the phosphorylated form of BTK</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="C5AR1" target="AVACOPAN">
      <data key="d4">14.0</data>
      <data key="d5">Avacopan antagonizes C5AR1</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="CASP1" target="CASPASE 1">
      <data key="d4">9.0</data>
      <data key="d5">CASP1 encodes Caspase 1</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="CCL18" target="C-C MOTIF CHEMOKINE LIGAND 18">
      <data key="d4">9.0</data>
      <data key="d5">CCL18 encodes C-C Motif Chemokine Ligand 18</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="CCL18" target="AD">
      <data key="d4">22.0</data>
      <data key="d5">CCL18 is involved in the immune response in AD
CCL18 is involved in the immune response and inflammation in ADCCL18 is a chemokine involved in the immune response and inflammation in AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198,b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="CCL18" target="T CELL">
      <data key="d4">16.0</data>
      <data key="d5">CCL18 promotes the attraction of inflammatory T cells</data>
      <data key="d6">6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="CCL18" target="DC">
      <data key="d4">16.0</data>
      <data key="d5">CCL18 promotes the attraction of inflammatory DC subtypes</data>
      <data key="d6">6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="CCL26" target="C-C MOTIF CHEMOKINE LIGAND 26">
      <data key="d4">9.0</data>
      <data key="d5">CCL26 encodes C-C Motif Chemokine Ligand 26</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="CCR4" target="C-C MOTIF CHEMOKINE RECEPTOR 4">
      <data key="d4">9.0</data>
      <data key="d5">CCR4 encodes C-C Motif Chemokine Receptor 4</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="CCR4" target="TH2 CELL">
      <data key="d4">8.0</data>
      <data key="d5">CCR4 is a hallmark of memory TH2 cells</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9</data>
    </edge>
    <edge source="CCR4" target="RANTES">
      <data key="d4">8.0</data>
      <data key="d5">RANTES binds to CCR4</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9</data>
    </edge>
    <edge source="CCR4" target="MCP1">
      <data key="d4">8.0</data>
      <data key="d5">MCP1 binds to CCR4</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9</data>
    </edge>
    <edge source="CCR4" target="CCL22">
      <data key="d4">8.0</data>
      <data key="d5">CCL22 binds to CCR4</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9</data>
    </edge>
    <edge source="CCR4" target="CCL17">
      <data key="d4">8.0</data>
      <data key="d5">CCL17 binds to CCR4</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9</data>
    </edge>
    <edge source="CCR4" target="RPT193">
      <data key="d4">15.0</data>
      <data key="d5">RPT193 is a small-molecule CCR4 antagonist
RPT193 targets the CCR4 receptor</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9,f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="JAK INHIBITORS" target="AD">
      <data key="d4">43.0</data>
      <data key="d5">JAK inhibitors are used to treat atopic dermatitis
JAK inhibitors are used for the therapy of atopic dermatitis
JAK inhibitors offer an opportunity for the effective treatment of AD</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e,dc905ba8b6eb7d84cf2776303211010d,e30574e513dd250992d637d808759c34</data>
    </edge>
    <edge source="JAK INHIBITORS" target="JAK">
      <data key="d4">18.0</data>
      <data key="d5">JAK inhibitors block the signal transduction pathways of multiple cytokine receptors</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="JAK INHIBITORS" target="JAK1">
      <data key="d4">18.0</data>
      <data key="d5">JAK inhibitors block the signal transduction pathways of JAK1</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="JAK INHIBITORS" target="JAK2">
      <data key="d4">18.0</data>
      <data key="d5">JAK inhibitors block the signal transduction pathways of JAK2</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="JAK INHIBITORS" target="JAK3">
      <data key="d4">18.0</data>
      <data key="d5">JAK inhibitors block the signal transduction pathways of JAK3</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="JAK INHIBITORS" target="TYK2">
      <data key="d4">18.0</data>
      <data key="d5">JAK inhibitors block the signal transduction pathways of TYK2</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="JAK INHIBITORS" target="SARS-COV-2">
      <data key="d4">14.0</data>
      <data key="d5">JAK inhibitors were used successfully in treating the cytokine storm generated by SARS-CoV-2</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="JAK INHIBITORS" target="MYELOFIBROSIS">
      <data key="d4">6.0</data>
      <data key="d5">JAK inhibitors are initially employed for the treatment of myelofibrosis</data>
      <data key="d6">e30574e513dd250992d637d808759c34</data>
    </edge>
    <edge source="TNF" target="ANDROGRAPHOLIDE">
      <data key="d4">7.0</data>
      <data key="d5">Andrographolide inhibits TNF</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="TNF" target="GOLIMUMAB">
      <data key="d4">16.0</data>
      <data key="d5">Golimumab inhibits TNF</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="TNF" target="INFLIXIMAB">
      <data key="d4">14.0</data>
      <data key="d5">Infliximab inhibits TNF</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="TNF" target="ALEXA FLUOR 488">
      <data key="d4">14.0</data>
      <data key="d5">Alexa Fluor 488 is used as a secondary antibody for TNF</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="TNF" target="DONKEY ANTI-RABBIT IGG">
      <data key="d4">7.0</data>
      <data key="d5">Donkey anti-rabbit IgG is used as a secondary antibody for TNF</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="TNF" target="SSC">
      <data key="d4">8.0</data>
      <data key="d5">TNF is a proinflammatory cytokine involved in systemic sclerosis</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="TNF" target="TH2">
      <data key="d4">14.0</data>
      <data key="d5">TNF is a cytokine involved in T helper cell responses</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="TNF" target="TNFR1">
      <data key="d4">16.0</data>
      <data key="d5">TNFR1 is a receptor for TNF involved in cell survival and death responses
TNF binds to TNFR1</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="TNF" target="TNFR2">
      <data key="d4">16.0</data>
      <data key="d5">TNFR2 is a receptor for TNF involved in cell survival responses
TNF binds to TNFR2</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="TNF" target="MONOCYTES">
      <data key="d4">7.0</data>
      <data key="d5">Monocytes produce TNF</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="TNF" target="MACROPHAGES">
      <data key="d4">7.0</data>
      <data key="d5">Macrophages produce TNF</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="TNF" target="T CELLS">
      <data key="d4">6.0</data>
      <data key="d5">T cells can express TNF</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="TNF" target="B CELLS">
      <data key="d4">6.0</data>
      <data key="d5">B cells can express TNF</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="TNF" target="NK CELLS">
      <data key="d4">6.0</data>
      <data key="d5">NK cells can express TNF</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="TNF" target="MAST CELLS">
      <data key="d4">6.0</data>
      <data key="d5">Mast cells can express TNF</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="TNF" target="&#913;SMA">
      <data key="d4">22.0</data>
      <data key="d5">TNF suppresses &#945;SMA expression in human dermal fibroblasts
TNF suppresses &#945;SMA expression in human dermal fibroblasts</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e,a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="TNF" target="TYPE 1 COLLAGEN">
      <data key="d4">16.0</data>
      <data key="d5">TNF-co-stimulation of SSc patient T cells results in elevated type 1 collagen expression by fibroblasts</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TNF" target="PULMONARY FIBROSIS">
      <data key="d4">16.0</data>
      <data key="d5">TNF is involved in fibrotic disease progression and resolution</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TNF" target="PROFIBROTIC MACROPHAGES">
      <data key="d4">14.0</data>
      <data key="d5">TNF affects the numbers and programming status of profibrotic macrophages</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TNF" target="PROFIBROTIC CYTOKINES">
      <data key="d4">8.0</data>
      <data key="d5">TNF-co-stimulation of SSc patient T cells results in increased secretion of profibrotic cytokines</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TNF" target="TGF&#914;1">
      <data key="d4">7.0</data>
      <data key="d5">TNF suppresses TGF&#946;1-induced myofibroblast genes</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="TNF" target="COL1A1">
      <data key="d4">7.0</data>
      <data key="d5">TNF suppresses TGF&#946;1-induced Col1a1 expression</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="TNF" target="FIBRONECTIN">
      <data key="d4">7.0</data>
      <data key="d5">TNF suppresses TGF&#946;1-induced fibronectin expression</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="TNF" target="MYOFIBROBLAST">
      <data key="d4">8.0</data>
      <data key="d5">TNF drives conversion to myofibroblasts in DD</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="TNF" target="WNT SIGNALING">
      <data key="d4">7.0</data>
      <data key="d5">TNF activates Wnt signaling in DD</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="TNF" target="IL-33">
      <data key="d4">7.0</data>
      <data key="d5">TNF signals through TNFR2 to initiate IL-33 production</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="TNF" target="INTESTINAL MYOFIBROBLASTS">
      <data key="d4">8.0</data>
      <data key="d5">TNF increases proliferation and collagen accumulation in intestinal myofibroblasts</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="TNF" target="TIMP-1">
      <data key="d4">7.0</data>
      <data key="d5">TNF induces expression of TIMP-1</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="TNF" target="ERK1/2">
      <data key="d4">7.0</data>
      <data key="d5">TNF induces activation of ERK1/2</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="TNF" target="DD">
      <data key="d4">8.0</data>
      <data key="d5">TNF treatment drives conversion to myofibroblasts in Dupuytren&#8217;s disease</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="TNF" target="STROMAL CELLS">
      <data key="d4">7.0</data>
      <data key="d5">TNF signals through TNFR2 on stromal cells to initiate IL-33 production</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="TNF" target="MI">
      <data key="d4">16.0</data>
      <data key="d5">TNF levels increase after myocardial infarction</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="TNF" target="ETANERCEPT">
      <data key="d4">9.0</data>
      <data key="d5">Etanercept inhibits TNF to treat autoimmune diseases</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="TNF" target="ALIMUMAB">
      <data key="d4">8.0</data>
      <data key="d5">Alimumab is an anti-TNF monoclonal antibody</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="TNF" target="LUMBAR SPINAL FIBROSIS">
      <data key="d4">7.0</data>
      <data key="d5">TNF is involved in the pathogenesis of Lumbar Spinal Fibrosis</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="EPITHELIAL CELLS" target="HVEM">
      <data key="d4">14.0</data>
      <data key="d5">HVEM is expressed on epithelial cells</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="EPITHELIAL CELLS" target="LT&#914;R">
      <data key="d4">14.0</data>
      <data key="d5">LT&#946;R is expressed on epithelial cells</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="EPITHELIAL CELLS" target="LIGHT">
      <data key="d4">16.0</data>
      <data key="d5">LIGHT can act on epithelial cells to drive pro-fibrotic and anti-fibrotic effects
LIGHT acts on epithelial cells to drive pro-fibrotic and anti-fibrotic effects</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a,68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="EPITHELIAL CELLS" target="TNFSF14">
      <data key="d4">8.0</data>
      <data key="d5">TNFSF14 can act on epithelial cells to drive pro-fibrotic and anti-fibrotic effects</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="LESIONAL SKIN" target="AD">
      <data key="d4">1.0</data>
      <data key="d5">Lesional skin is affected in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="NON-LESIONAL SKIN" target="AD">
      <data key="d4">21.0</data>
      <data key="d5">Non-lesional skin shows molecular abnormalities in atopic dermatitis
Non-lesional skin is affected in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="HEALTHY CONTROLS" target="ATOPIC DERMATITIS">
      <data key="d4">2.0</data>
      <data key="d5">Healthy Controls are used as a comparison group in research on Atopic Dermatitis
Healthy controls are used for comparison with patients with atopic dermatitis</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd,691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="BIOMARKERS" target="OX40">
      <data key="d4">7.0</data>
      <data key="d5">Anti-OX40 therapy affects biomarkers in the treatment of atopic dermatitis</data>
      <data key="d6">100dd7646c10899301b3c0631183da16</data>
    </edge>
    <edge source="BIOMARKERS" target="AD">
      <data key="d4">7.0</data>
      <data key="d5">Biomarkers are used to assess the severity and progression of atopic dermatitis</data>
      <data key="d6">100dd7646c10899301b3c0631183da16</data>
    </edge>
    <edge source="ECZEMA" target="IGE">
      <data key="d4">7.0</data>
      <data key="d5">Increased levels of IgE are commonly detected in patients with eczema</data>
      <data key="d6">f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="ECZEMA" target="OMALIZUMAB">
      <data key="d4">1.0</data>
      <data key="d5">Omalizumab is used in the treatment of severe recalcitrant atopic eczema</data>
      <data key="d6">f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="ECZEMA" target="AD">
      <data key="d4">10.0</data>
      <data key="d5">Atopic dermatitis (AD) is a type of eczema
Eczema is a symptom of AD</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89,89dbac0da39e4de2b602052cd792b90d</data>
    </edge>
    <edge source="ECZEMA" target="ATOPIC DERMATITIS">
      <data key="d4">19.0</data>
      <data key="d5">Eczema is another term for Atopic Dermatitis
Eczema is a symptom of Atopic Dermatitis</data>
      <data key="d6">691cb2e23ac3c6e591129d16714f8ef8,6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ECZEMA" target="NANOTECHNOLOGY">
      <data key="d4">7.0</data>
      <data key="d5">Nanotechnology offers a method for treating eczema</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="ECZEMA" target="METHOTREXATE">
      <data key="d4">16.0</data>
      <data key="d5">Methotrexate targets immune system cells causing eczema</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="CD80" target="CD80 MOLECULE">
      <data key="d4">9.0</data>
      <data key="d5">CD80 encodes CD80 Molecule</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="CD80" target="CD28">
      <data key="d4">41.0</data>
      <data key="d5">CD80 interacts with CD28 for T-cell activation
CD28 binds to CD80 to provide a costimulatory signal for T-cell activation
CD28 and CD80 are involved in positive costimulatory pathways</data>
      <data key="d6">4842292208575bd45b2b5998513dd087,503107475d2e9dac49abd8ebcbadd9f5,855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="CD80" target="CTLA-4">
      <data key="d4">40.0</data>
      <data key="d5">CTLA-4 binds to CD80, reducing IL-2 production and T cell proliferation
CTLA-4 and CD80 are involved in negative costimulatory pathways
CTLA-4 interacts with CD80 in immune response regulation</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b,4d0e8ae9371a435885994b4161126bc3,855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="CD80" target="SCTLA-4">
      <data key="d4">28.0</data>
      <data key="d5">sCTLA-4 may inhibit early T-cell activation by blocking CD80&#8212;CD28 interaction
sCTLA-4 blocks CD80 interaction</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b,9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="ABATACEPT" target="SSC">
      <data key="d4">40.0</data>
      <data key="d5">Abatacept is used to block T-cell costimulation in systemic sclerosis
Abatacept prevents inflammation-driven fibrosis in systemic sclerosis
Abatacept induced clinical improvement in SSc patients
Abatacept is being evaluated for its effects in treating systemic sclerosis</data>
      <data key="d6">4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,855c455b4c9592746834ee3a4e0e6b81,9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="ABATACEPT" target="ASSET TRIAL">
      <data key="d4">17.0</data>
      <data key="d5">ASSET trial is a clinical trial assessing the efficacy of abatacept in systemic sclerosis
The ASSET trial is studying the efficacy of subcutaneous abatacept in dcSSc</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5,855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="ABATACEPT" target="INFLAMMATION-DRIVEN DERMAL FIBROSIS">
      <data key="d4">8.0</data>
      <data key="d5">Abatacept prevents and induces regression of inflammation-driven dermal fibrosis in SSc</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="ABATACEPT" target="DIGESTIVE INVOLVEMENT">
      <data key="d4">8.0</data>
      <data key="d5">Abatacept improves digestive involvement in SSc</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="ABATACEPT" target="LUNG FIBROSIS">
      <data key="d4">8.0</data>
      <data key="d5">Abatacept prevents lung fibrosis in SSc</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="ABATACEPT" target="PULMONARY HYPERTENSION">
      <data key="d4">8.0</data>
      <data key="d5">Abatacept attenuates pulmonary hypertension in SSc</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="ABATACEPT" target="INFLAMMATORY JOINT INVOLVEMENT">
      <data key="d4">7.0</data>
      <data key="d5">Abatacept shows effectiveness on inflammatory joint involvement in SSc</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="ABATACEPT" target="PLACEBO-CONTROLLED RANDOMIZED TRIAL">
      <data key="d4">7.0</data>
      <data key="d5">Abatacept showed clinical improvement of skin fibrosis in a placebo-controlled randomized trial</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="ABATACEPT" target="CTLA-4">
      <data key="d4">16.0</data>
      <data key="d5">Abatacept is a recombinant fusion protein comprising the extracellular domain of CTLA-4</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="ABATACEPT" target="FRA-2 TRANSGENIC MOUSE MODEL">
      <data key="d4">16.0</data>
      <data key="d5">Abatacept alleviates interstitial lung disease and pulmonary hypertension in the Fra-2 transgenic mouse model</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="ABATACEPT" target="CGVHD">
      <data key="d4">14.0</data>
      <data key="d5">Abatacept improves gastrointestinal involvement in chronic graft-vs.-host disease</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="ABATACEPT" target="LIVER">
      <data key="d4">14.0</data>
      <data key="d5">Abatacept decreases liver transaminase levels</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="ABATACEPT" target="COLON">
      <data key="d4">14.0</data>
      <data key="d5">Abatacept improves colon inflammation</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="ABATACEPT" target="EUSTAR">
      <data key="d4">14.0</data>
      <data key="d5">Abatacept induced clinical improvement in systemic sclerosis patients in the EUSTAR cohort</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="ABATACEPT" target="DCSSC">
      <data key="d4">22.0</data>
      <data key="d5">Abatacept was added to standard therapy in patients with diffuse cutaneous systemic sclerosis
Abatacept is being evaluated for its effects in treating diffuse cutaneous systemic sclerosis</data>
      <data key="d6">4d0e8ae9371a435885994b4161126bc3,9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="ABATACEPT" target="JOINT">
      <data key="d4">7.0</data>
      <data key="d5">Abatacept showed effectiveness on inflammatory joint involvement in SSc</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="ABATACEPT" target="MRSS">
      <data key="d4">8.0</data>
      <data key="d5">Abatacept therapy led to a significant decrease in mRSS in SSc patients</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="ABATACEPT" target="RA">
      <data key="d4">9.0</data>
      <data key="d5">Abatacept is widely used in the treatment of rheumatoid arthritis</data>
      <data key="d6">4d0e8ae9371a435885994b4161126bc3</data>
    </edge>
    <edge source="CHI3L1" target="CHITINASE 3-LIKE 1">
      <data key="d4">9.0</data>
      <data key="d5">CHI3L1 encodes Chitinase 3-Like 1</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="CSF1" target="COLONY-STIMULATING FACTOR 1">
      <data key="d4">9.0</data>
      <data key="d5">CSF1 encodes Colony-Stimulating Factor 1</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="CXCL1" target="C-X-C MOTIF CHEMOKINE LIGAND 1">
      <data key="d4">9.0</data>
      <data key="d5">CXCL1 encodes C-X-C Motif Chemokine Ligand 1</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="CXCL1" target="AD">
      <data key="d4">8.0</data>
      <data key="d5">CXCL1 is involved in the immune response in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="CXCL8" target="C-X-C MOTIF CHEMOKINE LIGAND 8">
      <data key="d4">9.0</data>
      <data key="d5">CXCL8 encodes C-X-C Motif Chemokine Ligand 8</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="MELANOMA" target="IL24">
      <data key="d4">7.0</data>
      <data key="d5">IL24 is associated with Melanoma</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="CXCL13" target="C-X-C MOTIF CHEMOKINE LIGAND 13">
      <data key="d4">9.0</data>
      <data key="d5">CXCL13 encodes C-X-C Motif Chemokine Ligand 13</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="CXCR5" target="C-X-C MOTIF CHEMOKINE RECEPTOR 5">
      <data key="d4">9.0</data>
      <data key="d5">CXCR5 encodes C-X-C Motif Chemokine Receptor 5</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="DCD" target="DERMCIDIN">
      <data key="d4">9.0</data>
      <data key="d5">DCD encodes Dermcidin</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="DEFB4A" target="DEFENSIN &#914; 4A">
      <data key="d4">9.0</data>
      <data key="d5">DEFB4A encodes Defensin &#946; 4A</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="DEFB103B" target="DEFENSIN &#914; 103B">
      <data key="d4">9.0</data>
      <data key="d5">DEFB103B encodes Defensin &#946; 103B</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="EGF" target="EPIDERMAL GROWTH FACTOR">
      <data key="d4">9.0</data>
      <data key="d5">EGF encodes Epidermal Growth Factor</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="EPGN" target="EPITHELIAL MITOGEN">
      <data key="d4">9.0</data>
      <data key="d5">EPGN encodes Epithelial Mitogen</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="ERBB4" target="ERB-B2 RECEPTOR TYROSINE KINASE 4">
      <data key="d4">9.0</data>
      <data key="d5">ERBB4 encodes Erb-B2 Receptor Tyrosine Kinase 4</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="FOSTAMATINIB" target="SYK">
      <data key="d4">24.0</data>
      <data key="d5">Fostamatinib is a SYK inhibitor used to treat HS
Fostamatinib is a SYK inhibitor</data>
      <data key="d6">b62ecc47bf54393bc78dd65986b949d6,e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="GAS6" target="GROWTH ARREST SPECIFIC 6">
      <data key="d4">9.0</data>
      <data key="d5">GAS6 encodes Growth Arrest Specific 6</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="GDNF" target="GLIAL CELL DERIVED NEUROTROPHIC FACTOR">
      <data key="d4">9.0</data>
      <data key="d5">GDNF encodes Glial Cell Derived Neurotrophic Factor</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="GJB2" target="GAP JUNCTION PROTEIN &#914;2">
      <data key="d4">9.0</data>
      <data key="d5">GJB2 encodes Gap Junction Protein &#946;2</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="HBEGF" target="HEPARIN BINDING EGF-LIKE GROWTH FACTOR">
      <data key="d4">9.0</data>
      <data key="d5">HBEGF encodes Heparin Binding EGF-Like Growth Factor</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="HGF" target="HEPATOCYTE GROWTH FACTOR">
      <data key="d4">9.0</data>
      <data key="d5">HGF encodes Hepatocyte Growth Factor</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="HRG" target="HISTIDINE-RICH GLYCOPROTEIN">
      <data key="d4">9.0</data>
      <data key="d5">HRG encodes Histidine-Rich Glycoprotein</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="IFNA1" target="INTERFERON &#913;1">
      <data key="d4">9.0</data>
      <data key="d5">IFNA1 encodes Interferon &#945;1</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="IGF2" target="INSULIN-LIKE GROWTH FACTOR 2">
      <data key="d4">9.0</data>
      <data key="d5">IGF2 encodes Insulin-Like Growth Factor 2</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="IGHD" target="IMMUNOGLOBULIN HEAVY CONSTANT &#916;">
      <data key="d4">9.0</data>
      <data key="d5">IGHD encodes Immunoglobulin Heavy Constant &#948;</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="IGHG3" target="IMMUNOGLOBULIN HEAVY CONSTANT &#915;3">
      <data key="d4">9.0</data>
      <data key="d5">IGHG3 encodes Immunoglobulin Heavy Constant &#947;3</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="IGKV1D-13" target="IMMUNOGLOBULIN &#922; VARIABLE 1D-13">
      <data key="d4">9.0</data>
      <data key="d5">IGKV1D-13 encodes Immunoglobulin &#954; Variable 1D-13</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="IGLV" target="IMMUNOGLOBULIN &#923; VARIABLE CLUSTER">
      <data key="d4">9.0</data>
      <data key="d5">IGLV encodes Immunoglobulin &#955; Variable Cluster</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="IL1A" target="INTERLEUKIN 1&#913;">
      <data key="d4">9.0</data>
      <data key="d5">IL1A encodes Interleukin 1&#945;</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="ACNE" target="BARICITINIB">
      <data key="d4">2.0</data>
      <data key="d5">There was no increase in acne under baricitinib</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="IL1B" target="INTERLEUKIN 1&#914;">
      <data key="d4">9.0</data>
      <data key="d5">IL1B encodes Interleukin 1&#946;</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="IL1B" target="ANDROGRAPHOLIDE">
      <data key="d4">7.0</data>
      <data key="d5">Andrographolide inhibits IL1B</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="IL2" target="INTERLEUKIN 2">
      <data key="d4">9.0</data>
      <data key="d5">IL2 encodes Interleukin 2</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="RITUXIMAB" target="CD20">
      <data key="d4">16.0</data>
      <data key="d5">Rituximab targets CD20 on B cells</data>
      <data key="d6">b62ecc47bf54393bc78dd65986b949d6</data>
    </edge>
    <edge source="RITUXIMAB" target="SYSTEMIC SCLEROSIS">
      <data key="d4">8.0</data>
      <data key="d5">Rituximab is being tested for its efficacy in treating systemic sclerosis</data>
      <data key="d6">423195c6b63ad0a6773374364ebf3612</data>
    </edge>
    <edge source="IL2RA" target="INTERLEUKIN 2 RECEPTOR SUBUNIT &#913;">
      <data key="d4">9.0</data>
      <data key="d5">IL2RA encodes Interleukin 2 Receptor Subunit &#945;</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="IL4" target="INTERLEUKIN 4">
      <data key="d4">9.0</data>
      <data key="d5">IL4 encodes Interleukin 4</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="ALLERGIC RHINITIS" target="IL13">
      <data key="d4">8.0</data>
      <data key="d5">IL13 is associated with Allergic rhinitis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="ALLERGIC RHINITIS" target="AD">
      <data key="d4">13.0</data>
      <data key="d5">Allergic rhinitis is an atopic comorbidity of atopic dermatitis
Some patients with AD also have allergic rhinitis</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d,89dbac0da39e4de2b602052cd792b90d</data>
    </edge>
    <edge source="ALLERGIC RHINITIS" target="ATOPIC DERMATITIS">
      <data key="d4">15.0</data>
      <data key="d5">Allergic Rhinitis is a condition that children with Atopic Dermatitis may develop
Allergic Rhinitis is associated with Atopic Dermatitis</data>
      <data key="d6">691cb2e23ac3c6e591129d16714f8ef8,6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="FOOD ALLERGY" target="ATOPIC DERMATITIS">
      <data key="d4">7.0</data>
      <data key="d5">Food allergy is a comorbidity of AD</data>
      <data key="d6">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </edge>
    <edge source="DUPILUMAB" target="ATOPIC DERMATITIS">
      <data key="d4">49.0</data>
      <data key="d5">Dupilumab is used in the treatment of atopic dermatitis
Dupilumab is approved for the treatment of moderate-to-severe Atopic Dermatitis
Dupilumab is an IL-4Ra inhibitor approved for the treatment of AD
Dupilumab is used to target IL-4R&#945; in the treatment of atopic dermatitis
Dupilumab is a biologic agent targeting interleukin-4Ra in atopic dermatitis treatment</data>
      <data key="d6">1596d061dbe1a1c9e8f31a02a21e5524,3dfbb4c51838e0951f53ce951395225f,693a2aac101eaaadf92614317a1e4da8,e075bccd45593ae008b2ce7f9ed8ff6c,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="DUPILUMAB" target="IL-4R&#913;">
      <data key="d4">80.0</data>
      <data key="d5">IL-4R&#945; is the receptor subunit targeted by dupilumab in the treatment of atopic dermatitis
Dupilumab targets IL-4R&#945; in the treatment of Atopic Dermatitis
Dupilumab targets IL-4R&#945;
Dupilumab antagonizes IL-4R&#945;, blocking IL-4 and IL-13 signaling
Dupilumab targets IL-4R&#945;, showing clinical efficacy in atopic dermatitis
Dupilumab binds to IL-4R&#945;</data>
      <data key="d6">104cc78517b2eca2e9cb7e00de1fe4b0,48de7eebab3f3b418feb35a152df38fd,693a2aac101eaaadf92614317a1e4da8,78e26c66107dba37ac4bab65406b43a0,96e553a44a27e728c27c4892045ec5c2,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="DUPILUMAB" target="AD">
      <data key="d4">69.0</data>
      <data key="d5">Dupilumab is used to treat atopic dermatitis
Dupilumab is approved for the treatment of moderate-to-severe atopic dermatitis
Dupilumab is evaluated for the treatment of AD
Dupilumab has shown clinical efficacy in patients with atopic dermatitis
Dupilumab is approved for atopic dermatitis
Dupilumab is used in the treatment of atopic dermatitis</data>
      <data key="d6">104cc78517b2eca2e9cb7e00de1fe4b0,78e26c66107dba37ac4bab65406b43a0,96e553a44a27e728c27c4892045ec5c2,a867a1e73cef039eb3f28e072463b838,dc905ba8b6eb7d84cf2776303211010d,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="DUPILUMAB" target="FDA">
      <data key="d4">27.0</data>
      <data key="d5">Dupilumab is approved by the FDA for the treatment of atopic dermatitis
The FDA approved dupilumab for AD treatment</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c,dc905ba8b6eb7d84cf2776303211010d</data>
    </edge>
    <edge source="DUPILUMAB" target="IL-13R&#913;1">
      <data key="d4">16.0</data>
      <data key="d5">Dupilumab blocks IL-13 signaling through the type 2 receptor, which involves IL-13R&#945;1</data>
      <data key="d6">96e553a44a27e728c27c4892045ec5c2</data>
    </edge>
    <edge source="DUPILUMAB" target="SOLO 1">
      <data key="d4">16.0</data>
      <data key="d5">SOLO 1 is a clinical trial of Dupilumab</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="DUPILUMAB" target="SOLO 2">
      <data key="d4">16.0</data>
      <data key="d5">SOLO 2 is a clinical trial of Dupilumab</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="DUPILUMAB" target="CHRONOS">
      <data key="d4">16.0</data>
      <data key="d5">CHRONOS is a clinical trial of Dupilumab</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="DUPILUMAB" target="CONJUNCTIVITIS">
      <data key="d4">1.0</data>
      <data key="d5">Dupilumab can cause conjunctivitis as a side effect</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="DUPILUMAB" target="PHASE III PROGRAMME">
      <data key="d4">9.0</data>
      <data key="d5">Dupilumab's efficacy was supported by real-world data in the phase III programme</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="DUPILUMAB" target="EYE DISORDERS">
      <data key="d4">21.0</data>
      <data key="d5">Dupilumab caused eye disorders in 11% of patients
Dupilumab is associated with the development of eye disorders</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41,78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="DUPILUMAB" target="CHILDREN">
      <data key="d4">9.0</data>
      <data key="d5">Dupilumab is approved for children aged 6 years and older</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="DUPILUMAB" target="ADULTS">
      <data key="d4">9.0</data>
      <data key="d5">Dupilumab's efficacy was supported in adults</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="DUPILUMAB" target="PATIENTS">
      <data key="d4">9.0</data>
      <data key="d5">Dupilumab is used to treat patients with atopic dermatitis</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="DUPILUMAB" target="USA">
      <data key="d4">8.0</data>
      <data key="d5">Dupilumab is being studied in the USA</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="DUPILUMAB" target="EU">
      <data key="d4">1.0</data>
      <data key="d5">Dupilumab is being studied in the EU</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="DUPILUMAB" target="NASAL POLYPOSIS">
      <data key="d4">2.0</data>
      <data key="d5">Dupilumab is approved for the treatment of nasal polyposis</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41</data>
    </edge>
    <edge source="DUPILUMAB" target="ITCH">
      <data key="d4">16.0</data>
      <data key="d5">Dupilumab improves itch by targeting IL-4 and IL-13</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="DUPILUMAB" target="NERVE ENDINGS">
      <data key="d4">7.0</data>
      <data key="d5">Dupilumab affects nerve endings</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="DUPILUMAB" target="JAK">
      <data key="d4">16.0</data>
      <data key="d5">Dupilumab regulates the JAK/STAT pathway and inhibits JAK</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="DUPILUMAB" target="IL-4R">
      <data key="d4">9.0</data>
      <data key="d5">Dupilumab targets IL-4R and is used for treating AD</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </edge>
    <edge source="DUPILUMAB" target="IL-4RA">
      <data key="d4">18.0</data>
      <data key="d5">Dupilumab targets IL-4Ra</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="DUPILUMAB" target="SANOFI">
      <data key="d4">14.0</data>
      <data key="d5">Sanofi produces dupilumab</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="DUPILUMAB" target="REGENERON">
      <data key="d4">14.0</data>
      <data key="d5">Regeneron produces dupilumab</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="IL10" target="INTERLEUKIN 10">
      <data key="d4">1.0</data>
      <data key="d5">IL10 encodes Interleukin 10</data>
      <data key="d6">cdfcc39154accbac074c924676dc701e</data>
    </edge>
    <edge source="IL10" target="NICOTINAMIDE">
      <data key="d4">7.0</data>
      <data key="d5">Nicotinamide is involved in the regulation of IL10</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL10" target="NIACIN">
      <data key="d4">7.0</data>
      <data key="d5">Niacin is involved in the regulation of IL10</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL10" target="CYCLOSPORINE A">
      <data key="d4">8.0</data>
      <data key="d5">Cyclosporine A is involved in the regulation of IL10</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="NICOTINAMIDE" target="TACROLIMUS">
      <data key="d4">14.0</data>
      <data key="d5">Tacrolimus and Nicotinamide are used together in nanotechnology-based therapeutic approaches</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </edge>
    <edge source="CYCLOSPORINE" target="AD">
      <data key="d4">7.0</data>
      <data key="d5">Cyclosporine is used in systemic therapy for AD</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </edge>
    <edge source="CYCLOSPORINE A" target="ATOPIC DERMATITIS">
      <data key="d4">6.0</data>
      <data key="d5">Cyclosporine A is an immunosuppressant used in the systemic treatment of Atopic Dermatitis</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="CYCLOSPORINE A" target="AD">
      <data key="d4">14.0</data>
      <data key="d5">Cyclosporine A is used to treat AD</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="CYCLOSPORINE A" target="HEADACHES">
      <data key="d4">12.0</data>
      <data key="d5">Headaches are a side effect of cyclosporine A</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="CYCLOSPORINE A" target="NEPHROTOXICITY">
      <data key="d4">12.0</data>
      <data key="d5">Nephrotoxicity is a side effect of cyclosporine A</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="CYCLOSPORINE A" target="HYPERTENSION">
      <data key="d4">12.0</data>
      <data key="d5">Hypertension is a side effect of cyclosporine A</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="CYCLOSPORINE A" target="TACROLIMUS">
      <data key="d4">14.0</data>
      <data key="d5">Cyclosporine A and Tacrolimus are used together in nanotechnology-based therapeutic approaches</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </edge>
    <edge source="METHOTREXATE" target="ATOPIC DERMATITIS">
      <data key="d4">14.0</data>
      <data key="d5">Methotrexate is an immunosuppressant used in the systemic treatment of Atopic Dermatitis
Methotrexate is used to treat severe forms of AD</data>
      <data key="d6">1596d061dbe1a1c9e8f31a02a21e5524,693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="METHOTREXATE" target="AD">
      <data key="d4">21.0</data>
      <data key="d5">Methotrexate is used to treat AD
Methotrexate is used in systemic therapy for AD</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd,48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="METHOTREXATE" target="ANAEMIA">
      <data key="d4">12.0</data>
      <data key="d5">Anaemia is a side effect of methotrexate</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="METHOTREXATE" target="LEUKOPENIA">
      <data key="d4">12.0</data>
      <data key="d5">Leukopenia is a side effect of methotrexate</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="METHOTREXATE" target="HEPATOTOXICITY">
      <data key="d4">2.0</data>
      <data key="d5">Hepatotoxicity is a side effect of methotrexate</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="METHOTREXATE" target="T CELLS">
      <data key="d4">16.0</data>
      <data key="d5">Methotrexate targets T cells in the skin</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="METHOTREXATE" target="CYTOKINES">
      <data key="d4">14.0</data>
      <data key="d5">Methotrexate modifies cytokines</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="METHOTREXATE" target="MONOCYTES">
      <data key="d4">14.0</data>
      <data key="d5">Methotrexate calms down hyperactive monocytes</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="MYCOPHENOLATE MOFETIL" target="ATOPIC DERMATITIS">
      <data key="d4">8.0</data>
      <data key="d5">Mycophenolate mofetil is used to treat severe forms of AD</data>
      <data key="d6">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </edge>
    <edge source="MYCOPHENOLATE MOFETIL" target="SSC">
      <data key="d4">14.0</data>
      <data key="d5">Mycophenolate mofetil is used as a standard therapy drug in SSc</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="MYCOPHENOLATE MOFETIL" target="SYSTEMIC SCLEROSIS">
      <data key="d4">1.0</data>
      <data key="d5">Mycophenolate Mofetil is used in the treatment of Systemic Sclerosis</data>
      <data key="d6">8e5a1be9981340d419f7b3ad27076009</data>
    </edge>
    <edge source="IL12A" target="ADAMANTIADES&#8211;BEH&#199;ET&#8217;S DISEASE">
      <data key="d4">7.0</data>
      <data key="d5">IL12A is associated with Adamantiades&#8211;Beh&#231;et&#8217;s disease</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL12A" target="PRIMARY BILIARY CHOLANGIITIS">
      <data key="d4">7.0</data>
      <data key="d5">IL12A is associated with Primary biliary cholangiitis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="USTEKINUMAB" target="FSH">
      <data key="d4">7.0</data>
      <data key="d5">Ustekinumab targets FSH</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="USTEKINUMAB" target="HCG">
      <data key="d4">7.0</data>
      <data key="d5">Ustekinumab targets HCG</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="USTEKINUMAB" target="LH">
      <data key="d4">7.0</data>
      <data key="d5">Ustekinumab targets LH</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="USTEKINUMAB" target="LTA4H">
      <data key="d4">7.0</data>
      <data key="d5">Ustekinumab targets LTA4H</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="USTEKINUMAB" target="IL-12">
      <data key="d4">8.0</data>
      <data key="d5">Ustekinumab targets IL-12 to treat moderate-to-severe atopic dermatitis</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </edge>
    <edge source="USTEKINUMAB" target="IL-23">
      <data key="d4">8.0</data>
      <data key="d5">Ustekinumab targets IL-23 to treat moderate-to-severe atopic dermatitis</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </edge>
    <edge source="IL12B" target="PSORIASIS">
      <data key="d4">8.0</data>
      <data key="d5">IL12B is associated with Psoriasis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="PSORIASIS" target="IL19">
      <data key="d4">8.0</data>
      <data key="d5">IL19 is associated with Psoriasis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="PSORIASIS" target="IL20">
      <data key="d4">8.0</data>
      <data key="d5">IL20 is associated with Psoriasis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="PSORIASIS" target="IL24">
      <data key="d4">8.0</data>
      <data key="d5">IL24 is associated with Psoriasis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="PSORIASIS" target="IL26">
      <data key="d4">8.0</data>
      <data key="d5">IL26 is associated with Psoriasis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="PSORIASIS" target="LCE3D">
      <data key="d4">1.0</data>
      <data key="d5">LCE3D is associated with Psoriasis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="PSORIASIS" target="AD">
      <data key="d4">26.0</data>
      <data key="d5">RNA-Seq data from psoriasis and AD were obtained for analysis
Psoriasis has biomarkers indicative of disease progression similar to AD</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c,b28eeca0ff01a7715947d55a04978a43</data>
    </edge>
    <edge source="PSORIASIS" target="SECUKINUMAB">
      <data key="d4">9.0</data>
      <data key="d5">Secukinumab is FDA-approved for the treatment of moderate-to-severe plaque psoriasis</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </edge>
    <edge source="PSORIASIS" target="TAPINAROF">
      <data key="d4">16.0</data>
      <data key="d5">Tapinarof reduces inflammatory responses in psoriasis
Tapinarof decreases inflammatory reactions in psoriasis</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="PSORIASIS" target="LY3471851">
      <data key="d4">1.0</data>
      <data key="d5">LY3471851 is investigated for the treatment of Psoriasis</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="PSORIASIS" target="RHIL-2">
      <data key="d4">7.0</data>
      <data key="d5">Recombinant human IL-2 (rhIL-2) is being tested for its potential to restore tolerance and improve psoriasis</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="PSORIASIS" target="AKP-11">
      <data key="d4">7.0</data>
      <data key="d5">AKP-11 is in clinical development for psoriasis</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9</data>
    </edge>
    <edge source="PSORIASIS" target="PHASE I TRIAL">
      <data key="d4">6.0</data>
      <data key="d5">Phase I trial generated promising results for psoriasis</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="PSORIASIS" target="IL-36R">
      <data key="d4">7.0</data>
      <data key="d5">IL-36R is increased in psoriasis</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="PSORIASIS" target="SPESOLIMAB">
      <data key="d4">8.0</data>
      <data key="d5">Spesolimab is effective in treating a rare type of psoriasis</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="PSORIASIS" target="IL-22">
      <data key="d4">7.0</data>
      <data key="d5">IL-22 is involved in inflammation and immune response in psoriasis</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="PSORIASIS" target="IL-31">
      <data key="d4">7.0</data>
      <data key="d5">IL-31 is involved in inflammation and immune response in psoriasis</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="PSORIASIS" target="IL-37">
      <data key="d4">1.0</data>
      <data key="d5">IL-37 is involved in inflammation and immune response in psoriasis</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="PSORIASIS" target="NANOTECHNOLOGY">
      <data key="d4">7.0</data>
      <data key="d5">Nanotechnology offers a method for treating psoriasis</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="IL13" target="PENICILLIN ALLERGY">
      <data key="d4">8.0</data>
      <data key="d5">IL13 is associated with Penicillin allergy</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="OMALIZUMAB" target="IGE">
      <data key="d4">26.0</data>
      <data key="d5">Omalizumab is a monoclonal antibody targeting IgE
Omalizumab targets IgE
Omalizumab targets IgE to treat allergic conditions</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41,48288f3ec2832850282f95d4e38d10e1,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="OMALIZUMAB" target="AD">
      <data key="d4">8.0</data>
      <data key="d5">Omalizumab has shown clinical benefits in selected patients with atopic dermatitis</data>
      <data key="d6">104cc78517b2eca2e9cb7e00de1fe4b0</data>
    </edge>
    <edge source="OMALIZUMAB" target="ATOPIC DERMATITIS">
      <data key="d4">15.0</data>
      <data key="d5">Omalizumab is used in the treatment of Atopic Dermatitis
Omalizumab is used to target IgE in the treatment of atopic dermatitis</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="OMALIZUMAB" target="CLINICAL IMPROVEMENT">
      <data key="d4">8.0</data>
      <data key="d5">Omalizumab showed clinical improvement in patients</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="OMALIZUMAB" target="QUALITY OF LIFE">
      <data key="d4">1.0</data>
      <data key="d5">Omalizumab improved quality of life in patients</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="OMALIZUMAB" target="JAK">
      <data key="d4">16.0</data>
      <data key="d5">Omalizumab regulates the JAK/STAT pathway and inhibits JAK</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="OMALIZUMAB" target="IMMUNOGLOBULIN E">
      <data key="d4">8.0</data>
      <data key="d5">Omalizumab targets Immunoglobulin E</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </edge>
    <edge source="IL16" target="ALLERGIC ASTHMA">
      <data key="d4">7.0</data>
      <data key="d5">IL16 is associated with Allergic asthma</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="ALLERGIC ASTHMA" target="ATOPIC DERMATITIS">
      <data key="d4">7.0</data>
      <data key="d5">Allergic asthma is a comorbidity of AD</data>
      <data key="d6">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </edge>
    <edge source="ALLERGIC ASTHMA" target="MEPOLIZUMAB">
      <data key="d4">8.0</data>
      <data key="d5">Mepolizumab is used to treat allergic asthma</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d</data>
    </edge>
    <edge source="ALLERGIC ASTHMA" target="AEROALLERGENS">
      <data key="d4">7.0</data>
      <data key="d5">Aeroallergens can trigger allergic asthma</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIMEKIZUMAB" target="IL17F">
      <data key="d4">14.0</data>
      <data key="d5">Bimekizumab inhibits IL17F</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="BRODALUMAB" target="IL17R">
      <data key="d4">14.0</data>
      <data key="d5">Brodalumab inhibits IL17R</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="BRODALUMAB" target="KRT6A">
      <data key="d4">14.0</data>
      <data key="d5">Brodalumab targets KRT6A</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="IL17F" target="CANDIDIASIS">
      <data key="d4">8.0</data>
      <data key="d5">IL17F is associated with Candidiasis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL17F" target="ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS">
      <data key="d4">8.0</data>
      <data key="d5">IL17F is associated with Acute generalized exanthematous pustulosis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL17F" target="MAIL DISEASES">
      <data key="d4">7.0</data>
      <data key="d5">IL17F is associated with Mail diseases</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="CANDIDIASIS" target="IL17R">
      <data key="d4">7.0</data>
      <data key="d5">IL17R is associated with Candidiasis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="CANDIDIASIS" target="IL22">
      <data key="d4">7.0</data>
      <data key="d5">IL22 is associated with Candidiasis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL22RA1" target="SPONDYLOARTHROPATHY">
      <data key="d4">7.0</data>
      <data key="d5">IL22RA1 is associated with Spondyloarthropathy</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL22RA1" target="AUTOIMMUNE UVEITIS">
      <data key="d4">7.0</data>
      <data key="d5">IL22RA1 is associated with Autoimmune uveitis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL23A" target="AUTOIMMUNE DISEASE">
      <data key="d4">8.0</data>
      <data key="d5">IL23A is associated with Autoimmune disease</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL24" target="CHRONIC SPONTANEOUS URTICARIA">
      <data key="d4">7.0</data>
      <data key="d5">IL24 is associated with Chronic spontaneous urticaria</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="IL24" target="SPONDYLARTHROPATHY">
      <data key="d4">7.0</data>
      <data key="d5">IL24 is associated with Spondylarthropathy</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="JAK3" target="NK CELL ENTEROPATHY">
      <data key="d4">7.0</data>
      <data key="d5">JAK3 is associated with NK cell enteropathy</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="JAK3" target="AG-490">
      <data key="d4">8.0</data>
      <data key="d5">AG-490 inhibits JAK3</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK3" target="ATRACTYLENOLIDE-I">
      <data key="d4">7.0</data>
      <data key="d5">Atractylenolide-I inhibits JAK3</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK3" target="AZD1480">
      <data key="d4">7.0</data>
      <data key="d5">AZD1480 inhibits JAK3</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK3" target="BMS-911543">
      <data key="d4">7.0</data>
      <data key="d5">BMS-911543 inhibits JAK3</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK3" target="CURCUMOL">
      <data key="d4">7.0</data>
      <data key="d5">Curcumol inhibits JAK3</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK3" target="CYT387">
      <data key="d4">7.0</data>
      <data key="d5">Cyt387 inhibits JAK3</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK3" target="DELGOCITINIB">
      <data key="d4">7.0</data>
      <data key="d5">Delgocitinib inhibits JAK3</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK3" target="FEDRATINIB">
      <data key="d4">7.0</data>
      <data key="d5">Fedratinib inhibits JAK3</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK3" target="UPADACITINIB">
      <data key="d4">16.0</data>
      <data key="d5">Upadacitinib inhibits JAK3</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="JAK3" target="WHI-P154">
      <data key="d4">14.0</data>
      <data key="d5">WHI-P154 inhibits JAK3</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="JAK3" target="XL019">
      <data key="d4">12.0</data>
      <data key="d5">XL019 inhibits JAK3</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="JAK3" target="JAK FAMILY">
      <data key="d4">16.0</data>
      <data key="d5">JAK3 is a member of the JAK family of tyrosine kinases</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="JAK3" target="ATI-1777">
      <data key="d4">8.0</data>
      <data key="d5">ATI-1777 targets JAK3</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="RUXOLITINIB" target="ATOPIC DERMATITIS">
      <data key="d4">16.0</data>
      <data key="d5">Ruxolitinib is used in the treatment of atopic dermatitis</data>
      <data key="d6">e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="RUXOLITINIB" target="AD">
      <data key="d4">16.0</data>
      <data key="d5">Ruxolitinib is used for treating atopic dermatitis</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="RUXOLITINIB" target="VITILIGO">
      <data key="d4">14.0</data>
      <data key="d5">Ruxolitinib has potential for treating vitiligo</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="RUXOLITINIB" target="CUTANEOUS LUPUS">
      <data key="d4">14.0</data>
      <data key="d5">Ruxolitinib has potential for treating cutaneous lupus</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="RUXOLITINIB" target="JAK1">
      <data key="d4">16.0</data>
      <data key="d5">Ruxolitinib targets JAK1
Ruxolitinib targets JAK1</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5,f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="RUXOLITINIB" target="JAK2">
      <data key="d4">8.0</data>
      <data key="d5">Ruxolitinib targets JAK2</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="RUXOLITINIB" target="NCT03745638">
      <data key="d4">7.0</data>
      <data key="d5">NCT03745638 is a clinical trial involving Ruxolitinib</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="RUXOLITINIB" target="NCT03745651">
      <data key="d4">7.0</data>
      <data key="d5">NCT03745651 is a clinical trial involving Ruxolitinib</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="RUXOLITINIB" target="JAK">
      <data key="d4">14.0</data>
      <data key="d5">Ruxolitinib is a selective JAK inhibitor</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="RUXOLITINIB" target="OPZELURA">
      <data key="d4">14.0</data>
      <data key="d5">Ruxolitinib is the active ingredient in Opzelura</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="CERDULATINIB" target="AD">
      <data key="d4">16.0</data>
      <data key="d5">Cerdulatinib is used for treating atopic dermatitis</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="CERDULATINIB" target="SYK">
      <data key="d4">24.0</data>
      <data key="d5">Cerdulatinib targets SYK
Cerdulatinib targets SYK</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e,f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="CERDULATINIB" target="PAN-JAK">
      <data key="d4">8.0</data>
      <data key="d5">Cerdulatinib targets Pan-JAK</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="CERDULATINIB" target="JAK">
      <data key="d4">14.0</data>
      <data key="d5">Cerdulatinib is a selective JAK inhibitor</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="CERDULATINIB" target="JAK1">
      <data key="d4">8.0</data>
      <data key="d5">Cerdulatinib targets JAK1</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </edge>
    <edge source="DELGOCITINIB" target="JAK2">
      <data key="d4">7.0</data>
      <data key="d5">Delgocitinib inhibits JAK2</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="DELGOCITINIB" target="JAK1">
      <data key="d4">15.0</data>
      <data key="d5">Delgocitinib inhibits JAK1
Delgocitinib targets JAK1</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d,cccfd5ff480e281556e2210cd0e5c4b5</data>
    </edge>
    <edge source="DELGOCITINIB" target="AD">
      <data key="d4">30.0</data>
      <data key="d5">Delgocitinib is used for treating atopic dermatitis
Delgocitinib is a JAK inhibitor that was under clinical development for Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b,c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="DELGOCITINIB" target="CHRONIC HAND ECZEMA">
      <data key="d4">14.0</data>
      <data key="d5">Delgocitinib is being developed for treating chronic hand eczema</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="DELGOCITINIB" target="JAPAN">
      <data key="d4">12.0</data>
      <data key="d5">Japan is a country where delgocitinib was approved for Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="DELGOCITINIB" target="PAN-JAK">
      <data key="d4">8.0</data>
      <data key="d5">Delgocitinib targets Pan-JAK</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="DELGOCITINIB" target="NCT03725722">
      <data key="d4">7.0</data>
      <data key="d5">NCT03725722 is a clinical trial involving Delgocitinib</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="DELGOCITINIB" target="JAK">
      <data key="d4">14.0</data>
      <data key="d5">Delgocitinib is a JAK inhibitor</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="DELGOCITINIB" target="TYK2">
      <data key="d4">14.0</data>
      <data key="d5">Delgocitinib is a TYK2 inhibitor</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="KRT6A" target="LINGUA PLICATA">
      <data key="d4">7.0</data>
      <data key="d5">KRT6A is associated with Lingua plicata</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="KRT6A" target="CHEILITIS">
      <data key="d4">7.0</data>
      <data key="d5">KRT6A is associated with Cheilitis</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="KRT16" target="PALMOPLANTAR KERATODERMA">
      <data key="d4">7.0</data>
      <data key="d5">KRT16 is associated with Palmoplantar keratoderma</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="KRT16" target="ACITRETIN">
      <data key="d4">14.0</data>
      <data key="d5">Acitretin targets KRT16</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="KRT77" target="EPIDERMOLYTIC PALMOPLANTAR KERATODERMA">
      <data key="d4">7.0</data>
      <data key="d5">KRT77 is associated with Epidermolytic palmoplantar keratoderma</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="KRT77" target="BUSCHKE-OLLENDORFF SYNDROME">
      <data key="d4">7.0</data>
      <data key="d5">KRT77 is associated with Buschke-Ollendorff syndrome</data>
      <data key="d6">573fb6fa0673eb9462aa9862888079f3</data>
    </edge>
    <edge source="MMP1" target="APRATASTAT">
      <data key="d4">7.0</data>
      <data key="d5">Apratastat inhibits MMP1</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="MMP1" target="DOXYCYCLINE">
      <data key="d4">14.0</data>
      <data key="d5">Doxycycline inhibits MMP1</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="MMP9" target="APRATASTAT">
      <data key="d4">7.0</data>
      <data key="d5">Apratastat inhibits MMP9</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="MMP12" target="AD">
      <data key="d4">8.0</data>
      <data key="d5">MMP12 is involved in the immune response in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="NERVE GROWTH FACTOR" target="TROPOMYOSIN RECEPTOR KINASE">
      <data key="d4">7.0</data>
      <data key="d5">Nerve growth factor is involved in pathways related to inflammation in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="PI3" target="3,3&#8217;-DIINDOLYLMETHANE">
      <data key="d4">6.0</data>
      <data key="d5">3,3&#8217;-Diindolylmethane regulates PI3</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="PI3" target="ACITRETIN">
      <data key="d4">14.0</data>
      <data key="d5">Acitretin targets PI3</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="PI3" target="DOXYCYCLINE">
      <data key="d4">14.0</data>
      <data key="d5">Doxycycline targets PI3</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="PI3" target="AD">
      <data key="d4">8.0</data>
      <data key="d5">PI3 is involved in the immune response in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="PSORIATIC ARTHRITIS" target="TNIP1">
      <data key="d4">14.0</data>
      <data key="d5">TNIP1 is associated with psoriatic arthritis</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="PSORIATIC ARTHRITIS" target="SECUKINUMAB">
      <data key="d4">9.0</data>
      <data key="d5">Secukinumab is FDA-approved for the treatment of active psoriatic arthritis</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </edge>
    <edge source="TNFRSF4" target="OX-40 LIGAND">
      <data key="d4">18.0</data>
      <data key="d5">TNFRSF4 encodes the receptor for OX-40 ligand</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="TNFSF11" target="AUTOIMMUNE DISEASES">
      <data key="d4">14.0</data>
      <data key="d5">TNFSF11 is associated with autoimmune diseases</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="TNFSF13" target="AUTOIMMUNE DISEASES">
      <data key="d4">14.0</data>
      <data key="d5">TNFSF13 is associated with autoimmune diseases</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="AUTOIMMUNE DISEASES" target="TNFSF13B">
      <data key="d4">14.0</data>
      <data key="d5">TNFSF13B is associated with autoimmune diseases</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="AUTOIMMUNE DISEASES" target="WIF1">
      <data key="d4">14.0</data>
      <data key="d5">WIF1 is associated with autoimmune diseases</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="AUTOIMMUNE DISEASES" target="TNFSF4">
      <data key="d4">1.0</data>
      <data key="d5">TNFSF4 is a shared gene in multiple autoimmune diseases</data>
      <data key="d6">7b454335c2f5651d86f712037a0dc0ff</data>
    </edge>
    <edge source="TNFSF13B" target="SIALADENITIS">
      <data key="d4">14.0</data>
      <data key="d5">TNFSF13B is associated with sialadenitis</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="TNFSF13B" target="SJOGREN SYNDROME">
      <data key="d4">14.0</data>
      <data key="d5">TNFSF13B is associated with Sjogren syndrome</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="TNFSF13B" target="BAFF">
      <data key="d4">9.0</data>
      <data key="d5">BAFF is encoded by the TNFSF13B gene</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </edge>
    <edge source="BELIMUMAB" target="MULTIPLE SCLEROSIS">
      <data key="d4">8.0</data>
      <data key="d5">Belimumab is being tested for its efficacy in treating multiple sclerosis</data>
      <data key="d6">423195c6b63ad0a6773374364ebf3612</data>
    </edge>
    <edge source="BELIMUMAB" target="RELAPSING-REMITTING MULTIPLE SCLEROSIS">
      <data key="d4">8.0</data>
      <data key="d5">Belimumab is being tested for its efficacy in treating relapsing-remitting multiple sclerosis</data>
      <data key="d6">423195c6b63ad0a6773374364ebf3612</data>
    </edge>
    <edge source="BELIMUMAB" target="CHRONIC OBSTRUCTIVE PULMONARY DISEASE">
      <data key="d4">7.0</data>
      <data key="d5">Belimumab is being tested for its efficacy in treating chronic obstructive pulmonary disease</data>
      <data key="d6">423195c6b63ad0a6773374364ebf3612</data>
    </edge>
    <edge source="BELIMUMAB" target="EMPHYSEMA">
      <data key="d4">7.0</data>
      <data key="d5">Belimumab is being tested for its efficacy in treating emphysema</data>
      <data key="d6">423195c6b63ad0a6773374364ebf3612</data>
    </edge>
    <edge source="BELIMUMAB" target="JOHNS HOPKINS UNIVERSITY">
      <data key="d4">7.0</data>
      <data key="d5">Johns Hopkins University is involved in the clinical testing of Belimumab</data>
      <data key="d6">423195c6b63ad0a6773374364ebf3612</data>
    </edge>
    <edge source="BELIMUMAB" target="GLAXOSMITHKLINE">
      <data key="d4">8.0</data>
      <data key="d5">GlaxoSmithKline is developing Belimumab</data>
      <data key="d6">423195c6b63ad0a6773374364ebf3612</data>
    </edge>
    <edge source="BELIMUMAB" target="HOSPITAL FOR SPECIAL SURGERY, NEW YORK">
      <data key="d4">7.0</data>
      <data key="d5">Hospital for Special Surgery, New York is involved in the clinical testing of Belimumab</data>
      <data key="d6">423195c6b63ad0a6773374364ebf3612</data>
    </edge>
    <edge source="BELIMUMAB" target="UNIVERSITY OF ALABAMA AT BIRMINGHAM">
      <data key="d4">7.0</data>
      <data key="d5">University of Alabama at Birmingham is involved in the clinical testing of Belimumab</data>
      <data key="d6">423195c6b63ad0a6773374364ebf3612</data>
    </edge>
    <edge source="BELIMUMAB" target="SYSTEMIC SCLEROSIS">
      <data key="d4">8.0</data>
      <data key="d5">Belimumab is used in the treatment of Systemic Sclerosis</data>
      <data key="d6">8e5a1be9981340d419f7b3ad27076009</data>
    </edge>
    <edge source="BELIMUMAB" target="BAFF">
      <data key="d4">18.0</data>
      <data key="d5">Belimumab inhibits BAFF</data>
      <data key="d6">0c7502a2bfe653785647d754ed10f4e3</data>
    </edge>
    <edge source="BLISIBIMOD" target="IGA NEPHROPATHY">
      <data key="d4">8.0</data>
      <data key="d5">Blisibimod is used in the treatment of IgA Nephropathy</data>
      <data key="d6">8e5a1be9981340d419f7b3ad27076009</data>
    </edge>
    <edge source="TNFSF14" target="HERPES SIMPLEX">
      <data key="d4">14.0</data>
      <data key="d5">TNFSF14 is associated with herpes simplex</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="TNFSF14" target="LIGHT">
      <data key="d4">27.0</data>
      <data key="d5">TNFSF14 is the gene encoding LIGHT
LIGHT is encoded by the TNFSF14 gene</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a,df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="TNFSF14" target="FIBROBLASTS">
      <data key="d4">8.0</data>
      <data key="d5">TNFSF14 can act on fibroblasts to drive pro-fibrotic and anti-fibrotic effects</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="TNFSF14" target="MACROPHAGES">
      <data key="d4">8.0</data>
      <data key="d5">TNFSF14 can act on macrophages to drive pro-fibrotic and anti-fibrotic effects</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="TNFSF14" target="SMOOTH MUSCLE CELLS">
      <data key="d4">8.0</data>
      <data key="d5">TNFSF14 can act on smooth muscle cells to drive pro-fibrotic and anti-fibrotic effects</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="TNFSF14" target="GRANULOCYTES">
      <data key="d4">8.0</data>
      <data key="d5">TNFSF14 can act on granulocytes to drive pro-fibrotic and anti-fibrotic effects</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="HERPES SIMPLEX" target="BARICITINIB">
      <data key="d4">12.0</data>
      <data key="d5">Herpes simplex infections were more frequent in patients treated with baricitinib</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="TNIP1" target="SYSTEMIC LUPUS ERYTHEMATOSUS">
      <data key="d4">14.0</data>
      <data key="d5">TNIP1 is associated with systemic lupus erythematosus</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="SYSTEMIC LUPUS ERYTHEMATOSUS" target="LY3471851">
      <data key="d4">7.0</data>
      <data key="d5">LY3471851 is investigated for the treatment of Systemic Lupus Erythematosus</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="SYSTEMIC LUPUS ERYTHEMATOSUS" target="RHIL-2">
      <data key="d4">7.0</data>
      <data key="d5">Recombinant human IL-2 (rhIL-2) is being tested for its potential to restore tolerance and improve systemic lupus erythematosus</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="3,3&#8217;-DIINDOLYLMETHANE" target="HIF1A">
      <data key="d4">12.0</data>
      <data key="d5">3,3&#8217;-Diindolylmethane regulates HIF1A</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="AG-490" target="JAK2">
      <data key="d4">8.0</data>
      <data key="d5">AG-490 inhibits JAK2</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK2" target="ATRACTYLENOLIDE-I">
      <data key="d4">7.0</data>
      <data key="d5">Atractylenolide-I inhibits JAK2</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK2" target="AZD1480">
      <data key="d4">7.0</data>
      <data key="d5">AZD1480 inhibits JAK2</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK2" target="BMS-911543">
      <data key="d4">7.0</data>
      <data key="d5">BMS-911543 inhibits JAK2</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK2" target="CURCUMOL">
      <data key="d4">7.0</data>
      <data key="d5">Curcumol inhibits JAK2</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK2" target="CYT387">
      <data key="d4">7.0</data>
      <data key="d5">Cyt387 inhibits JAK2</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK2" target="FEDRATINIB">
      <data key="d4">7.0</data>
      <data key="d5">Fedratinib inhibits JAK2</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK2" target="FILGOTINIB">
      <data key="d4">7.0</data>
      <data key="d5">Filgotinib inhibits JAK2</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK2" target="UPADACITINIB">
      <data key="d4">16.0</data>
      <data key="d5">Upadacitinib inhibits JAK2</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="JAK2" target="WHI-P154">
      <data key="d4">14.0</data>
      <data key="d5">WHI-P154 inhibits JAK2</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="JAK2" target="XL019">
      <data key="d4">12.0</data>
      <data key="d5">XL019 inhibits JAK2</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="JAK2" target="BARICITINIB">
      <data key="d4">8.0</data>
      <data key="d5">JAK2 is targeted by baricitinib in the treatment of atopic dermatitis</data>
      <data key="d6">e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="JAK2" target="JAK FAMILY">
      <data key="d4">16.0</data>
      <data key="d5">JAK2 is a member of the JAK family of tyrosine kinases</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="JAK2" target="GM-CSF">
      <data key="d4">7.0</data>
      <data key="d5">GM-CSF signaling is dependent on JAK2</data>
      <data key="d6">a867a1e73cef039eb3f28e072463b838</data>
    </edge>
    <edge source="JAK2" target="G-CSF">
      <data key="d4">7.0</data>
      <data key="d5">G-CSF signaling is dependent on JAK2</data>
      <data key="d6">a867a1e73cef039eb3f28e072463b838</data>
    </edge>
    <edge source="JAK2" target="EPO">
      <data key="d4">7.0</data>
      <data key="d5">EPO signaling is dependent on JAK2</data>
      <data key="d6">a867a1e73cef039eb3f28e072463b838</data>
    </edge>
    <edge source="JAK2" target="JAK1">
      <data key="d4">7.0</data>
      <data key="d5">JAK1 and JAK2 are both part of the Janus kinase family involved in cytokine receptor signaling</data>
      <data key="d6">a867a1e73cef039eb3f28e072463b838</data>
    </edge>
    <edge source="JAK2" target="CYTOKINES">
      <data key="d4">7.0</data>
      <data key="d5">JAK2 is linked to the receptors of cytokines</data>
      <data key="d6">a867a1e73cef039eb3f28e072463b838</data>
    </edge>
    <edge source="JAK2" target="ANTITUMOUR DEFENCE">
      <data key="d4">6.0</data>
      <data key="d5">JAK2 is involved in mechanisms of antitumour defence</data>
      <data key="d6">a867a1e73cef039eb3f28e072463b838</data>
    </edge>
    <edge source="ANDROGRAPHOLIDE" target="NFKB1">
      <data key="d4">7.0</data>
      <data key="d5">Andrographolide inhibits NFKB1</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="ANDROGRAPHOLIDE" target="NFKB2">
      <data key="d4">7.0</data>
      <data key="d5">Andrographolide inhibits NFKB2</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="APRATASTAT" target="ADAM17">
      <data key="d4">7.0</data>
      <data key="d5">Apratastat inhibits ADAM17</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="APRATASTAT" target="MMP13">
      <data key="d4">7.0</data>
      <data key="d5">Apratastat inhibits MMP13</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="ADAM17" target="TNFR2">
      <data key="d4">7.0</data>
      <data key="d5">ADAM17 deficiency favors overactivation of TNFR2</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="ADAM17" target="STNF">
      <data key="d4">8.0</data>
      <data key="d5">ADAM17 cleaves mTNF to release sTNF</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="ADAM17" target="LDLR">
      <data key="d4">7.0</data>
      <data key="d5">ADAM17 deficiency in Ldlr-deficient mice favors atherosclerosis progression</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="ATRACTYLENOLIDE-I" target="JAK1">
      <data key="d4">7.0</data>
      <data key="d5">Atractylenolide-I inhibits JAK1</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK1" target="AZD1480">
      <data key="d4">7.0</data>
      <data key="d5">AZD1480 inhibits JAK1</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK1" target="BMS-911543">
      <data key="d4">7.0</data>
      <data key="d5">BMS-911543 inhibits JAK1</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK1" target="CURCUMOL">
      <data key="d4">7.0</data>
      <data key="d5">Curcumol inhibits JAK1</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK1" target="CYT387">
      <data key="d4">7.0</data>
      <data key="d5">Cyt387 inhibits JAK1</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK1" target="FEDRATINIB">
      <data key="d4">7.0</data>
      <data key="d5">Fedratinib inhibits JAK1</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK1" target="FILGOTINIB">
      <data key="d4">7.0</data>
      <data key="d5">Filgotinib inhibits JAK1</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="JAK1" target="UPADACITINIB">
      <data key="d4">41.0</data>
      <data key="d5">Upadacitinib inhibits JAK1
JAK1 is targeted by upadacitinib in the treatment of atopic dermatitis
Upadacitinib is an oral JAK1 inhibitor
Upadacitinib targets JAK1</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60,cccfd5ff480e281556e2210cd0e5c4b5,e075bccd45593ae008b2ce7f9ed8ff6c,e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="JAK1" target="WHI-P154">
      <data key="d4">14.0</data>
      <data key="d5">WHI-P154 inhibits JAK1</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="JAK1" target="XL019">
      <data key="d4">12.0</data>
      <data key="d5">XL019 inhibits JAK1</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="JAK1" target="INCB 54707">
      <data key="d4">12.0</data>
      <data key="d5">INCB 54707 inhibits JAK1</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="JAK1" target="ABROCITINIB">
      <data key="d4">16.0</data>
      <data key="d5">JAK1 is targeted by abrocitinib in the treatment of atopic dermatitis
Abrocitinib targets JAK1</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="JAK1" target="BARICITINIB">
      <data key="d4">8.0</data>
      <data key="d5">Baricitinib is an oral JAK1/JAK2 inhibitor</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="JAK1" target="PF-04965842">
      <data key="d4">8.0</data>
      <data key="d5">PF-04965842 is an oral JAK1 inhibitor</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="JAK1" target="JAK FAMILY">
      <data key="d4">16.0</data>
      <data key="d5">JAK1 is a member of the JAK family of tyrosine kinases</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="JAK1" target="BREPOCITINIB">
      <data key="d4">16.0</data>
      <data key="d5">Brepocitinib targets JAK1
Brepocitinib targets JAK1</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5,f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="JAK1" target="ATI-1777">
      <data key="d4">8.0</data>
      <data key="d5">ATI-1777 targets JAK1</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="JAK1" target="BACRICITINIB">
      <data key="d4">8.0</data>
      <data key="d5">Bacricitinib targets JAK1</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </edge>
    <edge source="JAK1" target="CIBINQO">
      <data key="d4">16.0</data>
      <data key="d5">Cibinqo inhibits JAK1</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="BALSALAZIDE" target="ALOX5">
      <data key="d4">7.0</data>
      <data key="d5">Balsalazide inhibits ALOX5</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="BALSALAZIDE" target="PPARG">
      <data key="d4">7.0</data>
      <data key="d5">Balsalazide inhibits PPARG</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="PPARG" target="CIGLITAZONE">
      <data key="d4">6.0</data>
      <data key="d5">Ciglitazone regulates PPARG</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="CIGLITAZONE" target="GPD1">
      <data key="d4">6.0</data>
      <data key="d5">Ciglitazone regulates GPD1</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="CIGLITAZONE" target="TBXA2R">
      <data key="d4">6.0</data>
      <data key="d5">Ciglitazone regulates TBXA2R</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="FEDRATINIB" target="BRD4">
      <data key="d4">7.0</data>
      <data key="d5">Fedratinib inhibits BRD4</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="FEDRATINIB" target="TYK2">
      <data key="d4">7.0</data>
      <data key="d5">Fedratinib inhibits TYK2</data>
      <data key="d6">62b4bd8f530adae989e4349d1e58f11d</data>
    </edge>
    <edge source="TYK2" target="JAK FAMILY">
      <data key="d4">9.0</data>
      <data key="d5">TYK2 is a member of the JAK family of tyrosine kinases</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="TYK2" target="BREPOCITINIB">
      <data key="d4">8.0</data>
      <data key="d5">Brepocitinib targets TYK2</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="NR1I2" target="RIFAMPICIN">
      <data key="d4">7.0</data>
      <data key="d5">Rifampicin targets NR1I2</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="UPADACITINIB" target="ATOPIC DERMATITIS">
      <data key="d4">24.0</data>
      <data key="d5">Upadacitinib is used in the treatment of atopic dermatitis
Upadacitinib is a Janus kinase (JAK) inhibitor used as a targeted therapy for Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="UPADACITINIB" target="NCT02925117">
      <data key="d4">8.0</data>
      <data key="d5">NCT02925117 is a phase 2b trial for upadacitinib in AD</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="UPADACITINIB" target="NCT03569293">
      <data key="d4">8.0</data>
      <data key="d5">NCT03569293 is a phase 3 trial for upadacitinib monotherapy in AD</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="UPADACITINIB" target="NCT03607422">
      <data key="d4">8.0</data>
      <data key="d5">NCT03607422 is a phase 3 trial for upadacitinib monotherapy in AD</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="UPADACITINIB" target="NCT03568318">
      <data key="d4">8.0</data>
      <data key="d5">NCT03568318 is a phase 3 trial for upadacitinib with topical corticosteroids in AD</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="UPADACITINIB" target="AD">
      <data key="d4">16.0</data>
      <data key="d5">Upadacitinib is used in the treatment of atopic dermatitis
Upadacitinib is a JAK inhibitor used for treating moderate to severe AD</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd,a867a1e73cef039eb3f28e072463b838</data>
    </edge>
    <edge source="UPADACITINIB" target="NCT03646604">
      <data key="d4">7.0</data>
      <data key="d5">NCT03646604 is a clinical trial involving Upadacitinib</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="UPADACITINIB" target="JAK">
      <data key="d4">14.0</data>
      <data key="d5">Upadacitinib is a JAK inhibitor</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="APRIL" target="BAFF">
      <data key="d4">32.0</data>
      <data key="d5">APRIL and BAFF are members of the TNF Superfamily involved in B cell maturation and fibrosis
BAFF and APRIL are both involved in B-cell regulation
APRIL and BAFF are both involved in B cell regulation</data>
      <data key="d6">0c7502a2bfe653785647d754ed10f4e3,8e5a1be9981340d419f7b3ad27076009,c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="APRIL" target="TACI">
      <data key="d4">15.0</data>
      <data key="d5">APRIL binds to TACI with high affinity
APRIL binds to TACI</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="APRIL" target="BCMA">
      <data key="d4">15.0</data>
      <data key="d5">APRIL binds to BCMA with high affinity
APRIL binds to BCMA</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="APRIL" target="B LYMPHOCYTES">
      <data key="d4">8.0</data>
      <data key="d5">APRIL is involved in B cell maturation and differentiation</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="APRIL" target="T LYMPHOCYTES">
      <data key="d4">7.0</data>
      <data key="d5">APRIL is involved in T cell responses</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="APRIL" target="MONOCYTES">
      <data key="d4">7.0</data>
      <data key="d5">APRIL is involved in monocyte responses</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="APRIL" target="PATHOGENIC TISSUE REMODELING">
      <data key="d4">8.0</data>
      <data key="d5">APRIL contributes to pathogenic tissue remodeling</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="APRIL" target="ILD">
      <data key="d4">6.0</data>
      <data key="d5">Elevated serum APRIL levels are found in patients with ILD</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="APRIL" target="ATOPIC DERMATITIS">
      <data key="d4">7.0</data>
      <data key="d5">Elevated serum APRIL levels are associated with disease severity in AD</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="APRIL" target="AE">
      <data key="d4">7.0</data>
      <data key="d5">Elevated serum APRIL levels are associated with disease severity in AE</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="APRIL" target="SSC">
      <data key="d4">7.0</data>
      <data key="d5">Elevated serum APRIL levels are found in patients with SSc</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="APRIL" target="LUNG">
      <data key="d4">7.0</data>
      <data key="d5">High APRIL levels indicate pulmonary involvement in SSc</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="APRIL" target="ANTI-TOPO I ANTIBODIES">
      <data key="d4">6.0</data>
      <data key="d5">Increased production of APRIL is associated with increased anti-topo I antibodies</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="APRIL" target="ATOPIC ECZEMA">
      <data key="d4">7.0</data>
      <data key="d5">Elevated serum APRIL levels are associated with disease severity in pediatric atopic eczema</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="APRIL" target="TACI-FC FUSION PROTEIN">
      <data key="d4">27.0</data>
      <data key="d5">TACI-Fc fusion protein targets the APRIL protein
TACI-Fc fusion protein targets APRIL</data>
      <data key="d6">0c7502a2bfe653785647d754ed10f4e3,423195c6b63ad0a6773374364ebf3612</data>
    </edge>
    <edge source="APRIL" target="ATACICEPT">
      <data key="d4">18.0</data>
      <data key="d5">Atacicept inhibits APRIL</data>
      <data key="d6">0c7502a2bfe653785647d754ed10f4e3</data>
    </edge>
    <edge source="BAFF" target="TACI">
      <data key="d4">15.0</data>
      <data key="d5">BAFF binds to TACI with high affinity
BAFF binds to TACI</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="BAFF" target="BCMA">
      <data key="d4">14.0</data>
      <data key="d5">BAFF binds to BCMA with lesser affinity
BAFF binds to BCMA</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="BAFF" target="BAFF-R">
      <data key="d4">8.0</data>
      <data key="d5">BAFF binds to BAFF-R with high affinity</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="BAFF" target="B LYMPHOCYTES">
      <data key="d4">8.0</data>
      <data key="d5">BAFF is involved in B cell maturation and differentiation</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="BAFF" target="T LYMPHOCYTES">
      <data key="d4">7.0</data>
      <data key="d5">BAFF is involved in T cell responses</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="BAFF" target="MONOCYTES">
      <data key="d4">7.0</data>
      <data key="d5">BAFF is involved in monocyte responses</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="BAFF" target="NASH">
      <data key="d4">16.0</data>
      <data key="d5">Elevated serum BAFF levels are associated with NASH severity
Elevated serum BAFF levels are associated with increased severity of NASH</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7,c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="BAFF" target="AUTOIMMUNE HEPATITIS">
      <data key="d4">9.0</data>
      <data key="d5">Elevated BAFF levels are associated with advanced fibrosis in autoimmune hepatitis
Elevated BAFF levels are associated with advanced fibrosis in autoimmune hepatitis</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7,c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="BAFF" target="PATHOGENIC TISSUE REMODELING">
      <data key="d4">8.0</data>
      <data key="d5">BAFF contributes to pathogenic tissue remodeling</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="BAFF" target="SERUM BAFF LEVELS">
      <data key="d4">8.0</data>
      <data key="d5">Elevated serum BAFF levels are associated with fibrosis severity</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="BAFF" target="HEPATOCYTE">
      <data key="d4">7.0</data>
      <data key="d5">Higher serum BAFF levels are associated with hepatocyte ballooning</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="BAFF" target="NAFLD">
      <data key="d4">7.0</data>
      <data key="d5">BAFF-/- mice show reduced fibrosis and hepatic steatosis in NAFLD</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="BAFF" target="MIXED CONNECTIVE TISSUE DISEASE">
      <data key="d4">7.0</data>
      <data key="d5">Elevated serum BAFF levels are found in patients with mixed connective tissue disease</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="BAFF" target="ILD">
      <data key="d4">7.0</data>
      <data key="d5">Elevated serum BAFF levels are found in patients with ILD</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="BAFF" target="BALF">
      <data key="d4">6.0</data>
      <data key="d5">Elevated BAFF levels are found in the BALF of a mouse model of PF</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="BAFF" target="PF">
      <data key="d4">7.0</data>
      <data key="d5">BAFF inhibition reduces PF in a mouse model</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="BAFF" target="SSC">
      <data key="d4">8.0</data>
      <data key="d5">Elevated serum BAFF levels are found in patients with SSc</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="BAFF" target="B CELL">
      <data key="d4">21.0</data>
      <data key="d5">BAFF stimulates B cells to upregulate profibrotic markersB cell BAFFR expression is increased in SSc patients</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="BAFF" target="TSK/+ MICE">
      <data key="d4">7.0</data>
      <data key="d5">Elevated serum BAFF levels are found in TSK/+ mice</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="BAFF" target="COLLAGEN">
      <data key="d4">7.0</data>
      <data key="d5">BAFF-stimulated B cells upregulate collagen in SSc fibroblasts</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="BAFF" target="&#913;SMA">
      <data key="d4">7.0</data>
      <data key="d5">BAFF-stimulated B cells upregulate &#945;SMA in SSc fibroblasts</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="BAFF" target="TIMP1">
      <data key="d4">7.0</data>
      <data key="d5">BAFF-stimulated B cells upregulate TIMP1 in SSc fibroblasts</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="BAFF" target="BEFFS">
      <data key="d4">6.0</data>
      <data key="d5">BAFF inhibition reduces fibrotic IL-6 producing Beffs</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="BAFF" target="BREGS">
      <data key="d4">6.0</data>
      <data key="d5">BAFF inhibition does not affect regulatory IL-10 producing Bregs</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="BAFF" target="FIBROSIS SCORE">
      <data key="d4">7.0</data>
      <data key="d5">Higher BAFF levels are associated with a higher fibrosis score</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="BAFF" target="BLEOMYCIN">
      <data key="d4">7.0</data>
      <data key="d5">BAFF inhibition reduces fibrosis in a bleomycin-induced pulmonary fibrosis model</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="BAFF" target="BAFFR">
      <data key="d4">7.0</data>
      <data key="d5">BAFF binds to BAFFR</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="BAFF" target="TACI-FC FUSION PROTEIN">
      <data key="d4">36.0</data>
      <data key="d5">TACI-Fc fusion protein targets the BAFF protein
TACI-Fc fusion protein inhibits BAFF
TACI-Fc fusion protein targets BAFF</data>
      <data key="d6">0c7502a2bfe653785647d754ed10f4e3,423195c6b63ad0a6773374364ebf3612,8e5a1be9981340d419f7b3ad27076009</data>
    </edge>
    <edge source="BAFF" target="RC18">
      <data key="d4">9.0</data>
      <data key="d5">RC18 inhibits BAFF</data>
      <data key="d6">8e5a1be9981340d419f7b3ad27076009</data>
    </edge>
    <edge source="BAFF" target="ANTI-BAFF MAB">
      <data key="d4">18.0</data>
      <data key="d5">Anti-BAFF monoclonal antibody targets BAFF</data>
      <data key="d6">0c7502a2bfe653785647d754ed10f4e3</data>
    </edge>
    <edge source="BAFF" target="RELAPSING-REMITTING MULTIPLE SCLEROSIS">
      <data key="d4">14.0</data>
      <data key="d5">BAFF is involved in the pathogenesis of relapsing-remitting multiple sclerosis</data>
      <data key="d6">0c7502a2bfe653785647d754ed10f4e3</data>
    </edge>
    <edge source="BAFF" target="ATACICEPT">
      <data key="d4">18.0</data>
      <data key="d5">Atacicept inhibits BAFF</data>
      <data key="d6">0c7502a2bfe653785647d754ed10f4e3</data>
    </edge>
    <edge source="BAFF" target="FIBROBLASTS">
      <data key="d4">8.0</data>
      <data key="d5">BAFF acts on fibroblasts to drive pro-fibrotic and anti-fibrotic effects</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </edge>
    <edge source="BAFF" target="B CELLS">
      <data key="d4">8.0</data>
      <data key="d5">BAFF acts on B cells to drive pro-fibrotic and anti-fibrotic effects</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </edge>
    <edge source="TNFSF4" target="OX40L">
      <data key="d4">24.0</data>
      <data key="d5">TNFSF4 encodes the OX40 ligand
OX40L is also known as TNFSF4</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14,7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="TNFSF4" target="SLE">
      <data key="d4">32.0</data>
      <data key="d5">TNFSF4 is a susceptibility gene for systemic lupus erythematosus
TNFSF4 is associated with systemic lupus erythematosus</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14,8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="TNFSF4" target="SSC">
      <data key="d4">43.0</data>
      <data key="d5">TNFSF4 is associated with systemic sclerosis
TNFSF4 is associated with systemic sclerosis susceptibility
TNFSF4 is identified as a susceptibility gene for the development of systemic sclerosis</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14,7b454335c2f5651d86f712037a0dc0ff,8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="TNFSF4" target="RS1234314">
      <data key="d4">40.0</data>
      <data key="d5">rs1234314 is a SNP in the TNFSF4 gene region
TNFSF4 and SNP rs1234314 are associated with systemic sclerosis
TNFSF4 and SNP rs1234314 are associated with systemic sclerosis</data>
      <data key="d6">40ad2241836485e0bf264bdfb62fd789,c69c7fb997f95c56cc077b3975f41923,f9c444698bb08349abe4244fb771c1ee</data>
    </edge>
    <edge source="TNFSF4" target="RS1234315">
      <data key="d4">16.0</data>
      <data key="d5">rs1234315 is a SNP in the TNFSF4 gene region</data>
      <data key="d6">f9c444698bb08349abe4244fb771c1ee</data>
    </edge>
    <edge source="TNFSF4" target="RS2205960">
      <data key="d4">72.0</data>
      <data key="d5">rs2205960 is a SNP in the TNFSF4 gene region
TNFSF4 and SNP rs2205960 are associated with systemic sclerosis susceptibility
TNFSF4 and SNP rs2205960 are associated with systemic sclerosis susceptibility
TNFSF4 and SNP rs2205960 are associated with systemic sclerosis
TNFSF4 and SNP rs2205960 are associated with systemic sclerosis susceptibility</data>
      <data key="d6">40ad2241836485e0bf264bdfb62fd789,8ce8c356713490cd2c680f505bcd050b,c69c7fb997f95c56cc077b3975f41923,d8a485eb1e9435b083d5ef6a17f06ea5,f9c444698bb08349abe4244fb771c1ee</data>
    </edge>
    <edge source="TNFSF4" target="RS844644">
      <data key="d4">40.0</data>
      <data key="d5">rs844644 is a SNP in the TNFSF4 gene region
TNFSF4 and SNP rs844644 are associated with systemic sclerosis
TNFSF4 and SNP rs844644 are associated with systemic sclerosis</data>
      <data key="d6">40ad2241836485e0bf264bdfb62fd789,c69c7fb997f95c56cc077b3975f41923,f9c444698bb08349abe4244fb771c1ee</data>
    </edge>
    <edge source="TNFSF4" target="RS12039904">
      <data key="d4">16.0</data>
      <data key="d5">rs12039904 is a SNP in the TNFSF4 gene region</data>
      <data key="d6">f9c444698bb08349abe4244fb771c1ee</data>
    </edge>
    <edge source="TNFSF4" target="RS2795288">
      <data key="d4">16.0</data>
      <data key="d5">rs2795288 is a SNP in the TNFSF4 gene region</data>
      <data key="d6">f9c444698bb08349abe4244fb771c1ee</data>
    </edge>
    <edge source="TNFSF4" target="RS844648">
      <data key="d4">40.0</data>
      <data key="d5">rs844648 is a SNP in the TNFSF4 gene region
TNFSF4 and SNP rs844648 are linked to systemic sclerosis
TNFSF4 and SNP rs844648 are associated with systemic sclerosis</data>
      <data key="d6">40ad2241836485e0bf264bdfb62fd789,c69c7fb997f95c56cc077b3975f41923,f9c444698bb08349abe4244fb771c1ee</data>
    </edge>
    <edge source="TNFSF4" target="RS844665">
      <data key="d4">21.0</data>
      <data key="d5">rs844665 is a SNP in the TNFSF4 gene region
TNFSF4 and SNP rs844665 are not significantly associated with systemic sclerosis</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923,f9c444698bb08349abe4244fb771c1ee</data>
    </edge>
    <edge source="TNFSF4" target="RS10912580">
      <data key="d4">16.0</data>
      <data key="d5">rs10912580 is a SNP in the TNFSF4 gene region</data>
      <data key="d6">f9c444698bb08349abe4244fb771c1ee</data>
    </edge>
    <edge source="TNFSF4" target="RS855648">
      <data key="d4">16.0</data>
      <data key="d5">TNFSF4 and SNP rs855648 are linked to systemic sclerosis</data>
      <data key="d6">d8a485eb1e9435b083d5ef6a17f06ea5</data>
    </edge>
    <edge source="TNFSF4" target="RS944648">
      <data key="d4">16.0</data>
      <data key="d5">TNFSF4 and SNP rs944648 are linked to systemic sclerosis</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="TNFSF4" target="RA">
      <data key="d4">16.0</data>
      <data key="d5">TNFSF4 is associated with rheumatoid arthritis</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="TNFSF4" target="MHC CLASS II">
      <data key="d4">14.0</data>
      <data key="d5">TNFSF4 is associated with MHC class II</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="TNFSF4" target="PTPN22">
      <data key="d4">14.0</data>
      <data key="d5">TNFSF4 is associated with PTPN22</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="TNFSF4" target="AIF1">
      <data key="d4">14.0</data>
      <data key="d5">TNFSF4 is associated with AIF1</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="TNFSF4" target="IRF5">
      <data key="d4">14.0</data>
      <data key="d5">TNFSF4 is associated with IRF5</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="TNFSF4" target="STAT4">
      <data key="d4">14.0</data>
      <data key="d5">TNFSF4 is associated with STAT4</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="TNFSF4" target="FAS">
      <data key="d4">14.0</data>
      <data key="d5">TNFSF4 is associated with FAS</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="TNFSF4" target="GENE&#8211;GENE INTERACTION">
      <data key="d4">14.0</data>
      <data key="d5">TNFSF4 is involved in gene&#8211;gene interactions</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="TNFSF4" target="GENE&#8211;ENVIRONMENT INTERACTION">
      <data key="d4">14.0</data>
      <data key="d5">TNFSF4 is involved in gene&#8211;environment interactions</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="TNFSF4" target="CAUCASIAN">
      <data key="d4">14.0</data>
      <data key="d5">TNFSF4 is associated with systemic sclerosis in North American Caucasians</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="TNFSF4" target="LSSC">
      <data key="d4">14.0</data>
      <data key="d5">TNFSF4 is associated with limited systemic sclerosis</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="TNFSF4" target="DSSC">
      <data key="d4">14.0</data>
      <data key="d5">TNFSF4 is associated with diffuse systemic sclerosis</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="TNFSF4" target="AUTOANTIBODY">
      <data key="d4">14.0</data>
      <data key="d5">TNFSF4 is associated with SSc-associated autoantibody subsets</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="TNFSF4" target="SNPS">
      <data key="d4">8.0</data>
      <data key="d5">SNPs within the promoter region of TNFSF4 are associated with SSc susceptibility</data>
      <data key="d6">7b454335c2f5651d86f712037a0dc0ff</data>
    </edge>
    <edge source="TNFSF4" target="PROMOTER REGION">
      <data key="d4">8.0</data>
      <data key="d5">SNPs within the promoter region of TNFSF4 are associated with SSc</data>
      <data key="d6">7b454335c2f5651d86f712037a0dc0ff</data>
    </edge>
    <edge source="TNFSF4" target="GENETIC STRUCTURE">
      <data key="d4">7.0</data>
      <data key="d5">Determining the variation in the genetic structure of TNFSF4 will help understand its role in SSc</data>
      <data key="d6">7b454335c2f5651d86f712037a0dc0ff</data>
    </edge>
    <edge source="TNFSF4" target="OX40">
      <data key="d4">6.0</data>
      <data key="d5">OX40 is also known as TNFSF4</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="ACITRETIN" target="RARA">
      <data key="d4">14.0</data>
      <data key="d5">Acitretin targets RARA</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="ACITRETIN" target="RARB">
      <data key="d4">14.0</data>
      <data key="d5">Acitretin targets RARB</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="ACITRETIN" target="RARG">
      <data key="d4">14.0</data>
      <data key="d5">Acitretin targets RARG</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="ACITRETIN" target="RBP1">
      <data key="d4">14.0</data>
      <data key="d5">Acitretin targets RBP1</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="ACITRETIN" target="RXRA">
      <data key="d4">14.0</data>
      <data key="d5">Acitretin targets RXRA</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="ACITRETIN" target="RXRB">
      <data key="d4">14.0</data>
      <data key="d5">Acitretin targets RXRB</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="ACITRETIN" target="RXRG">
      <data key="d4">14.0</data>
      <data key="d5">Acitretin targets RXRG</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="ACITRETIN" target="STAT3">
      <data key="d4">14.0</data>
      <data key="d5">Acitretin targets STAT3</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="CYPROTERONE ACETATE" target="ADORA1">
      <data key="d4">14.0</data>
      <data key="d5">Cyproterone acetate antagonizes ADORA1</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="DOXYCYCLINE" target="MMP8">
      <data key="d4">14.0</data>
      <data key="d5">Doxycycline inhibits MMP8</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="ETANERCEPT" target="TNFRSF1A">
      <data key="d4">16.0</data>
      <data key="d5">Etanercept antagonizes TNFRSF1A</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="ETANERCEPT" target="LIVER FIBROSIS">
      <data key="d4">7.0</data>
      <data key="d5">Etanercept decreases liver fibrosis progression</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="ETANERCEPT" target="TNFR1">
      <data key="d4">7.0</data>
      <data key="d5">Etanercept decreases TNFR1 expression</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="ETANERCEPT" target="COLLAGEN">
      <data key="d4">7.0</data>
      <data key="d5">Etanercept decreases collagen accumulation</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="ETANERCEPT" target="HEMOSIDERIN">
      <data key="d4">7.0</data>
      <data key="d5">Etanercept decreases hemosiderin accumulation</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="ETANERCEPT" target="LIVER">
      <data key="d4">7.0</data>
      <data key="d5">Etanercept decreases collagen and hemosiderin accumulation in the liver</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="ETANERCEPT" target="PULMONARY FIBROSIS">
      <data key="d4">7.0</data>
      <data key="d5">Etanercept is used in clinical trials to treat Pulmonary Fibrosis</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="METFORMIN" target="ACACB">
      <data key="d4">14.0</data>
      <data key="d5">Metformin targets ACACB</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="RIFAMPICIN" target="SLCO1A2">
      <data key="d4">7.0</data>
      <data key="d5">Rifampicin targets SLCO1A2</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="RIFAMPICIN" target="SLCO1B1">
      <data key="d4">7.0</data>
      <data key="d5">Rifampicin targets SLCO1B1</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="RIFAMPICIN" target="SLCO1B3">
      <data key="d4">7.0</data>
      <data key="d5">Rifampicin targets SLCO1B3</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="SECUKINUMAB" target="IL-17A">
      <data key="d4">17.0</data>
      <data key="d5">Secukinumab targets IL-17A to treat moderate-to-severe atopic dermatitis
Secukinumab targets IL-17A</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9,2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </edge>
    <edge source="SECUKINUMAB" target="ANKYLOSING SPONDYLITIS">
      <data key="d4">9.0</data>
      <data key="d5">Secukinumab is FDA-approved for the treatment of ankylosing spondylitis</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </edge>
    <edge source="SECUKINUMAB" target="ATOPIC DERMATITIS">
      <data key="d4">14.0</data>
      <data key="d5">Secukinumab is investigated for the treatment of Atopic Dermatitis
Secukinumab is used to target IL-17A in the treatment of atopic dermatitis</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="SECUKINUMAB" target="AD">
      <data key="d4">7.0</data>
      <data key="d5">Secukinumab was explored for AD treatment</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </edge>
    <edge source="SECUKINUMAB" target="PLAQUE PSORIASIS">
      <data key="d4">8.0</data>
      <data key="d5">Secukinumab is used to treat plaque psoriasis</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </edge>
    <edge source="SECUKINUMAB" target="INTERLEUKIN-17A">
      <data key="d4">8.0</data>
      <data key="d5">Secukinumab targets Interleukin-17a</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </edge>
    <edge source="SPESOLIMAB" target="AD">
      <data key="d4">19.0</data>
      <data key="d5">Spesolimab is being explored for atopic dermatitis
Spesolimab is being studied in a phase-II trial for AD</data>
      <data key="d6">6309eeea565f06479830cec32938abc9,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="SPESOLIMAB" target="ATOPIC DERMATITIS">
      <data key="d4">21.0</data>
      <data key="d5">Spesolimab is used to target IL-36R in the treatment of atopic dermatitis
Spesolimab is a biologic agent targeting interleukin-36R in atopic dermatitis treatment</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="SPESOLIMAB" target="IL-36R">
      <data key="d4">8.0</data>
      <data key="d5">Spesolimab targets IL-36R</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="VILOBELIMAB" target="C5">
      <data key="d4">1.0</data>
      <data key="d5">Vilobelimab inhibits C5</data>
      <data key="d6">c44ec79872ab10cbe7336182f183ff60</data>
    </edge>
    <edge source="IL-17A" target="AD">
      <data key="d4">16.0</data>
      <data key="d5">IL-17A is involved in the immune response and inflammation in ADIL-17A is a cytokine involved in the immune response and inflammation in AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="IL-36R" target="AD">
      <data key="d4">7.0</data>
      <data key="d5">IL-36R is increased in AD</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IL-36R" target="S. AUREUS">
      <data key="d4">7.0</data>
      <data key="d5">S. aureus infection leads to inflammation relying on IL-36R</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="JAK" target="AD">
      <data key="d4">29.0</data>
      <data key="d5">JAK is involved in signaling pathways for immune response in AD
JAK inhibitors are used in the treatment of AD
JAK is involved in the pathophysiology of AD</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c,2cec06c4d46f5ff9ee936a78d8b077cd,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="JAK" target="IL-31">
      <data key="d4">16.0</data>
      <data key="d5">JAK is involved in the signaling pathway of IL-31</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="JAK" target="ABROCITINIB">
      <data key="d4">14.0</data>
      <data key="d5">Abrocitinib is a JAK inhibitor</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="JAK" target="BARICITINIB">
      <data key="d4">14.0</data>
      <data key="d5">Baricitinib is a JAK inhibitor</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="JAK" target="BREPOCITINIB">
      <data key="d4">14.0</data>
      <data key="d5">Brepocitinib is a selective JAK inhibitor</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="IL-12" target="CAMP">
      <data key="d4">6.0</data>
      <data key="d5">cAMP mediates downstream events culminating in the inhibition of IL-12 secretion</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="IL-12" target="TH1">
      <data key="d4">8.0</data>
      <data key="d5">IL-12 drives the differentiation of Th1 cells</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </edge>
    <edge source="IL-23" target="CAMP">
      <data key="d4">6.0</data>
      <data key="d5">cAMP mediates downstream events culminating in the inhibition of IL-23 secretion</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="IL-23" target="ATOPIC DERMATITIS">
      <data key="d4">7.0</data>
      <data key="d5">IL-23 is implicated in Atopic Dermatitis</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IL-23" target="RISANKIZUMAB">
      <data key="d4">8.0</data>
      <data key="d5">Risankizumab is an anti-IL-23 antibody</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IL-23" target="AD">
      <data key="d4">8.0</data>
      <data key="d5">IL-23 is involved in the immune response and inflammation in AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="OX40" target="OX40L">
      <data key="d4">205.0</data>
      <data key="d5">OX40 binds to OX40L to potentiate pro-inflammatory T-cell responses
OX40 binds to OX40L and plays a central role in the pathogenesis of AD
OX40 binds to OX40L and is involved in the immune response
OX40 and OX40L are involved in the immune response and are targets for inhibitors in atopic dermatitis treatment
OX40 binds to its ligand OX40L
OX40 binds to OX40L and contributes to T cell activation
OX40 interacts with OX40L in the immune response
OX40 and OX40L interactions are crucial for the generation of Th2 memory cells in Atopic Dermatitis
OX40 binds to OX40L and generates a costimulatory signal
OX40 and OX40L are co-localized in the skin and interact to modulate immune responses
OX40 binds to OX40L and generates a costimulatory signal
OX40 and OX40L are involved in positive costimulatory pathways
OX40 interacts with OX40L in T cell costimulation
OX40L is the ligand for OX40 and provides a costimulatory signal
OX40 binds to OX40L and modulates T-cell activity
OX40 binds to OX40L and modulates activated T-cell activity
OX40L binds to OX40</data>
      <data key="d6">100dd7646c10899301b3c0631183da16,1b656cfce91ff9ccec4223703489dab3,3287c502f10f4651d2f56bf39ee7bb7a,44f2592262cac835560b4c149fee8d2b,4842292208575bd45b2b5998513dd087,4d0e8ae9371a435885994b4161126bc3,6309eeea565f06479830cec32938abc9,691cb2e23ac3c6e591129d16714f8ef8,78e26c66107dba37ac4bab65406b43a0,7c13f41d7349d9d2e56c36e00c0ca2d9,855c455b4c9592746834ee3a4e0e6b81,89dbac0da39e4de2b602052cd792b90d,8ce8c356713490cd2c680f505bcd050b,c95d22c2a90e77cd22bd0d280d55b26a,dc905ba8b6eb7d84cf2776303211010d,e075bccd45593ae008b2ce7f9ed8ff6c,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="OX40" target="ROCATINLIMAB">
      <data key="d4">68.0</data>
      <data key="d5">Rocatinlimab is an anti-OX40 antibody
Rocatinlimab is an anti-OX40 monoclonal antibody
Rocatinlimab targets OX40 to deplete activated T-cells
Rocatinlimab is an anti-OX40 monoclonal antibody</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688,4842292208575bd45b2b5998513dd087,dc905ba8b6eb7d84cf2776303211010d,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="OX40" target="EFFECTOR T-CELLS">
      <data key="d4">16.0</data>
      <data key="d5">OX40 potentiates the expansion of effector T-cells</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="OX40" target="REGULATORY T-CELLS">
      <data key="d4">14.0</data>
      <data key="d5">OX40 is expressed on regulatory T-cells</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="OX40" target="MEMORY T-CELLS">
      <data key="d4">14.0</data>
      <data key="d5">OX40 is expressed on reactivated memory T-cells</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="OX40" target="EFFECTOR MEMORY T-CELLS">
      <data key="d4">14.0</data>
      <data key="d5">OX40 promotes the expansion of effector memory T-cells</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="OX40" target="PERIPHERAL BLOOD MONONUCLEAR CELLS">
      <data key="d4">21.0</data>
      <data key="d5">OX40 is expressed on peripheral blood mononuclear cells in AD patients
OX40 is expressed on peripheral blood mononuclear cells in AD</data>
      <data key="d6">4842292208575bd45b2b5998513dd087,89dbac0da39e4de2b602052cd792b90d</data>
    </edge>
    <edge source="OX40" target="GBR 830">
      <data key="d4">56.0</data>
      <data key="d5">GBR 830 is a monoclonal antibody against OX40
GBR 830 is a monoclonal antibody against OX40
GBR 830 is an anti-OX40 monoclonal antibody
GBR 830 is an antibody directed against OX40</data>
      <data key="d6">4842292208575bd45b2b5998513dd087,6309eeea565f06479830cec32938abc9,dc905ba8b6eb7d84cf2776303211010d,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="OX40" target="AMLITELIMAB">
      <data key="d4">18.0</data>
      <data key="d5">Amlitelimab blocks interactions between OX40 and OX40L</data>
      <data key="d6">b876251511f570468eb5b6ee6a239cc6</data>
    </edge>
    <edge source="OX40" target="T-CELL">
      <data key="d4">35.0</data>
      <data key="d5">OX40 is involved in T-cell functioning
OX40 is expressed predominantly on effector and regulatory T-cells
OX40 is expressed when T-cells, including effector and regulatory T-cells (Tregs), are stimulated</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd,b201c6ff3e22b2475c8c59260a0eb6a7,dc905ba8b6eb7d84cf2776303211010d</data>
    </edge>
    <edge source="OX40" target="AD">
      <data key="d4">41.0</data>
      <data key="d5">Expression of OX40 is increased in AD lesions
OX40 expression was analyzed on PBMCs from patients with AD
OX40 is highly expressed in skin-homing T cells and monocytes in AD patients
OX40 expression is increased in the skin of patients with AD
OX40 expression is increased in atopic dermatitis</data>
      <data key="d6">100dd7646c10899301b3c0631183da16,2e9a8d71f6bd251a0b13458c39e69746,6b099960b0a39866e3aa6b908f1886e4,89dbac0da39e4de2b602052cd792b90d,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="OX40" target="KHK4083">
      <data key="d4">24.0</data>
      <data key="d5">KHK4083 is an anti-OX40 monoclonal antibody
KHK4083 is an antibody directed against OX40</data>
      <data key="d6">6309eeea565f06479830cec32938abc9,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="OX40" target="TH2 CELL">
      <data key="d4">8.0</data>
      <data key="d5">OX40 is involved in the Th2 pathway</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="OX40" target="T-CELLS">
      <data key="d4">16.0</data>
      <data key="d5">OX40 is expressed when T-cells are stimulated</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="OX40" target="TH22">
      <data key="d4">6.0</data>
      <data key="d5">Blocking OX40 may prevent further Th22 pathway activation</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </edge>
    <edge source="OX40" target="TREGS">
      <data key="d4">7.0</data>
      <data key="d5">Blocking OX40 may promote the proliferation of Tregs and T-cell tolerance</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </edge>
    <edge source="OX40" target="ATOPIC DERMATITIS">
      <data key="d4">17.0</data>
      <data key="d5">OX40 plays a central role in the pathogenesis of Atopic Dermatitis
OX40 is targeted by monoclonal antibodies in clinical trials for atopic dermatitis</data>
      <data key="d6">68015074236b0144899baa38d01ae467,691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="OX40" target="DERMIS">
      <data key="d4">8.0</data>
      <data key="d5">OX40+ cells are co-located within the dermis in Atopic Dermatitis</data>
      <data key="d6">691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="OX40" target="ANTIGEN-ACTIVATION">
      <data key="d4">7.0</data>
      <data key="d5">Antigen-Activation triggers T-cell expression of OX40 in Atopic Dermatitis</data>
      <data key="d6">691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="OX40" target="HC">
      <data key="d4">8.0</data>
      <data key="d5">OX40 expression was analyzed on PBMCs from healthy controls</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="OX40" target="CD4">
      <data key="d4">6.0</data>
      <data key="d5">CD4 was used to stain cells for OX40 analysis</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="OX40" target="CD8">
      <data key="d4">6.0</data>
      <data key="d5">CD8 was used to stain cells for OX40 analysis</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="OX40" target="CD14">
      <data key="d4">6.0</data>
      <data key="d5">CD14 was used to stain cells for OX40 analysis</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="OX40" target="CD45RO">
      <data key="d4">6.0</data>
      <data key="d5">CD45RO was used to stain cells for OX40 analysis</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="OX40" target="CD56">
      <data key="d4">6.0</data>
      <data key="d5">CD56 was used to stain cells for OX40 analysis</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="OX40" target="CLA">
      <data key="d4">6.0</data>
      <data key="d5">CLA was used to stain cells for OX40 analysis</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="OX40" target="SOX40">
      <data key="d4">8.0</data>
      <data key="d5">OX40 is the membrane-bound form of the soluble protein sOX40</data>
      <data key="d6">6b099960b0a39866e3aa6b908f1886e4</data>
    </edge>
    <edge source="OX40" target="SCORAD">
      <data key="d4">16.0</data>
      <data key="d5">OX40 expression in CD4+CD45RO+CLA+/- T cells inversely correlates with SCORAD</data>
      <data key="d6">6b099960b0a39866e3aa6b908f1886e4</data>
    </edge>
    <edge source="OX40" target="T CELLS">
      <data key="d4">17.0</data>
      <data key="d5">OX40 is highly expressed by skin-homing memory-prone CLA+ T cells in AD patients
OX40 is expressed on T cells in AD</data>
      <data key="d6">6b099960b0a39866e3aa6b908f1886e4,89dbac0da39e4de2b602052cd792b90d</data>
    </edge>
    <edge source="OX40" target="MONOCYTES">
      <data key="d4">8.0</data>
      <data key="d5">OX40 is highly expressed by monocytes in AD patients</data>
      <data key="d6">6b099960b0a39866e3aa6b908f1886e4</data>
    </edge>
    <edge source="OX40" target="CD8+ T CELLS">
      <data key="d4">7.0</data>
      <data key="d5">CD8+ T cells in AD patients express OX40</data>
      <data key="d6">6b099960b0a39866e3aa6b908f1886e4</data>
    </edge>
    <edge source="OX40" target="IGE">
      <data key="d4">5.0</data>
      <data key="d5">OX40 expression does not correlate with serum IgE levels</data>
      <data key="d6">6b099960b0a39866e3aa6b908f1886e4</data>
    </edge>
    <edge source="OX40" target="CLA+ T CELLS">
      <data key="d4">9.0</data>
      <data key="d5">OX40 is highly expressed by CLA+ T cells in AD patients</data>
      <data key="d6">6b099960b0a39866e3aa6b908f1886e4</data>
    </edge>
    <edge source="OX40" target="CLA- T CELLS">
      <data key="d4">8.0</data>
      <data key="d5">OX40 is expressed by CLA- T cells in AD patients</data>
      <data key="d6">6b099960b0a39866e3aa6b908f1886e4</data>
    </edge>
    <edge source="OX40" target="CD4+CD45RO+CLA+ T CELLS">
      <data key="d4">17.0</data>
      <data key="d5">OX40 is highly expressed by CD4+CD45RO+CLA+ T cells in AD patients
CD4+CD45RO+CLA+ T cells express high levels of OX40 in AD</data>
      <data key="d6">6b099960b0a39866e3aa6b908f1886e4,89dbac0da39e4de2b602052cd792b90d</data>
    </edge>
    <edge source="OX40" target="CD4+CD45RO+CLA- T CELLS">
      <data key="d4">8.0</data>
      <data key="d5">OX40 is expressed by CD4+CD45RO+CLA- T cells in AD patients</data>
      <data key="d6">6b099960b0a39866e3aa6b908f1886e4</data>
    </edge>
    <edge source="OX40" target="CD8+CD45RO+CLA+ T CELLS">
      <data key="d4">7.0</data>
      <data key="d5">OX40 is expressed by CD8+CD45RO+CLA+ T cells in AD patients</data>
      <data key="d6">6b099960b0a39866e3aa6b908f1886e4</data>
    </edge>
    <edge source="OX40" target="CD8+CD45RO+CLA- T CELLS">
      <data key="d4">7.0</data>
      <data key="d5">OX40 is expressed by CD8+CD45RO+CLA- T cells in AD patients</data>
      <data key="d6">6b099960b0a39866e3aa6b908f1886e4</data>
    </edge>
    <edge source="OX40" target="T CELL">
      <data key="d4">40.0</data>
      <data key="d5">OX40 expression is increased on skin-homing T cells
OX40 is involved in T cell costimulation
OX40 is expressed on CD4+ and CD8+ T cells</data>
      <data key="d6">100dd7646c10899301b3c0631183da16,4d0e8ae9371a435885994b4161126bc3,8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="OX40" target="SKIN THICKNESS">
      <data key="d4">7.0</data>
      <data key="d5">Anti-OX40 therapy affects skin thickness in the treatment of atopic dermatitis</data>
      <data key="d6">100dd7646c10899301b3c0631183da16</data>
    </edge>
    <edge source="OX40" target="EASI">
      <data key="d4">7.0</data>
      <data key="d5">Anti-OX40 therapy affects EASI score in the treatment of atopic dermatitis</data>
      <data key="d6">100dd7646c10899301b3c0631183da16</data>
    </edge>
    <edge source="OX40" target="ATOPIC DISEASES">
      <data key="d4">8.0</data>
      <data key="d5">OX40 system is closely correlated with atopic diseases</data>
      <data key="d6">100dd7646c10899301b3c0631183da16</data>
    </edge>
    <edge source="OX40" target="T-REG CELL">
      <data key="d4">7.0</data>
      <data key="d5">OX40 mediates inactivation of T-reg cell function</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="OX40" target="DC">
      <data key="d4">7.0</data>
      <data key="d5">OX40 unleashes DCs by inactivating T-reg cells, allowing adaptive immune response</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="OX40" target="SSC">
      <data key="d4">24.0</data>
      <data key="d5">OX40 levels are significantly increased in systemic sclerosis patients
Serum levels of OX40 are elevated in patients with systemic sclerosis</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b,8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="OX40" target="SLE">
      <data key="d4">6.0</data>
      <data key="d5">OX40 levels are compared between systemic sclerosis and lupus patients</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="OX40" target="GITR">
      <data key="d4">6.0</data>
      <data key="d5">GITR possesses an intracellular domain with significant homology to OX40</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="OX40" target="CD134">
      <data key="d4">6.0</data>
      <data key="d5">OX40 is also known as CD134</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="OX40" target="ANTIGEN PRESENTING CELLS">
      <data key="d4">7.0</data>
      <data key="d5">OX40 is expressed on antigen presenting cells</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="OX40" target="ULCERATIVE COLITIS">
      <data key="d4">8.0</data>
      <data key="d5">OX40 is targeted by monoclonal antibodies in clinical trials for ulcerative colitis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="OX40L" target="AMLITELIMAB">
      <data key="d4">70.0</data>
      <data key="d5">Amlitelimab is an anti-OX40L antibody
Amlitelimab binds to OX40L and blocks interactions with OX40
Amlitelimab binds to OX40L and blocks its interaction with OX40
Amlitelimab binds OX40L and blocks its interaction with OX40</data>
      <data key="d6">b201c6ff3e22b2475c8c59260a0eb6a7,b876251511f570468eb5b6ee6a239cc6,dc905ba8b6eb7d84cf2776303211010d,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="OX40L" target="DENDRITIC CELLS (DCS)">
      <data key="d4">16.0</data>
      <data key="d5">OX40L is expressed on dendritic cells</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="OX40L" target="ENDOTHELIAL CELLS">
      <data key="d4">30.0</data>
      <data key="d5">OX40L is expressed on endothelial cells
OX40L is expressed on endothelial cells</data>
      <data key="d6">4842292208575bd45b2b5998513dd087,b201c6ff3e22b2475c8c59260a0eb6a7</data>
    </edge>
    <edge source="OX40L" target="MACROPHAGES">
      <data key="d4">14.0</data>
      <data key="d5">OX40L is expressed on macrophages</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="OX40L" target="B-CELLS">
      <data key="d4">14.0</data>
      <data key="d5">OX40L is expressed on activated B-cells</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="OX40L" target="PERIPHERAL BLOOD MONONUCLEAR CELLS">
      <data key="d4">14.0</data>
      <data key="d5">OX40L is expressed on peripheral blood mononuclear cells in AD patients</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="OX40L" target="GBR 830">
      <data key="d4">16.0</data>
      <data key="d5">GBR 830 treatment reduces OX40L expression</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="OX40L" target="ANTIGEN-PRESENTING CELLS">
      <data key="d4">26.0</data>
      <data key="d5">OX40L is expressed on antigen-presenting cells
OX40L is expressed on activated antigen-presenting cells</data>
      <data key="d6">b201c6ff3e22b2475c8c59260a0eb6a7,dc905ba8b6eb7d84cf2776303211010d</data>
    </edge>
    <edge source="OX40L" target="AD">
      <data key="d4">58.0</data>
      <data key="d5">OX40L plays a central role in pro-inflammatory T-cell responses in atopic dermatitis
Expression of OX40L is increased in AD lesions
OX40L expression was analyzed on PBMCs from patients with AD
OX40L is highly expressed in monocytes in AD patients
OX40L is expressed by cells in the skin of patients with AD
OX40L is involved in the pathogenesis of atopic dermatitis</data>
      <data key="d6">100dd7646c10899301b3c0631183da16,2e9a8d71f6bd251a0b13458c39e69746,6b099960b0a39866e3aa6b908f1886e4,89dbac0da39e4de2b602052cd792b90d,b201c6ff3e22b2475c8c59260a0eb6a7,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="OX40L" target="T-CELL">
      <data key="d4">16.0</data>
      <data key="d5">OX40L blocks T-cell activation</data>
      <data key="d6">b201c6ff3e22b2475c8c59260a0eb6a7</data>
    </edge>
    <edge source="OX40L" target="KY1005">
      <data key="d4">16.0</data>
      <data key="d5">KY1005 is an anti-OX40L biologic</data>
      <data key="d6">6309eeea565f06479830cec32938abc9</data>
    </edge>
    <edge source="OX40L" target="TSLP">
      <data key="d4">10.0</data>
      <data key="d5">TSLP activates antigen-presenting cells to produce OX40L
TSLP causes antigen-presenting cells to produce OX40L</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd,3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="OX40L" target="TH2">
      <data key="d4">21.0</data>
      <data key="d5">OX40L encourages and maintains the growth of Th2 central memory cells
OX40L interaction may promote T helper 2 cytokines</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd,8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="OX40L" target="ATOPIC DERMATITIS">
      <data key="d4">17.0</data>
      <data key="d5">OX40L plays a central role in the pathogenesis of Atopic Dermatitis
OX40L is targeted by monoclonal antibodies in clinical trials for atopic dermatitis</data>
      <data key="d6">68015074236b0144899baa38d01ae467,691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="OX40L" target="DERMIS">
      <data key="d4">8.0</data>
      <data key="d5">OX40L+ cells are co-located within the dermis in Atopic Dermatitis</data>
      <data key="d6">691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="OX40L" target="APC">
      <data key="d4">7.0</data>
      <data key="d5">APCs express OX40L in Atopic Dermatitis</data>
      <data key="d6">691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="OX40L" target="MAST CELLS">
      <data key="d4">39.0</data>
      <data key="d5">Mast cells express OX40L in Atopic Dermatitis
Mast cells in AD skin express OX40L
Mast cells express OX40L in the skin of patients with ADOX40L is expressed on mast cells in AD</data>
      <data key="d6">691cb2e23ac3c6e591129d16714f8ef8,6b099960b0a39866e3aa6b908f1886e4,89dbac0da39e4de2b602052cd792b90d</data>
    </edge>
    <edge source="OX40L" target="ANTIGEN-ACTIVATION">
      <data key="d4">7.0</data>
      <data key="d5">Antigen-Activation triggers APC expression of OX40L in Atopic Dermatitis</data>
      <data key="d6">691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="OX40L" target="HC">
      <data key="d4">8.0</data>
      <data key="d5">OX40L expression was analyzed on PBMCs from healthy controls</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="OX40L" target="TRYPTASE">
      <data key="d4">5.0</data>
      <data key="d5">Both OX40L and Tryptase are targeted by specific monoclonal antibodies for analysis</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd</data>
    </edge>
    <edge source="OX40L" target="MONOCLONAL MOUSE ANTI-OX40L">
      <data key="d4">7.0</data>
      <data key="d5">Monoclonal mouse anti-OX40L is used to target OX40L in immunohistochemistry</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd</data>
    </edge>
    <edge source="OX40L" target="SOX40L">
      <data key="d4">8.0</data>
      <data key="d5">OX40L is the membrane-bound form of the soluble protein sOX40L</data>
      <data key="d6">6b099960b0a39866e3aa6b908f1886e4</data>
    </edge>
    <edge source="OX40L" target="MONOCYTES">
      <data key="d4">23.0</data>
      <data key="d5">Monocytes express high levels of OX40L in both AD patients and healthy controlsOX40L is highly expressed by monocytes in AD patients
OX40L is expressed primarily by monocytes in AD</data>
      <data key="d6">6b099960b0a39866e3aa6b908f1886e4,89dbac0da39e4de2b602052cd792b90d</data>
    </edge>
    <edge source="OX40L" target="IGE">
      <data key="d4">7.0</data>
      <data key="d5">Increased expression of OX40L on B cells is associated with the level of total IgE in allergic asthma patients</data>
      <data key="d6">89dbac0da39e4de2b602052cd792b90d</data>
    </edge>
    <edge source="OX40L" target="MURINE ASTHMA MODELS">
      <data key="d4">7.0</data>
      <data key="d5">OX40L is highly expressed by a variety of cells within the lung during an induced allergic reaction in murine asthma models</data>
      <data key="d6">89dbac0da39e4de2b602052cd792b90d</data>
    </edge>
    <edge source="OX40L" target="B CELLS">
      <data key="d4">23.0</data>
      <data key="d5">OX40L is expressed on B cells in allergic asthma
OX40L is expressed on activated B cells</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3,89dbac0da39e4de2b602052cd792b90d</data>
    </edge>
    <edge source="OX40L" target="LUNG">
      <data key="d4">7.0</data>
      <data key="d5">OX40L is expressed in the lung during allergic reactions in murine asthma models</data>
      <data key="d6">89dbac0da39e4de2b602052cd792b90d</data>
    </edge>
    <edge source="OX40L" target="ATOPIC DISEASES">
      <data key="d4">8.0</data>
      <data key="d5">OX40L is involved in the pathogenesis of atopic diseases</data>
      <data key="d6">100dd7646c10899301b3c0631183da16</data>
    </edge>
    <edge source="OX40L" target="T CELL">
      <data key="d4">25.0</data>
      <data key="d5">OX40L is involved in the activation of T cells in the skin
OX40L is involved in T cell costimulation
OX40L is expressed on T cells</data>
      <data key="d6">100dd7646c10899301b3c0631183da16,4d0e8ae9371a435885994b4161126bc3,8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="OX40L" target="SSC">
      <data key="d4">36.0</data>
      <data key="d5">OX40L is overexpressed in patients with systemic sclerosis
OX40L is overexpressed in patients with systemic sclerosis
OX40L is implicated in systemic sclerosis</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="OX40L" target="T CELLS">
      <data key="d4">15.0</data>
      <data key="d5">OX40L is overexpressed in lesional skin T cellsOX40L enhances T cell survival</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="OX40L" target="IL-2">
      <data key="d4">8.0</data>
      <data key="d5">OX40L upregulates IL-2 production</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="OX40L" target="B CELL">
      <data key="d4">31.0</data>
      <data key="d5">OX40L enhances B cell proliferation and differentiationOX40L is overexpressed in lesional skin B cells
OX40L is expressed on B cells and is critical in differentiation and antibody production</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b,8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="OX40L" target="DERMAL FIBROBLASTS">
      <data key="d4">14.0</data>
      <data key="d5">OX40L is overexpressed in resting and activated dermal fibroblasts</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="OX40L" target="MMP">
      <data key="d4">16.0</data>
      <data key="d5">OX40L modulates MMP expressionOX40L modulates MMP expression in fibrotic mice
OX40L signaling affects MMP-mediated proteolytic cleavage of CD27</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3,44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="OX40L" target="BLEOMYCIN MOUSE MODEL">
      <data key="d4">30.0</data>
      <data key="d5">OX40L blockade prevents dermal fibrosis in the Bleomycin mouse model
OX40L signaling affects dermal fibrosis in the bleomycin mouse model</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3,9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="OX40L" target="FRA-2 TRANSGENIC MOUSE MODEL">
      <data key="d4">16.0</data>
      <data key="d5">OX40L blockade alleviates pulmonary hypertension in the Fra-2 transgenic mouse model</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="OX40L" target="SERUM">
      <data key="d4">7.0</data>
      <data key="d5">Increased expression of OX40L is observed in the serum of SSc patients</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="OX40L" target="DENDRITIC CELL">
      <data key="d4">16.0</data>
      <data key="d5">OX40L is expressed on dendritic cells</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="OX40L" target="MACROPHAGE">
      <data key="d4">16.0</data>
      <data key="d5">OX40L is expressed on macrophages</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="OX40L" target="NK CELL">
      <data key="d4">16.0</data>
      <data key="d5">OX40L is expressed on natural killer cells</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="OX40L" target="ENDOTHELIAL CELL">
      <data key="d4">16.0</data>
      <data key="d5">OX40L is expressed on endothelial cells</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="OX40L" target="SMOOTH MUSCLE CELL">
      <data key="d4">16.0</data>
      <data key="d5">OX40L is expressed on smooth muscle cells</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="OX40L" target="FOXP3+ REGULATORY T CELL">
      <data key="d4">14.0</data>
      <data key="d5">OX40L interactions inhibit the formation of Foxp3+ regulatory T cells</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="OX40L" target="TYPE I INTERFERON">
      <data key="d4">14.0</data>
      <data key="d5">OX40L with type I interferon may have a Th1 inducing effect</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="OX40L" target="C57/BL6">
      <data key="d4">12.0</data>
      <data key="d5">OX40L transgenic mice on the C57/BL6 background develop organ specific inflammation</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="OX40L" target="NON-OBESE DIABETIC MOUSE">
      <data key="d4">12.0</data>
      <data key="d5">Blocking OX40&#8211;OX40L interactions prevented the development of diabetes in the non-obese diabetic mouse</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="OX40L" target="EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS">
      <data key="d4">12.0</data>
      <data key="d5">Blocking OX40&#8211;OX40L interactions prevented the development of experimental autoimmune encephalomyelitis</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="OX40L" target="CD252">
      <data key="d4">6.0</data>
      <data key="d5">OX40L is also known as CD252</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="OX40L" target="DENDRITIC CELLS">
      <data key="d4">16.0</data>
      <data key="d5">OX40L is expressed on dendritic cells</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="SLE">
      <data key="d4">18.0</data>
      <data key="d5">OX40L is implicated in systemic lupus erythematosus</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="PAH">
      <data key="d4">16.0</data>
      <data key="d5">OX40L overexpression is associated with pulmonary arterial hypertension</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="DERMAL FIBROSIS">
      <data key="d4">18.0</data>
      <data key="d5">OX40L is implicated in dermal fibrosis</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="LUNG FIBROSIS">
      <data key="d4">18.0</data>
      <data key="d5">OX40L is implicated in lung fibrosis</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="CD90">
      <data key="d4">14.0</data>
      <data key="d5">OX40L is expressed by cells positive for CD90 in fibrotic skin</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="&#913;SMA">
      <data key="d4">14.0</data>
      <data key="d5">OX40L is expressed by cells positive for &#945;SMA in fibrotic skin</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="LDLR-/- MICE">
      <data key="d4">14.0</data>
      <data key="d5">OX40L signaling affects atherosclerosis in LDLR-/- mice</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="GATA-3">
      <data key="d4">14.0</data>
      <data key="d5">OX40L signaling affects Th2 cell promotion, reducing GATA-3 positive cells</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="CD4">
      <data key="d4">14.0</data>
      <data key="d5">OX40L signaling affects CD4 positive T cells</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="SOLUBLE OX40L">
      <data key="d4">16.0</data>
      <data key="d5">Soluble OX40L levels are higher in SSc patients and serve as a biomarker for fibrosis</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="INFLAMMATION-DRIVEN FIBROSIS">
      <data key="d4">16.0</data>
      <data key="d5">OX40L is implicated in inflammation-driven fibrosis</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="FIBROSING ALVEOLITIS">
      <data key="d4">16.0</data>
      <data key="d5">OX40L is implicated in fibrosing alveolitis</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="LUNG VESSEL REMODELING">
      <data key="d4">16.0</data>
      <data key="d5">OX40L is implicated in lung vessel remodeling</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="HYDROXYPROLINE">
      <data key="d4">14.0</data>
      <data key="d5">OX40L signaling affects hydroxyproline content in fibrotic tissues</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="TH2 CELLS">
      <data key="d4">14.0</data>
      <data key="d5">OX40L signaling promotes Th2 cell polarization</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="PBS">
      <data key="d4">10.0</data>
      <data key="d5">PBS is used as a control in studies involving OX40L</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="ANTI-OX40L ANTIBODY">
      <data key="d4">16.0</data>
      <data key="d5">Anti-OX40L antibody is used to block OX40L signaling</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="PULMONARY ARTERIOLE">
      <data key="d4">14.0</data>
      <data key="d5">OX40L signaling affects pulmonary arterioles in PAH</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="MEDIAL MUSCULAR HYPERTROPHY">
      <data key="d4">14.0</data>
      <data key="d5">OX40L signaling affects medial muscular hypertrophy in PAH</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="INTIMAL FIBROSIS">
      <data key="d4">14.0</data>
      <data key="d5">OX40L signaling affects intimal fibrosis in PAH</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="WESTERN-TYPE DIET">
      <data key="d4">12.0</data>
      <data key="d5">Western-type diet is used to study the effects of OX40L signaling in atherosclerosis</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="CHOW DIET">
      <data key="d4">10.0</data>
      <data key="d5">Chow diet is used as a control in studies involving OX40L</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="OX40L" target="ASTHMA">
      <data key="d4">8.0</data>
      <data key="d5">OX40L is targeted by monoclonal antibodies in clinical trials for asthma</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="ROCATINLIMAB" target="AD">
      <data key="d4">84.0</data>
      <data key="d5">Rocatinlimab is investigated for the treatment of AD
Rocatinlimab is under investigation for the treatment of moderate-to-severe atopic dermatitis
Rocatinlimab is used to treat atopic dermatitis
Rocatinlimab is being studied as a treatment for atopic dermatitis
Rocatinlimab is being tested in clinical trials for atopic dermatitis</data>
      <data key="d6">3287c502f10f4651d2f56bf39ee7bb7a,475995d7d211bbfde6d8ba52f324d688,4842292208575bd45b2b5998513dd087,b201c6ff3e22b2475c8c59260a0eb6a7,dc905ba8b6eb7d84cf2776303211010d</data>
    </edge>
    <edge source="ROCATINLIMAB" target="AMG 451">
      <data key="d4">32.0</data>
      <data key="d5">AMG 451 is another name for Rocatinlimab
AMG 451 is another name for rocatinlimab, used in clinical trials</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688,4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="ROCATINLIMAB" target="KHK4083">
      <data key="d4">16.0</data>
      <data key="d5">KHK4083 is another name for Rocatinlimab
KHK4083 is another name for rocatinlimab, used in clinical trials</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688,4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="ROCATINLIMAB" target="T-CELLS">
      <data key="d4">16.0</data>
      <data key="d5">Rocatinlimab selectively depletes OX40+ activated T-cells</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="TH2">
      <data key="d4">14.0</data>
      <data key="d5">Rocatinlimab is expected to control Th2-driven conditions</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="PYREXIA">
      <data key="d4">38.0</data>
      <data key="d5">Pyrexia was a common infusion reaction reported in patients treated with rocatinlimab
Pyrexia is a side effect observed after the first administration of rocatinlimab
Pyrexia was a frequent treatment-emergent adverse event in patients treated with rocatinlimab</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688,b201c6ff3e22b2475c8c59260a0eb6a7,dc905ba8b6eb7d84cf2776303211010d</data>
    </edge>
    <edge source="ROCATINLIMAB" target="CHILLS">
      <data key="d4">33.0</data>
      <data key="d5">Chills were a common infusion reaction reported in patients treated with rocatinlimab
Chills are a side effect observed after the first administration of rocatinlimab
Chills were a frequent treatment-emergent adverse event in patients treated with rocatinlimab</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688,b201c6ff3e22b2475c8c59260a0eb6a7,dc905ba8b6eb7d84cf2776303211010d</data>
    </edge>
    <edge source="ROCATINLIMAB" target="APHTHOUS ULCERS">
      <data key="d4">10.0</data>
      <data key="d5">Aphthous ulcers were reported in patients treated with rocatinlimab</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="BLOOD URIC ACID">
      <data key="d4">10.0</data>
      <data key="d5">Blood uric acid levels increased in some patients treated with rocatinlimab</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="NASOPHARYNGITIS">
      <data key="d4">22.0</data>
      <data key="d5">Nasopharyngitis was reported in patients treated with rocatinlimab
Nasopharyngitis was a treatment-emergent adverse event in patients treated with rocatinlimab</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688,b201c6ff3e22b2475c8c59260a0eb6a7</data>
    </edge>
    <edge source="ROCATINLIMAB" target="ERYTHEMA">
      <data key="d4">10.0</data>
      <data key="d5">Erythema was reported in patients treated with rocatinlimab</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="HORDEOLUM">
      <data key="d4">10.0</data>
      <data key="d5">Hordeolum was reported in patients treated with rocatinlimab</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="PRURITUS">
      <data key="d4">14.0</data>
      <data key="d5">Pruritus was measured using the NRS score in patients treated with rocatinlimab</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="TH1">
      <data key="d4">14.0</data>
      <data key="d5">Th1-related genes were downregulated after rocatinlimab treatment</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="TH22">
      <data key="d4">14.0</data>
      <data key="d5">Th22-related genes were downregulated after rocatinlimab treatment</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="MRNA">
      <data key="d4">14.0</data>
      <data key="d5">mRNA expression levels were analyzed to assess the impact of rocatinlimab treatment</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="POLYMERASE CHAIN REACTION">
      <data key="d4">16.0</data>
      <data key="d5">Polymerase chain reaction analysis revealed reduced OX40 mRNA expression after rocatinlimab treatment</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="TEAE">
      <data key="d4">12.0</data>
      <data key="d5">Treatment-emergent adverse events were reported in patients treated with rocatinlimab</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="TH2/TH22">
      <data key="d4">14.0</data>
      <data key="d5">Th2/Th22-related molecules were reduced in proteomic analysis after rocatinlimab treatment</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="PROTEOMIC ANALYSIS">
      <data key="d4">16.0</data>
      <data key="d5">Proteomic analysis was conducted to study protein expression changes in AD patients treated with rocatinlimab</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="GENOMIC PROFILE">
      <data key="d4">16.0</data>
      <data key="d5">Genomic profile analysis was conducted to study gene expression changes in AD patients treated with rocatinlimab</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="TRANSCRIPTOMIC PROFILE">
      <data key="d4">16.0</data>
      <data key="d5">Transcriptomic profile analysis was conducted to study RNA expression changes in AD patients treated with rocatinlimab</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="PLACEBO">
      <data key="d4">14.0</data>
      <data key="d5">Placebo was used as a control in clinical trials evaluating rocatinlimab</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="PHASE 1">
      <data key="d4">16.0</data>
      <data key="d5">Phase 1 clinical trial evaluated the safety and dosage of rocatinlimab in AD patients</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="PHASE 2B">
      <data key="d4">16.0</data>
      <data key="d5">Phase 2b clinical trial evaluated the efficacy and safety of rocatinlimab in AD patients</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="PHASE 3">
      <data key="d4">16.0</data>
      <data key="d5">Phase 3 clinical trial is planned to further evaluate rocatinlimab in AD patients</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="IGG1">
      <data key="d4">7.0</data>
      <data key="d5">IgG1 is a subclass of immunoglobulin G, which rocatinlimab belongs to</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="MONOCLONAL ANTIBODY">
      <data key="d4">7.0</data>
      <data key="d5">Monoclonal antibody is a type of protein that rocatinlimab is classified as</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="TH2-DRIVEN CONDITIONS">
      <data key="d4">7.0</data>
      <data key="d5">Th2-driven conditions are immune responses primarily mediated by Th2 cells, often associated with allergies and atopic dermatitis</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="CLONAL T-CELLS">
      <data key="d4">7.0</data>
      <data key="d5">Clonal T-cells are a population of T-cells that expand from a single cell, targeted by rocatinlimab</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="INFUSION REACTIONS">
      <data key="d4">6.0</data>
      <data key="d5">Infusion reactions are adverse effects that occur during or after the administration of a drug, such as rocatinlimab</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="ROCATINLIMAB" target="HEAD AND NECK">
      <data key="d4">16.0</data>
      <data key="d5">Rocatinlimab doses resulted in greater head and neck EASI score improvements</data>
      <data key="d6">b876251511f570468eb5b6ee6a239cc6</data>
    </edge>
    <edge source="ROCATINLIMAB" target="NCT05398445">
      <data key="d4">12.0</data>
      <data key="d5">NCT05398445 is the clinical trial identifier for evaluating rocatinlimab</data>
      <data key="d6">b876251511f570468eb5b6ee6a239cc6</data>
    </edge>
    <edge source="ROCATINLIMAB" target="AMLITELIMAB">
      <data key="d4">16.0</data>
      <data key="d5">Both amlitelimab and rocatinlimab target the OX40-OX40L pathway</data>
      <data key="d6">dc905ba8b6eb7d84cf2776303211010d</data>
    </edge>
    <edge source="ROCATINLIMAB" target="PHASE 3 TRIAL">
      <data key="d4">8.0</data>
      <data key="d5">Rocatinlimab is being evaluated in a Phase 3 trial for atopic dermatitis</data>
      <data key="d6">dc905ba8b6eb7d84cf2776303211010d</data>
    </edge>
    <edge source="ROCATINLIMAB" target="SKIN TRANSCRIPTOMIC ANALYSIS">
      <data key="d4">1.0</data>
      <data key="d5">Skin transcriptomic analysis supports the durability of the response with rocatinlimab</data>
      <data key="d6">dc905ba8b6eb7d84cf2776303211010d</data>
    </edge>
    <edge source="ROCATINLIMAB" target="SOX40">
      <data key="d4">18.0</data>
      <data key="d5">Rocatinlimab selectively depletes sOX40+ activated T-cells</data>
      <data key="d6">b201c6ff3e22b2475c8c59260a0eb6a7</data>
    </edge>
    <edge source="ROCATINLIMAB" target="NCT03096223">
      <data key="d4">14.0</data>
      <data key="d5">NCT03096223 is a clinical trial studying rocatinlimab in moderate-to-severe atopic dermatitis</data>
      <data key="d6">b201c6ff3e22b2475c8c59260a0eb6a7</data>
    </edge>
    <edge source="ROCATINLIMAB" target="NCT03703102">
      <data key="d4">14.0</data>
      <data key="d5">NCT03703102 is a phase 2b clinical trial studying rocatinlimab in moderate-to-severe atopic dermatitis</data>
      <data key="d6">b201c6ff3e22b2475c8c59260a0eb6a7</data>
    </edge>
    <edge source="ROCATINLIMAB" target="OX-40">
      <data key="d4">8.0</data>
      <data key="d5">Rocatinlimab targets OX-40</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </edge>
    <edge source="AMLITELIMAB" target="T-CELL">
      <data key="d4">16.0</data>
      <data key="d5">Amlitelimab aims to restore immune homeostasis between pro-inflammatory and anti-inflammatory T-cells</data>
      <data key="d6">b876251511f570468eb5b6ee6a239cc6</data>
    </edge>
    <edge source="AMLITELIMAB" target="TH1">
      <data key="d4">14.0</data>
      <data key="d5">Amlitelimab blocks Th1 inflammation</data>
      <data key="d6">b876251511f570468eb5b6ee6a239cc6</data>
    </edge>
    <edge source="AMLITELIMAB" target="TH22">
      <data key="d4">14.0</data>
      <data key="d5">Amlitelimab blocks Th22 inflammation</data>
      <data key="d6">b876251511f570468eb5b6ee6a239cc6</data>
    </edge>
    <edge source="AMLITELIMAB" target="AD">
      <data key="d4">50.0</data>
      <data key="d5">Amlitelimab was evaluated in a phase 2a trial for patients with atopic dermatitis
Amlitelimab is used to treat moderate-to-severe atopic dermatitis
Amlitelimab is being studied as a treatment for atopic dermatitis</data>
      <data key="d6">b201c6ff3e22b2475c8c59260a0eb6a7,b876251511f570468eb5b6ee6a239cc6,dc905ba8b6eb7d84cf2776303211010d</data>
    </edge>
    <edge source="AMLITELIMAB" target="HYPERSENSITIVITY">
      <data key="d4">12.0</data>
      <data key="d5">Amlitelimab caused a possible mild and self-limited hypersensitivity reaction in one subject</data>
      <data key="d6">b876251511f570468eb5b6ee6a239cc6</data>
    </edge>
    <edge source="AMLITELIMAB" target="TEAE">
      <data key="d4">14.0</data>
      <data key="d5">TEAEs were reported in subjects treated with amlitelimab</data>
      <data key="d6">b876251511f570468eb5b6ee6a239cc6</data>
    </edge>
    <edge source="AMLITELIMAB" target="NCT03161288">
      <data key="d4">26.0</data>
      <data key="d5">NCT03161288 is the clinical trial identifier for evaluating amlitelimab
NCT03161288 is a clinical trial studying amlitelimab in healthy subjects</data>
      <data key="d6">b201c6ff3e22b2475c8c59260a0eb6a7,b876251511f570468eb5b6ee6a239cc6</data>
    </edge>
    <edge source="AMLITELIMAB" target="NCT03754309">
      <data key="d4">16.0</data>
      <data key="d5">NCT03754309 is the clinical trial identifier for evaluating amlitelimab
NCT03754309 is a phase 2a clinical trial studying amlitelimab in moderate-to-severe atopic dermatitis</data>
      <data key="d6">b201c6ff3e22b2475c8c59260a0eb6a7,b876251511f570468eb5b6ee6a239cc6</data>
    </edge>
    <edge source="AMLITELIMAB" target="IL-22">
      <data key="d4">25.0</data>
      <data key="d5">Amlitelimab treatment leads to a significant decrease in IL-22 serum levels
Amlitelimab reduces IL-22 serum levels</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd,dc905ba8b6eb7d84cf2776303211010d</data>
    </edge>
    <edge source="AMLITELIMAB" target="NCT05131477">
      <data key="d4">16.0</data>
      <data key="d5">Amlitelimab is being evaluated in a Phase 2b study (NCT05131477) for atopic dermatitis</data>
      <data key="d6">dc905ba8b6eb7d84cf2776303211010d</data>
    </edge>
    <edge source="AMLITELIMAB" target="NCT05492578">
      <data key="d4">16.0</data>
      <data key="d5">Amlitelimab is being evaluated in a long-term extension study (NCT05492578) for atopic dermatitis</data>
      <data key="d6">dc905ba8b6eb7d84cf2776303211010d</data>
    </edge>
    <edge source="AMLITELIMAB" target="NCT05421598">
      <data key="d4">14.0</data>
      <data key="d5">Amlitelimab is being evaluated for the treatment of moderate-to-severe asthma (NCT05421598)</data>
      <data key="d6">dc905ba8b6eb7d84cf2776303211010d</data>
    </edge>
    <edge source="AMLITELIMAB" target="HEADACHE">
      <data key="d4">12.0</data>
      <data key="d5">Headache was a treatment-emergent adverse event in patients treated with amlitelimab</data>
      <data key="d6">b201c6ff3e22b2475c8c59260a0eb6a7</data>
    </edge>
    <edge source="AMLITELIMAB" target="VITAL SIGNS">
      <data key="d4">12.0</data>
      <data key="d5">Changes in vital signs were monitored in clinical trials of amlitelimab</data>
      <data key="d6">b201c6ff3e22b2475c8c59260a0eb6a7</data>
    </edge>
    <edge source="AMLITELIMAB" target="LABORATORY SAFETY DATA">
      <data key="d4">12.0</data>
      <data key="d5">Laboratory safety data were monitored in clinical trials of amlitelimab</data>
      <data key="d6">b201c6ff3e22b2475c8c59260a0eb6a7</data>
    </edge>
    <edge source="AMLITELIMAB" target="ANTI-VIRAL ANTIBODY">
      <data key="d4">12.0</data>
      <data key="d5">Anti-viral antibody levels were monitored in clinical trials of amlitelimab</data>
      <data key="d6">b201c6ff3e22b2475c8c59260a0eb6a7</data>
    </edge>
    <edge source="AMLITELIMAB" target="VIRAL DNA">
      <data key="d4">12.0</data>
      <data key="d5">Viral DNA levels were monitored in clinical trials of amlitelimab</data>
      <data key="d6">b201c6ff3e22b2475c8c59260a0eb6a7</data>
    </edge>
    <edge source="AMLITELIMAB" target="CYTOKINES">
      <data key="d4">12.0</data>
      <data key="d5">Cytokine levels were monitored in clinical trials of amlitelimab</data>
      <data key="d6">b201c6ff3e22b2475c8c59260a0eb6a7</data>
    </edge>
    <edge source="AMLITELIMAB" target="ELECTROCARDIOGRAMS">
      <data key="d4">12.0</data>
      <data key="d5">Electrocardiograms were monitored in clinical trials of amlitelimab</data>
      <data key="d6">b201c6ff3e22b2475c8c59260a0eb6a7</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="PRURITUS">
      <data key="d4">36.0</data>
      <data key="d5">Pruritus is a symptom of atopic dermatitis
Pruritus is a common symptom of atopic dermatitis
Pruritus is a symptom of Atopic Dermatitis</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b,691cb2e23ac3c6e591129d16714f8ef8,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="TOPICAL CORTICOSTEROIDS">
      <data key="d4">24.0</data>
      <data key="d5">Topical corticosteroids are used in the treatment of atopic dermatitis
Topical corticosteroids are used to treat AD flares</data>
      <data key="d6">1596d061dbe1a1c9e8f31a02a21e5524,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="CALCINEURIN INHIBITORS">
      <data key="d4">22.0</data>
      <data key="d5">Calcineurin inhibitors are used in the treatment of atopic dermatitis
Calcineurin inhibitors, such as pimecrolimus and tacrolimus, are used as topical treatments for Atopic Dermatitis</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="CRISABOROLE">
      <data key="d4">30.0</data>
      <data key="d5">Crisaborole is used in the treatment of atopic dermatitis
Crisaborole is a topical treatment approved for Atopic Dermatitis
Crisaborole is used to treat AD</data>
      <data key="d6">1596d061dbe1a1c9e8f31a02a21e5524,693a2aac101eaaadf92614317a1e4da8,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="PHOTOTHERAPY">
      <data key="d4">22.0</data>
      <data key="d5">Phototherapy is used in the treatment of atopic dermatitis
Phototherapy is a treatment approach for Atopic Dermatitis that involves the use of ultraviolet light</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="IMMUNOSUPPRESSANTS">
      <data key="d4">20.0</data>
      <data key="d5">Conventional systemic immunosuppressants are used in the treatment of atopic dermatitis
Immunosuppressants are systemic agents used in the treatment of Atopic Dermatitis</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="TRALOKINUMAB">
      <data key="d4">46.0</data>
      <data key="d5">Tralokinumab is used in the treatment of atopic dermatitis
Tralokinumab is in advanced-stage trials for Atopic Dermatitis
Tralokinumab is an anti-IL-13 inhibitor approved for the treatment of AD
Tralokinumab is used to target IL-13 in the treatment of atopic dermatitis
Tralokinumab is a biologic agent targeting interleukin-13 in atopic dermatitis treatment</data>
      <data key="d6">1596d061dbe1a1c9e8f31a02a21e5524,3dfbb4c51838e0951f53ce951395225f,693a2aac101eaaadf92614317a1e4da8,e075bccd45593ae008b2ce7f9ed8ff6c,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="ABROCITINIB">
      <data key="d4">17.0</data>
      <data key="d5">Abrocitinib is used in the treatment of atopic dermatitis
Abrocitinib is a Janus kinase (JAK) inhibitor used as a targeted therapy for Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="BARICITINIB">
      <data key="d4">33.0</data>
      <data key="d5">Baricitinib is used in the treatment of atopic dermatitis
Baricitinib is a JAK1/2 inhibitor approved for the treatment of AD
Baricitinib is a Janus kinase (JAK) inhibitor used as a targeted therapy for Atopic Dermatitis</data>
      <data key="d6">1596d061dbe1a1c9e8f31a02a21e5524,6ada075e562abd7bd445164e9fc309b4,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="LEBRIKIZUMAB">
      <data key="d4">29.0</data>
      <data key="d5">Lebrikizumab is in clinical development for the treatment of atopic dermatitis
Lebrikizumab is in advanced-stage trials for Atopic Dermatitis
Lebrikizumab is used to target IL-13 in the treatment of atopic dermatitis
Lebrikizumab is a biologic agent targeting interleukin-13 in atopic dermatitis treatment</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f,693a2aac101eaaadf92614317a1e4da8,e075bccd45593ae008b2ce7f9ed8ff6c,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="NEMOLIZUMAB">
      <data key="d4">14.0</data>
      <data key="d5">Nemolizumab is in clinical development for the treatment of atopic dermatitis</data>
      <data key="d6">e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="TH2">
      <data key="d4">30.0</data>
      <data key="d5">Th2 cells are involved in the immune response in atopic dermatitis
TH2 cells are involved in the adaptive immune response in atopic dermatitis
Th2 cells are involved in the immune response and associated with cytokine production in Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4,83eb9003d42977bb83fea1d123dd5ab9,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="TH22">
      <data key="d4">23.0</data>
      <data key="d5">Th22 cells are involved in the immune response in atopic dermatitis
TH22 cells are part of the adaptive immune response in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="TH1">
      <data key="d4">23.0</data>
      <data key="d5">Th1 cells are involved in the immune response in atopic dermatitis
TH1 cells are part of the adaptive immune response in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="FILAGGRIN">
      <data key="d4">25.0</data>
      <data key="d5">Filaggrin is downregulated in atopic dermatitis
Filaggrin (FLG) has the greatest genetic association with Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="LORICRIN">
      <data key="d4">16.0</data>
      <data key="d5">Loricrin is downregulated in atopic dermatitis</data>
      <data key="d6">e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="TSLP">
      <data key="d4">16.0</data>
      <data key="d5">TSLP is involved in the immune response in atopic dermatitis</data>
      <data key="d6">e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="IL-25">
      <data key="d4">23.0</data>
      <data key="d5">IL-25 is involved in the immune response in atopic dermatitis
IL-25 is a cytokine involved in the immune response and associated with Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="IL-33">
      <data key="d4">16.0</data>
      <data key="d5">IL-33 is involved in the immune response in atopic dermatitis</data>
      <data key="d6">e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="IGE">
      <data key="d4">47.0</data>
      <data key="d5">IgE is involved in the immune response in atopic dermatitis
Increased IgE serum level is a hallmark of Atopic Dermatitis
IgE is involved in sensitization to environmental allergens in atopic dermatitis
IgE levels are elevated in up to 80% of patients with Atopic Dermatitis
IgE levels are measured in patients with atopic dermatitis</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd,48288f3ec2832850282f95d4e38d10e1,691cb2e23ac3c6e591129d16714f8ef8,83eb9003d42977bb83fea1d123dd5ab9,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="HISTAMINE">
      <data key="d4">9.0</data>
      <data key="d5">Histamine is involved in pruritus in atopic dermatitis</data>
      <data key="d6">e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="EASI">
      <data key="d4">17.0</data>
      <data key="d5">EASI is a measure used to assess the severity of atopic dermatitis
EASI is used to measure the extent and severity of Atopic Dermatitis</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="IL-31">
      <data key="d4">15.0</data>
      <data key="d5">IL-31 is involved in the immune response and pruritus in atopic dermatitis
IL-31 is a cytokine involved in the immune response and associated with Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="INTERCELLULAR LIPIDS">
      <data key="d4">8.0</data>
      <data key="d5">Intercellular lipids are disrupted in atopic dermatitis</data>
      <data key="d6">e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="TIGHT JUNCTIONS">
      <data key="d4">8.0</data>
      <data key="d5">Tight junctions are disrupted in atopic dermatitis</data>
      <data key="d6">e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="EPIDERMIS">
      <data key="d4">16.0</data>
      <data key="d5">The epidermis is affected by atopic dermatitis
The epidermis is affected in Atopic Dermatitis</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1,e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="ALARMIN CYTOKINES">
      <data key="d4">1.0</data>
      <data key="d5">Alarmin cytokines are involved in the immune response in atopic dermatitis</data>
      <data key="d6">e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="TYPE 2 T HELPER CELLS">
      <data key="d4">9.0</data>
      <data key="d5">Type 2 T helper cells are inappropriately activated in Atopic Dermatitis</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="TYPE 2 INNATE LYMPHOID CELLS">
      <data key="d4">9.0</data>
      <data key="d5">Type 2 innate lymphoid cells are inappropriately activated in Atopic Dermatitis</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="CORTICOSTEROIDS">
      <data key="d4">6.0</data>
      <data key="d5">Corticosteroids are systemic agents used in the treatment of Atopic Dermatitis</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="PIMECROLIMUS">
      <data key="d4">14.0</data>
      <data key="d5">Pimecrolimus is a topical treatment approved for Atopic Dermatitis
Pimecrolimus is used to treat AD</data>
      <data key="d6">1596d061dbe1a1c9e8f31a02a21e5524,693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="TACROLIMUS">
      <data key="d4">14.0</data>
      <data key="d5">Tacrolimus is a topical treatment approved for Atopic Dermatitis
Tacrolimus is used to treat AD</data>
      <data key="d6">1596d061dbe1a1c9e8f31a02a21e5524,693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="STAPHYLOCOCCUS AUREUS">
      <data key="d4">22.0</data>
      <data key="d5">Patients with Atopic Dermatitis are at increased risk of infection from Staphylococcus aureus
Staphylococcus aureus overgrows in the skin of atopic dermatitis patients</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8,83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="HERPES SIMPLEX TYPE 1 VIRUS">
      <data key="d4">14.0</data>
      <data key="d5">Patients with Atopic Dermatitis are at increased risk of infection from Herpes simplex type 1 virus</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="CARDIOVASCULAR DISEASES">
      <data key="d4">12.0</data>
      <data key="d5">Cardiovascular diseases are comorbidities associated with Atopic Dermatitis</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="NEUROPSYCHIATRIC DISEASES">
      <data key="d4">12.0</data>
      <data key="d5">Neuropsychiatric diseases are comorbidities associated with Atopic Dermatitis</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="MALIGNANT DISEASES">
      <data key="d4">12.0</data>
      <data key="d5">Malignant diseases are comorbidities associated with Atopic Dermatitis</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="ANXIETY">
      <data key="d4">12.0</data>
      <data key="d5">Anxiety is more common in patients with Atopic Dermatitis</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="DEPRESSION">
      <data key="d4">12.0</data>
      <data key="d5">Depression is more common in patients with Atopic Dermatitis</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="ATTENTION-DEFICIT/HYPERACTIVITY DISORDER">
      <data key="d4">12.0</data>
      <data key="d5">ADHD is more common in patients with Atopic Dermatitis</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="ITCH">
      <data key="d4">29.0</data>
      <data key="d5">Persistent itch is a primary symptom of Atopic Dermatitis
Itch is a common symptom associated with atopic dermatitis</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8,83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="REDNESS">
      <data key="d4">20.0</data>
      <data key="d5">Marked redness is a primary symptom of Atopic Dermatitis</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="CRACKING">
      <data key="d4">16.0</data>
      <data key="d5">Cracking of the skin is a symptom of Atopic Dermatitis</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="DRYNESS">
      <data key="d4">16.0</data>
      <data key="d5">Dryness of the skin is a symptom of Atopic Dermatitis</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="T CELLS">
      <data key="d4">21.0</data>
      <data key="d5">T cells are increased in the circulation and skin tissue of patients with Atopic Dermatitis
T cells are effectors in the inflammatory reaction in atopic dermatitis</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8,83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="B CELLS">
      <data key="d4">9.0</data>
      <data key="d5">B cells are increased in the circulation and skin tissue of patients with Atopic Dermatitis
B cells are involved in the immune response in atopic dermatitis</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8,83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="CYTOKINES">
      <data key="d4">16.0</data>
      <data key="d5">Cytokines, including IL-13 and IL-4, are involved in tissue inflammation and epidermal barrier dysfunction in Atopic Dermatitis
Cytokines are involved in the inflammatory response in atopic dermatitis and are targeted by biologics</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8,83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="EMOLLIENTS">
      <data key="d4">6.0</data>
      <data key="d5">Emollients are used as topical therapies to moisturize and soothe the skin in Atopic Dermatitis</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="AZATHIOPRINE">
      <data key="d4">14.0</data>
      <data key="d5">Azathioprine is an immunosuppressant used in the systemic treatment of Atopic Dermatitis
Azathioprine is used to treat severe forms of AD</data>
      <data key="d6">1596d061dbe1a1c9e8f31a02a21e5524,693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="T HELPER CELLS">
      <data key="d4">8.0</data>
      <data key="d5">T helper cells, including Th2 cells, are involved in the immune response in Atopic Dermatitis</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="INNATE LYMPHOID CELLS">
      <data key="d4">8.0</data>
      <data key="d5">Innate lymphoid cells, including ILC2 cells, are involved in the immune response in Atopic Dermatitis</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="EPIDERMAL BARRIER">
      <data key="d4">27.0</data>
      <data key="d5">The epidermal barrier is dysfunctional in Atopic Dermatitis
Epidermal barrier dysfunction is a key feature of AD
The epidermal barrier is compromised in Atopic Dermatitis</data>
      <data key="d6">1596d061dbe1a1c9e8f31a02a21e5524,693a2aac101eaaadf92614317a1e4da8,6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="CICLOSPORIN A">
      <data key="d4">8.0</data>
      <data key="d5">Ciclosporin A is used to treat severe forms of AD</data>
      <data key="d6">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="IMMUNE RESPONSE">
      <data key="d4">9.0</data>
      <data key="d5">Dysregulated immune response is involved in AD</data>
      <data key="d6">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="SKIN MICROBIOME">
      <data key="d4">15.0</data>
      <data key="d5">Skin microbiome influences AD
The skin microbiome can influence the development and progression of atopic dermatitis</data>
      <data key="d6">1596d061dbe1a1c9e8f31a02a21e5524,83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="ITCH-SCRATCH CYCLE">
      <data key="d4">8.0</data>
      <data key="d5">Itch-scratch cycle worsens AD symptoms</data>
      <data key="d6">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="ALLERGIC RHINO-CONJUNCTIVITIS">
      <data key="d4">7.0</data>
      <data key="d5">Allergic rhino-conjunctivitis is a comorbidity of AD</data>
      <data key="d6">1596d061dbe1a1c9e8f31a02a21e5524</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="CARDIOVASCULAR DISORDERS">
      <data key="d4">12.0</data>
      <data key="d5">Cardiovascular disorders are potential comorbidities of AD
Cardiovascular disorders are significant comorbidities associated with Atopic Dermatitis</data>
      <data key="d6">1596d061dbe1a1c9e8f31a02a21e5524,6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="NEUROPSYCHIATRIC DISORDERS">
      <data key="d4">7.0</data>
      <data key="d5">Neuropsychiatric disorders are potential comorbidities of AD
Neuropsychiatric disorders are significant comorbidities associated with Atopic Dermatitis</data>
      <data key="d6">1596d061dbe1a1c9e8f31a02a21e5524,6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="AD">
      <data key="d4">1.0</data>
      <data key="d5">Atopic Dermatitis is also referred to as AD</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="SCORAD">
      <data key="d4">25.0</data>
      <data key="d5">SCORAD is used to assess the severity of Atopic Dermatitis
SCORAD is used to assess the severity of Atopic Dermatitis
SCORAD is used to assess the severity of atopic dermatitis</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd,48288f3ec2832850282f95d4e38d10e1,691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="TCS">
      <data key="d4">8.0</data>
      <data key="d5">Topical corticosteroids are used to reduce inflammation in Atopic Dermatitis</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="IL-22">
      <data key="d4">15.0</data>
      <data key="d5">IL-22 is part of the transcriptomic signature in Atopic Dermatitis
IL-22 is a cytokine involved in the immune response and associated with Atopic Dermatitis</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1,6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="RISANKIZUMAB">
      <data key="d4">14.0</data>
      <data key="d5">Risankizumab is investigated for the treatment of Atopic Dermatitis
Risankizumab is used to target IL-23 in the treatment of atopic dermatitis</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="TREG CELL">
      <data key="d4">8.0</data>
      <data key="d5">Treg cells do not properly exert their dampening activity in Atopic Dermatitis</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="INTRINSIC AD">
      <data key="d4">8.0</data>
      <data key="d5">Intrinsic AD is a subtype of Atopic Dermatitis</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="ASIAN PATIENTS">
      <data key="d4">7.0</data>
      <data key="d5">Asian patients are studied in the context of Atopic Dermatitis</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="TRANSCRIPTOMIC SIGNATURE">
      <data key="d4">8.0</data>
      <data key="d5">IL-22 is part of the transcriptomic signature in Atopic Dermatitis</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="POLYSENSITIZATION">
      <data key="d4">7.0</data>
      <data key="d5">Polysensitization is a symptom of Atopic Dermatitis</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="OLIGOSENSITIZATION">
      <data key="d4">7.0</data>
      <data key="d5">Oligosensitization is a symptom of Atopic Dermatitis</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="ETRASIMOD">
      <data key="d4">8.0</data>
      <data key="d5">Etrasimod is being advanced into phase 3 clinical trials for the treatment of atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="ASLAN004">
      <data key="d4">22.0</data>
      <data key="d5">ASLAN004 is undergoing multiple ascending dose studies for the treatment of atopic dermatitis
ASLAN004 is used to target IL-13R&#945;1 in the treatment of atopic dermatitis
ASLAN004 is a biologic agent targeting interleukin-13Ra1 in atopic dermatitis treatment</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f,83eb9003d42977bb83fea1d123dd5ab9,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="FB-401">
      <data key="d4">36.0</data>
      <data key="d5">FB-401 is being tested in clinical trials for the treatment of atopic dermatitis in children and adults
FB-401 is used as a bacterial replacement therapy in the treatment of atopic dermatitis
FB-401 targets TNFR activation and bacterial substitution in atopic dermatitis treatment</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f,83eb9003d42977bb83fea1d123dd5ab9,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="KY1005">
      <data key="d4">15.0</data>
      <data key="d5">KY1005 has shown positive phase 2a results for the treatment of moderate to severe atopic dermatitis
KY1005 is used to target OX40L in the treatment of atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="DIFAMILAST">
      <data key="d4">8.0</data>
      <data key="d5">Difamilast (OPA-15406) is a drug candidate for atopic dermatitis, currently in phase 3 studies in Japan</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="RPT193">
      <data key="d4">15.0</data>
      <data key="d5">RPT193 is being tested in a phase 1b trial for the treatment of atopic dermatitis
RPT193 is used to target CCR4 in the treatment of atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="STAPHYLOCOCCUS HOMINIS">
      <data key="d4">7.0</data>
      <data key="d5">Staphylococcus hominis can help in the recovery of skin microbiome in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="STAPHYLOCOCCUS EPIDERMIDIS">
      <data key="d4">7.0</data>
      <data key="d5">Staphylococcus epidermidis can help in the recovery of skin microbiome in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="ARYL-HYDROCARBON RECEPTOR">
      <data key="d4">7.0</data>
      <data key="d5">Aryl-hydrocarbon receptor is targeted for intervention in the early stages of atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="ALARMINS">
      <data key="d4">7.0</data>
      <data key="d5">Alarmins are targeted for intervention in the early stages of atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="SPHINGOSINE 1-PHOSPHATE RECEPTOR">
      <data key="d4">7.0</data>
      <data key="d5">Sphingosine 1-phosphate receptor is involved in the migratory activity of T cells in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="C-C CHEMOKINE RECEPTOR 4">
      <data key="d4">7.0</data>
      <data key="d5">C-C chemokine receptor 4 is involved in the migration of T cells into the skin in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="JANUS KINASES">
      <data key="d4">7.0</data>
      <data key="d5">Janus kinases are involved in the signal transduction of cytokine receptors and are targeted by JAK inhibitors in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="TROPOMYOSIN RECEPTOR KINASE">
      <data key="d4">7.0</data>
      <data key="d5">Tropomyosin receptor kinase is involved in pathways related to nerve growth factor in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="BRUTON TYROSINE KINASE">
      <data key="d4">7.0</data>
      <data key="d5">Bruton tyrosine kinase is involved in the signal transduction of the B cell receptor in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="HISTAMINE RECEPTOR 4">
      <data key="d4">7.0</data>
      <data key="d5">Histamine receptor 4 is involved in immunomodulatory mechanisms in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="PHOSPHODIESTERASE 4">
      <data key="d4">25.0</data>
      <data key="d5">Phosphodiesterase 4 is targeted by inhibitors to increase cellular levels of cAMP and reduce inflammation in atopic dermatitis
Inhibitors of Phosphodiesterase 4 (PDE4) are used to reduce inflammation in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="MAST CELLS">
      <data key="d4">15.0</data>
      <data key="d5">Mast cells express high-affinity receptors for IgE and are involved in the immune response in atopic dermatitis
Mast cells are elevated in the skin of Atopic Dermatitis patients</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4,83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="DENDRITIC CELLS">
      <data key="d4">7.0</data>
      <data key="d5">Dendritic cells express high-affinity receptors for IgE and are involved in the immune response in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="SENSING NEURONS">
      <data key="d4">2.0</data>
      <data key="d5">Sensing neurons in the skin can be activated by multiple mediators generated during the inflammatory reaction in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="INNATE IMMUNITY">
      <data key="d4">8.0</data>
      <data key="d5">Innate immunity is the first line of defense activated in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="ADAPTIVE IMMUNITY">
      <data key="d4">8.0</data>
      <data key="d5">Adaptive immunity is activated following innate immunity in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="IMMUNOLOGICAL MARCH">
      <data key="d4">8.0</data>
      <data key="d5">The immunological march describes the progression of immune responses in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="IL-31 RECEPTOR">
      <data key="d4">16.0</data>
      <data key="d5">Blockade of IL-31 receptor (IL-31R) is a strategy to reduce itching in atopic dermatitis</data>
      <data key="d6">e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="NEUROKININ 1 RECEPTOR">
      <data key="d4">16.0</data>
      <data key="d5">Blockade of Neurokinin 1 receptor (NK1R) is a strategy to reduce itching in atopic dermatitis</data>
      <data key="d6">e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="PURINORECEPTOR 3">
      <data key="d4">16.0</data>
      <data key="d5">Blockade of Purinoreceptor 3 (P2X3) is a strategy to reduce itching in atopic dermatitis</data>
      <data key="d6">e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="OX40 LIGAND">
      <data key="d4">14.0</data>
      <data key="d5">OX40L is involved in the immune response in atopic dermatitis</data>
      <data key="d6">e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="T HELPER CELL">
      <data key="d4">14.0</data>
      <data key="d5">T helper cells (TH cells) play a crucial role in the immune response in atopic dermatitis</data>
      <data key="d6">e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="THYMIC STROMAL LYMPHOPOIETIN">
      <data key="d4">14.0</data>
      <data key="d5">TSLP is involved in the initiation of allergic inflammation in atopic dermatitis</data>
      <data key="d6">e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="B244">
      <data key="d4">28.0</data>
      <data key="d5">B244 is used as a nitric oxide donor in the treatment of atopic dermatitis
B244 is used for microbiome modulation in atopic dermatitis treatment</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="SHA9">
      <data key="d4">28.0</data>
      <data key="d5">ShA9 is used as a targeted microbiome transplant in the treatment of atopic dermatitis
ShA9 is a microbiota selected for transplant in atopic dermatitis treatment</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="CLS-001">
      <data key="d4">28.0</data>
      <data key="d5">CLS-001 is used as a cell membrane enhancer in the treatment of atopic dermatitis
CLS-001 is a small molecule used in atopic dermatitis treatment</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="ATX201">
      <data key="d4">28.0</data>
      <data key="d5">ATx201 is used for its protonophore activity in the treatment of atopic dermatitis
Atx201 is a small molecule used in atopic dermatitis treatment</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="EDP1815">
      <data key="d4">28.0</data>
      <data key="d5">EDP1815 is used to modulate systemic inflammation in the treatment of atopic dermatitis
EDP1815 is used for systemic inflammation regulation in atopic dermatitis treatment</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="STMC-103H">
      <data key="d4">28.0</data>
      <data key="d5">STMC-103H is used to modulate the immune system via microbiome manipulation in the treatment of atopic dermatitis
STMC-103H is used for microbiome modulation in atopic dermatitis treatment</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="TAPINAROF">
      <data key="d4">28.0</data>
      <data key="d5">Tapinarof is used as an AhR agonist in the treatment of atopic dermatitis
Tapinarof is a biologic agent used as an Ahr agonist in atopic dermatitis treatment</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="TEZEPELUMAB">
      <data key="d4">28.0</data>
      <data key="d5">Tezepelumab is used to target TSLP in the treatment of atopic dermatitis
Tezepelumab is a biologic agent targeting TSLP in atopic dermatitis treatment</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="ETOKIMAB">
      <data key="d4">28.0</data>
      <data key="d5">Etokimab is used to target IL-33 in the treatment of atopic dermatitis
Etokimab is a biologic agent targeting interleukin-33 in atopic dermatitis treatment</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="REGN3500">
      <data key="d4">28.0</data>
      <data key="d5">REGN3500 is used to target IL-33 in the treatment of atopic dermatitis
REGN3500 is a biologic agent targeting interleukin-33 in atopic dermatitis treatment</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="ASTEGOLIMAB">
      <data key="d4">21.0</data>
      <data key="d5">Astegolimab is used to target IL-33 in the treatment of atopic dermatitis
Astegolimab is a biologic agent targeting interleukin-33 in atopic dermatitis treatment</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="MEDI3506">
      <data key="d4">21.0</data>
      <data key="d5">MEDI3506 is used to target IL-33 in the treatment of atopic dermatitis
MEDI3506 is a biologic agent targeting interleukin-33 in atopic dermatitis treatment</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="BERMEKIMAB">
      <data key="d4">21.0</data>
      <data key="d5">Bermekimab is used to target IL-1&#945; in the treatment of atopic dermatitis
Bermekimab is a biologic agent targeting interleukin-1a in atopic dermatitis treatment</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="GBR 830">
      <data key="d4">7.0</data>
      <data key="d5">GBR 830 is used to target OX40 in the treatment of atopic dermatitis</data>
      <data key="d6">e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="KHK4083">
      <data key="d4">7.0</data>
      <data key="d5">KHK4083 is used to target OX40 in the treatment of atopic dermatitis</data>
      <data key="d6">e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="CBP-201">
      <data key="d4">14.0</data>
      <data key="d5">CBP-201 is used to target IL-4R&#945; in the treatment of atopic dermatitis
CBP-201 is a biologic agent targeting interleukin-4Ra in atopic dermatitis treatment</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f,e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="AK120">
      <data key="d4">7.0</data>
      <data key="d5">AK120 is used to target IL-4R&#945; in the treatment of atopic dermatitis</data>
      <data key="d6">e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="BENRALIZUMAB">
      <data key="d4">7.0</data>
      <data key="d5">Benralizumab is used to target IL-5R&#945; in the treatment of atopic dermatitis</data>
      <data key="d6">e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="FB825">
      <data key="d4">7.0</data>
      <data key="d5">FB825 is used to target mIgE in the treatment of atopic dermatitis</data>
      <data key="d6">e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="FEZAKINUMAB">
      <data key="d4">7.0</data>
      <data key="d5">Fezakinumab is used to target IL-22 in the treatment of atopic dermatitis</data>
      <data key="d6">e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="LEO 138559">
      <data key="d4">7.0</data>
      <data key="d5">LEO 138559 is used to target IL-22R1 in the treatment of atopic dermatitis</data>
      <data key="d6">e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="LY3471851">
      <data key="d4">7.0</data>
      <data key="d5">LY3471851 is used to target rhIL-2 to Treg cells in the treatment of atopic dermatitis</data>
      <data key="d6">e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="EOSINOPHILS">
      <data key="d4">8.0</data>
      <data key="d5">Eosinophils are elevated in the skin of Atopic Dermatitis patients</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="LYMPHOCYTES">
      <data key="d4">8.0</data>
      <data key="d5">Lymphocytes infiltrate the skin in Atopic Dermatitis patients</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="IMMUNOGLOBULIN E">
      <data key="d4">8.0</data>
      <data key="d5">Immunoglobulin E (IgE) levels are increased in Atopic Dermatitis patients</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="ITCHING">
      <data key="d4">9.0</data>
      <data key="d5">Itching is a common symptom of Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="RASH">
      <data key="d4">9.0</data>
      <data key="d5">Rash is a common symptom of Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="BLEEDING">
      <data key="d4">7.0</data>
      <data key="d5">Bleeding can occur in Atopic Dermatitis patients due to intense scratching</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="EROSIONS">
      <data key="d4">7.0</data>
      <data key="d5">Erosions are areas of skin damage that can occur in Atopic Dermatitis patients due to scratching</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="PLAQUES">
      <data key="d4">8.0</data>
      <data key="d5">Plaques are thickened areas of skin that are common in Atopic Dermatitis patients</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="ASTHMA">
      <data key="d4">23.0</data>
      <data key="d5">Asthma is a respiratory condition that children with Atopic Dermatitis may develop
Asthma is associated with Atopic Dermatitis
Asthma is a common comorbidity in patients with atopic dermatitis</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd,691cb2e23ac3c6e591129d16714f8ef8,6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="FOOD ALLERGIES">
      <data key="d4">7.0</data>
      <data key="d5">Food Allergies are conditions that children with Atopic Dermatitis may develop</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="COMMON COLD">
      <data key="d4">6.0</data>
      <data key="d5">The common cold is a condition that children with Atopic Dermatitis have a 75% risk of developing</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="GENETICS">
      <data key="d4">8.0</data>
      <data key="d5">Genetics is a factor in the onset and severity of Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="SKIN BARRIER">
      <data key="d4">9.0</data>
      <data key="d5">Abnormalities in the skin barrier contribute to the pathophysiology of Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="IMMUNE SYSTEM">
      <data key="d4">9.0</data>
      <data key="d5">Dysregulation of the immune system plays a significant role in the pathogenesis of Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="INTERLEUKINS">
      <data key="d4">8.0</data>
      <data key="d5">Interleukins influence the immunological pathway in Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="JANUS KINASE">
      <data key="d4">8.0</data>
      <data key="d5">Janus Kinase inhibitors like Baricitinib, Upadacitinib, and Abrocitinib are used as targeted therapies for Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="BIOLOGIC MEDICATIONS">
      <data key="d4">7.0</data>
      <data key="d5">Biologic medications are in various stages of approval or development for treating Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="SMALL MOLECULES">
      <data key="d4">7.0</data>
      <data key="d5">Small molecules have emerged as non-biologic targeted therapies for Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="PERSONALIZED MEDICINE">
      <data key="d4">7.0</data>
      <data key="d5">Personalized medicine is a potential approach for targeted translational research in Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="CLINICAL TRIALS">
      <data key="d4">7.0</data>
      <data key="d5">Clinical trials explore the efficacy and safety of new treatments for Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="PSYCHOLOGICAL FACTORS">
      <data key="d4">6.0</data>
      <data key="d5">Psychological factors can influence the onset and severity of Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="DRUGS">
      <data key="d4">7.0</data>
      <data key="d5">Drugs, including both biologic and non-biologic therapies, are used to treat or manage Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="ENVIRONMENTAL INFLUENCES">
      <data key="d4">7.0</data>
      <data key="d5">Environmental influences affect the onset and severity of Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="FLG GENE">
      <data key="d4">9.0</data>
      <data key="d5">The FLG gene encodes filaggrin, which is crucial for skin barrier function and is associated with Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="SKIN MICROORGANISMS">
      <data key="d4">7.0</data>
      <data key="d5">Skin microorganisms can influence the development and severity of Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="TOPICAL TREATMENTS">
      <data key="d4">7.0</data>
      <data key="d5">Topical treatments are used to manage Atopic Dermatitis symptoms</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="SYSTEMIC TREATMENTS">
      <data key="d4">7.0</data>
      <data key="d5">Systemic treatments are used to manage Atopic Dermatitis symptoms</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="STRATUM CORNEUM FORMATION">
      <data key="d4">8.0</data>
      <data key="d5">Stratum corneum formation is affected in Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="EPIDERMAL COMPLEX">
      <data key="d4">1.0</data>
      <data key="d5">The epidermal complex is affected in Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="BDP">
      <data key="d4">14.0</data>
      <data key="d5">BDP-loaded PMs provided better AD skin healing</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="NICLOSAMIDE">
      <data key="d4">14.0</data>
      <data key="d5">Niclosamide is a small molecule used in atopic dermatitis treatment</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="OMIGANAN">
      <data key="d4">14.0</data>
      <data key="d5">Omiganan is a small molecule used in atopic dermatitis treatment</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="TH2 CELLS">
      <data key="d4">9.0</data>
      <data key="d5">Th2 cells dominate in Atopic Dermatitis</data>
      <data key="d6">691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="SOX40">
      <data key="d4">15.0</data>
      <data key="d5">Serum levels of sOX40 are decreased in patients with Atopic Dermatitis
sOX40 levels are measured in patients with atopic dermatitis</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd,691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="DRY SKIN">
      <data key="d4">9.0</data>
      <data key="d5">Dry skin is a symptom of Atopic Dermatitis</data>
      <data key="d6">691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="MEMORY T CELLS">
      <data key="d4">8.0</data>
      <data key="d5">Memory T cells are central for the chronicity of Atopic Dermatitis</data>
      <data key="d6">691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="PBMCS">
      <data key="d4">7.0</data>
      <data key="d5">PBMCs are isolated for research in Atopic Dermatitis</data>
      <data key="d6">691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="PLASMA">
      <data key="d4">7.0</data>
      <data key="d5">Plasma is collected for research in Atopic Dermatitis</data>
      <data key="d6">691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="ENZYME-LINKED IMMUNOASSAY (ELISA)">
      <data key="d4">7.0</data>
      <data key="d5">ELISA is used to measure the concentration of soluble OX40 in blood samples from patients with Atopic Dermatitis</data>
      <data key="d6">691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="FLOW CYTOMETRY">
      <data key="d4">7.0</data>
      <data key="d5">Flow Cytometry is used to analyze the expression of OX40 by activated skin-homing CD4+ T cells in Atopic Dermatitis</data>
      <data key="d6">691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="IMMUNOFLUORESCENCE">
      <data key="d4">7.0</data>
      <data key="d5">Immunofluorescence shows the co-location of OX40+ and OX40L+ cells within the dermis in Atopic Dermatitis</data>
      <data key="d6">691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="EPIDERMAL BARRIER DYSFUNCTION">
      <data key="d4">8.0</data>
      <data key="d5">Epidermal Barrier Dysfunction causes dry skin and inflammation in Atopic Dermatitis</data>
      <data key="d6">691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="HANIFIN &amp; RAJKA CRITERIA">
      <data key="d4">7.0</data>
      <data key="d5">Hanifin &amp; Rajka Criteria are used to diagnose patients with Atopic Dermatitis</data>
      <data key="d6">691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="RHINITIS">
      <data key="d4">8.0</data>
      <data key="d5">Rhinitis is a common comorbidity in patients with atopic dermatitis</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="SOX40L">
      <data key="d4">8.0</data>
      <data key="d5">sOX40L levels are measured in patients with atopic dermatitis</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="PERIPHERAL BLOOD MONONUCLEAR CELLS">
      <data key="d4">7.0</data>
      <data key="d5">PBMCs from patients with atopic dermatitis are analyzed by flow cytometry</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="LIGHT">
      <data key="d4">30.0</data>
      <data key="d5">LIGHT is induced in atopic dermatitis
LIGHT is induced in AD and regulates skin fibrosis</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2,df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="PLACEBO">
      <data key="d4">7.0</data>
      <data key="d5">Placebo is used as a control in clinical trials for atopic dermatitis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="KYMAB LIMITED">
      <data key="d4">6.0</data>
      <data key="d5">Kymab Limited is involved in clinical trials for atopic dermatitis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="ICHNOS SCIENCES SA">
      <data key="d4">6.0</data>
      <data key="d5">Ichnos Sciences SA is involved in clinical trials for atopic dermatitis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="ATOPIC DERMATITIS" target="GLENMARK PHARMACEUTICALS S.A.">
      <data key="d4">6.0</data>
      <data key="d5">Glenmark Pharmaceuticals S.A. is involved in clinical trials for atopic dermatitis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="PRURITUS" target="IL-31">
      <data key="d4">44.0</data>
      <data key="d5">IL-31 amplifies pruritus
IL-31 functions to evoke itch, a symptom known as pruritus
IL-31 induces pruritus symptoms in AD patients</data>
      <data key="d6">3df8535e965efb96f5094169610507ff,4842292208575bd45b2b5998513dd087,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="PRURITUS" target="HISTAMINE">
      <data key="d4">18.0</data>
      <data key="d5">Histamine amplifies pruritus</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="PRURITUS" target="AD">
      <data key="d4">98.0</data>
      <data key="d5">Pruritus is a symptom of atopic dermatitis
Pruritus is a common symptom in atopic dermatitis
Pruritus is a common symptom of atopic dermatitis
Pruritus is a common symptom in atopic dermatitis
Pruritus is a symptom of atopic dermatitis
Pruritus, or itching, is a common symptom associated with Atopic Dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e,28f548554737fcc026b968db6bbafa30,3287c502f10f4651d2f56bf39ee7bb7a,90f4809673ca34628b0e607908f0bf0b,b201c6ff3e22b2475c8c59260a0eb6a7,b876251511f570468eb5b6ee6a239cc6</data>
    </edge>
    <edge source="PRURITUS" target="NRS">
      <data key="d4">26.0</data>
      <data key="d5">NRS is used to measure the intensity of pruritus
NRS is used to measure the intensity of pruritus</data>
      <data key="d6">3287c502f10f4651d2f56bf39ee7bb7a,b876251511f570468eb5b6ee6a239cc6</data>
    </edge>
    <edge source="PRURITUS" target="NEMOLIZUMAB">
      <data key="d4">8.0</data>
      <data key="d5">Nemolizumab is used to mitigate IL-31&#8211;dependent processes, including pruritus</data>
      <data key="d6">f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="PRURITUS" target="PP-NRS-11">
      <data key="d4">8.0</data>
      <data key="d5">Pruritus is measured by the PP-NRS-11 tool</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="PRURITUS" target="B244">
      <data key="d4">7.0</data>
      <data key="d5">B244 induced significant improvement of pruritus in AD</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="PRURITUS" target="LEBRIKIZUMAB">
      <data key="d4">14.0</data>
      <data key="d5">Lebrikizumab showed improvement in pruritus NRS</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41</data>
    </edge>
    <edge source="PRURITUS" target="MEPOLIZUMAB">
      <data key="d4">12.0</data>
      <data key="d5">Mepolizumab failed to show a significant decrease in pruritus</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41</data>
    </edge>
    <edge source="PRURITUS" target="H1R">
      <data key="d4">8.0</data>
      <data key="d5">H1R in the skin induces pruritus</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="TOPICAL CORTICOSTEROIDS" target="AD">
      <data key="d4">8.0</data>
      <data key="d5">Topical corticosteroids are used to reduce inflammation in atopic dermatitis</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </edge>
    <edge source="TOPICAL CORTICOSTEROIDS" target="TRALOKINUMAB">
      <data key="d4">8.0</data>
      <data key="d5">Tralokinumab is used with topical corticosteroids for treating AD</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="CRISABOROLE" target="PHOSPHODIESTERASE-4">
      <data key="d4">7.0</data>
      <data key="d5">Crisaborole targets Phosphodiesterase-4 in the treatment of Atopic Dermatitis</data>
      <data key="d6">693a2aac101eaaadf92614317a1e4da8</data>
    </edge>
    <edge source="CRISABOROLE" target="PDE-4">
      <data key="d4">9.0</data>
      <data key="d5">Crisaborole is a topical PDE-4 inhibitor</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="CRISABOROLE" target="AD">
      <data key="d4">41.0</data>
      <data key="d5">Crisaborole is approved for the treatment of mild to moderate atopic dermatitis
Crisaborole is a topical PDE4 inhibitor approved for the treatment of Atopic Dermatitis
Crisaborole is used for treating AD</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c,442e7fad2fab75fa2449309783294d89,90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="CRISABOROLE" target="EMA">
      <data key="d4">14.0</data>
      <data key="d5">The European Medicines Agency is responsible for the approval of drugs like crisaborole in Europe</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="TRALOKINUMAB" target="AD">
      <data key="d4">33.0</data>
      <data key="d5">Tralokinumab is used to treat atopic dermatitis
Tralokinumab is evaluated for the treatment of AD
Tralokinumab has shown initial success in treating atopic dermatitis</data>
      <data key="d6">104cc78517b2eca2e9cb7e00de1fe4b0,96e553a44a27e728c27c4892045ec5c2,dc905ba8b6eb7d84cf2776303211010d</data>
    </edge>
    <edge source="TRALOKINUMAB" target="EMA">
      <data key="d4">8.0</data>
      <data key="d5">Tralokinumab received a positive opinion from the EMA</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="TRALOKINUMAB" target="ECZTRA1">
      <data key="d4">24.0</data>
      <data key="d5">Tralokinumab showed superiority to placebo in the ECZTRA1 study
Tralokinumab was evaluated in the ECZTRA1 study</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41,78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="TRALOKINUMAB" target="ECZTRA2">
      <data key="d4">24.0</data>
      <data key="d5">Tralokinumab showed superiority to placebo in the ECZTRA2 study
Tralokinumab was evaluated in the ECZTRA2 study</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41,78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="TRALOKINUMAB" target="EMA/CHMP/202204/2021">
      <data key="d4">8.0</data>
      <data key="d5">Tralokinumab received a positive opinion from the EMA</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="TRALOKINUMAB" target="ITCH">
      <data key="d4">16.0</data>
      <data key="d5">Tralokinumab improves itch by targeting IL-13</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="TRALOKINUMAB" target="NERVE ENDINGS">
      <data key="d4">7.0</data>
      <data key="d5">Tralokinumab affects nerve endings</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="TRALOKINUMAB" target="INTERLEUKIN-13RA1">
      <data key="d4">8.0</data>
      <data key="d5">Tralokinumab targets Interleukin-13Ra1</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </edge>
    <edge source="ABROCITINIB" target="AD">
      <data key="d4">16.0</data>
      <data key="d5">Abrocitinib is used in the treatment of atopic dermatitis
Abrocitinib is a JAK inhibitor used for treating moderate to severe AD</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd,a867a1e73cef039eb3f28e072463b838</data>
    </edge>
    <edge source="ABROCITINIB" target="NCT03627767">
      <data key="d4">7.0</data>
      <data key="d5">NCT03627767 is a clinical trial involving Abrocitinib</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="BARICITINIB" target="NCT02576938">
      <data key="d4">8.0</data>
      <data key="d5">NCT02576938 is a phase 2 trial for baricitinib in AD</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="BARICITINIB" target="BREEZE-AD1">
      <data key="d4">8.0</data>
      <data key="d5">BREEZE-AD1 is a phase 3 trial for baricitinib in AD</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="BARICITINIB" target="BREEZE-AD2">
      <data key="d4">8.0</data>
      <data key="d5">BREEZE-AD2 is a phase 3 trial for baricitinib in AD</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="BARICITINIB" target="BREEZE-AD3">
      <data key="d4">8.0</data>
      <data key="d5">BREEZE-AD3 is a phase 3 trial for baricitinib in AD</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="BARICITINIB" target="BREEZE-AD5">
      <data key="d4">8.0</data>
      <data key="d5">BREEZE-AD5 is a phase 3 trial for baricitinib in AD</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="BARICITINIB" target="BREEZE-AD6">
      <data key="d4">8.0</data>
      <data key="d5">BREEZE-AD6 is a phase 3 trial for baricitinib in AD</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="BARICITINIB" target="BREEZE-AD4">
      <data key="d4">8.0</data>
      <data key="d5">BREEZE-AD4 is a phase 3 trial for baricitinib in AD patients with inadequate response to cyclosporine</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="BARICITINIB" target="NCT03428100">
      <data key="d4">8.0</data>
      <data key="d5">NCT03428100 is a phase 3 trial for baricitinib in AD patients with inadequate response to cyclosporine</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="BARICITINIB" target="AD">
      <data key="d4">39.0</data>
      <data key="d5">Baricitinib is approved for treating atopic dermatitis
Baricitinib is used in the treatment of atopic dermatitis
Baricitinib is a JAK1/JAK2 inhibitor being studied for atopic dermatitis
Baricitinib is a JAK inhibitor used for treating moderate to severe AD</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d,2cec06c4d46f5ff9ee936a78d8b077cd,a867a1e73cef039eb3f28e072463b838,c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="BARICITINIB" target="ECZEMA HERPETICUM">
      <data key="d4">12.0</data>
      <data key="d5">Eczema herpeticum was more frequent in patients treated with baricitinib</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="BARICITINIB" target="NCT03952559">
      <data key="d4">7.0</data>
      <data key="d5">NCT03952559 is a clinical trial involving Baricitinib</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="LEBRIKIZUMAB" target="AD">
      <data key="d4">24.0</data>
      <data key="d5">Lebrikizumab is evaluated for the treatment of AD
Lebrikizumab has shown initial success in treating atopic dermatitis</data>
      <data key="d6">104cc78517b2eca2e9cb7e00de1fe4b0,96e553a44a27e728c27c4892045ec5c2</data>
    </edge>
    <edge source="LEBRIKIZUMAB" target="PERIOSTIN">
      <data key="d4">8.0</data>
      <data key="d5">Lebrikizumab's efficacy in asthma is higher in patients with high levels of periostin</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="LEBRIKIZUMAB" target="FEV1">
      <data key="d4">1.0</data>
      <data key="d5">Lebrikizumab increases FEV1 in asthma patients</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="LEBRIKIZUMAB" target="ASTHMA">
      <data key="d4">8.0</data>
      <data key="d5">Lebrikizumab is used in the treatment of asthma</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="LEBRIKIZUMAB" target="ARBAN">
      <data key="d4">16.0</data>
      <data key="d5">ARBAN is a clinical trial of Lebrikizumab</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="LEBRIKIZUMAB" target="TREBLE">
      <data key="d4">16.0</data>
      <data key="d5">TREBLE is a clinical trial of Lebrikizumab</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="LEBRIKIZUMAB" target="EASI">
      <data key="d4">14.0</data>
      <data key="d5">Lebrikizumab showed improvement in EASI scores</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41</data>
    </edge>
    <edge source="LEBRIKIZUMAB" target="ITCH">
      <data key="d4">16.0</data>
      <data key="d5">Lebrikizumab improves itch by targeting IL-13</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="LEBRIKIZUMAB" target="NERVE ENDINGS">
      <data key="d4">7.0</data>
      <data key="d5">Lebrikizumab affects nerve endings</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="LEBRIKIZUMAB" target="INTERLEUKIN-13">
      <data key="d4">8.0</data>
      <data key="d5">Lebrikizumab targets Interleukin-13</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </edge>
    <edge source="NEMOLIZUMAB" target="IL-31">
      <data key="d4">18.0</data>
      <data key="d5">Nemolizumab targets IL-31 to treat moderate-to-severe atopic dermatitis
Nemolizumab mitigates IL-31&#8211;dependent processes by antagonizing its receptor
Nemolizumab targets the IL-31 receptor</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9,f14a13d54127c3baadeb0b34d40928c9,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="NEMOLIZUMAB" target="ITCH">
      <data key="d4">16.0</data>
      <data key="d5">Nemolizumab reduces pruritus in atopic dermatitis</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="NEMOLIZUMAB" target="IL-31R&#913;">
      <data key="d4">16.0</data>
      <data key="d5">Nemolizumab targets IL-31R&#945;</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="NEMOLIZUMAB" target="PRURIGO NODULARIS">
      <data key="d4">14.0</data>
      <data key="d5">Nemolizumab shows promising results in prurigo nodularis</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="NEMOLIZUMAB" target="PHASE IIA STUDY">
      <data key="d4">7.0</data>
      <data key="d5">Phase IIa study showed nemolizumab reduced pruritus</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="NEMOLIZUMAB" target="PHASE III STUDY">
      <data key="d4">7.0</data>
      <data key="d5">Phase III study confirmed nemolizumab's efficacy in pruritus</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="NEMOLIZUMAB" target="NCT03989349">
      <data key="d4">7.0</data>
      <data key="d5">NCT03989349 is a clinical trial involving Nemolizumab</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="NEMOLIZUMAB" target="NCT03985943">
      <data key="d4">7.0</data>
      <data key="d5">NCT03985943 is a clinical trial involving Nemolizumab</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="NEMOLIZUMAB" target="IL-31RA">
      <data key="d4">16.0</data>
      <data key="d5">Nemolizumab targets IL-31RA to control AD inflammation and pruritus</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="NEMOLIZUMAB" target="INTERLEUKIN-31">
      <data key="d4">8.0</data>
      <data key="d5">Nemolizumab targets Interleukin-31</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </edge>
    <edge source="TH2" target="AD">
      <data key="d4">25.0</data>
      <data key="d5">Th2 pathway is implicated in the pathogenesis of atopic dermatitis
T helper 2 cells play a key role in atopic dermatitis
TH2 cells are involved in the immune response in atopic dermatitis
Th2 cells are involved in the immune response and inflammation in AD</data>
      <data key="d6">143d2dc302af5606656797bff162e23e,41ccc4b41bd57cf2bda4dbb6c7ae4198,a867a1e73cef039eb3f28e072463b838,dc905ba8b6eb7d84cf2776303211010d</data>
    </edge>
    <edge source="TH2" target="IL-31">
      <data key="d4">7.0</data>
      <data key="d5">IL-31 is produced by Th2 cells</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </edge>
    <edge source="TH2" target="SPINK5">
      <data key="d4">7.0</data>
      <data key="d5">SPINK5 mutations favor a pro-TH2 micromilieu</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="TH2" target="IL-5">
      <data key="d4">7.0</data>
      <data key="d5">IL-5 is involved in the TH2 immune response</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="TH2" target="IGE">
      <data key="d4">8.0</data>
      <data key="d5">Increased IgE serum level is a hallmark of a TH2 immune response</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="TH2" target="IMMUNE POLARIZATION">
      <data key="d4">8.0</data>
      <data key="d5">TH2 cells are involved in immune polarization</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="TH2" target="IFN&#915;">
      <data key="d4">14.0</data>
      <data key="d5">IFN&#947; is a cytokine involved in T helper cell responses</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="TH2" target="TNFR2">
      <data key="d4">14.0</data>
      <data key="d5">Impaired TNF/TNFR2 signaling enhances Th2 polarization</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TH2" target="BALF">
      <data key="d4">14.0</data>
      <data key="d5">Inhibiting TNFR2 via antibody treatment led to increased expression of Th2 inflammatory cytokines in BALF</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TH2" target="LIGHT">
      <data key="d4">12.0</data>
      <data key="d5">LIGHT is associated with Th2 polarization in SSc</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2</data>
    </edge>
    <edge source="TH22" target="AD">
      <data key="d4">22.0</data>
      <data key="d5">Th22 pathway is implicated in the pathogenesis of atopic dermatitis
T helper 22 cells are implicated in atopic dermatitis
Th22 cells are involved in the immune response and inflammation in AD</data>
      <data key="d6">143d2dc302af5606656797bff162e23e,41ccc4b41bd57cf2bda4dbb6c7ae4198,dc905ba8b6eb7d84cf2776303211010d</data>
    </edge>
    <edge source="TH1" target="AD">
      <data key="d4">7.0</data>
      <data key="d5">Th1 pathway is implicated in the pathogenesis of atopic dermatitis</data>
      <data key="d6">dc905ba8b6eb7d84cf2776303211010d</data>
    </edge>
    <edge source="TH1" target="INTERFERON-&#915;">
      <data key="d4">16.0</data>
      <data key="d5">Interferon-&#947; production is impaired in OX40 deficient models affecting Th1 differentiation</data>
      <data key="d6">b201c6ff3e22b2475c8c59260a0eb6a7</data>
    </edge>
    <edge source="TH1" target="IL-22">
      <data key="d4">7.0</data>
      <data key="d5">IL-22 is induced by staphylococcal exotoxins in TH1 cells</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="TH1" target="TNFR2">
      <data key="d4">14.0</data>
      <data key="d5">Impaired TNF/TNFR2 signaling inhibits Th1 differentiation</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TH1" target="LIGHT">
      <data key="d4">19.0</data>
      <data key="d5">LIGHT suppresses Th1 chemokine expression
LIGHT suppression of Th1 chemokines is consistent with Th2/Th17 polarization in SSc</data>
      <data key="d6">05c97152fe02249153103be341d65b67,5f37466ca41c9b8b06ed8be0303d49f2</data>
    </edge>
    <edge source="FILAGGRIN" target="IL-22">
      <data key="d4">24.0</data>
      <data key="d5">IL-22 downregulates filaggrin expression
IL-22 downregulates filaggrin expression</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1,4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="FILAGGRIN" target="AD">
      <data key="d4">32.0</data>
      <data key="d5">Filaggrin is suppressed in chronic atopic dermatitis
Filaggrin is involved in the immune response in AD
Mutations in the filaggrin gene are implicated in atopic dermatitis
Mutations in the filaggrin gene affect epidermal barrier function in AD</data>
      <data key="d6">143d2dc302af5606656797bff162e23e,3ea70e257330c812b52334ca1f90d807,b19f42c9497f71b231222cd953036d6b,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="FILAGGRIN" target="IL-33">
      <data key="d4">14.0</data>
      <data key="d5">IL-33 downregulates the expression of filaggrin, contributing to epidermal barrier dysfunctionIL-33 contributes to epidermal barrier dysfunction by downregulating filaggrin expression</data>
      <data key="d6">f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="FILAGGRIN" target="VTP-38543">
      <data key="d4">6.0</data>
      <data key="d5">VTP-38543 increased mRNA expression of filaggrin</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d</data>
    </edge>
    <edge source="FILAGGRIN" target="PRO-FLG">
      <data key="d4">8.0</data>
      <data key="d5">Pro-FLG is dephosphorylated and proteolytically cleaved to form FLG monomers</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="FILAGGRIN" target="STRATUM CORNEUM">
      <data key="d4">8.0</data>
      <data key="d5">Filaggrin is crucial for Stratum Corneum formation and keratin buildup</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="LORICRIN" target="AD">
      <data key="d4">15.0</data>
      <data key="d5">Loricrin is suppressed in chronic atopic dermatitis
Loricrin is involved in the immune response in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="LORICRIN" target="VTP-38543">
      <data key="d4">6.0</data>
      <data key="d5">VTP-38543 increased mRNA expression of loricrin</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d</data>
    </edge>
    <edge source="TSLP" target="DENDRITIC CELLS (DCS)">
      <data key="d4">16.0</data>
      <data key="d5">TSLP activates dendritic cells to express OX40L</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="TSLP" target="DENDRITIC CELLS">
      <data key="d4">8.0</data>
      <data key="d5">TSLP is highly expressed in skin epithelial cells in AD and its receptor TSLPR is expressed on dendritic cells</data>
      <data key="d6">f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="TSLP" target="TSLPR">
      <data key="d4">8.0</data>
      <data key="d5">TSLP binds to its receptor TSLPR</data>
      <data key="d6">f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="TSLP" target="TEZEPELUMAB">
      <data key="d4">23.0</data>
      <data key="d5">Tezepelumab is an anti-TSLP monoclonal antibody
Tezepelumab is an anti-TSLP antibody
Tezepelumab is an anti-TSLP antibody</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807,849e0980ffd6a7e1cf0b8d3d1fbacd98,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="TSLP" target="T CELLS">
      <data key="d4">8.0</data>
      <data key="d5">TSLP is highly expressed in skin epithelial cells in AD and its receptor TSLPR is expressed on T cells</data>
      <data key="d6">f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="TSLP" target="B CELLS">
      <data key="d4">8.0</data>
      <data key="d5">TSLP is highly expressed in skin epithelial cells in AD and its receptor TSLPR is expressed on B cells</data>
      <data key="d6">f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="TSLP" target="MAST CELLS">
      <data key="d4">8.0</data>
      <data key="d5">TSLP is highly expressed in skin epithelial cells in AD and its receptor TSLPR is expressed on mast cells</data>
      <data key="d6">f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="TSLP" target="BASOPHILS">
      <data key="d4">8.0</data>
      <data key="d5">TSLP is highly expressed in skin epithelial cells in AD and its receptor TSLPR is expressed on basophils</data>
      <data key="d6">f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="TSLP" target="EOSINOPHILS">
      <data key="d4">8.0</data>
      <data key="d5">TSLP is highly expressed in skin epithelial cells in AD and its receptor TSLPR is expressed on eosinophils</data>
      <data key="d6">f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="TSLP" target="AD">
      <data key="d4">31.0</data>
      <data key="d5">TSLP is involved in the immune response in AD
TSLP is a cytokine that promotes Th2 responses and is increased in AD skinTSLP is involved in the immune response and inflammation in AD
TSLP expression is elevated in AD</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807,41ccc4b41bd57cf2bda4dbb6c7ae4198,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="TSLP" target="HY209">
      <data key="d4">7.0</data>
      <data key="d5">HY209 significantly decreased TSLP levels</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d</data>
    </edge>
    <edge source="TSLP" target="DC">
      <data key="d4">7.0</data>
      <data key="d5">TSLP affects DCs</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="TSLP" target="SPINK5">
      <data key="d4">7.0</data>
      <data key="d5">SPINK5 infiltrates TSLP during inflammation</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="TSLP" target="TH2 CELL">
      <data key="d4">8.0</data>
      <data key="d5">TSLP activates Th2 cells</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="TSLP" target="IL-5">
      <data key="d4">7.0</data>
      <data key="d5">TSLP promotes the production of IL-5</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="TSLP" target="MAST CELL">
      <data key="d4">7.0</data>
      <data key="d5">TSLP affects mast cells</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="TSLP" target="NATURAL KILLER CELL">
      <data key="d4">7.0</data>
      <data key="d5">TSLP affects natural killer cells</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="TSLP" target="ENDOTHELIAL CELLS">
      <data key="d4">8.0</data>
      <data key="d5">TSLP activates endothelial cells during inflammation</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </edge>
    <edge source="TSLP" target="DCS">
      <data key="d4">8.0</data>
      <data key="d5">TSLP activates dendritic cells (DCs) during inflammation</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </edge>
    <edge source="TSLP" target="TRAIL">
      <data key="d4">7.0</data>
      <data key="d5">TRAIL is necessary for the upregulation of TSLP</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="IL-25" target="DENDRITIC CELLS (DCS)">
      <data key="d4">16.0</data>
      <data key="d5">IL-25 activates dendritic cells to express OX40L</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="IL-25" target="AD">
      <data key="d4">21.0</data>
      <data key="d5">IL-25 is involved in the immune response in AD
IL-25 is involved in the immune response and inflammation in ADIL-25 is a cytokine involved in the immune response and inflammation in AD</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807,41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="IL-25" target="FLG">
      <data key="d4">7.0</data>
      <data key="d5">IL-25 reduces FLG expression</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="IL-25" target="SPINK5">
      <data key="d4">7.0</data>
      <data key="d5">SPINK5 infiltrates IL-25 during inflammation</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IL-25" target="MAST CELLS">
      <data key="d4">8.0</data>
      <data key="d5">Mast cells produce IL-25, central to the pathogenesis of Atopic Dermatitis</data>
      <data key="d6">691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="IL-33" target="DENDRITIC CELLS (DCS)">
      <data key="d4">16.0</data>
      <data key="d5">IL-33 stimulates dendritic cells to express OX40L</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="IL-33" target="TYPE 2 INNATE LYMPHOID CELLS">
      <data key="d4">16.0</data>
      <data key="d5">IL-33 stimulates type 2 innate lymphoid cells</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="IL-33" target="IL-5">
      <data key="d4">21.0</data>
      <data key="d5">IL-33 induces the production of IL-5IL-33 enhances type 2 responses through the induction of IL-5
IL-33 increases the production of IL-5</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="IL-33" target="IFN-&#915;">
      <data key="d4">14.0</data>
      <data key="d5">IL-33 enhances type 1 responses through the induction of IFN-&#947;IL-33 induces the production of IFN-&#947;</data>
      <data key="d6">f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="IL-33" target="ANB020">
      <data key="d4">8.0</data>
      <data key="d5">ANB020 is an anti&#8211;IL-33 monoclonal antibody</data>
      <data key="d6">f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="IL-33" target="PF-06817024">
      <data key="d4">8.0</data>
      <data key="d5">PF-06817024 is an anti&#8211;IL-33 monoclonal antibody</data>
      <data key="d6">f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="IL-33" target="AD">
      <data key="d4">29.0</data>
      <data key="d5">IL-33 is involved in the immune response in AD
IL-33 is involved in the immune response and inflammation in ADIL-33 is a cytokine involved in the immune response and inflammation in AD
IL-33 is released by keratinocytes in AD</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807,41ccc4b41bd57cf2bda4dbb6c7ae4198,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IL-33" target="SPINK5">
      <data key="d4">7.0</data>
      <data key="d5">SPINK5 infiltrates IL-33 during inflammation</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IL-33" target="TH2 CELL">
      <data key="d4">8.0</data>
      <data key="d5">IL-33 activates Th2 responses</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IL-33" target="ETOKIMAB">
      <data key="d4">8.0</data>
      <data key="d5">Etokimab is an anti-IL-33 monoclonal antibody</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IL-33" target="ITEPEKIMAB">
      <data key="d4">8.0</data>
      <data key="d5">Itepekimab is an IL-33 inhibitor</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IL-33" target="TNFR2">
      <data key="d4">7.0</data>
      <data key="d5">TNFR2 signaling initiates IL-33 production</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="IL-33" target="ST2">
      <data key="d4">7.0</data>
      <data key="d5">IL-33 signals via ST2 on local immune cells</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="IGE" target="PLASMA CELLS">
      <data key="d4">16.0</data>
      <data key="d5">Plasma cells produce IgE in response to IL-4 and IL-13 stimulation in atopic dermatitis</data>
      <data key="d6">e075bccd45593ae008b2ce7f9ed8ff6c</data>
    </edge>
    <edge source="IGE" target="AD">
      <data key="d4">37.0</data>
      <data key="d5">Increased levels of IgE are commonly detected in AD patients
IgE sensitization is involved in atopic dermatitis
IgE responses correlate with atopic dermatitis severity
IgE is involved in the immune response and inflammation in AD</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41,143d2dc302af5606656797bff162e23e,41ccc4b41bd57cf2bda4dbb6c7ae4198,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="IGE" target="DC">
      <data key="d4">14.0</data>
      <data key="d5">IgE-bearing dendritic cells capture and present allergens</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41</data>
    </edge>
    <edge source="IGE" target="ADAPT">
      <data key="d4">14.0</data>
      <data key="d5">The ADAPT study was designed to verify the role of IgE in atopic dermatitis</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41</data>
    </edge>
    <edge source="IGE" target="ANTI-IGE">
      <data key="d4">9.0</data>
      <data key="d5">Anti-IgE biologics target IgE to treat allergic conditions</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IGE" target="IMMUNOADSORPTION">
      <data key="d4">8.0</data>
      <data key="d5">Immunoadsorption is used to remove IgE from the blood</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IGE" target="ALLERGIC REACTIONS">
      <data key="d4">9.0</data>
      <data key="d5">IgE is involved in allergic reactions</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IGE" target="ENVIRONMENTAL ALLERGENS">
      <data key="d4">8.0</data>
      <data key="d5">IgE mediates allergic reactions to environmental allergens</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IGE" target="ALLERGIC DISEASES">
      <data key="d4">9.0</data>
      <data key="d5">IgE is involved in allergic diseases</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IGE" target="SYK">
      <data key="d4">14.0</data>
      <data key="d5">SYK is a crucial signaling molecule for the high-affinity receptor for IgE</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="IGE" target="LANGERHANS CELLS">
      <data key="d4">12.0</data>
      <data key="d5">IgE is expressed on Langerhans cells</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="IGE" target="INFLAMMATORY DENDRITIC EPIDERMAL CELLS">
      <data key="d4">12.0</data>
      <data key="d5">IgE is expressed on inflammatory dendritic epidermal cells</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="IGE" target="HY209">
      <data key="d4">7.0</data>
      <data key="d5">HY209 significantly decreased serum IgE levels</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d</data>
    </edge>
    <edge source="IGE" target="TH2 CELL">
      <data key="d4">8.0</data>
      <data key="d5">IgE is involved in the Th2 immune response</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="IGE" target="NICOTINAMIDE (VITAMIN B3)">
      <data key="d4">7.0</data>
      <data key="d5">Nicotinamide (Vitamin B3) decreases IgE titers</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="IGE" target="HYDROCORTISONE">
      <data key="d4">14.0</data>
      <data key="d5">HC-NPs suppressed inflammatory cascades including IgE</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="IGE" target="CARDIAC FIBROBLAST">
      <data key="d4">12.0</data>
      <data key="d5">IgE treatment induces activation and matrix protein production in cardiac fibroblasts</data>
      <data key="d6">d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="PLASMA CELLS" target="B CELLS">
      <data key="d4">9.0</data>
      <data key="d5">B cells differentiate into plasma cells to produce antibodies</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="PLASMA CELLS" target="COMPLEMENT ACTIVATION">
      <data key="d4">6.0</data>
      <data key="d5">Complement activation is enriched in the plasma cell population</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="PLASMA CELLS" target="B CELL ACTIVATION">
      <data key="d4">6.0</data>
      <data key="d5">Positive regulation of B cell activation is enriched in the plasma cell population</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="PLASMA CELLS" target="ANTIBACTERIAL HUMORAL RESPONSE">
      <data key="d4">6.0</data>
      <data key="d5">Antibacterial humoral response is enriched in the plasma cell population</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="PLASMA CELLS" target="CD138">
      <data key="d4">25.0</data>
      <data key="d5">CD138 is a marker found on plasma cells
CD138 is a marker found on plasma cells</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606,b62ecc47bf54393bc78dd65986b949d6</data>
    </edge>
    <edge source="PLASMA CELLS" target="CD70">
      <data key="d4">8.0</data>
      <data key="d5">CD70:CD27 interactions promote the differentiation of B cells into plasma cells</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="HISTAMINE" target="HYDROCORTISONE">
      <data key="d4">14.0</data>
      <data key="d5">HC-NPs suppressed inflammatory cascades including histamine release</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="EASI" target="AD">
      <data key="d4">120.0</data>
      <data key="d5">EASI is a tool used to measure the extent and severity of atopic dermatitis
EASI is used to measure the extent and severity of atopic dermatitis
EASI is used to measure the severity of atopic dermatitis
EASI is used to measure the extent and severity of atopic dermatitis
The Eczema Area Severity Index is used to assess the severity of atopic dermatitis
EASI is used to measure the severity of AD
EASI is used to measure the extent and severity of eczema
EASI is a measure of eczema severity in AD
EASI is a clinical tool used to assess the severity of AD
EASI is used to evaluate disease severity in AD
EASI score is used to measure the severity of AD
EASI score is used to measure the severity of atopic dermatitis</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d,100dd7646c10899301b3c0631183da16,143d2dc302af5606656797bff162e23e,28f548554737fcc026b968db6bbafa30,2cec06c4d46f5ff9ee936a78d8b077cd,3287c502f10f4651d2f56bf39ee7bb7a,3ea70e257330c812b52334ca1f90d807,475995d7d211bbfde6d8ba52f324d688,8246ea974dfb00cb5e3d984004e21a9e,849e0980ffd6a7e1cf0b8d3d1fbacd98,89dbac0da39e4de2b602052cd792b90d,b201c6ff3e22b2475c8c59260a0eb6a7</data>
    </edge>
    <edge source="EASI" target="IL-22">
      <data key="d4">16.0</data>
      <data key="d5">IL-22 serum levels correlate with the EASI score</data>
      <data key="d6">dc905ba8b6eb7d84cf2776303211010d</data>
    </edge>
    <edge source="EASI" target="EASI75">
      <data key="d4">9.0</data>
      <data key="d5">EASI75 represents a 75% improvement in EASI from baseline</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="EASI" target="EASI90">
      <data key="d4">9.0</data>
      <data key="d5">EASI90 represents a 90% improvement in EASI from baseline</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="EASI" target="PP-NRS-11">
      <data key="d4">6.0</data>
      <data key="d5">PP-NRS-11 correlates weakly with EASI</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="EASI" target="SKIN LESIONS">
      <data key="d4">8.0</data>
      <data key="d5">Skin lesions are measured by EASI in atopic dermatitis</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="EASI" target="KHK4083">
      <data key="d4">8.0</data>
      <data key="d5">KHK4083 resulted in a 74% reduction in the EASI score in a phase Ib trial</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="IL-31" target="T-HELPER (TH)2 CELLS">
      <data key="d4">18.0</data>
      <data key="d5">Th2 cells produce IL-31</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="IL-31" target="GBR 830">
      <data key="d4">16.0</data>
      <data key="d5">GBR 830 treatment reduces IL-31 mRNA levels</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="IL-31" target="AD">
      <data key="d4">48.0</data>
      <data key="d5">IL-31 is a key cytokine involved in the pathophysiology of atopic dermatitis and is associated with itch
IL-31 is involved in the immune response in AD
IL-31 correlates with disease severity in atopic dermatitis
IL-31 is a cytokine involved in the inflammatory response in atopic dermatitis
IL-31 is involved in inflammation and immune response in AD</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b,849e0980ffd6a7e1cf0b8d3d1fbacd98,a867a1e73cef039eb3f28e072463b838,b19f42c9497f71b231222cd953036d6b,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="IL-31" target="DENDRITIC CELL">
      <data key="d4">7.0</data>
      <data key="d5">IL-31 is produced by mature dendritic cells</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </edge>
    <edge source="IL-31" target="TH2 CELLS">
      <data key="d4">24.0</data>
      <data key="d5">IL-31 is produced by Th2 cells
IL-31 is produced by TH2 cells</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b,f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="IL-31" target="DENDRITIC CELLS">
      <data key="d4">8.0</data>
      <data key="d5">IL-31 is produced by mature dendritic cells</data>
      <data key="d6">f2aa3fd6ae3f1853347874c50afb60ea</data>
    </edge>
    <edge source="IL-31" target="FLG">
      <data key="d4">7.0</data>
      <data key="d5">IL-31 reduces FLG expression</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="IL-4R&#913;" target="AD">
      <data key="d4">9.0</data>
      <data key="d5">IL-4R&#945; is important in the pathobiology of atopic dermatitis</data>
      <data key="d6">104cc78517b2eca2e9cb7e00de1fe4b0</data>
    </edge>
    <edge source="IL-4R&#913;" target="JAK/STAT PATHWAY">
      <data key="d4">16.0</data>
      <data key="d5">IL-4R&#945; is involved in the JAK/STAT signaling pathway</data>
      <data key="d6">104cc78517b2eca2e9cb7e00de1fe4b0</data>
    </edge>
    <edge source="IL-4R&#913;" target="IL-2R&#915;">
      <data key="d4">7.0</data>
      <data key="d5">IL-4R&#945; is part of the type I receptor with IL-2R&#947;</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="IL-4R&#913;" target="IL-13R&#913;1">
      <data key="d4">21.0</data>
      <data key="d5">IL-4R&#945; is part of the type II receptor with IL-13R&#945;1
IL-4R&#945; and IL-13R&#945;1 heterodimerize to mediate signal transduction</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41,78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="IL-4R&#913;" target="CBP-201">
      <data key="d4">8.0</data>
      <data key="d5">CBP-201 is an IL-4R&#945; antagonist</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="IL-4R&#913;" target="AK120">
      <data key="d4">7.0</data>
      <data key="d5">AK120 is an antibody directed against IL-4R&#945;</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="IL-4R&#913;" target="TYPE I RECEPTOR">
      <data key="d4">7.0</data>
      <data key="d5">IL-4R&#945; is part of the type I receptor</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="IL-4R&#913;" target="TYPE II RECEPTOR">
      <data key="d4">7.0</data>
      <data key="d5">IL-4R&#945; is part of the type II receptor</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="TH2 CELLS" target="GITR">
      <data key="d4">7.0</data>
      <data key="d5">Th2 cells are responsive to GITR stimulation</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="TH1 CELLS" target="GITR">
      <data key="d4">7.0</data>
      <data key="d5">Th1 cells are not responsive to GITR stimulation</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="EPIDERMIS" target="AD">
      <data key="d4">9.0</data>
      <data key="d5">The epidermis is affected by atopic dermatitis</data>
      <data key="d6">f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="EPIDERMIS" target="TH2 CELL">
      <data key="d4">8.0</data>
      <data key="d5">TH2 cells are an important component of the epidermal infiltrates in atopic dermatitis</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="EPIDERMIS" target="TAC">
      <data key="d4">7.0</data>
      <data key="d5">Higher TAC levels were observed in the epidermis with PLG-based nanoparticles</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="EPIDERMAL BARRIER" target="AD">
      <data key="d4">34.0</data>
      <data key="d5">Epidermal barrier disruption contributes to atopic dermatitis
The epidermal barrier is compromised in atopic dermatitis
Epidermal barrier dysfunction is a characteristic of atopic dermatitis</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d,143d2dc302af5606656797bff162e23e,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="IL-22" target="AD">
      <data key="d4">65.0</data>
      <data key="d5">IL-22 is involved in the pathogenesis of atopic dermatitis
IL-22 is involved in the pathogenesis of atopic dermatitis
IL-22 is involved in the pathophysiology of chronic atopic dermatitis lesions
IL-22 is involved in the immune response in AD
IL-22 is a cytokine involved in the inflammatory response in atopic dermatitis
IL-22 is involved in inflammation and immune response in AD</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98,a867a1e73cef039eb3f28e072463b838,b19f42c9497f71b231222cd953036d6b,b876251511f570468eb5b6ee6a239cc6,dc905ba8b6eb7d84cf2776303211010d,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="IL-22" target="SCORAD">
      <data key="d4">16.0</data>
      <data key="d5">IL-22 serum levels correlate with the SCORAD score</data>
      <data key="d6">dc905ba8b6eb7d84cf2776303211010d</data>
    </edge>
    <edge source="IL-22" target="FEZAKINUMAB">
      <data key="d4">24.0</data>
      <data key="d5">Fezakinumab targets IL-22 to treat moderate-to-severe atopic dermatitis
Fezakinumab is an anti-IL-22 antibody investigated for the treatment of AD
Fezakinumab is used for the downregulation of IL-22</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9,2cec06c4d46f5ff9ee936a78d8b077cd,48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IL-22" target="KERATINOCYTE">
      <data key="d4">7.0</data>
      <data key="d5">IL-22 inhibits keratinocyte differentiation</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </edge>
    <edge source="IL-22" target="IL-22R">
      <data key="d4">9.0</data>
      <data key="d5">IL-22 binds to its receptor IL-22R</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IL-22" target="IL-22R1">
      <data key="d4">9.0</data>
      <data key="d5">IL-22R1 binds IL-22 and forms a receptor complex</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IL-22" target="STAPHYLOCOCCAL EXOTOXINS">
      <data key="d4">8.0</data>
      <data key="d5">Staphylococcal exotoxins induce IL-22 production</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IL-22" target="FLG">
      <data key="d4">15.0</data>
      <data key="d5">IL-22 reduces FLG expression
IL-22 downregulates FLG in keratinocytes</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd,41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="AD" target="GBR 830">
      <data key="d4">34.0</data>
      <data key="d5">GBR 830 is investigated for the treatment of AD
GBR 830 showed promising results in a phase IIa trial for atopic dermatitis</data>
      <data key="d6">4842292208575bd45b2b5998513dd087,6309eeea565f06479830cec32938abc9</data>
    </edge>
    <edge source="AD" target="SERUM">
      <data key="d4">38.0</data>
      <data key="d5">Serum samples were collected to analyze proteomic profiles in AD patients
Serum biomarkers are increased in moderate-to-severe atopic dermatitis
Serum biomarkers are used to predict therapeutic responses in atopic dermatitis</data>
      <data key="d6">104cc78517b2eca2e9cb7e00de1fe4b0,475995d7d211bbfde6d8ba52f324d688,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="HEAD AND NECK">
      <data key="d4">14.0</data>
      <data key="d5">Head and neck regions were specifically evaluated for EASI score improvements in AD patients</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="AD" target="NRS">
      <data key="d4">30.0</data>
      <data key="d5">Numeric Rating Scale is used to measure the severity of pruritus in AD patients
NRS is used to measure pruritus in atopic dermatitis</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30,475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="AD" target="EASI75">
      <data key="d4">16.0</data>
      <data key="d5">EASI75 is a measure indicating a 75% improvement in the Eczema Area and Severity Index score</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="AD" target="EASI SCORE">
      <data key="d4">8.0</data>
      <data key="d5">EASI score is a measure used to assess the severity of atopic dermatitis</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="AD" target="PRURITUS NRS SCORE">
      <data key="d4">7.0</data>
      <data key="d5">Pruritus NRS score is a measure used to assess the severity of itching in atopic dermatitis patients</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="AD" target="SKIN BIOPSY">
      <data key="d4">8.0</data>
      <data key="d5">Skin biopsy specimens were collected to analyze the effects of rocatinlimab on gene and protein expression</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="AD" target="SERUM SAMPLES">
      <data key="d4">8.0</data>
      <data key="d5">Serum samples were collected to analyze the effects of rocatinlimab on protein expression</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="AD" target="HEAD AND NECK EASI SCORE">
      <data key="d4">1.0</data>
      <data key="d5">Head and neck EASI score is a measure used to assess the severity of atopic dermatitis in the head and neck regions</data>
      <data key="d6">475995d7d211bbfde6d8ba52f324d688</data>
    </edge>
    <edge source="AD" target="VIGA">
      <data key="d4">28.0</data>
      <data key="d5">vIGA is used to assess the severity of atopic dermatitis
The validated Investigator Global Assessment is used to evaluate the severity of atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e,b876251511f570468eb5b6ee6a239cc6</data>
    </edge>
    <edge source="AD" target="SCORAD">
      <data key="d4">48.0</data>
      <data key="d5">SCORAD is used to assess the severity of atopic dermatitis
SCORAD is used to assess the severity of atopic dermatitis
The Scoring of Atopic Dermatitis is used to assess the intensity and extent of atopic dermatitis
SCORAD is used to assess the severity of atopic dermatitis
SCORAD is a clinical tool used to assess the severity of AD</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d,143d2dc302af5606656797bff162e23e,28f548554737fcc026b968db6bbafa30,2cec06c4d46f5ff9ee936a78d8b077cd,b876251511f570468eb5b6ee6a239cc6</data>
    </edge>
    <edge source="AD" target="PLACEBO">
      <data key="d4">12.0</data>
      <data key="d5">Placebo was used as a control in the clinical trials for atopic dermatitis</data>
      <data key="d6">b876251511f570468eb5b6ee6a239cc6</data>
    </edge>
    <edge source="AD" target="EASI-75">
      <data key="d4">2.0</data>
      <data key="d5">EASI-75 is a measure used to assess improvement in atopic dermatitis</data>
      <data key="d6">b201c6ff3e22b2475c8c59260a0eb6a7</data>
    </edge>
    <edge source="AD" target="TH2 CELL">
      <data key="d4">18.0</data>
      <data key="d5">Th2 cells are excessively activated in atopic dermatitis
TH2 cells are an important component of the dermal and epidermal infiltrates in atopic dermatitis
TH2 cells are a numerically important component of the dermal and epidermal infiltrates in AD</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9,442e7fad2fab75fa2449309783294d89,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="ILC2">
      <data key="d4">8.0</data>
      <data key="d5">ILC2 cells are excessively activated in atopic dermatitis</data>
      <data key="d6">f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="IL-5">
      <data key="d4">40.0</data>
      <data key="d5">IL-5 is a key cytokine involved in the pathophysiology of atopic dermatitis
IL-5 is involved in the immune response in AD
IL-5 is a cytokine involved in the inflammatory response in atopic dermatitis
IL-5 is a Th2 cytokine that plays a pivotal role in ADIL-5 is involved in the immune response and inflammation in AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198,a867a1e73cef039eb3f28e072463b838,b19f42c9497f71b231222cd953036d6b,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="IFN-&#915;">
      <data key="d4">32.0</data>
      <data key="d5">IFN-&#947; is involved in the pathophysiology of chronic atopic dermatitis lesions
IFN-&#947; is involved in the immune response in AD
IFN-&#947; is a cytokine involved in the immune response and inflammation in ADIFN-&#947; is involved in the immune response and inflammation in AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198,b19f42c9497f71b231222cd953036d6b,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="K16">
      <data key="d4">15.0</data>
      <data key="d5">Keratin 16 is increased in atopic dermatitis lesions
K16 is involved in the immune response in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="KI67">
      <data key="d4">22.0</data>
      <data key="d5">Ki67 is increased in atopic dermatitis lesions
Ki67 is involved in the immune response in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="PERIPLAKIN">
      <data key="d4">7.0</data>
      <data key="d5">Periplakin is suppressed in chronic atopic dermatitis</data>
      <data key="d6">f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="T CELL">
      <data key="d4">8.0</data>
      <data key="d5">T cells are involved in the pathophysiology of atopic dermatitis</data>
      <data key="d6">f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="DC">
      <data key="d4">8.0</data>
      <data key="d5">Dendritic cells are involved in the pathophysiology of atopic dermatitis</data>
      <data key="d6">f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="MYELOID CELL">
      <data key="d4">8.0</data>
      <data key="d5">Myeloid cells are involved in the pathophysiology of atopic dermatitis</data>
      <data key="d6">f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="SPONGIOSIS">
      <data key="d4">7.0</data>
      <data key="d5">Spongiosis is seen in atopic dermatitis</data>
      <data key="d6">f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="EPIDERMAL THICKNESS">
      <data key="d4">14.0</data>
      <data key="d5">Epidermal thickness is increased in atopic dermatitis lesions</data>
      <data key="d6">f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="EPIDERMAL HYPERPLASIA">
      <data key="d4">14.0</data>
      <data key="d5">Epidermal hyperplasia is seen in atopic dermatitis</data>
      <data key="d6">f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="ITCH">
      <data key="d4">18.0</data>
      <data key="d5">Itch is a common symptom of atopic dermatitis
Itch is a common symptom in atopic dermatitis
Itch is a key symptom in AD</data>
      <data key="d6">143d2dc302af5606656797bff162e23e,3ce96e927d65736b305f792977fed4b9,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="LESION">
      <data key="d4">9.0</data>
      <data key="d5">Lesions are areas of damaged skin in atopic dermatitis</data>
      <data key="d6">f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="CHRONIC LESION">
      <data key="d4">16.0</data>
      <data key="d5">Chronic lesions are characterized by increased inflammation in atopic dermatitis</data>
      <data key="d6">f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="ACUTE LESION">
      <data key="d4">16.0</data>
      <data key="d5">Acute lesions are characterized by significant increases in type 2 and type 22 cytokines in atopic dermatitis</data>
      <data key="d6">f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="BIOMARKER">
      <data key="d4">16.0</data>
      <data key="d5">Biomarkers are indicators of atopic dermatitis</data>
      <data key="d6">f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="HISTOLOGIC PROFILING">
      <data key="d4">14.0</data>
      <data key="d5">Histologic profiling is used to study tissue structure in atopic dermatitis</data>
      <data key="d6">f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="TYPE 2 PATHWAY">
      <data key="d4">27.0</data>
      <data key="d5">The type 2 pathway is involved in the pathophysiology of atopic dermatitis
Type 2 pathway is involved in the immune response in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="TYPE 22 PATHWAY">
      <data key="d4">24.0</data>
      <data key="d5">The type 22 pathway is involved in chronic atopic dermatitis
Type 22 pathway is involved in the immune response in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="TYPE 1 PATHWAY">
      <data key="d4">24.0</data>
      <data key="d5">The type 1 pathway is involved in chronic atopic dermatitis
Type 1 pathway is involved in the immune response in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="TYPE 17 PATHWAY">
      <data key="d4">24.0</data>
      <data key="d5">The type 17 pathway is involved in atopic dermatitis
Type 17 pathway is involved in the immune response in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b,f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="TYPE 9 PATHWAY">
      <data key="d4">2.0</data>
      <data key="d5">The type 9 pathway is involved in atopic dermatitis</data>
      <data key="d6">f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="IL-9">
      <data key="d4">8.0</data>
      <data key="d5">IL-9 is involved in the pathophysiology of atopic dermatitis, particularly in pediatric cases</data>
      <data key="d6">f66eb51473925a8084dad1745be63b78</data>
    </edge>
    <edge source="AD" target="CORTICOSTEROIDS">
      <data key="d4">22.0</data>
      <data key="d5">Corticosteroids are used to treat AD
Corticosteroids are used in the treatment of AD</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd,48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="AD" target="TCS">
      <data key="d4">28.0</data>
      <data key="d5">TCS is used in combination therapy studies for AD
TCS is used in combination therapy for atopic dermatitis</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30,96e553a44a27e728c27c4892045ec5c2</data>
    </edge>
    <edge source="AD" target="CYTOKINES">
      <data key="d4">14.0</data>
      <data key="d5">AD is characterized by dysfunction in multiple immune pathways involving cytokines</data>
      <data key="d6">96e553a44a27e728c27c4892045ec5c2</data>
    </edge>
    <edge source="AD" target="CYTOKINE RECEPTORS">
      <data key="d4">2.0</data>
      <data key="d5">AD involves dysfunction in pathways mediated by cytokine receptors</data>
      <data key="d6">96e553a44a27e728c27c4892045ec5c2</data>
    </edge>
    <edge source="AD" target="TYPE 1 IMMUNE PATHWAY">
      <data key="d4">7.0</data>
      <data key="d5">AD involves dysfunction in the type 1 immune pathway</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="AD" target="TYPE 2 IMMUNE PATHWAY">
      <data key="d4">7.0</data>
      <data key="d5">AD involves dysfunction in the type 2 immune pathway</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="AD" target="TYPE 17 IMMUNE PATHWAY">
      <data key="d4">7.0</data>
      <data key="d5">AD involves dysfunction in the type 17 immune pathway</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="AD" target="TYPE 22 IMMUNE PATHWAY">
      <data key="d4">7.0</data>
      <data key="d5">AD involves dysfunction in the type 22 immune pathway</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="AD" target="INTRINSIC AD">
      <data key="d4">6.0</data>
      <data key="d5">Intrinsic AD is a subtype of atopic dermatitis</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="AD" target="EXTRINSIC AD">
      <data key="d4">6.0</data>
      <data key="d5">Extrinsic AD is a subtype of atopic dermatitis</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="AD" target="ADULT AD">
      <data key="d4">6.0</data>
      <data key="d5">Adult AD is a subtype of atopic dermatitis</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="AD" target="PAEDIATRIC AD">
      <data key="d4">6.0</data>
      <data key="d5">Paediatric AD is a subtype of atopic dermatitis</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="AD" target="ETHNIC ORIGIN AD">
      <data key="d4">6.0</data>
      <data key="d5">Ethnic origin AD is a subtype of atopic dermatitis</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="AD" target="ENDOTYPES">
      <data key="d4">7.0</data>
      <data key="d5">Endotypes are subsets of AD patients with common underlying mechanisms</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="AD" target="CCL5">
      <data key="d4">10.0</data>
      <data key="d5">CCL5 is involved in the immune response in AD
CCL5 is involved in the immune response and inflammation in ADCCL5 is a chemokine involved in the immune response and inflammation in AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198,b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="AD" target="CCL13">
      <data key="d4">8.0</data>
      <data key="d5">CCL13 is involved in the immune response in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="AD" target="IL-32">
      <data key="d4">8.0</data>
      <data key="d5">IL-32 is involved in the immune response in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="AD" target="MX1">
      <data key="d4">8.0</data>
      <data key="d5">MX1 is involved in the immune response in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="AD" target="CXCL9">
      <data key="d4">8.0</data>
      <data key="d5">CXCL9 is involved in the immune response in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="AD" target="IL-23P19">
      <data key="d4">8.0</data>
      <data key="d5">IL-23p19 is involved in the immune response in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="AD" target="IL-23P40">
      <data key="d4">8.0</data>
      <data key="d5">IL-23p40 is involved in the immune response in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="AD" target="T CELLS">
      <data key="d4">9.0</data>
      <data key="d5">T cells are involved in the immune response in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="AD" target="ILC2S">
      <data key="d4">16.0</data>
      <data key="d5">ILC2s are involved in the immune response in AD
Type 2 innate lymphoid cells are involved in the immune response and inflammation in AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198,b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="AD" target="DCS">
      <data key="d4">9.0</data>
      <data key="d5">DCs are involved in the immune response in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="AD" target="IDECS">
      <data key="d4">8.0</data>
      <data key="d5">IDECs are involved in the immune response in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="AD" target="INVOLUCRIN">
      <data key="d4">8.0</data>
      <data key="d5">Involucrin is involved in the immune response in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="AD" target="PPL">
      <data key="d4">8.0</data>
      <data key="d5">PPL is involved in the immune response in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="AD" target="IVL">
      <data key="d4">8.0</data>
      <data key="d5">IVL is involved in the immune response in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="AD" target="ELAFIN">
      <data key="d4">8.0</data>
      <data key="d5">Elafin is involved in the immune response in AD</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="AD" target="TCI">
      <data key="d4">14.0</data>
      <data key="d5">TCI is used as rescue therapy in combination therapy for atopic dermatitis</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="AD" target="IGA">
      <data key="d4">23.0</data>
      <data key="d5">IGA is used to measure the severity of atopic dermatitis
IGA is a measure of disease severity in AD</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="AD" target="VAS">
      <data key="d4">16.0</data>
      <data key="d5">VAS is used to measure pruritus in atopic dermatitis</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="AD" target="BSA">
      <data key="d4">2.0</data>
      <data key="d5">BSA is used to measure the extent of atopic dermatitis</data>
      <data key="d6">28f548554737fcc026b968db6bbafa30</data>
    </edge>
    <edge source="AD" target="TOPICAL CALCINEURIN INHIBITOR">
      <data key="d4">8.0</data>
      <data key="d5">Topical calcineurin inhibitors are used to treat atopic dermatitis</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </edge>
    <edge source="AD" target="NCT02300701">
      <data key="d4">8.0</data>
      <data key="d5">NCT02300701 is a study focused on severe recalcitrant atopic eczema</data>
      <data key="d6">104cc78517b2eca2e9cb7e00de1fe4b0</data>
    </edge>
    <edge source="AD" target="IL-13R&#913;1">
      <data key="d4">8.0</data>
      <data key="d5">IL-13R&#945;1 is involved in the signaling pathways of atopic dermatitis</data>
      <data key="d6">104cc78517b2eca2e9cb7e00de1fe4b0</data>
    </edge>
    <edge source="AD" target="IMMUNE RESPONSE">
      <data key="d4">27.0</data>
      <data key="d5">The immune response is involved in the pathophysiology of atopic dermatitis
The immune response is a critical pathway in the pathogenesis and treatment of Atopic Dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e,90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="INFLAMMATORY RESPONSE">
      <data key="d4">9.0</data>
      <data key="d5">The inflammatory response is involved in the pathophysiology of atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="AD" target="LANGERHANS CELLS">
      <data key="d4">8.0</data>
      <data key="d5">Langerhans cells are defective in atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="AD" target="STAPHYLOCOCCUS AUREUS">
      <data key="d4">7.0</data>
      <data key="d5">Staphylococcus aureus may trigger atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="AD" target="KERATINOCYTE">
      <data key="d4">8.0</data>
      <data key="d5">Keratinocyte damage contributes to barrier dysfunction in atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="AD" target="DENDRITIC CELLS">
      <data key="d4">16.0</data>
      <data key="d5">Dendritic cells activate the adaptive immune response in atopic dermatitis
Dendritic cells are involved in the immune response and inflammation in AD</data>
      <data key="d6">143d2dc302af5606656797bff162e23e,41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="AD" target="ERYTHEMA">
      <data key="d4">16.0</data>
      <data key="d5">Erythema is a clinical sign of atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="AD" target="OEDEMA">
      <data key="d4">16.0</data>
      <data key="d5">Oedema is a clinical sign of atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="AD" target="INDURATION">
      <data key="d4">16.0</data>
      <data key="d5">Induration is a clinical sign of atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="AD" target="PAPULATION">
      <data key="d4">16.0</data>
      <data key="d5">Papulation is a clinical sign of atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="AD" target="EXCORIATION">
      <data key="d4">16.0</data>
      <data key="d5">Excoriation is a clinical sign of atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="AD" target="LICHENIFICATION">
      <data key="d4">16.0</data>
      <data key="d5">Lichenification is a clinical sign of atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="AD" target="OOZING">
      <data key="d4">16.0</data>
      <data key="d5">Oozing is a clinical sign of atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="AD" target="DRYNESS">
      <data key="d4">16.0</data>
      <data key="d5">Dryness is a clinical sign of atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="AD" target="SLEEPLESSNESS">
      <data key="d4">14.0</data>
      <data key="d5">Sleeplessness is a symptom of atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="AD" target="QUALITY OF LIFE">
      <data key="d4">23.0</data>
      <data key="d5">Quality of life is affected by atopic dermatitis
Better management of AD aims to improve the quality of life</data>
      <data key="d6">143d2dc302af5606656797bff162e23e,e30574e513dd250992d637d808759c34</data>
    </edge>
    <edge source="AD" target="DISEASE CONTROL">
      <data key="d4">16.0</data>
      <data key="d5">Disease control is a key aspect in the management of atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="AD" target="EPIGENETIC">
      <data key="d4">7.0</data>
      <data key="d5">Epigenetic mechanisms may play a role in the pathophysiology of atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="AD" target="ADAPTIVE IMMUNE SYSTEM">
      <data key="d4">8.0</data>
      <data key="d5">The adaptive immune system is involved in the pathophysiology of atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="AD" target="TH2 RESPONSE">
      <data key="d4">9.0</data>
      <data key="d5">TH2 response plays a key role in atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="AD" target="TH17 RESPONSE">
      <data key="d4">7.0</data>
      <data key="d5">TH17 response is implicated in atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="AD" target="TH22 RESPONSE">
      <data key="d4">7.0</data>
      <data key="d5">TH22 response is implicated in atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="AD" target="NEURO-IMMUNOLOGICAL">
      <data key="d4">7.0</data>
      <data key="d5">Neuro-immunological mechanisms are relevant in atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="AD" target="KERATINOCYTE DAMAGE">
      <data key="d4">8.0</data>
      <data key="d5">Keratinocyte damage contributes to barrier dysfunction in atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="AD" target="DENDRITIC CELL ACTIVATION">
      <data key="d4">8.0</data>
      <data key="d5">Dendritic cell activation plays a role in the immune response in atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="AD" target="B244">
      <data key="d4">8.0</data>
      <data key="d5">B244 is in clinical development for treating AD</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="AD" target="S. AUREUS">
      <data key="d4">24.0</data>
      <data key="d5">High colonization with S. aureus impacts the immune system and inflammatory reaction in AD
S. aureus is often found on the skin of AD patients and contributes to the disease</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807,41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="AD" target="PETROLATUM">
      <data key="d4">6.0</data>
      <data key="d5">Petrolatum modulates antimicrobial and epidermal barrier function in AD</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="AD" target="AHR">
      <data key="d4">23.0</data>
      <data key="d5">AhR is involved in the pathophysiology of AD
AhR plays a dual role in the development of skin inflammation, including AD</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807,6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="AD" target="TAPINAROF">
      <data key="d4">16.0</data>
      <data key="d5">Tapinarof reduces inflammatory responses in AD
Tapinarof decreases inflammatory reactions in AD</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="AD" target="SPINK5">
      <data key="d4">7.0</data>
      <data key="d5">Mutations in SPINK5 favor inflammation in AD</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="AD" target="TEZEPELUMAB">
      <data key="d4">28.0</data>
      <data key="d5">Tezepelumab showed results in AD
Tezepelumab showed results in a phase IIa study for atopic dermatitis
Tezepelumab was tested in a phase IIa trial for AD</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807,6309eeea565f06479830cec32938abc9,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="AD" target="EASI50">
      <data key="d4">1.0</data>
      <data key="d5">EASI50 is a clinical endpoint in AD studies</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="AD" target="EPIDERMAL BARRIER FUNCTION">
      <data key="d4">8.0</data>
      <data key="d5">Epidermal barrier function is disturbed in AD</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="AD" target="EMOLLIENTS">
      <data key="d4">7.0</data>
      <data key="d5">Emollients are used to improve barrier function in AD</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="AD" target="MOISTURIZERS">
      <data key="d4">7.0</data>
      <data key="d5">Moisturizers are used to improve barrier function in AD</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="AD" target="ETOKIMAB">
      <data key="d4">35.0</data>
      <data key="d5">Etokimab showed improvement in a proof-of-concept study for atopic dermatitis
Etokimab is a drug that failed to meet the primary endpoint in a phase 2b clinical trial for Atopic Dermatitis
Etokimab was tested in a phase II b clinical study for AD</data>
      <data key="d6">6309eeea565f06479830cec32938abc9,849e0980ffd6a7e1cf0b8d3d1fbacd98,90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="BERMEKIMAB">
      <data key="d4">21.0</data>
      <data key="d5">Bermekimab showed promising efficacy in a phase IIa study for atopic dermatitis
Bermekimab was tested in phase-II trials for AD</data>
      <data key="d6">6309eeea565f06479830cec32938abc9,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="AD" target="KHK4083">
      <data key="d4">16.0</data>
      <data key="d5">KHK4083 showed promising results in a phase Ib trial for atopic dermatitis</data>
      <data key="d6">6309eeea565f06479830cec32938abc9</data>
    </edge>
    <edge source="AD" target="KY1005">
      <data key="d4">16.0</data>
      <data key="d5">KY1005 showed interesting results in a phase IIa study for atopic dermatitis
KY1005 is a drug that completed phase 2a clinical trials for Atopic Dermatitis</data>
      <data key="d6">6309eeea565f06479830cec32938abc9,90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="EOSINOPHILS">
      <data key="d4">22.0</data>
      <data key="d5">Eosinophils are involved in the inflammatory infiltrate of atopic dermatitis
Eosinophils are involved in the immune response and inflammation in AD</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41,41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="AD" target="RHIL-2">
      <data key="d4">7.0</data>
      <data key="d5">Recombinant human IL-2 (rhIL-2) is being tested for its potential to restore tolerance and improve atopic dermatitis</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="AD" target="PDE4">
      <data key="d4">8.0</data>
      <data key="d5">Increased PDE4 activity is a target for the therapy of allergic disorders including atopic dermatitis</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="AD" target="LOTAMILAST">
      <data key="d4">7.0</data>
      <data key="d5">Lotamilast is in development for the treatment of atopic dermatitis</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="AD" target="DIFAMILAST">
      <data key="d4">7.0</data>
      <data key="d5">Difamilast is in development for the treatment of atopic dermatitis</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="AD" target="ROFLUMILAST">
      <data key="d4">6.0</data>
      <data key="d5">Roflumilast is tested for the treatment of atopic dermatitis</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="AD" target="HISTAMINE H4 RECEPTOR">
      <data key="d4">8.0</data>
      <data key="d5">Histamine H4 receptor (H4R) is a target for immunomodulation in inflammatory skin disorders including atopic dermatitis</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="AD" target="AKP-11">
      <data key="d4">7.0</data>
      <data key="d5">AKP-11 is in clinical development for AD</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9</data>
    </edge>
    <edge source="AD" target="BREPOCITINIB">
      <data key="d4">14.0</data>
      <data key="d5">Brepocitinib is in clinical development for treating atopic dermatitis</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="AD" target="JAKTINIB">
      <data key="d4">14.0</data>
      <data key="d5">Jaktinib is in clinical development for treating atopic dermatitis</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="AD" target="ATI-1777">
      <data key="d4">14.0</data>
      <data key="d5">ATI-1777 is in clinical development for treating atopic dermatitis</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="AD" target="CEE321">
      <data key="d4">14.0</data>
      <data key="d5">CEE321 is in clinical development for treating atopic dermatitis</data>
      <data key="d6">c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="AD" target="SHR0302">
      <data key="d4">21.0</data>
      <data key="d5">SHR0302 is in clinical development for treating atopic dermatitis
SHR0302 is in development for the treatment of atopic dermatitis</data>
      <data key="d6">a867a1e73cef039eb3f28e072463b838,c46e8b6ee0c29e37b7f18c42558d7a3e</data>
    </edge>
    <edge source="AD" target="BEN2293">
      <data key="d4">15.0</data>
      <data key="d5">BEN2293 is in development for the treatment of atopic dermatitis
BEN2293 is being tested in a phase I/II study for atopic dermatitis</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d,a867a1e73cef039eb3f28e072463b838</data>
    </edge>
    <edge source="AD" target="TAUREOXYCHOLIC ACID">
      <data key="d4">6.0</data>
      <data key="d5">Taureoxycholic acid is used in an animal model of atopic dermatitis</data>
      <data key="d6">a867a1e73cef039eb3f28e072463b838</data>
    </edge>
    <edge source="AD" target="JAKI">
      <data key="d4">32.0</data>
      <data key="d5">JAK inhibitors are used in the treatment of atopic dermatitis
JAK inhibitors have exhibited efficacy in treating atopic dermatitis
JAK inhibitors are small molecules used for rapid relief in pruritus and inflammation in Atopic Dermatitis</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d,90f4809673ca34628b0e607908f0bf0b,a867a1e73cef039eb3f28e072463b838</data>
    </edge>
    <edge source="AD" target="HY209">
      <data key="d4">7.0</data>
      <data key="d5">HY209 reduced TH2 inflammation in an animal model of atopic dermatitis</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d</data>
    </edge>
    <edge source="AD" target="LXR&#913;">
      <data key="d4">8.0</data>
      <data key="d5">LXR&#945; is involved in the regulation of epidermal barrier function and skin inflammation in atopic dermatitis</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d</data>
    </edge>
    <edge source="AD" target="LXR&#914;">
      <data key="d4">8.0</data>
      <data key="d5">LXR&#946; is involved in the regulation of epidermal barrier function and skin inflammation in atopic dermatitis</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d</data>
    </edge>
    <edge source="AD" target="VTP-38543">
      <data key="d4">7.0</data>
      <data key="d5">VTP-38543 is being tested in a phase I/II study for atopic dermatitis</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d</data>
    </edge>
    <edge source="AD" target="ALX 101">
      <data key="d4">7.0</data>
      <data key="d5">ALX 101 is being tested in a phase IIb study for atopic dermatitis</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d</data>
    </edge>
    <edge source="AD" target="ASTHMA">
      <data key="d4">13.0</data>
      <data key="d5">Asthma is an atopic comorbidity of atopic dermatitis
Some patients with AD also have asthma</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d,89dbac0da39e4de2b602052cd792b90d</data>
    </edge>
    <edge source="AD" target="ANXIETY">
      <data key="d4">7.0</data>
      <data key="d5">Anxiety is a neuropsychiatric comorbidity of atopic dermatitis</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d</data>
    </edge>
    <edge source="AD" target="DEPRESSION">
      <data key="d4">7.0</data>
      <data key="d5">Depression is a neuropsychiatric comorbidity of atopic dermatitis</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d</data>
    </edge>
    <edge source="AD" target="CARDIOVASCULAR DISORDERS">
      <data key="d4">7.0</data>
      <data key="d5">Cardiovascular disorders are non-atopic comorbidities of atopic dermatitis</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d</data>
    </edge>
    <edge source="AD" target="MICROBIOME">
      <data key="d4">15.0</data>
      <data key="d5">Microbiome-derived signals contribute to the pathogenesis of atopic dermatitis
The microbiome, including skin and gut microbiomes, plays a role in the pathogenesis and treatment of Atopic Dermatitis</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d,90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="TAPE-STRIP">
      <data key="d4">1.0</data>
      <data key="d5">Tape-strip specimens are used to study atopic dermatitis</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d</data>
    </edge>
    <edge source="AD" target="GUT MICROBIOME">
      <data key="d4">16.0</data>
      <data key="d5">The gut microbiome is involved in the pathogenesis and treatment of Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="BIOLOGICS">
      <data key="d4">23.0</data>
      <data key="d5">Biologics are drugs with a slow but pathway-specific mode of action used for long-term control and disease modification in Atopic Dermatitis
JAK inhibitors help overcome some drawbacks of biologics in the treatment of AD</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b,e30574e513dd250992d637d808759c34</data>
    </edge>
    <edge source="AD" target="EPITHELIAL EVENTS">
      <data key="d4">14.0</data>
      <data key="d5">Epithelial events are dynamic processes involved in the immune response in Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="ETRASIMOD">
      <data key="d4">14.0</data>
      <data key="d5">Etrasimod is a drug advancing into phase 3 clinical trials for Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="AOBIOME">
      <data key="d4">12.0</data>
      <data key="d5">AOBiome is a company conducting clinical trials for pruritus associated with Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="ARENA PHARMACEUTICALS">
      <data key="d4">12.0</data>
      <data key="d5">Arena Pharmaceuticals is advancing etrasimod into phase 3 clinical trials for Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="EUROPE">
      <data key="d4">7.0</data>
      <data key="d5">Europe is a region where cost-effectiveness considerations impact drug development for Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="HEALTH TECHNOLOGY ASSESSMENT AGENCIES">
      <data key="d4">7.0</data>
      <data key="d5">Health technology assessment agencies influence drug development and market access in dermatology</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="THIRD-PARTY PAYERS">
      <data key="d4">7.0</data>
      <data key="d5">Third-party payers are entities that impact drug development and patient access in dermatology</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="ATOPIC MARCH">
      <data key="d4">8.0</data>
      <data key="d5">The atopic march refers to the progression of allergic diseases, which can be impacted by early intervention in Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="COMORBIDITIES">
      <data key="d4">8.0</data>
      <data key="d5">Comorbidities are additional diseases or conditions that occur with Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="BIOREPOSITORIES">
      <data key="d4">7.0</data>
      <data key="d5">Biorepositories collect samples like microbiome, cellular, and fluid blood samples for research in Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="TAPE-STRIP SPECIMENS">
      <data key="d4">7.0</data>
      <data key="d5">Tape-strip specimens are non-invasive samples collected for research in Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="PREDICTIVE BIOMARKERS">
      <data key="d4">8.0</data>
      <data key="d5">Predictive biomarkers are used for innovative molecular taxonomy and companion diagnostics in Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="PROGNOSTIC BIOMARKERS">
      <data key="d4">8.0</data>
      <data key="d5">Prognostic biomarkers are used for predicting disease outcomes and guiding treatment in Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="DRUG TARGETS">
      <data key="d4">8.0</data>
      <data key="d5">Drug targets are specific molecules or pathways identified for therapeutic intervention in Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="THERAPEUTICS">
      <data key="d4">8.0</data>
      <data key="d5">Therapeutics are drugs or treatments developed for managing Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="TRANSLATIONAL EFFORTS">
      <data key="d4">7.0</data>
      <data key="d5">Translational efforts convert scientific knowledge into drug discovery and development for Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="PRECLINICAL DEVELOPMENT">
      <data key="d4">7.0</data>
      <data key="d5">Preclinical development involves testing new drugs in the lab before clinical trials in Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="CLINICAL DEVELOPMENT">
      <data key="d4">7.0</data>
      <data key="d5">Clinical development involves testing new drugs in human trials for Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="COMPANION DIAGNOSTICS">
      <data key="d4">8.0</data>
      <data key="d5">Companion diagnostics are tests used alongside therapeutics to guide treatment decisions in Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="MARKET ACCESS">
      <data key="d4">7.0</data>
      <data key="d5">Market access involves the process of making new drugs available to patients, influenced by cost-effectiveness considerations</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="COST-EFFECTIVENESS">
      <data key="d4">7.0</data>
      <data key="d5">Cost-effectiveness is a consideration for third-party payers when evaluating new drugs for Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="REAL-WORLD DATA">
      <data key="d4">7.0</data>
      <data key="d5">Real-world data provides evidence from actual patient experiences to support drug development in Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="PATIENT ADVOCACY">
      <data key="d4">7.0</data>
      <data key="d5">Patient advocacy involves efforts by patients to influence drug development and access in Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="PHARMACOLOGICAL INTERVENTION">
      <data key="d4">8.0</data>
      <data key="d5">Pharmacological intervention involves using drugs to treat or prevent Atopic Dermatitis and its comorbidities</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="SYSTEMIC THERAPY">
      <data key="d4">8.0</data>
      <data key="d5">Systemic therapy involves using drugs that affect the entire body to treat Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="TOPICAL THERAPY">
      <data key="d4">8.0</data>
      <data key="d5">Topical therapy involves applying drugs directly to the skin to treat Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="SEVERITY SCALES">
      <data key="d4">7.0</data>
      <data key="d5">Severity scales are used to define the severity of Atopic Dermatitis and guide treatment decisions</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="DISEASE MODIFICATION">
      <data key="d4">8.0</data>
      <data key="d5">Disease modification involves altering the course of Atopic Dermatitis to prevent progression and comorbidities</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="PHARMACEUTICAL COMPANIES">
      <data key="d4">7.0</data>
      <data key="d5">Pharmaceutical companies develop and market new drugs for Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="DRUG DISCOVERY">
      <data key="d4">7.0</data>
      <data key="d5">Drug discovery involves identifying new compounds for treating Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="AD" target="FLG">
      <data key="d4">9.0</data>
      <data key="d5">Decreased levels of FLG are associated with the development and progression of AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="AD" target="IL-8">
      <data key="d4">16.0</data>
      <data key="d5">IL-8 is a cytokine involved in the immune response and inflammation in ADIL-8 is involved in the immune response and inflammation in AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="AD" target="MIP-1&#913;">
      <data key="d4">14.0</data>
      <data key="d5">MIP-1&#945; is involved in the immune response and inflammation in ADMIP-1&#945; is a chemokine involved in the immune response and inflammation in AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="AD" target="MIP-1&#914;">
      <data key="d4">14.0</data>
      <data key="d5">MIP-1&#946; is involved in the immune response and inflammation in ADMIP-1&#946; is a chemokine involved in the immune response and inflammation in AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="AD" target="MCP-1">
      <data key="d4">14.0</data>
      <data key="d5">MCP-1 is a chemokine involved in the immune response and inflammation in ADMCP-1 is involved in the immune response and inflammation in AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="AD" target="KLK7">
      <data key="d4">14.0</data>
      <data key="d5">KLK7 is involved in the skin barrier function in ADKLK7 is a serine protease involved in skin barrier function in AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="AD" target="STAT 6">
      <data key="d4">7.0</data>
      <data key="d5">STAT 6 is a protein involved in the immune response in AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="AD" target="CTLA4">
      <data key="d4">25.0</data>
      <data key="d5">CTLA4 is a protein involved in the immune response in AD
CTLA4 is responsible for the development of atopic dermatitis</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198,6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="AD" target="CCL22">
      <data key="d4">14.0</data>
      <data key="d5">CCL22 is involved in the immune response and inflammation in ADCCL22 is a chemokine involved in the immune response and inflammation in AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="AD" target="CCL17">
      <data key="d4">14.0</data>
      <data key="d5">CCL17 is a chemokine involved in the immune response and inflammation in ADCCL17 is involved in the immune response and inflammation in AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="AD" target="CCL11">
      <data key="d4">14.0</data>
      <data key="d5">CCL11 is involved in the immune response and inflammation in ADCCL11 is a chemokine involved in the immune response and inflammation in AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="AD" target="POLLUTION">
      <data key="d4">8.0</data>
      <data key="d5">Exposure to pollution can weaken the skin&#8217;s microbial barrier, potentially leading to AD development</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="AD" target="SOAP">
      <data key="d4">8.0</data>
      <data key="d5">Excessive use of soap can weaken the skin&#8217;s microbial barrier, potentially leading to AD development</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="AD" target="BASOPHILS">
      <data key="d4">8.0</data>
      <data key="d5">Basophils are involved in the immune response and inflammation in AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="AD" target="MAST CELLS">
      <data key="d4">8.0</data>
      <data key="d5">Mast cells are involved in the immune response and inflammation in AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="AD" target="MACROPHAGES">
      <data key="d4">8.0</data>
      <data key="d5">Macrophages are involved in the immune response and inflammation in AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="AD" target="SPINK">
      <data key="d4">7.0</data>
      <data key="d5">SPINK is involved in the skin barrier function in AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="AD" target="CLAUDINS">
      <data key="d4">7.0</data>
      <data key="d5">Claudins are involved in the skin barrier function in AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="AD" target="STAT6">
      <data key="d4">25.0</data>
      <data key="d5">STAT6 is involved in the immune response in AD
STAT6 is responsible for the development of atopic dermatitis</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198,6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="AD" target="CTLA-4">
      <data key="d4">7.0</data>
      <data key="d5">CTLA-4 is involved in the immune response in AD</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="AD" target="MSB-01">
      <data key="d4">14.0</data>
      <data key="d5">MSB-01 is used to investigate microbiome transplantation and bacterial modulation in AD</data>
      <data key="d6">6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="AD" target="DB-001">
      <data key="d4">14.0</data>
      <data key="d5">DB-001 is used to investigate microbiome transplantation and bacterial modulation in AD</data>
      <data key="d6">6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="AD" target="ROSEMONAS MUCOSA">
      <data key="d4">12.0</data>
      <data key="d5">Rosemonas mucosa is found in greater abundance in the skin microbiome of AD patients</data>
      <data key="d6">6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="AD" target="NITROSOMONAS EUTROPHA">
      <data key="d4">14.0</data>
      <data key="d5">Nitrosomonas eutropha is used to treat AD by producing nitric oxide</data>
      <data key="d6">6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="AD" target="OMEGANAN PENTACHLORIDE">
      <data key="d4">12.0</data>
      <data key="d5">Omeganan pentachloride is undergoing clinical testing as a topical treatment for managing dysbiosis in AD</data>
      <data key="d6">6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="AD" target="EDP1815">
      <data key="d4">12.0</data>
      <data key="d5">EDP1815 is a microbiome modifier in phase I trials for AD treatment</data>
      <data key="d6">6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="AD" target="STMC-103H">
      <data key="d4">12.0</data>
      <data key="d5">STMC-103H is a microbiome modifier in phase I trials for AD treatment</data>
      <data key="d6">6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="AD" target="KBL69">
      <data key="d4">12.0</data>
      <data key="d5">KBL69 is a microbiome modifier in phase I trials for AD treatment</data>
      <data key="d6">6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="AD" target="ITCHINESS">
      <data key="d4">7.0</data>
      <data key="d5">Itchiness is a common symptom in AD</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="AD" target="ITEPEKIMAB">
      <data key="d4">7.0</data>
      <data key="d5">Itepekimab was tested in a phase II clinical trial for AD</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="AD" target="IL-37">
      <data key="d4">14.0</data>
      <data key="d5">IL-37 is involved in inflammation and immune response in AD
Children with AD exhibit significantly lower levels of IL-37 in their skin barrier</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="AD" target="FOLLICULITIS">
      <data key="d4">6.0</data>
      <data key="d5">Folliculitis is a common adverse event in AD treatment</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="AD" target="UPPER-RESPIRATORY-TRACT INFECTIONS">
      <data key="d4">6.0</data>
      <data key="d5">Upper-respiratory-tract infections are a common adverse event in AD treatment</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="AD" target="PAIN">
      <data key="d4">7.0</data>
      <data key="d5">Pain is a common symptom in AD</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="AD" target="AZATHIOPRINE">
      <data key="d4">7.0</data>
      <data key="d5">Azathioprine is used in systemic therapy for AD</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </edge>
    <edge source="AD" target="TOPICAL CALCINEURIN INHIBITORS">
      <data key="d4">8.0</data>
      <data key="d5">Topical calcineurin inhibitors (TCIs) are used for anti-inflammatory therapy in AD</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </edge>
    <edge source="AD" target="ITCHING">
      <data key="d4">9.0</data>
      <data key="d5">Itching is a common symptom of AD that treatments aim to eliminate</data>
      <data key="d6">2cec06c4d46f5ff9ee936a78d8b077cd</data>
    </edge>
    <edge source="AD" target="DLQI">
      <data key="d4">8.0</data>
      <data key="d5">DLQI is used to evaluate the impact of AD on quality of life</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="AD" target="PRURITUS/ITCH NUMERIC RATING SCALE">
      <data key="d4">8.0</data>
      <data key="d5">The Pruritus/Itch Numeric Rating Scale is used to evaluate the severity of itching in AD</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="AD" target="NANOTECHNOLOGY">
      <data key="d4">7.0</data>
      <data key="d5">Nanotechnology offers a method for treating AD</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="AD" target="NANOPARTICLES">
      <data key="d4">8.0</data>
      <data key="d5">Nanoparticles are used in drug delivery systems for treating AD</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="AD" target="POLYMERIC PARTICULATES">
      <data key="d4">7.0</data>
      <data key="d5">Polymeric particulates are used as carriers in drug delivery systems for treating AD</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="AD" target="DENDRIMERS">
      <data key="d4">7.0</data>
      <data key="d5">Dendrimers are used as carriers in drug delivery systems for treating AD</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="AD" target="DENDRITIC-CORE MULTI-SHELL NANO TRANSPORTERS">
      <data key="d4">7.0</data>
      <data key="d5">Dendritic-core multi-shell nano transporters are used as carriers in drug delivery systems for treating AD</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="AD" target="LIPID NANOPARTICLES">
      <data key="d4">7.0</data>
      <data key="d5">Lipid nanoparticles serve as carriers in drug delivery systems for treating AD</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="AD" target="CHITOSAN-BASED NANOPARTICLES">
      <data key="d4">8.0</data>
      <data key="d5">Chitosan-based nanoparticles are used for drug delivery in treating AD</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="AD" target="NIC-CS-NPS">
      <data key="d4">8.0</data>
      <data key="d5">NIC-CS-NPs are used for treating AD</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="AD" target="EAR SKIN">
      <data key="d4">7.0</data>
      <data key="d5">Ear skin thickness is measured in AD studies</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="AD" target="SPLEEN INDEX">
      <data key="d4">7.0</data>
      <data key="d5">Spleen index is measured to assess immune activation in AD studies</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="AD" target="HISTOPATHOLOGY">
      <data key="d4">7.0</data>
      <data key="d5">Histopathology is used to examine DNCB-induced AD skin lesions</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="AD" target="HYALURONIC ACID (HA)-DECORATED TAC-LOADED NPS">
      <data key="d4">8.0</data>
      <data key="d5">Hyaluronic Acid (HA)-decorated TAC-loaded NPs are used for treating AD</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="AD" target="NIOSOMES">
      <data key="d4">7.0</data>
      <data key="d5">Niosomes are used for drug delivery in treating AD</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="AD" target="POLYMERIC NANOPARTICLES">
      <data key="d4">7.0</data>
      <data key="d5">Polymeric nanoparticles are used for the topical administration of medicinal compounds in treating AD</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="AD" target="BETAMETHASONE VALERATE (BMV)-LOADED CHITOSAN NPS">
      <data key="d4">8.0</data>
      <data key="d5">Betamethasone Valerate (BMV)-loaded chitosan NPs are used for treating AD</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="AD" target="PHYTOCERAMIDES">
      <data key="d4">7.0</data>
      <data key="d5">Phytoceramides are used for treating AD</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="AD" target="NLCS">
      <data key="d4">8.0</data>
      <data key="d5">NLCs emerged as an innovative topical treatment for AD</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="AD" target="BECLOMETHASONE DIPROPIONATE (BDP)">
      <data key="d4">8.0</data>
      <data key="d5">BDP is used as a topical medication for treating AD</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="AD" target="PLA">
      <data key="d4">7.0</data>
      <data key="d5">PLA-based NPs are used for targeted and topical SC administration in AD</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="AD" target="BALB/C MICE">
      <data key="d4">6.0</data>
      <data key="d5">BALB/c mice are used in in vivo skin irritation tests for AD</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="AD" target="ADBRY">
      <data key="d4">16.0</data>
      <data key="d5">ADBRY is approved for AD treatment</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="AD" target="OPZELURA">
      <data key="d4">16.0</data>
      <data key="d5">Opzelura is approved for AD treatment</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="AD" target="NF-&#922;B">
      <data key="d4">14.0</data>
      <data key="d5">NF-&#954;B is involved in the pathophysiology of AD</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="AD" target="IL-4R">
      <data key="d4">14.0</data>
      <data key="d5">IL-4R is involved in the pathophysiology of AD</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="AD" target="IL-13R">
      <data key="d4">14.0</data>
      <data key="d5">IL-13R is involved in the pathophysiology of AD</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="AD" target="NOS2">
      <data key="d4">14.0</data>
      <data key="d5">NOS2 is used to monitor the severity of AD</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="AD" target="INOS">
      <data key="d4">14.0</data>
      <data key="d5">iNOS is used to monitor the severity of AD</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="AD" target="BIOLOGICAL THERAPIES">
      <data key="d4">16.0</data>
      <data key="d5">Biological therapies are advanced treatments for AD</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="AD" target="NANOCARRIERS">
      <data key="d4">9.0</data>
      <data key="d5">Nanocarriers are innovative therapeutic delivery systems for AD
Nanocarriers are specifically designed for the management of AD</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c,e30574e513dd250992d637d808759c34</data>
    </edge>
    <edge source="AD" target="BIOLOGICAL PHARMACEUTICALS">
      <data key="d4">8.0</data>
      <data key="d5">Biological pharmaceuticals are used as viable options for the management of AD</data>
      <data key="d6">e30574e513dd250992d637d808759c34</data>
    </edge>
    <edge source="AD" target="NANOPARTICLE SYSTEMS">
      <data key="d4">7.0</data>
      <data key="d5">Nanoparticle systems are fine-tuned for AD management</data>
      <data key="d6">e30574e513dd250992d637d808759c34</data>
    </edge>
    <edge source="AD" target="NANOMEDICINE">
      <data key="d4">8.0</data>
      <data key="d5">Nanomedicine techniques are set to revolutionize the treatment of AD</data>
      <data key="d6">e30574e513dd250992d637d808759c34</data>
    </edge>
    <edge source="AD" target="BIOTHERAPEUTICS">
      <data key="d4">8.0</data>
      <data key="d5">Biotherapeutics targeting pathways implicated in AD hold huge promise</data>
      <data key="d6">e30574e513dd250992d637d808759c34</data>
    </edge>
    <edge source="AD" target="PATHWAYS">
      <data key="d4">1.0</data>
      <data key="d5">Pathways are implicated in the pathophysiology of AD</data>
      <data key="d6">e30574e513dd250992d637d808759c34</data>
    </edge>
    <edge source="AD" target="THERAPEUTIC STRATEGIES">
      <data key="d4">8.0</data>
      <data key="d5">Therapeutic strategies are tailored for the management of AD</data>
      <data key="d6">e30574e513dd250992d637d808759c34</data>
    </edge>
    <edge source="AD" target="PATHOPHYSIOLOGY">
      <data key="d4">8.0</data>
      <data key="d5">Understanding the pathophysiology of AD helps in developing therapeutic strategies</data>
      <data key="d6">e30574e513dd250992d637d808759c34</data>
    </edge>
    <edge source="AD" target="DRUG DELIVERY MECHANISMS">
      <data key="d4">7.0</data>
      <data key="d5">Advanced drug delivery mechanisms are being developed for AD</data>
      <data key="d6">e30574e513dd250992d637d808759c34</data>
    </edge>
    <edge source="AD" target="THERAPEUTIC TARGETS">
      <data key="d4">8.0</data>
      <data key="d5">Therapeutic targets are identified for the treatment of AD</data>
      <data key="d6">e30574e513dd250992d637d808759c34</data>
    </edge>
    <edge source="AD" target="PRECLINICAL RESEARCH">
      <data key="d4">7.0</data>
      <data key="d5">Preclinical research has facilitated the development of treatments for AD</data>
      <data key="d6">e30574e513dd250992d637d808759c34</data>
    </edge>
    <edge source="AD" target="CLINICAL RESEARCH">
      <data key="d4">8.0</data>
      <data key="d5">Clinical research has led to more treatment options for AD</data>
      <data key="d6">e30574e513dd250992d637d808759c34</data>
    </edge>
    <edge source="AD" target="MULTIDISCIPLINARY APPROACH">
      <data key="d4">7.0</data>
      <data key="d5">A multidisciplinary approach enhances the management of AD</data>
      <data key="d6">e30574e513dd250992d637d808759c34</data>
    </edge>
    <edge source="AD" target="THERAPY COMPLIANCE">
      <data key="d4">6.0</data>
      <data key="d5">Improved therapy compliance is a goal in the treatment of AD</data>
      <data key="d6">e30574e513dd250992d637d808759c34</data>
    </edge>
    <edge source="AD" target="SEVERE AD">
      <data key="d4">8.0</data>
      <data key="d5">New therapies have significantly advanced the management of severe AD</data>
      <data key="d6">e30574e513dd250992d637d808759c34</data>
    </edge>
    <edge source="AD" target="NANOTECHNOLOGY-BASED DRUG DELIVERY SYSTEMS">
      <data key="d4">1.0</data>
      <data key="d5">Nanotechnology-based drug delivery systems may significantly improve the treatment of AD</data>
      <data key="d6">e30574e513dd250992d637d808759c34</data>
    </edge>
    <edge source="AD" target="PBMCS">
      <data key="d4">8.0</data>
      <data key="d5">PBMCs were collected from patients with AD</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="AD" target="SOX40">
      <data key="d4">22.0</data>
      <data key="d5">sOX40 was measured in serum from patients with AD
sOX40 serum levels are associated with atopic comorbidities and disease activity in children with AD
Serum levels of sOX40 are decreased in patients with AD</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746,6b099960b0a39866e3aa6b908f1886e4,89dbac0da39e4de2b602052cd792b90d</data>
    </edge>
    <edge source="AD" target="SOX40L">
      <data key="d4">13.0</data>
      <data key="d5">sOX40L was measured in serum from patients with AD
Serum levels of sOX40L show no significant differences between patients with AD and healthy controls</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746,89dbac0da39e4de2b602052cd792b90d</data>
    </edge>
    <edge source="AD" target="PLASMA">
      <data key="d4">8.0</data>
      <data key="d5">Plasma was collected from patients with AD</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="AD" target="ATOPIC DISEASES">
      <data key="d4">1.0</data>
      <data key="d5">Atopic dermatitis is a type of atopic disease</data>
      <data key="d6">100dd7646c10899301b3c0631183da16</data>
    </edge>
    <edge source="AD" target="SKIN THICKNESS">
      <data key="d4">7.0</data>
      <data key="d5">Skin thickness is used to evaluate the severity of atopic dermatitis</data>
      <data key="d6">100dd7646c10899301b3c0631183da16</data>
    </edge>
    <edge source="TNFSF" target="FIBROBLASTS">
      <data key="d4">9.0</data>
      <data key="d5">TNFSF members can act on fibroblasts to perpetuate fibrosis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="TNFSF" target="MACROPHAGES">
      <data key="d4">9.0</data>
      <data key="d5">TNFSF members can act on macrophages to perpetuate fibrosis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="TNFSF" target="T CELLS">
      <data key="d4">9.0</data>
      <data key="d5">TNFSF members can act on T cells to perpetuate fibrosis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="ENDOTHELIAL CELLS" target="NOTCH SIGNALING PATHWAY">
      <data key="d4">6.0</data>
      <data key="d5">The Notch signaling pathway interacts with endothelial cells</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="ENDOTHELIAL CELLS" target="HVEM">
      <data key="d4">14.0</data>
      <data key="d5">HVEM is expressed on endothelial cells</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="ENDOTHELIAL CELLS" target="GITRL">
      <data key="d4">7.0</data>
      <data key="d5">GITRL is mainly expressed on endothelial cells</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="MACROPHAGES" target="M2 MACROPHAGES">
      <data key="d4">16.0</data>
      <data key="d5">M2 macrophages are a profibrotic phenotype of macrophages</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="MACROPHAGES" target="HVEM">
      <data key="d4">14.0</data>
      <data key="d5">HVEM is expressed on macrophages</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="MACROPHAGES" target="TACI">
      <data key="d4">7.0</data>
      <data key="d5">TACI is expressed in macrophages and plays a role in M1 polarization and inflammation</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="MACROPHAGES" target="RANKL">
      <data key="d4">14.0</data>
      <data key="d5">RANKL activates lung macrophages in silicosis</data>
      <data key="d6">d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="MACROPHAGES" target="MMP-12">
      <data key="d4">12.0</data>
      <data key="d5">Macrophages in silicosis exhibit a high MMP-12 phenotype</data>
      <data key="d6">d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="MACROPHAGES" target="GITRL">
      <data key="d4">7.0</data>
      <data key="d5">GITRL is mainly expressed on macrophages</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="MACROPHAGES" target="TNF&#913;">
      <data key="d4">8.0</data>
      <data key="d5">TNF&#945; can act on macrophages to drive pro-fibrotic and anti-fibrotic effects</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="MACROPHAGES" target="LIGHT">
      <data key="d4">16.0</data>
      <data key="d5">LIGHT can act on macrophages to drive pro-fibrotic and anti-fibrotic effects
LIGHT acts on macrophages to drive pro-fibrotic and anti-fibrotic effects</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a,68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="MACROPHAGES" target="TNFSF2">
      <data key="d4">8.0</data>
      <data key="d5">TNFSF2 can act on macrophages to drive pro-fibrotic and anti-fibrotic effects</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="MACROPHAGES" target="TL1A">
      <data key="d4">8.0</data>
      <data key="d5">TL1A acts on macrophages to drive pro-fibrotic and anti-fibrotic effects</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </edge>
    <edge source="CD86" target="CD28">
      <data key="d4">41.0</data>
      <data key="d5">CD86 interacts with CD28 for T-cell activation
CD28 binds to CD86 to provide a costimulatory signal for T-cell activation
CD28 and CD86 are involved in positive costimulatory pathways</data>
      <data key="d6">4842292208575bd45b2b5998513dd087,503107475d2e9dac49abd8ebcbadd9f5,855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="CD86" target="CTLA-4">
      <data key="d4">40.0</data>
      <data key="d5">CTLA-4 binds to CD86, reducing IL-2 production and T cell proliferation
CTLA-4 and CD86 are involved in negative costimulatory pathways
CTLA-4 interacts with CD86 in immune response regulation</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b,4d0e8ae9371a435885994b4161126bc3,855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="CD86" target="SCTLA-4">
      <data key="d4">16.0</data>
      <data key="d5">sCTLA-4 may inhibit early T-cell activation by blocking CD86&#8212;CD28 interaction
sCTLA-4 blocks CD86 interaction</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b,9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="CD28" target="SSC">
      <data key="d4">19.0</data>
      <data key="d5">CD28 is overexpressed in patients with systemic sclerosis
CD28 is implicated in the pathogenesis of systemic sclerosis</data>
      <data key="d6">4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="CD28" target="IL-2 SECRETION">
      <data key="d4">8.0</data>
      <data key="d5">CD28 binding to CD80 and CD86 induces IL-2 secretion</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="CD28" target="SERUM">
      <data key="d4">7.0</data>
      <data key="d5">Increased expression of CD28 is observed in the serum of SSc patients</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="CD28" target="T CELL">
      <data key="d4">8.0</data>
      <data key="d5">CD28 is involved in T cell costimulation</data>
      <data key="d6">4d0e8ae9371a435885994b4161126bc3</data>
    </edge>
    <edge source="PERIPHERAL BLOOD MONONUCLEAR CELLS" target="FLOW CYTOMETRY">
      <data key="d4">7.0</data>
      <data key="d5">Flow cytometry is used to analyze PBMCs from patients with atopic dermatitis</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd</data>
    </edge>
    <edge source="GBR 830" target="ECZEMA AREA AND SEVERITY INDEX (EASI)">
      <data key="d4">16.0</data>
      <data key="d5">GBR 830 treatment improves EASI scores</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="GBR 830" target="CCL11">
      <data key="d4">16.0</data>
      <data key="d5">GBR 830 treatment reduces CCL11 mRNA levels</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="GBR 830" target="CCL17">
      <data key="d4">16.0</data>
      <data key="d5">GBR 830 treatment reduces CCL17 mRNA levels</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="GBR 830" target="S100">
      <data key="d4">16.0</data>
      <data key="d5">GBR 830 treatment reduces S100 mRNA levels</data>
      <data key="d6">4842292208575bd45b2b5998513dd087</data>
    </edge>
    <edge source="MRNA" target="POLY(A)">
      <data key="d4">7.0</data>
      <data key="d5">Poly(A) is a sequence of adenine nucleotides added to RNA molecules</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="MRNA" target="STRANDED MRNA LIBRARIES">
      <data key="d4">7.0</data>
      <data key="d5">Stranded mRNA libraries are collections of mRNA sequences used for sequencing</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="CCL11" target="T CELL">
      <data key="d4">16.0</data>
      <data key="d5">CCL11 promotes the attraction of inflammatory T cells</data>
      <data key="d6">6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="CCL11" target="DC">
      <data key="d4">16.0</data>
      <data key="d5">CCL11 promotes the attraction of inflammatory DC subtypes</data>
      <data key="d6">6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="CCL11" target="TRAIL">
      <data key="d4">7.0</data>
      <data key="d5">TRAIL is necessary for the upregulation of CCL11</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="CCL17" target="T CELL">
      <data key="d4">16.0</data>
      <data key="d5">CCL17 promotes the attraction of inflammatory T cells</data>
      <data key="d6">6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="CCL17" target="DC">
      <data key="d4">16.0</data>
      <data key="d5">CCL17 promotes the attraction of inflammatory DC subtypes</data>
      <data key="d6">6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="KHK4083" target="IGA">
      <data key="d4">7.0</data>
      <data key="d5">KHK4083 led to IGA 0/1 in 35% of patients in a phase Ib trial</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="KHK4083" target="PHASE IB TRIAL">
      <data key="d4">8.0</data>
      <data key="d5">KHK4083 was tested in a phase Ib trial</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="KHK4083" target="PHASE IIB TRIAL">
      <data key="d4">7.0</data>
      <data key="d5">KHK4083 results from the phase IIb trial are pending</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="ERYTHEMA" target="INFANTILE ATOPIC DERMATITIS">
      <data key="d4">7.0</data>
      <data key="d5">Erythema is poorly defined redness of the skin, often seen in infantile Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ERYTHEMA" target="MICE">
      <data key="d4">12.0</data>
      <data key="d5">Mice treated with NPs exhibited improved control over erythema intensity</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="ERYTHEMA" target="ER143">
      <data key="d4">14.0</data>
      <data key="d5">ER143 reduced erythema by 98% after local use on mouse ears</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="SERUM" target="SOX40">
      <data key="d4">15.0</data>
      <data key="d5">Serum levels of sOX40 are measured in patients with atopic dermatitis
Serum levels of sOX40 are measured in AD</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd,89dbac0da39e4de2b602052cd792b90d</data>
    </edge>
    <edge source="SERUM" target="SOX40L">
      <data key="d4">15.0</data>
      <data key="d5">Serum levels of sOX40L are measured in patients with atopic dermatitis
Serum levels of sOX40L are measured in AD</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd,89dbac0da39e4de2b602052cd792b90d</data>
    </edge>
    <edge source="SERUM" target="ICOS">
      <data key="d4">7.0</data>
      <data key="d5">Increased expression of ICOS is observed in the serum of SSc patients</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="SERUM" target="CTLA-4">
      <data key="d4">7.0</data>
      <data key="d5">Increased expression of CTLA-4 is observed in the serum of SSc patients</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="SERUM" target="PD1">
      <data key="d4">7.0</data>
      <data key="d5">Increased expression of PD1 is observed in the serum of SSc patients</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="SERUM" target="DCSSC">
      <data key="d4">7.0</data>
      <data key="d5">Increased levels of certain proteins in serum correlate with disease activity and severity in dcSSc</data>
      <data key="d6">4d0e8ae9371a435885994b4161126bc3</data>
    </edge>
    <edge source="SERUM" target="PH">
      <data key="d4">7.0</data>
      <data key="d5">Increased levels of certain proteins in serum correlate with disease severity in pulmonary hypertension</data>
      <data key="d6">4d0e8ae9371a435885994b4161126bc3</data>
    </edge>
    <edge source="SERUM" target="SCD27">
      <data key="d4">7.0</data>
      <data key="d5">Serum levels of soluble CD27 correlate with disease severity in SSc</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="HEAD AND NECK" target="CATINLIMAB">
      <data key="d4">14.0</data>
      <data key="d5">Catinlimab is being evaluated for its efficacy in treating head and neck disease</data>
      <data key="d6">b876251511f570468eb5b6ee6a239cc6</data>
    </edge>
    <edge source="EASI75" target="ASLAN004">
      <data key="d4">8.0</data>
      <data key="d5">ASLAN004 achieved EASI75 in 67% of patients</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="PLACEBO" target="CLINICAL TRIALS">
      <data key="d4">6.0</data>
      <data key="d5">Placebo is used as a control in clinical trials</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </edge>
    <edge source="PLACEBO" target="SALINE">
      <data key="d4">6.0</data>
      <data key="d5">Saline is often used as a placebo in clinical trials</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="PLACEBO" target="PRA023">
      <data key="d4">7.0</data>
      <data key="d5">PRA023 is compared to a placebo in clinical trials</data>
      <data key="d6">423195c6b63ad0a6773374364ebf3612</data>
    </edge>
    <edge source="PLACEBO" target="IGA NEPHROPATHY">
      <data key="d4">7.0</data>
      <data key="d5">Placebo is used as a control in studies for IgA Nephropathy</data>
      <data key="d6">8e5a1be9981340d419f7b3ad27076009</data>
    </edge>
    <edge source="PLACEBO" target="SYSTEMIC SCLEROSIS">
      <data key="d4">1.0</data>
      <data key="d5">Placebo is used as a control in studies for Systemic Sclerosis</data>
      <data key="d6">8e5a1be9981340d419f7b3ad27076009</data>
    </edge>
    <edge source="PLACEBO" target="CROHN DISEASE">
      <data key="d4">7.0</data>
      <data key="d5">Placebo is used as a control in clinical trials for Crohn's disease</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="PLACEBO" target="CALCIFIC AORTIC STENOSIS">
      <data key="d4">7.0</data>
      <data key="d5">Placebo is used as a control in clinical trials for calcific aortic stenosis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="PLACEBO" target="ASTHMA">
      <data key="d4">7.0</data>
      <data key="d5">Placebo is used as a control in clinical trials for asthma</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="PLACEBO" target="ULCERATIVE COLITIS">
      <data key="d4">7.0</data>
      <data key="d5">Placebo is used as a control in clinical trials for ulcerative colitis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="VIGA" target="PP-NRS-11">
      <data key="d4">6.0</data>
      <data key="d5">PP-NRS-11 correlates weakly with vIGA</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="SCORAD" target="OSCORAD">
      <data key="d4">8.0</data>
      <data key="d5">oSCORAD is a version of SCORAD excluding subjective symptoms</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="SCORAD" target="SCORAD75">
      <data key="d4">9.0</data>
      <data key="d5">SCORAD75 represents a 75% improvement in SCORAD from baseline</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="SCORAD" target="ITCH">
      <data key="d4">7.0</data>
      <data key="d5">Itch is a subjective symptom considered in the SCORAD assessment</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="SCORAD" target="SLEEPLESSNESS">
      <data key="d4">7.0</data>
      <data key="d5">Sleeplessness is a subjective symptom considered in the SCORAD assessment</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="SCORAD" target="SKIN LESIONS">
      <data key="d4">8.0</data>
      <data key="d5">Skin lesions are measured by SCORAD in atopic dermatitis</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="SCORAD" target="MEPOLIZUMAB">
      <data key="d4">12.0</data>
      <data key="d5">Mepolizumab failed to show a significant decrease in SCORAD</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41</data>
    </edge>
    <edge source="SCORAD" target="SOX40">
      <data key="d4">6.0</data>
      <data key="d5">sOX40 levels in children with AD correlated with SCORAD</data>
      <data key="d6">6b099960b0a39866e3aa6b908f1886e4</data>
    </edge>
    <edge source="ASTHMA" target="FEV1">
      <data key="d4">7.0</data>
      <data key="d5">FEV1 is a measure of lung function in asthma</data>
      <data key="d6">b19f42c9497f71b231222cd953036d6b</data>
    </edge>
    <edge source="ASTHMA" target="IL-5">
      <data key="d4">14.0</data>
      <data key="d5">IL-5 is important in asthma</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="ASTHMA" target="SOX40">
      <data key="d4">7.0</data>
      <data key="d5">sOX40 serum levels are significantly higher in AD patients with asthma compared to those without</data>
      <data key="d6">6b099960b0a39866e3aa6b908f1886e4</data>
    </edge>
    <edge source="ASTHMA" target="LIGHT">
      <data key="d4">30.0</data>
      <data key="d5">LIGHT is induced in asthma
LIGHT is induced in asthma and regulates fibrosis in the lungs</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2,df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="ASTHMA" target="TL1A">
      <data key="d4">7.0</data>
      <data key="d5">Blocking TL1A signaling attenuates pathology in asthma models</data>
      <data key="d6">05c97152fe02249153103be341d65b67</data>
    </edge>
    <edge source="ASTHMA" target="GENENTECH, INC.">
      <data key="d4">6.0</data>
      <data key="d5">Genentech, Inc. is involved in clinical trials for asthma</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="VIRUS-SPECIFIC ANTIBODY" target="CYTOTOXIC T-CELL">
      <data key="d4">12.0</data>
      <data key="d5">Virus-specific antibody production and cytotoxic T-cell response were not affected in the viral infection model</data>
      <data key="d6">b201c6ff3e22b2475c8c59260a0eb6a7</data>
    </edge>
    <edge source="SOX40" target="MAST CELL DEGRANULATION">
      <data key="d4">8.0</data>
      <data key="d5">Soluble OX40 inhibits Mast Cell Degranulation, reducing the inflammatory response in Atopic Dermatitis</data>
      <data key="d6">691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="SOX40" target="HC">
      <data key="d4">7.0</data>
      <data key="d5">sOX40 was measured in serum from healthy controls</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="SOX40" target="ENZYME-LINKED IMMUNOASSAY">
      <data key="d4">8.0</data>
      <data key="d5">ELISA is used to measure serum levels of sOX40 in patients with atopic dermatitis</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd</data>
    </edge>
    <edge source="SOX40" target="CHILDREN WITH AD">
      <data key="d4">8.0</data>
      <data key="d5">Serum levels of sOX40 are measured in children with atopic dermatitis</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd</data>
    </edge>
    <edge source="SOX40" target="ADULTS WITH AD">
      <data key="d4">8.0</data>
      <data key="d5">Serum levels of sOX40 are measured in adults with atopic dermatitis</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd</data>
    </edge>
    <edge source="CYTOKINES" target="BIOLOGICS">
      <data key="d4">8.0</data>
      <data key="d5">Biologics target key effectors like cytokines in immune responses</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="CYTOKINES" target="PDE4">
      <data key="d4">14.0</data>
      <data key="d5">PDE4 helps immune cells release cytokines</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="B CELLS" target="B CELL RECEPTOR SIGNALING PATHWAY">
      <data key="d4">6.0</data>
      <data key="d5">B cell receptor signaling pathway is enriched in B cells</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="B CELLS" target="IFN-&#915; MEDIATED SIGNALING PATHWAY">
      <data key="d4">6.0</data>
      <data key="d5">IFN-&#947; mediated signaling pathway is enriched in B cells</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="B CELLS" target="CD20">
      <data key="d4">9.0</data>
      <data key="d5">CD20 is a marker found on B cells</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606</data>
    </edge>
    <edge source="B CELLS" target="GITRL">
      <data key="d4">7.0</data>
      <data key="d5">GITRL is mainly expressed on B cells</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="B CELLS" target="CD27">
      <data key="d4">14.0</data>
      <data key="d5">CD27 is expressed on specific subsets of B cells</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="IFN-&#915;" target="STROMAL CELLS">
      <data key="d4">7.0</data>
      <data key="d5">IFN-&#947; interacts with various stromal cell clusters</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="IFN-&#915;" target="CAMP">
      <data key="d4">6.0</data>
      <data key="d5">cAMP mediates downstream events culminating in the inhibition of IFN-&#947; secretion</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="IFN-&#915;" target="HYDROCORTISONE">
      <data key="d4">14.0</data>
      <data key="d5">HC-NPs suppressed inflammatory cascades including IFN-&#947;</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="IFN-&#915;" target="SSC">
      <data key="d4">8.0</data>
      <data key="d5">IFN-&#947; is a proinflammatory cytokine involved in systemic sclerosis</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="IFN-&#915;" target="ICOS">
      <data key="d4">8.0</data>
      <data key="d5">ICOS induces the synthesis of IFN-&#947; in activated T cells</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="PBMCS" target="FICOLL-PAQUE">
      <data key="d4">8.0</data>
      <data key="d5">Ficoll-Paque is used for density gradient centrifugation to isolate PBMCs in research on Atopic Dermatitis
Ficoll-Paque was used to isolate PBMCs</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746,691cb2e23ac3c6e591129d16714f8ef8</data>
    </edge>
    <edge source="PBMCS" target="HC">
      <data key="d4">8.0</data>
      <data key="d5">PBMCs were collected from healthy controls</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="PBMCS" target="MOUSE IGG">
      <data key="d4">6.0</data>
      <data key="d5">Mouse IgG was used to block unspecific binding in PBMCs</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="PBMCS" target="BOVINE SERUM ALBUMIN (BSA)">
      <data key="d4">6.0</data>
      <data key="d5">Bovine Serum Albumin was used in wash buffer for PBMCs</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="PBMCS" target="SODIUM AZIDE">
      <data key="d4">6.0</data>
      <data key="d5">Sodium Azide was used in wash buffer for PBMCs</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="PBMCS" target="FORMALDEHYDE">
      <data key="d4">7.0</data>
      <data key="d5">Formaldehyde was used to fix PBMCs</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="NOTCH SIGNALING" target="GAMMA-SECRETASE">
      <data key="d4">9.0</data>
      <data key="d5">Gamma-secretase is involved in the regulation of Notch signaling</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="RNA-SEQ" target="RNA">
      <data key="d4">8.0</data>
      <data key="d5">RNA is analyzed using RNA-Seq</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="RNA-SEQ" target="GRCH38">
      <data key="d4">8.0</data>
      <data key="d5">GRCh38 is a reference genome assembly used for mapping reads in RNA-Seq experiments</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="RNA-SEQ" target="DESEQ">
      <data key="d4">8.0</data>
      <data key="d5">DESeq is a software tool used for differential expression analysis in RNA-Seq data</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="RNA-SEQ" target="SCIDAP">
      <data key="d4">16.0</data>
      <data key="d5">SciDAP is a platform used for scientific data analysis, including RNA-Seq dataSciDAP is used for analyzing RNA-Seq data</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="RNA-SEQ" target="TRIM GALORE">
      <data key="d4">7.0</data>
      <data key="d5">Trim Galore is used for trimming adapters in RNA-Seq data</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="RNA-SEQ" target="CELLPHONEDB">
      <data key="d4">7.0</data>
      <data key="d5">CellPhoneDB is used for analyzing cell-cell communication in RNA-Seq data</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="RNA-SEQ" target="PCA">
      <data key="d4">14.0</data>
      <data key="d5">PCA is used for principal component analysis in RNA-Seq data</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="RNA-SEQ" target="FDR">
      <data key="d4">14.0</data>
      <data key="d5">FDR is used to control the false discovery rate in RNA-Seq data</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="RNA-SEQ" target="STUDENT&#8217;S T TEST">
      <data key="d4">12.0</data>
      <data key="d5">Student&#8217;s t test is used for statistical analysis in RNA-Seq data</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="RNA-SEQ" target="MANN-WHITNEY U TEST">
      <data key="d4">12.0</data>
      <data key="d5">Mann-Whitney U test is used for statistical analysis in RNA-Seq data</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="RNA-SEQ" target="ILLUMINA NOVASEQ 6000">
      <data key="d4">16.0</data>
      <data key="d5">Illumina NovaSeq 6000 is used for sequencing in RNA-Seq</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="RNA-SEQ" target="NEW ENGLAND BIOLABS">
      <data key="d4">14.0</data>
      <data key="d5">New England Biolabs provides reagents for RNA-Seq</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="RNA-SEQ" target="GENOMATIX">
      <data key="d4">14.0</data>
      <data key="d5">Genomatix is used for creating biological networks from RNA-Seq data</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="RNA-SEQ" target="TRIM GALORE RNA-SEQ PIPELINE">
      <data key="d4">7.0</data>
      <data key="d5">Trim Galore RNA-Seq pipeline is a software tool used for trimming adapters in RNA-Seq data</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="RNA-SEQ" target="SSC">
      <data key="d4">7.0</data>
      <data key="d5">RNA sequencing is used to analyze the transcriptome of SSc patients</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="IMMUNOPATHOGENESIS" target="SSC">
      <data key="d4">1.0</data>
      <data key="d5">The study furthers understanding of the complex immunopathogenesis of SSc</data>
      <data key="d6">7b454335c2f5651d86f712037a0dc0ff</data>
    </edge>
    <edge source="FALSE DISCOVERY RATE" target="BENJAMINI AND HOCHBERG METHOD">
      <data key="d4">7.0</data>
      <data key="d5">Benjamini and Hochberg method is used to control the false discovery rate</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="CLINICAL TRIALS" target="TREATMENT-EMERGENT ADVERSE EVENT">
      <data key="d4">7.0</data>
      <data key="d5">Treatment-emergent adverse events are monitored during clinical trials</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </edge>
    <edge source="FIBROBLASTS" target="CD34+CD45+ MONOCYTIC CELLS">
      <data key="d4">7.0</data>
      <data key="d5">CD34+CD45+ monocytic cells differentiate into collagen-producing fibroblasts</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="FIBROBLASTS" target="HVEM">
      <data key="d4">14.0</data>
      <data key="d5">HVEM is expressed on fibroblasts</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="FIBROBLASTS" target="LT&#914;R">
      <data key="d4">14.0</data>
      <data key="d5">LT&#946;R is expressed on fibroblasts</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="FIBROBLASTS" target="CD70">
      <data key="d4">21.0</data>
      <data key="d5">CD70 is expressed on fibroblasts
CD70 on fibroblasts is proposed as a target in fibrotic diseases</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3,4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="FIBROBLASTS" target="SCD27">
      <data key="d4">7.0</data>
      <data key="d5">sCD27 inhibits fibroblast extracellular matrix protein production</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="FIBROBLASTS" target="CD4 T CELLS">
      <data key="d4">6.0</data>
      <data key="d5">Activated CD4 T cells drive fibroblast CD70 activation</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="FIBROBLASTS" target="TNF&#913;">
      <data key="d4">8.0</data>
      <data key="d5">TNF&#945; can act on fibroblasts to drive pro-fibrotic and anti-fibrotic effects</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="FIBROBLASTS" target="LIGHT">
      <data key="d4">16.0</data>
      <data key="d5">LIGHT can act on fibroblasts to drive pro-fibrotic and anti-fibrotic effects
LIGHT acts on fibroblasts to drive pro-fibrotic and anti-fibrotic effects</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a,68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="FIBROBLASTS" target="TL1A">
      <data key="d4">16.0</data>
      <data key="d5">TL1A can act on fibroblasts to drive pro-fibrotic and anti-fibrotic effects
TL1A acts on fibroblasts to drive pro-fibrotic and anti-fibrotic effects</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a,68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="FIBROBLASTS" target="TNFSF2">
      <data key="d4">8.0</data>
      <data key="d5">TNFSF2 can act on fibroblasts to drive pro-fibrotic and anti-fibrotic effects</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="FIBROBLASTS" target="TNFSF15">
      <data key="d4">8.0</data>
      <data key="d5">TNFSF15 can act on fibroblasts to drive pro-fibrotic and anti-fibrotic effects</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="SMOOTH MUSCLE CELLS" target="HVEM">
      <data key="d4">14.0</data>
      <data key="d5">HVEM is expressed on smooth muscle cells</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="SMOOTH MUSCLE CELLS" target="LT&#914;R">
      <data key="d4">14.0</data>
      <data key="d5">LT&#946;R is expressed on smooth muscle cells</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="SMOOTH MUSCLE CELLS" target="LIGHT">
      <data key="d4">16.0</data>
      <data key="d5">LIGHT can act on smooth muscle cells to drive pro-fibrotic and anti-fibrotic effects
LIGHT acts on smooth muscle cells to drive pro-fibrotic and anti-fibrotic effects</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a,68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="T CELLS" target="CCL20">
      <data key="d4">7.0</data>
      <data key="d5">Keratinocyte-derived CCL20 interacts with T cells</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="T CELLS" target="T CELL RECEPTOR SIGNALING PATHWAY">
      <data key="d4">6.0</data>
      <data key="d5">T cell receptor signaling pathway is enriched in T cells</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="T CELLS" target="T CELL COSTIMULATION">
      <data key="d4">6.0</data>
      <data key="d5">T cell costimulation is enriched in T cells</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="T CELLS" target="TNF-MEDIATED SIGNALING">
      <data key="d4">6.0</data>
      <data key="d5">Regulation of TNF-mediated signaling is enriched in T cells</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="T CELLS" target="S1P">
      <data key="d4">14.0</data>
      <data key="d5">S1P affects the segregation of T cells</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="T CELLS" target="CLA">
      <data key="d4">7.0</data>
      <data key="d5">CLA is expressed on T cells in AD</data>
      <data key="d6">89dbac0da39e4de2b602052cd792b90d</data>
    </edge>
    <edge source="T CELLS" target="CD4">
      <data key="d4">7.0</data>
      <data key="d5">CD4 is expressed on T cells in AD</data>
      <data key="d6">89dbac0da39e4de2b602052cd792b90d</data>
    </edge>
    <edge source="T CELLS" target="CD45RO">
      <data key="d4">7.0</data>
      <data key="d5">CD45RO is expressed on T cells in AD</data>
      <data key="d6">89dbac0da39e4de2b602052cd792b90d</data>
    </edge>
    <edge source="T CELLS" target="CD8">
      <data key="d4">7.0</data>
      <data key="d5">CD8 is expressed on T cells in AD</data>
      <data key="d6">89dbac0da39e4de2b602052cd792b90d</data>
    </edge>
    <edge source="T CELLS" target="ICOS">
      <data key="d4">8.0</data>
      <data key="d5">ICOS induces proinflammatory and pro-fibrotic cytokine synthesis in activated T cells</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="T CELLS" target="MMP">
      <data key="d4">14.0</data>
      <data key="d5">MMPs condition human na&#239;ve T cells to prime TH2 phenotype via an OX40L-dependent pathway</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="T CELLS" target="HVEM">
      <data key="d4">14.0</data>
      <data key="d5">HVEM is expressed on T cells</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="T CELLS" target="TL1A">
      <data key="d4">16.0</data>
      <data key="d5">TL1A is required for severe bowel pathology through activation of T cells
TL1A acts on T cells to drive pro-fibrotic and anti-fibrotic effects</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a,c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="T CELLS" target="CD27">
      <data key="d4">14.0</data>
      <data key="d5">CD27 is expressed on specific subsets of T cells</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="T CELLS" target="TNF&#913;">
      <data key="d4">8.0</data>
      <data key="d5">TNF&#945; can act on T cells to drive pro-fibrotic and anti-fibrotic effects</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="T CELLS" target="TNFSF2">
      <data key="d4">8.0</data>
      <data key="d5">TNFSF2 can act on T cells to drive pro-fibrotic and anti-fibrotic effects</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="MYELOID CELLS" target="INFLAMMATORY RESPONSE">
      <data key="d4">6.0</data>
      <data key="d5">Inflammatory response is enriched in the myeloid cell population</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="MYELOID CELLS" target="NEUTROPHIL CHEMOTAXIS">
      <data key="d4">6.0</data>
      <data key="d5">Neutrophil chemotaxis is enriched in the myeloid cell population</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="MAST CELLS" target="HIGH-AFFINITY IGE RECEPTOR">
      <data key="d4">7.0</data>
      <data key="d5">High-affinity IgE receptor is expressed in mast cells in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="MAST CELLS" target="TRYPTASE">
      <data key="d4">9.0</data>
      <data key="d5">Tryptase staining confirms the presence of OX40L-expressing mast cells in AD skin
Tryptase staining confirms the presence of mast cells</data>
      <data key="d6">6b099960b0a39866e3aa6b908f1886e4,89dbac0da39e4de2b602052cd792b90d</data>
    </edge>
    <edge source="MAST CELLS" target="DERMIS">
      <data key="d4">7.0</data>
      <data key="d5">Mast cells are located in the dermis of patients with AD</data>
      <data key="d6">89dbac0da39e4de2b602052cd792b90d</data>
    </edge>
    <edge source="CTLA-4" target="SSC">
      <data key="d4">47.0</data>
      <data key="d5">CTLA-4 is overexpressed in patients with systemic sclerosis
CTLA-4 might contribute to systemic sclerosis
CTLA-4 polymorphisms confer susceptibility to systemic sclerosis
CTLA-4 is overexpressed in patients with systemic sclerosis</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="CTLA-4" target="CTLA4-B7">
      <data key="d4">8.0</data>
      <data key="d5">CTLA-4 is involved in the CTLA4-B7 negative costimulatory pathway</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="CTLA-4" target="SCTLA-4">
      <data key="d4">14.0</data>
      <data key="d5">sCTLA-4 competes with CTLA-4 for binding</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="CTLA-4" target="M2 MACROPHAGES">
      <data key="d4">14.0</data>
      <data key="d5">Blocking CTLA-4 decreases M2 macrophage differentiation</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="ICOS" target="SSC">
      <data key="d4">17.0</data>
      <data key="d5">ICOS is overexpressed in patients with systemic sclerosis
ICOS is overexpressed in patients with systemic sclerosis</data>
      <data key="d6">4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="ICOS" target="B7RP1">
      <data key="d4">24.0</data>
      <data key="d5">ICOS binds to B7RP1 in the ICOS-B7RP1 costimulatory pathway
ICOS and B7RP1 are involved in positive costimulatory pathways</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5,855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="ICOS" target="FIBROBLAST">
      <data key="d4">7.0</data>
      <data key="d5">ICOS promotes fibroblast activation</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="ICOS" target="EXTRACELLULAR MATRIX">
      <data key="d4">7.0</data>
      <data key="d5">ICOS promotes extracellular matrix synthesis</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="ICOS" target="T CELL">
      <data key="d4">8.0</data>
      <data key="d5">ICOS is involved in T cell costimulation</data>
      <data key="d6">4d0e8ae9371a435885994b4161126bc3</data>
    </edge>
    <edge source="CD70" target="CD27">
      <data key="d4">48.0</data>
      <data key="d5">CD70 binds to CD27 in the CD70-CD27 costimulatory pathway
CD70 interacts with CD27 in T cell activation
CD70 binds to CD27 and is involved in T and B cell signaling
CD27 interacts with CD70 to provide stimulatory signals for T and B cell activation
CD70 binds to CD27</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3,4cf23e218b6aab3c77115173b5c7c2fd,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="CD70" target="T CELL">
      <data key="d4">8.0</data>
      <data key="d5">CD70 is involved in T cell activation</data>
      <data key="d6">4d0e8ae9371a435885994b4161126bc3</data>
    </edge>
    <edge source="CD70" target="SSC">
      <data key="d4">7.0</data>
      <data key="d5">Differential expression of CD70 is associated with disease severity in SSc</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD70" target="FIBROTIC DISEASES">
      <data key="d4">7.0</data>
      <data key="d5">CD70 is proposed as a target in fibrotic diseases</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD70" target="EPIGENETIC">
      <data key="d4">7.0</data>
      <data key="d5">Differential expression of CD70 is associated with epigenetic changes in SSc</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD70" target="DISEASE PATHOGENESIS">
      <data key="d4">1.0</data>
      <data key="d5">CD70 is involved in the disease pathogenesis of SSc</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD27" target="T CELL">
      <data key="d4">8.0</data>
      <data key="d5">CD27 is involved in T cell activation</data>
      <data key="d6">4d0e8ae9371a435885994b4161126bc3</data>
    </edge>
    <edge source="CD27" target="GITR">
      <data key="d4">6.0</data>
      <data key="d5">GITR possesses an intracellular domain with significant homology to CD27</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="CD27" target="NK CELLS">
      <data key="d4">14.0</data>
      <data key="d5">CD27 is expressed on NK cells</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="CD27" target="HEMATOPOIETIC STEM CELLS">
      <data key="d4">14.0</data>
      <data key="d5">CD27 is expressed on hematopoietic stem cells</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="CD27" target="EFFECTOR T CELLS">
      <data key="d4">14.0</data>
      <data key="d5">CD27 signaling affects the formation of effector T cells</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="CD27" target="MEMORY T CELLS">
      <data key="d4">14.0</data>
      <data key="d5">CD27 signaling affects the formation of memory T cells</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3</data>
    </edge>
    <edge source="CD27" target="NA&#207;VE T CELLS">
      <data key="d4">21.0</data>
      <data key="d5">CD27 signaling primes na&#239;ve T cells
CD27 is expressed on na&#239;ve T cells</data>
      <data key="d6">1b656cfce91ff9ccec4223703489dab3,4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD27" target="SCD27">
      <data key="d4">8.0</data>
      <data key="d5">CD27 is cleaved to form soluble CD27</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD27" target="CHRONIC RENAL NEPHRITIS">
      <data key="d4">7.0</data>
      <data key="d5">CD27+ B cells are increased in chronic renal nephritis</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD27" target="CIRRHOSIS">
      <data key="d4">7.0</data>
      <data key="d5">CD27+ B cells are depleted in cirrhotic patients</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD27" target="TNF-BETA">
      <data key="d4">6.0</data>
      <data key="d5">Loss of CD27+ B cells is accompanied by impaired TNF-beta secretion</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD27" target="IGG">
      <data key="d4">6.0</data>
      <data key="d5">Loss of CD27+ B cells is accompanied by impaired IgG production</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD27" target="CD95">
      <data key="d4">6.0</data>
      <data key="d5">CD27+ B cells in cirrhotic patients show increased levels of CD95</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD27" target="FASL">
      <data key="d4">6.0</data>
      <data key="d5">Increased FasL exposure drives depletion of CD27+ B cells</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD27" target="ENDOTOXIN">
      <data key="d4">6.0</data>
      <data key="d5">Increased endotoxin exposure drives depletion of CD27+ B cells</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD27" target="EAM">
      <data key="d4">7.0</data>
      <data key="d5">Depletion of CD27+ NK cells during EAM increases disease severity</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD27" target="EOSINOPHILS">
      <data key="d4">6.0</data>
      <data key="d5">CD27+ NK cells limit eosinophil infiltration</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD27" target="SSC">
      <data key="d4">7.0</data>
      <data key="d5">Serum levels of soluble CD27 correlate with disease severity in SSc</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD27" target="MEMORY T LYMPHOCYTES">
      <data key="d4">7.0</data>
      <data key="d5">CD27 is expressed on memory T lymphocytes</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD27" target="NA&#207;VE B CELLS">
      <data key="d4">7.0</data>
      <data key="d5">CD27 expression is absent from na&#239;ve B cells</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD27" target="MEMORY B LYMPHOCYTES">
      <data key="d4">7.0</data>
      <data key="d5">CD27 is upregulated in memory B lymphocytes</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD27" target="ACUTE INFLAMMATORY STATE">
      <data key="d4">7.0</data>
      <data key="d5">High CD27 expression and sCD27 secretion occur in an acute inflammatory state</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD27" target="RENAL DISEASES">
      <data key="d4">7.0</data>
      <data key="d5">CD27+ B cells are found in renal diseases</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD27" target="SYSTEMIC INFECTION">
      <data key="d4">7.0</data>
      <data key="d5">Depletion of CD27+ memory B cells contributes to systemic infection risk</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD27" target="CARDIAC INFILTRATING EOSINOPHILS">
      <data key="d4">7.0</data>
      <data key="d5">Depletion of CD27+ NK cells results in an influx of cardiac infiltrating eosinophils</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD27" target="CARDIAC FIBROBLASTS">
      <data key="d4">7.0</data>
      <data key="d5">CD27+ NK cells alter eosinophil-related chemokines by cardiac fibroblasts</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd</data>
    </edge>
    <edge source="CD40" target="CD154">
      <data key="d4">48.0</data>
      <data key="d5">CD40 binds to CD154 in the CD40-CD154 costimulatory pathway
CD154 binds to CD40 and activates antigen-presenting cells
CD40 and CD154 are involved in positive costimulatory pathways
CD40 interacts with CD154 in immune response regulation</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b,4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5,855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="CD40" target="FIBROBLAST">
      <data key="d4">14.0</data>
      <data key="d5">CD40 expression is increased in skin fibroblasts</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="CD40" target="SSC">
      <data key="d4">14.0</data>
      <data key="d5">CD40 expression is increased in the serum of systemic sclerosis patients</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="B CELL" target="CD20">
      <data key="d4">9.0</data>
      <data key="d5">CD20 is expressed on the surface of B cells</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="B CELL" target="CD138">
      <data key="d4">8.0</data>
      <data key="d5">CD138 is expressed on plasma cells, which are derived from B cells</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="B CELL" target="FOSTAMATINIB DISODIUM">
      <data key="d4">7.0</data>
      <data key="d5">Fostamatinib disodium is used in B cell stimulation experiments</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="B CELL" target="IBRUTINIB">
      <data key="d4">7.0</data>
      <data key="d5">Ibrutinib is used in B cell stimulation experiments</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="B CELL" target="ACALABRUTINIB">
      <data key="d4">7.0</data>
      <data key="d5">Acalabrutinib is used in B cell stimulation experiments</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="B CELL" target="DMSO">
      <data key="d4">6.0</data>
      <data key="d5">DMSO is used as a control in B cell stimulation experiments</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="B CELL" target="PBS">
      <data key="d4">12.0</data>
      <data key="d5">PBS is used to wash B cells in experiments</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="B CELL" target="EASYSEP">
      <data key="d4">14.0</data>
      <data key="d5">EasySep is used for isolating B cells</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="B CELL" target="LYMPHOPREP">
      <data key="d4">14.0</data>
      <data key="d5">Lymphoprep is used for isolating lymphocytes, including B cells</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="B CELL" target="GOAT F(AB&#8242;)2 ANTI-HUMAN IGM">
      <data key="d4">14.0</data>
      <data key="d5">Goat F(ab&#8242;)2 Anti-Human IgM is used for stimulating B cells</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="B CELL" target="GOAT F(AB&#8242;)2 ANTI-HUMAN IGG">
      <data key="d4">14.0</data>
      <data key="d5">Goat F(ab&#8242;)2 Anti-Human IgG is used for stimulating B cells</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="B CELL" target="MIGE">
      <data key="d4">7.0</data>
      <data key="d5">B cells express membrane-bound IgE</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="B CELL" target="LYMPHOBLASTS">
      <data key="d4">7.0</data>
      <data key="d5">Lymphoblasts are immature B cells</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="B CELL" target="SSC">
      <data key="d4">9.0</data>
      <data key="d5">B cells are involved in the pathogenesis of systemic sclerosis</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="T CELL" target="CD3">
      <data key="d4">9.0</data>
      <data key="d5">CD3 is a protein complex and T cell co-receptor involved in activating T cells</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="T CELL" target="TREG CELL">
      <data key="d4">9.0</data>
      <data key="d5">Treg cells are a subset of T cells that help regulate the immune response</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="T CELL" target="TH2 CELL">
      <data key="d4">8.0</data>
      <data key="d5">TH2 cells are a subset of T cells involved in the immune response</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="T CELL" target="CCL22">
      <data key="d4">16.0</data>
      <data key="d5">CCL22 promotes the attraction of inflammatory T cells</data>
      <data key="d6">6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="T CELL" target="CCL5">
      <data key="d4">16.0</data>
      <data key="d5">CCL5 promotes the attraction of inflammatory T cells</data>
      <data key="d6">6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="T CELL" target="SSC">
      <data key="d4">18.0</data>
      <data key="d5">T cells are involved in the pathogenesis of systemic sclerosis
T cell costimulatory pathways play a critical role in the pathogenesis of systemic sclerosis</data>
      <data key="d6">4d0e8ae9371a435885994b4161126bc3,503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="T CELL" target="SCTLA-4">
      <data key="d4">16.0</data>
      <data key="d5">sCTLA-4 may inhibit early T-cell activation</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="T CELL" target="PD-1">
      <data key="d4">16.0</data>
      <data key="d5">PD-1 regulates T cell tolerance</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="T CELL" target="IL-2">
      <data key="d4">8.0</data>
      <data key="d5">IL-2 is involved in the activation and proliferation of T cells</data>
      <data key="d6">4d0e8ae9371a435885994b4161126bc3</data>
    </edge>
    <edge source="T-SNE" target="DIMENSIONAL REDUCTION">
      <data key="d4">6.0</data>
      <data key="d5">t-SNE is a dimensional reduction technique</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="GENES" target="TRANSCRIPTS">
      <data key="d4">9.0</data>
      <data key="d5">Genes are transcribed into RNA molecules called transcripts</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="CELLPHONEDB" target="LIGAND">
      <data key="d4">8.0</data>
      <data key="d5">CellPhoneDB is used to analyze ligand-receptor interactions</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="CELLPHONEDB" target="RECEPTOR">
      <data key="d4">8.0</data>
      <data key="d5">CellPhoneDB is used to analyze receptor-ligand interactions</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="LIGAND" target="CIRCOS PLOT">
      <data key="d4">7.0</data>
      <data key="d5">Circos plot visualizes interactions between ligands and receptors</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="RECEPTOR" target="CIRCOS PLOT">
      <data key="d4">7.0</data>
      <data key="d5">Circos plot visualizes interactions between receptors and ligands</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="MARKER GENES" target="SUBCLUSTERS">
      <data key="d4">7.0</data>
      <data key="d5">Marker genes identify specific subclusters of keratinocytes</data>
      <data key="d6">bae090d8a29c15868ba1c4f29ae79e99</data>
    </edge>
    <edge source="CD8+ T CELLS" target="CD8">
      <data key="d4">9.0</data>
      <data key="d5">CD8 is a marker found on CD8+ T cells</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606</data>
    </edge>
    <edge source="CD8+ T CELLS" target="DNAM-1">
      <data key="d4">14.0</data>
      <data key="d5">Upregulation of DNAM-1 in CD8+ T cells is associated with disease severity in systemic sclerosis</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="BCR" target="TCR">
      <data key="d4">16.0</data>
      <data key="d5">MiXCR software was used to extract TCR and BCR CDR3 sequences from RNA-Seq data</data>
      <data key="d6">b28eeca0ff01a7715947d55a04978a43</data>
    </edge>
    <edge source="TCR" target="MHC">
      <data key="d4">16.0</data>
      <data key="d5">TCR binds to MHC molecules carrying peptide antigens</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="C1Q" target="C3B">
      <data key="d4">7.0</data>
      <data key="d5">C1q and C3b are both involved in the complement system</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="C1Q" target="C4D">
      <data key="d4">7.0</data>
      <data key="d5">C1q and C4d are both involved in the complement system</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="IGG" target="TL1A">
      <data key="d4">6.0</data>
      <data key="d5">IgG is used as a control in studies of TL1A-driven inflammation</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="SYK" target="PHOSPHO-SYK">
      <data key="d4">8.0</data>
      <data key="d5">Phospho-SYK is the phosphorylated form of SYK</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="ACALABRUTINIB" target="CCL4">
      <data key="d4">8.0</data>
      <data key="d5">Acalabrutinib suppresses CCL4 expression</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="IBRUTINIB" target="CCL4">
      <data key="d4">8.0</data>
      <data key="d5">Ibrutinib suppresses CCL4 expression</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="CCL4" target="LIVER FIBROSIS">
      <data key="d4">14.0</data>
      <data key="d5">CCl4 is used to induce liver fibrosis in experimental models
CCl4 is used to induce liver fibrosis in experimental models</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51,d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="CD3+ T CELLS" target="CD3">
      <data key="d4">9.0</data>
      <data key="d5">CD3 is a marker found on T cells</data>
      <data key="d6">411a4d246f0a9321e52971446a5a0606</data>
    </edge>
    <edge source="LEUKOCYTE" target="H4R">
      <data key="d4">8.0</data>
      <data key="d5">H4R exerts immunoregulatory activities on leukocytes</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="LEUKOCYTE" target="GITR">
      <data key="d4">7.0</data>
      <data key="d5">GITR signaling affects leukocyte recruitment</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="CD20" target="ALEXA FLUOR 594">
      <data key="d4">14.0</data>
      <data key="d5">Alexa Fluor 594 is used as a secondary antibody for CD20</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="CD20" target="DONKEY ANTI-MOUSE IGG">
      <data key="d4">7.0</data>
      <data key="d5">Donkey anti-mouse IgG is used as a secondary antibody for CD20</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="CD138" target="ALEXA FLUOR 594">
      <data key="d4">14.0</data>
      <data key="d5">Alexa Fluor 594 is used as a secondary antibody for CD138</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="CD138" target="DONKEY ANTI-MOUSE IGG">
      <data key="d4">7.0</data>
      <data key="d5">Donkey anti-mouse IgG is used as a secondary antibody for CD138</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="GEPS" target="GENOMATIX">
      <data key="d4">2.0</data>
      <data key="d5">GePS is a version of Genomatix software</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="GAMMA-SECRETASE" target="NCSTN">
      <data key="d4">8.0</data>
      <data key="d5">NCSTN is a component of the gamma-secretase complex</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="GAMMA-SECRETASE" target="PSENEN">
      <data key="d4">8.0</data>
      <data key="d5">PSENEN is a component of the gamma-secretase complex</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="GAMMA-SECRETASE" target="PSEN1">
      <data key="d4">8.0</data>
      <data key="d5">PSEN1 is a component of the gamma-secretase complex</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="TYPE I IFNS" target="MX1">
      <data key="d4">16.0</data>
      <data key="d5">MX1 is an interferon response gene</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="TYPE I IFNS" target="IFI27">
      <data key="d4">16.0</data>
      <data key="d5">IFI27 is an interferon response gene</data>
      <data key="d6">e340a83f7cba0ea5be731b1f682ea7c7</data>
    </edge>
    <edge source="IFI27" target="NETS">
      <data key="d4">14.0</data>
      <data key="d5">IFI27 expression is proposed to be driven by NETs</data>
      <data key="d6">b62ecc47bf54393bc78dd65986b949d6</data>
    </edge>
    <edge source="NETS" target="PDCS">
      <data key="d4">16.0</data>
      <data key="d5">NETs interact with pDCs in lesional HS skin</data>
      <data key="d6">b62ecc47bf54393bc78dd65986b949d6</data>
    </edge>
    <edge source="DERMIS" target="TH2 CELL">
      <data key="d4">8.0</data>
      <data key="d5">TH2 cells are an important component of the dermal infiltrates in atopic dermatitis</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="DERMIS" target="TAC">
      <data key="d4">7.0</data>
      <data key="d5">Higher TAC levels were observed in the dermis with PLG-based nanoparticles</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="MICE" target="S. AUREUS">
      <data key="d4">12.0</data>
      <data key="d5">Mice are used to study the effects of S. aureus on skin inflammation</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="MICE" target="TEWL">
      <data key="d4">12.0</data>
      <data key="d5">Mice treated with NPs exhibited improved control over TEWL</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="MICE" target="DERMATITIS">
      <data key="d4">12.0</data>
      <data key="d5">Mice treated with NPs exhibited improved control over dermatitis index</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="MICE" target="ER143">
      <data key="d4">14.0</data>
      <data key="d5">ER143 reduced erythema and swelling in mice</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="MICE" target="DNAM-1">
      <data key="d4">14.0</data>
      <data key="d5">DNAM-1 gene invalidation is studied in mice</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="ILLUMINA NEXTSEQ" target="RNA">
      <data key="d4">16.0</data>
      <data key="d5">RNA sequencing was performed using the Illumina NextSeq platform</data>
      <data key="d6">b28eeca0ff01a7715947d55a04978a43</data>
    </edge>
    <edge source="RNA" target="QIAGEN">
      <data key="d4">14.0</data>
      <data key="d5">QIAGEN provides reagents for RNA isolation</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="COLLAGEN" target="LIGHT">
      <data key="d4">20.0</data>
      <data key="d5">LIGHT induces collagen deposition
Genetic deletion of LIGHT reduces collagen deposition in UUO-induced mice</data>
      <data key="d6">05c97152fe02249153103be341d65b67,5f37466ca41c9b8b06ed8be0303d49f2</data>
    </edge>
    <edge source="COLLAGEN" target="ANTI-TL1A ANTIBODY">
      <data key="d4">8.0</data>
      <data key="d5">Anti-TL1A antibody reduces collagen deposition</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="COLLAGEN" target="LIVER FIBROSIS">
      <data key="d4">7.0</data>
      <data key="d5">Collagen deposition is measured to assess liver fibrosis</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="FORMALIN-FIXED, PARAFFIN-EMBEDDED TISSUE" target="TISSUE">
      <data key="d4">7.0</data>
      <data key="d5">Formalin-fixed, paraffin-embedded tissue is a method of preserving tissue samples for histological analysis</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="DAPI" target="4&#8242;,6-DIAMIDINO-2-PHENYLINDOLE">
      <data key="d4">9.0</data>
      <data key="d5">DAPI is a fluorescent stain that binds strongly to DNA</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="DAPI" target="VECTASHIELD">
      <data key="d4">14.0</data>
      <data key="d5">VECTASHIELD is used as a mounting medium with DAPI</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="DONKEY SERUM" target="IMMUNOFLUORESCENCE">
      <data key="d4">12.0</data>
      <data key="d5">Donkey serum is used as a blocking agent in immunofluorescence</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="ZEISS AXIOSKOP 2" target="IMMUNOFLUORESCENCE">
      <data key="d4">14.0</data>
      <data key="d5">Zeiss Axioskop 2 is used for imaging in immunofluorescence</data>
      <data key="d6">2a0384addc6e7fd709e0508b83496cd7</data>
    </edge>
    <edge source="KERATINOCYTE" target="AHR">
      <data key="d4">8.0</data>
      <data key="d5">AhR involves keratinocyte expression</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="KERATINOCYTE" target="SPINK5">
      <data key="d4">7.0</data>
      <data key="d5">SPINK5 is prevalent in keratinocytes</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="CORTICOSTEROIDS" target="GLUCOSE INTOLERANCE">
      <data key="d4">12.0</data>
      <data key="d5">Glucose intolerance is a side effect of corticosteroids</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="CORTICOSTEROIDS" target="HEADACHES">
      <data key="d4">12.0</data>
      <data key="d5">Headaches are a side effect of corticosteroids</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="CORTICOSTEROIDS" target="DEPRESSION">
      <data key="d4">12.0</data>
      <data key="d5">Depression is a side effect of corticosteroids</data>
      <data key="d6">48de7eebab3f3b418feb35a152df38fd</data>
    </edge>
    <edge source="PIMECROLIMUS" target="LEO 29102">
      <data key="d4">6.0</data>
      <data key="d5">LEO 29102 was compared with pimecrolimus in a phase II study</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="PIMECROLIMUS" target="CALCINEURIN INHIBITOR">
      <data key="d4">8.0</data>
      <data key="d5">Pimecrolimus is a topical calcineurin inhibitor</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="TACROLIMUS" target="HYALURONIC ACID">
      <data key="d4">14.0</data>
      <data key="d5">Tacrolimus and Hyaluronic acid are used together in nanotechnology-based therapeutic approaches</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </edge>
    <edge source="STAPHYLOCOCCUS AUREUS" target="STAPHYLOCOCCUS HOMINIS A9">
      <data key="d4">9.0</data>
      <data key="d5">Staphylococcus hominis A9 targets Staphylococcus aureus and inhibits its toxin production</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="ITCH" target="SCRATCH">
      <data key="d4">8.0</data>
      <data key="d5">Scratching is a response to itch, exacerbating atopic dermatitis</data>
      <data key="d6">143d2dc302af5606656797bff162e23e</data>
    </edge>
    <edge source="ITCH" target="VIXARELIMAB">
      <data key="d4">16.0</data>
      <data key="d5">Vixarelimab reduces pruritus in atopic dermatitis</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="ITCH" target="SUBSTANCE P">
      <data key="d4">16.0</data>
      <data key="d5">Substance P is involved in the initiation and transmission of itch</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="ITCH" target="NK1R">
      <data key="d4">16.0</data>
      <data key="d5">NK1R is involved in the transmission of itch signals</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="ITCH" target="SERLOPITANT">
      <data key="d4">14.0</data>
      <data key="d5">Serlopitant reduces pruritus</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="ITCH" target="TRADIPITANT">
      <data key="d4">14.0</data>
      <data key="d5">Tradipitant reduces pruritus</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="ITCH" target="P2XR3">
      <data key="d4">14.0</data>
      <data key="d5">P2XR3 is associated with itch</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="ITCH" target="BLU-5937">
      <data key="d4">14.0</data>
      <data key="d5">BLU-5937 is in development to treat pruritus</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="CRACKING" target="POEM">
      <data key="d4">8.0</data>
      <data key="d5">Cracking is one of the symptoms assessed in the POEM tool</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="TH2 CELL" target="CHEMOTACTIC MEDIATOR">
      <data key="d4">7.0</data>
      <data key="d5">TH2 cells are recruited by locally produced chemotactic mediators</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="TH2 CELL" target="IMMUNE SYSTEM">
      <data key="d4">1.0</data>
      <data key="d5">TH2 cells are part of the immune system</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="TH2 CELL" target="CRTH2">
      <data key="d4">8.0</data>
      <data key="d5">CRTH2 is preferentially expressed on TH2 cells and directs their migration into the skin in AD</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9</data>
    </edge>
    <edge source="TH2 CELL" target="RPT193">
      <data key="d4">7.0</data>
      <data key="d5">RPT193 selectively blocks the recruitment of TH2 cells in allergic diseases</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9</data>
    </edge>
    <edge source="ILC2" target="TL1A">
      <data key="d4">14.0</data>
      <data key="d5">TL1A acts as a costimulatory molecule for ILC2s
TL1A activates ILC2 cells</data>
      <data key="d6">05c97152fe02249153103be341d65b67,c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="IL-5" target="EOSINOPHILS">
      <data key="d4">34.0</data>
      <data key="d5">IL-5 is involved in eosinophil biology
IL-5 causes eosinophils to migrate</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41,3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="IL-5" target="MEPOLIZUMAB">
      <data key="d4">16.0</data>
      <data key="d5">Mepolizumab targets IL-5</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41</data>
    </edge>
    <edge source="IL-5" target="EOSINOPHILIC ESOPHAGITIS">
      <data key="d4">14.0</data>
      <data key="d5">IL-5 is important in eosinophilic esophagitis</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="IL-5" target="CSA">
      <data key="d4">14.0</data>
      <data key="d5">CsA-loaded nanoparticles reduce IL-5 levels</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="IL-5" target="HYDROCORTISONE">
      <data key="d4">14.0</data>
      <data key="d5">HC-NPs suppressed inflammatory cascades including IL-5</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="IL-5" target="TRAIL">
      <data key="d4">7.0</data>
      <data key="d5">TRAIL is necessary for the production of IL-5</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="DC" target="LANGERHANS CELLS">
      <data key="d4">14.0</data>
      <data key="d5">Langerhans cells are a type of dendritic cell</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41</data>
    </edge>
    <edge source="DC" target="CCL22">
      <data key="d4">16.0</data>
      <data key="d5">CCL22 promotes the attraction of inflammatory DC subtypes</data>
      <data key="d6">6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="DC" target="CCL5">
      <data key="d4">16.0</data>
      <data key="d5">CCL5 promotes the attraction of inflammatory DC subtypes</data>
      <data key="d6">6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="DC" target="AHR">
      <data key="d4">8.0</data>
      <data key="d5">AhR involves epidermal DCs&#8217; residence</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="DC" target="MMP-2">
      <data key="d4">14.0</data>
      <data key="d5">MMP-2 stimulates dendritic cells to up-regulate OX40L</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="DC" target="MMP">
      <data key="d4">14.0</data>
      <data key="d5">MMPs condition dendritic cells to prime TH2 phenotype via an OX40L-dependent pathway</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="IL-13R&#913;1" target="JAK/STAT PATHWAY">
      <data key="d4">16.0</data>
      <data key="d5">IL-13R&#945;1 is involved in the JAK/STAT signaling pathway</data>
      <data key="d6">104cc78517b2eca2e9cb7e00de1fe4b0</data>
    </edge>
    <edge source="IL-13R&#913;1" target="ASLAN004">
      <data key="d4">8.0</data>
      <data key="d5">ASLAN004 is directed against IL-13R&#945;1</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="IL-13R&#913;1" target="TYPE II RECEPTOR">
      <data key="d4">7.0</data>
      <data key="d5">IL-13R&#945;1 is part of the type II receptor</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="HYPERTENSION" target="HCM">
      <data key="d4">14.0</data>
      <data key="d5">Hypertension can induce hypertrophic cardiomyopathy</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="HYPERTENSION" target="ANG-II">
      <data key="d4">14.0</data>
      <data key="d5">Ang-II-induced hypertension is associated with cardiac hypertrophy</data>
      <data key="d6">d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="BIOLOGICS" target="CYTOKINE RECEPTORS">
      <data key="d4">8.0</data>
      <data key="d5">Biologics target cytokine receptors in immune responses</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="IL-13R&#913;2" target="MOUSE MODEL">
      <data key="d4">12.0</data>
      <data key="d5">Loss of IL-13R&#945;2 was shown to be deleterious in a mouse model of cutaneous inflammation</data>
      <data key="d6">96e553a44a27e728c27c4892045ec5c2</data>
    </edge>
    <edge source="PF-04965842" target="NCT02780167">
      <data key="d4">8.0</data>
      <data key="d5">NCT02780167 is a phase 2 study for PF-04965842 in AD</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="PF-04965842" target="JADE MONO-1">
      <data key="d4">8.0</data>
      <data key="d5">JADE Mono-1 is a phase 3 trial for PF-04965842 in AD</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="PF-04965842" target="JADE MONO-2">
      <data key="d4">8.0</data>
      <data key="d5">JADE Mono-2 is a phase 3 trial for PF-04965842 in AD</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="PF-04965842" target="JADE EXTEND">
      <data key="d4">1.0</data>
      <data key="d5">JADE EXTEND is a phase 3 long-term extension study for PF-04965842 in AD</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="PDE-4" target="CAMP">
      <data key="d4">7.0</data>
      <data key="d5">Inhibition of PDE-4 increases levels of cAMP</data>
      <data key="d6">e95d4d15e4f3110c91a3d3fcb5910d06</data>
    </edge>
    <edge source="PERIOSTIN" target="LIGHT">
      <data key="d4">14.0</data>
      <data key="d5">LIGHT induces periostin production in keratinocytes</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2</data>
    </edge>
    <edge source="ILC2S" target="TL1A">
      <data key="d4">8.0</data>
      <data key="d5">TL1A acts on ILC2s to drive pro-fibrotic and anti-fibrotic effects</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </edge>
    <edge source="DCS" target="AHR">
      <data key="d4">6.0</data>
      <data key="d5">AhR is expressed in dendritic cells</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="DCS" target="S1P">
      <data key="d4">12.0</data>
      <data key="d5">S1P affects dendritic cells</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="DCS" target="GITRL">
      <data key="d4">7.0</data>
      <data key="d5">GITRL is mainly expressed on DCs</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="MAST CELL" target="NIC-CS-NPS">
      <data key="d4">7.0</data>
      <data key="d5">NIC-CS-NPs decreased mast cell infiltration in DNCB-induced AD skin lesions</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="MAST CELL" target="EOE">
      <data key="d4">7.0</data>
      <data key="d5">Mast cells are involved in the inflammation of the esophagus in EoE</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="IL-17C" target="MOR106">
      <data key="d4">9.0</data>
      <data key="d5">MOR106 targets IL-17C to treat moderate-to-severe atopic dermatitis</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </edge>
    <edge source="FEZAKINUMAB" target="PHASE IIA STUDY">
      <data key="d4">7.0</data>
      <data key="d5">Fezakinumab is being investigated in a Phase IIa study</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="FEZAKINUMAB" target="PROOF-OF-CONCEPT STUDY">
      <data key="d4">7.0</data>
      <data key="d5">Fezakinumab was investigated in a proof-of-concept study</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="FEZAKINUMAB" target="PLACEBO GROUP">
      <data key="d4">7.0</data>
      <data key="d5">Fezakinumab was compared to a placebo group in a study</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="INTERLEUKIN" target="IMMUNE SYSTEM">
      <data key="d4">8.0</data>
      <data key="d5">Interleukins play important roles in the immune system</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </edge>
    <edge source="IGG1&#922;" target="MONOCLONAL ANTIBODIES">
      <data key="d4">7.0</data>
      <data key="d5">IgG1&#954; is used in monoclonal antibodies for therapeutic purposes</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </edge>
    <edge source="IGG1&#923;" target="MONOCLONAL ANTIBODIES">
      <data key="d4">1.0</data>
      <data key="d5">IgG1&#955; is used in monoclonal antibodies for therapeutic purposes</data>
      <data key="d6">1d0c4a4cd555b7ecd0b9d7b0310e9fe9</data>
    </edge>
    <edge source="IMMUNE SYSTEM" target="TREG CELL">
      <data key="d4">8.0</data>
      <data key="d5">Treg cells are part of the immune system</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="DENDRITIC CELLS" target="HIGH-AFFINITY IGE RECEPTOR">
      <data key="d4">7.0</data>
      <data key="d5">High-affinity IgE receptor is expressed in dendritic cells in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="TEZEPELUMAB" target="EASI50">
      <data key="d4">7.0</data>
      <data key="d5">Tezepelumab showed results in achieving EASI50 in AD</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="TEZEPELUMAB" target="SEVERE AND UNCONTROLLED ALLERGIC ASTHMA">
      <data key="d4">1.0</data>
      <data key="d5">Tezepelumab showed results in severe and uncontrolled allergic asthma</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="TEZEPELUMAB" target="SEVERE ALLERGIC ASTHMA">
      <data key="d4">8.0</data>
      <data key="d5">Tezepelumab showed convincing results in patients with severe and uncontrolled allergic asthma</data>
      <data key="d6">6309eeea565f06479830cec32938abc9</data>
    </edge>
    <edge source="TEZEPELUMAB" target="THYMIC STROMAL LYMPHOPOIETIN">
      <data key="d4">16.0</data>
      <data key="d5">Tezepelumab targets TSLP to modulate the immune response in atopic dermatitis</data>
      <data key="d6">e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="BASOPHILS" target="BENRALIZUMAB">
      <data key="d4">16.0</data>
      <data key="d5">Benralizumab depletes basophils</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41</data>
    </edge>
    <edge source="EOSINOPHILS" target="EOSINOPHIL-DERIVED NEUROTOXIN">
      <data key="d4">14.0</data>
      <data key="d5">Eosinophil-derived neurotoxin is released by eosinophils</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41</data>
    </edge>
    <edge source="EOSINOPHILS" target="EOSINOPHIL CATIONIC PROTEIN">
      <data key="d4">14.0</data>
      <data key="d5">Eosinophil cationic protein is released by eosinophils</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41</data>
    </edge>
    <edge source="EOSINOPHILS" target="MEPOLIZUMAB">
      <data key="d4">14.0</data>
      <data key="d5">Mepolizumab reduces eosinophilia</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41</data>
    </edge>
    <edge source="EOSINOPHILS" target="BENRALIZUMAB">
      <data key="d4">16.0</data>
      <data key="d5">Benralizumab depletes eosinophils</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41</data>
    </edge>
    <edge source="EOSINOPHILS" target="HVEM">
      <data key="d4">14.0</data>
      <data key="d5">HVEM is expressed on eosinophils</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="IMMUNOGLOBULIN E" target="FB825/ANTI-C&#917;MX">
      <data key="d4">8.0</data>
      <data key="d5">FB825/anti-C&#949;mX targets Immunoglobulin E</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </edge>
    <edge source="ALLERGIC RHINO-CONJUNCTIVITIS" target="AEROALLERGENS">
      <data key="d4">7.0</data>
      <data key="d5">Aeroallergens can trigger allergic rhino-conjunctivitis</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="PHOSPHODIESTERASE 4" target="ANTI-INFLAMMATORY CYTOKINES">
      <data key="d4">7.0</data>
      <data key="d5">Anti-inflammatory cytokines are generated by increasing cAMP levels through PDE4 inhibitors in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="FIBROBLAST" target="HYDROCORTISONE">
      <data key="d4">14.0</data>
      <data key="d5">HC-NPs blocked or significantly decreased fibroblast infiltration</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="FIBROBLAST" target="SSC">
      <data key="d4">9.0</data>
      <data key="d5">Fibroblasts are involved in the fibrosis seen in systemic sclerosis</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="FIBROBLAST" target="EXTRACELLULAR MATRIX">
      <data key="d4">1.0</data>
      <data key="d5">Fibroblasts produce extracellular matrix, contributing to fibrosis</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="FIBROBLAST" target="M2 MACROPHAGES">
      <data key="d4">16.0</data>
      <data key="d5">M2 macrophages promote fibroblast activation</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="FIBROBLAST" target="TNFR1">
      <data key="d4">16.0</data>
      <data key="d5">TNFR1 signaling is essential for fibroblast formation</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="INTERLEUKIN-22" target="FEZAKIMUAB">
      <data key="d4">8.0</data>
      <data key="d5">Fezakimuab targets Interleukin-22</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </edge>
    <edge source="INTERLEUKIN-23" target="RISANKIZUMAB">
      <data key="d4">8.0</data>
      <data key="d5">Risankizumab targets Interleukin-23</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </edge>
    <edge source="EDEMA" target="INFANTILE ATOPIC DERMATITIS">
      <data key="d4">7.0</data>
      <data key="d5">Edema is swelling of the skin, often seen in infantile Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="EDEMA" target="CLOBETASOL PROPIONATE (CP)">
      <data key="d4">7.0</data>
      <data key="d5">Clobetasol Propionate (CP) significantly inhibits edema</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="LICHENIFICATION" target="CHILDHOOD ATOPIC DERMATITIS">
      <data key="d4">7.0</data>
      <data key="d5">Lichenification is the thickening of the skin due to chronic scratching, often seen in childhood Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="XEROSIS" target="CHILDHOOD ATOPIC DERMATITIS">
      <data key="d4">7.0</data>
      <data key="d5">Xerosis is increased dryness of the skin, often seen in childhood Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="ELASTIN" target="MMP-12">
      <data key="d4">14.0</data>
      <data key="d5">MMP-12 may lead to elastin degradation</data>
      <data key="d6">d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="FIBRONECTIN" target="LIGHT">
      <data key="d4">6.0</data>
      <data key="d5">Genetic deletion of LIGHT reduces fibronectin expression in UUO-induced mice</data>
      <data key="d6">05c97152fe02249153103be341d65b67</data>
    </edge>
    <edge source="KERATIN" target="STRATUM CORNEUM FORMATION">
      <data key="d4">8.0</data>
      <data key="d5">Keratin buildup is crucial for the formation of the stratum corneum</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="MICROBIOME" target="MSB-01">
      <data key="d4">7.0</data>
      <data key="d5">MSB-01 is a topical product in clinical development for modulating the skin microbiome</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="MICROBIOME" target="DB-001">
      <data key="d4">7.0</data>
      <data key="d5">DB-001 is a topical product in clinical development for modulating the skin microbiome</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="POEM" target="RECAP">
      <data key="d4">8.0</data>
      <data key="d5">POEM correlates well with RECAP</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="POEM" target="BLEEDING">
      <data key="d4">8.0</data>
      <data key="d5">Bleeding is one of the symptoms assessed in the POEM tool</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="POEM" target="WEEPING/OOZING">
      <data key="d4">8.0</data>
      <data key="d5">Weeping/oozing is one of the symptoms assessed in the POEM tool</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="POEM" target="FLAKING">
      <data key="d4">8.0</data>
      <data key="d5">Flaking is one of the symptoms assessed in the POEM tool</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="POEM" target="DRYNESS OF THE SKIN">
      <data key="d4">8.0</data>
      <data key="d5">Dryness of the skin is one of the symptoms assessed in the POEM tool</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="ROSEOMONAS MUCOSA" target="FB-401">
      <data key="d4">8.0</data>
      <data key="d5">FB-401 is a product combining three strains of Roseomonas mucosa</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="FB-401" target="TLR5">
      <data key="d4">22.0</data>
      <data key="d5">FB-401 activates tissue repair and anti-inflammatory activity via TLR5
FB-401 inhibits TLR5 signaling</data>
      <data key="d6">6059a6e2710b7df94c6a09e5eb7b024a,f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="FB-401" target="TNFR">
      <data key="d4">22.0</data>
      <data key="d5">FB-401 activates tissue repair and anti-inflammatory activity via TNFR
FB-401 inhibits TNFR signaling</data>
      <data key="d6">6059a6e2710b7df94c6a09e5eb7b024a,f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="FB-401" target="FORTE BIOSCIENCES">
      <data key="d4">8.0</data>
      <data key="d5">Forte Biosciences is conducting clinical trials of FB-401 for atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="STAPHYLOCOCCUS HOMINIS A9" target="SHA9">
      <data key="d4">8.0</data>
      <data key="d5">ShA9 is a lyophilized strain of Staphylococcus hominis A9</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="STAPHYLOCOCCUS HOMINIS A9" target="S. AUREUS">
      <data key="d4">16.0</data>
      <data key="d5">Staphylococcus hominis A9 kills S. aureus and inhibits its toxins</data>
      <data key="d6">6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="NITRIC OXIDE" target="B244">
      <data key="d4">8.0</data>
      <data key="d5">B244 produces nitric oxide</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="NITROSOMONAS EUTROPHA" target="B244">
      <data key="d4">8.0</data>
      <data key="d5">B244 contains Nitrosomonas eutropha</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="B244" target="INFLAMMATORY REACTION">
      <data key="d4">7.0</data>
      <data key="d5">B244 is used to measure the clinical response of the inflammatory reaction in atopic dermatitis</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="B244" target="AOBIOME">
      <data key="d4">1.0</data>
      <data key="d5">AOBiome is involved in the development of B244 for atopic dermatitis</data>
      <data key="d6">f1897c89e321a3a80924fd72a56e90df</data>
    </edge>
    <edge source="B244" target="RCT">
      <data key="d4">7.0</data>
      <data key="d5">B244 was tested in a randomized controlled trial</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="B244" target="PHASE IIA">
      <data key="d4">7.0</data>
      <data key="d5">B244 was tested in a phase IIa trial</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="B244" target="PHASE IB">
      <data key="d4">7.0</data>
      <data key="d5">B244 was tested in a phase Ib trial</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="B244" target="PHASE IIB">
      <data key="d4">7.0</data>
      <data key="d5">B244 is currently in a phase IIb trial</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="S. AUREUS" target="NICLOSAMIDE">
      <data key="d4">7.0</data>
      <data key="d5">Niclosamide inhibits the growth of S. aureus</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="S. AUREUS" target="OMIGANAN PENTACHLORIDE">
      <data key="d4">7.0</data>
      <data key="d5">Omiganan pentachloride is used to control the overgrowth of S. aureus in AD</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="S. AUREUS" target="ADAPTIVE IMMUNE RESPONSE">
      <data key="d4">7.0</data>
      <data key="d5">High colonization with S. aureus impacts the adaptive immune response</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="S. AUREUS" target="&#916;-TOXIN">
      <data key="d4">14.0</data>
      <data key="d5">&#948;-toxin is produced by S. aureus and can trigger mast cells</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="S. AUREUS" target="&#913;-TOXIN">
      <data key="d4">14.0</data>
      <data key="d5">&#945;-toxin is produced by S. aureus and can damage host cells</data>
      <data key="d6">41ccc4b41bd57cf2bda4dbb6c7ae4198</data>
    </edge>
    <edge source="NICLOSAMIDE" target="HISTOLOGICAL MODIFICATIONS">
      <data key="d4">6.0</data>
      <data key="d5">Niclosamide showed significant histological modifications</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="NICLOSAMIDE" target="TRANSCRIPTIONAL MODIFICATIONS">
      <data key="d4">6.0</data>
      <data key="d5">Niclosamide showed significant transcriptional modifications</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="NICLOSAMIDE" target="BARRIER FUNCTION">
      <data key="d4">6.0</data>
      <data key="d5">Niclosamide impacts the barrier function</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="OMIGANAN PENTACHLORIDE" target="DYSBIOSIS">
      <data key="d4">7.0</data>
      <data key="d5">Omiganan pentachloride is used to control dysbiosis</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="AHR" target="COAL TAR">
      <data key="d4">14.0</data>
      <data key="d5">Coal tar binds to AhR and restores filaggrin expression
Coal tar binds to AhR</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="AHR" target="TAPINAROF">
      <data key="d4">17.0</data>
      <data key="d5">Tapinarof is a natural AhR agonist
Tapinarof is a natural agonist of AhR that decreases inflammatory reactions
Tapinarof is a natural agonist of AhR</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807,6059a6e2710b7df94c6a09e5eb7b024a,849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="AHR" target="FLG">
      <data key="d4">14.0</data>
      <data key="d5">Coal tar binds to AhR and restores FLG expression</data>
      <data key="d6">6059a6e2710b7df94c6a09e5eb7b024a</data>
    </edge>
    <edge source="COAL TAR" target="FLG">
      <data key="d4">7.0</data>
      <data key="d5">Coal tar restores FLG expression</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="TAPINAROF" target="INVESTIGATOR GLOBAL ASSESSMENT (IGA)">
      <data key="d4">7.0</data>
      <data key="d5">Tapinarof showed results in achieving IGA 0/1 in AD</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="SPINK5" target="ALARMINS">
      <data key="d4">7.0</data>
      <data key="d5">SPINK5 mutations lead to the generation of alarmins</data>
      <data key="d6">3ea70e257330c812b52334ca1f90d807</data>
    </edge>
    <edge source="ADAPTIVE IMMUNE RESPONSE" target="TREG CELL">
      <data key="d4">8.0</data>
      <data key="d5">Treg cells are involved in the adaptive immune response</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="ADAPTIVE IMMUNE RESPONSE" target="ANTIGEN">
      <data key="d4">8.0</data>
      <data key="d5">Antigen presentation is the starting point for the adaptive immune response</data>
      <data key="d6">849e0980ffd6a7e1cf0b8d3d1fbacd98</data>
    </edge>
    <edge source="ETOKIMAB" target="CXCR1">
      <data key="d4">12.0</data>
      <data key="d5">Etokimab inhibited CXCR1-dependent neutrophil migration</data>
      <data key="d6">6309eeea565f06479830cec32938abc9</data>
    </edge>
    <edge source="KY1005" target="TEFF CELL">
      <data key="d4">8.0</data>
      <data key="d5">KY1005 inhibits the effector T cell response</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="KY1005" target="TREG CELL">
      <data key="d4">8.0</data>
      <data key="d5">KY1005 maintains regulatory T cell activity</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="KY1005" target="PHASE IIA STUDY">
      <data key="d4">8.0</data>
      <data key="d5">KY1005 showed interesting results in a phase IIa study</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="KY1005" target="KYMAB">
      <data key="d4">16.0</data>
      <data key="d5">KY1005 is developed by Kymab
Kymab has shown positive phase 2a results for KY1005 in atopic dermatitis</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0,83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="KY1005" target="OX40 LIGAND">
      <data key="d4">16.0</data>
      <data key="d5">KY1005 targets OX40L to modulate the immune response in atopic dermatitis</data>
      <data key="d6">e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="KY1005" target="IMMUNE SYSTEM DISEASES">
      <data key="d4">8.0</data>
      <data key="d5">KY1005 is used in clinical trials for immune system diseases</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="TREG CELL" target="IL-2">
      <data key="d4">8.0</data>
      <data key="d5">IL-2 is involved in the activation and proliferation of Treg cells</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="TREG CELL" target="LY3471851">
      <data key="d4">8.0</data>
      <data key="d5">LY3471851 leads to activation and proliferation of Treg cells</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="TREG CELL" target="AUTOIMMUNE DISORDERS">
      <data key="d4">8.0</data>
      <data key="d5">Treg cells are involved in autoimmune disorders</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="TREG CELL" target="RHIL-2">
      <data key="d4">9.0</data>
      <data key="d5">Recombinant human IL-2 (rhIL-2) targets the IL-2 receptor complex on T cells, leading to activation and proliferation of Treg cells</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="TREG CELL" target="NCT04081350">
      <data key="d4">7.0</data>
      <data key="d5">NCT04081350 is a clinical trial involving Treg cells</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="IL-2R&#915;" target="TYPE I RECEPTOR">
      <data key="d4">7.0</data>
      <data key="d5">IL-2R&#947; is part of the type I receptor</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="CBP-201" target="PLACEBO GROUP">
      <data key="d4">8.0</data>
      <data key="d5">CBP-201 showed better results compared to the placebo group</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="AK120" target="MODERATE-TO-SEVERE AD">
      <data key="d4">7.0</data>
      <data key="d5">AK120 is being tested in patients with moderate-to-severe AD</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="AK120" target="HEALTHY SUBJECTS">
      <data key="d4">7.0</data>
      <data key="d5">AK120 is being tested in healthy subjects</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="ASLAN004" target="ASLAN">
      <data key="d4">8.0</data>
      <data key="d5">ASLAN004 is developed by ASLAN</data>
      <data key="d6">78e26c66107dba37ac4bab65406b43a0</data>
    </edge>
    <edge source="ASLAN004" target="ASAN PHARMACEUTICALS">
      <data key="d4">8.0</data>
      <data key="d5">Asan Pharmaceuticals is conducting studies on ASLAN004 for atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ASLAN004" target="INTERLEUKIN-4RA">
      <data key="d4">8.0</data>
      <data key="d5">ASLAN004 targets Interleukin-4Ra</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </edge>
    <edge source="KYMAB" target="BIOLOGIC THERAPIES">
      <data key="d4">6.0</data>
      <data key="d5">Kymab develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="MEPOLIZUMAB" target="TARC">
      <data key="d4">12.0</data>
      <data key="d5">Mepolizumab failed to show a significant decrease in TARC</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41</data>
    </edge>
    <edge source="MEPOLIZUMAB" target="IL5R">
      <data key="d4">16.0</data>
      <data key="d5">Mepolizumab inhibits IL-5 by targeting IL5R</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="MEPOLIZUMAB" target="INTERLEUKIN-5">
      <data key="d4">8.0</data>
      <data key="d5">Mepolizumab targets Interleukin-5</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </edge>
    <edge source="BENRALIZUMAB" target="IL-5R&#913;">
      <data key="d4">16.0</data>
      <data key="d5">Benralizumab targets IL-5R&#945;</data>
      <data key="d6">0007aca7507e3e422ad87a90c0fd2c41</data>
    </edge>
    <edge source="BENRALIZUMAB" target="IL5R">
      <data key="d4">16.0</data>
      <data key="d5">Benralizumab inhibits IL-5 by targeting IL5R</data>
      <data key="d6">3df8535e965efb96f5094169610507ff</data>
    </edge>
    <edge source="BENRALIZUMAB" target="INTERLEUKIN-5RA">
      <data key="d4">8.0</data>
      <data key="d5">Benralizumab targets Interleukin-5Ra</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </edge>
    <edge source="MIGE" target="ANTI-C&#917;MX (FB825)">
      <data key="d4">8.0</data>
      <data key="d5">Anti-C&#949;mX (FB825) targets mIgE to deplete IgE-committed B cells</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IL-22R" target="IL-22R1">
      <data key="d4">7.0</data>
      <data key="d5">IL-22R1 is a subunit of the IL-22 receptor complex</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IL-22R" target="IL-10R2">
      <data key="d4">7.0</data>
      <data key="d5">IL-10R2 is a subunit of the IL-22 receptor complex</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IL-22R1" target="IL-20">
      <data key="d4">7.0</data>
      <data key="d5">IL-20 binds to IL-22R1 and IL-20R2 receptor complexes</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IL-22R1" target="IL-24">
      <data key="d4">7.0</data>
      <data key="d5">IL-24 binds to IL-22R1 and IL-20R2 receptor complexes</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IL-22R1" target="LEO 138559">
      <data key="d4">7.0</data>
      <data key="d5">LEO 138559 is an antibody directed against IL-22R1</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IL-22R1" target="IL-20R2">
      <data key="d4">8.0</data>
      <data key="d5">IL-20R2 forms a complex with IL-22R1</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IL-22R1" target="RECEPTOR COMPLEX">
      <data key="d4">7.0</data>
      <data key="d5">IL-22R1 forms part of the receptor complex</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="LEO 138559" target="PHASE I STUDIES">
      <data key="d4">7.0</data>
      <data key="d5">LEO 138559 is being investigated in Phase I studies</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IL-2" target="LY3471851">
      <data key="d4">8.0</data>
      <data key="d5">LY3471851 is designed to target the IL-2 receptor complex on T cells</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IL-2" target="RECOMBINANT HUMAN IL-2">
      <data key="d4">8.0</data>
      <data key="d5">Recombinant human IL-2 is a lab-produced form of IL-2</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="IL-2" target="IL-2 RECEPTOR">
      <data key="d4">9.0</data>
      <data key="d5">IL-2 binds to the IL-2 receptor on T cells, leading to their activation and proliferation</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="IL-2" target="TAC">
      <data key="d4">7.0</data>
      <data key="d5">TAC-loaded PLG-based NPs reduce IL-2 expression</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="IL-2" target="SSC">
      <data key="d4">8.0</data>
      <data key="d5">IL-2 is a cytokine involved in systemic sclerosis</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="LY3471851" target="ULCERATIVE COLITIS">
      <data key="d4">7.0</data>
      <data key="d5">LY3471851 is investigated for the treatment of Ulcerative Colitis</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="ULCERATIVE COLITIS" target="RHIL-2">
      <data key="d4">7.0</data>
      <data key="d5">Recombinant human IL-2 (rhIL-2) is being tested for its potential to restore tolerance and improve ulcerative colitis</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="ULCERATIVE COLITIS" target="GASTROINTESTINAL TRACT">
      <data key="d4">8.0</data>
      <data key="d5">Ulcerative colitis affects the gastrointestinal tract</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="ULCERATIVE COLITIS" target="TL1A">
      <data key="d4">8.0</data>
      <data key="d5">TL1A is targeted by anti-TL1A antibody in the treatment of ulcerative colitis</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="ULCERATIVE COLITIS" target="ANTI-TNF THERAPY">
      <data key="d4">16.0</data>
      <data key="d5">Anti-TNF therapy is used to treat ulcerative colitis</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="ULCERATIVE COLITIS" target="MDGN-002">
      <data key="d4">14.0</data>
      <data key="d5">MDGN-002 is used in clinical trials to treat Ulcerative Colitis</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="ULCERATIVE COLITIS" target="PF-06480605">
      <data key="d4">8.0</data>
      <data key="d5">PF-06480605 is being tested for its efficacy in treating ulcerative colitis</data>
      <data key="d6">423195c6b63ad0a6773374364ebf3612</data>
    </edge>
    <edge source="ULCERATIVE COLITIS" target="KYOWA KIRIN, INC.">
      <data key="d4">6.0</data>
      <data key="d5">Kyowa Kirin, Inc. is involved in clinical trials for ulcerative colitis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="ULCERATIVE COLITIS" target="KYOWA KIRIN CO., LTD.">
      <data key="d4">6.0</data>
      <data key="d5">Kyowa Kirin Co., Ltd. is involved in clinical trials for ulcerative colitis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="IL-20R2" target="IL-20R1">
      <data key="d4">8.0</data>
      <data key="d5">IL-20R1 forms a complex with IL-20R2</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="RECOMBINANT HUMAN IL-2" target="PEGYLATED">
      <data key="d4">7.0</data>
      <data key="d5">Recombinant human IL-2 is pegylated to improve its properties</data>
      <data key="d6">48288f3ec2832850282f95d4e38d10e1</data>
    </edge>
    <edge source="PDE4" target="LEO 29102">
      <data key="d4">15.0</data>
      <data key="d5">LEO 29102 is a PDE inhibitor with selectivity for the PDE4D isoform
LEO 29102 targets the PDE4 enzyme</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89,f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="PDE4" target="PDE4 INHIBITOR">
      <data key="d4">8.0</data>
      <data key="d5">PDE4 inhibitors target PDE4 to reduce inflammation</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="PDE4" target="LOTAMILAST">
      <data key="d4">8.0</data>
      <data key="d5">Lotamilast targets the PDE4 enzyme</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="PDE4" target="DIFAMILAST">
      <data key="d4">8.0</data>
      <data key="d5">Difamilast targets the PDE4 enzyme</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="PDE4" target="DRM02">
      <data key="d4">8.0</data>
      <data key="d5">DRM02 targets the PDE4 enzyme</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="PDE4" target="ROFLUMILAST">
      <data key="d4">8.0</data>
      <data key="d5">Roflumilast targets the PDE4 enzyme</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="PDE4" target="HEMAY-808">
      <data key="d4">8.0</data>
      <data key="d5">Hemay-808 targets the PDE4 enzyme</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="PDE4" target="PF-07038124">
      <data key="d4">8.0</data>
      <data key="d5">PF-07038124 targets the PDE4 enzyme</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="LOTAMILAST" target="NCT03394677">
      <data key="d4">7.0</data>
      <data key="d5">NCT03394677 is a clinical trial involving Lotamilast</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="LOTAMILAST" target="NCT02950922">
      <data key="d4">7.0</data>
      <data key="d5">NCT02950922 is a clinical trial involving Lotamilast</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="DIFAMILAST" target="OTSUKA">
      <data key="d4">8.0</data>
      <data key="d5">Otsuka is conducting phase 3 studies on difamilast for atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="DIFAMILAST" target="NCT02945657">
      <data key="d4">7.0</data>
      <data key="d5">NCT02945657 is a clinical trial involving Difamilast</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="ROFLUMILAST" target="NCT04156191">
      <data key="d4">7.0</data>
      <data key="d5">NCT04156191 is a clinical trial involving Roflumilast</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="LEO 29102" target="NCT01037881">
      <data key="d4">7.0</data>
      <data key="d5">NCT01037881 is a clinical trial involving LEO 29102</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="HISTAMINE H4 RECEPTOR" target="ADRIFORANT">
      <data key="d4">7.0</data>
      <data key="d5">Adriforant is an H4R antagonist tested for inflammatory skin disorders</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="HISTAMINE H4 RECEPTOR" target="LEO 152020">
      <data key="d4">6.0</data>
      <data key="d5">LEO 152020 is an oral H4R antagonist currently in phase I</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="ADRIFORANT" target="H4R">
      <data key="d4">8.0</data>
      <data key="d5">Adriforant targets the H4R receptor</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="ADRIFORANT" target="NCT03517566">
      <data key="d4">7.0</data>
      <data key="d5">NCT03517566 is a clinical trial involving Adriforant</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="LEO 152020" target="HISTAMINE RECEPTOR 4">
      <data key="d4">16.0</data>
      <data key="d5">LEO 152020 targets Histamine Receptor 4 (H4R) to reduce inflammation in atopic dermatitis</data>
      <data key="d6">e9841b88c9fab58c5175af409653da50</data>
    </edge>
    <edge source="H2R" target="GASTROINTESTINAL TRACT">
      <data key="d4">7.0</data>
      <data key="d5">H2R is mainly localized in the gastrointestinal tract</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="H3R" target="CENTRAL NERVOUS SYSTEM">
      <data key="d4">7.0</data>
      <data key="d5">H3R is localized in the central nervous system</data>
      <data key="d6">442e7fad2fab75fa2449309783294d89</data>
    </edge>
    <edge source="GASTROINTESTINAL TRACT" target="EOSINOPHILIC ESOPHAGITIS">
      <data key="d4">8.0</data>
      <data key="d5">Eosinophilic esophagitis affects the gastrointestinal tract</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="GASTROINTESTINAL TRACT" target="TL1A">
      <data key="d4">7.0</data>
      <data key="d5">TL1A is studied in disease models involving the gastrointestinal tract</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="H4R" target="LEO 152020/JW1601">
      <data key="d4">8.0</data>
      <data key="d5">LEO 152020/JW1601 targets the H4R receptor</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="CRTH2" target="FEVIPIPRANT">
      <data key="d4">7.0</data>
      <data key="d5">Fevipiprant is a CRTH2 antagonist</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9</data>
    </edge>
    <edge source="CRTH2" target="TEMAPIPRANT">
      <data key="d4">7.0</data>
      <data key="d5">Temapiprant is a CRTH2 antagonist</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9</data>
    </edge>
    <edge source="RPT193" target="RAPT THERAPEUTICS">
      <data key="d4">8.0</data>
      <data key="d5">RAPT Therapeutics is conducting a phase 1b trial of RPT193 for atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="RPT193" target="NCT04271514">
      <data key="d4">7.0</data>
      <data key="d5">NCT04271514 is a clinical trial involving RPT193</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="S1P" target="S1PR1">
      <data key="d4">8.0</data>
      <data key="d5">S1P acts via S1PR1</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9</data>
    </edge>
    <edge source="S1P" target="S1PR3">
      <data key="d4">8.0</data>
      <data key="d5">S1P acts via S1PR3</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9</data>
    </edge>
    <edge source="S1P" target="S1PR4">
      <data key="d4">8.0</data>
      <data key="d5">S1P acts via S1PR4</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9</data>
    </edge>
    <edge source="S1P" target="S1PR5">
      <data key="d4">8.0</data>
      <data key="d5">S1P acts via S1PR5</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9</data>
    </edge>
    <edge source="S1P" target="EPIDERMAL KERATINOCYTES">
      <data key="d4">12.0</data>
      <data key="d5">S1P has biological activity on epidermal keratinocytes</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="S1PR1" target="FINGOLIMOD">
      <data key="d4">8.0</data>
      <data key="d5">Fingolimod is an S1PR1 agonist</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9</data>
    </edge>
    <edge source="S1PR1" target="SIPONIMOD">
      <data key="d4">8.0</data>
      <data key="d5">Siponimod is an S1PR1 agonist</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9</data>
    </edge>
    <edge source="S1PR1" target="ETRASIMOD">
      <data key="d4">16.0</data>
      <data key="d5">Etrasimod induces sustained internalization of the S1PR1 receptor
Etrasimod targets the S1PR1 receptor</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9,f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="S1PR1" target="AKP-11">
      <data key="d4">8.0</data>
      <data key="d5">AKP-11 is a highly selective S1PR1 agonist</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9</data>
    </edge>
    <edge source="S1PR1" target="SCD-044">
      <data key="d4">8.0</data>
      <data key="d5">SCD-044 targets the S1PR1 receptor</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="S1PR1" target="LC51-0255">
      <data key="d4">8.0</data>
      <data key="d5">LC51-0255 targets the S1PR1 receptor</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="S1PR1" target="BMS-986166">
      <data key="d4">8.0</data>
      <data key="d5">BMS-986166 targets the S1PR1 receptor</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="S1PR1" target="KT-474">
      <data key="d4">8.0</data>
      <data key="d5">KT-474 targets the S1PR1 receptor</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="S1PR1" target="AKP-19">
      <data key="d4">8.0</data>
      <data key="d5">AKP-19 targets the S1PR1 receptor</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="S1PR3" target="FINGOLIMOD">
      <data key="d4">8.0</data>
      <data key="d5">Fingolimod is an S1PR3 agonist</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9</data>
    </edge>
    <edge source="S1PR4" target="FINGOLIMOD">
      <data key="d4">8.0</data>
      <data key="d5">Fingolimod is an S1PR4 agonist</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9</data>
    </edge>
    <edge source="S1PR4" target="ETRASIMOD">
      <data key="d4">8.0</data>
      <data key="d5">Etrasimod targets the S1PR4 receptor</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="S1PR5" target="FINGOLIMOD">
      <data key="d4">8.0</data>
      <data key="d5">Fingolimod is an S1PR5 agonist</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9</data>
    </edge>
    <edge source="S1PR5" target="SIPONIMOD">
      <data key="d4">8.0</data>
      <data key="d5">Siponimod is an S1PR5 agonist</data>
      <data key="d6">3ce96e927d65736b305f792977fed4b9</data>
    </edge>
    <edge source="S1PR5" target="ETRASIMOD">
      <data key="d4">8.0</data>
      <data key="d5">Etrasimod targets the S1PR5 receptor</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="ETRASIMOD" target="ARENA PHARMACEUTICALS">
      <data key="d4">8.0</data>
      <data key="d5">Arena Pharmaceuticals is advancing etrasimod into phase 3 clinical trials for atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="ETRASIMOD" target="NCT04162769">
      <data key="d4">7.0</data>
      <data key="d5">NCT04162769 is a clinical trial involving Etrasimod</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="SCD-044" target="NCT04684485">
      <data key="d4">7.0</data>
      <data key="d5">NCT04684485 is a clinical trial involving SCD-044</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="BMS-986166" target="NCT03038711">
      <data key="d4">7.0</data>
      <data key="d5">NCT03038711 is a clinical trial involving BMS-986166</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="KT-474" target="NCT04772885">
      <data key="d4">7.0</data>
      <data key="d5">NCT04772885 is a clinical trial involving KT-474</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="MULTIPLE SCLEROSIS" target="OCRELIZUMAB">
      <data key="d4">8.0</data>
      <data key="d5">Ocrelizumab is used to treat multiple sclerosis</data>
      <data key="d6">423195c6b63ad0a6773374364ebf3612</data>
    </edge>
    <edge source="IL-31R&#913;" target="OSMR&#914;">
      <data key="d4">18.0</data>
      <data key="d5">IL-31 signals through the heterodimerization of IL-31R&#945; and OSMR&#946;</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="OSMR&#914;" target="VIXARELIMAB">
      <data key="d4">24.0</data>
      <data key="d5">Vixarelimab targets OSMR&#946;
Vixarelimab targets the OSMR&#946; receptor</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b,f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="VIXARELIMAB" target="PHASE IB STUDY">
      <data key="d4">7.0</data>
      <data key="d5">Phase Ib study showed vixarelimab reduced pruritus</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="VIXARELIMAB" target="NCT03816891">
      <data key="d4">7.0</data>
      <data key="d5">NCT03816891 is a clinical trial involving Vixarelimab</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="SUBSTANCE P" target="NK1R">
      <data key="d4">18.0</data>
      <data key="d5">Substance P signals through NK1R</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="NK1R" target="SERLOPITANT">
      <data key="d4">22.0</data>
      <data key="d5">Serlopitant is a NK1R antagonist
Serlopitant targets the NK1R receptor</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b,f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="NK1R" target="TRADIPITANT">
      <data key="d4">22.0</data>
      <data key="d5">Tradipitant is a NK1R antagonist
Tradipitant targets the NK1R receptor</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b,f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="SERLOPITANT" target="ATOMIK STUDY">
      <data key="d4">6.0</data>
      <data key="d5">ATOMIK study evaluated serlopitant in atopic dermatitis</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="SERLOPITANT" target="NCT02975206">
      <data key="d4">7.0</data>
      <data key="d5">NCT02975206 is a clinical trial involving Serlopitant</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="TRADIPITANT" target="EPIONE STUDY">
      <data key="d4">6.0</data>
      <data key="d5">EPIONE study evaluated tradipitant in reducing pruritus</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="TRADIPITANT" target="NCT03568331">
      <data key="d4">7.0</data>
      <data key="d5">NCT03568331 is a clinical trial involving Tradipitant</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="P2XR3" target="BLU-5937">
      <data key="d4">14.0</data>
      <data key="d5">BLU-5937 is a selective P2X3 antagonist</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="BLU-5937" target="BLUEPRINT TRIAL">
      <data key="d4">1.0</data>
      <data key="d5">BLUEPRINT trial is exploring the effect of BLU-5937 on pruritus</data>
      <data key="d6">0ba9fbea14e0c2c1d01a12ffaacfda9b</data>
    </edge>
    <edge source="BLU-5937" target="P2X3">
      <data key="d4">8.0</data>
      <data key="d5">BLU-5937 targets the P2X3 receptor</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="BLU-5937" target="NCT04693195">
      <data key="d4">7.0</data>
      <data key="d5">NCT04693195 is a clinical trial involving BLU-5937</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="BREPOCITINIB" target="NCT03903822">
      <data key="d4">7.0</data>
      <data key="d5">NCT03903822 is a clinical trial involving Brepocitinib</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="JAKTINIB" target="PAN-JAK">
      <data key="d4">8.0</data>
      <data key="d5">Jaktinib targets Pan-JAK</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="JAKTINIB" target="NCT04539639">
      <data key="d4">7.0</data>
      <data key="d5">NCT04539639 is a clinical trial involving Jaktinib</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="ATI-1777" target="NCT04598269">
      <data key="d4">7.0</data>
      <data key="d5">NCT04598269 is a clinical trial involving ATI-1777</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="CEE321" target="PAN-JAK">
      <data key="d4">8.0</data>
      <data key="d5">CEE321 targets Pan-JAK</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="CEE321" target="NCT04612062">
      <data key="d4">7.0</data>
      <data key="d5">NCT04612062 is a clinical trial involving CEE321</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="SHR0302" target="NCT04717310">
      <data key="d4">7.0</data>
      <data key="d5">NCT04717310 is a clinical trial involving SHR0302</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="SHR0302" target="NCT04162899">
      <data key="d4">1.0</data>
      <data key="d5">NCT04162899 is a clinical trial involving SHR0302</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="TRKS" target="NEUROTROPHINS">
      <data key="d4">6.0</data>
      <data key="d5">Neurotrophins bind to tropomyosin receptor kinases</data>
      <data key="d6">a867a1e73cef039eb3f28e072463b838</data>
    </edge>
    <edge source="BEN2293" target="TRK">
      <data key="d4">8.0</data>
      <data key="d5">BEN2293 targets the TRK receptor</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="BEN2293" target="NCT04737304">
      <data key="d4">7.0</data>
      <data key="d5">NCT04737304 is a clinical trial involving BEN2293</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="TAUREOXYCHOLIC ACID" target="NF-&#922;B">
      <data key="d4">6.0</data>
      <data key="d5">Taureoxycholic acid inhibits NF-&#954;B</data>
      <data key="d6">a867a1e73cef039eb3f28e072463b838</data>
    </edge>
    <edge source="TAUREOXYCHOLIC ACID" target="P38 KINASE">
      <data key="d4">1.0</data>
      <data key="d5">Taureoxycholic acid inhibits P38 kinase</data>
      <data key="d6">a867a1e73cef039eb3f28e072463b838</data>
    </edge>
    <edge source="NF-&#922;B" target="HY209">
      <data key="d4">6.0</data>
      <data key="d5">HY209 inhibits nuclear factor &#954;B</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d</data>
    </edge>
    <edge source="NF-&#922;B" target="TNFR1">
      <data key="d4">8.0</data>
      <data key="d5">TNFR1 signals to induce NF-&#954;B activation</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="P38 KINASE" target="HY209">
      <data key="d4">6.0</data>
      <data key="d5">HY209 inhibits p38 kinase</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d</data>
    </edge>
    <edge source="JAKI" target="POST-AUTHORIZATION SAFETY STUDIES">
      <data key="d4">7.0</data>
      <data key="d5">Post-authorization safety studies are important for evaluating the safety profile of JAK inhibitors</data>
      <data key="d6">a867a1e73cef039eb3f28e072463b838</data>
    </edge>
    <edge source="JAKI" target="REAL-WORLD REGISTRIES">
      <data key="d4">7.0</data>
      <data key="d5">Real-world registries are important for evaluating the safety profile of JAK inhibitors</data>
      <data key="d6">a867a1e73cef039eb3f28e072463b838</data>
    </edge>
    <edge source="JAKI" target="PHARMACOVIGILANCE">
      <data key="d4">8.0</data>
      <data key="d5">Pharmacovigilance is the process of monitoring the benefit-risk ratio of drugs like JAK inhibitors in Atopic Dermatitis</data>
      <data key="d6">90f4809673ca34628b0e607908f0bf0b</data>
    </edge>
    <edge source="HY209" target="CCL17/TARC">
      <data key="d4">7.0</data>
      <data key="d5">HY209 significantly decreased CCL17/TARC levels</data>
      <data key="d6">0829313703a7d2bae5436a9ee542334d</data>
    </edge>
    <edge source="HY209" target="GPCR19">
      <data key="d4">8.0</data>
      <data key="d5">HY209 targets the GPCR19 receptor</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="HY209" target="NCT04530643">
      <data key="d4">7.0</data>
      <data key="d5">NCT04530643 is a clinical trial involving HY209</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="VTP-38543" target="LIVER X RECEPTOR-&#914;">
      <data key="d4">8.0</data>
      <data key="d5">VTP-38543 targets the Liver X receptor-&#946;</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="VTP-38543" target="NCT02655679">
      <data key="d4">7.0</data>
      <data key="d5">NCT02655679 is a clinical trial involving VTP-38543</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="ALX 101" target="LIVER X RECEPTOR">
      <data key="d4">8.0</data>
      <data key="d5">ALX 101 targets the Liver X receptor</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="ALX 101" target="NCT03859986">
      <data key="d4">7.0</data>
      <data key="d5">NCT03859986 is a clinical trial involving ALX 101</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="SPHINGOSINE 1-PHOSPHATE RECEPTOR" target="SPHINGOSINE 1-PHOSPHATE">
      <data key="d4">7.0</data>
      <data key="d5">Sphingosine 1-phosphate is a signaling molecule involved in the migration of T cells in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="C-C CHEMOKINE RECEPTOR 4" target="C-C CHEMOKINE">
      <data key="d4">7.0</data>
      <data key="d5">C-C chemokine is involved in the migration of T cells into the skin in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="JANUS KINASES" target="JANUS KINASE INHIBITORS">
      <data key="d4">7.0</data>
      <data key="d5">Janus kinase inhibitors target JAKs involved in cytokine receptor signal transduction in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="BRUTON TYROSINE KINASE" target="B CELL RECEPTOR">
      <data key="d4">7.0</data>
      <data key="d5">B cell receptor is involved in the immune response in atopic dermatitis</data>
      <data key="d6">83eb9003d42977bb83fea1d123dd5ab9</data>
    </edge>
    <edge source="INNATE IMMUNITY" target="TL1A">
      <data key="d4">7.0</data>
      <data key="d5">TL1A signals through innate immunity</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="ADAPTIVE IMMUNITY" target="TL1A">
      <data key="d4">7.0</data>
      <data key="d5">TL1A signals through adaptive immunity</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="OX40 LIGAND" target="REGULATORY T CELL">
      <data key="d4">8.0</data>
      <data key="d5">OX40 ligand is involved in the activation of regulatory T cells</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="THYMIC STROMAL LYMPHOPOIETIN" target="LIGHT">
      <data key="d4">16.0</data>
      <data key="d5">LIGHT controls the expression of TSLP</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2</data>
    </edge>
    <edge source="LEO 152020/JW1601" target="NCT04203836">
      <data key="d4">7.0</data>
      <data key="d5">NCT04203836 is a clinical trial involving LEO 152020/JW1601</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="DRM02" target="NCT01993420">
      <data key="d4">7.0</data>
      <data key="d5">NCT01993420 is a clinical trial involving DRM02</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="HEMAY-808" target="NCT04352595">
      <data key="d4">7.0</data>
      <data key="d5">NCT04352595 is a clinical trial involving Hemay-808</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="PF-07038124" target="NCT04664153">
      <data key="d4">7.0</data>
      <data key="d5">NCT04664153 is a clinical trial involving PF-07038124</data>
      <data key="d6">f14a13d54127c3baadeb0b34d40928c9</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="ABBVIE">
      <data key="d4">6.0</data>
      <data key="d5">AbbVie develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="ALLMIRAL">
      <data key="d4">6.0</data>
      <data key="d5">Allmiral develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="ANAPTYSBIO">
      <data key="d4">6.0</data>
      <data key="d5">AnaptysBio develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="ARENA">
      <data key="d4">6.0</data>
      <data key="d5">Arena develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="ASANA BIOSCIENCES">
      <data key="d4">6.0</data>
      <data key="d5">Asana Biosciences develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="BAYER HEALTH">
      <data key="d4">6.0</data>
      <data key="d5">Bayer Health develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="BIOVERSYS">
      <data key="d4">6.0</data>
      <data key="d5">BioVerSys develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="B&#214;HRINGER-INGELHEIM">
      <data key="d4">6.0</data>
      <data key="d5">B&#246;hringer-Ingelheim develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="BRISTOL MYERS SQUIBB">
      <data key="d4">6.0</data>
      <data key="d5">Bristol Myers Squibb develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="DOMAIN THERAPEUTICS">
      <data key="d4">6.0</data>
      <data key="d5">Domain Therapeutics develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="GALAPAGOS/MORPHOSYS">
      <data key="d4">6.0</data>
      <data key="d5">Galapagos/MorphoSys develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="GALDERMA">
      <data key="d4">6.0</data>
      <data key="d5">Galderma develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="GLENMARK">
      <data key="d4">6.0</data>
      <data key="d5">Glenmark develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="GSK">
      <data key="d4">6.0</data>
      <data key="d5">GSK develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="INCYTE">
      <data key="d4">6.0</data>
      <data key="d5">Incyte develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="IQVIA">
      <data key="d4">6.0</data>
      <data key="d5">IQVIA develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="JANSSEN">
      <data key="d4">6.0</data>
      <data key="d5">Janssen develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="KIRIN">
      <data key="d4">6.0</data>
      <data key="d5">Kirin develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="LEO PHARMA">
      <data key="d4">6.0</data>
      <data key="d5">LEO Pharma develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="LG CHEM">
      <data key="d4">6.0</data>
      <data key="d5">LG Chem develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="LILLY">
      <data key="d4">6.0</data>
      <data key="d5">Lilly develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="L&#8217;OR&#201;AL">
      <data key="d4">6.0</data>
      <data key="d5">L&#8217;Or&#233;al develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="MENLOTX">
      <data key="d4">6.0</data>
      <data key="d5">MenloTx develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="NOVARTIS">
      <data key="d4">6.0</data>
      <data key="d5">Novartis develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="VIFOR PHARMA">
      <data key="d4">6.0</data>
      <data key="d5">Vifor Pharma develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="PFIZER">
      <data key="d4">6.0</data>
      <data key="d5">Pfizer develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="PIERRE FABRE">
      <data key="d4">6.0</data>
      <data key="d5">Pierre Fabre develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="SANOFI/REGENERON">
      <data key="d4">6.0</data>
      <data key="d5">Sanofi/Regeneron develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="UCB">
      <data key="d4">6.0</data>
      <data key="d5">UCB develops biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="BIOLOGIC THERAPIES" target="DAVOS BIOSCIENCES">
      <data key="d4">1.0</data>
      <data key="d5">Davos Biosciences is involved in the development of biologic therapies</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="EOSINOPHILIC ASTHMA" target="AEROALLERGENS">
      <data key="d4">7.0</data>
      <data key="d5">Aeroallergens can trigger eosinophilic asthma</data>
      <data key="d6">08e39958b85d84950ab7173daab9111b</data>
    </edge>
    <edge source="PFIZER" target="PF-06480605">
      <data key="d4">8.0</data>
      <data key="d5">Pfizer is developing PF-06480605</data>
      <data key="d6">423195c6b63ad0a6773374364ebf3612</data>
    </edge>
    <edge source="LYMPHOCYTES" target="TL1A">
      <data key="d4">7.0</data>
      <data key="d5">TL1A promotes mucus production independently of lymphocytes</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="PLAQUES" target="ELBOWS">
      <data key="d4">6.0</data>
      <data key="d5">The elbows are one of the common sites affected by Atopic Dermatitis plaques</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="PLAQUES" target="KNEES">
      <data key="d4">6.0</data>
      <data key="d5">The knees are one of the common sites affected by Atopic Dermatitis plaques</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="PLAQUES" target="FACE">
      <data key="d4">6.0</data>
      <data key="d5">The face is one of the common sites affected by Atopic Dermatitis plaques</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="PLAQUES" target="NECK">
      <data key="d4">6.0</data>
      <data key="d5">The neck is one of the common sites affected by Atopic Dermatitis plaques</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="PLAQUES" target="WRISTS">
      <data key="d4">6.0</data>
      <data key="d5">The wrists are one of the common sites affected by Atopic Dermatitis plaques</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="VESICLES" target="INFANTILE ATOPIC DERMATITIS">
      <data key="d4">7.0</data>
      <data key="d5">Vesicles are small blisters seen in infantile Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="EXCORIATIONS" target="INFANTILE ATOPIC DERMATITIS">
      <data key="d4">7.0</data>
      <data key="d5">Excoriations are scratch marks seen in infantile Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="SEROUS EXUDATE" target="INFANTILE ATOPIC DERMATITIS">
      <data key="d4">7.0</data>
      <data key="d5">Serous Exudate is a clear fluid discharge seen in infantile Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="CHEEKS" target="INFANTILE ATOPIC DERMATITIS">
      <data key="d4">6.0</data>
      <data key="d5">The cheeks are one of the common sites affected by infantile Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="SCALP" target="INFANTILE ATOPIC DERMATITIS">
      <data key="d4">6.0</data>
      <data key="d5">The scalp is one of the common sites affected by infantile Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="HANDS" target="ADULT ATOPIC DERMATITIS">
      <data key="d4">6.0</data>
      <data key="d5">The hands are commonly affected by chronic hand eczema in adult Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="HEAD&#8211;NECK DERMATITIS" target="ADULT ATOPIC DERMATITIS">
      <data key="d4">6.0</data>
      <data key="d5">Head&#8211;Neck Dermatitis is a form of Atopic Dermatitis affecting the upper trunk, shoulders, and scalp in adults</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="INTERLEUKINS" target="CIBINQO">
      <data key="d4">16.0</data>
      <data key="d5">Cibinqo controls interleukins</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="DNA METHYLATION" target="FLG GENE">
      <data key="d4">7.0</data>
      <data key="d5">DNA methylation can influence the expression of the FLG gene associated with Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="FLG GENE" target="FLG NULL MUTATIONS">
      <data key="d4">8.0</data>
      <data key="d5">FLG null mutations result in a lack of functional filaggrin protein, increasing the risk of Atopic Dermatitis</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="FLG GENE" target="FLG COPY NUMBER VARIATIONS">
      <data key="d4">8.0</data>
      <data key="d5">FLG copy number variations can affect filaggrin levels and Atopic Dermatitis risk</data>
      <data key="d6">6ada075e562abd7bd445164e9fc309b4</data>
    </edge>
    <edge source="IL-8" target="CSA">
      <data key="d4">7.0</data>
      <data key="d5">CsA-loaded nanoparticles reduce IL-8 levels</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="IL-8" target="LIGHT">
      <data key="d4">7.0</data>
      <data key="d5">LIGHT stimulates the release of IL-8 from human hepatoma cells</data>
      <data key="d6">05c97152fe02249153103be341d65b67</data>
    </edge>
    <edge source="IL-8" target="H2O2">
      <data key="d4">6.0</data>
      <data key="d5">H2O2 amplifies LIGHT-stimulated release of IL-8</data>
      <data key="d6">05c97152fe02249153103be341d65b67</data>
    </edge>
    <edge source="MCP-1" target="ANG II">
      <data key="d4">7.0</data>
      <data key="d5">Ang II induces the synthesis of MCP-1</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="MCP-1" target="CD34+CD45+ MONOCYTIC CELLS">
      <data key="d4">7.0</data>
      <data key="d5">MCP-1 mediates the cardiac infiltration of CD34+CD45+ monocytic cells</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="EOSINOPHILIC ESOPHAGITIS" target="LIGHT">
      <data key="d4">28.0</data>
      <data key="d5">LIGHT is induced in eosinophilic esophagitis
LIGHT is induced in EoE and regulates fibrosis</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2,df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="TREGS" target="GITR">
      <data key="d4">25.0</data>
      <data key="d5">GITR is constitutively expressed by Tregs
GITR is constitutively expressed by Tregs and plays a role in their function</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9,d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="TREGS" target="FLS">
      <data key="d4">7.0</data>
      <data key="d5">FLS expressing GITRL cause a reduction in Foxp3 expression in Tregs</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="NANOTECHNOLOGY" target="CANCER">
      <data key="d4">7.0</data>
      <data key="d5">Nanotechnology offers a method for treating cancer</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="CHITOSAN" target="BETAMETHASONE VALERATE (BMV)">
      <data key="d4">7.0</data>
      <data key="d5">Betamethasone Valerate is loaded into chitosan nanoparticles for treating AD</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="CHITOSAN" target="BMV">
      <data key="d4">13.0</data>
      <data key="d5">BMV is encapsulated in chitosan gel for extended drug retention
BMV is encapsulated in chitosan-based nanoparticles</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5,bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="CHITOSAN" target="HYDROCORTISONE (HC)">
      <data key="d4">6.0</data>
      <data key="d5">HC is used in chitosan-based nanoparticles for topical administration</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="CHITOSAN" target="HYDROXYTYROSOL (HT)">
      <data key="d4">1.0</data>
      <data key="d5">HT is used in chitosan-based nanoparticles for topical administration</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="CHITOSAN" target="HYDROXYTYROSOL">
      <data key="d4">16.0</data>
      <data key="d5">Chitosan-based NPs were used for the topical administration of hydroxytyrosol</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="CHITOSAN" target="FUCOIDAN">
      <data key="d4">16.0</data>
      <data key="d5">Fucoidan/chitosan-based NPs were formulated for the topical application of MTX</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="CHITOSAN" target="MTX">
      <data key="d4">16.0</data>
      <data key="d5">Fucoidan/chitosan-based NPs were formulated for the topical application of MTX</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="TACROLIMUS (FK506)" target="NIC-CS-NPS">
      <data key="d4">8.0</data>
      <data key="d5">NIC-CS-NPs contain Tacrolimus (FK506) for treating AD</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="NICOTINAMIDE (NIC)" target="NIC-CS-NPS">
      <data key="d4">8.0</data>
      <data key="d5">NIC-CS-NPs contain Nicotinamide (NIC) for treating AD</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="SPRAGUE DAWLEY RATS" target="NIC-CS-NPS">
      <data key="d4">7.0</data>
      <data key="d5">NIC-CS-NPs showed sustained skin permeation in Sprague Dawley rats</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="BABL/C MICE" target="DNCB">
      <data key="d4">7.0</data>
      <data key="d5">DNCB is used to induce AD-like skin lesions in BABL/c mice</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="HYALURONIC ACID (HA)" target="TAC-LOADED NANOPARTICLES">
      <data key="d4">7.0</data>
      <data key="d5">Hyaluronic Acid is used to decorate TAC-loaded nanoparticles for treating AD</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="CARBOPOL&#174;980" target="PHYTOCERAMIDES">
      <data key="d4">14.0</data>
      <data key="d5">Carbopol&#174;980 is used as a gel in nanocarriers containing phytoceramides for drug delivery
Carbopol&#174;980 is used as a gel to deliver phytoceramides</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5,8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="PHYTOCERAMIDES" target="STARCH">
      <data key="d4">6.0</data>
      <data key="d5">Phytoceramides are included in starch-based nanocarriers for drug delivery</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="PHYTOCERAMIDES" target="LECITHIN">
      <data key="d4">6.0</data>
      <data key="d5">Phytoceramides are included in lecithin-based nanocarriers for drug delivery</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="PHYTOCERAMIDES" target="MICROEMULSIONS">
      <data key="d4">1.0</data>
      <data key="d5">Phytoceramides are included in microemulsions for drug delivery</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="PHYTOCERAMIDES" target="STARCH-BASED MICROEMULSIONS">
      <data key="d4">7.0</data>
      <data key="d5">Starch-based microemulsions are used in nanocarriers containing phytoceramides for drug delivery</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="PHYTOCERAMIDES" target="LECITHIN-BASED MICROEMULSIONS">
      <data key="d4">1.0</data>
      <data key="d5">Lecithin-based microemulsions are used in nanocarriers containing phytoceramides for drug delivery</data>
      <data key="d6">8246ea974dfb00cb5e3d984004e21a9e</data>
    </edge>
    <edge source="PHYTOCERAMIDES" target="SC">
      <data key="d4">8.0</data>
      <data key="d5">Phytoceramides are concentrated within the stratum corneum</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="STARCH" target="ER143">
      <data key="d4">14.0</data>
      <data key="d5">ER143 was encapsulated in starch-based nanocapsules</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="SC" target="TAC">
      <data key="d4">7.0</data>
      <data key="d5">Higher TAC levels were observed in the stratum corneum with PLG-based nanoparticles</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="ALBINO WISTAR RATS" target="TEWL">
      <data key="d4">6.0</data>
      <data key="d5">Albino Wistar Rats showed reduced TEWL with treatment</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="TEWL" target="CSA">
      <data key="d4">8.0</data>
      <data key="d5">CsA-loaded nanoparticles reduce TEWL</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="GLYCYRRHIZIC ACID (GA)" target="BALB/C MICE">
      <data key="d4">8.0</data>
      <data key="d5">Glycyrrhizic Acid (GA) reduces scratching and erythema in BALB/c mice</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="CYCLOSPORINE A (CSA)" target="HUMAN EPIDERMIS">
      <data key="d4">7.0</data>
      <data key="d5">Cyclosporine A (CsA) is delivered effectively in the human epidermis</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="TAC" target="RABBITS">
      <data key="d4">6.0</data>
      <data key="d5">TAC showed no irritation in rabbits</data>
      <data key="d6">6aef5adb1be227170f66c76a292c25e5</data>
    </edge>
    <edge source="TAC" target="HA">
      <data key="d4">7.0</data>
      <data key="d5">HA-based nanoparticles improve TAC deposition</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="TAC" target="CHOLESTEROL">
      <data key="d4">7.0</data>
      <data key="d5">Cholesterol-based nanoparticles improve TAC deposition</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="TAC" target="NIC">
      <data key="d4">7.0</data>
      <data key="d5">NIC improves TAC solubility and skin penetration</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="TAC" target="PLG">
      <data key="d4">7.0</data>
      <data key="d5">PLG-based NPs are used for the topical delivery of TAC</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="NLCS" target="METHOTREXATE (MTX)">
      <data key="d4">7.0</data>
      <data key="d5">MTX-loaded NLCs enhance MTX bioavailability and dermal penetration</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="MOUSE" target="RANKL">
      <data key="d4">12.0</data>
      <data key="d5">RANKL signaling is reduced in a mouse model of silicosis treated with Ac-SDKP</data>
      <data key="d6">d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="MOUSE" target="AC-SDKP">
      <data key="d4">12.0</data>
      <data key="d5">Ac-SDKP reduces RANKL signaling in a mouse model of silicosis</data>
      <data key="d6">d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="HACAT CELLS" target="C6">
      <data key="d4">6.0</data>
      <data key="d5">C6-loaded HA&#8211;Chol&#8211;NPs with NIC exhibited similar green fluorescence to HA&#8211;Chol&#8211;NPs alone in HaCaT cells</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="PLGA" target="CSA">
      <data key="d4">7.0</data>
      <data key="d5">PLGA-based nanoparticles are used for topical delivery of CsA</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="CSA" target="INF-&#915;">
      <data key="d4">14.0</data>
      <data key="d5">CsA-loaded nanoparticles reduce INF-&#947; levels</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="CSA" target="OVA-IGE">
      <data key="d4">14.0</data>
      <data key="d5">CsA-loaded nanoparticles reduce OVA-IgE serum levels</data>
      <data key="d6">bddc3b1a7f098e71f0aa64adec047124</data>
    </edge>
    <edge source="HYDROCORTISONE" target="IL-12P70">
      <data key="d4">14.0</data>
      <data key="d5">HC-NPs suppressed inflammatory cascades including IL-12p70</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="HYDROCORTISONE" target="PROSTAGLANDIN-E2">
      <data key="d4">14.0</data>
      <data key="d5">HC-NPs suppressed inflammatory cascades including prostaglandin-E2 expression</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="HYDROCORTISONE" target="VEGF-&#913;">
      <data key="d4">14.0</data>
      <data key="d5">HC-NPs suppressed inflammatory cascades including VEGF-&#945;</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="HYDROCORTISONE" target="ELASTIC FIBER">
      <data key="d4">14.0</data>
      <data key="d5">HC-NPs blocked or significantly decreased elastic fiber fragmentation</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="HNE" target="ER143">
      <data key="d4">16.0</data>
      <data key="d5">ER143 is a synthetic HNE inhibitor</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="DESONIDE" target="EUDRAGIT&#174; RL100">
      <data key="d4">14.0</data>
      <data key="d5">Desonide was encapsulated in Eudragit&#174; RL100 nanocapsules</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="DESONIDE" target="ACAI OIL">
      <data key="d4">14.0</data>
      <data key="d5">Desonide was encapsulated using acai oil as the core</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="DESONIDE" target="MEDIUM-CHAIN TRIGLYCERIDES">
      <data key="d4">14.0</data>
      <data key="d5">Desonide was encapsulated using medium-chain triglycerides as the core</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="BDP" target="HPMC">
      <data key="d4">14.0</data>
      <data key="d5">BDP-loaded polymeric micelles were incorporated into an HPMC hydrogel</data>
      <data key="d6">3dfbb4c51838e0951f53ce951395225f</data>
    </edge>
    <edge source="AMDITELIMAB" target="OX-40">
      <data key="d4">8.0</data>
      <data key="d5">Amditelimab targets OX-40</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </edge>
    <edge source="HYALURONIC ACID" target="BETAMETHASONE">
      <data key="d4">14.0</data>
      <data key="d5">Betamethasone and Hyaluronic acid are used together in nanotechnology-based therapeutic approaches</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </edge>
    <edge source="BETAMETHASONE" target="DIFLUCORTOLONE VALERATE">
      <data key="d4">14.0</data>
      <data key="d5">Betamethasone and Diflucortolone valerate are used together in nanotechnology-based therapeutic approaches</data>
      <data key="d6">cccfd5ff480e281556e2210cd0e5c4b5</data>
    </edge>
    <edge source="CIBINQO" target="JADE TEEN">
      <data key="d4">14.0</data>
      <data key="d5">JADE TEEN trial supports cibinqo label expansion</data>
      <data key="d6">286730b1c1f680ac465cc21d522fda0c</data>
    </edge>
    <edge source="SEVERE AD" target="TRADITIONAL TREATMENTS">
      <data key="d4">7.0</data>
      <data key="d5">Severe AD was previously resistant to traditional treatments</data>
      <data key="d6">e30574e513dd250992d637d808759c34</data>
    </edge>
    <edge source="PLASMA" target="HC">
      <data key="d4">8.0</data>
      <data key="d5">Plasma was collected from healthy controls</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="HC" target="SOX40L">
      <data key="d4">7.0</data>
      <data key="d5">sOX40L was measured in serum from healthy controls</data>
      <data key="d6">2e9a8d71f6bd251a0b13458c39e69746</data>
    </edge>
    <edge source="SOX40L" target="ENZYME-LINKED IMMUNOASSAY">
      <data key="d4">8.0</data>
      <data key="d5">ELISA is used to measure serum levels of sOX40L in patients with atopic dermatitis</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd</data>
    </edge>
    <edge source="SOX40L" target="CHILDREN WITH AD">
      <data key="d4">8.0</data>
      <data key="d5">Serum levels of sOX40L are measured in children with atopic dermatitis</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd</data>
    </edge>
    <edge source="SOX40L" target="ADULTS WITH AD">
      <data key="d4">1.0</data>
      <data key="d5">Serum levels of sOX40L are measured in adults with atopic dermatitis</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd</data>
    </edge>
    <edge source="TRYPTASE" target="MONOCLONAL RABBIT ANTI-TRYPTASE">
      <data key="d4">7.0</data>
      <data key="d5">Monoclonal rabbit anti-tryptase is used to target tryptase in immunohistochemistry</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd</data>
    </edge>
    <edge source="MONOCLONAL RABBIT ANTI-TRYPTASE" target="DONKEY ANTI-RABBIT ALEXA 647">
      <data key="d4">6.0</data>
      <data key="d5">Donkey anti-rabbit Alexa 647 is used as a secondary antibody for monoclonal rabbit anti-tryptase</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd</data>
    </edge>
    <edge source="MONOCLONAL MOUSE ANTI-OX40L" target="DONKEY ANTI-MOUSE ALEXA 488">
      <data key="d4">6.0</data>
      <data key="d5">Donkey anti-mouse Alexa 488 is used as a secondary antibody for monoclonal mouse anti-OX40L</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd</data>
    </edge>
    <edge source="MONOCLONAL MOUSE ANTI-OX40L" target="MOUSE IGG1 ISOTYPE CONTROL">
      <data key="d4">5.0</data>
      <data key="d5">Mouse IgG1 isotype control is used as a negative control for monoclonal mouse anti-OX40L</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd</data>
    </edge>
    <edge source="MOUNTING MEDIUM" target="TISSUE SECTIONS">
      <data key="d4">5.0</data>
      <data key="d5">Mounting Medium is used to fix tissue sections for microscopy analysis</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd</data>
    </edge>
    <edge source="PRISM 6" target="STATISTICAL ANALYSIS">
      <data key="d4">6.0</data>
      <data key="d5">Prism 6 is used for statistical analysis and graphing</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd</data>
    </edge>
    <edge source="MANN-WHITNEY RANK SUM TEST" target="UNPAIRED DATA">
      <data key="d4">6.0</data>
      <data key="d5">Mann-Whitney rank sum test is used for comparing unpaired data</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd</data>
    </edge>
    <edge source="WILCOXON SIGNED-RANK TEST" target="PAIRED DATA">
      <data key="d4">6.0</data>
      <data key="d5">Wilcoxon signed-rank test is used for comparing paired data</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd</data>
    </edge>
    <edge source="SPEARMAN&#8217;S RHO" target="CORRELATION">
      <data key="d4">6.0</data>
      <data key="d5">Spearman&#8217;s rho is used to test correlations</data>
      <data key="d6">348f2797841cbef27311b03f2cd788dd</data>
    </edge>
    <edge source="LUNG" target="ILD">
      <data key="d4">8.0</data>
      <data key="d5">Interstitial lung disease affects the lungs in SSc</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="LUNG" target="PULMONARY HYPERTENSION">
      <data key="d4">1.0</data>
      <data key="d5">Pulmonary hypertension affects the lungs in SSc</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="LUNG" target="TL1A">
      <data key="d4">14.0</data>
      <data key="d5">Membrane-restricted TL1A in the lung activates both innate and adaptive immunity
TL1A is associated with inflammation and fibrosis of the lung</data>
      <data key="d6">05c97152fe02249153103be341d65b67,c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="LUNG" target="GITR">
      <data key="d4">8.0</data>
      <data key="d5">GITR signaling was studied in the context of lung injury and fibrosis</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="SYSTEMIC SCLEROSIS" target="SSC">
      <data key="d4">10.0</data>
      <data key="d5">Systemic sclerosis is also referred to as SSc</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="SYSTEMIC SCLEROSIS" target="VISCERAL ORGANS">
      <data key="d4">16.0</data>
      <data key="d5">Systemic sclerosis presents with fibrosis in visceral organs</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="SYSTEMIC SCLEROSIS" target="LUNGS">
      <data key="d4">16.0</data>
      <data key="d5">Systemic sclerosis presents with fibrosis in the lungs</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="SYSTEMIC SCLEROSIS" target="HEART">
      <data key="d4">2.0</data>
      <data key="d5">Systemic sclerosis presents with fibrosis in the heart</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="SYSTEMIC SCLEROSIS" target="LIGHT">
      <data key="d4">16.0</data>
      <data key="d5">LIGHT is induced in SSc and regulates skin fibrosis</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2</data>
    </edge>
    <edge source="SYSTEMIC SCLEROSIS" target="MMF">
      <data key="d4">1.0</data>
      <data key="d5">MMF is used to treat systemic sclerosis</data>
      <data key="d6">423195c6b63ad0a6773374364ebf3612</data>
    </edge>
    <edge source="SYSTEMIC SCLEROSIS" target="ANTI-BAFF MAB">
      <data key="d4">8.0</data>
      <data key="d5">Anti-BAFF mAb is used in the treatment of Systemic Sclerosis</data>
      <data key="d6">8e5a1be9981340d419f7b3ad27076009</data>
    </edge>
    <edge source="SSC" target="RA">
      <data key="d4">7.0</data>
      <data key="d5">Rheumatoid arthritis is an autoimmune disease that shares some pathogenesis mechanisms with systemic sclerosis</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="SSC" target="SLE">
      <data key="d4">21.0</data>
      <data key="d5">Systemic lupus erythematosus is an autoimmune disease that shares some pathogenesis mechanisms with systemic sclerosis
Patients were excluded if they met ACR criteria for SLE, but one patient was diagnosed with SLE</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5,f9c444698bb08349abe4244fb771c1ee</data>
    </edge>
    <edge source="SSC" target="SJ&#214;GREN'S SYNDROME">
      <data key="d4">7.0</data>
      <data key="d5">Sj&#246;gren's syndrome is an autoimmune disease that shares some pathogenesis mechanisms with systemic sclerosis</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="SSC" target="POLYMYOSITIS">
      <data key="d4">7.0</data>
      <data key="d5">Polymyositis is an autoimmune disease that shares some pathogenesis mechanisms with systemic sclerosis</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="SSC" target="DCSSC">
      <data key="d4">9.0</data>
      <data key="d5">Diffuse cutaneous systemic sclerosis is a subtype of systemic sclerosis</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="SSC" target="CD226">
      <data key="d4">14.0</data>
      <data key="d5">CD226 polymorphisms are associated with genetic susceptibility to systemic sclerosis</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="SSC" target="DNAM-1">
      <data key="d4">14.0</data>
      <data key="d5">DNAM-1 is overexpressed in the skin of systemic sclerosis patients</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="SSC" target="SCTLA-4">
      <data key="d4">30.0</data>
      <data key="d5">Increased sCTLA-4 serum levels are observed in systemic sclerosis patients
Elevated levels of soluble CTLA-4 are observed in systemic sclerosis</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b,9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="SSC" target="PD-L1">
      <data key="d4">16.0</data>
      <data key="d5">Soluble PD-L1 is elevated in systemic sclerosis patients</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="SSC" target="PD-L2">
      <data key="d4">16.0</data>
      <data key="d5">Soluble PD-L2 is elevated in systemic sclerosis patients</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="SSC" target="PD-1">
      <data key="d4">16.0</data>
      <data key="d5">Soluble PD-1 is elevated in systemic sclerosis patients</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="SSC" target="BLEOMYCIN MOUSE MODEL">
      <data key="d4">16.0</data>
      <data key="d5">The Bleomycin mouse model mimics early and inflammatory stages of systemic sclerosis</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="SSC" target="FRA-2 TRANSGENIC MOUSE MODEL">
      <data key="d4">16.0</data>
      <data key="d5">The Fra-2 transgenic mouse model mimics features of systemic sclerosis</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="SSC" target="RODNAN SKIN SCORE">
      <data key="d4">8.0</data>
      <data key="d5">The Rodnan skin score is used to measure skin thickness in systemic sclerosis</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="SSC" target="MONOCYTE">
      <data key="d4">7.0</data>
      <data key="d5">Monocyte infiltration is reduced in systemic sclerosis lesions with Abatacept treatment</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="SSC" target="PROINFLAMMATORY CYTOKINES">
      <data key="d4">8.0</data>
      <data key="d5">Proinflammatory cytokines are involved in systemic sclerosis</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="SSC" target="PROFIBROTIC CYTOKINES">
      <data key="d4">8.0</data>
      <data key="d5">Profibrotic cytokines are involved in systemic sclerosis</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="SSC" target="TIGHT SKIN-1 MOUSE MODEL">
      <data key="d4">8.0</data>
      <data key="d5">The Tight skin-1 mouse model is used to study non-inflammatory dermal fibrosis in systemic sclerosis</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="SSC" target="GASTROINTESTINAL INVOLVEMENT">
      <data key="d4">8.0</data>
      <data key="d5">Gastrointestinal involvement is a symptom of systemic sclerosis</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="SSC" target="CARDIAC HEMODYNAMIC IMPAIRMENT">
      <data key="d4">8.0</data>
      <data key="d5">Cardiac hemodynamic impairment is a symptom of systemic sclerosis</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="SSC" target="FIBROGENIC MARKERS">
      <data key="d4">8.0</data>
      <data key="d5">Fibrogenic markers are elevated in systemic sclerosis</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="SSC" target="T-CELL PROLIFERATION">
      <data key="d4">8.0</data>
      <data key="d5">T-cell proliferation is observed in systemic sclerosis</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="SSC" target="M1 MACROPHAGES">
      <data key="d4">1.0</data>
      <data key="d5">M1 macrophages are involved in systemic sclerosis</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="SSC" target="PEMBROLIZUMAB">
      <data key="d4">14.0</data>
      <data key="d5">Pembrolizumab induced sclerodermoid reactions resembling SSc</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="SSC" target="CYCLOPHOSPHAMIDE">
      <data key="d4">14.0</data>
      <data key="d5">Cyclophosphamide is used as a standard therapy drug in SSc</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="SSC" target="ANIMAL MODELS">
      <data key="d4">7.0</data>
      <data key="d5">Animal models are used to study the pathogenesis of systemic sclerosis</data>
      <data key="d6">4d0e8ae9371a435885994b4161126bc3</data>
    </edge>
    <edge source="SSC" target="AUTOIMMUNITY">
      <data key="d4">1.0</data>
      <data key="d5">Systemic sclerosis is an autoimmune disease</data>
      <data key="d6">4d0e8ae9371a435885994b4161126bc3</data>
    </edge>
    <edge source="SSC" target="RS1234314">
      <data key="d4">42.0</data>
      <data key="d5">SNP rs1234314 is associated with systemic sclerosis susceptibility
SNP rs1234314 is associated with systemic sclerosis
SNP rs1234314 is associated with systemic sclerosis</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14,40ad2241836485e0bf264bdfb62fd789,d8a485eb1e9435b083d5ef6a17f06ea5</data>
    </edge>
    <edge source="SSC" target="RS2205960">
      <data key="d4">64.0</data>
      <data key="d5">SNP rs2205960 is associated with systemic sclerosis susceptibility
SNP rs2205960 is associated with systemic sclerosis susceptibility
SNP rs2205960 is associated with systemic sclerosis susceptibility
SNP rs2205960 is associated with systemic sclerosis
SNP rs2205960 is associated with systemic sclerosis susceptibility</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14,40ad2241836485e0bf264bdfb62fd789,8ce8c356713490cd2c680f505bcd050b,c69c7fb997f95c56cc077b3975f41923,d8a485eb1e9435b083d5ef6a17f06ea5</data>
    </edge>
    <edge source="SSC" target="RS844648">
      <data key="d4">50.0</data>
      <data key="d5">SNP rs844648 is associated with systemic sclerosis susceptibility
SNP rs844648 is associated with systemic sclerosis susceptibility
SNP rs844648 is associated with systemic sclerosis
SNP rs844648 is associated with systemic sclerosis</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14,40ad2241836485e0bf264bdfb62fd789,c69c7fb997f95c56cc077b3975f41923,d8a485eb1e9435b083d5ef6a17f06ea5</data>
    </edge>
    <edge source="SSC" target="RS844644">
      <data key="d4">42.0</data>
      <data key="d5">SNP rs844644 is protective against systemic sclerosis
SNP rs844644 is associated with systemic sclerosis
SNP rs844644 is associated with systemic sclerosis</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14,40ad2241836485e0bf264bdfb62fd789,d8a485eb1e9435b083d5ef6a17f06ea5</data>
    </edge>
    <edge source="SSC" target="IRF5">
      <data key="d4">14.0</data>
      <data key="d5">IRF5 is associated with systemic sclerosis</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14</data>
    </edge>
    <edge source="SSC" target="FAS">
      <data key="d4">14.0</data>
      <data key="d5">FAS is associated with systemic sclerosis</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14</data>
    </edge>
    <edge source="SSC" target="PERIPHERAL BLOOD CELLS">
      <data key="d4">12.0</data>
      <data key="d5">Peripheral blood cells from SSc patients show upregulation of type I interferon associated gene transcripts</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14</data>
    </edge>
    <edge source="SSC" target="TYPE I INTERFERON">
      <data key="d4">12.0</data>
      <data key="d5">Type I interferon associated gene transcripts are upregulated in SSc</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14</data>
    </edge>
    <edge source="SSC" target="ANTINUCLEAR ANTIBODIES">
      <data key="d4">14.0</data>
      <data key="d5">Patients with SSc have circulating antinuclear antibodies</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14</data>
    </edge>
    <edge source="SSC" target="EXTRACELLULAR MATRIX">
      <data key="d4">16.0</data>
      <data key="d5">Excessive extracellular matrix deposition is a feature of systemic sclerosis</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14</data>
    </edge>
    <edge source="SSC" target="VASCULOPATHY">
      <data key="d4">16.0</data>
      <data key="d5">Vasculopathy is a feature of systemic sclerosis</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14</data>
    </edge>
    <edge source="SSC" target="PULMONARY FIBROSIS">
      <data key="d4">6.0</data>
      <data key="d5">Pulmonary fibrosis is a symptom associated with systemic sclerosis</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="SSC" target="PULMONARY HYPERTENSION">
      <data key="d4">1.0</data>
      <data key="d5">Pulmonary hypertension is a symptom associated with systemic sclerosis</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="SSC" target="RS844665">
      <data key="d4">19.0</data>
      <data key="d5">SNP rs844665 is not significantly associated with systemic sclerosis
SNP rs844665 is associated with systemic sclerosis</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923,d8a485eb1e9435b083d5ef6a17f06ea5</data>
    </edge>
    <edge source="SSC" target="RS855648">
      <data key="d4">21.0</data>
      <data key="d5">SNP rs855648 is associated with systemic sclerosis
SNP rs855648 is associated with systemic sclerosis susceptibility</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923,d8a485eb1e9435b083d5ef6a17f06ea5</data>
    </edge>
    <edge source="SSC" target="ANTI-CENTROMERE">
      <data key="d4">30.0</data>
      <data key="d5">Anti-centromere antibodies are associated with systemic sclerosis
Anti-centromere antibodies are associated with systemic sclerosis</data>
      <data key="d6">40ad2241836485e0bf264bdfb62fd789,d8a485eb1e9435b083d5ef6a17f06ea5</data>
    </edge>
    <edge source="SSC" target="ANTI-TOPOISOMERASE I">
      <data key="d4">30.0</data>
      <data key="d5">Anti-topoisomerase I antibodies are associated with systemic sclerosis
Anti-topoisomerase I antibodies are associated with systemic sclerosis</data>
      <data key="d6">40ad2241836485e0bf264bdfb62fd789,d8a485eb1e9435b083d5ef6a17f06ea5</data>
    </edge>
    <edge source="SSC" target="ANTI-RNA POLYMERASE III">
      <data key="d4">18.0</data>
      <data key="d5">Anti-RNA polymerase III antibodies are associated with systemic sclerosis
Anti-RNA polymerase III antibodies are associated with systemic sclerosis</data>
      <data key="d6">40ad2241836485e0bf264bdfb62fd789,d8a485eb1e9435b083d5ef6a17f06ea5</data>
    </edge>
    <edge source="SSC" target="RS944648">
      <data key="d4">14.0</data>
      <data key="d5">SNP rs944648 is associated with systemic sclerosis susceptibility</data>
      <data key="d6">8ce8c356713490cd2c680f505bcd050b</data>
    </edge>
    <edge source="SSC" target="ODDS RATIOS">
      <data key="d4">6.0</data>
      <data key="d5">Odds ratios observed in the study are statistically significant for SSc</data>
      <data key="d6">7b454335c2f5651d86f712037a0dc0ff</data>
    </edge>
    <edge source="SSC" target="TNFR1">
      <data key="d4">9.0</data>
      <data key="d5">Elevated serum concentration of soluble TNFR1 correlates with SSc disease severity</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="SSC" target="FIBROPROLIFERATIVE">
      <data key="d4">16.0</data>
      <data key="d5">Systemic sclerosis is a fibroproliferative disease</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="SSC" target="LIGHT">
      <data key="d4">8.0</data>
      <data key="d5">LIGHT is involved in the pathogenesis of systemic sclerosis</data>
      <data key="d6">05c97152fe02249153103be341d65b67</data>
    </edge>
    <edge source="SSC" target="TRAIL">
      <data key="d4">8.0</data>
      <data key="d5">TRAIL treatment is investigated for its efficacy in systemic sclerosis</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="SSC" target="DERMAL MYOFIBROBLASTS">
      <data key="d4">8.0</data>
      <data key="d5">Dermal myofibroblasts are the principal cell type responsible for fibrosis in systemic sclerosis</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="SSC" target="BLEOMYCIN">
      <data key="d4">7.0</data>
      <data key="d5">Bleomycin is used to induce skin fibrosis in a mouse model of systemic sclerosis</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="SSC" target="TSK-1">
      <data key="d4">7.0</data>
      <data key="d5">Tsk-1 is a genetic mouse model used to study systemic sclerosis</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="RA" target="PTPN22">
      <data key="d4">16.0</data>
      <data key="d5">PTPN22 is associated with rheumatoid arthritis</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14</data>
    </edge>
    <edge source="RA" target="STAT4">
      <data key="d4">16.0</data>
      <data key="d5">STAT4 is a susceptibility gene for rheumatoid arthritis</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14</data>
    </edge>
    <edge source="SLE" target="PTPN22">
      <data key="d4">16.0</data>
      <data key="d5">PTPN22 is associated with systemic lupus erythematosus</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14</data>
    </edge>
    <edge source="SLE" target="STAT4">
      <data key="d4">16.0</data>
      <data key="d5">STAT4 is a susceptibility gene for systemic lupus erythematosus</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14</data>
    </edge>
    <edge source="SLE" target="IRF5">
      <data key="d4">14.0</data>
      <data key="d5">IRF5 is associated with systemic lupus erythematosus</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14</data>
    </edge>
    <edge source="SLE" target="FAS">
      <data key="d4">14.0</data>
      <data key="d5">FAS is associated with systemic lupus erythematosus</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14</data>
    </edge>
    <edge source="SLE" target="PERIPHERAL BLOOD CELLS">
      <data key="d4">12.0</data>
      <data key="d5">Peripheral blood cells from SLE patients show upregulation of type I interferon associated gene transcripts</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14</data>
    </edge>
    <edge source="SLE" target="TYPE I INTERFERON">
      <data key="d4">12.0</data>
      <data key="d5">Type I interferon associated gene transcripts are upregulated in SLE</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14</data>
    </edge>
    <edge source="SLE" target="ANTINUCLEAR ANTIBODIES">
      <data key="d4">14.0</data>
      <data key="d5">Patients with SLE have circulating antinuclear antibodies</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14</data>
    </edge>
    <edge source="DCSSC" target="MRSS">
      <data key="d4">8.0</data>
      <data key="d5">Modified-Rodnan skin score is used to measure skin thickness in diffuse cutaneous systemic sclerosis</data>
      <data key="d6">4d0e8ae9371a435885994b4161126bc3</data>
    </edge>
    <edge source="ASSET TRIAL" target="NCT02161406">
      <data key="d4">7.0</data>
      <data key="d5">ASSET trial is identified by the clinical trial identifier NCT02161406</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="PD1-PDL1/2" target="PD1">
      <data key="d4">8.0</data>
      <data key="d5">PD1 is involved in the PD1-PDL1/2 negative costimulatory pathway</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="PULMONARY HYPERTENSION" target="RS2205960">
      <data key="d4">1.0</data>
      <data key="d5">SNP rs2205960 is not significantly associated with pulmonary hypertension in systemic sclerosis</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="PULMONARY HYPERTENSION" target="RS844648">
      <data key="d4">5.0</data>
      <data key="d5">SNP rs844648 is not significantly associated with pulmonary hypertension in systemic sclerosis</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="PULMONARY HYPERTENSION" target="RS844644">
      <data key="d4">5.0</data>
      <data key="d5">SNP rs844644 is not significantly associated with pulmonary hypertension in systemic sclerosis</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="PULMONARY HYPERTENSION" target="RS1234314">
      <data key="d4">5.0</data>
      <data key="d5">SNP rs1234314 is not significantly associated with pulmonary hypertension in systemic sclerosis</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="T CELL RECEPTOR (TCR)" target="NAIVE T CELLS">
      <data key="d4">8.0</data>
      <data key="d5">T cell receptor (TCR) is involved in the activation of naive T cells</data>
      <data key="d6">503107475d2e9dac49abd8ebcbadd9f5</data>
    </edge>
    <edge source="PD1" target="PDL1">
      <data key="d4">16.0</data>
      <data key="d5">PD1 and PDL1 are involved in negative costimulatory pathways</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="PD1" target="PDL2">
      <data key="d4">16.0</data>
      <data key="d5">PD1 and PDL2 are involved in negative costimulatory pathways</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="PD1" target="PD1-L">
      <data key="d4">8.0</data>
      <data key="d5">PD1 interacts with PD1-L in immune response regulation</data>
      <data key="d6">4d0e8ae9371a435885994b4161126bc3</data>
    </edge>
    <edge source="DERMAL FIBROBLASTS" target="LT&#914;R">
      <data key="d4">14.0</data>
      <data key="d5">LT&#946;R is expressed on dermal fibroblasts and mediates LIGHT-induced fibrosis</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2</data>
    </edge>
    <edge source="DERMAL FIBROBLASTS" target="HVEM">
      <data key="d4">14.0</data>
      <data key="d5">HVEM is expressed on dermal fibroblasts and mediates LIGHT-induced fibrosis</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2</data>
    </edge>
    <edge source="MMP-2" target="CARDIAC FIBROSIS">
      <data key="d4">12.0</data>
      <data key="d5">Activation of MMP-2 is associated with fibrosis resolution in cardiac fibrosis</data>
      <data key="d6">d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="PAH" target="CD40L">
      <data key="d4">14.0</data>
      <data key="d5">Soluble CD40L serum concentrations are associated with pulmonary arterial hypertension</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="DIGITAL ULCERS" target="CD40L">
      <data key="d4">14.0</data>
      <data key="d5">Soluble CD40L serum concentrations are associated with digital ulcers</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="PERIPHERAL MICROANGIOPATHY" target="CD40L">
      <data key="d4">14.0</data>
      <data key="d5">Soluble CD40L serum concentrations are associated with peripheral microangiopathy</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="IMATINIB MESYLATE" target="CD40L">
      <data key="d4">14.0</data>
      <data key="d5">CD40L levels are associated with clinical improvement during Imatinib Mesylate treatment</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="DNAM-1" target="CD226">
      <data key="d4">16.0</data>
      <data key="d5">CD226 encodes DNAM-1</data>
      <data key="d6">44f2592262cac835560b4c149fee8d2b</data>
    </edge>
    <edge source="DNAM-1" target="BLEOMYCIN MOUSE MODEL">
      <data key="d4">16.0</data>
      <data key="d5">DNAM-1 gene invalidation prevents dermal fibrosis in the Bleomycin mouse model</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="DNAM-1" target="CD112">
      <data key="d4">8.0</data>
      <data key="d5">CD112 interacts with DNAM-1 in immune response modulation</data>
      <data key="d6">4d0e8ae9371a435885994b4161126bc3</data>
    </edge>
    <edge source="DNAM-1" target="CD155">
      <data key="d4">8.0</data>
      <data key="d5">CD155 interacts with DNAM-1 in immune response modulation</data>
      <data key="d6">4d0e8ae9371a435885994b4161126bc3</data>
    </edge>
    <edge source="PD-1" target="PD-L1">
      <data key="d4">14.0</data>
      <data key="d5">PD-1 is antagonized by PD-L1</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="PD-1" target="PD-L2">
      <data key="d4">14.0</data>
      <data key="d5">PD-1 is antagonized by PD-L2</data>
      <data key="d6">9867d43adab0ba5db44961fae4863eee</data>
    </edge>
    <edge source="PD-1" target="PEMBROLIZUMAB">
      <data key="d4">18.0</data>
      <data key="d5">Pembrolizumab is a PD-1 inhibitor</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="M2 MACROPHAGES" target="TREG">
      <data key="d4">16.0</data>
      <data key="d5">Treg cells promote M2 macrophage polarization and activation</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="INTERSTITIAL LUNG DISEASE" target="LUNGS">
      <data key="d4">8.0</data>
      <data key="d5">Interstitial lung disease affects the lungs</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="INTERSTITIAL LUNG DISEASE" target="PRA023">
      <data key="d4">14.0</data>
      <data key="d5">PRA023 is used in clinical trials to treat Interstitial Lung Disease</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="LIVER" target="NON-ALCOHOLIC STEATOHEPATITIS">
      <data key="d4">8.0</data>
      <data key="d5">Non-alcoholic steatohepatitis affects the liver</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="LIVER" target="NON-ALCOHOLIC FATTY LIVER DISEASE">
      <data key="d4">8.0</data>
      <data key="d5">Non-alcoholic fatty liver disease affects the liver</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="LIVER" target="PRIMARY BILIARY CHOLANGITIS">
      <data key="d4">1.0</data>
      <data key="d5">Primary biliary cholangitis affects the liver</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="LIVER" target="TNFR1">
      <data key="d4">8.0</data>
      <data key="d5">TNFR1 plays a key role in liver fibrosis formation</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="LIVER" target="TL1A">
      <data key="d4">7.0</data>
      <data key="d5">TL1A is upregulated in liver tissue in fibrosis</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="LIVER" target="GITR">
      <data key="d4">7.0</data>
      <data key="d5">GITR signaling is implicated in liver disease</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="DNAM" target="CD112">
      <data key="d4">16.0</data>
      <data key="d5">DNAM and CD112 are involved in positive costimulatory pathways</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="TREG" target="TGF&#914;">
      <data key="d4">16.0</data>
      <data key="d5">TGF&#946; is secreted by Treg cells</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="TGF&#914;" target="TAPI-1">
      <data key="d4">14.0</data>
      <data key="d5">TAPI-1 reduces mRNA expression of TGF&#946;</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TGF&#914;" target="LIGHT">
      <data key="d4">23.0</data>
      <data key="d5">LIGHT induces the expression of TGF&#946;, a primary fibrotic cytokine
LIGHT may induce TGF&#946; in hepatic macrophages</data>
      <data key="d6">05c97152fe02249153103be341d65b67,5f37466ca41c9b8b06ed8be0303d49f2</data>
    </edge>
    <edge source="TGF&#914;" target="TRAIL">
      <data key="d4">7.0</data>
      <data key="d5">TRAIL is necessary for the upregulation of TGF&#946;</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="MMPS" target="APCS">
      <data key="d4">9.0</data>
      <data key="d5">MMPs stimulate APCs to upregulate positive costimulatory molecules</data>
      <data key="d6">855c455b4c9592746834ee3a4e0e6b81</data>
    </edge>
    <edge source="ILD" target="DERMAL FIBROSIS">
      <data key="d4">7.0</data>
      <data key="d5">Dermal fibrosis correlates with more severe interstitial lung disease</data>
      <data key="d6">4d0e8ae9371a435885994b4161126bc3</data>
    </edge>
    <edge source="PH" target="NVC">
      <data key="d4">6.0</data>
      <data key="d5">Nailfold vascular capillaroscopy is used to diagnose and monitor pulmonary hypertension</data>
      <data key="d6">4d0e8ae9371a435885994b4161126bc3</data>
    </edge>
    <edge source="RS1234314" target="LSSC">
      <data key="d4">7.0</data>
      <data key="d5">SNP rs1234314 is more common in limited systemic sclerosis compared to controls</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="RS1234314" target="DSSC">
      <data key="d4">7.0</data>
      <data key="d5">SNP rs1234314 is more common in diffuse systemic sclerosis compared to controls</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="RS1234314" target="ACA">
      <data key="d4">7.0</data>
      <data key="d5">SNP rs1234314 is associated with ACA-positive systemic sclerosis</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="RS1234314" target="ATA">
      <data key="d4">7.0</data>
      <data key="d5">SNP rs1234314 is associated with ATA-positive systemic sclerosis</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="RS1234314" target="ARA">
      <data key="d4">5.0</data>
      <data key="d5">SNP rs1234314 is not significantly associated with ARA-positive systemic sclerosis</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="RS1234314" target="PULMONARY FIBROSIS">
      <data key="d4">5.0</data>
      <data key="d5">SNP rs1234314 is not significantly associated with pulmonary fibrosis in systemic sclerosis</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="RS1234314" target="LIMITED SYSTEMIC SCLEROSIS">
      <data key="d4">12.0</data>
      <data key="d5">SNP rs1234314 is associated with limited systemic sclerosis</data>
      <data key="d6">40ad2241836485e0bf264bdfb62fd789</data>
    </edge>
    <edge source="RS1234314" target="DIFFUSE SYSTEMIC SCLEROSIS">
      <data key="d4">12.0</data>
      <data key="d5">SNP rs1234314 is associated with diffuse systemic sclerosis</data>
      <data key="d6">40ad2241836485e0bf264bdfb62fd789</data>
    </edge>
    <edge source="RS2205960" target="LSSC">
      <data key="d4">7.0</data>
      <data key="d5">SNP rs2205960 is more common in limited systemic sclerosis compared to controls</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="RS2205960" target="DSSC">
      <data key="d4">7.0</data>
      <data key="d5">SNP rs2205960 is more common in diffuse systemic sclerosis compared to controls</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="RS2205960" target="ATA">
      <data key="d4">7.0</data>
      <data key="d5">SNP rs2205960 is more frequent in ATA-positive systemic sclerosis compared to controls</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="RS2205960" target="RS855648">
      <data key="d4">7.0</data>
      <data key="d5">SNP rs2205960 and SNP rs855648 interact to increase the risk of systemic sclerosis</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="RS2205960" target="ARA">
      <data key="d4">5.0</data>
      <data key="d5">SNP rs2205960 is not significantly associated with ARA-positive systemic sclerosis</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="RS2205960" target="PULMONARY FIBROSIS">
      <data key="d4">5.0</data>
      <data key="d5">SNP rs2205960 is not significantly associated with pulmonary fibrosis in systemic sclerosis</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="RS2205960" target="LIMITED SYSTEMIC SCLEROSIS">
      <data key="d4">12.0</data>
      <data key="d5">SNP rs2205960 is associated with limited systemic sclerosis</data>
      <data key="d6">40ad2241836485e0bf264bdfb62fd789</data>
    </edge>
    <edge source="RS2205960" target="DIFFUSE SYSTEMIC SCLEROSIS">
      <data key="d4">12.0</data>
      <data key="d5">SNP rs2205960 is associated with diffuse systemic sclerosis</data>
      <data key="d6">40ad2241836485e0bf264bdfb62fd789</data>
    </edge>
    <edge source="RS844648" target="DSSC">
      <data key="d4">7.0</data>
      <data key="d5">SNP rs844648 is more common in diffuse systemic sclerosis compared to controls</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="RS844648" target="ARA">
      <data key="d4">7.0</data>
      <data key="d5">SNP rs844648 is associated with ARA-positive systemic sclerosis</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="RS844648" target="ACA">
      <data key="d4">5.0</data>
      <data key="d5">SNP rs844648 is not significantly associated with ACA-positive systemic sclerosis</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="RS844648" target="PULMONARY FIBROSIS">
      <data key="d4">5.0</data>
      <data key="d5">SNP rs844648 is not significantly associated with pulmonary fibrosis in systemic sclerosis</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="RS844648" target="LIMITED SYSTEMIC SCLEROSIS">
      <data key="d4">12.0</data>
      <data key="d5">SNP rs844648 is associated with limited systemic sclerosis</data>
      <data key="d6">40ad2241836485e0bf264bdfb62fd789</data>
    </edge>
    <edge source="RS844648" target="DIFFUSE SYSTEMIC SCLEROSIS">
      <data key="d4">12.0</data>
      <data key="d5">SNP rs844648 is associated with diffuse systemic sclerosis</data>
      <data key="d6">40ad2241836485e0bf264bdfb62fd789</data>
    </edge>
    <edge source="RS844644" target="DSSC">
      <data key="d4">7.0</data>
      <data key="d5">SNP rs844644 is less common in diffuse systemic sclerosis compared to controls</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="RS844644" target="ACA">
      <data key="d4">5.0</data>
      <data key="d5">SNP rs844644 is not significantly associated with ACA-positive systemic sclerosis</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="RS844644" target="ATA">
      <data key="d4">5.0</data>
      <data key="d5">SNP rs844644 is not significantly associated with ATA-positive systemic sclerosis</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="RS844644" target="ARA">
      <data key="d4">5.0</data>
      <data key="d5">SNP rs844644 is not significantly associated with ARA-positive systemic sclerosis</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="RS844644" target="PULMONARY FIBROSIS">
      <data key="d4">5.0</data>
      <data key="d5">SNP rs844644 is not significantly associated with pulmonary fibrosis in systemic sclerosis</data>
      <data key="d6">c69c7fb997f95c56cc077b3975f41923</data>
    </edge>
    <edge source="RS844644" target="LIMITED SYSTEMIC SCLEROSIS">
      <data key="d4">12.0</data>
      <data key="d5">SNP rs844644 is associated with limited systemic sclerosis</data>
      <data key="d6">40ad2241836485e0bf264bdfb62fd789</data>
    </edge>
    <edge source="RS844644" target="DIFFUSE SYSTEMIC SCLEROSIS">
      <data key="d4">12.0</data>
      <data key="d5">SNP rs844644 is associated with diffuse systemic sclerosis</data>
      <data key="d6">40ad2241836485e0bf264bdfb62fd789</data>
    </edge>
    <edge source="PTPN22" target="TIDM">
      <data key="d4">16.0</data>
      <data key="d5">PTPN22 is associated with type I diabetes mellitus</data>
      <data key="d6">04bc518ea94163a4c2e74dcf1f885d14</data>
    </edge>
    <edge source="ANTINUCLEAR ANTIBODIES" target="HEP-2 CELLS">
      <data key="d4">16.0</data>
      <data key="d5">HEp-2 cells were used as an antigen substrate to test for antinuclear antibodies</data>
      <data key="d6">f9c444698bb08349abe4244fb771c1ee</data>
    </edge>
    <edge source="HEP-2 CELLS" target="ANTI-CENTROMERE ANTIBODIES">
      <data key="d4">16.0</data>
      <data key="d5">HEp-2 cells were used to identify anti-centromere antibodies</data>
      <data key="d6">f9c444698bb08349abe4244fb771c1ee</data>
    </edge>
    <edge source="TOPOISOMERASE I" target="ANTI-RNA POLYMERASE III ANTIBODIES">
      <data key="d4">12.0</data>
      <data key="d5">Topoisomerase I and anti-RNA polymerase III antibodies were determined by different assays</data>
      <data key="d6">f9c444698bb08349abe4244fb771c1ee</data>
    </edge>
    <edge source="PERIPHERAL BLOOD" target="GENOMIC DNA">
      <data key="d4">14.0</data>
      <data key="d5">Genomic DNA was extracted from peripheral blood</data>
      <data key="d6">f9c444698bb08349abe4244fb771c1ee</data>
    </edge>
    <edge source="GENOMIC DNA" target="HAPMAP">
      <data key="d4">12.0</data>
      <data key="d5">HapMap data was used for allele call validation</data>
      <data key="d6">f9c444698bb08349abe4244fb771c1ee</data>
    </edge>
    <edge source="GENOMIC DNA" target="CEPH">
      <data key="d4">12.0</data>
      <data key="d5">CEPH samples were used as positive controls in genotyping assays</data>
      <data key="d6">f9c444698bb08349abe4244fb771c1ee</data>
    </edge>
    <edge source="CAUCASIAN" target="HWE">
      <data key="d4">12.0</data>
      <data key="d5">HWE testing was performed on SNPs in Caucasian controls</data>
      <data key="d6">f9c444698bb08349abe4244fb771c1ee</data>
    </edge>
    <edge source="HWE" target="LD">
      <data key="d4">14.0</data>
      <data key="d5">HWE and LD were calculated for TNFSF4 SNPs</data>
      <data key="d6">f9c444698bb08349abe4244fb771c1ee</data>
    </edge>
    <edge source="OMNIBUS TEST" target="CART">
      <data key="d4">2.0</data>
      <data key="d5">Omnibus test and CART analysis were used to explore SNP interactions</data>
      <data key="d6">f9c444698bb08349abe4244fb771c1ee</data>
    </edge>
    <edge source="PULMONARY FIBROSIS" target="LUNGS">
      <data key="d4">8.0</data>
      <data key="d5">Pulmonary fibrosis affects the lungs</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="PULMONARY FIBROSIS" target="BLEOMYCIN">
      <data key="d4">16.0</data>
      <data key="d5">Bleomycin is used to induce pulmonary fibrosis in mouse models</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="PULMONARY FIBROSIS" target="TNF-/-">
      <data key="d4">14.0</data>
      <data key="d5">TNF-/- mice are protected from pulmonary fibrosis</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="PULMONARY FIBROSIS" target="TNFTM/TM">
      <data key="d4">14.0</data>
      <data key="d5">TNFtm/tm mice are protected from pulmonary fibrosis</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="PULMONARY FIBROSIS" target="GITR">
      <data key="d4">1.0</data>
      <data key="d5">GITR signaling is implicated in the development of pulmonary fibrosis</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="SNPS" target="GENOTYPING">
      <data key="d4">7.0</data>
      <data key="d5">Higher resolution genotyping will help identify SNPs involved in SSc pathogenesis</data>
      <data key="d6">7b454335c2f5651d86f712037a0dc0ff</data>
    </edge>
    <edge source="SNPS" target="DNA SEQUENCING">
      <data key="d4">7.0</data>
      <data key="d5">DNA sequencing of the TNFSF4 gene region will help identify SNPs involved in SSc</data>
      <data key="d6">7b454335c2f5651d86f712037a0dc0ff</data>
    </edge>
    <edge source="LUNGS" target="IDIOPATHIC PULMONARY FIBROSIS">
      <data key="d4">8.0</data>
      <data key="d5">Idiopathic pulmonary fibrosis affects the lungs</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="LUNGS" target="ACUTE RESPIRATORY DISTRESS SYNDROME">
      <data key="d4">8.0</data>
      <data key="d5">Acute respiratory distress syndrome affects the lungs</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="LUNGS" target="CYSTIC FIBROSIS">
      <data key="d4">8.0</data>
      <data key="d5">Cystic fibrosis affects the lungs</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="HEART" target="MYOCARDITIS">
      <data key="d4">8.0</data>
      <data key="d5">Myocarditis affects the heart</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="HEART" target="ISCHEMIC MYOCARDIAL INFARCTION">
      <data key="d4">8.0</data>
      <data key="d5">Ischemic myocardial infarction affects the heart</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="HEART" target="NON-ISCHEMIC HYPERTROPHIC CARDIOMYOPATHY">
      <data key="d4">8.0</data>
      <data key="d5">Non-ischemic hypertrophic cardiomyopathy affects the heart</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="HEART" target="TNFR1">
      <data key="d4">8.0</data>
      <data key="d5">TNFR1 signaling is essential for cardiac fibrosis</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="KIDNEY" target="ACUTE KIDNEY INJURY">
      <data key="d4">8.0</data>
      <data key="d5">Acute kidney injury affects the kidney</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="KIDNEY" target="CHRONIC KIDNEY DISEASE">
      <data key="d4">8.0</data>
      <data key="d5">Chronic kidney disease affects the kidney</data>
      <data key="d6">080b1dc5fcc0eee3645a06983a0de603</data>
    </edge>
    <edge source="MYOFIBROBLASTS" target="TAPI-1">
      <data key="d4">14.0</data>
      <data key="d5">TAPI-1 reduces the number of myofibroblasts</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="MYOFIBROBLASTS" target="TL1A">
      <data key="d4">8.0</data>
      <data key="d5">TL1A induces differentiation of lung fibroblasts to myofibroblasts</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="TNFR1" target="CELL DEATH">
      <data key="d4">7.0</data>
      <data key="d5">TNFR1 has potential to induce cell death response</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TNFR1" target="TACE">
      <data key="d4">8.0</data>
      <data key="d5">TACE processes soluble TNFR1</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TNFR1" target="DERMAL T CELLS">
      <data key="d4">16.0</data>
      <data key="d5">TNFR1 is upregulated on dermal T cells from patients with diffuse cutaneous SSc</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TNFR1" target="SOLUBLE TNFR1">
      <data key="d4">9.0</data>
      <data key="d5">Elevated serum concentration of soluble TNFR1 correlates with SSc disease severity</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TNFR1" target="LIVER FIBROSIS">
      <data key="d4">24.0</data>
      <data key="d5">TNFR1 plays a key role in liver fibrosis formationTNFR1 inhibition reduces liver fibrosis</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="TNFR1" target="NAFLD">
      <data key="d4">16.0</data>
      <data key="d5">TNFR1 inhibition reduces NAFLD activity</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="TNFR1" target="LT&#913;3">
      <data key="d4">7.0</data>
      <data key="d5">LT&#945;3 signals through TNFR1</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="TNFR1" target="CARDIAC FIBROSIS">
      <data key="d4">26.0</data>
      <data key="d5">TNFR1-KO mice show reduced cardiac fibrosis
TNFR1 signaling is essential for cardiac fibrosis</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51,df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="TNFR1" target="CARDIAC TISSUE">
      <data key="d4">8.0</data>
      <data key="d5">TNFR1 signaling is essential for decreasing cardiac collagen deposition</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="TNFR1" target="CD34+CD45+ MONOCYTIC CELLS">
      <data key="d4">7.0</data>
      <data key="d5">TNFR1 signaling is essential for reducing CD34+CD45+ monocytic infiltration</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="TNFR1" target="M2-LIKE CELLS">
      <data key="d4">16.0</data>
      <data key="d5">TNFR1 signaling is essential for the presence of pro-fibrotic M2-like cells</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="TNFR1" target="M1-LIKE CELLS">
      <data key="d4">12.0</data>
      <data key="d5">TNFR1 signaling does not affect early pro-inflammatory M1-like cells</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="TNFR1" target="WT-BONE MARROW">
      <data key="d4">14.0</data>
      <data key="d5">Reconstitution with WT-bone marrow restores TNFR1 signaling</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="TNFR2" target="TRAF1">
      <data key="d4">8.0</data>
      <data key="d5">TNFR2 recruits TRAF1</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TNFR2" target="TRAF2">
      <data key="d4">8.0</data>
      <data key="d5">TNFR2 recruits TRAF2</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TNFR2" target="DERMAL T CELLS">
      <data key="d4">16.0</data>
      <data key="d5">TNFR2 is upregulated on dermal T cells from patients with diffuse cutaneous SSc</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TNFR2" target="CD4+CD25+ T-CELL">
      <data key="d4">14.0</data>
      <data key="d5">Impaired TNF/TNFR2 signaling inhibits CD4+CD25+ T-cell differentiation</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TNFR2" target="HYPERSENSITIVITY PNEUMONITIS">
      <data key="d4">14.0</data>
      <data key="d5">TNFR2 signaling is elevated in fibrotic samples of hypersensitivity pneumonitis</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TNFR2" target="STNF">
      <data key="d4">7.0</data>
      <data key="d5">sTNF is upregulated in non-fibrotic HP patients</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="TNFR2" target="INTESTINAL MYOFIBROBLASTS">
      <data key="d4">8.0</data>
      <data key="d5">TNFR2 mediates TNF-induced proliferation and collagen accumulation in intestinal myofibroblasts</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="TNFR2" target="CARDIAC FIBROSIS">
      <data key="d4">19.0</data>
      <data key="d5">TNFR2-KO mice do not show reduced cardiac fibrosis
TNFR2 does not significantly affect cardiac fibrosis</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51,df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="TNFR2" target="AKT PATHWAY">
      <data key="d4">14.0</data>
      <data key="d5">TNFR2 activates the AKT pathway</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="TNFR2" target="NF-&#922;B PATHWAY">
      <data key="d4">14.0</data>
      <data key="d5">TNFR2 inhibits the NF-&#954;B pathway</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="NK CELLS" target="GITR">
      <data key="d4">18.0</data>
      <data key="d5">GITR may be found on activated NK cells
GITR is expressed on activated NK cells</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9,d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="IDIOPATHIC PULMONARY FIBROSIS" target="LIGHT">
      <data key="d4">30.0</data>
      <data key="d5">LIGHT is induced in idiopathic pulmonary fibrosis
LIGHT is induced in IPF and regulates fibrosis in the lungs</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2,df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="IDIOPATHIC PULMONARY FIBROSIS" target="TNFR2-FC">
      <data key="d4">7.0</data>
      <data key="d5">TNFR2-Fc is used in clinical trials to treat Idiopathic Pulmonary Fibrosis</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="ACUTE RESPIRATORY DISTRESS SYNDROME" target="LIGHT">
      <data key="d4">14.0</data>
      <data key="d5">Elevated LIGHT is associated with ARDS in bacterial sepsis</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2</data>
    </edge>
    <edge source="MYOCARDITIS" target="CVD">
      <data key="d4">7.0</data>
      <data key="d5">Myocarditis is a type of cardiovascular disease</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="DUPUYTREN&#8217;S DISEASE" target="ANTI-TNF THERAPY">
      <data key="d4">8.0</data>
      <data key="d5">Anti-TNF therapy is used to treat Dupuytren&#8217;s disease</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="DUPUYTREN&#8217;S DISEASE" target="NCT03180957">
      <data key="d4">7.0</data>
      <data key="d5">NCT03180957 is a clinical trial targeting Dupuytren&#8217;s disease</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="ACUTE KIDNEY INJURY" target="LIGHT">
      <data key="d4">14.0</data>
      <data key="d5">Elevated LIGHT is associated with AKI in bacterial sepsis</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2</data>
    </edge>
    <edge source="NON-ALCOHOLIC FATTY LIVER DISEASE" target="LIGHT">
      <data key="d4">28.0</data>
      <data key="d5">LIGHT is induced in non-alcoholic fatty liver disease
LIGHT is induced in NAFLD and regulates liver fibrosis</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2,df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="NON-ALCOHOLIC FATTY LIVER DISEASE" target="HVEM">
      <data key="d4">12.0</data>
      <data key="d5">HVEM mRNA expression is increased in NAFLD tissue</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2</data>
    </edge>
    <edge source="NON-ALCOHOLIC FATTY LIVER DISEASE" target="LT&#914;R">
      <data key="d4">2.0</data>
      <data key="d5">LT&#946;R mRNA expression is increased in NAFLD tissue</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2</data>
    </edge>
    <edge source="PRIMARY BILIARY CHOLANGITIS" target="RANKL">
      <data key="d4">1.0</data>
      <data key="d5">RANKL is upregulated in primary biliary cholangitis</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="FR1" target="TRADD">
      <data key="d4">8.0</data>
      <data key="d5">FR1 recruits TRADD</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TACE" target="TAPI-1">
      <data key="d4">16.0</data>
      <data key="d5">TAPI-1 blocks TACE</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TACE" target="SOLUBLE TNFR1">
      <data key="d4">8.0</data>
      <data key="d5">TACE processes soluble TNFR1</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TACE" target="STNF">
      <data key="d4">8.0</data>
      <data key="d5">TACE cleaves mTNF to release sTNF</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="TAPI-1" target="COL1A1">
      <data key="d4">14.0</data>
      <data key="d5">TAPI-1 reduces mRNA expression of Col1a1</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TAPI-1" target="&#913;SMA">
      <data key="d4">14.0</data>
      <data key="d5">TAPI-1 reduces mRNA expression of &#945;SMA</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="&#913;SMA" target="TGF&#914;1">
      <data key="d4">8.0</data>
      <data key="d5">TGF&#946;1 increases &#945;SMA expression</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="&#913;SMA" target="LIGHT">
      <data key="d4">21.0</data>
      <data key="d5">LIGHT induces &#945;SMA accumulation
LIGHT increases &#945;SMA expression in murine hepatic fibroblasts</data>
      <data key="d6">05c97152fe02249153103be341d65b67,5f37466ca41c9b8b06ed8be0303d49f2</data>
    </edge>
    <edge source="&#913;SMA" target="LIVER FIBROSIS">
      <data key="d4">7.0</data>
      <data key="d5">&#945;SMA is used as a marker to measure liver fibrosis</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="IPF" target="STNFR1">
      <data key="d4">14.0</data>
      <data key="d5">sTNFR1 is increased in the fibroblast supernatant from IPF patients</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="BLEOMYCIN" target="MLE-12 CELLS">
      <data key="d4">7.0</data>
      <data key="d5">Bleomycin is used to treat MLE-12 cells to induce cell injury</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="BALF" target="GITR">
      <data key="d4">6.0</data>
      <data key="d5">GITR-/- BALF has lower cellularity compared to GITR+/+ BALF</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="SOLUBLE TNFR1" target="BLEOMYCIN-INDUCED MURINE MODEL">
      <data key="d4">8.0</data>
      <data key="d5">Soluble TNFR1 levels are increased in the bleomycin-induced murine model of SSc</data>
      <data key="d6">5ec1ebf4e260eb1f8fda8acdf06cd39e</data>
    </edge>
    <edge source="TGF-&#914;1" target="DERMAL MYOFIBROBLASTS">
      <data key="d4">8.0</data>
      <data key="d5">TGF-&#946;1 induces dermal myofibroblasts transdifferentiation</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="LIVER FIBROSIS" target="TL1A">
      <data key="d4">7.0</data>
      <data key="d5">TL1A is associated with liver fibrosis</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="LIVER FIBROSIS" target="PEGYLATED TRAIL">
      <data key="d4">8.0</data>
      <data key="d5">PEGylated TRAIL is used to treat liver fibrosis</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="LIVER FIBROSIS" target="COLLAGEN DEPOSITION">
      <data key="d4">7.0</data>
      <data key="d5">Collagen deposition is a marker of liver fibrosis</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="NAFLD" target="HFD">
      <data key="d4">7.0</data>
      <data key="d5">HFD is used to induce NAFLD in experimental models</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="NAFLD" target="LIGHT">
      <data key="d4">7.0</data>
      <data key="d5">Serum LIGHT is significantly increased in NAFLD patients</data>
      <data key="d6">05c97152fe02249153103be341d65b67</data>
    </edge>
    <edge source="NAFLD" target="HVEM">
      <data key="d4">6.0</data>
      <data key="d5">HVEM mRNA expression is significantly increased in NAFLD tissue</data>
      <data key="d6">05c97152fe02249153103be341d65b67</data>
    </edge>
    <edge source="NAFLD" target="LT&#914;R">
      <data key="d4">6.0</data>
      <data key="d5">LT&#946;R mRNA expression is significantly increased in NAFLD tissue</data>
      <data key="d6">05c97152fe02249153103be341d65b67</data>
    </edge>
    <edge source="CARDIAC INFLAMMATION" target="CVD">
      <data key="d4">7.0</data>
      <data key="d5">Cardiac inflammation is a common feature of many cardiovascular diseases</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="CVD" target="MI">
      <data key="d4">7.0</data>
      <data key="d5">Myocardial infarction is a type of cardiovascular disease</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="CVD" target="HCM">
      <data key="d4">7.0</data>
      <data key="d5">Hypertrophic cardiomyopathy is a type of cardiovascular disease</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="CVD" target="HF">
      <data key="d4">7.0</data>
      <data key="d5">Heart failure is a type of cardiovascular disease</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="MI" target="ISCHEMIC CARDIOMYOPATHY">
      <data key="d4">18.0</data>
      <data key="d5">Myocardial infarction is a form of ischemic cardiomyopathy</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="MI" target="NECROSIS">
      <data key="d4">18.0</data>
      <data key="d5">Myocardial infarction is characterized by cardiomyocyte necrosis</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="MI" target="POST-MI HF">
      <data key="d4">16.0</data>
      <data key="d5">Heart failure can develop after a myocardial infarction</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="MI" target="LEFT CORONARY ARTERY">
      <data key="d4">14.0</data>
      <data key="d5">Myocardial infarction can be induced by ligating the left coronary artery</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="MI" target="VENTRICULAR DILATATION">
      <data key="d4">14.0</data>
      <data key="d5">Loss of TNFR2 signal exaggerates ventricular dilatation after MI</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="MI" target="LT&#913;">
      <data key="d4">16.0</data>
      <data key="d5">LT&#945; levels increase after myocardial infarction</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="MI" target="OPG">
      <data key="d4">14.0</data>
      <data key="d5">OPG levels are significantly higher in patients with chronic fibrosis after myocardial infarction</data>
      <data key="d6">d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="HCM" target="ANG II">
      <data key="d4">7.0</data>
      <data key="d5">Ang II induces HCM in a mouse model</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="HCM" target="NON-ISCHEMIC CARDIOMYOPATHY">
      <data key="d4">16.0</data>
      <data key="d5">Hypertrophic cardiomyopathy is a form of non-ischemic cardiomyopathy</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="HCM" target="AORTIC VALVE STENOSIS">
      <data key="d4">14.0</data>
      <data key="d5">Aortic valve stenosis can induce hypertrophic cardiomyopathy</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="HCM" target="CARDIAC HYPERTROPHY">
      <data key="d4">16.0</data>
      <data key="d5">Hypertrophic cardiomyopathy is characterized by cardiac hypertrophy</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="HCM" target="VASCULAR RAREFACTION">
      <data key="d4">14.0</data>
      <data key="d5">Hypertrophic cardiomyopathy is characterized by vascular rarefaction</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="HF" target="ISCHEMIC CARDIOMYOPATHY">
      <data key="d4">16.0</data>
      <data key="d5">Ischemic cardiomyopathy can lead to heart failure</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="HF" target="NON-ISCHEMIC CARDIOMYOPATHY">
      <data key="d4">16.0</data>
      <data key="d5">Non-ischemic cardiomyopathy can lead to heart failure</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="HF" target="OPG">
      <data key="d4">14.0</data>
      <data key="d5">Higher OPG levels are associated with increased left ventricular mass index and myocardial stiffness in HF patients</data>
      <data key="d6">d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="LT&#913;3" target="INFLAMMATORY DISEASES">
      <data key="d4">8.0</data>
      <data key="d5">LT&#945;3 signals through TNFR1 and has unique roles in initiation and exacerbation of some inflammatory diseasesLT&#945;3 has unique roles in initiation and exacerbation of some inflammatory diseases</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="ANG II" target="CARDIAC FIBROSIS">
      <data key="d4">7.0</data>
      <data key="d5">Ang II induces the development of cardiac fibrosis</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="CARDIAC FIBROSIS" target="TNFR1-KO">
      <data key="d4">7.0</data>
      <data key="d5">TNFR1-KO mice show reduced cardiac fibrosis</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="CARDIAC FIBROSIS" target="TNFR2-KO">
      <data key="d4">7.0</data>
      <data key="d5">TNFR2-KO mice do not show reduced cardiac fibrosis</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="CARDIAC FIBROSIS" target="DOUBLE RECEPTOR KNOCKOUT">
      <data key="d4">8.0</data>
      <data key="d5">Double receptor knockout mice are protected from cardiac fibrosis</data>
      <data key="d6">a10787d7fbb1307be263e86dc7b33a51</data>
    </edge>
    <edge source="CARDIAC FIBROSIS" target="ANG-II">
      <data key="d4">16.0</data>
      <data key="d5">Ang-II induces the development of cardiac fibrosis</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="CARDIAC FIBROSIS" target="OPG">
      <data key="d4">16.0</data>
      <data key="d5">OPG pathways are involved in the pathology of cardiac fibrosis</data>
      <data key="d6">d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="CARDIAC FIBROSIS" target="PROCOLLAGEN &#913;1">
      <data key="d4">12.0</data>
      <data key="d5">Inactivation of procollagen &#945;1 synthesis is associated with less interstitial cardiac fibrosis</data>
      <data key="d6">d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="LIGHT" target="HVEM">
      <data key="d4">41.0</data>
      <data key="d5">LIGHT binds to HVEM
LIGHT acts through HVEM to regulate fibrosis
LIGHT binds to HVEM</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2,c95d22c2a90e77cd22bd0d280d55b26a,df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="LIGHT" target="LT&#914;R">
      <data key="d4">34.0</data>
      <data key="d5">LIGHT binds to LT&#946;R
LIGHT acts through LT&#946;R to regulate fibrosis</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2,df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="LIGHT" target="DCR3">
      <data key="d4">16.0</data>
      <data key="d5">LIGHT binds to DcR3</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="LIGHT" target="FIBROPROLIFERATIVE">
      <data key="d4">14.0</data>
      <data key="d5">LIGHT is involved in fibroproliferative diseases</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="LIGHT" target="HVEM-L">
      <data key="d4">18.0</data>
      <data key="d5">HVEM-L is another name for LIGHT</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="LIGHT" target="CD258">
      <data key="d4">18.0</data>
      <data key="d5">CD258 is another name for LIGHT</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="LIGHT" target="ACUTE HYPOXIC RESPIRATORY FAILURE">
      <data key="d4">14.0</data>
      <data key="d5">Elevated LIGHT is associated with AHRF in bacterial sepsis</data>
      <data key="d6">5f37466ca41c9b8b06ed8be0303d49f2</data>
    </edge>
    <edge source="LIGHT" target="NASH">
      <data key="d4">7.0</data>
      <data key="d5">LIGHT is involved in the transition from NAFLD to NASH</data>
      <data key="d6">05c97152fe02249153103be341d65b67</data>
    </edge>
    <edge source="LIGHT" target="HEPATIC STEATOSIS">
      <data key="d4">7.0</data>
      <data key="d5">Genetic deletion of LIGHT results in reduced hepatic steatosis</data>
      <data key="d6">05c97152fe02249153103be341d65b67</data>
    </edge>
    <edge source="LIGHT" target="EOE">
      <data key="d4">7.0</data>
      <data key="d5">LIGHT promotes inflammation and remodeling in eosinophilic esophagitis</data>
      <data key="d6">05c97152fe02249153103be341d65b67</data>
    </edge>
    <edge source="LIGHT" target="ICAM-1">
      <data key="d4">6.0</data>
      <data key="d5">LIGHT controls tethering of eosinophils to fibroblasts via ICAM-1</data>
      <data key="d6">05c97152fe02249153103be341d65b67</data>
    </edge>
    <edge source="LIGHT" target="CKD">
      <data key="d4">7.0</data>
      <data key="d5">LIGHT is implicated in the development of renal fibrosis in chronic kidney disease</data>
      <data key="d6">05c97152fe02249153103be341d65b67</data>
    </edge>
    <edge source="LIGHT" target="UUO">
      <data key="d4">7.0</data>
      <data key="d5">Genetic deletion of LIGHT reduces renal fibrosis in UUO-induced mice</data>
      <data key="d6">05c97152fe02249153103be341d65b67</data>
    </edge>
    <edge source="LIGHT" target="LDO">
      <data key="d4">6.0</data>
      <data key="d5">LIGHT plays a significant role in connective tissue remodeling in primary acquired lacrimal duct obstruction</data>
      <data key="d6">05c97152fe02249153103be341d65b67</data>
    </edge>
    <edge source="LIGHT" target="CBS001">
      <data key="d4">8.0</data>
      <data key="d5">CBS001 is an anti-LIGHT monoclonal antibody</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="LIGHT" target="GRANULOCYTES">
      <data key="d4">16.0</data>
      <data key="d5">LIGHT can act on granulocytes to drive pro-fibrotic and anti-fibrotic effects
LIGHT acts on granulocytes to drive pro-fibrotic and anti-fibrotic effects</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a,68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="HVEM" target="TNFRSF14">
      <data key="d4">18.0</data>
      <data key="d5">TNFRSF14 is the gene encoding HVEM</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="HVEM" target="LDO">
      <data key="d4">6.0</data>
      <data key="d5">HVEM is expressed in lacrimal sac walls and correlates with fibrosis severity</data>
      <data key="d6">05c97152fe02249153103be341d65b67</data>
    </edge>
    <edge source="LT&#914;R" target="TNFRSF3">
      <data key="d4">18.0</data>
      <data key="d5">TNFRSF3 is the gene encoding LT&#946;R</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="LT&#914;R" target="LDO">
      <data key="d4">6.0</data>
      <data key="d5">LT&#946;R is expressed in lacrimal sac walls and correlates with fibrosis severity</data>
      <data key="d6">05c97152fe02249153103be341d65b67</data>
    </edge>
    <edge source="LT&#914;R" target="BAMINERCEPT">
      <data key="d4">16.0</data>
      <data key="d5">Baminercept is a lymphotoxin-beta receptor fusion protein</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="DCR3" target="TNFRSF6B">
      <data key="d4">2.0</data>
      <data key="d5">TNFRSF6B is the gene encoding DcR3</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="DCR3" target="TL1A">
      <data key="d4">6.0</data>
      <data key="d5">TL1A signal can be neutralized by its soluble decoy receptor, DcR3</data>
      <data key="d6">05c97152fe02249153103be341d65b67</data>
    </edge>
    <edge source="FIBROPROLIFERATIVE" target="CONNECTIVE TISSUE">
      <data key="d4">14.0</data>
      <data key="d5">Fibroproliferative diseases affect connective tissue</data>
      <data key="d6">df74aa1b86eeeb811ca5586767ae3a71</data>
    </edge>
    <edge source="NASH" target="SERUM BAFF LEVELS">
      <data key="d4">8.0</data>
      <data key="d5">Elevated serum BAFF levels are associated with NASH severity</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="SIMPLE STEATOSIS" target="SERUM BAFF LEVELS">
      <data key="d4">7.0</data>
      <data key="d5">Serum BAFF levels help distinguish NASH from simple steatosis</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="EOE" target="TRAIL">
      <data key="d4">15.0</data>
      <data key="d5">TRAIL is significantly upregulated in EoE patients
TRAIL expression is required for esophageal remodeling in EoE</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a,d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="EOE" target="A FUMIGATUS">
      <data key="d4">6.0</data>
      <data key="d5">A fumigatus is used in a mouse model to study EoE</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="EOE" target="ESOPHAGUS">
      <data key="d4">7.0</data>
      <data key="d5">The esophagus is the tissue affected in eosinophilic esophagitis</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="EOE" target="ESOPHAGEAL EOSINOPHIL">
      <data key="d4">7.0</data>
      <data key="d5">Esophageal eosinophils are involved in the inflammation of the esophagus in EoE</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="EOE" target="ESOPHAGEAL CIRCUMFERENCE">
      <data key="d4">6.0</data>
      <data key="d5">Enlargement of the esophageal circumference is a symptom of EoE</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="EOE" target="ESOPHAGEAL REMODELING">
      <data key="d4">6.0</data>
      <data key="d5">Esophageal remodeling is a histological change observed in EoE</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="TL1A" target="DR3">
      <data key="d4">23.0</data>
      <data key="d5">TL1A signals through DR3 to induce the NF-kB pathway
TL1A-DR3 signaling promotes fibrosis
TL1A binds to DR3</data>
      <data key="d6">05c97152fe02249153103be341d65b67,c525762bb827485bceeb9f09bb4bcfe0,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="TL1A" target="COLITIS">
      <data key="d4">15.0</data>
      <data key="d5">Blocking TL1A signaling attenuates pathology in colitis models
TL1A is targeted by anti-TL1A antibody in the treatment of colitis</data>
      <data key="d6">05c97152fe02249153103be341d65b67,c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="TL1A" target="TRANSGENIC MICE">
      <data key="d4">6.0</data>
      <data key="d5">Transgenic mice expressing membrane-restricted TL1A show elevated proinflammatory cytokines</data>
      <data key="d6">05c97152fe02249153103be341d65b67</data>
    </edge>
    <edge source="TL1A" target="SMALL INTESTINE">
      <data key="d4">6.0</data>
      <data key="d5">Membrane-restricted TL1A in the small intestine primarily activates T cells</data>
      <data key="d6">05c97152fe02249153103be341d65b67</data>
    </edge>
    <edge source="TL1A" target="BOWEL">
      <data key="d4">9.0</data>
      <data key="d5">Soluble TL1A leads to bowel pathology
TL1A is associated with pathology of the bowel</data>
      <data key="d6">05c97152fe02249153103be341d65b67,c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="TL1A" target="HDM">
      <data key="d4">7.0</data>
      <data key="d5">TL1A-driven inflammation is studied using HDM as an airway irritant</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="TL1A" target="MUCUS">
      <data key="d4">8.0</data>
      <data key="d5">TL1A-driven IL-13 signaling increases mucus production</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="TL1A" target="INTESTINAL INFLAMMATION">
      <data key="d4">8.0</data>
      <data key="d5">TL1A is associated with intestinal inflammation</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="TL1A" target="INTESTINAL FIBROSIS">
      <data key="d4">8.0</data>
      <data key="d5">TL1A is associated with intestinal fibrosis</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="TL1A" target="MACROPHAGE RECRUITMENT">
      <data key="d4">7.0</data>
      <data key="d5">TL1A promotes macrophage recruitment</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="TL1A" target="PRA023">
      <data key="d4">16.0</data>
      <data key="d5">PRA023 is an anti-TL1A monoclonal antibody</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="TL1A" target="ANTI-TL1A MAB">
      <data key="d4">9.0</data>
      <data key="d5">Anti-TL1A mAb targets the TL1A protein</data>
      <data key="d6">423195c6b63ad0a6773374364ebf3612</data>
    </edge>
    <edge source="TL1A" target="TNFSF15">
      <data key="d4">9.0</data>
      <data key="d5">TL1A is encoded by the TNFSF15 gene</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </edge>
    <edge source="DR3" target="COLONIC FIBROBLASTS">
      <data key="d4">8.0</data>
      <data key="d5">DR3 signaling on colonic fibroblasts promotes intestinal fibrosis</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="DR3" target="PTX-35">
      <data key="d4">16.0</data>
      <data key="d5">PTX-35 is an anti-DR3 monoclonal antibody</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="ANTI-TL1A ANTIBODY" target="MMP7">
      <data key="d4">7.0</data>
      <data key="d5">Anti-TL1A antibody reduces expression of MMP7</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="ANTI-TL1A ANTIBODY" target="MMP10">
      <data key="d4">7.0</data>
      <data key="d5">Anti-TL1A antibody reduces expression of MMP10</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="TISSUE REMODELING" target="TNFSF MEMBERS">
      <data key="d4">17.0</data>
      <data key="d5">TNFSF members are involved in driving tissue remodelingTNFSF members are implicated in driving tissue remodeling</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </edge>
    <edge source="TACI" target="M1 POLARIZATION">
      <data key="d4">7.0</data>
      <data key="d5">TACI is involved in M1 polarization</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="SERUM BAFF LEVELS" target="HEPATOCYTE BALLOONING">
      <data key="d4">8.0</data>
      <data key="d5">Elevated serum BAFF levels are associated with hepatocyte ballooning</data>
      <data key="d6">c525762bb827485bceeb9f09bb4bcfe0</data>
    </edge>
    <edge source="RANKL" target="RANK">
      <data key="d4">15.0</data>
      <data key="d5">RANKL binds to RANK to activate and differentiate osteoclasts
RANKL binds to RANK</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="RANKL" target="OPG">
      <data key="d4">32.0</data>
      <data key="d5">OPG binds to RANKL, preventing RANKL/RANK interaction
OPG inhibits ECM degradation by blocking RANKL-RANK interactions
RANKL binds to OPG</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7,c95d22c2a90e77cd22bd0d280d55b26a,d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="RANKL" target="OSTEOCLAST">
      <data key="d4">24.0</data>
      <data key="d5">RANKL activates and differentiates osteoclasts
RANKL stimulates osteoclast formation</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7,d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="RANKL" target="ECM">
      <data key="d4">7.0</data>
      <data key="d5">Elevated levels of OPG can inhibit ECM degradation by blocking RANKL-RANK interactions</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="RANKL" target="PBC">
      <data key="d4">17.0</data>
      <data key="d5">RANKL is upregulated in multiple fibrotic liver diseases including PBC
RANKL is upregulated in PBC and may play a key role in its pathogenesis</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7,d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="RANKL" target="BONE">
      <data key="d4">8.0</data>
      <data key="d5">RANKL is involved in maintaining bone homeostasis</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="RANKL" target="BONE RESORPTION">
      <data key="d4">8.0</data>
      <data key="d5">RANKL activates osteoclasts to promote bone resorption</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="RANKL" target="CHOLANGIOCYTES">
      <data key="d4">14.0</data>
      <data key="d5">Cholangiocytes in PBC patients express elevated levels of RANKL</data>
      <data key="d6">d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="RANKL" target="LIVER CIRRHOSIS">
      <data key="d4">16.0</data>
      <data key="d5">RANKL expression is significantly elevated in the serum of patients with liver cirrhosis</data>
      <data key="d6">d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="RANKL" target="FIBROTIC LUNG DISEASE">
      <data key="d4">14.0</data>
      <data key="d5">The RANKL-RANK-OPG axis is implicated in fibrotic lung disease</data>
      <data key="d6">d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="RANKL" target="SILICOSIS">
      <data key="d4">16.0</data>
      <data key="d5">RANKL is involved in the pathogenesis of silicosis</data>
      <data key="d6">d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="RANKL" target="OSTEOBLASTS">
      <data key="d4">14.0</data>
      <data key="d5">Human osteoblasts with a CFTR mutation show RANKL overexpression</data>
      <data key="d6">d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="RANKL" target="DENOSUMAB">
      <data key="d4">9.0</data>
      <data key="d5">Denosumab targets RANKL in clinical trials</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="OPG" target="OSTEOCLAST">
      <data key="d4">7.0</data>
      <data key="d5">OPG inhibits osteoclast activation</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="OPG" target="OSTEOBLAST">
      <data key="d4">6.0</data>
      <data key="d5">OPG is expressed mostly by osteoblasts</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="OPG" target="BONE RESORPTION">
      <data key="d4">7.0</data>
      <data key="d5">OPG inhibits bone resorption by blocking RANKL-RANK interactions</data>
      <data key="d6">b2aae16813e647959b783a39ef9a19a7</data>
    </edge>
    <edge source="OPG" target="OSTEOBLASTS">
      <data key="d4">14.0</data>
      <data key="d5">Human osteoblasts with a CFTR mutation show decreased OPG production</data>
      <data key="d6">d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="OPG" target="TRAIL">
      <data key="d4">6.0</data>
      <data key="d5">TRAIL binds to OPG, a soluble decoy receptor</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="LIVER CIRRHOSIS" target="GITR">
      <data key="d4">8.0</data>
      <data key="d5">GITR is upregulated in patients with liver cirrhosis</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="CF" target="CFTR">
      <data key="d4">18.0</data>
      <data key="d5">CFTR mutation is associated with cystic fibrosis</data>
      <data key="d6">d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="GITR" target="CD25-CD4+ T CELLS">
      <data key="d4">21.0</data>
      <data key="d5">GITR is expressed by CD25-CD4+ T cells at a lower level
GITR is expressed at a lower level by resting CD25-CD4+ T cells</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9,d2c44662af9752fc9f82c86121ede7c0</data>
    </edge>
    <edge source="GITR" target="GITRL">
      <data key="d4">16.0</data>
      <data key="d5">GITR is activated by its ligand GITRL
GITRL binds to GITR</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9,c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="GITR" target="4-1BB">
      <data key="d4">6.0</data>
      <data key="d5">GITR possesses an intracellular domain with significant homology to 4-1BB</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="GITR" target="DTA-1">
      <data key="d4">8.0</data>
      <data key="d5">Stimulation of GITR with DTA-1 results in promotion of proliferative responses and cytokine production</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="GITR" target="FOXP3">
      <data key="d4">8.0</data>
      <data key="d5">GITR signaling dampens Foxp3-mediated suppressive action in Tregs</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="GITR" target="GITR-/- MICE">
      <data key="d4">7.0</data>
      <data key="d5">GITR-/- mice lack the GITR gene and are used to study GITR function</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="GITR" target="GITR+/+ MICE">
      <data key="d4">7.0</data>
      <data key="d5">GITR+/+ mice have normal GITR expression and are used as controls</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="GITR" target="FC-GITR FUSION PROTEIN">
      <data key="d4">7.0</data>
      <data key="d5">Fc-GITR fusion protein is used to disrupt GITRL/GITR signaling</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="GITR" target="MPO">
      <data key="d4">6.0</data>
      <data key="d5">GITR-/- mice show reduced MPO activity compared to GITR+/+ mice</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="GITR" target="CD25+CD4+ T CELLS">
      <data key="d4">9.0</data>
      <data key="d5">GITR is constitutively expressed by CD25+CD4+ T cells (Tregs) and plays a role in their function</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="GITR" target="ARTHRITIC MOUSE">
      <data key="d4">7.0</data>
      <data key="d5">GITR signaling was studied in arthritic mouse models</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="GITR" target="SYNOVIA">
      <data key="d4">7.0</data>
      <data key="d5">GITR signaling was studied in inflamed synovia</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="GITR" target="FIBROTIC MODELS">
      <data key="d4">7.0</data>
      <data key="d5">GITR signaling was studied in fibrotic models</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="GITR" target="GRANULOCYTES">
      <data key="d4">7.0</data>
      <data key="d5">GITR signaling affects granulocyte infiltration in lung tissue</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="GITR" target="TH2 CYTOKINE">
      <data key="d4">7.0</data>
      <data key="d5">GITR signaling influences Th2 cytokine production</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="GITR" target="TH1 CYTOKINE">
      <data key="d4">7.0</data>
      <data key="d5">GITR signaling does not influence Th1 cytokine production</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="GITR" target="LUNG INJURY">
      <data key="d4">8.0</data>
      <data key="d5">GITR signaling is implicated in lung injury</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="GITR" target="CELL INJURY">
      <data key="d4">7.0</data>
      <data key="d5">GITR signaling is implicated in cell injury</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="GITR" target="EPITHELIAL TO MESENCHYMAL TRANSITION (EMT)">
      <data key="d4">7.0</data>
      <data key="d5">GITR signaling is implicated in EMT</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="GITR" target="CIRRHOSIS">
      <data key="d4">8.0</data>
      <data key="d5">GITR is upregulated in patients with cirrhosis</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="GITR" target="HISTOLOGICAL SIGNS">
      <data key="d4">7.0</data>
      <data key="d5">GITR-/- mice show reduced histological signs of lung injury</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="GITR" target="PRO-INFLAMMATORY ENVIRONMENT">
      <data key="d4">8.0</data>
      <data key="d5">GITR signaling creates a pro-inflammatory environment</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="GITR" target="ANTI-INFLAMMATORY ENVIRONMENT">
      <data key="d4">1.0</data>
      <data key="d5">Disruption of GITR signaling creates an anti-inflammatory environment</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="MLE-12 CELLS" target="MENSC">
      <data key="d4">8.0</data>
      <data key="d5">MenSC reduce bleomycin-induced cell injury in MLE-12 cells</data>
      <data key="d6">7c13f41d7349d9d2e56c36e00c0ca2d9</data>
    </edge>
    <edge source="TRAIL" target="DR4">
      <data key="d4">25.0</data>
      <data key="d5">TRAIL binds to DR4 to induce apoptosis
TRAIL binds to DR4, initiating apoptosis
TRAIL binds to DR4</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd,c95d22c2a90e77cd22bd0d280d55b26a,d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="TRAIL" target="DR5">
      <data key="d4">25.0</data>
      <data key="d5">TRAIL binds to DR5 to induce apoptosis
TRAIL binds to DR5, initiating apoptosis
TRAIL binds to DR5</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd,c95d22c2a90e77cd22bd0d280d55b26a,d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="TRAIL" target="DCR1">
      <data key="d4">20.0</data>
      <data key="d5">TRAIL binds to DcR1 but does not induce apoptosis
TRAIL binds to DcR1, which lacks a death domain
TRAIL binds to DcR1</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd,c95d22c2a90e77cd22bd0d280d55b26a,d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="TRAIL" target="DCR2">
      <data key="d4">15.0</data>
      <data key="d5">TRAIL binds to DcR2 but does not induce apoptosis
TRAIL binds to DcR2, which has a truncated non-functional death domain
TRAIL binds to DcR2</data>
      <data key="d6">4cf23e218b6aab3c77115173b5c7c2fd,c95d22c2a90e77cd22bd0d280d55b26a,d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="TRAIL" target="AHSCS">
      <data key="d4">17.0</data>
      <data key="d5">TRAIL selectively targets aHSCs to treat liver fibrosis
TRAIL can induce apoptosis in aHSCs</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a,d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="TRAIL" target="MID-1">
      <data key="d4">7.0</data>
      <data key="d5">TRAIL upregulates MID-1 expression</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="TRAIL" target="CCL24">
      <data key="d4">7.0</data>
      <data key="d5">TRAIL is necessary for the upregulation of CCL24</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="TRAIL" target="TNFSF10">
      <data key="d4">9.0</data>
      <data key="d5">TRAIL is also known as TNFSF10</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="TRAIL" target="CD253">
      <data key="d4">9.0</data>
      <data key="d5">TRAIL is also known as CD253</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="TRAIL" target="APOPTOSIS">
      <data key="d4">1.0</data>
      <data key="d5">Apoptosis is induced by TRAIL</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="TRAIL" target="MFBS">
      <data key="d4">9.0</data>
      <data key="d5">TRAIL can induce apoptosis in MFBs</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="DR4" target="FADD">
      <data key="d4">8.0</data>
      <data key="d5">DR4 recruits FADD to form the death-inducing signaling complex</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="DR4" target="TNFRSF10A">
      <data key="d4">8.0</data>
      <data key="d5">DR4 is also known as TNFRSF10A</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="DR5" target="FADD">
      <data key="d4">8.0</data>
      <data key="d5">DR5 recruits FADD to form the death-inducing signaling complex</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="DR5" target="TNFRSF10B">
      <data key="d4">8.0</data>
      <data key="d5">DR5 is also known as TNFRSF10B</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="DCR1" target="TNFRSF10C">
      <data key="d4">7.0</data>
      <data key="d5">DcR1 is also known as TNFRSF10C</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="DCR2" target="TNFRSF10D">
      <data key="d4">7.0</data>
      <data key="d5">DcR2 is also known as TNFRSF10D</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="FADD" target="PROCASPASE-8">
      <data key="d4">8.0</data>
      <data key="d5">FADD recruits and activates procaspase-8</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="MID-1" target="PP2A">
      <data key="d4">7.0</data>
      <data key="d5">MID-1 inhibits PP2A activity</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="MID-1" target="SIRNA">
      <data key="d4">7.0</data>
      <data key="d5">siRNA targets MID-1 in TRAIL deficient mice</data>
      <data key="d6">d4797ed1483e5057bcd8301eaa509d5e</data>
    </edge>
    <edge source="LUMBAR SPINAL FIBROSIS" target="TNF BLOCKER">
      <data key="d4">8.0</data>
      <data key="d5">TNF blocker is used to treat lumbar spinal fibrosis</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="LUMBAR SPINAL FIBROSIS" target="ANTI-TNF THERAPY">
      <data key="d4">8.0</data>
      <data key="d5">Anti-TNF therapy is used to treat lumbar spinal fibrosis</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="LUMBAR SPINAL FIBROSIS" target="NCT00385086">
      <data key="d4">7.0</data>
      <data key="d5">NCT00385086 is a clinical trial targeting lumbar spinal fibrosis</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="LUMBAR SPINAL FIBROSIS" target="POST OPERATIVE SCIATICA">
      <data key="d4">7.0</data>
      <data key="d5">Post Operative Sciatica can be caused by Lumbar Spinal Fibrosis</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="ANTI-TNF THERAPY" target="NCT03747068">
      <data key="d4">14.0</data>
      <data key="d5">NCT03747068 is a clinical trial involving anti-TNF therapy</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="ANTI-TNF THERAPY" target="TNF BLOCKER">
      <data key="d4">8.0</data>
      <data key="d5">TNF blocker is a type of anti-TNF therapy</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="TNF BLOCKER" target="NCT00385086">
      <data key="d4">2.0</data>
      <data key="d5">NCT00385086 is a clinical trial involving TNF blocker</data>
      <data key="d6">c95d22c2a90e77cd22bd0d280d55b26a</data>
    </edge>
    <edge source="TNF BLOCKER" target="POST OPERATIVE SCIATICA">
      <data key="d4">7.0</data>
      <data key="d5">TNF blockers are used in clinical trials to treat Post Operative Sciatica</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="UNIVERSITY OF TORONTO" target="CROHN DISEASE">
      <data key="d4">6.0</data>
      <data key="d5">University of Toronto is involved in clinical trials for Crohn's disease</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="CBS001" target="CHRONIC INFLAMMATORY DISEASE">
      <data key="d4">7.0</data>
      <data key="d5">CBS001 is used in clinical trials to treat Chronic Inflammatory Disease</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="NON-EOSINOPHILIC ASTHMA" target="AVTX-002">
      <data key="d4">14.0</data>
      <data key="d5">AVTX-002 is used in clinical trials to treat Non-Eosinophilic Asthma</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="COVID-19 PNEUMONIA" target="CERC-002">
      <data key="d4">16.0</data>
      <data key="d5">CERC-002 is used in clinical trials to treat COVID-19 Pneumonia</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="ACUTE LUNG INJURY" target="CERC-002">
      <data key="d4">16.0</data>
      <data key="d5">CERC-002 is used in clinical trials to treat Acute Lung Injury</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="ARDS" target="CERC-002">
      <data key="d4">16.0</data>
      <data key="d5">CERC-002 is used in clinical trials to treat ARDS</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="CROHN DISEASE" target="MDGN-002">
      <data key="d4">14.0</data>
      <data key="d5">MDGN-002 is used in clinical trials to treat Crohn Disease</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="CROHN DISEASE" target="DENOSUMAB">
      <data key="d4">7.0</data>
      <data key="d5">Denosumab is used in clinical trials for Crohn's disease</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="CROHN DISEASE" target="UNIVERSITY OF MANITOBA">
      <data key="d4">6.0</data>
      <data key="d5">University of Manitoba is involved in clinical trials for Crohn's disease</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="CROHN DISEASE" target="MCMASTER UNIVERSITY">
      <data key="d4">6.0</data>
      <data key="d5">McMaster University is involved in clinical trials for Crohn's disease</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="BAMINERCEPT" target="PRIMARY SJ&#214;GREN&#8217;S SYNDROME">
      <data key="d4">14.0</data>
      <data key="d5">Baminercept is used in clinical trials to treat Primary Sj&#246;gren&#8217;s Syndrome</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="PRA023" target="DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS">
      <data key="d4">14.0</data>
      <data key="d5">PRA023 is used in clinical trials to treat Diffuse Cutaneous Systemic Sclerosis</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="PRA023" target="HEALTHY VOLUNTEER">
      <data key="d4">7.0</data>
      <data key="d5">PRA023 is tested in clinical trials involving Healthy Volunteers</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="PRA023" target="MODERATELY TO SEVERELY ACTIVE CROHN&#8217;S DISEASE">
      <data key="d4">7.0</data>
      <data key="d5">PRA023 is used in clinical trials to treat Moderately to Severely Active Crohn&#8217;s Disease</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="PRA023" target="MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS">
      <data key="d4">7.0</data>
      <data key="d5">PRA023 is used in clinical trials to treat Moderately to Severely Active Ulcerative Colitis</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="PRA023" target="HEALTHY">
      <data key="d4">1.0</data>
      <data key="d5">PRA023 is tested in clinical trials involving Healthy individuals</data>
      <data key="d6">7f559ad7372a4e35e90b43cc67047b0f</data>
    </edge>
    <edge source="PRA023" target="PROMETHEUS BIOSCIENCES, INC.">
      <data key="d4">8.0</data>
      <data key="d5">Prometheus Biosciences, Inc. is developing PRA023</data>
      <data key="d6">423195c6b63ad0a6773374364ebf3612</data>
    </edge>
    <edge source="PRA023" target="CELERION">
      <data key="d4">7.0</data>
      <data key="d5">Celerion is involved in the clinical testing of PRA023</data>
      <data key="d6">423195c6b63ad0a6773374364ebf3612</data>
    </edge>
    <edge source="TACI-FC FUSION PROTEIN" target="IGA NEPHROPATHY">
      <data key="d4">8.0</data>
      <data key="d5">TACI-Fc fusion protein is being tested for its efficacy in treating IgA nephropathy</data>
      <data key="d6">423195c6b63ad0a6773374364ebf3612</data>
    </edge>
    <edge source="TACI-FC FUSION PROTEIN" target="REMEGEN CO., LTD.">
      <data key="d4">8.0</data>
      <data key="d5">RemeGen Co., Ltd. is developing TACI-Fc fusion protein</data>
      <data key="d6">423195c6b63ad0a6773374364ebf3612</data>
    </edge>
    <edge source="TACI-FC FUSION PROTEIN" target="VERA THERAPEUTICS, INC.">
      <data key="d4">8.0</data>
      <data key="d5">Vera Therapeutics, Inc. is developing TACI-Fc fusion protein</data>
      <data key="d6">423195c6b63ad0a6773374364ebf3612</data>
    </edge>
    <edge source="IGA NEPHROPATHY" target="ATACICEPT">
      <data key="d4">8.0</data>
      <data key="d5">Atacicept is used in the treatment of IgA Nephropathy</data>
      <data key="d6">8e5a1be9981340d419f7b3ad27076009</data>
    </edge>
    <edge source="IGA NEPHROPATHY" target="ANTI-BAFF PEPTIBODY">
      <data key="d4">8.0</data>
      <data key="d5">Anti-BAFF peptibody is used in the treatment of IgA Nephropathy</data>
      <data key="d6">8e5a1be9981340d419f7b3ad27076009</data>
    </edge>
    <edge source="RELAPSING-REMITTING MULTIPLE SCLEROSIS" target="ATACICEPT">
      <data key="d4">16.0</data>
      <data key="d5">Atacicept is used in clinical trials for treating relapsing-remitting multiple sclerosis</data>
      <data key="d6">0c7502a2bfe653785647d754ed10f4e3</data>
    </edge>
    <edge source="DENOSUMAB" target="CALCIFIC AORTIC STENOSIS">
      <data key="d4">7.0</data>
      <data key="d5">Denosumab is used in clinical trials for calcific aortic stenosis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="CALCIFIC AORTIC STENOSIS" target="ALENDRONIC ACID">
      <data key="d4">7.0</data>
      <data key="d5">Alendronic acid is used in clinical trials for calcific aortic stenosis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="CALCIFIC AORTIC STENOSIS" target="UNIVERSITY OF EDINBURGH">
      <data key="d4">6.0</data>
      <data key="d5">University of Edinburgh is involved in clinical trials for calcific aortic stenosis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="CALCIFIC AORTIC STENOSIS" target="BRITISH HEART FOUNDATION">
      <data key="d4">6.0</data>
      <data key="d5">British Heart Foundation is involved in clinical trials for calcific aortic stenosis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="CALCIFIC AORTIC STENOSIS" target="NHS LOTHIAN">
      <data key="d4">6.0</data>
      <data key="d5">NHS Lothian is involved in clinical trials for calcific aortic stenosis</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="IMMUNE SYSTEM DISEASES" target="KYMAB LIMITED">
      <data key="d4">6.0</data>
      <data key="d5">Kymab Limited is involved in clinical trials for immune system diseases</data>
      <data key="d6">68015074236b0144899baa38d01ae467</data>
    </edge>
    <edge source="TNFSF MEMBERS" target="FIBROTIC DISEASE">
      <data key="d4">9.0</data>
      <data key="d5">TNFSF members are upregulated in fibrotic disease states</data>
      <data key="d6">516e41e96d2e72d45bf1e2c69da7f18a</data>
    </edge>
  </graph>
</graphml>